<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40352170</PMID><DateCompleted><Year>2025</Year><Month>05</Month><Day>12</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2807-2618</ISSN><JournalIssue CitedMedium="Internet"><Volume>5</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Narra J</Title><ISOAbbreviation>Narra J</ISOAbbreviation></Journal><ArticleTitle>A novel diastolic dysfunction score: A proposed diagnostic predictor for left ventricular dysfunction in obese population.</ArticleTitle><Pagination><StartPage>e1564</StartPage><MedlinePgn>e1564</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e1564</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.52225/narra.v5i1.1564</ELocationID><Abstract><AbstractText>Obesity-related diastolic dysfunction is an emerging contributor to heart failure and cardiovascular mortality. However, effective and accessible diagnostic tools are still limited. Current methods for assessing diastolic dysfunction are often invasive or technologically demanding, making them impractical for routine clinical use and community settings. The aim of this study was to develop a novel, non-invasive scoring system designed to predict diastolic dysfunction in obese adults, addressing this diagnostic gap. This community-based, prospective cross-sectional study was conducted in Jakarta, Indonesia, from March to November 2021, and included 82 participants aged 18 to 60 years, all with a body mass index (BMI) &#x2265;25&#x2005;kg/m<sup>2</sup>. Patients with acute or critical illnesses, valvular heart diseases, or acute confusional states were excluded. Each participant underwent blood tests, polysomnography, and echocardiography. Of the study population, 80.5% were diagnosed with obstructive sleep apnea (OSA), and 12.2% exhibited diastolic dysfunction, all within the OSA group. The novel scoring system integrates four predictors: oxygen desaturation index (ODI) &#x2265;39 (score 1; prevalence ratio: 4-31 (95% confidence interval (CI): 1.58-11.75)), HbAiC &#x2265;5.95% (score 2; prevalence ratio: 6.32 (95%CI: 2.84-14.06)), pulmonary artery wedge pressure (PAWP) &#x2265;10&#x2005;mmHg (score 1; prevalence ratio: 5.95 (95%CI: 2.30-15.39)), and global longitudinal strain (GLS) &#x2265;-16.95% (score 1; prevalence ratio: 4.32 (95%CI: 1.87-9.99)). A score of &#x2265;2 predicted diastolic dysfunction with 90% sensitivity, with positive predictive value and negative predictive value of 40.91% and 98.33%, respectively. In conclusion, the diastolic dysfunction score is a simple and practical tool for the early detection of diastolic dysfunction in obese individuals without cardiovascular symptoms.</AbstractText><CopyrightInformation>&#xa9; 2025 The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kamelia</LastName><ForeName>Telly</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Division of Respirology and Critical Care, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Respirology and Critical Care, Department of Internal Medicine, Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rumende</LastName><ForeName>Cleopas M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Division of Respirology and Critical Care, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Makmun</LastName><ForeName>Lukman H</ForeName><Initials>LH</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Timan</LastName><ForeName>Ina S</ForeName><Initials>IS</Initials><AffiliationInfo><Affiliation>Department of Clinical Pathology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Djauzi</LastName><ForeName>Samsuridjal</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Allergy and Immunology, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prihartono</LastName><ForeName>Joedo</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Public Health, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fardizza</LastName><ForeName>Fauziah</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Otorhinolaryngology-Head and Neck Surgery, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tabri</LastName><ForeName>Nur A</ForeName><Initials>NA</Initials><AffiliationInfo><Affiliation>Division of Respirology and Critical Care, Department of Internal Medicine, Faculty of Medicine, Universitas Hasanuddin, Makassar, Indonesia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>04</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Indonesia</Country><MedlineTA>Narra J</MedlineTA><NlmUniqueID>9918625888906676</NlmUniqueID><ISSNLinking>2807-2618</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009765" MajorTopicYN="Y">Obesity</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018487" MajorTopicYN="Y">Ventricular Dysfunction, Left</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007214" MajorTopicYN="N" Type="Geographic">Indonesia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003971" MajorTopicYN="N">Diastole</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004452" MajorTopicYN="N">Echocardiography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020181" MajorTopicYN="N">Sleep Apnea, Obstructive</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015992" MajorTopicYN="N">Body Mass Index</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Global longitudinal strain</Keyword><Keyword MajorTopicYN="N">HbA1C</Keyword><Keyword MajorTopicYN="N">obesity</Keyword><Keyword MajorTopicYN="N">oxygen desaturation index</Keyword><Keyword MajorTopicYN="N">pulmonary artery wedge pressure</Keyword></KeywordList><CoiStatement>There are no disclosed conflicts of interest for any of the authors.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>10</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>3</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>5</Month><Day>12</Day><Hour>12</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>5</Month><Day>12</Day><Hour>12</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>5</Month><Day>12</Day><Hour>6</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>4</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40352170</ArticleId><ArticleId IdType="pmc">PMC12059840</ArticleId><ArticleId IdType="doi">10.52225/narra.v5i1.1564</ArticleId><ArticleId IdType="pii">NarraJ-5-e1564</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>GBD 2015 Obesity Collaborators, Afshin A, Forouzanfar MH, et al. . Health effects of overweight and obesity in 195 countries over 25 years. N Engl J Med 2017;377(1):13&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5477817</ArticleId><ArticleId IdType="pubmed">28604169</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. Obesity and overweight. Available from: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight. Accessed: 30 December 2024.</Citation></Reference><Reference><Citation>World Health Organization. Regional office for the Western Pacific. The Asia-Pacific perspective: Redefining obesity and its treatment. Sydney: Health Communications; 2000.</Citation></Reference><Reference><Citation>Powell-Wiley TM, Poirier P, Burke LE, et al. . Obesity and cardiovascular disease: A scientific statement from the American heart association. Circulation 2021;143(21):e984&#x2013;e1010.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8493650</ArticleId><ArticleId IdType="pubmed">33882682</ArticleId></ArticleIdList></Reference><Reference><Citation>Cahyono A, Hermani B, Mangunkusumo E, et al. . Hubungan obstructive sleep apnea dengan penyakit sistem kardiovaskuler. Oto Rhino Laryngologica Indonesiana 2011;41.</Citation></Reference><Reference><Citation>Nagueh SF, Smiseth OA, Appleton CP, et al. . Recommendations for the evaluation of left ventricular diastolic function by echocardiography: An update from the American society of echocardiography and the European association of cardiovascular imaging. J Am Soc Echocardiogr 2016;29(4):277&#x2013;314.</Citation><ArticleIdList><ArticleId IdType="pubmed">27037982</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang SN, Juang JJM, Tsai CT, et al. . A novel integrated score index of echocardiographic indices for the evaluation of left ventricular diastolic function. PLoS One 2015;10(11):e0142175.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4640516</ArticleId><ArticleId IdType="pubmed">26555598</ArticleId></ArticleIdList></Reference><Reference><Citation>Fudim M, Shahid I, Emani S, et al. . Evaluation and treatment of central sleep apnea in patients with heart failure. Curr Probl Cardiol 2022;47(12):101364.</Citation><ArticleIdList><ArticleId IdType="pubmed">35995244</ArticleId></ArticleIdList></Reference><Reference><Citation>Carneiro G, Zanella MT. Obesity metabolic and hormonal disorders associated with obstructive sleep apnea and their impact on the risk of cardiovascular events. Metabolism 2018;84:76&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">29534971</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung F, Liao P, Elsaid H, et al. . Oxygen desaturation index from nocturnal oximetry: A sensitive and specific tool to detect sleep-disordered breathing in surgical patients. Anesth Analg 2012;114(5):993&#x2013;1000.</Citation><ArticleIdList><ArticleId IdType="pubmed">22366847</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao Y, Zhong X, Huang R, et al. . The evaluation of the severity of nocturnal oxygen desaturation of patients with obstructive sleep apnea hypopnea syndrome. Zhonghua Nei Ke Za Zhi 2007;46(6):458&#x2013;461.</Citation><ArticleIdList><ArticleId IdType="pubmed">17663818</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. Use of glycated haemoglobin (HbA1c) in the diagnosis of diabetes mellitus: Geneva: World Health Organization; 2011.</Citation></Reference><Reference><Citation>Patil VC, Patil HV, Shah KB, et al. . Diastolic dysfunction in asymptomatic type 2 diabetes mellitus with normal systolic function. J Cardiovasc Dis Res 2011;2(4):213&#x2013;222.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3224441</ArticleId><ArticleId IdType="pubmed">22135479</ArticleId></ArticleIdList></Reference><Reference><Citation>Hassan Ayman KM, Abdallah Mahmoud A, Abdel-Mageed Eman A, et al. . Correlation between left ventricular diastolic dysfunction and dyslipidaemia in asymptomatic patients with new-onset type 2 diabetes mellitus. Egypt J Intern Med 2021;33(1).</Citation></Reference><Reference><Citation>Ogilvie RP, Genuardi MV, Magnani JW, et al. . Association between sleep disordered breathing and left ventricular function: A cross-sectional analysis of the ECHO-SOL Ancillary Study. Circ Cardiovasc Imaging 2020;13(5):e009074.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8117672</ArticleId><ArticleId IdType="pubmed">32408831</ArticleId></ArticleIdList></Reference><Reference><Citation>Agrawal V, D'Alto M, Naeije R, et al. . Echocardiographic detection of occult diastolic dysfunction in pulmonary hypertension after fluid challenge. J Am Heart Assoc 2019;8(17):e012504.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6755835</ArticleId><ArticleId IdType="pubmed">31475602</ArticleId></ArticleIdList></Reference><Reference><Citation>Mascherbauer J, Zotter-Tufaro C, Duca F, et al. . Wedge pressure rather than left ventricular end-diastolic pressure predicts outcome in heart failure with preserved ejection fraction. JACC Heart Fail 2017;5(11):795&#x2013;801.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6197424</ArticleId><ArticleId IdType="pubmed">29032138</ArticleId></ArticleIdList></Reference><Reference><Citation>Biering-Sorensen T, Biering-Sorensen SR, Olsen FJ, et al. . Global longitudinal strain by echocardiography predicts long-term risk of cardiovascular morbidity and mortality in a low-risk general population: The Copenhagen city heart study. Circ Cardiovasc Imaging 2017;10(3):e005521.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5363277</ArticleId><ArticleId IdType="pubmed">28264868</ArticleId></ArticleIdList></Reference><Reference><Citation>Worsnop CJ, Naughton MT, Barter CE, et al. . The prevalence of obstructive sleep apnea in hypertensives. Am J Respir Crit Care Med 1998;157(1):111&#x2013;115.</Citation><ArticleIdList><ArticleId IdType="pubmed">9445287</ArticleId></ArticleIdList></Reference><Reference><Citation>Leung M, Wong VW, Hudson M, et al. . Impact of improved glycemic control on cardiac function in type 2 diabetes mellitus. Circ Cardiovasc Imaging 2016;9(3):e003643.</Citation><ArticleIdList><ArticleId IdType="pubmed">26962125</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagueh SF. Left ventricular diastolic function: Understanding pathophysiology, diagnosis, and prognosis with echocardiography. JACC Cardiovasc Imaging 2020;13(1 Pt 2): 228&#x2013;244.</Citation><ArticleIdList><ArticleId IdType="pubmed">30982669</ArticleId></ArticleIdList></Reference><Reference><Citation>Ebong IA, Goff DC Jr, Rodriguez CJ, et al. . Mechanisms of heart failure in obesity. Obes Res Clin Pract 2014;8(6):e540- e548.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4250935</ArticleId><ArticleId IdType="pubmed">25434909</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong CY, O'Moore-Sullivan T, Leano R, et al. . Alterations of left ventricular myocardial characteristics associated with obesity. Circulation 2004;110(19):3081&#x2013;3087.</Citation><ArticleIdList><ArticleId IdType="pubmed">15520317</ArticleId></ArticleIdList></Reference><Reference><Citation>Papanikolaou J, Ntalapascha M, Makris D, et al. . Diastolic dysfunction in men with severe obstructive sleep apnea syndrome but without cardiovascular or oxidative stress-related comorbidities. Ther Adv Respir Dis 2019;13:1753466619880076.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6769220</ArticleId><ArticleId IdType="pubmed">31566076</ArticleId></ArticleIdList></Reference><Reference><Citation>Touil I, Amor HIH, Kechida M, et al. . Predictive echocardiographic factors of severe obstructive sleep apnea. Pan Afr Med J 2021;38:359.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8308867</ArticleId><ArticleId IdType="pubmed">34367438</ArticleId></ArticleIdList></Reference><Reference><Citation>Leite AR, Martinez DM, Garcia-Rosa ML, et al. . Risk of obstructive sleep apnea and echocardiographic parameters. Arq Bras Cardiol 2019;113(6):1084&#x2013;1089.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7021261</ArticleId><ArticleId IdType="pubmed">31553383</ArticleId></ArticleIdList></Reference><Reference><Citation>Wachter R, LQthje L, Klemmstein D, et al. . Impact of obstructive sleep apnoea on diastolic function. Eur Respir J 2013;41(2):376&#x2013;383.</Citation><ArticleIdList><ArticleId IdType="pubmed">22790918</ArticleId></ArticleIdList></Reference><Reference><Citation>Gami AS, Howard DE, Olson EJ, et al. . Day-night pattern of sudden death in obstructive sleep apnea. N Engl J Med 2005;352(12):1206&#x2013;1214.</Citation><ArticleIdList><ArticleId IdType="pubmed">15788497</ArticleId></ArticleIdList></Reference><Reference><Citation>Dematteis M, Julien C, Guillermet C, et al. . Intermittent hypoxia induces early functional cardiovascular remodeling in mice. Am J Respir Crit Care Med 2008;177(2):227&#x2013;235.</Citation><ArticleIdList><ArticleId IdType="pubmed">17962641</ArticleId></ArticleIdList></Reference><Reference><Citation>Shepard JW Jr, Garrison MW, Grither DA, et al. . Relationship of ventricular ectopy to oxyhemoglobin desaturation in patients with obstructive sleep apnea. Chest 1985;88(3):335&#x2013;340.</Citation><ArticleIdList><ArticleId IdType="pubmed">2411477</ArticleId></ArticleIdList></Reference><Reference><Citation>Somers V. Sympathetic neural mechanisms in obstructive sleep apnea. Am J Hypertens 1996;9(4):180A.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC185826</ArticleId><ArticleId IdType="pubmed">7560081</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson GV, Pepperell JCT, Segal HC, et al. . Circulating cardiovascular risk factors in obstructive sleep apnoea: data from randomised controlled trials. Thorax 2004;59(9):777&#x2013;782.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1747125</ArticleId><ArticleId IdType="pubmed">15333855</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanriverdi H, Evrengul H, Kilic ID, et al. . Aortic pressures, stiffness and left ventricular function in coronary slow flow phenomenon. Cardiology 2010;116(4):261&#x2013;267.</Citation><ArticleIdList><ArticleId IdType="pubmed">20798537</ArticleId></ArticleIdList></Reference><Reference><Citation>Temirbekov D, GQne&#xa7; S, Yazici ZM, et al. . The ignored parameter in the diagnosis of obstructive sleep apnea syndrome: The oxygen desaturation index. Turk Arch Otorhinolaryngol 2018;56(1):1&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6017211</ArticleId><ArticleId IdType="pubmed">29988275</ArticleId></ArticleIdList></Reference><Reference><Citation>Ernst G, Bosio M, Salvado A, et al. . Difference between apnea-hypopnea index (AHI) and oxygen desaturation index (ODI): Proportional increase associated with degree of obesity. Sleep Breath 2016;20(4):1175&#x2013;1183.</Citation><ArticleIdList><ArticleId IdType="pubmed">27026417</ArticleId></ArticleIdList></Reference><Reference><Citation>Levelt E, Mahmod M, Piechnik SK, et al. . Relationship between left ventricular structural and metabolic remodeling in type 2 diabetes. Diabetes 2016;65(1):44&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4890658</ArticleId><ArticleId IdType="pubmed">26438611</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong TC, Piehler KM, Kang IA, et al. . Myocardial extracellular volume fraction quantified by cardiovascular magnetic resonance is increased in diabetes and associated with mortality and incident heart failure admission. Eur Heart J 2014;35(10):657&#x2013;664.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3945798</ArticleId><ArticleId IdType="pubmed">23756336</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimizu I, Minamino T, Toko H, et al. . Excessive cardiac insulin signaling exacerbates systolic dysfunction induced by pressure overload in rodents. J Clin Invest 2010;120(5):1506&#x2013;1514.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2860916</ArticleId><ArticleId IdType="pubmed">20407209</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehrke M, Marx N. Diabetes mellitus and heart failure. Am J Cardiol 2017;120(1S):S37&#x2013;S47.</Citation><ArticleIdList><ArticleId IdType="pubmed">28606342</ArticleId></ArticleIdList></Reference><Reference><Citation>Falcao-Pires I, Hamdani N, Borbely A, et al. . Diabetes mellitus worsens diastolic left ventricular dysfunction in aortic stenosis through altered myocardial structure and cardiomyocyte stiffness. Circulation 2011;124(10):1151&#x2013;1159.</Citation><ArticleIdList><ArticleId IdType="pubmed">21844073</ArticleId></ArticleIdList></Reference><Reference><Citation>American Diabetes Association . Standards of medical care in diabetes 2022 - abridged for primary care providers. Clin Diabetes 2022;40(1):10&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8865785</ArticleId><ArticleId IdType="pubmed">35221470</ArticleId></ArticleIdList></Reference><Reference><Citation>Okura H, Inoue H, Tomon M, et al. . Impaired glucose tolerance as a determinant of early deterioration of left ventricular diastolic function in middle-aged healthy subjects. Am J Cardiol 2000;85(6):790&#x2013;792, A9.</Citation><ArticleIdList><ArticleId IdType="pubmed">12000065</ArticleId></ArticleIdList></Reference><Reference><Citation>Reddy Y, El-Sabbagh A, Nishimura RA. Comparing pulmonary arterialwedge pressure and left ventricular end diastolic pressure for assessment of left-sided filling pressures. JAMA Cardiol 2018;3(6):453&#x2013;454.</Citation><ArticleIdList><ArticleId IdType="pubmed">29590308</ArticleId></ArticleIdList></Reference><Reference><Citation>Makmun LH, Kamelia T, Yusuf PA. Pulmonary artery wedge pressure formula using echocardiography finding. Acta Med Indones 2023;55(2):219&#x2013;222.</Citation><ArticleIdList><ArticleId IdType="pubmed">37524598</ArticleId></ArticleIdList></Reference><Reference><Citation>Vitarelli A, D'Orazio S, Caranci F, et al. . Left ventricular torsion abnormalities in patients with obstructive sleep apnea syndrome: an early sign of subclinical dysfunction. Int J Cardiol 2013;165(3):512&#x2013;518.</Citation><ArticleIdList><ArticleId IdType="pubmed">21962612</ArticleId></ArticleIdList></Reference><Reference><Citation>Park SJ, Miyazaki C, Bruce CJ, et al. . Left ventricular torsion by two-dimensional speckle tracking echocardiography in patients with diastolic dysfunction and normal ejection fraction. J Am Soc Echocardiogr 2008;21(10):1129&#x2013;1137.</Citation><ArticleIdList><ArticleId IdType="pubmed">18486443</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40674447</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2047-2412</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Jul</Month><Day>17</Day></PubDate></JournalIssue><Title>European heart journal. Cardiovascular Imaging</Title><ISOAbbreviation>Eur Heart J Cardiovasc Imaging</ISOAbbreviation></Journal><ArticleTitle>Discordance in left ventricular assessment by CMR versus echocardiography and potential impact on management of ischaemic left ventricular dysfunction.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">jeaf209</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/ehjci/jeaf209</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Betemariam</LastName><ForeName>Tesfamariam Aklilu</ForeName><Initials>TA</Initials><AffiliationInfo><Affiliation>British Heart Foundation Centre of Research Excellence at the School of Cardiovascular and Metabolic Medicine &amp; Sciences, King's College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Addis Ababa University, College of Health Sciences, School of Medicine, Addis Ababa, Ethiopia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morgan</LastName><ForeName>Holly P</ForeName><Initials>HP</Initials><AffiliationInfo><Affiliation>British Heart Foundation Centre of Research Excellence at the School of Cardiovascular and Metabolic Medicine &amp; Sciences, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kapetanakis</LastName><ForeName>Stamatis</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>St Thomas' Hospital, Guy's and St Thomas' NHS Foundation Trust, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mancio</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>British Heart Foundation Centre of Research Excellence at the School of Cardiovascular and Metabolic Medicine &amp; Sciences, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alskaf</LastName><ForeName>Ebraham</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0003-4007-6854</Identifier><AffiliationInfo><Affiliation>British Heart Foundation Centre of Research Excellence at the School of Cardiovascular and Metabolic Medicine &amp; Sciences, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Okafor</LastName><ForeName>Joseph</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-1021-6134</Identifier><AffiliationInfo><Affiliation>Royal Brompton Hospital, Guy's and St Thomas' NHS Foundation Trust, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Senior</LastName><ForeName>Roxy</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Royal Brompton Hospital, Guy's and St Thomas' NHS Foundation Trust, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Matthew</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-8256-195X</Identifier><AffiliationInfo><Affiliation>British Heart Foundation Centre of Research Excellence at the School of Cardiovascular and Metabolic Medicine &amp; Sciences, King's College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Addis Ababa University, College of Health Sciences, School of Medicine, Addis Ababa, Ethiopia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chiribiri</LastName><ForeName>Amedeo</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-3394-4289</Identifier><AffiliationInfo><Affiliation>School of Biomedical Engineering and Imaging Sciences, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perera</LastName><ForeName>Divaka</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0001-6362-1291</Identifier><AffiliationInfo><Affiliation>British Heart Foundation Centre of Research Excellence at the School of Cardiovascular and Metabolic Medicine &amp; Sciences, King's College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Addis Ababa University, College of Health Sciences, School of Medicine, Addis Ababa, Ethiopia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur Heart J Cardiovasc Imaging</MedlineTA><NlmUniqueID>101573788</NlmUniqueID><ISSNLinking>2047-2404</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cardiovascular magnetic resonance imaging</Keyword><Keyword MajorTopicYN="N">coronary artery disease</Keyword><Keyword MajorTopicYN="N">heart failure</Keyword><Keyword MajorTopicYN="N">left ventricular ejection fraction</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>7</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>17</Day><Hour>18</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>17</Day><Hour>18</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>17</Day><Hour>14</Hour><Minute>2</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40674447</ArticleId><ArticleId IdType="doi">10.1093/ehjci/jeaf209</ArticleId><ArticleId IdType="pii">8205653</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40343453</PMID><DateCompleted><Year>2025</Year><Month>08</Month><Day>05</Day></DateCompleted><DateRevised><Year>2025</Year><Month>08</Month><Day>06</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1435-1803</ISSN><JournalIssue CitedMedium="Internet"><Volume>120</Volume><Issue>4</Issue><PubDate><Year>2025</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Basic research in cardiology</Title><ISOAbbreviation>Basic Res Cardiol</ISOAbbreviation></Journal><ArticleTitle>CD163<sup>+</sup> macrophages attenuate pressure overload-induced left ventricular systolic dysfunction and cardiac mitochondrial dysfunction via interleukin-10.</ArticleTitle><Pagination><StartPage>727</StartPage><EndPage>744</EndPage><MedlinePgn>727-744</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00395-025-01114-z</ELocationID><Abstract><AbstractText>Macrophage depletion exacerbates pressure overload-induced heart failure, but therapeutic translation is hindered by macrophage subset heterogeneity. The functional role of CD163<sup>+</sup> macrophages in heart failure remains unclear. Transverse aortic constriction (TAC) was employed to induce pressure overload. Cd163<sup>-/-</sup> mice exhibited significantly aggravated TAC-induced left ventricular systolic dysfunction, as demonstrated by reduced ejection fraction, fractional shortening, and global longitudinal strain, compared to wild-type (WT) controls. RNA sequencing of cardiac tissues revealed significant differential gene expression between TAC-treated WT and Cd163<sup>-/-</sup> mice, especially in pathways governing mitochondrial bioenergetics and homeostasis. Transmission electron microscopy confirmed greater accumulation of dysfunctional mitochondria in cardiomyocytes of Cd163<sup>-/-</sup> mice relative to WT following TAC. Additionally, the proportion of CD163<sup>+</sup> macrophages among cardiac macrophages increased post-TAC. Serum IL-10 levels and cardiac macrophage IL-10 expression were significantly diminished in Cd163<sup>-/-</sup> mice compared to WT after TAC. IL-10 supplementation effectively reversed the TAC-induced impairment in left ventricular systolic function in both WT and Cd163<sup>-/-</sup> mice, and reduced NADH/NAD<sup>+</sup> ratios, reduced mitochondrial dysfunction, and improved mitochondrial membrane potential in Cd163<sup>-/-</sup> mice. Cross-sectional clinical data supported these findings, showing decreased IL-10 levels as a significant risk factor for heart failure in hypertensive patients (odds ratio: 0.397; 95% CI 0.203-0.775; p&#x2009;=&#x2009;0.007). Collectively, these results highlight the protective role of CD163<sup>+</sup> macrophages against pressure overload-induced left ventricular dysfunction and mitochondrial dysfunction through IL-10-dependent pathways.</AbstractText><CopyrightInformation>&#xa9; 2025. Springer-Verlag GmbH Germany, part of Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Ni</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>School of Medicine, Xiamen Cardiovascular Hospital, Xiamen University, Jinshan Road 2999, Xiamen, 361015, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Qingchun East Road 3, Hangzhou, 310016, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Ge</LastName><ForeName>Xiaofeng</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>School of Medicine, Xiamen Cardiovascular Hospital, Xiamen University, Jinshan Road 2999, Xiamen, 361015, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Liu</LastName><ForeName>Yang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>School of Medicine, Xiamen Cardiovascular Hospital, Xiamen University, Jinshan Road 2999, Xiamen, 361015, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Liaoning University of Traditional Chinese Medicine, Chongshan East Road 79, Shenyang, 110032, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Chen</LastName><ForeName>Jingyu</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>School of Medicine, Xiamen Cardiovascular Hospital, Xiamen University, Jinshan Road 2999, Xiamen, 361015, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Lin</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>School of Medicine, Xiamen Cardiovascular Hospital, Xiamen University, Jinshan Road 2999, Xiamen, 361015, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Linjian</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>School of Medicine, Xiamen Cardiovascular Hospital, Xiamen University, Jinshan Road 2999, Xiamen, 361015, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Zhaokai</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>School of Medicine, Xiamen Cardiovascular Hospital, Xiamen University, Jinshan Road 2999, Xiamen, 361015, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Peng</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>School of Medicine, Xiamen Cardiovascular Hospital, Xiamen University, Jinshan Road 2999, Xiamen, 361015, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Shufen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>School of Medicine, Xiamen Cardiovascular Hospital, Xiamen University, Jinshan Road 2999, Xiamen, 361015, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Junhui</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>School of Medicine, Xiamen Cardiovascular Hospital, Xiamen University, Jinshan Road 2999, Xiamen, 361015, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Le</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>School of Medicine, Xiamen Cardiovascular Hospital, Xiamen University, Jinshan Road 2999, Xiamen, 361015, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fan</LastName><ForeName>Xiabin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>School of Medicine, Xiamen Cardiovascular Hospital, Xiamen University, Jinshan Road 2999, Xiamen, 361015, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Gang</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>School of Medicine, Xiamen Cardiovascular Hospital, Xiamen University, Jinshan Road 2999, Xiamen, 361015, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>School of Medicine, Xiamen Cardiovascular Hospital, Xiamen University, Jinshan Road 2999, Xiamen, 361015, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ye</LastName><ForeName>Yuanchao</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Washington, 750 Republican Street, Seattle, WA, 98109, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Jiancang</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Qingchun East Road 3, Hangzhou, 310016, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dai</LastName><ForeName>Cuilian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>School of Medicine, Xiamen Cardiovascular Hospital, Xiamen University, Jinshan Road 2999, Xiamen, 361015, China. daicl@xmu.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Binbin</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0001-9454-6984</Identifier><AffiliationInfo><Affiliation>School of Medicine, Xiamen Cardiovascular Hospital, Xiamen University, Jinshan Road 2999, Xiamen, 361015, China. liubinbin@xmu.edu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>2019YFE0113900</GrantID><Agency>National Key Research and Development Program of China</Agency><Country/></Grant><Grant><GrantID>3502Z20204005</GrantID><Agency>Xiamen Medical and Health Key Project</Agency><Country/></Grant><Grant><GrantID>2021QNB021</GrantID><Agency>Fujian Provincial Health Technology Project</Agency><Country/></Grant><Grant><GrantID>2023</GrantID><Agency>Scientific Research Foundation of the Xiamen Human Resource Ministry for Returned Chinese Scholars</Agency><Country/></Grant><Grant><GrantID>2024J011424</GrantID><Agency>Natural Science Foundation of Fujian Province</Agency><Country/></Grant><Grant><GrantID>2024J011428</GrantID><Agency>Natural Science Foundation of Fujian Province</Agency><Country/></Grant><Grant><GrantID>3502Z20224ZD1182</GrantID><Agency>Xiamen Medical and Health Project</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>05</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Basic Res Cardiol</MedlineTA><NlmUniqueID>0360342</NlmUniqueID><ISSNLinking>0300-8428</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000098902">CD163 Antigen</NameOfSubstance></Chemical><Chemical><RegistryNumber>130068-27-8</RegistryNumber><NameOfSubstance UI="D016753">Interleukin-10</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015214">Antigens, Differentiation, Myelomonocytic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011956">Receptors, Cell Surface</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015703">Antigens, CD</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C556062">IL10 protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000098902" MajorTopicYN="N">CD163 Antigen</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018487" MajorTopicYN="Y">Ventricular Dysfunction, Left</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016753" MajorTopicYN="Y">Interleukin-10</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008264" MajorTopicYN="Y">Macrophages</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015214" MajorTopicYN="Y">Antigens, Differentiation, Myelomonocytic</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011956" MajorTopicYN="Y">Receptors, Cell Surface</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015703" MajorTopicYN="Y">Antigens, CD</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008929" MajorTopicYN="Y">Mitochondria, Heart</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016277" MajorTopicYN="Y">Ventricular Function, Left</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006333" MajorTopicYN="Y">Heart Failure</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D032383" MajorTopicYN="Y">Myocytes, Cardiac</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CD163</Keyword><Keyword MajorTopicYN="N">Dysfunctional mitochondria</Keyword><Keyword MajorTopicYN="N">Heart failure</Keyword><Keyword MajorTopicYN="N">Interleukin-10</Keyword><Keyword MajorTopicYN="N">Pressure overload</Keyword></KeywordList><CoiStatement>Declarations. Conflict of interest: None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>12</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>5</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>4</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>6</Day><Hour>0</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>5</Month><Day>9</Day><Hour>18</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>5</Month><Day>9</Day><Hour>12</Hour><Minute>50</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40343453</ArticleId><ArticleId IdType="doi">10.1007/s00395-025-01114-z</ArticleId><ArticleId IdType="pii">10.1007/s00395-025-01114-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bajpai G, Schneider C, Wong N, Bredemeyer A, Hulsmans M, Nahrendorf M, Epelman S, Kreisel D, Liu Y, Itoh A, Shankar TS, Selzman CH, Drakos SG, Lavine KJ (2018) The human heart contains distinct macrophage subsets with divergent origins and functions. Nat Med 24:1234&#x2013;1245. https://doi.org/10.1038/s41591-018-0059-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-018-0059-x</ArticleId><ArticleId IdType="pubmed">29892064</ArticleId><ArticleId IdType="pmc">6082687</ArticleId></ArticleIdList></Reference><Reference><Citation>Bloom MW, Greenberg B, Jaarsma T, Januzzi JL, Lam CSP, Maggioni AP, Trochu J-N, Butler J (2017) Heart failure with reduced ejection fraction. Nat Rev Dis Primers 3:1&#x2013;19. https://doi.org/10.1038/nrdp.2017.58</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2017.58</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L, Mei W, Song J, Chen K, Ni W, Wang L, Li Z, Ge X, Su L, Jiang C, Liu B, Dai C (2024) CD163 protein inhibits lipopolysaccharide-induced macrophage transformation from M2 to M1 involved in disruption of the TWEAK-Fn14 interaction. Heliyon 10:e23223. https://doi.org/10.1016/j.heliyon.2023.e23223</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.heliyon.2023.e23223</ArticleId><ArticleId IdType="pubmed">38148798</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen R, Zhang H, Tang B, Luo Y, Yang Y, Zhong X, Chen S, Xu X, Huang S, Liu C (2024) Macrophages in cardiovascular diseases: molecular mechanisms and therapeutic targets. Sig Transduct Target Ther 9:1&#x2013;44. https://doi.org/10.1038/s41392-024-01840-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-024-01840-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S, Saeed AFUH, Liu Q, Jiang Q, Xu H, Xiao GG, Rao L, Duo Y (2023) Macrophages in immunoregulation and therapeutics. Sig Transduct Target Ther 8:1&#x2013;35. https://doi.org/10.1038/s41392-023-01452-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-023-01452-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai C, Yao X, Gordon EM, Barochia A, Cuento RA, Kaler M, Meyer KS, Keeran KJ, Nugent GZ, Jeffries KR, Qu X, Yu Z-X, Aponte A, Gucek M, Dagur PK, McCoy JP, Levine SJ (2016) A CCL24-dependent pathway augments eosinophilic airway inflammation in house dust mite-challenged Cd163&#x2212;/&#x2212; mice. Mucosal Immunol 9:702&#x2013;717. https://doi.org/10.1038/mi.2015.94</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mi.2015.94</ArticleId><ArticleId IdType="pubmed">26376364</ArticleId></ArticleIdList></Reference><Reference><Citation>Durda P, Raffield LM, Lange EM, Olson NC, Jenny NS, Cushman M, Deichgraeber P, Grarup N, Jonsson A, Hansen T, Mychaleckyj JC, Psaty BM, Reiner AP, Tracy RP, Lange LA (2022) Circulating soluble CD163, associations with cardiovascular outcomes and mortality, and identification of genetic variants in older individuals: the cardiovascular health study. J Am Heart Assoc 11:e024374. https://doi.org/10.1161/JAHA.121.024374</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/JAHA.121.024374</ArticleId><ArticleId IdType="pubmed">36314488</ArticleId><ArticleId IdType="pmc">9673628</ArticleId></ArticleIdList></Reference><Reference><Citation>Epelman S, Lavine KJ, Beaudin AE, Sojka DK, Carrero JA, Calderon B, Brija T, Gautier EL, Ivanov S, Satpathy AT, Schilling JD, Schwendener R, Sergin I, Razani B, Forsberg EC, Yokoyama WM, Unanue ER, Colonna M, Randolph GJ, Mann DL (2014) Embryonic and adult-derived resident cardiac macrophages are maintained through distinct mechanisms at steady state and during inflammation. Immunity 40:91&#x2013;104. https://doi.org/10.1016/j.immuni.2013.11.019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2013.11.019</ArticleId><ArticleId IdType="pubmed">24439267</ArticleId><ArticleId IdType="pmc">3923301</ArticleId></ArticleIdList></Reference><Reference><Citation>Etzerodt A, Moestrup SK (2013) CD163 and inflammation: biological, diagnostic, and therapeutic aspects. Antioxid Redox Signal 18:2352&#x2013;2363. https://doi.org/10.1089/ars.2012.4834</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/ars.2012.4834</ArticleId><ArticleId IdType="pubmed">22900885</ArticleId><ArticleId IdType="pmc">3638564</ArticleId></ArticleIdList></Reference><Reference><Citation>Etzerodt A, Rasmussen MR, Svendsen P, Chalaris A, Schwarz J, Galea I, M&#xf8;ller HJ, Moestrup SK (2014) Structural basis for inflammation-driven shedding of CD163 ectodomain and tumor necrosis factor-&#x3b1; in macrophages. J Biol Chem 289:778&#x2013;788. https://doi.org/10.1074/jbc.M113.520213</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M113.520213</ArticleId><ArticleId IdType="pubmed">24275664</ArticleId></ArticleIdList></Reference><Reference><Citation>Heidt T, Courties G, Dutta P, Sager HB, Sebas M, Iwamoto Y, Sun Y, Da Silva N, Panizzi P, van der Lahn AM, Swirski FK, Weissleder R, Nahrendorf M (2014) Differential contribution of monocytes to heart macrophages in steady-state and after myocardial infarction. Circ Res 115:284&#x2013;295. https://doi.org/10.1161/CIRCRESAHA.115.303567</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.115.303567</ArticleId><ArticleId IdType="pubmed">24786973</ArticleId><ArticleId IdType="pmc">4082439</ArticleId></ArticleIdList></Reference><Reference><Citation>Heusch G, Kleinbongard P (2025) The spleen in ischaemic heart disease. Nat Rev Cardiol. https://doi.org/10.1038/s41569-024-01114-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41569-024-01114-x</ArticleId><ArticleId IdType="pubmed">40544172</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong Y-X, Wu C, Li J-Z, Song F, Hu Y, Han Y, Mao Y-J, Wu W-Y, Wang Y, Li G (2024) SUMOylation of TP53INP1 is involved in miR-30a-5p-regulated heart senescence. Exp Mol Med 56:2519&#x2013;2534. https://doi.org/10.1038/s12276-024-01347-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s12276-024-01347-3</ArticleId><ArticleId IdType="pubmed">39511427</ArticleId><ArticleId IdType="pmc">11612193</ArticleId></ArticleIdList></Reference><Reference><Citation>Hulsmans M, Sager HB, Roh JD, Valero-Mu&#xf1;oz M, Houstis NE, Iwamoto Y, Sun Y, Wilson RM, Wojtkiewicz G, Tricot B, Osborne MT, Hung J, Vinegoni C, Naxerova K, Sosnovik DE, Zile MR, Bradshaw AD, Liao R, Tawakol A, Weissleder R, Rosenzweig A, Swirski FK, Sam F, Nahrendorf M (2018) Cardiac macrophages promote diastolic dysfunction. J Exp Med 215:423&#x2013;440. https://doi.org/10.1084/jem.20171274</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20171274</ArticleId><ArticleId IdType="pubmed">29339450</ArticleId><ArticleId IdType="pmc">5789416</ArticleId></ArticleIdList></Reference><Reference><Citation>Ip WKE, Hoshi N, Shouval DS, Snapper S, Medzhitov R (2017) Anti-inflammatory effect of IL-10 mediated by metabolic reprogramming of macrophages. Science 356:513&#x2013;519. https://doi.org/10.1126/science.aal3535</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aal3535</ArticleId><ArticleId IdType="pubmed">28473584</ArticleId><ArticleId IdType="pmc">6260791</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia D, Chen S, Bai P, Luo C, Liu J, Sun A, Ge J (2022) Cardiac resident macrophage-derived legumain improves cardiac repair by promoting clearance and degradation of apoptotic cardiomyocytes after myocardial infarction. Circulation 145:1542&#x2013;1556. https://doi.org/10.1161/CIRCULATIONAHA.121.057549</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.121.057549</ArticleId><ArticleId IdType="pubmed">35430895</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung M, Ma Y, Iyer RP, DeLeon-Pennell KY, Yabluchiansky A, Garrett MR, Lindsey ML (2017) IL-10 improves cardiac remodeling after myocardial infarction by stimulating M2 macrophage polarization and fibroblast activation. Basic Res Cardiol 112:33. https://doi.org/10.1007/s00395-017-0622-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00395-017-0622-5</ArticleId><ArticleId IdType="pubmed">28439731</ArticleId><ArticleId IdType="pmc">5575998</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaur K, Sharma AK, Singal PK (2006) Significance of changes in TNF-&#x3b1; and IL-10 levels in the progression of heart failure subsequent to myocardial infarction. Am J Physiol-Heart Circ Physiol. https://doi.org/10.1152/ajpheart.01327.2005</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpheart.01327.2005</ArticleId><ArticleId IdType="pubmed">16461369</ArticleId></ArticleIdList></Reference><Reference><Citation>Kehat I, Molkentin JD (2010) Molecular pathways underlying cardiac remodeling during pathophysiologic stimulation. Circulation. https://doi.org/10.1161/CIRCULATIONAHA.110.942268</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.110.942268</ArticleId><ArticleId IdType="pubmed">21173361</ArticleId><ArticleId IdType="pmc">3076218</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim D, Paggi JM, Park C, Bennett C, Salzberg SL (2019) Graph-based genome alignment and genotyping with HISAT2 and HISAT-genotype. Nat Biotechnol 37:907&#x2013;915. https://doi.org/10.1038/s41587-019-0201-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41587-019-0201-4</ArticleId><ArticleId IdType="pubmed">31375807</ArticleId><ArticleId IdType="pmc">7605509</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim SR, Lee S-G, Kim SH, Kim JH, Choi E, Cho W, Rim JH, Hwang I, Lee CJ, Lee M, Oh C-M, Jeon JY, Gee HY, Kim J-H, Lee B-W, Kang ES, Cha B-S, Lee M-S, Yu J-W, Cho JW, Kim J-S, Lee Y-H (2020) SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease. Nat Commun 11:2127. https://doi.org/10.1038/s41467-020-15983-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-15983-6</ArticleId><ArticleId IdType="pubmed">32358544</ArticleId><ArticleId IdType="pmc">7195385</ArticleId></ArticleIdList></Reference><Reference><Citation>Kristiansen M, Graversen JH, Jacobsen C, Sonne O, Hoffman H-J, Law SKA, Moestrup SK (2001) Identification of the haemoglobin scavenger receptor. Nature 409:198&#x2013;201. https://doi.org/10.1038/35051594</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/35051594</ArticleId><ArticleId IdType="pubmed">11196644</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao X, Shen Y, Zhang R, Sugi K, Vasudevan NT, Alaiti MA, Sweet DR, Zhou L, Qing Y, Gerson SL, Fu C, Wynshaw-Boris A, Hu R, Schwartz MA, Fujioka H, Richardson B, Cameron MJ, Hayashi H, Stamler JS, Jain MK (2018) Distinct roles of resident and nonresident macrophages in nonischemic cardiomyopathy. Proc Natl Acad Sci U S A 115:E4661&#x2013;E4669. https://doi.org/10.1073/pnas.1720065115</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1720065115</ArticleId><ArticleId IdType="pubmed">29712858</ArticleId><ArticleId IdType="pmc">5960298</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao Y, Smyth GK, Shi W (2014) featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics 30:923&#x2013;930. https://doi.org/10.1093/bioinformatics/btt656</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btt656</ArticleId><ArticleId IdType="pubmed">24227677</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu B, Maekawa T, Yoshida K, Ly NH, Inoue K, Hasegawa A, Chatton B, Ogura A, Ishii S (2019) Telomere shortening by transgenerational transmission of TNF-&#x3b1;-induced TERRA via ATF7. Nucleic Acids Res 47:283&#x2013;298. https://doi.org/10.1093/nar/gky1149</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gky1149</ArticleId><ArticleId IdType="pubmed">30407559</ArticleId></ArticleIdList></Reference><Reference><Citation>McEvoy JW, McCarthy CP, Bruno RM, Brouwers S, Canavan MD, Ceconi C, Christodorescu RM, Daskalopoulou SS, Ferro CJ, Gerdts E, Hanssen H, Harris J, Lauder L, McManus RJ, Molloy GJ, Rahimi K, Regitz-Zagrosek V, Rossi GP, Sandset EC, Scheenaerts B, Staessen JA, Uchmanowicz I, Volterrani M, Touyz RM, ESC Scientific Document Group (2024) 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J 45:3912&#x2013;4018. https://doi.org/10.1093/eurheartj/ehae178</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehae178</ArticleId><ArticleId IdType="pubmed">39210715</ArticleId></ArticleIdList></Reference><Reference><Citation>Metra M, Teerlink JR (2017) Heart failure. Lancet 390:1981&#x2013;1995. https://doi.org/10.1016/S0140-6736(17)31071-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(17)31071-1</ArticleId><ArticleId IdType="pubmed">28460827</ArticleId></ArticleIdList></Reference><Reference><Citation>Mithal DS, Chandel NS (2021) The Gro3p factor: Restoring NAD+/NADH homeostasis to ameliorate mitochondrial disease. Cell Metab 33:1905&#x2013;1907. https://doi.org/10.1016/j.cmet.2021.09.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2021.09.006</ArticleId><ArticleId IdType="pubmed">34614406</ArticleId></ArticleIdList></Reference><Reference><Citation>Ni S-H, Xu J-D, Sun S-N, Li Y, Zhou Z, Li H, Liu X, Deng J-P, Huang Y-S, Chen Z-X, Feng W-J, Wang J-J, Xian S-X, Yang Z-Q, Wang S, Wang L-J, Lu L (2022) Single-cell transcriptomic analyses of cardiac immune cells reveal that Rel-driven CD72-positive macrophages induce cardiomyocyte injury. Cardiovasc Res 118:1303&#x2013;1320. https://doi.org/10.1093/cvr/cvab193</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cvr/cvab193</ArticleId><ArticleId IdType="pubmed">34100920</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicol&#xe1;s-&#xc1;vila JA, Lechuga-Vieco AV, Esteban-Mart&#xed;nez L, S&#xe1;nchez-D&#xed;az M, D&#xed;az-Garc&#xed;a E, Santiago DJ, Rubio-Ponce A, Li JL, Balachander A, Quintana JA, Mart&#xed;nez-de-Mena R, Castej&#xf3;n-Vega B, Pun-Garc&#xed;a A, Trav&#xe9;s PG, Bonz&#xf3;n-Kulichenko E, Garc&#xed;a-marqu&#xe9;s F, Cuss&#xf3; L, A-Gonz&#xe1;lez N, Gonz&#xe1;lez-Guerra A, Roche-Molina M, Martin-Salamanca S, Crainiciuc G, Guzm&#xe1;n G, Larrazabal J, Herrero-Gal&#xe1;n E, Alegre-Cebollada J, Lemke G, Rothlin CV, Jimenez-Borreguero LJ, Reyes G, Castrillo A, Desco M, Mu&#xf1;oz-C&#xe1;noves P, Ib&#xe1;&#xf1;ez B, Torres M, Ng LG, Priori SG, Bueno H, V&#xe1;zquez J, Cordero MD, Bernal JA, Enr&#xed;quez JA, Hidalgo A (2020) A network of macrophages supports mitochondrial homeostasis in the heart. Cell 183:94-109.e23. https://doi.org/10.1016/j.cell.2020.08.031</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.08.031</ArticleId><ArticleId IdType="pubmed">32937105</ArticleId></ArticleIdList></Reference><Reference><Citation>Nielsen MJ, Madsen M, M&#xf8;ller HJ, Moestrup SK (2006) The macrophage scavenger receptor CD163: endocytic properties of cytoplasmic tail variants. J Leukoc Biol 79:837&#x2013;845. https://doi.org/10.1189/jlb.1005602</Citation><ArticleIdList><ArticleId IdType="doi">10.1189/jlb.1005602</ArticleId><ArticleId IdType="pubmed">16434690</ArticleId></ArticleIdList></Reference><Reference><Citation>Pereira AHM, Cardoso AC, Franchini KG (2021) Isolation, culture, and immunostaining of neonatal rat ventricular myocytes. STAR Protoc 2:100950. https://doi.org/10.1016/j.xpro.2021.100950</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xpro.2021.100950</ArticleId><ArticleId IdType="pubmed">34820638</ArticleId><ArticleId IdType="pmc">8599495</ArticleId></ArticleIdList></Reference><Reference><Citation>Philippidis P, Mason JC, Evans BJ, Nadra I, Taylor KM, Haskard DO, Landis RC (2004) Hemoglobin scavenger receptor CD163 mediates interleukin-10 release and heme oxygenase-1 synthesis: antiinflammatory monocyte-macrophage responses in vitro, in resolving skin blisters in vivo, and after cardiopulmonary bypass surgery. Circ Res 94:119&#x2013;126. https://doi.org/10.1161/01.RES.0000109414.78907.F9</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.RES.0000109414.78907.F9</ArticleId><ArticleId IdType="pubmed">14656926</ArticleId></ArticleIdList></Reference><Reference><Citation>Revelo XS, Parthiban P, Chen C, Barrow F, Fredrickson G, Wang H, Y&#xfc;cel D, Herman A, van Berlo JH (2021) Cardiac resident macrophages prevent fibrosis and stimulate angiogenesis. Circ Res 129:1086&#x2013;1101. https://doi.org/10.1161/CIRCRESAHA.121.319737</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.121.319737</ArticleId><ArticleId IdType="pubmed">34645281</ArticleId><ArticleId IdType="pmc">8638822</ArticleId></ArticleIdList></Reference><Reference><Citation>Rickham PP (1964) HUMAN EXPERIMENTATION CODE OF ETHICS OF THE WORLD MEDICAL ASSOCIATION DECLARATION OF HELSINKI. Br Med J 2:177. https://doi.org/10.1136/bmj.2.5402.177</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.2.5402.177</ArticleId><ArticleId IdType="pubmed">14150898</ArticleId></ArticleIdList></Reference><Reference><Citation>Sano M, Minamino T, Toko H, Miyauchi H, Orimo M, Qin Y, Akazawa H, Tateno K, Kayama Y, Harada M, Shimizu I, Asahara T, Hamada H, Tomita S, Molkentin JD, Zou Y, Komuro I (2007) p53-induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload. Nature 446:444&#x2013;448. https://doi.org/10.1038/nature05602</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature05602</ArticleId><ArticleId IdType="pubmed">17334357</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato T, Kameyama T, Noto T, Nakadate T, Ueno H, Yamada K, Inoue H (2014) The impact of anti-inflammatory cytokines provoked by CD163 positive macrophages on ventricular functional recovery after myocardial infarction. J Thromb Thrombolysis 37:139&#x2013;147. https://doi.org/10.1007/s11239-013-0971-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11239-013-0971-3</ArticleId><ArticleId IdType="pubmed">23873589</ArticleId></ArticleIdList></Reference><Reference><Citation>Schiattarella GG, Hill JA (2015) Inhibition of hypertrophy is a good therapeutic strategy in ventricular pressure overload. Circulation 131:1435&#x2013;1447. https://doi.org/10.1161/CIRCULATIONAHA.115.013894</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.115.013894</ArticleId><ArticleId IdType="pubmed">25901069</ArticleId><ArticleId IdType="pmc">4408778</ArticleId></ArticleIdList></Reference><Reference><Citation>Sikka G, Miller KL, Steppan J, Pandey D, Jung SM, Fraser CD, Ellis C, Ross D, Vandegaer K, Bedja D, Gabrielson K, Walston JD, Berkowitz DE, Barouch LA (2013) Interleukin 10 knockout frail mice develop cardiac and vascular dysfunction with increased age. Exp Gerontol 48:128&#x2013;135. https://doi.org/10.1016/j.exger.2012.11.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.exger.2012.11.001</ArticleId><ArticleId IdType="pubmed">23159957</ArticleId></ArticleIdList></Reference><Reference><Citation>Stafford N, Assrafally F, Prehar S, Zi M, De Morais AM, Maqsood A, Cartwright EJ, Mueller W, Oceandy D (2020) Signaling via the Interleukin-10 receptor attenuates cardiac hypertrophy in mice during pressure overload, but not isoproterenol infusion. Front Pharmacol 11:559220. https://doi.org/10.3389/fphar.2020.559220</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2020.559220</ArticleId><ArticleId IdType="pubmed">33192505</ArticleId><ArticleId IdType="pmc">7662881</ArticleId></ArticleIdList></Reference><Reference><Citation>Suetomi T, Willeford A, Brand CS, Cho Y, Ross RS, Miyamoto S, Brown JH (2018) Inflammation and NLRP3 inflammasome activation initiated in response to pressure overload by Ca2+/Calmodulin-dependent protein kinase II &#x3b4; signaling in cardiomyocytes are essential for adverse cardiac remodeling. Circulation 138:2530&#x2013;2544. https://doi.org/10.1161/CIRCULATIONAHA.118.034621</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.118.034621</ArticleId><ArticleId IdType="pubmed">30571348</ArticleId><ArticleId IdType="pmc">6309790</ArticleId></ArticleIdList></Reference><Reference><Citation>Sulahian TH, H&#xf6;gger P, Wahner AE, Wardwell K, Goulding NJ, Sorg C, Droste A, Stehling M, Wallace PK, Morganelli PM, Guyre PM (2000) Human monocytes express CD163, which is upregulated by IL-10 and identical to p155. Cytokine 12:1312&#x2013;1321. https://doi.org/10.1006/cyto.2000.0720</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/cyto.2000.0720</ArticleId><ArticleId IdType="pubmed">10975989</ArticleId></ArticleIdList></Reference><Reference><Citation>Takimoto E, Yao A, Toko H, Takano H, Shimoyama M, Sonoda M, Wakimoto K, Takahashi T, Akazawa H, Mizukami M, Nagai T, Nagai R, Komuro I (2002) Sodium calcium exchanger plays a key role in alteration of cardiac function in response to pressure overload. FASEB J 16:373&#x2013;378. https://doi.org/10.1096/fj.01-0735com</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.01-0735com</ArticleId><ArticleId IdType="pubmed">11874986</ArticleId></ArticleIdList></Reference><Reference><Citation>Tham YK, Bernardo BC, Ooi JYY, Weeks KL, McMullen JR (2015) Pathophysiology of cardiac hypertrophy and heart failure: signaling pathways and novel therapeutic targets. Arch Toxicol 89:1401&#x2013;1438. https://doi.org/10.1007/s00204-015-1477-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00204-015-1477-x</ArticleId><ArticleId IdType="pubmed">25708889</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Gorp H, Delputte PL, Nauwynck HJ (2010) Scavenger receptor CD163, a Jack-of-all-trades and potential target for cell-directed therapy. Mol Immunol 47:1650&#x2013;1660. https://doi.org/10.1016/j.molimm.2010.02.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molimm.2010.02.008</ArticleId><ArticleId IdType="pubmed">20299103</ArticleId></ArticleIdList></Reference><Reference><Citation>Verma SK, Krishnamurthy P, Barefield D, Singh N, Gupta R, Lambers E, Thal M, Mackie A, Hoxha E, Ramirez V, Qin G, Sadayappan S, Ghosh AK, Kishore R (2012) Interleukin-10 treatment attenuates pressure overload-induced hypertrophic remodeling and improves heart function via signal transducers and activators of transcription 3-dependent inhibition of nuclear factor-&#x3ba;B. Circulation 126:418&#x2013;429. https://doi.org/10.1161/CIRCULATIONAHA.112.112185</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.112.112185</ArticleId><ArticleId IdType="pubmed">22705886</ArticleId><ArticleId IdType="pmc">3422741</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, Wang X, Chen J, Liu Y, Wang G, Chen L, Ni W, Jia Y, Dai C, Shao W, Liu B (2024) Low-intensity exercise training improves systolic function of heart during metastatic melanoma-induced cachexia in mice. Heliyon 10:e25562. https://doi.org/10.1016/j.heliyon.2024.e25562</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.heliyon.2024.e25562</ArticleId><ArticleId IdType="pubmed">38370171</ArticleId><ArticleId IdType="pmc">10874746</ArticleId></ArticleIdList></Reference><Reference><Citation>Watson CJ, Glezeva N, Horgan S, Gallagher J, Phelan D, McDonald K, Tolan M, Baugh J, Collier P, Ledwidge M (2020) Atrial tissue pro-fibrotic M2 macrophage marker CD163+ gene expression of procollagen and b-type natriuretic peptide. J Am Heart Assoc. https://doi.org/10.1161/JAHA.119.013416</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/JAHA.119.013416</ArticleId><ArticleId IdType="pubmed">33241727</ArticleId><ArticleId IdType="pmc">7763760</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu L, Li J, Chen L, Xue M, Zheng Y, Meng F, Jiang H, Shi Z, Zhang P, Dai C (2022) The efficacy and safety of phase I cardiac rehabilitation in patients hospitalized in cardiac intensive care unit with acute decompensated heart failure: a study protocol for a randomized controlled clinical trial. Front Cardiovasc Med. https://doi.org/10.3389/fcvm.2022.788503</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2022.788503</ArticleId><ArticleId IdType="pubmed">36818913</ArticleId><ArticleId IdType="pmc">9813219</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang H, Wang H, Levine YA, Gunasekaran MK, Wang Y, Addorisio M, Zhu S, Li W, Li J, de Kleijn DP, Olofsson PS, Warren HS, He M, Al-Abed Y, Roth J, Antoine DJ, Chavan SS, Andersson U, Tracey KJ (2016) Identification of CD163 as an antiinflammatory receptor for HMGB1-haptoglobin complexes. JCI Insight 1:85375. https://doi.org/10.1172/jci.insight.85375</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.85375</ArticleId><ArticleId IdType="pubmed">27294203</ArticleId></ArticleIdList></Reference><Reference><Citation>York AG, Skadow MH, Oh J, Qu R, Zhou QD, Hsieh W-Y, Mowel WK, Brewer JR, Kaffe E, Williams KJ, Kluger Y, Smale ST, Crawford JM, Bensinger SJ, Flavell RA (2024) IL-10 constrains sphingolipid metabolism to limit inflammation. Nature 627:628&#x2013;635. https://doi.org/10.1038/s41586-024-07098-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-024-07098-5</ArticleId><ArticleId IdType="pubmed">38383790</ArticleId><ArticleId IdType="pmc">10954550</ArticleId></ArticleIdList></Reference><Reference><Citation>Yue Y, Huang S, Wang L, Wu Z, Liang M, Li H, Lv L, Li W, Wu Z (2020) M2b macrophages regulate cardiac fibroblast activation and alleviate cardiac fibrosis after reperfusion injury. Circ J advpub. https://doi.org/10.1253/circj.CJ-19-0959</Citation><ArticleIdList><ArticleId IdType="doi">10.1253/circj.CJ-19-0959</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang K, Wang Y, Chen S, Mao J, Jin Y, Ye H, Zhang Y, Liu X, Gong C, Cheng X, Huang X, Hoeft A, Chen Q, Li X, Fang X (2023) TREM2hi resident macrophages protect the septic heart by maintaining cardiomyocyte homeostasis. Nat Metab 5:129&#x2013;146. https://doi.org/10.1038/s42255-022-00715-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42255-022-00715-5</ArticleId><ArticleId IdType="pubmed">36635449</ArticleId><ArticleId IdType="pmc">9886554</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhuang L, Jia K, Chen C, Li Z, Zhao J, Hu J, Zhang H, Fan Q, Huang C, Xie H, Lu L, Shen W, Ning G, Wang J, Zhang R, Chen K, Yan X (2022) DYRK1B-STAT3 drives cardiac hypertrophy and heart failure by impairing mitochondrial bioenergetics. Circulation 145:829&#x2013;846. https://doi.org/10.1161/CIRCULATIONAHA.121.055727</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.121.055727</ArticleId><ArticleId IdType="pubmed">35235343</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40536467</PMID><DateRevised><Year>2025</Year><Month>06</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2452-302X</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Jun</Month><Day>04</Day></PubDate></JournalIssue><Title>JACC. Basic to translational science</Title><ISOAbbreviation>JACC Basic Transl Sci</ISOAbbreviation></Journal><ArticleTitle>Controlled Right Ventricular Pressure Overload Can Rescue Left Ventricular Dysfunction by Promoting Biventricular Adaptive Hypertrophy.</ArticleTitle><Pagination><StartPage>101259</StartPage><MedlinePgn>101259</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jacbts.2025.02.018</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2452-302X(25)00107-X</ELocationID><Abstract><AbstractText>Pulmonary artery banding (PAB) has been investigated as a therapy for left ventricular (LV) dysfunction in pediatric dilated cardiomyopathy; however, the underlying mechanisms of action of PAB-induced LV rehabilitation remain unknown. This study aims to establish a small animal model of PAB-treated LV dysfunction to document the biventricular hemodynamic and tissue-level modifications promoted by PAB. Sprague-Dawley rats underwent left anterior descending (LAD) artery ligation (LV dysfunction model) followed by PAB 1-week post-injury (LAD + PAB, n = 13). Controls consisted of sham (n = 16), PAB-only (n = 16), and LAD rats (n = 15). The animals underwent weekly echocardiography and terminal histopathology 4 weeks after surgery. Data shown as mean &#xb1; SEM or median (Q1-Q3). LAD + PAB rats exhibited positive LV remodeling (LV end-diastolic volume: 0.49 &#xb1; 0.02 mL vs 0.66 &#xb1; 0.03 mL; P &lt; 0.001), improvement of LV ejection fraction (0.48 &#xb1; 0.01 vs. 0.36 &#xb1; 0.01; P &lt; 0.001), and normalization of mitral valve Doppler E/A (1.43 &#xb1; 0.03 vs 1.91 &#xb1; 0.09; P &lt; 0.001) compared to LAD animals. Histologic analysis documented LV hypertrophy (wall thickness/body weight: 9.3 &#xb1; 0.4 &#x3bc;m/g vs 7.2 &#xb1; 0.3 &#x3bc;m/g; P = 0.005), increased LV cardiomyocyte diameter (14.8 [Q1-Q3: 13.9-15.7] &#x3bc;m vs 11.3 [Q1-Q3: 10.8-11.7] &#x3bc;m; P = 0.001), and augmented neoangiogenesis (6.5 &#xb1; 0.2 vessels/mm<sup>2</sup> vs 4.7 &#xb1; 0.5 vessels/mm<sup>2</sup>; P = 0.005) in LAD + PAB vs LAD hearts. Mechanistically, we observed reduced LV fibrosis (9.8% [Q1-Q3: 7.7%-13.4%] vs 17.4% [Q1-Q3: 14.8%-20.2%]; P = 0.003) and fibroblast cellular senescence (5.7% [Q1-Q3: 4%-10.7%] vs 16.1% [7.6%-18.4%], P = 0.029), and preserved phospholamban (PLN) phosphorylation in the LV of LAD + PAB vs LAD rats (increased PLN/PLN: 0.6 &#xb1; 0.1 vs 1.0 &#xb1; 0.1; P = 0.008). In our model, PAB induced positive LV remodeling and improved LV systolic-diastolic function. PAB stimulated biventricular compensated hypertrophy that may constitute a potential adaptive mechanism which can rescue residual LV function and limit LV fibrosis/injury.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ponzoni</LastName><ForeName>Matteo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Surgery, The Hospital for Sick Children, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yeganeh</LastName><ForeName>Azadeh</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Program in Molecular Medicine, SickKids Research Institute, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Libo</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Program in Molecular Medicine, SickKids Research Institute, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Program in Molecular Medicine, SickKids Research Institute, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vanama</LastName><ForeName>Ramesh B</ForeName><Initials>RB</Initials><AffiliationInfo><Affiliation>Program in Molecular Medicine, SickKids Research Institute, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hogarth</LastName><ForeName>Kaley</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Program in Molecular Medicine, SickKids Research Institute, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Phi</LastName><ForeName>Quynh N</ForeName><Initials>QN</Initials><AffiliationInfo><Affiliation>Program in Molecular Medicine, SickKids Research Institute, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Jing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Program in Molecular Medicine, SickKids Research Institute, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karim</LastName><ForeName>Loukmane</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Program in Molecular Medicine, SickKids Research Institute, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coles</LastName><ForeName>John G</ForeName><Initials>JG</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Surgery, The Hospital for Sick Children, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maynes</LastName><ForeName>Jason T</ForeName><Initials>JT</Initials><AffiliationInfo><Affiliation>Program in Molecular Medicine, SickKids Research Institute, Toronto, Ontario, Canada; Department of Anesthesia and Pain Medicine, The Hospital for Sick Children, Toronto, Ontario, Canada; Department of Anesthesiology and Pain Medicine, University of Toronto, Toronto, Ontario, Canada. Electronic address: jason.maynes@sickkids.ca.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>06</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JACC Basic Transl Sci</MedlineTA><NlmUniqueID>101677259</NlmUniqueID><ISSNLinking>2452-302X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">dilated cardiomyopathy</Keyword><Keyword MajorTopicYN="N">experimental model</Keyword><Keyword MajorTopicYN="N">left ventricular dysfunction</Keyword><Keyword MajorTopicYN="N">pulmonary artery banding</Keyword></KeywordList><CoiStatement>Funding Support and Author Disclosures This work was supported by the Canadian Institutes for Health Research, the Labatt Family Heart Centre Innovation Fund, The Hospital for Sick Children, Toronto, Ontario, Canada; the SickKids Foundation through the Curtis Joseph and Harold Groves Chair in Anesthesia and Pain Medicine and the Department of Anesthesiology and Pain Medicine, University of Toronto, through a Merit Award. Dr Coles has been supported by Coles Professional Medicine Corporation. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>12</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>1</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>2</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>6</Month><Day>19</Day><Hour>12</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>6</Month><Day>19</Day><Hour>12</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>6</Month><Day>19</Day><Hour>10</Hour><Minute>31</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40536467</ArticleId><ArticleId IdType="doi">10.1016/j.jacbts.2025.02.018</ArticleId><ArticleId IdType="pii">S2452-302X(25)00107-X</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40555010</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>27</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2772-963X</ISSN><JournalIssue CitedMedium="Internet"><Volume>4</Volume><Issue>7</Issue><PubDate><Year>2025</Year><Month>Jul</Month></PubDate></JournalIssue><Title>JACC. Advances</Title><ISOAbbreviation>JACC Adv</ISOAbbreviation></Journal><ArticleTitle>Artificial Intelligence for Detection of Prognostically Significant Left Ventricular Dysfunction From Echocardiography.</ArticleTitle><Pagination><StartPage>101891</StartPage><MedlinePgn>101891</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">101891</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jacadv.2025.101891</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2772-963X(25)00311-4</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Identification of left ventricular (LV) dysfunction following echocardiographic investigations remains problematic, particularly when the ejection fraction (EF) is preserved.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">The authors examined the operational characteristics of artificial intelligence LV dysfunction (AI-LVD) identification from routinely obtained echocardiographic measurements.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Following initial training in 126,136 (imputation cohort) and 254,735 (training cohort) cases from the National Echo Database of Australia, the AI-LVD was tested in 81,509 cases (last echo January 1, 2000-May 21, 2019) with no mitral valve intervention or pacemaker. This cohort comprised 41,796 men (51.3%) aged 62.3 &#xb1; 17.1 years and 39,713 women aged 63.2 &#xb1; 18.4 years, in whom 4,490 (5.5%), 3,734 (4.6%), and 59,297 (72.7%) had reduced, mildly reduced, and preserved EF, while 13,988 (17.2%) had no recorded EF and 39,940 (45.2%) had "indeterminate" filling pressures.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Overall, the AI-LVD generated a (sex-specific) output in decile distributions consistent with increasingly higher levels of LV dysfunction and mortality-actual 5-year mortality rising from 5.7% to 66.3% and 2.3% to 64.2% in men and women, respectively. The prognostic capacity of the AI-LVD persisted in preserved EF, when adjusting for age, year of echo, and missing echo parameters-with adjusted hazard for all-cause mortality during 1,541 (812-2,682) days follow-up 4.93-fold (95% CI: 4.35-5.59) and 7.11-fold (95% CI: 5.85-8.64) higher in the highest vs lowest decile group in men and women, respectively.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">A new AI-LVD algorithm using only echocardiographic measurements can reliably identify prognostically important LV dysfunction, including in preserved EF, even when key reporting parameters are missing. The AI-LVD can be used in real-time during routine echocardiography reporting.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Playford</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Institute for Health Research, The University of Notre Dame Australia, Fremantle, Western Australia, Australia. Electronic address: dplayford@neda.net.au.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stewart</LastName><ForeName>Simon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute for Health Research, The University of Notre Dame Australia, Fremantle, Western Australia, Australia; BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Watts</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Echo IQ Ltd, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kezurer</LastName><ForeName>Dean</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Echo IQ Ltd, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chan</LastName><ForeName>Yih-Kai</ForeName><Initials>YK</Initials><AffiliationInfo><Affiliation>Mary MacKillop Institute for Health Research, Australian Catholic University, Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Strange</LastName><ForeName>Geoff</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Institute for Health Research, The University of Notre Dame Australia, Fremantle, Western Australia, Australia; Heart Research Institute, University of Sydney, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>06</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JACC Adv</MedlineTA><NlmUniqueID>9918419284106676</NlmUniqueID><ISSNLinking>2772-963X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">artificial intelligence</Keyword><Keyword MajorTopicYN="N">diastolic dysfunction</Keyword><Keyword MajorTopicYN="N">echocardiography</Keyword><Keyword MajorTopicYN="N">heart failure</Keyword><Keyword MajorTopicYN="N">left ventricular dysfunction</Keyword><Keyword MajorTopicYN="N">systolic dysfunction</Keyword></KeywordList><CoiStatement>Funding support and author disclosures Dr Playford has received consulting fees from Echo IQ and investigator fees from NEDA. Dr Stewart is supported by the National Health and Medical Research Council of Australia (GNT1135894); has received consulting fees from Echo IQ and NEDA; and is the Director of Research for NEDA. Dr Watts is an employee of Echo IQ. Dr Strange has received consulting fees from Echo IQ and investigator fees from NEDA. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>4</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>5</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>5</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>6</Month><Day>25</Day><Hour>0</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>6</Month><Day>25</Day><Hour>0</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>6</Month><Day>24</Day><Hour>18</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>6</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40555010</ArticleId><ArticleId IdType="pmc">PMC12240068</ArticleId><ArticleId IdType="doi">10.1016/j.jacadv.2025.101891</ArticleId><ArticleId IdType="pii">S2772-963X(25)00311-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>McDonagh T.A., Metra M., Adamo M., et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42:3599&#x2013;3726. doi: 10.1093/eurheartj/ehab368.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehab368</ArticleId><ArticleId IdType="pubmed">34447992</ArticleId></ArticleIdList></Reference><Reference><Citation>Heidenreich P.A., Bozkurt B., Aguilar D., et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines. J Am Coll Cardiol. 2022;79(17):e263&#x2013;e421.</Citation><ArticleIdList><ArticleId IdType="pubmed">35379503</ArticleId></ArticleIdList></Reference><Reference><Citation>McDonagh T.A., Metra M., Adamo M., et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2023;44:3627&#x2013;3639. doi: 10.1093/eurheartj/ehad195.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehad195</ArticleId><ArticleId IdType="pubmed">37622666</ArticleId></ArticleIdList></Reference><Reference><Citation>Maddox T.M., Januzzi J.L., Allen L.A., et al. 2024 ACC expert consensus decision pathway for treatment of heart failure with reduced ejection fraction. J Am Coll Cardiol. 2024;83:1444&#x2013;1488. doi: 10.1016/j.jacc.2023.12.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2023.12.024</ArticleId><ArticleId IdType="pubmed">38466244</ArticleId></ArticleIdList></Reference><Reference><Citation>Anker S.D., Butler J., Filippatos G., et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385:1451&#x2013;1461. doi: 10.1056/NEJMoa2107038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2107038</ArticleId><ArticleId IdType="pubmed">34449189</ArticleId></ArticleIdList></Reference><Reference><Citation>Nassif M.E., Windsor S.L., Borlaug B.A., et al. The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial. Nat Med. 2021;27:1954&#x2013;1960. doi: 10.1038/s41591-021-01536-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01536-x</ArticleId><ArticleId IdType="pmc">PMC8604725</ArticleId><ArticleId IdType="pubmed">34711976</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon S.D., McMurray J.J.V., Claggett B., et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387:1089&#x2013;1098. doi: 10.1056/nejmoa2206286.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejmoa2206286</ArticleId><ArticleId IdType="pubmed">36027570</ArticleId></ArticleIdList></Reference><Reference><Citation>Jasinska-Piadlo A., Campbell P. Management of patients with heart failure and preserved ejection fraction. Heart. 2023;109:874&#x2013;883. doi: 10.1136/heartjnl-2022-321097.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/heartjnl-2022-321097</ArticleId><ArticleId IdType="pmc">PMC10314029</ArticleId><ArticleId IdType="pubmed">36948571</ArticleId></ArticleIdList></Reference><Reference><Citation>Playford D., Strange G., Celermajer D.S., et al. Diastolic dysfunction and mortality in 436 360 men and women: the National Echo Database Australia (NEDA) Eur Heart J Cardiovasc Imag. 2020;22:505&#x2013;515. doi: 10.1093/ehjci/jeaa253.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ehjci/jeaa253</ArticleId><ArticleId IdType="pmc">PMC8081414</ArticleId><ArticleId IdType="pubmed">33245344</ArticleId></ArticleIdList></Reference><Reference><Citation>Stewart S., Playford D., Scalia G.M., et al. Ejection fraction and mortality: a nationwide register based cohort study of 499,153 women and men. Eur J Heart Fail. 2020;23:406&#x2013;416. doi: 10.1002/ejhf.2047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ejhf.2047</ArticleId><ArticleId IdType="pubmed">33150657</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan S.S., Beach L.B., Yancy C.W. Sex-based differences in heart failure: JACC Focus Seminar 7/7. J Am Coll Cardiol. 2022;79:1530&#x2013;1541. doi: 10.1016/j.jacc.2022.02.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2022.02.013</ArticleId><ArticleId IdType="pubmed">35422249</ArticleId></ArticleIdList></Reference><Reference><Citation>Strange G., Celermajer D.S., Marwick T., et al. The National Echocardiography Database Australia (NEDA): rationale and methodology. Am Heart J. 2018;204:186&#x2013;189. doi: 10.1016/j.ahj.2018.07.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ahj.2018.07.001</ArticleId><ArticleId IdType="pubmed">30098706</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen J.F., Korevaar D.A., Altman D.G., et al. STARD 2015 guidelines for reporting diagnostic accuracy studies: explanation and elaboration. BMJ Open. 2016;6 doi: 10.1136/bmjopen-2016-012799.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2016-012799</ArticleId><ArticleId IdType="pmc">PMC5128957</ArticleId><ArticleId IdType="pubmed">28137831</ArticleId></ArticleIdList></Reference><Reference><Citation>Strange G., Stewart S., Watts A., Playford D. Enhanced detection of severe aortic stenosis via artificial intelligence: a clinical cohort study. Open Heart. 2023;10 doi: 10.1136/openhrt-2023-002265.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/openhrt-2023-002265</ArticleId><ArticleId IdType="pmc">PMC10373677</ArticleId><ArticleId IdType="pubmed">37491129</ArticleId></ArticleIdList></Reference><Reference><Citation>Strom J.B., Playford D., Stewart S., Strange G. An artificial intelligence algorithm for detection of severe aortic stenosis. JACC Adv. 2024;3 doi: 10.1016/j.jacadv.2024.101176.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacadv.2024.101176</ArticleId><ArticleId IdType="pmc">PMC11450902</ArticleId><ArticleId IdType="pubmed">39372458</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah A.M., Cikes M., Prasad N., et al. Echocardiographic features of patients with heart failure and preserved left ventricular ejection fraction. J Am Coll Cardiol. 2019;74:2858&#x2013;2873. doi: 10.1016/j.jacc.2019.09.063.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2019.09.063</ArticleId><ArticleId IdType="pubmed">31806129</ArticleId></ArticleIdList></Reference><Reference><Citation>Sengupta P.P., Shrestha S., Berthon B., et al. Proposed requirements for cardiovascular imaging-related machine learning evaluation (PRIME): a checklist. JACC Cardiovasc Imaging. 2020;13:2017&#x2013;2035. doi: 10.1016/j.jcmg.2020.07.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcmg.2020.07.015</ArticleId><ArticleId IdType="pmc">PMC7953597</ArticleId><ArticleId IdType="pubmed">32912474</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldstein A., Kapelner A., Bleich J., Pitkin E. Peeking inside the black box: visualizing statistical learning with plots of individual conditional expectation. J Comput Graph Stat. 2015;24:44&#x2013;65. doi: 10.1080/10618600.2014.907095.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/10618600.2014.907095</ArticleId></ArticleIdList></Reference><Reference><Citation>Lang R.M., Badano L.P., Mor-Avi V., et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2015;16:233&#x2013;271. doi: 10.1093/ehjci/jev014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ehjci/jev014</ArticleId><ArticleId IdType="pubmed">25712077</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagueh S.F., Smiseth O.A., Appleton C.P., et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2016;17:1321&#x2013;1360. doi: 10.1093/ehjci/jew082.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ehjci/jew082</ArticleId><ArticleId IdType="pubmed">27422899</ArticleId></ArticleIdList></Reference><Reference><Citation>Antoniades C., Oikonomou E.K. Artificial intelligence in cardiovascular imaging&#x2014;principles, expectations, and limitations. Eur Heart J. 2024;45:1322&#x2013;1326. doi: 10.1093/eurheartj/ehab678.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehab678</ArticleId><ArticleId IdType="pmc">PMC11015951</ArticleId><ArticleId IdType="pubmed">34557898</ArticleId></ArticleIdList></Reference><Reference><Citation>Spencer K.T., Arling B., Sevenster M., et al. Identifying errors and inconsistencies in real time while using facilitated echocardiographic reporting. J Am Soc Echocardiogr. 2015;28:88&#x2013;92.e81. doi: 10.1016/j.echo.2014.09.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.echo.2014.09.005</ArticleId><ArticleId IdType="pubmed">25441328</ArticleId></ArticleIdList></Reference><Reference><Citation>He B., Kwan A.C., Cho J.H., et al. Blinded, randomized trial of sonographer versus AI cardiac function assessment. Nature. 2023;616:520&#x2013;524. doi: 10.1038/s41586-023-05947-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-023-05947-3</ArticleId><ArticleId IdType="pmc">PMC10115627</ArticleId><ArticleId IdType="pubmed">37020027</ArticleId></ArticleIdList></Reference><Reference><Citation>Tromp J., Sarra C., Nidhal B., et al. Nurse-led home-based detection of cardiac dysfunction by ultrasound: results of the CUMIN pilot study. Eur Heart J Digit Health. 2024;5:163&#x2013;169. doi: 10.1093/ehjdh/ztad079.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ehjdh/ztad079</ArticleId><ArticleId IdType="pmc">PMC10944680</ArticleId><ArticleId IdType="pubmed">38505488</ArticleId></ArticleIdList></Reference><Reference><Citation>Onishi T., Saha S.K., Delgado-Montero A., et al. Global longitudinal strain and global circumferential strain by speckle-tracking echocardiography and feature-tracking cardiac magnetic resonance imaging: comparison with left ventricular ejection fraction. J Am Soc Echocardiogr. 2015;28:587&#x2013;596. doi: 10.1016/j.echo.2014.11.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.echo.2014.11.018</ArticleId><ArticleId IdType="pubmed">25577185</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagueh S.F., Khan S.U. Left atrial strain for assessment of left ventricular diastolic function: focus on populations with normal LVEF. JACC Cardiovasc Imaging. 2023;16:691&#x2013;707. doi: 10.1016/j.jcmg.2022.10.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcmg.2022.10.011</ArticleId><ArticleId IdType="pubmed">36752445</ArticleId></ArticleIdList></Reference><Reference><Citation>Raafs A.G., Boscutti A., Henkens M.T.H.M., et al. Global longitudinal strain is incremental to left ventricular ejection fraction for the prediction of outcome in optimally treated dilated cardiomyopathy patients. J Am Heart Assoc. 2022;11 doi: 10.1161/jaha.121.024505.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/jaha.121.024505</ArticleId><ArticleId IdType="pmc">PMC9075270</ArticleId><ArticleId IdType="pubmed">35253464</ArticleId></ArticleIdList></Reference><Reference><Citation>Groenewegen A., Rutten F.H., Mosterd A., Hoes A.W. Epidemiology of heart failure. Eur J Heart Fail. 2020;22:1342&#x2013;1356. doi: 10.1002/ejhf.1858.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ejhf.1858</ArticleId><ArticleId IdType="pmc">PMC7540043</ArticleId><ArticleId IdType="pubmed">32483830</ArticleId></ArticleIdList></Reference><Reference><Citation>Reddy Y.N.V., Carter R.E., Obokata M., Redfield M.M., Borlaug B.A. A simple, evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction. Circulation. 2018;138:861&#x2013;870. doi: 10.1161/circulationaha.118.034646.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/circulationaha.118.034646</ArticleId><ArticleId IdType="pmc">PMC6202181</ArticleId><ArticleId IdType="pubmed">29792299</ArticleId></ArticleIdList></Reference><Reference><Citation>Pieske B., Tsch&#xf6;pe C., Boer R.A., et al. How to diagnose heart failure with preserved ejection fraction: the HFA&#x2013;PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) Eur J Heart Fail. 2020;22:391&#x2013;412. doi: 10.1002/ejhf.1741.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ejhf.1741</ArticleId><ArticleId IdType="pubmed">32133741</ArticleId></ArticleIdList></Reference><Reference><Citation>Rivera-Toquica A., Echeverr&#xed;a L.E., Arias-Barrera C.A., et al. Adherence to treatment guidelines in ambulatory heart failure patients with reduced ejection fraction in a Latin-American country: observational study of the Colombian Heart Failure Registry (RECOLFACA) Cardiology. 2024;149:1&#x2013;9. doi: 10.1159/000535916.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000535916</ArticleId><ArticleId IdType="pmc">PMC11152016</ArticleId><ArticleId IdType="pubmed">38359813</ArticleId></ArticleIdList></Reference><Reference><Citation>Carnicelli A.P., Li Z., Greiner M.A., et al. Sacubitril/valsartan adherence and postdischarge outcomes among patients hospitalized for heart failure with reduced ejection fraction. JACC Heart Fail. 2021;9:876&#x2013;886. doi: 10.1016/j.jchf.2021.06.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jchf.2021.06.018</ArticleId><ArticleId IdType="pubmed">34509408</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40731889</PMID><DateCompleted><Year>2025</Year><Month>07</Month><Day>30</Day></DateCompleted><DateRevised><Year>2025</Year><Month>08</Month><Day>01</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1648-9144</ISSN><JournalIssue CitedMedium="Internet"><Volume>61</Volume><Issue>7</Issue><PubDate><Year>2025</Year><Month>Jul</Month><Day>11</Day></PubDate></JournalIssue><Title>Medicina (Kaunas, Lithuania)</Title><ISOAbbreviation>Medicina (Kaunas)</ISOAbbreviation></Journal><ArticleTitle>Echocardiographic Evidence of Left Ventricular Dysfunction in COPD: Relationship with Disease Severity.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1260</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/medicina61071260</ELocationID><Abstract><AbstractText><i>Background and Objectives</i>: Chronic obstructive pulmonary disease (COPD) significantly impacts morbidity and mortality, often due to cardiovascular comorbidities that are frequently overlooked. This study examines the prevalence of left ventricular dysfunction in COPD patients and its association with disease severity, hypoxemia, and exacerbation frequency. <i>Materials and Methods</i>: COPD patients (<i>n</i> = 114) were evaluated using spirometry and transthoracic echocardiography. Statistical analysis utilized Student's <i>t</i>-test, chi-square test, and multivariable logistic regression with 1000 bootstrapping iterations, considering <i>p</i> &lt; 0.05 as significant differences. <i>Results</i>: Most patients were classified as Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage III (40.4%) and stage IV (44.7%). Diastolic dysfunction was present in 67.5% of the patients (Grade 1: 53.5%, Grade 2: 13. 2%, Grade 3: 0.0.9%), while 18.4% exhibited systolic dysfunction (LVEF &lt; 50%). The prevalence of diastolic dysfunction increased significantly, from 41.2% in GOLD stage II to 92. 2% in GOLD stage IV (<i>p</i> &lt; 0.001). Independent predictors of diastolic dysfunction included GOLD stage IV (Odds Ratio [OR]: 5.39, 95% Confidence Interval [CI]: 1. 42-23.35, <i>p</i> &lt; 0.001), older age (OR: 1.02 per year, 95% CI: 1.01-1.04, <i>p</i> = 0.025), and a history of frequent exacerbations (OR: 1.09 per event, 95% CI: 1.01-1.17, <i>p</i> = 0.039). Systolic dysfunction correlated significantly with GOLD stage IV (OR: 1.83, <i>p</i> = 0.014), oxygen saturation below 88% (OR: 3.12, <i>p</i> = 0.036), and having three or more exacerbations (OR: 4.18, <i>p</i> = 0.008). <i>Conclusions</i>: This study reveals a high prevalence of left ventricular dysfunction in COPD patients, linked to disease severity, hypoxemia, and frequent exacerbations. It supports incorporating complementary echocardiographic assessments in managing advanced COPD, especially for those with frequent exacerbations or oxygen desaturation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bhattacharjee</LastName><ForeName>Rounak</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Medicine, Lumding Civil Hospital, Lumding 782447, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deb</LastName><ForeName>Tanushree</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Medicine, Pragjyotishpur Medical College and Hospital, Guwahati 781009, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roy</LastName><ForeName>Prosenjit</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Medicine, Nalbari Medical College and Hospital, Nalbari 781351, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bhattacharjee</LastName><ForeName>Prithwiraj</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Medicine, Silchar Medical College and Hospital, Silchar 788014, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosas</LastName><ForeName>Israel Maldonado</ForeName><Initials>IM</Initials><Identifier Source="ORCID">0000-0003-2765-6176</Identifier><AffiliationInfo><Affiliation>Citmer Reproductive Medicine, Mexico City 11520, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roychoudhury</LastName><ForeName>Shubhadeep</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-4174-1852</Identifier><AffiliationInfo><Affiliation>Department of Life Science and Bioinformatics, Assam University, Silchar 788011, India.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Medicina (Kaunas)</MedlineTA><NlmUniqueID>9425208</NlmUniqueID><ISSNLinking>1010-660X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029424" MajorTopicYN="Y">Pulmonary Disease, Chronic Obstructive</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018487" MajorTopicYN="Y">Ventricular Dysfunction, Left</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004452" MajorTopicYN="Y">Echocardiography</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013147" MajorTopicYN="N">Spirometry</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016015" MajorTopicYN="N">Logistic Models</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">GOLD stage</Keyword><Keyword MajorTopicYN="N">chronic obstructive pulmonary disease</Keyword><Keyword MajorTopicYN="N">diastolic dysfunction</Keyword><Keyword MajorTopicYN="N">exacerbation</Keyword><Keyword MajorTopicYN="N">hypoxemia</Keyword><Keyword MajorTopicYN="N">systolic dysfunction</Keyword></KeywordList><CoiStatement>The authors have no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>5</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>6</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>30</Day><Hour>6</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>30</Day><Hour>6</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>30</Day><Hour>1</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>7</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40731889</ArticleId><ArticleId IdType="pmc">PMC12301051</ArticleId><ArticleId IdType="doi">10.3390/medicina61071260</ArticleId><ArticleId IdType="pii">medicina61071260</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization (WHO) The Top 10 Causes of Death. WHO; Geneva, Switzerland: 2025.</Citation></Reference><Reference><Citation>Agust&#xed; A., Celli B.R., Criner G.J., Halpin D., Anzueto A., Barnes P., Bourbeau J., Han M.K., Martinez F.J., Montes de Oca M., et al. Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary. Eur. Respir. J. 2023;61:2300239. doi: 10.1183/13993003.00239-2023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.00239-2023</ArticleId><ArticleId IdType="pmc">PMC10066569</ArticleId><ArticleId IdType="pubmed">36858443</ArticleId></ArticleIdList></Reference><Reference><Citation>Waschki B., Watz H., Holz O., Magnussen H., Olejnicka B., Welte T., Rabe K.F., Janciauskiene S. Plasminogen Activator Inhibitor-1 Is Elevated in Patients with COPD Independent of Metabolic and Cardiovascular Function. Taylor &amp; Francis; Abingdon, UK: 2017. pp. 981&#x2013;987.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5367764</ArticleId><ArticleId IdType="pubmed">28356730</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnes P.J., Celli B.R. Systemic Manifestations and Comorbidities of COPD. Volume 33. European Respiratory Society; Lausanne, Switzerland: 2009. pp. 1165&#x2013;1185.</Citation><ArticleIdList><ArticleId IdType="pubmed">19407051</ArticleId></ArticleIdList></Reference><Reference><Citation>Kibbler J., Wade C., Mussell G., Ripley D.P., Bourke S.C., Steer J. Systematic Review and Meta-Analysis of Prevalence of Undiagnosed Major Cardiac Comorbidities in COPD. ERJ Open Res. 2023;9:548&#x2013;2023. doi: 10.1183/23120541.00548-2023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/23120541.00548-2023</ArticleId><ArticleId IdType="pmc">PMC10680032</ArticleId><ArticleId IdType="pubmed">38020568</ArticleId></ArticleIdList></Reference><Reference><Citation>MacNee W., Maclay J., McAllister D. Cardiovascular Injury and Repair in Chronic Obstructive Pulmonary Disease. Proc. Am. Thorac. Soc. 2008;5:824&#x2013;833. doi: 10.1513/pats.200807-071TH.</Citation><ArticleIdList><ArticleId IdType="doi">10.1513/pats.200807-071TH</ArticleId><ArticleId IdType="pmc">PMC2643206</ArticleId><ArticleId IdType="pubmed">19017737</ArticleId></ArticleIdList></Reference><Reference><Citation>Goudis C.A. Chronic Obstructive Pulmonary Disease and Atrial Fibrillation: An Unknown Relationship. J. Cardiol. 2017;69:699&#x2013;705. doi: 10.1016/j.jjcc.2016.12.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jjcc.2016.12.013</ArticleId><ArticleId IdType="pubmed">28188041</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhatt S.P., Dransfield M.T. Chronic Obstructive Pulmonary Disease and Cardiovascular Disease. Volume 162. Elsevier; Amsterdam, The Netherlands: 2013. pp. 237&#x2013;251.</Citation><ArticleIdList><ArticleId IdType="pubmed">23727296</ArticleId></ArticleIdList></Reference><Reference><Citation>Fabbri L.M., Luppi F., Begh&#xe9; B., Rabe K.F. Complex Chronic Comorbidities of COPD. Volume 31. European Respiratory Society; Lausanne, Switzerland: 2007. pp. 204&#x2013;212.</Citation><ArticleIdList><ArticleId IdType="pubmed">18166598</ArticleId></ArticleIdList></Reference><Reference><Citation>Sin D.D., Man S.P. Why Are Patients with Chronic Obstructive Pulmonary Disease at Increased Risk of Cardiovascular Diseases? The Potential Role of Systemic Inflammation in Chronic Obstructive Pulmonary Disease. Volume 107. Lippincott Williams &amp; Wilkins; Philadelphia, PA, USA: 2003. pp. 1514&#x2013;1519.</Citation><ArticleIdList><ArticleId IdType="pubmed">12654609</ArticleId></ArticleIdList></Reference><Reference><Citation>Hawkins N.M., Petrie M.C., Jhund P.S., Chalmers G.W., Dunn F.G., McMurray J.J. Heart Failure and Chronic Obstructive Pulmonary Disease: Diagnostic Pitfalls and Epidemiology. Eur. J. Heart Fail. 2009;11:130&#x2013;139. doi: 10.1093/eurjhf/hfn013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurjhf/hfn013</ArticleId><ArticleId IdType="pmc">PMC2639415</ArticleId><ArticleId IdType="pubmed">19168510</ArticleId></ArticleIdList></Reference><Reference><Citation>Vogelmeier C.F., Criner G.J., Martinez F.J., Anzueto A., Barnes P.J., Bourbeau J., Celli B.R., Chen R., Decramer M., Fabbri L.M., et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. Am. J. Respir. Crit. Care Med. 2017;195:557&#x2013;582. doi: 10.1164/rccm.201701-0218PP.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.201701-0218PP</ArticleId><ArticleId IdType="pubmed">28128970</ArticleId></ArticleIdList></Reference><Reference><Citation>Celli B.R., Decramer M., Wedzicha J.A., Wilson K.C., Agust&#xed; A., Criner G.J., MacNee W., Make B.J., Rennard S.I., Stockley R.A., et al. An Official American Thoracic Society/European Respiratory Society Statement: Research Questions in COPD. Eur. Respir. J. 2015;45:879&#x2013;905. doi: 10.1183/09031936.00009015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/09031936.00009015</ArticleId><ArticleId IdType="pubmed">25829431</ArticleId></ArticleIdList></Reference><Reference><Citation>Houben-Wilke S., J&#xf6;rres R.A., Bals R., Franssen F.M.E., Gl&#xe4;ser S., Holle R., Karch A., Koch A., Magnussen H., Obst A., et al. Peripheral Artery Disease and Its Clinical Relevance in Patients with Chronic Obstructive Pulmonary Disease in the COPD and Systemic Consequences-Comorbidities Network Study. Am. J. Respir. Crit. Care Med. 2017;195:189&#x2013;197. doi: 10.1164/rccm.201602-0354OC.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.201602-0354OC</ArticleId><ArticleId IdType="pubmed">27532739</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xfc;llerova H., Agusti A., Erqou S., Mapel D.W. Cardiovascular Comorbidity in COPD: Systematic Literature Review. Chest. 2013;144:1163&#x2013;1178. doi: 10.1378/chest.12-2847.</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.12-2847</ArticleId><ArticleId IdType="pubmed">23722528</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaidi S.A.J., Ghafoor A., Kim J., Abbas Z., Lee S.W. HeartEnsembleNet: An Innovative Hybrid Ensemble Learning Approach for Cardiovascular Risk Prediction. Healthcare. 2025;13:507. doi: 10.3390/healthcare13050507.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/healthcare13050507</ArticleId><ArticleId IdType="pmc">PMC11898877</ArticleId><ArticleId IdType="pubmed">40077069</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller M.R., Hankinson J., Brusasco V., Burgos F., Casaburi R., Coates A., Crapo R., Enright P., van der Grinten C.P.M., Gustafsson P., et al. Standardisation of Spirometry. Eur. Respir. J. 2005;26:319&#x2013;338. doi: 10.1183/09031936.05.00034805.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/09031936.05.00034805</ArticleId><ArticleId IdType="pubmed">16055882</ArticleId></ArticleIdList></Reference><Reference><Citation>Lang R.M., Badano L.P., Mor-Avi V., Afilalo J., Armstrong A., Ernande L., Flachskampf F.A., Foster E., Goldstein S.A., Kuznetsova T., et al. Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J. Am. Soc. Echocardiogr. 2015;28:233&#x2013;271. doi: 10.1016/j.echo.2014.10.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.echo.2014.10.003</ArticleId><ArticleId IdType="pubmed">25559473</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagueh S.F., Smiseth O.A., Appleton C.P., Byrd B.F., Dokainish H., Edvardsen T., Flachskampf F.A., Gillebert T.C., Klein A.L., Lancellotti P., et al. Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J. Am. Soc. Echocardiogr. 2016;29:277&#x2013;314. doi: 10.1016/j.echo.2016.01.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.echo.2016.01.011</ArticleId><ArticleId IdType="pubmed">27037982</ArticleId></ArticleIdList></Reference><Reference><Citation>Efron B., Tibshirani R.J. An Introduction to the Bootstrap. Chapman and Hall/CRC; Boca Raton, FL, USA: 1994.</Citation></Reference><Reference><Citation>Benjamini Y., Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. J. R. Stat. Soc. Ser. B Stat. Methodol. 1995;57:289&#x2013;300. doi: 10.1111/j.2517-6161.1995.tb02031.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.2517-6161.1995.tb02031.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Freixa X., Portillo K., Par&#xe9; C., Garcia-Aymerich J., Gomez F.P., Benet M., Roca J., Farrero E., Ferrer J., Fernandez-Palomeque C. Echocardiographic Abnormalities in Patients with COPD at Their First Hospital Admission. Eur. Respir. J. 2013;41:784&#x2013;791. doi: 10.1183/09031936.00222511.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/09031936.00222511</ArticleId><ArticleId IdType="pubmed">23018914</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Y., Huang Y., Feng Y., Zhang J., Bai L., Huang W., Li M. Impact of Chronic Obstructive Pulmonary Diseases on Left Ventricular Diastolic Function in Hospitalized Elderly Patients. CIA. 2014;10:81&#x2013;87. doi: 10.2147/CIA.S71878.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/CIA.S71878</ArticleId><ArticleId IdType="pmc">PMC4279668</ArticleId><ArticleId IdType="pubmed">25565790</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabit R., Bolton C.E., Fraser A.G., Edwards J.M., Edwards P.H., Ionescu A.A., Cockcroft J.R., Shale D.J. Sub-Clinical Left and Right Ventricular Dysfunction in Patients with COPD. Respir. Med. 2010;104:1171&#x2013;1178. doi: 10.1016/j.rmed.2010.01.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rmed.2010.01.020</ArticleId><ArticleId IdType="pubmed">20185285</ArticleId></ArticleIdList></Reference><Reference><Citation>Funk G.-C., Lang I., Schenk P., Valipour A., Hartl S., Burghuber O.C. Left Ventricular Diastolic Dysfunction in Patients with COPD in the Presence and Absence of Elevated Pulmonary Arterial Pressure. Chest. 2008;133:1354&#x2013;1359. doi: 10.1378/chest.07-2685.</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.07-2685</ArticleId><ArticleId IdType="pubmed">18339780</ArticleId></ArticleIdList></Reference><Reference><Citation>Vonk-Noordegraaf A., Marcus J.T., Holverda S., Roseboom B., Postmus P.E. Early Changes of Cardiac Structure and Function in COPD Patients with Mild Hypoxemia. Chest. 2005;127:1898&#x2013;1903. doi: 10.1378/chest.127.6.1898.</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.127.6.1898</ArticleId><ArticleId IdType="pubmed">15947300</ArticleId></ArticleIdList></Reference><Reference><Citation>Elwing J., Panos R.J. Pulmonary Hypertension Associated with COPD. Int. J. Chronic Obstr. Pulm. Dis. 2008;3:55&#x2013;70. doi: 10.2147/copd.s1170.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/copd.s1170</ArticleId><ArticleId IdType="pmc">PMC2528217</ArticleId><ArticleId IdType="pubmed">18488429</ArticleId></ArticleIdList></Reference><Reference><Citation>Ambrose J.A., Barua R.S. The Pathophysiology of Cigarette Smoking and Cardiovascular Disease: An Update. J. Am. Coll. Cardiol. 2004;43:1731&#x2013;1737. doi: 10.1016/j.jacc.2003.12.047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2003.12.047</ArticleId><ArticleId IdType="pubmed">15145091</ArticleId></ArticleIdList></Reference><Reference><Citation>Gan W.Q., Man S.F.P., Senthilselvan A., Sin D.D. Association between Chronic Obstructive Pulmonary Disease and Systemic Inflammation: A Systematic Review and a Meta-Analysis. Thorax. 2004;59:574&#x2013;580. doi: 10.1136/thx.2003.019588.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/thx.2003.019588</ArticleId><ArticleId IdType="pmc">PMC1747070</ArticleId><ArticleId IdType="pubmed">15223864</ArticleId></ArticleIdList></Reference><Reference><Citation>Paulus W.J., Tsch&#xf6;pe C. A Novel Paradigm for Heart Failure with Preserved Ejection Fraction: Comorbidities Drive Myocardial Dysfunction and Remodeling through Coronary Microvascular Endothelial Inflammation. J. Am. Coll. Cardiol. 2013;62:263&#x2013;271. doi: 10.1016/j.jacc.2013.02.092.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2013.02.092</ArticleId><ArticleId IdType="pubmed">23684677</ArticleId></ArticleIdList></Reference><Reference><Citation>Watz H., Waschki B., Meyer T., Kretschmar G., Kirsten A., Claussen M., Magnussen H. Decreasing Cardiac Chamber Sizes and Associated Heart Dysfunction in COPD. Chest. 2010;138:32&#x2013;38. doi: 10.1378/chest.09-2810.</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.09-2810</ArticleId><ArticleId IdType="pubmed">20190002</ArticleId></ArticleIdList></Reference><Reference><Citation>J&#xf6;rgensen K., M&#xfc;ller M.F., Nel J., Upton R.N., Houltz E., Ricksten S.-E. Reduced Intrathoracic Blood Volume and Left and Right Ventricular Dimensions in Patients with Severe Emphysema. Chest. 2007;131:1050&#x2013;1057. doi: 10.1378/chest.06-2245.</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.06-2245</ArticleId><ArticleId IdType="pubmed">17426209</ArticleId></ArticleIdList></Reference><Reference><Citation>Goudis C.A., Konstantinidis A.K., Ntalas I.V., Korantzopoulos P. Electrocardiographic Abnormalities and Cardiac Arrhythmias in Chronic Obstructive Pulmonary Disease. Int. J. Cardiol. 2015;199:264&#x2013;273. doi: 10.1016/j.ijcard.2015.06.096.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijcard.2015.06.096</ArticleId><ArticleId IdType="pubmed">26218181</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang C.L., Robinson S.C., Mills G.D., Sullivan G.D., Karalus N.C., McLachlan J.D., Hancox R.J. Biochemical Markers of Cardiac Dysfunction Predict Mortality in Acute Exacerbations of COPD. Thorax. 2011;66:764&#x2013;768. doi: 10.1136/thx.2010.155333.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/thx.2010.155333</ArticleId><ArticleId IdType="pubmed">21474497</ArticleId></ArticleIdList></Reference><Reference><Citation>Kunisaki K.M., Dransfield M.T., Anderson J.A., Brook R.D., Calverley P.M.A., Celli B.R., Crim C., Hartley B.F., Martinez F.J., Newby D.E., et al. Exacerbations of Chronic Obstructive Pulmonary Disease and Cardiac Events. A Post Hoc Cohort Analysis from the SUMMIT Randomized Clinical Trial. Am. J. Respir. Crit. Care Med. 2018;198:51&#x2013;57. doi: 10.1164/rccm.201711-2239OC.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.201711-2239OC</ArticleId><ArticleId IdType="pmc">PMC6913068</ArticleId><ArticleId IdType="pubmed">29442524</ArticleId></ArticleIdList></Reference><Reference><Citation>Ergan B., Nava S. Long-Term Oxygen Therapy in COPD Patients Who Do Not Meet the Actual Recommendations. COPD J. Chronic Obstr. Pulm. Dis. 2017;14:351&#x2013;366. doi: 10.1080/15412555.2017.1319918.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15412555.2017.1319918</ArticleId><ArticleId IdType="pubmed">28506089</ArticleId></ArticleIdList></Reference><Reference><Citation>Robertson N.M., Centner C.S., Siddharthan T. Integrating Artificial Intelligence in the Diagnosis of COPD Globally: A Way Forward. Chronic Obstr. Pulm. Dis. J. COPD Found. 2023;11:114. doi: 10.15326/jcopdf.2023.0449.</Citation><ArticleIdList><ArticleId IdType="doi">10.15326/jcopdf.2023.0449</ArticleId><ArticleId IdType="pmc">PMC10913925</ArticleId><ArticleId IdType="pubmed">37828644</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">40730941</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>01</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2253</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Jul</Month><Day>29</Day></PubDate></JournalIssue><Title>BMC anesthesiology</Title><ISOAbbreviation>BMC Anesthesiol</ISOAbbreviation></Journal><ArticleTitle>Patterns of left and right ventricular dysfunction and their clinical outcomes in septic patients.</ArticleTitle><Pagination><StartPage>364</StartPage><MedlinePgn>364</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">364</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12871-025-03233-5</ELocationID><Abstract><AbstractText Label="BACKGROUND">To investigate the various types of left ventricular (LV) and right ventricular (RV) dysfunction and their association with clinical outcomes in septic patients.</AbstractText><AbstractText Label="METHODS">We retrospectively reviewed a cohort of sepsis and septic shock patients admitted to a tertiary hospital intensive care unit (ICU). Left ventricular dysfunction was determined by left ventricular ejection fraction (LVEF). Right ventricular systolic dysfunction (RVSD) was determined by tricuspid annular plane systolic excursion (TAPSE), fractional area change (FAC), or RV S&#x2019; velocity. Cardiac function was categorized into five types: (1) normal cardiac function (LVEF&#x2009;&gt;&#x2009;50% but &#x2264;&#x2009;70%, TAPSE&#x2009;&#x2265;&#x2009;17&#xa0;mm, RV FAC&#x2009;&#x2265;&#x2009;35%, and RV S&#x2019; &#x2265;9.5&#xa0;cm/sec); (2) biventricular dysfunction (LVEF&#x2009;&#x2264;&#x2009;50%, TAPSE&#x2009;&lt;&#x2009;17&#xa0;mm or RV FAC&#x2009;&lt;&#x2009;35% or RV S&#x2019; &lt; 9.5&#xa0;cm/sec); (3) isolated LV dysfunction (LVEF&#x2009;&#x2264;&#x2009;50%, TAPSE&#x2009;&#x2265;&#x2009;17&#xa0;mm, RV FAC&#x2009;&#x2265;&#x2009;35%, and RV S&#x2019; &#x2265;9.5&#xa0;cm/sec); (4) isolated RV dysfunction (LVEF&#x2009;&gt;&#x2009;50%, TAPSE&#x2009;&lt;&#x2009;17&#xa0;mm or RV FAC&#x2009;&lt;&#x2009;35% or RV S&#x2019; &lt; 9.5&#xa0;cm/sec); and (5) hyperdynamic LV function (LVEF&#x2009;&gt;&#x2009;70%, TAPSE&#x2009;&#x2265;&#x2009;17&#xa0;mm, RV FAC&#x2009;&#x2265;&#x2009;35%, and RV S&#x2019; &#x2265;9.5&#xa0;cm/sec). The primary outcome was 30-day mortality.</AbstractText><AbstractText Label="RESULTS">A cohort of 702 septic patients was analyzed. Patients with biventricular dysfunction (<i>n</i>&#x2009;=&#x2009;113) and isolated RV dysfunction (<i>n</i>&#x2009;=&#x2009;117) exhibited mortality rates of 34.5% and 36.7%, respectively. In comparison, lower mortality rates were observed in patients with isolated LV dysfunction (<i>n</i>&#x2009;=&#x2009;72), hyperdynamic LV function (<i>n</i>&#x2009;=&#x2009;86), and normal cardiac function (<i>n</i>&#x2009;=&#x2009;314), with rates of 15.3%, 15.1% and 9.2%, respectively. Cox regression analysis confirmed that biventricular dysfunction (hazard ratio [HR] 2.312, 95% confidence interval [CI] 1.291&#x2013;4.139, <i>p&#x2009;=</i>&#x2009;0.005) and isolated RV dysfunction (HR 2.655, 95% CI 1.455&#x2013;4.843, <i>p&#x2009;=</i>&#x2009;0.001) were independently associated with 30-day mortality. Neither isolated LV dysfunction (HR 1.171, 95% CI 0.463&#x2013;2.960, <i>p&#x2009;=</i>&#x2009;0.739) nor hyperdynamic LV function (HR 2.153, 95% CI 0.971&#x2013;4.773, <i>p&#x2009;=</i>&#x2009;0.059) were independently associated with 30-day mortality.</AbstractText><AbstractText Label="CONCLUSIONS">Septic patients with biventricular dysfunction or isolated RV dysfunction had significantly higher 30-day mortality rates compared to those with normal cardiac function. Notably, hyperdynamic LV function also showed a trend toward higher 30-day mortality than normal cardiac function, although this association did not reach statistical significance. In contrast, isolated LV dysfunction was not associated with 30-day mortality.</AbstractText><AbstractText Label="SUPPLEMENTARY INFORMATION">The online version contains supplementary material available at 10.1186/s12871-025-03233-5.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Hongmin</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Health Care, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 1# Shuai Fu Yuan, Dong Cheng District, Beijing, 100730, China. ozohom@163.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Beijun</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Critical Care Medicine, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Ye</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Alabama at Birmingham Heersink School of Medicine, Alabama, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Qing</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xiaoting</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>2022-CCUSG-A-01</GrantID><Agency>Beijing Critical Care Ultrasound Research Association</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Anesthesiol</MedlineTA><NlmUniqueID>100968535</NlmUniqueID><ISSNLinking>1471-2253</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Prognosis</Keyword><Keyword MajorTopicYN="N">Sepsis</Keyword><Keyword MajorTopicYN="N">Ventricular dysfunction</Keyword></KeywordList><CoiStatement>Declarations. Ethics approval and consent to participate: This study was approved by the ethics committee of Peking Union Medical College Hospital, Beijing, China (Approval No. ZS-2166). Written informed consent for the use of patient&#x2019;s medical record was was signed by the patients or their surrogates. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>2</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>6</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>30</Day><Hour>0</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>30</Day><Hour>0</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>29</Day><Hour>23</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>7</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40730941</ArticleId><ArticleId IdType="pmc">PMC12309113</ArticleId><ArticleId IdType="doi">10.1186/s12871-025-03233-5</ArticleId><ArticleId IdType="pii">10.1186/s12871-025-03233-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cecconi M, Evans L, Levy M, Rhodes A. Sepsis and septic shock. Lancet. 2018;392(10141):75&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pubmed">29937192</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaieski DF, Edwards JM, Kallan MJ, Carr BG. Benchmarking the incidence and mortality of severe sepsis in the united States. Crit Care Med. 2013;41(5):1167&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">23442987</ArticleId></ArticleIdList></Reference><Reference><Citation>Vieillard-Baron A, Caille V, Charron C, Belliard G, Page B, Jardin F. Actual incidence of global left ventricular hypokinesia in adult septic shock. Crit Care Med. 2008;36(6):1701&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">18496368</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehrman RR, Sullivan AN, Favot MJ, et al. Pathophysiology, echocardiographic evaluation, biomarker findings, and prognostic implications of septic cardiomyopathy: a review of the literature. Crit Care. 2018;22:112.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5934857</ArticleId><ArticleId IdType="pubmed">29724231</ArticleId></ArticleIdList></Reference><Reference><Citation>Pulido JN, Afessa B, Masaki M, et al. Clinical spectrum, frequency, and significance of myocardial dysfunction in severe sepsis and septic shock. Mayo Clin Proc. 2012;87(7):620&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3538477</ArticleId><ArticleId IdType="pubmed">22683055</ArticleId></ArticleIdList></Reference><Reference><Citation>Geri G, Vignon P, Aubry A, et al. Cardiovascular clusters in septic shock combining clinical and echocardiographic parameters: a post hoc analysis. Intensive Care Med. 2019;45(5):657&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">30888443</ArticleId></ArticleIdList></Reference><Reference><Citation>Vallabhajosyula S, Kumar M, Pandompatam G, et al. Prognostic impact of isolated right ventricular dysfunction in sepsis and septic shock: an 8-year historical cohort study. Ann Intensive Care. 2017;7(1):94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5589718</ArticleId><ArticleId IdType="pubmed">28884343</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollenberg SM, Singer M. Pathophysiology of sepsis-induced cardiomyopathy. Nat Rev Cardiol. 2021;18(6):424&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">33473203</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H, Zhang D, Wang X, et al. Prognostic implication of a novel right ventricular injury score in septic patients. ESC Heart Fail. 2023;10(2):1205&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10053157</ArticleId><ArticleId IdType="pubmed">36683014</ArticleId></ArticleIdList></Reference><Reference><Citation>Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for Sepsis and septic shock (Sepsis-3). JAMA. 2016;315(8):801&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4968574</ArticleId><ArticleId IdType="pubmed">26903338</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaidi A, Knight DS, Augustine DX, et al. Echocardiographic assessment of the right heart in adults: a practical guideline from the British society of echocardiography. Echo Res Pract. 2020;7(1):G19&#x2013;1941.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7077526</ArticleId><ArticleId IdType="pubmed">32105053</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanfilippo F, Huang S, Herpain A, et al. The PRICES statement: an ESICM expert consensus on methodology for conducting and reporting critical care echocardiography research studies. Intensive Care Med. 2021;47(1):1&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">33275163</ArticleId></ArticleIdList></Reference><Reference><Citation>VanDyck TJ, Pinsky MR. Hemodynamic monitoring in cardiogenic shock. Curr Opin Crit Care. 2021;27:454&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8243821</ArticleId><ArticleId IdType="pubmed">33967209</ArticleId></ArticleIdList></Reference><Reference><Citation>Jardin F, Dubourg O, Bourdarias JP. Echocardiographic pattern of acute Cor pulmonale. Chest. 1997;111(1):209&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">8996019</ArticleId></ArticleIdList></Reference><Reference><Citation>Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, Flachskampf FA, Foster E, Goldstein SA, Kuznetsova T, Lancellotti P, Muraru D, Picard MH, Rietzschel ER, Rudski L, Spencer KT, Tsang W, Voigt JU. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American society of echocardiography and the European association of cardiovascular imaging. Eur Heart J Cardiovasc Imaging. 2015;16:233&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">25712077</ArticleId></ArticleIdList></Reference><Reference><Citation>Beaubien-Souligny W, Rola P, Haycock K, Bouchard J, Lamarche Y, Spiegel R, Denault AY. Quantifying systemic congestion with Point-Of-Care ultrasound: development of the venous excess ultrasound grading system. Ultrasound J. 2020;12:16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7142196</ArticleId><ArticleId IdType="pubmed">32270297</ArticleId></ArticleIdList></Reference><Reference><Citation>Spiegel R, Teeter W, Sullivan S, Tupchong K, Mohammed N, Sutherland M, Leibner E, Rola P, Galvagno SM Jr, Murthi SB. The use of venous doppler to predict adverse kidney events in a general ICU cohort. Crit Care. 2020;24:615.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7574322</ArticleId><ArticleId IdType="pubmed">33076961</ArticleId></ArticleIdList></Reference><Reference><Citation>Chockalingam A, Mehra A, Dorairajan S, et al. Acute left ventricular dysfunction in the critically ill. Chest. 2010;138:198&#x2013;207.</Citation><ArticleIdList><ArticleId IdType="pubmed">20605820</ArticleId></ArticleIdList></Reference><Reference><Citation>Park JH, Kang SJ, Song JK, et al. Left ventricular apical ballooning due to severe physical stress in patients admitted to the medical ICU. Chest. 2005;128:296&#x2013;302.</Citation><ArticleIdList><ArticleId IdType="pubmed">16002949</ArticleId></ArticleIdList></Reference><Reference><Citation>Mekontso Dessap A, Boissier F, Charron C, et al. Acute Cor pulmonale during protective ventilation for acute respiratory distress syndrome: prevalence, predictors, and clinical impact. Intensive Care Med. 2016;42:862&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">26650055</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanspa MJ, Cirulis MM, Wiley BM, et al. Right ventricular dysfunction in early Sepsis and septic shock. Chest. 2021;159(3):1055&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7965651</ArticleId><ArticleId IdType="pubmed">33068615</ArticleId></ArticleIdList></Reference><Reference><Citation>Vallabhajosyula S, Shankar A, Vojjini R, et al. Impact of right ventricular dysfunction on Short-term and Long-term mortality in sepsis: A Meta-analysis of 1,373 patients. Chest. 2021;159(6):2254&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8579312</ArticleId><ArticleId IdType="pubmed">33359215</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H, Huang W, Zhang Q, et al. Prevalence and prognostic value of various types of right ventricular dysfunction in mechanically ventilated septic patients. Ann Intensive Care. 2021;11:108.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8276910</ArticleId><ArticleId IdType="pubmed">34255224</ArticleId></ArticleIdList></Reference><Reference><Citation>Dugar S, Sato R, Chawla S, et al. Is left ventricular systolic dysfunction associated with increased mortality among patients with Sepsis and septic shock. Chest. 2023;163:1437&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pubmed">36646415</ArticleId></ArticleIdList></Reference><Reference><Citation>Vieillard-Baron A, Cecconi M. Understanding cardiac failure in sepsis. Intensive Care Med. 2014;40(10):1560&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">24966063</ArticleId></ArticleIdList></Reference><Reference><Citation>Oberhoffer M, Karzai W, Meier-Hellmann A, B&#xf6;gel D, Fassbinder J, Reinhart K. Sensitivity and specificity of various markers of inflammation for the prediction of tumor necrosis factor-alpha and interleukin-6 in patients with sepsis. Crit Care Med. 1999;27(9):1814&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">10507603</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincent JL, Donadello K, Schmit X. Biomarkers in the critically ill patient: C-reactive protein. Crit Care Clin. 2011;27(2):241&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">21440199</ArticleId></ArticleIdList></Reference><Reference><Citation>Templin C, Ghadri JR, Diekmann J, et al. Clinical features and outcomes of Takotsubo (Stress) cardiomyopathy. N Engl J Med. 2015;373:929&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pubmed">26332547</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40741139</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>02</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2090-8016</ISSN><JournalIssue CitedMedium="Print"><Volume>2025</Volume><PubDate><Year>2025</Year></PubDate></JournalIssue><Title>Cardiology research and practice</Title><ISOAbbreviation>Cardiol Res Pract</ISOAbbreviation></Journal><ArticleTitle>Exercise-Based Cardiac Rehabilitation Improves Left Ventricular Dysfunction, Mitophagy, and Oxidative Stress Postmyocardial Infarction.</ArticleTitle><Pagination><StartPage>7778063</StartPage><MedlinePgn>7778063</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">7778063</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1155/crp/7778063</ELocationID><Abstract><AbstractText><b>Aim:</b> Left ventricular dysfunction, disturbed mitophagy, and persistent oxidative stress after myocardial infarction (MI) are critical drivers of myocardial injury and cardiac remodeling. Exercise-based cardiac rehabilitation (CR) is a cornerstone of post-MI treatment and management, yet its mechanistic effects on myocardial repair remain incompletely elucidated. This study aimed to the effect of exercise-based CR on the left ventricular dysfunction, mitophagy, and oxidative stress post-MI. <b>Methods:</b> Mendelian randomization analysis elucidated causal relationship between six physical activities and MI. Subsequently, 70 MI patients were randomized to control or exercise-based CR groups (moderate-to-vigorous physical activity intensity, 3&#x2009;days/week, 10-50&#x2009;min/day, 12&#x2009;weeks); left ventricular function, cardiopulmonary function, and SF-36 quality of life scale were assessed pre-/postintervention using standardized protocols. Additionally, 21 rats were allocated to Sham, MI, or MI&#x2009;+&#x2009;treadmill running groups (high-intensity interval exercise training, 5&#x2009;days/week, 30-50&#x2009;min/day, 10-25&#x2009;m/min, 4&#x2009;weeks); left ventricular function, mitophagy, and oxidative stress were detected postintervention. <b>Results:</b> Genetically predicted moderate-to-vigorous intensity physical activity was significantly associated with lower risk of MI (IVW OR&#x2009;=&#x2009;0.66, 95% CI: 0.54-0.81), with no causal links for other activities. Critically, clinical and animal studies demonstrated that exercise-based CR improved left ventricular systolic function (LVEF) after MI. Four-week exercise in MI rats enhanced mitophagy levels (LC3, FUNDC1, PINK1, and Parkin) and attenuated oxidative injury (MDA, GSH, SOD2, and GPX4) post-MI. Additionally, exercise-based CR also improved cardiopulmonary function (peak VO<sub>2</sub>/kg, peakVO<sub>2</sub>/pred%, and MET) in patients with MI and ameliorated mitochondrial damage in MI rats. However, GLS, secondary cardiopulmonary parameters (Wmax, HRR1min, peakVO<sub>2</sub>/HR, and peakVO<sub>2</sub>/HRpred%), and SF-36 (PCS and MCS) showed no significant changes, which may be associated with shorter duration of exercise intervention. <b>Conclusion:</b> Exercise-based CR significantly ameliorated left ventricular dysfunction, enhanced mitophagy levels, and attenuated oxidative stress post-MI, establishing its role in critical pathological mechanisms. Future studies should validate long-term sustainability of exercise-based CR and explore the interaction mechanism between mitophagy and oxidative stress in cardiac remodeling, providing personalized and precise exercise protocols for people at high risk of exercise.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 Changyong Wu et al. Cardiology Research and Practice published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Changyong</ForeName><Initials>C</Initials><Identifier Source="ORCID">0009-0003-8309-5083</Identifier><AffiliationInfo><Affiliation>Department of Cardiology, The First Affiliated Hospital of Kunming Medical University, Kunming, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Haojie</ForeName><Initials>H</Initials><Identifier Source="ORCID">0009-0009-5342-349X</Identifier><AffiliationInfo><Affiliation>Department of Cardiology, Xiangyun County People's Hospital, Dali, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Shuangfeng</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-2562-3760</Identifier><AffiliationInfo><Affiliation>Department of Cardiology, Fuwai Yunnan Cardiovascular Hospital, Kunming, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Jiang</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-0744-0802</Identifier><AffiliationInfo><Affiliation>Department of Reproduction and Genetics, The First Affiliated Hospital of Kunming Medical University, Kunming, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Ruijie</ForeName><Initials>R</Initials><Identifier Source="ORCID">0009-0006-1195-854X</Identifier><AffiliationInfo><Affiliation>Department of Cardiology, The First Affiliated Hospital of Kunming Medical University, Kunming, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Huang</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0003-1952-830X</Identifier><AffiliationInfo><Affiliation>Department of Cardiology, The First Affiliated Hospital of Kunming Medical University, Kunming, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bao</LastName><ForeName>Suli</ForeName><Initials>S</Initials><Identifier Source="ORCID">0009-0000-1574-1416</Identifier><AffiliationInfo><Affiliation>Department of Cardiology, The First Affiliated Hospital of Kunming Medical University, Kunming, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Menghan</ForeName><Initials>M</Initials><Identifier Source="ORCID">0009-0002-2099-5001</Identifier><AffiliationInfo><Affiliation>Department of Cardiology, The First Affiliated Hospital of Kunming Medical University, Kunming, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peng</LastName><ForeName>Yunzhu</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0009-0009-7726-1253</Identifier><AffiliationInfo><Affiliation>Kunming Medical University, Kunming, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiology, The Affiliated Hospital of Yunnan University, Kunming, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cardiol Res Pract</MedlineTA><NlmUniqueID>101516542</NlmUniqueID><ISSNLinking>2090-0597</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cardiac fibrosis</Keyword><Keyword MajorTopicYN="N">cardiac rehabilitation</Keyword><Keyword MajorTopicYN="N">exercise training</Keyword><Keyword MajorTopicYN="N">mitophagy</Keyword><Keyword MajorTopicYN="N">myocardial infarction</Keyword><Keyword MajorTopicYN="N">oxidative stress</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>3</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>7</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>31</Day><Hour>12</Hour><Minute>11</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>31</Day><Hour>12</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>31</Day><Hour>5</Hour><Minute>36</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>7</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40741139</ArticleId><ArticleId IdType="pmc">PMC12310327</ArticleId><ArticleId IdType="doi">10.1155/crp/7778063</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mensah G. A., Fuster V., Murray C. J. L., et al. Global Burden of Cardiovascular Diseases and Risks, 1990&#x2013;2022. Journal of the American College of Cardiology . 2023;82(25):2350&#x2013;2473. doi: 10.1016/j.jacc.2023.11.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2023.11.007</ArticleId><ArticleId IdType="pmc">PMC7615984</ArticleId><ArticleId IdType="pubmed">38092509</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas R. J., Beatty A. L., Beckie T. M., et al. Home-Based Cardiac Rehabilitation: A Scientific Statement From the American Association of Cardiovascular and Pulmonary Rehabilitation, The American Heart Association, and The American College of Cardiology. Circulation . 2019;140(1):e69&#x2013;e89. doi: 10.1161/cir.0000000000000663.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/cir.0000000000000663</ArticleId><ArticleId IdType="pubmed">31082266</ArticleId></ArticleIdList></Reference><Reference><Citation>Byrne R. A., Rossello X., Coughlan J. J., et al. ESC Guidelines for the Management of Acute Coronary Syndromes. European Heart Journal . 2023;38(44):3720&#x2013;3826.</Citation><ArticleIdList><ArticleId IdType="pubmed">37622654</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnett D. K., Blumenthal R. S., Albert M. A., et al. ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation . 2019;11(140):e563&#x2013;e595.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8351755</ArticleId><ArticleId IdType="pubmed">30879339</ArticleId></ArticleIdList></Reference><Reference><Citation>Pelliccia A., Sharma S., Gati S., et al. 2020 ESC Guidelines on Sports Cardiology and Exercise in Patients With Cardiovascular Disease. European Heart Journal . 2021;42(1):17&#x2013;96. doi: 10.1093/eurheartj/ehaa605.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehaa605</ArticleId><ArticleId IdType="pubmed">33180902</ArticleId></ArticleIdList></Reference><Reference><Citation>Nam H., Jeon H. E., Kim W. H., Joa K. L., Lee H. Effect of Maximal-Intensity and High-Intensity Interval Training on Exercise Capacity and Quality of Life in Patients With Acute Myocardial Infarction: A Randomized Controlled Trial. European Journal of Physical and Rehabilitation Medicine . 2024;60(1):104&#x2013;112. doi: 10.23736/s1973-9087.23.08094-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.23736/s1973-9087.23.08094-2</ArticleId><ArticleId IdType="pmc">PMC10938035</ArticleId><ArticleId IdType="pubmed">37906165</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin Y., Kumar Bundhun P., Yuan Z. L., Chen M. H. The Effect of High-Intensity Interval Training on Exercise Capacity in Post-Myocardial Infarction Patients: A Systematic Review and Meta-Analysis. European journal of preventive cardiology . 2022;29(3):475&#x2013;484. doi: 10.1093/eurjpc/zwab060.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurjpc/zwab060</ArticleId><ArticleId IdType="pubmed">34279621</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu C. Y., Chen X. C., Yang L., et al. Exercise Mediates Noncoding RNAs in Cardiovascular Diseases: Pathophysiological Roles and Clinical Application. Expert Reviews in Molecular Medicine . 2024;27(27):e2&#x2013;e24. doi: 10.1017/erm.2024.25.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/erm.2024.25</ArticleId><ArticleId IdType="pmc">PMC11707833</ArticleId><ArticleId IdType="pubmed">39567354</ArticleId></ArticleIdList></Reference><Reference><Citation>Tallquist M. D., Molkentin J. D. Redefining the Identity of Cardiac Fibroblasts. Nature Reviews Cardiology . 2017;14(8):484&#x2013;491. doi: 10.1038/nrcardio.2017.57.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrcardio.2017.57</ArticleId><ArticleId IdType="pmc">PMC6329009</ArticleId><ArticleId IdType="pubmed">28436487</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravindran R., Gustafsson &#xc5; B. Mitochondrial Quality Control in Cardiomyocytes: Safeguarding the Heart Against Disease and Ageing. Nature Reviews Cardiology . 2025</Citation><ArticleIdList><ArticleId IdType="pubmed">40113864</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin L. C., Tu B., Song K., et al. Mitochondrial Quality Control in Cardiac Fibrosis: Epigenetic Mechanisms and Therapeutic Strategies. Metabolism . 2023;145:p. 155626. doi: 10.1016/j.metabol.2023.155626.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.metabol.2023.155626</ArticleId><ArticleId IdType="pubmed">37302693</ArticleId></ArticleIdList></Reference><Reference><Citation>Doherty A., Smith-Byrne K., Ferreira T., et al. GWAS Identifies 14 Loci for Device-Measured Physical Activity and Sleep Duration. Nature Communications . 2018;9(1):p. 5257. doi: 10.1038/s41467-018-07743-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-07743-4</ArticleId><ArticleId IdType="pmc">PMC6288145</ArticleId><ArticleId IdType="pubmed">30531941</ArticleId></ArticleIdList></Reference><Reference><Citation>Qi G., Dutta D., Leroux A., et al. Genome-Wide Association Studies of 27 Accelerometry-Derived Physical Activity Measurements Identified Novel Loci and Genetic Mechanisms. Genetic Epidemiology . 2022;46(2):122&#x2013;138. doi: 10.1002/gepi.22441.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/gepi.22441</ArticleId><ArticleId IdType="pmc">PMC8863635</ArticleId><ArticleId IdType="pubmed">35043453</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z., Emmerich A., Pillon N. J., et al. Genome-Wide Association Analyses of Physical Activity and Sedentary Behavior Provide Insights into Underlying Mechanisms and Roles in Disease Prevention. Nature Genetics . 2022;54(9):1332&#x2013;1344. doi: 10.1038/s41588-022-01165-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-022-01165-1</ArticleId><ArticleId IdType="pmc">PMC9470530</ArticleId><ArticleId IdType="pubmed">36071172</ArticleId></ArticleIdList></Reference><Reference><Citation>Klimentidis Y. C., Raichlen D. A., Bea J., et al. Genome-Wide Association Study of Habitual Physical Activity in over 377,000 UK Biobank Participants Identifies Multiple Variants Including CADM2 and APOE. International Journal of Obesity . 2018;42(6):1161&#x2013;1176. doi: 10.1038/s41366-018-0120-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41366-018-0120-3</ArticleId><ArticleId IdType="pmc">PMC6195860</ArticleId><ArticleId IdType="pubmed">29899525</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartiala J. A., Han Y., Jia Q., et al. Genome-Wide Analysis Identifies Novel Susceptibility Loci for Myocardial Infarction. European Heart Journal . 2021;42(9):919&#x2013;933. doi: 10.1093/eurheartj/ehaa1040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehaa1040</ArticleId><ArticleId IdType="pmc">PMC7936531</ArticleId><ArticleId IdType="pubmed">33532862</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H., Qin S., Tang J., et al. Resistance Exercise Upregulates Irisin Expression and Suppresses Myocardial Fibrosis Following Myocardial Infarction via Activating AMPK-Sirt1 and Inactivating TGF&#x3b2;1-Smad2/3. Acta Physiologica . 2024;240(7):p. e14163. doi: 10.1111/apha.14163.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apha.14163</ArticleId><ArticleId IdType="pubmed">38752665</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodrigues E. A., Lima A. R. R., Gomes M. J., et al. Influence of Isolated Resistance Exercise on Cardiac Remodeling, Myocardial Oxidative Stress, and Metabolism in Infarcted Rats. Antioxidants . 2023;12(4):p. 896. doi: 10.3390/antiox12040896.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antiox12040896</ArticleId><ArticleId IdType="pmc">PMC10135620</ArticleId><ArticleId IdType="pubmed">37107271</ArticleId></ArticleIdList></Reference><Reference><Citation>Ambrosetti M., Abreu A., Corr&#xe0; U., et al. Secondary Prevention Through Comprehensive Cardiovascular Rehabilitation: From Knowledge to Implementation. 2020 Update. A Position Paper From the Secondary Prevention and Rehabilitation Section of the European Association of Preventive Cardiology. European Journal of Preventive Cardiology . 2021;28(5):460&#x2013;495. doi: 10.1177/2047487320913379.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2047487320913379</ArticleId><ArticleId IdType="pubmed">33611446</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang Q., Cai M., Zhang J., et al. Role of Muscle-Specific Histone Methyltransferase (Smyd1) in Exercise-Induced Cardioprotection Against Pathological Remodeling After Myocardial Infarction. International Journal of Molecular Sciences . 2020;21(19):p. 7010. doi: 10.3390/ijms21197010.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21197010</ArticleId><ArticleId IdType="pmc">PMC7582695</ArticleId><ArticleId IdType="pubmed">32977624</ArticleId></ArticleIdList></Reference><Reference><Citation>Guazzi M., Arena R., Halle M., Piepoli M. F., Myers J., Lavie C. J. 2016 Focused Update: Clinical Recommendations for Cardiopulmonary Exercise Testing Data Assessment in Specific Patient Populations. European Heart Journal . 2018;39(14):1144&#x2013;1161. doi: 10.1093/eurheartj/ehw180.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehw180</ArticleId><ArticleId IdType="pubmed">27141094</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Q., Li Y. S., Ren Q., et al. Efficacy and Safety of Moderate-Intensity Continuous Training on the Improvement of Cardiopulmonary Function in Patients After Transcatheter Aortic Valve Replacement (ENERGY): A Randomized Controlled Trial. Journal of the American Medical Directors Association . 2023;24(11):1783&#x2013;1790.e2. doi: 10.1016/j.jamda.2023.04.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jamda.2023.04.025</ArticleId><ArticleId IdType="pubmed">37295458</ArticleId></ArticleIdList></Reference><Reference><Citation>Lear S. A., Hu W., Rangarajan S., et al. The Effect of Physical Activity on Mortality and Cardiovascular Disease in 130 000 People From 17 High-Income, Middle-Income, and Low-Income Countries: The PURE Study. The Lancet . 2017;390(10113):2643&#x2013;2654. doi: 10.1016/s0140-6736(17)31634-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(17)31634-3</ArticleId><ArticleId IdType="pubmed">28943267</ArticleId></ArticleIdList></Reference><Reference><Citation>Sattelmair J., Pertman J., Ding E. L., Kohl H. W., 3rd, Haskell W., Lee I. M. Dose Response Between Physical Activity and Risk of Coronary Heart Disease: A Meta-Analysis. Circulation . 2011;124(7):789&#x2013;795. doi: 10.1161/circulationaha.110.010710.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/circulationaha.110.010710</ArticleId><ArticleId IdType="pmc">PMC3158733</ArticleId><ArticleId IdType="pubmed">21810663</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao S., Zhang Z., Long Q., et al. Association Between Time of Day of Sports-Related Physical Activity and the Onset of Acute Myocardial Infarction in a Chinese Population. PLoS One . 2016;11(1):p. e0146472. doi: 10.1371/journal.pone.0146472.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0146472</ArticleId><ArticleId IdType="pmc">PMC4709000</ArticleId><ArticleId IdType="pubmed">26752185</ArticleId></ArticleIdList></Reference><Reference><Citation>van de Vegte Y. J., Said M. A., Rienstra M., van der Harst P., Verweij N. Genome-Wide Association Studies and Mendelian Randomization Analyses for Leisure Sedentary Behaviours. Nature Communications . 2020;11(1):p. 1770. doi: 10.1038/s41467-020-15553-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-15553-w</ArticleId><ArticleId IdType="pmc">PMC7174427</ArticleId><ArticleId IdType="pubmed">32317632</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhuang Z., Gao M., Yang R., et al. Association of Physical Activity, Sedentary Behaviours and Sleep Duration With Cardiovascular Diseases and Lipid Profiles: A Mendelian Randomization Analysis. Lipids in Health and Disease . 2020;19(1):p. 86. doi: 10.1186/s12944-020-01257-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12944-020-01257-z</ArticleId><ArticleId IdType="pmc">PMC7206776</ArticleId><ArticleId IdType="pubmed">32384904</ArticleId></ArticleIdList></Reference><Reference><Citation>Im E., Kim G. S. Relationship Between Sleep Duration and Framingham Cardiovascular Risk Score and Prevalence of Cardiovascular Disease in Koreans. Medicine . 2017;96(37):p. e7744. doi: 10.1097/md.0000000000007744.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/md.0000000000007744</ArticleId><ArticleId IdType="pmc">PMC5604628</ArticleId><ArticleId IdType="pubmed">28906359</ArticleId></ArticleIdList></Reference><Reference><Citation>Tucker W. J., Beaudry R. I., Liang Y., et al. Meta-Analysis of Exercise Training on Left Ventricular Ejection Fraction in Heart Failure With Reduced Ejection Fraction: A 10-Year Update. Progress in Cardiovascular Diseases . 2019;62(2):163&#x2013;171. doi: 10.1016/j.pcad.2018.08.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pcad.2018.08.006</ArticleId><ArticleId IdType="pmc">PMC6445773</ArticleId><ArticleId IdType="pubmed">30227187</ArticleId></ArticleIdList></Reference><Reference><Citation>Dibben G. O., Faulkner J., Oldridge N., et al. Exercise-Based Cardiac Rehabilitation for Coronary Heart Disease: A Meta-Analysis. European Heart Journal . 2023;44(6):452&#x2013;469. doi: 10.1093/eurheartj/ehac747.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehac747</ArticleId><ArticleId IdType="pmc">PMC9902155</ArticleId><ArticleId IdType="pubmed">36746187</ArticleId></ArticleIdList></Reference><Reference><Citation>Eser P., Trachsel L. D., Marcin T., et al. Short- and Long-Term Effects of High-Intensity Interval Training vs. Moderate-Intensity Continuous Training on Left Ventricular Remodeling in Patients Early After ST-Segment Elevation Myocardial Infarction-The HIIT-EARLY Randomized Controlled Trial. Frontiers in cardiovascular medicine . 2022;9(9):p. 869501. doi: 10.3389/fcvm.2022.869501.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2022.869501</ArticleId><ArticleId IdType="pmc">PMC9247394</ArticleId><ArticleId IdType="pubmed">35783836</ArticleId></ArticleIdList></Reference><Reference><Citation>Dibben G., Faulkner J., Oldridge N., et al. Exercise-Based Cardiac Rehabilitation for Coronary Heart Disease. Cochrane Database of Systematic Reviews . 2021;11(11):p. Cd001800.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8571912</ArticleId><ArticleId IdType="pubmed">34741536</ArticleId></ArticleIdList></Reference><Reference><Citation>Frantz S., Hundertmark M. J., Schulz-Menger J., Bengel F. M., Bauersachs J. Left Ventricular Remodelling Post-Myocardial Infarction: Pathophysiology, Imaging, and Novel Therapies. European Heart Journal . 2022;43(27):2549&#x2013;2561. doi: 10.1093/eurheartj/ehac223.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehac223</ArticleId><ArticleId IdType="pmc">PMC9336586</ArticleId><ArticleId IdType="pubmed">35511857</ArticleId></ArticleIdList></Reference><Reference><Citation>Song W., Liang Q., Cai M., Tian Z. HIF-1&#x3b1;-Induced Up-Regulation of MicroRNA-126 Contributes to the Effectiveness of Exercise Training on Myocardial Angiogenesis in Myocardial Infarction Rats. Journal of Cellular and Molecular Medicine . 2020;24(22):12970&#x2013;12979. doi: 10.1111/jcmm.15892.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jcmm.15892</ArticleId><ArticleId IdType="pmc">PMC7701575</ArticleId><ArticleId IdType="pubmed">32939968</ArticleId></ArticleIdList></Reference><Reference><Citation>Hinton A., Jr., Claypool S. M., Neikirk K., et al. Mitochondrial Structure and Function in Human Heart Failure. Circulation Research . 2024;135(2):372&#x2013;396. doi: 10.1161/circresaha.124.323800.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/circresaha.124.323800</ArticleId><ArticleId IdType="pmc">PMC11225798</ArticleId><ArticleId IdType="pubmed">38963864</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Y., Xu J., Zou L., et al. Ceria Nanoparticles Alleviate Myocardial Ischemia-Reperfusion Injury by Inhibiting Cardiomyocyte Apoptosis via Alleviating ROS Mediated Excessive Mitochondrial Fission. Materials Today Bio . 2025;32(32):p. 101770. doi: 10.1016/j.mtbio.2025.101770.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mtbio.2025.101770</ArticleId><ArticleId IdType="pmc">PMC12033917</ArticleId><ArticleId IdType="pubmed">40290893</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding J., Zhang Z., Li S., et al. Mdivi-1 Alleviates Cardiac Fibrosis Post Myocardial Infarction at Infarcted Border Zone, Possibly via Inhibition of Drp1-Activated Mitochondrial Fission and Oxidative Stress. Archives of Biochemistry and Biophysics . 2022;718:p. 109147. doi: 10.1016/j.abb.2022.109147.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.abb.2022.109147</ArticleId><ArticleId IdType="pubmed">35143784</ArticleId></ArticleIdList></Reference><Reference><Citation>Lei Y., Gan M., Qiu Y., et al. The Role of Mitochondrial Dynamics and Mitophagy in Skeletal Muscle Atrophy: From Molecular Mechanisms to Therapeutic Insights. Cellular and Molecular Biology Letters . 2024;29(1):p. 59. doi: 10.1186/s11658-024-00572-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s11658-024-00572-y</ArticleId><ArticleId IdType="pmc">PMC11036639</ArticleId><ArticleId IdType="pubmed">38654156</ArticleId></ArticleIdList></Reference><Reference><Citation>Bishop D. J., Lee M. J., Picard M. Exercise as Mitochondrial Medicine: How Does the Exercise Prescription Affect Mitochondrial Adaptations to Training? Annual Review of Physiology . 2025;87(1):107&#x2013;129. doi: 10.1146/annurev-physiol-022724-104836.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-physiol-022724-104836</ArticleId><ArticleId IdType="pubmed">39656953</ArticleId></ArticleIdList></Reference><Reference><Citation>Guan Z., Chen J., Wang L., et al. Nuanxinkang Prevents the Development of Myocardial Infarction-Induced Chronic Heart Failure by Promoting PINK1/Parkin-Mediated Mitophagy. Phytomedicine . 2023;108:p. 154494. doi: 10.1016/j.phymed.2022.154494.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phymed.2022.154494</ArticleId><ArticleId IdType="pubmed">36279758</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai X., Zhang Z., Li X., Yang Y., Ding S. FUNDC1: An Emerging Mitochondrial and MAMs Protein for Mitochondrial Quality Control in Heart Diseases. International Journal of Molecular Sciences . 2023;11(24)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10252584</ArticleId><ArticleId IdType="pubmed">37298100</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu L., Shi X. Y., Liu Z. M., et al. Effects of Exercises with Different Durations and Intensities on Mitochondrial Autophagy and FUNDC1 Expression in Rat Skeletal Muscles. Sheng Li Xue Bao: Acta Physiologica Sinica . 2020;5(72):631&#x2013;642.</Citation><ArticleIdList><ArticleId IdType="pubmed">33106833</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao D., Sun Y., Tan Y., et al. Short-Duration Swimming Exercise after Myocardial Infarction Attenuates Cardiac Dysfunction and Regulates Mitochondrial Quality Control in Aged Mice. Oxidative Medicine and Cellular Longevity . 2018;2018(1):p. 4079041. doi: 10.1155/2018/4079041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2018/4079041</ArticleId><ArticleId IdType="pmc">PMC5925211</ArticleId><ArticleId IdType="pubmed">29849892</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Z. Y., Song K., Tu B., et al. Crosstalk Between Oxidative Stress and Epigenetic Marks: New Roles and Therapeutic Implications in Cardiac Fibrosis. Redox Biology . 2023;65:p. 102820. doi: 10.1016/j.redox.2023.102820.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.redox.2023.102820</ArticleId><ArticleId IdType="pmc">PMC10369469</ArticleId><ArticleId IdType="pubmed">37482041</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan Q., Liu S., Sun Y., et al. Targeting Oxidative Stress as a Preventive and Therapeutic Approach for Cardiovascular Disease. Journal of Translational Medicine . 2023;21(1):p. 519. doi: 10.1186/s12967-023-04361-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-023-04361-7</ArticleId><ArticleId IdType="pmc">PMC10394930</ArticleId><ArticleId IdType="pubmed">37533007</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40413662</PMID><DateRevised><Year>2025</Year><Month>05</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-1084</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>May</Month><Day>25</Day></PubDate></JournalIssue><Title>European radiology</Title><ISOAbbreviation>Eur Radiol</ISOAbbreviation></Journal><ArticleTitle>4D flow MRI-based grading of left ventricular diastolic dysfunction: a validation study against echocardiography.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00330-025-11703-0</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To assess the feasibility and accuracy of 4D flow MRI-based grading of left ventricular diastolic dysfunction, using echocardiography as the reference method.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Between October 2016 and February 2022, subjects were prospectively recruited for transthoracic echocardiographic evaluation of left ventricular diastolic function and 4D flow MRI at 3&#x2009;T. Echocardiographic grading of diastolic dysfunction was performed according to the multiparametric, threshold-based 2016 ASE/EACVI approach. Volumetric and echo-equivalent peak velocity grading parameters were evaluated from 4D flow magnitude and velocity data, respectively. Duration of vortical blood flow along the main pulmonary artery (t<sub>vortex</sub>) was employed as a surrogate grading parameter for echocardiographic tricuspid regurgitant peak velocity (TR). Correlations between grading parameters were analysed; agreement in grading of diastolic dysfunction between methods was assessed using a 5&#x2009;&#xd7;&#x2009;5 contingency table analysis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The study population consisted of 94 participants (mean age, 62&#x2009;&#xb1;&#x2009;12 years, 50 females, 34 with structural heart disease). All volumetric and echo-equivalent 4D flow grading parameters demonstrated strong to very strong correlations with echocardiography (r&#x2009;=&#x2009;0.75-0.92). Volumetric parameters showed significant biases between 4D flow and echocardiography. Employing bias-adjusted 4D flow grading cutoffs for volumetric parameter, echo-equivalent cutoffs for diastolic transmitral and myocardial peak velocities, and t<sub>vortex</sub>&#x2009;&gt;&#x2009;15% as a surrogate cutoff for TR&#x2009;&gt;&#x2009;2.8&#x2009;m/s, nearly perfect agreement in diastolic dysfunction grading between methods was observed (weighted kappa&#x2009;=&#x2009;0.84). There was no evidence for over- or underestimation of grades by 4D flow (p&#x2009;=&#x2009;0.53).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Grading of left ventricular diastolic dysfunction from a single 4D flow measurement is feasible and shows nearly perfect agreement with echocardiography.</AbstractText><AbstractText Label="KEY POINTS" NlmCategory="CONCLUSIONS">Question The lack of comparison studies with echocardiography currently limits cardiac MRI-based grading of diastolic dysfunction. Could 4D flow MRI serve as a viable technique? Findings A single 4D flow MRI measurement allows multiparametric grading of left ventricular diastolic dysfunction in nearly perfect agreement with echocardiography. Clinical relevance Agreement between 4D flow MRI and echocardiographic grading of left ventricular diastolic dysfunction is comparable to that observed in repeated echocardiographic evaluations, suggesting 4D flow as a viable alternative to echocardiography in selected patients, especially when comprehensive MRI is already performed.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Reiter</LastName><ForeName>Clemens</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Division of General Radiology, Department of Radiology, Medical University of Graz, Graz, Austria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Neuroradiology, Vascular and Interventional Radiology, Department of Radiology, Medical University of Graz, Graz, Austria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Cardiology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reiter</LastName><ForeName>Gert</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Division of General Radiology, Department of Radiology, Medical University of Graz, Graz, Austria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research and Development, Siemens Healthcare Diagnostics GmbH, Graz, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kolesnik</LastName><ForeName>Ewald</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scherr</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schmidt</LastName><ForeName>Albrecht</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fuchsj&#xe4;ger</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of General Radiology, Department of Radiology, Medical University of Graz, Graz, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reiter</LastName><ForeName>Ursula</ForeName><Initials>U</Initials><Identifier Source="ORCID">0000-0002-4374-2528</Identifier><AffiliationInfo><Affiliation>Division of General Radiology, Department of Radiology, Medical University of Graz, Graz, Austria. ursula.reiter@medunigraz.at.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>17934</GrantID><Agency>Oesterreichische Nationalbank</Agency><Country/></Grant><Grant><GrantID>Seed Grant 2020</GrantID><Agency>ESR/EIBIR</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>05</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Eur Radiol</MedlineTA><NlmUniqueID>9114774</NlmUniqueID><ISSNLinking>0938-7994</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Diagnostic imaging</Keyword><Keyword MajorTopicYN="N">Diastole</Keyword><Keyword MajorTopicYN="N">Left ventricular dysfunction</Keyword><Keyword MajorTopicYN="N">Magnetic resonance imaging</Keyword><Keyword MajorTopicYN="N">Validation study</Keyword></KeywordList><CoiStatement>Compliance with ethical standards. Guarantor: The scientific guarantor of this publication is Ursula Reiter. Conflict of interest: The authors of this manuscript declare relationships with the following companies: G.R. is a Research &amp; Development employee of Siemens Healthineers. The study was performed under a Master Research Agreement between the Medical University of Graz, Graz University of Technology, and Siemens Healthcare Diagnostics GmbH. U.R. is a member of the Scientific Editorial Board of European Radiology (section: Physics). As such, they did not participate in the selection or review processes for this article. The remaining authors of this manuscript declare no relationships with any companies whose products or services may be related to the subject matter of the article. Statistics and biometry: No complex statistical methods were necessary for this paper. Informed consent: Written informed consent was obtained from all patients in this study. Ethical approval: Institutional Review Board approval was obtained. Ethical committee: Medical University of Graz, Austria. ClinicalTrials.gov: NCT01728597 and NCT03253835. Study subjects or cohorts overlap: The diagnosis and grading of LV diastolic dysfunction based on the 2016 ASE/EACVI recommendations from 4D flow data with echocardiography as the reference method was not previously investigated. Data of study participants were included in the following previous publications, which focused on methodological aspects of 4D flow data evaluation or the introduction of novel 4D flow metrics: 4D flow data of ten subjects of the study population were included in the definition of an algorithm for automated mitral valve vortex ring extraction from 4D-flow MRI [55]. The impact of breath-holding on cine realtime volumetric function parameters was analysed previously from 56 subjects without signs and symptoms of cardiac diseases of this study population [56]. Volumetric function parameters of 60 subjects without signs and symptoms of cardiac diseases were analysed from native multi-slice 4D flow data and compared to cine real-time imaging [26]. Global myocardial feature tracking-derived strains of 24 participants without signs and symptoms of cardiac diseases were evaluated and compared with global strains of a pulmonary hypertension cohort [57]. 4D flow evaluation strategies for assessment of transmitral and myocardial velocities were analysed in 60 subjects without signs and symptoms of cardiac diseases with echocardiography as reference [20]. All participants of the present study were included in an evaluation introducing a novel, 4D flow-based single-parameter model for differentiation of advanced LV diastolic dysfunction, using echocardiographic grading as the reference method [24]. Methodology: Prospective study Diagnostic study Performed at one institution</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>11</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>4</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>4</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>5</Month><Day>25</Day><Hour>20</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>5</Month><Day>25</Day><Hour>20</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>5</Month><Day>25</Day><Hour>11</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40413662</ArticleId><ArticleId IdType="doi">10.1007/s00330-025-11703-0</ArticleId><ArticleId IdType="pii">10.1007/s00330-025-11703-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Heidenreich PA, Bozkurt B, Aguilar D et al (2022) 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. https://doi.org/10.1161/CIR.0000000000001063</Citation></Reference><Reference><Citation>Nagueh SF, Smiseth OA, Appleton CP et al (2016) Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 29:277&#x2013;314. https://doi.org/10.1016/j.echo.2016.01.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.echo.2016.01.011</ArticleId><ArticleId IdType="pubmed">27037982</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson S, Ring L, Oxborough D et al (2024) The assessment of left ventricular diastolic function: guidance and recommendations from the British Society of Echocardiography. Echo Res Pr 11:16. https://doi.org/10.1186/s44156-024-00051-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s44156-024-00051-2</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Leary JM, Assad TR, Xu M et al (2018) Lack of a tricuspid regurgitation Doppler signal and pulmonary hypertension by invasive measurement. J Am Heart Assoc. https://doi.org/10.1161/JAHA.118.009362</Citation></Reference><Reference><Citation>Rajiah PS, Moore A, Broncano J et al (2023) Diastology with cardiac MRI: a practical guide. Radiographics https://doi.org/10.1148/rg.220144</Citation></Reference><Reference><Citation>Chamsi-Pasha MA, Zhan Y, Debs D, Shah DJ (2020) CMR in the evaluation of diastolic dysfunction and phenotyping of HFpEF. JACC Cardiovasc Imaging 13:283&#x2013;296. https://doi.org/10.1016/j.jcmg.2019.02.031</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcmg.2019.02.031</ArticleId><ArticleId IdType="pubmed">31202753</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashkir Z, Myerson S, Neubauer S et al (2022) Four-dimensional flow cardiac magnetic resonance assessment of left ventricular diastolic function. Front Cardiovasc Med. https://doi.org/10.3389/fcvm.2022.866131</Citation></Reference><Reference><Citation>Dyverfeldt P, Bissell M, Barker AJ et al (2015) 4D flow cardiovascular magnetic resonance consensus statement. J Cardiovasc Magn Reson 17: 72. https://doi.org/10.1186/s12968-015-0174-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12968-015-0174-5</ArticleId><ArticleId IdType="pubmed">26257141</ArticleId><ArticleId IdType="pmc">4530492</ArticleId></ArticleIdList></Reference><Reference><Citation>Bissell MM, Raimondi F, Ait Ali L et al (2023) 4D flow cardiovascular magnetic resonance consensus statement: 2023 update. J Cardiovasc Magn Reson 25: 40. https://doi.org/10.1186/s12968-023-00942-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12968-023-00942-z</ArticleId><ArticleId IdType="pubmed">37474977</ArticleId><ArticleId IdType="pmc">10357639</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Hulst AE, Westenberg JJM, Kroft LJM et al (2010) Tetralogy of Fallot: 3D velocity-encoded MR imaging for evaluation of right ventricular valve flow and diastolic function in patients after correction. Radiology 256:724&#x2013;734. https://doi.org/10.1148/radiol.10092269</Citation><ArticleIdList><ArticleId IdType="doi">10.1148/radiol.10092269</ArticleId><ArticleId IdType="pubmed">20634432</ArticleId></ArticleIdList></Reference><Reference><Citation>She HL, Roest AAW, Calkoen EE et al (2017) Comparative evaluation of flow quantification across the atrioventricular valve in patients with functional univentricular heart after fontan&#x2019;s surgery and healthy controls: measurement by 4D flow magnetic resonance imaging and streamline visualization. Congenit Heart Dis 12:40&#x2013;48. https://doi.org/10.1111/chd.12397</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/chd.12397</ArticleId><ArticleId IdType="pubmed">27425568</ArticleId></ArticleIdList></Reference><Reference><Citation>Njoku P, Grafton-Clarke C, Assadi H et al (2022) Validation of time-resolved, automated peak trans-mitral velocity tracking: two center four-dimensional flow cardiovascular magnetic resonance study. Int J Cardiol 364:148&#x2013;156. https://doi.org/10.1016/j.ijcard.2022.06.032</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijcard.2022.06.032</ArticleId><ArticleId IdType="pubmed">35716937</ArticleId></ArticleIdList></Reference><Reference><Citation>Assadi H, Li R, Grafton-Clarke C et al (2023) Automated 4D flow cardiac MRI pipeline to derive peak mitral inflow diastolic velocities using short-axis cine stack: two centre validation study against echocardiographic pulse-wave doppler. BMC Cardiovasc Disord 23:24. https://doi.org/10.1186/s12872-023-03052-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12872-023-03052-x</ArticleId><ArticleId IdType="pubmed">36647000</ArticleId><ArticleId IdType="pmc">9843884</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorecka M, Bissell MM, Higgins DM et al (2022) Rationale and clinical applications of 4D flow cardiovascular magnetic resonance in assessment of valvular heart disease: a comprehensive review. J Cardiovasc Magn Reson 24:49. https://doi.org/10.1186/s12968-022-00882-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12968-022-00882-0</ArticleId><ArticleId IdType="pubmed">35989320</ArticleId><ArticleId IdType="pmc">9394062</ArticleId></ArticleIdList></Reference><Reference><Citation>Archer GT, Elhawaz A, Barker N et al (2020) Validation of four-dimensional flow cardiovascular magnetic resonance for aortic stenosis assessment. Sci Rep 10:10569</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-66659-6</ArticleId><ArticleId IdType="pubmed">32601326</ArticleId><ArticleId IdType="pmc">7324609</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia J, Barker AJ, Markl M (2019) The role of imaging of flow patterns by 4D flow MRI in aortic stenosis. JACC Cardiovasc Imaging 12:252&#x2013;266. https://doi.org/10.1016/j.jcmg.2018.10.034</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcmg.2018.10.034</ArticleId><ArticleId IdType="pubmed">30732721</ArticleId></ArticleIdList></Reference><Reference><Citation>Azarine A, Gar&#xe7;on P, Stansal A et al (2019) Four-dimensional flow MRI: principles and cardiovascular applications. Radiographics 39:632&#x2013;648. https://doi.org/10.1148/rg.2019180091</Citation><ArticleIdList><ArticleId IdType="doi">10.1148/rg.2019180091</ArticleId><ArticleId IdType="pubmed">30901284</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsiao A, Yousaf U, Alley MT et al (2015) Improved quantification and mapping of anomalous pulmonary venous flow with four-dimensional phase-contrast MRI and interactive streamline rendering. J Magn Reson Imaging 42:1765&#x2013;1776. https://doi.org/10.1002/jmri.24928</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmri.24928</ArticleId><ArticleId IdType="pubmed">25914149</ArticleId><ArticleId IdType="pmc">4843111</ArticleId></ArticleIdList></Reference><Reference><Citation>Zamani-Aliabadi SM, Qanadli SD, Fatehi-Feyzabad SH et al (2024) Assessment of 4D flow MRI for quantification of left-to-right shunt in pediatric patients with ventricular septal defect: comparison with right heart catheterization. Front Cardiovasc Med. https://doi.org/10.3389/fcvm.2024.1399110</Citation></Reference><Reference><Citation>Reiter C, Reiter G, Kr&#xe4;uter C et al (2024) Impact of the evaluation method on 4D flow-derived diastolic transmitral and myocardial peak velocities: comparison with echocardiography. Eur J Radiol 170:111247. https://doi.org/10.1016/j.ejrad.2023.111247</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejrad.2023.111247</ArticleId><ArticleId IdType="pubmed">38071909</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Schuppen J, Van Der Hulst AE, Den Harder JM et al (2024) Prerequisites for clinical implementation of whole-heart 4D-flow MRI: a Delphi analysis. Magn Reson Imaging 61:1618&#x2013;1628. https://doi.org/10.1002/jmri.29550</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmri.29550</ArticleId></ArticleIdList></Reference><Reference><Citation>Rizk J (2021) 4D flow MRI applications in congenital heart disease. Eur Radiol 31:1160&#x2013;1174. https://doi.org/10.1007/s00330-020-07210-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00330-020-07210-z</ArticleId><ArticleId IdType="pubmed">32870392</ArticleId></ArticleIdList></Reference><Reference><Citation>Sodhi A, Brown NK, Robinson JD et al (2024) Going with the flow: implementing a 4D flow MRI program at a children&#x2019;s hospital. Pediatr Radiol. https://doi.org/10.1007/s00247-024-06093-2</Citation></Reference><Reference><Citation>Reiter C, Reiter U, Kr&#xe4;uter C et al (2023) MR 4D flow-derived left atrial acceleration factor for differentiating advanced left ventricular diastolic dysfunction. Eur Radiol 34:4065&#x2013;4076. https://doi.org/10.1007/s00330-023-10386-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00330-023-10386-9</ArticleId><ArticleId IdType="pubmed">37953367</ArticleId><ArticleId IdType="pmc">11166802</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiter G, Kovacs G, Reiter C et al (2022) Left atrial acceleration factor as a magnetic resonance 4D flow measure of mean pulmonary artery wedge pressure in pulmonary hypertension. Front Cardiovasc Med. https://doi.org/10.3389/fcvm.2022.972142</Citation></Reference><Reference><Citation>Reiter C, Reiter G, Kr&#xe4;uter C et al (2023) Evaluation of left ventricular and left atrial volumetric function from native MR multislice 4D flow magnitude data. Eur Radiol 34:981&#x2013;993. https://doi.org/10.1007/s00330-023-10017-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00330-023-10017-3</ArticleId><ArticleId IdType="pubmed">37580598</ArticleId><ArticleId IdType="pmc">10853296</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiter G, Reiter U, Kovacs G et al (2015) Blood flow vortices along the main pulmonary artery measured with MR imaging for diagnosis of pulmonary hypertension. Radiology 275:71&#x2013;79. https://doi.org/10.1148/radiol.14140849</Citation><ArticleIdList><ArticleId IdType="doi">10.1148/radiol.14140849</ArticleId><ArticleId IdType="pubmed">25372980</ArticleId></ArticleIdList></Reference><Reference><Citation>Koo TK, Li MY (2016) A guideline of selecting and reporting intraclass correlation coefficients for reliability research. J Chiropr Med 15:155&#x2013;163. https://doi.org/10.1016/j.jcm.2016.02.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcm.2016.02.012</ArticleId><ArticleId IdType="pubmed">27330520</ArticleId><ArticleId IdType="pmc">4913118</ArticleId></ArticleIdList></Reference><Reference><Citation>Mukaka MM (2012) Statistics corner: a guide to appropriate use of correlation coefficient in medical research. Malawi Med J 24:69&#x2013;71</Citation><ArticleIdList><ArticleId IdType="pubmed">23638278</ArticleId><ArticleId IdType="pmc">3576830</ArticleId></ArticleIdList></Reference><Reference><Citation>McHugh ML (2012) Interrater reliability: the kappa statistic. Biochem Med 22:276&#x2013;282</Citation><ArticleIdList><ArticleId IdType="doi">10.11613/BM.2012.031</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawel-Boehm N, Hetzel SJ, Ambale-Venkatesh B et al (2020) Reference ranges (&#x201c;normal values&#x201d;) for cardiovascular magnetic resonance (CMR) in adults and children: 2020 update. J Cardiovasc Magn Reson 22:87. https://doi.org/10.1186/s12968-020-00683-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12968-020-00683-3</ArticleId><ArticleId IdType="pubmed">33308262</ArticleId><ArticleId IdType="pmc">7734766</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorosz JL, Lezotte DC, Weitzenkamp DA et al (2012) Performance of 3-dimensional echocardiography in measuring left ventricular volumes and ejection fraction. J Am Coll Cardiol 59:1799&#x2013;1808. https://doi.org/10.1016/j.jacc.2012.01.037</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2012.01.037</ArticleId><ArticleId IdType="pubmed">22575319</ArticleId><ArticleId IdType="pmc">3773600</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao L, Lu A, Tian J et al (2020) Effects of different LVEF assessed by echocardiography and CMR on the diagnosis and therapeutic decisions of cardiovascular diseases. Front Physiol. https://doi.org/10.3389/fphys.2020.00679</Citation></Reference><Reference><Citation>Shimada YJ, Shiota T (2011) A meta-analysis and investigation for the source of bias of left ventricular volumes and function by three-dimensional echocardiography in comparison with magnetic resonance imaging. Am J Cardiol 107:126&#x2013;138. https://doi.org/10.1016/j.amjcard.2010.08.058</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjcard.2010.08.058</ArticleId><ArticleId IdType="pubmed">21146700</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitlock M, Garg A, Gelow J et al (2010) Comparison of left and right atrial volume by echocardiography versus cardiac magnetic resonance imaging using the area-length method. Am J Cardiol 106:1345&#x2013;1350. https://doi.org/10.1016/j.amjcard.2010.06.065</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjcard.2010.06.065</ArticleId><ArticleId IdType="pubmed">21029836</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodevand O, Bjornerheim R, Ljosland M et al (1999) Left atrial volumes assessed by three- and two-dimensional echocardiography compared to MRI estimates. Int J Card Imaging 15:397&#x2013;410. https://doi.org/10.1023/A:1006276513186</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/A:1006276513186</ArticleId></ArticleIdList></Reference><Reference><Citation>Alattar Y, Soulat G, Gencer U et al (2022) Left ventricular diastolic early and late filling quantified from 4D flow magnetic resonance imaging. Diagn Interv Imaging 103:345&#x2013;352. https://doi.org/10.1016/j.diii.2022.02.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.diii.2022.02.003</ArticleId><ArticleId IdType="pubmed">35227634</ArticleId></ArticleIdList></Reference><Reference><Citation>Fyrdahl A, Ramos JG, Eriksson MJ et al (2020) Sector-wise golden-angle phase contrast with high temporal resolution for evaluation of left ventricular diastolic dysfunction. Magn Reson Med 83:1310&#x2013;1321. https://doi.org/10.1002/mrm.28018</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mrm.28018</ArticleId><ArticleId IdType="pubmed">31631403</ArticleId></ArticleIdList></Reference><Reference><Citation>Paelinck BP, De Roos A, Bax JJ et al (2005) Feasibility of tissue magnetic resonance imaging. J Am Coll Cardiol 45:1109&#x2013;1116. https://doi.org/10.1016/j.jacc.2004.12.051</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2004.12.051</ArticleId><ArticleId IdType="pubmed">15808772</ArticleId></ArticleIdList></Reference><Reference><Citation>Buss SJ, Krautz B, Schnackenburg B et al (2014) Classification of diastolic function with phase-contrast cardiac magnetic resonance imaging: validation with echocardiography and age-related reference values. Clin Res Cardiol 103:441&#x2013;450. https://doi.org/10.1007/s00392-014-0669-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00392-014-0669-3</ArticleId><ArticleId IdType="pubmed">24452509</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujikura K, Sathya B, Acharya T et al (2024) CMR provides comparable measurements of diastolic function as echocardiography. Sci Rep 14:11658. https://doi.org/10.1038/s41598-024-61992-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-024-61992-6</ArticleId><ArticleId IdType="pubmed">38778036</ArticleId><ArticleId IdType="pmc">11111683</ArticleId></ArticleIdList></Reference><Reference><Citation>Nogami M, Ohno Y, Koyama H et al (2009) Utility of phase contrast MR imaging for assessment of pulmonary flow and pressure estimation in patients with pulmonary hypertension: comparison with right heart catheterization and echocardiography. Magn Reson Imaging 30:973&#x2013;980. https://doi.org/10.1002/jmri.21935</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmri.21935</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramos JG, Fyrdahl A, Wieslander B et al (2020) Comprehensive cardiovascular magnetic resonance diastolic dysfunction grading shows very good agreement compared with echocardiography. JACC Cardiovasc Imaging 13:2530&#x2013;2542. https://doi.org/10.1016/j.jcmg.2020.06.027</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcmg.2020.06.027</ArticleId><ArticleId IdType="pubmed">32828779</ArticleId></ArticleIdList></Reference><Reference><Citation>Chemla D, Castelain V, Herv&#xe9; P et al (2002) Haemodynamic evaluation of pulmonary hypertension. Eur Respir J 20:1314&#x2013;1331. https://doi.org/10.1183/09031936.02.00068002</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/09031936.02.00068002</ArticleId><ArticleId IdType="pubmed">12449189</ArticleId></ArticleIdList></Reference><Reference><Citation>Humbert M, Kovacs G, Hoeper MM et al (2022) 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 43:3618&#x2013;3731. https://doi.org/10.1093/eurheartj/ehac237</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehac237</ArticleId><ArticleId IdType="pubmed">36017548</ArticleId></ArticleIdList></Reference><Reference><Citation>Chemla D, Castelain V, Provencher S et al (2009) Evaluation of various empirical formulas for estimating mean pulmonary artery pressure by using systolic pulmonary artery pressure in adults. Chest 135:760&#x2013;768. https://doi.org/10.1378/chest.08-0904</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.08-0904</ArticleId><ArticleId IdType="pubmed">18849403</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramos JG, Wieslander B, Fyrdahl A et al (2023) Pulmonary hypertension by catheterization is more accurately detected by cardiovascular magnetic resonance 4D-flow than echocardiography. JACC Cardiovasc Imaging 16:558&#x2013;559. https://doi.org/10.1016/j.jcmg.2022.09.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcmg.2022.09.006</ArticleId><ArticleId IdType="pubmed">36648043</ArticleId></ArticleIdList></Reference><Reference><Citation>Cadour F, Cour A, Senlis J et al (2024) How to use MRI in cardiac disease with diastolic dysfunction?. Br J Radiol 97:1203&#x2013;1213. https://doi.org/10.1093/bjr/tqae071</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bjr/tqae071</ArticleId><ArticleId IdType="pubmed">38574383</ArticleId><ArticleId IdType="pmc">11186565</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahrami HSZ, Pedersen FHG, Myhr KA et al (2021) Feasibility, repeatability, and reproducibility of contemporary diastolic parameters and classification. Int J Cardiovasc Imaging 37:931&#x2013;944. https://doi.org/10.1007/s10554-020-02069-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10554-020-02069-z</ArticleId><ArticleId IdType="pubmed">33394217</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiesemann S, Schmitter S, Demir A et al (2021) Impact of sequence type and field strength (1.5, 3, and 7T) on 4D flow MRI hemodynamic aortic parameters in healthy volunteers. Magn Reson Med 85:721&#x2013;733. https://doi.org/10.1002/mrm.28450</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mrm.28450</ArticleId><ArticleId IdType="pubmed">32754969</ArticleId></ArticleIdList></Reference><Reference><Citation>Strecker C, Harloff A, Wallis W, Markl M (2012) Flow-sensitive 4D MRI of the thoracic aorta: comparison of image quality, quantitative flow, and wall parameters at 1.5 T and 3 T. Magn Reson Imaging 36:1097&#x2013;1103. https://doi.org/10.1002/jmri.23735</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmri.23735</ArticleId></ArticleIdList></Reference><Reference><Citation>Bustamante M, Gupta V, Forsberg D et al (2018) Automated multi-atlas segmentation of cardiac 4D flow MRI. Med Image Anal 49:128&#x2013;140. https://doi.org/10.1016/j.media.2018.08.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.media.2018.08.003</ArticleId><ArticleId IdType="pubmed">30144652</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun X, Cheng L-H, Plein S et al (2024) Deep learning based automated left ventricle segmentation and flow quantification in 4D flow cardiac MRI. J Cardiovasc Magn Reson 26:100003. https://doi.org/10.1016/j.jocmr.2023.100003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jocmr.2023.100003</ArticleId><ArticleId IdType="pubmed">38211658</ArticleId><ArticleId IdType="pmc">11211221</ArticleId></ArticleIdList></Reference><Reference><Citation>Corrado PA, Wentland AL, Starekova J et al (2022) Fully automated intracardiac 4D flow MRI post-processing using deep learning for biventricular segmentation. Eur Radiol 32:5669&#x2013;5678. https://doi.org/10.1007/s00330-022-08616-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00330-022-08616-7</ArticleId><ArticleId IdType="pubmed">35175379</ArticleId></ArticleIdList></Reference><Reference><Citation>Kr&#xe4;uter C, Reiter U, Reiter C et al (2020) Automated mitral valve vortex ring extraction from 4D-flow MRI. Magn Reson Med 84:3396&#x2013;3408. https://doi.org/10.1002/mrm.28361</Citation></Reference><Reference><Citation>Reiter C, Reiter U, Kr&#xe4;uter C et al (2021) Differences in left ventricular and left atrial function assessed during breath-holding and breathing. Eur J Radiol 141:109756. https://doi.org/10.1016/j.ejrad.2021.109756</Citation></Reference><Reference><Citation>Nizhnikava V, Reiter U, Kovacs G et al (2024) Myocardial strain parameters in pulmonary hypertension are determined by changes in volumetric function rather than by hemodynamic alterations. Eur J Radiol. 170:111187. https://doi.org/10.1016/j.ejrad.2023.111187</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40482469</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2772-963X</ISSN><JournalIssue CitedMedium="Internet"><Volume>4</Volume><Issue>7</Issue><PubDate><Year>2025</Year><Month>Jul</Month></PubDate></JournalIssue><Title>JACC. Advances</Title><ISOAbbreviation>JACC Adv</ISOAbbreviation></Journal><ArticleTitle>Persistent Left Ventricular Dysfunction After Spontaneous Coronary Artery Dissection: A Report of the iSCAD Registry.</ArticleTitle><Pagination><StartPage>101854</StartPage><MedlinePgn>101854</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">101854</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jacadv.2025.101854</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2772-963X(25)00273-X</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Henkin</LastName><ForeName>Stanislav</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Heart and Vascular Center, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wood</LastName><ForeName>Malissa J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Naderi</LastName><ForeName>Sahar</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Kaiser Permanente Northern California, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gornik</LastName><ForeName>Heather L</ForeName><Initials>HL</Initials><AffiliationInfo><Affiliation>Harrington Heart &amp; Vascular Institute, University Hospitals, Cleveland, Ohio, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kadian-Dodov</LastName><ForeName>Daniella</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grodzinsky</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Diseases, Saint Luke's Mid America Heart Institute, University of Missouri, Kansas City, Missouri, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chi</LastName><ForeName>Gerald</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>PERFUSE Study Group, Division of Cardiovascular Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gibson</LastName><ForeName>C Michael</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>PERFUSE Study Group, Division of Cardiovascular Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leon</LastName><ForeName>Katherine K</ForeName><Initials>KK</Initials><AffiliationInfo><Affiliation>SCAD Alliance, Alexandria, Virginia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Esther S H</ForeName><Initials>ESH</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA. Electronic address: esther.kim@atriumhealth.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>06</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JACC Adv</MedlineTA><NlmUniqueID>9918419284106676</NlmUniqueID><ISSNLinking>2772-963X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">echocardiography</Keyword><Keyword MajorTopicYN="N">left ventricular dysfunction</Keyword><Keyword MajorTopicYN="N">myocardial infarction</Keyword><Keyword MajorTopicYN="N">spontaneous coronary artery dissection</Keyword></KeywordList><CoiStatement>Funding support and author disclosures This work was supported by the SCAD Alliance, a 501(3)c nonprofit organization. Dr Wood is a member of the Scientific Advisory Board of SCAD Alliance, the funder of this work. This is an unpaid position. She has no relationships with industry. Dr Naderi is a member of the Scientific Advisory Board of SCAD Alliance, the funder of this work. This is an unpaid position. She has no relationships with industry. Dr Kadian-Dodov is an advisor and has received honoraria from Boston Scientific and Abbott Laboratories. Ms Leon is the cofounder and executive director of SCAD Alliance, the funder of this work. She has no relationships with industry. Dr Kim is the Chair of the Scientific Advisory Board of SCAD Alliance, the funder of this work. She has no relationships with industry. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>12</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>4</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>4</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>6</Month><Day>8</Day><Hour>3</Hour><Minute>38</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>6</Month><Day>8</Day><Hour>3</Hour><Minute>37</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>6</Month><Day>7</Day><Hour>18</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>6</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40482469</ArticleId><ArticleId IdType="pmc">PMC12177160</ArticleId><ArticleId IdType="doi">10.1016/j.jacadv.2025.101854</ArticleId><ArticleId IdType="pii">S2772-963X(25)00273-X</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hayes S.N., Kim E.S.H., Saw J., et al. Spontaneous Coronary Artery Dissection: Current State of the Science: A Scientific Statement From the American Heart Association. Circulation. 2018;137(19):e523&#x2013;e557. doi: 10.1161/CIR.0000000000000564.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIR.0000000000000564</ArticleId><ArticleId IdType="pmc">PMC5957087</ArticleId><ArticleId IdType="pubmed">29472380</ArticleId></ArticleIdList></Reference><Reference><Citation>Sumner J.A., Kim E.S.H., Wood M.J., et al. Posttraumatic stress disorder after spontaneous coronary artery dissection: a report of the International Spontaneous Coronary Artery Dissection Registry. J Am Heart Assoc. 2024;13(7) doi: 10.1161/JAHA.123.032819.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/JAHA.123.032819</ArticleId><ArticleId IdType="pmc">PMC11179755</ArticleId><ArticleId IdType="pubmed">38533943</ArticleId></ArticleIdList></Reference><Reference><Citation>Diez-Villanueva P., Garcia-Guimaraes M., Sanz-Ruiz R., et al. Prognostic implications of left ventricular systolic dysfunction in patients with spontaneous coronary artery dissection. Eur Heart J Acute Cardiovasc Care. 2023;12(5):299&#x2013;305. doi: 10.1093/ehjacc/zuad035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ehjacc/zuad035</ArticleId><ArticleId IdType="pubmed">37010101</ArticleId></ArticleIdList></Reference><Reference><Citation>Franco C., Starovoytov A., Heydari M., Mancini G.B., Aymong E., Saw J. Changes in left ventricular function after spontaneous coronary artery dissection. Clin Cardiol. 2017;40(3):149&#x2013;154. doi: 10.1002/clc.22640.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/clc.22640</ArticleId><ArticleId IdType="pmc">PMC6490312</ArticleId><ArticleId IdType="pubmed">28218398</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40671668</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1445-5994</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Jul</Month><Day>17</Day></PubDate></JournalIssue><Title>Internal medicine journal</Title><ISOAbbreviation>Intern Med J</ISOAbbreviation></Journal><ArticleTitle>A tale of two echoes: ultraportable versus standard echocardiography in patients with left ventricular dysfunction.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1111/imj.70156</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Handheld echocardiography (HHE) is an emerging tool offering portability and convenience for cardiac imaging. However, its validity in hospitalised patients with left ventricular (LV) dysfunction is unclear.</AbstractText><AbstractText Label="AIMS" NlmCategory="OBJECTIVE">To determine the concordance of key LV and right ventricular (RV) echocardiographic parameters obtained by HHE and standard echocardiography (SE) in hospitalised patients with LV dysfunction.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This prospective study evaluated hospitalised patients with an echocardiogram during admission demonstrating LV ejection fraction (LVEF) &lt;50%. Key LV and right ventricular (RV) echocardiographic parameters were measured using both standard echocardiography (SE) and HHE. Concordance and differences between both imaging modalities were evaluated using Pearson correlation and paired Student t test, with significance defined as P &lt;&#x2009;0.05.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 156 patients were included. No significant differences were observed between SE and HH for LV end-diastolic diameter (5.23 &#xb1;&#x2009;0.87 vs. 5.28 &#xb1;&#x2009;0.72 cm respectively, P =&#x2009;0.348), LVEF (33.36 &#xb1;&#x2009;9.2 vs. 33.17 &#xb1;&#x2009;9.09, P =&#x2009;0.521), LV outflow tract velocity time integral (15.83 &#xb1;&#x2009;4.95 vs. 15.80 &#xb1;&#x2009;5.05, P =&#x2009;0.856) and inferior vena cava diameter (1.96 &#xb1;&#x2009;0.48 vs. 1.92 &#xb1;&#x2009;0.44, P =&#x2009;0.122). Significant differences were noted for RV basal diameter (3.87 &#xb1;&#x2009;0.63 cm vs. 3.76 &#xb1;&#x2009;0.68 cm, P &lt;&#x2009;0.001) and tricuspid annular systolic excursion (1.76 &#xb1;&#x2009;0.46 cm vs. 1.83 &#xb1;&#x2009;0.47 cm, P =&#x2009;0.025).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">HHE demonstrates strong concordance with SE for LV parameters. Discrepancies were observed for RV parameters, although the clinical implications of these differences are unclear. These findings highlight the evolving role of HHE as a reliable and accessible tool for experienced users, particularly for monitoring hospitalised patients such as those with acute heart failure, where the use of serial SE may enhance clinical decision-making but is limited by logistical barriers.</AbstractText><CopyrightInformation>&#xa9; 2025 The Author(s). Internal Medicine Journal published by John Wiley &amp; Sons Australia, Ltd on behalf of Royal Australasian College of Physicians.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Eng-Frost</LastName><ForeName>Joanne</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Flinders Medical Centre, Adelaide, South Australia, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>College of Medicine and Public Health, Flinders University, Adelaide, South Australia, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ravikulan</LastName><ForeName>Rohanti</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Flinders Medical Centre, Adelaide, South Australia, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chan</LastName><ForeName>Jasmine</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Flinders Medical Centre, Adelaide, South Australia, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Kate</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Flinders Medical Centre, Adelaide, South Australia, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lorensini</LastName><ForeName>Scott</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Flinders Medical Centre, Adelaide, South Australia, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>George</LastName><ForeName>Kate</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Flinders Medical Centre, Adelaide, South Australia, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rasheed</LastName><ForeName>Emilie</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Flinders Medical Centre, Adelaide, South Australia, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Allied Health and Human Performance, University of South Australia, Adelaide, South Australia, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lehman</LastName><ForeName>Sam</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Flinders Medical Centre, Adelaide, South Australia, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>College of Medicine and Public Health, Flinders University, Adelaide, South Australia, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Joseph</LastName><ForeName>Majo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Flinders Medical Centre, Adelaide, South Australia, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>College of Medicine and Public Health, Flinders University, Adelaide, South Australia, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Pasquale</LastName><ForeName>Carmine G</ForeName><Initials>CG</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Flinders Medical Centre, Adelaide, South Australia, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>College of Medicine and Public Health, Flinders University, Adelaide, South Australia, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>National Heart Foundation of Australia Tom Simpson Trust Fund (granted 2023/2024)</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Australia</Country><MedlineTA>Intern Med J</MedlineTA><NlmUniqueID>101092952</NlmUniqueID><ISSNLinking>1444-0903</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">echocardiography</Keyword><Keyword MajorTopicYN="N">handheld ultrasound</Keyword><Keyword MajorTopicYN="N">heart failure</Keyword><Keyword MajorTopicYN="N">left ventricular dysfunction</Keyword><Keyword MajorTopicYN="N">point&#x2010;of&#x2010;care</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>12</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>6</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>17</Day><Hour>6</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>17</Day><Hour>6</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>17</Day><Hour>5</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40671668</ArticleId><ArticleId IdType="doi">10.1111/imj.70156</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>Mok KL. Make it SIMPLE: enhanced shock management by focused cardiac ultrasound. J Intensive Care 2016; 4: 51.</Citation></Reference><Reference><Citation>Zieleskiewicz L, Muller L, Lakhal K, Meresse Z, Arbelot C, Bertrand PM et al. Point&#x2010;of&#x2010;care ultrasound in intensive care units: assessment of 1073 procedures in a multicentric, prospective, observational study. Intensive Care Med 2015; 41: 1638&#x2013;1647.</Citation></Reference><Reference><Citation>Gunst M, Ghaemmaghami V, Sperry J, Robinson M, O'Keeffe T, Friese R et al. Accuracy of cardiac function and volume status estimates using the bedside echocardiographic assessment in trauma/critical care. J Trauma 2008; 65: 509&#x2013;516.</Citation></Reference><Reference><Citation>Jenkins S, Shiha MG, Yones E, Wardley J, Ryding A, Sawh C et al. Cardiovascular examination using hand&#x2010;held cardiac ultrasound. J Echocardiogr 2021; 20: 1&#x2013;9.</Citation></Reference><Reference><Citation>Kerkhof DL, Gleason CN, Basilico FC, Corrado GD. Is there a role for limited echocardiography during the Preparticipation physical examination? PM&amp;R 2016; 8: S36&#x2013;S44.</Citation></Reference><Reference><Citation>Rasheed E, Perry R, Gluyas K, Eng&#x2010;Frost J, Lorensini S, George K et al. Cardiac point of care ultrasound: the solution to improving access and patient flow? Heart Lung Circ 2024; 33: S167&#x2013;S168.</Citation></Reference><Reference><Citation>Mjolstad OC, Dalen H, Graven T, Kleinau JO, Salvesen O, Haugen BO. Routinely adding ultrasound examinations by pocket&#x2010;sized ultrasound devices improves inpatient diagnostics in a medical department. Eur J Intern Med 2012; 23: 185&#x2013;191.</Citation></Reference><Reference><Citation>Engelman D, Kado JH, Rem&#xe9;nyi B, Colquhoun SM, Carapetis JR, Donath S et al. Focused cardiac ultrasound screening for rheumatic heart disease by briefly trained health workers: a study of diagnostic accuracy. Lancet Glob Health 2016; 4: e386&#x2013;e394.</Citation></Reference><Reference><Citation>Beaton A, Aliku T, Okello E, Lubega S, McCarter R, Lwabi P et al. The utility of handheld echocardiography for early diagnosis of rheumatic heart disease. J Am Soc Echocardiogr 2014; 27: 42&#x2013;49.</Citation></Reference><Reference><Citation>Yan BP, Fok JCY, Wong THY, Tse G, Lee APW, Yang XS et al. Junior medical student performed focused cardiac ultrasound after brief training to detect significant valvular heart disease. IJC Heart Vasc 2018; 19: 41&#x2013;45.</Citation></Reference><Reference><Citation>DeCara JM, Lang RM, Koch R, Bala R, Penzotti J, Spencer KT. The use of small personal ultrasound devices by internists without formal training in echocardiography. Eur J Echocardiogr 2003; 4: 141&#x2013;147.</Citation></Reference><Reference><Citation>Panoulas VF, Daigeler AL, Malaweera ASN, Lota AS, Baskaran D, Rahman S et al. Pocket&#x2010;size hand&#x2010;held cardiac ultrasound as an adjunct to clinical examination in the hands of medical students and junior doctors. Eur Heart J Cardiovasc Imaging 2013; 14: 323&#x2013;330.</Citation></Reference><Reference><Citation>Melamed R, Sprenkle MD, Ulstad VK, Herzog CA, Leatherman JW. Assessment of left ventricular function by intensivists using hand&#x2010;held echocardiography. Chest 2009; 135: 1416&#x2013;1420.</Citation></Reference><Reference><Citation>Moore CL, Rose GA, Tayal VS, Sullivan DM, Arrowood JA, Kline JA. Determination of left ventricular function by emergency physician echocardiography of hypotensive patients. Acad Emerg Med 2008; 9: 186&#x2013;193.</Citation></Reference><Reference><Citation>Randazzo MR, Snoey ER, Levitt MA, Binder K. Accuracy of emergency physician assessment of left ventricular ejection fraction and central venous pressure using echocardiography. Acad Emerg Med 2008; 10: 973&#x2013;977.</Citation></Reference><Reference><Citation>Cullen MW, Geske JB, Anavekar NS, Askew JW III, Lewis BR, Oh JK. Handheld echocardiography during hospitalization for acute myocardial infarction. Clin Cardiol 2017; 40: 993&#x2013;999.</Citation></Reference><Reference><Citation>Mansencal N, Vieillard&#x2010;Baron A, Beauchet A, Farcot JC, el Hajjam M, Dufaitre G et al. Triage patients with suspected pulmonary embolism in the emergency department using a portable ultrasound device. Echocardiography 2008; 25: 451&#x2013;456.</Citation></Reference><Reference><Citation>Jenkins S, Alabed S, Swift A, Marques G, Ryding A, Sawh C et al. Diagnostic accuracy of handheld cardiac ultrasound device for assessment of left ventricular structure and function: systematic review and meta&#x2010;analysis. Heart 2021; 107: 1826&#x2013;1834.</Citation></Reference><Reference><Citation>Testuz A, M&#xfc;ller H, Keller PF, Meyer P, Stampfli T, Sekoranja L et al. Diagnostic accuracy of pocket&#x2010;size handheld echocardiographs used by cardiologists in the acute care setting. Eur Heart J Cardiovasc Imaging 2012; 14: 38&#x2013;42.</Citation></Reference><Reference><Citation>Blume GG, Lechinewski LD, Vieira IP, Clausell N, Bertinato GP, Machado&#x2010;J&#xfa;nior PAB et al. Handheld echocardiography in a clinical practice scenario: concordances compared to standard echocardiographic reports. J Cardiovasc Imaging 2022; 30: 25.</Citation></Reference><Reference><Citation>Lang RM, Badano LP, Mor&#x2010;Avi V, Afilalo J, Armstrong A, Ernande L et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2015; 28: 1&#x2013;39.e14.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">40335237</PMID><DateRevised><Year>2025</Year><Month>05</Month><Day>07</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2213-1787</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>5</Issue><PubDate><Year>2025</Year><Month>May</Month></PubDate></JournalIssue><Title>JACC. Heart failure</Title><ISOAbbreviation>JACC Heart Fail</ISOAbbreviation></Journal><ArticleTitle>Days Alive Out of Hospital for Patients with Left Ventricular Dysfunction: From the STICH Trial.</ArticleTitle><Pagination><StartPage>867</StartPage><EndPage>869</EndPage><MedlinePgn>867-869</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jchf.2025.02.019</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2213-1779(25)00248-3</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Faridi</LastName><ForeName>Kamil F</ForeName><Initials>KF</Initials><AffiliationInfo><Affiliation>Yale School of Medicine, New Haven, Connecticut, USA; Center for Outcomes Research and Evaluation, Yale New Haven Health, New Haven, Connecticut, USA. Electronic address: kamil.faridi@yale.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Haocheng</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Yale School of Medicine, New Haven, Connecticut, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parise</LastName><ForeName>Helen</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Yale School of Medicine, New Haven, Connecticut, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahmad</LastName><ForeName>Tariq</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Yale School of Medicine, New Haven, Connecticut, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mori</LastName><ForeName>Makoto</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Yale School of Medicine, New Haven, Connecticut, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chung</LastName><ForeName>Mabel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Massachusetts General Hospital, Boston, Massachusetts, USA; Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yeh</LastName><ForeName>Robert W</ForeName><Initials>RW</Initials><AffiliationInfo><Affiliation>Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petrie</LastName><ForeName>Mark C</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>University of Glasgow, Glasgow, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Panza</LastName><ForeName>Julio A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>New York Medical College, Valhalla, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rouleau</LastName><ForeName>Jean L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Universit&#xe9; de Montr&#xe9;al, Montr&#xe9;al, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dabrowski</LastName><ForeName>Rafal</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>National Institute of Cardiology, Warsaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Velazquez</LastName><ForeName>Eric J</ForeName><Initials>EJ</Initials><AffiliationInfo><Affiliation>Yale School of Medicine, New Haven, Connecticut, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JACC Heart Fail</MedlineTA><NlmUniqueID>101598241</NlmUniqueID><ISSNLinking>2213-1779</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>10</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>1</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>2</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>5</Month><Day>8</Day><Hour>0</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>5</Month><Day>8</Day><Hour>0</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>5</Month><Day>7</Day><Hour>21</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40335237</ArticleId><ArticleId IdType="doi">10.1016/j.jchf.2025.02.019</ArticleId><ArticleId IdType="pii">S2213-1779(25)00248-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">40390264</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1540-8167</ISSN><JournalIssue CitedMedium="Internet"><Volume>36</Volume><Issue>7</Issue><PubDate><Year>2025</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Journal of cardiovascular electrophysiology</Title><ISOAbbreviation>J Cardiovasc Electrophysiol</ISOAbbreviation></Journal><ArticleTitle>For Whom Does the Bell Toll? Outcomes of Catheter Ablation of Ventricular Tachycardia in Patients With Severe Left Ventricular Dysfunction.</ArticleTitle><Pagination><StartPage>1588</StartPage><EndPage>1589</EndPage><MedlinePgn>1588-1589</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/jce.16732</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Liuba</LastName><ForeName>Ioan</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0001-7370-6993</Identifier><AffiliationInfo><Affiliation>Section of Cardiac Pacing and Electrophysiology, Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Santangeli</LastName><ForeName>Pasquale</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-0023-9666</Identifier><AffiliationInfo><Affiliation>Section of Cardiac Pacing and Electrophysiology, Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>05</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Cardiovasc Electrophysiol</MedlineTA><NlmUniqueID>9010756</NlmUniqueID><ISSNLinking>1045-3873</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>5</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>5</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>5</Month><Day>20</Day><Hour>6</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>5</Month><Day>20</Day><Hour>6</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>5</Month><Day>20</Day><Hour>1</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40390264</ArticleId><ArticleId IdType="doi">10.1111/jce.16732</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>P. Santangeli, J. E. Rame, E. Y. Birati, and F. E. Marchlinski, &#x201c;Management of Ventricular Arrhythmias in Patients With Advanced Heart Failure,&#x201d; Journal of the American College of Cardiology 69 (2017): 1842&#x2013;1860, https://doi.org/10.1016/j.jacc.2017.01.047.</Citation></Reference><Reference><Citation>S. V&#xe1;zquez&#x2010;Calvo, I. Roca&#x2010;Luque, and T. F. Althoff, &#x201c;Management of Ventricular Arrhythmias in Heart Failure,&#x201d; Current Heart Failure Reports 20 (2023): 237&#x2013;253, https://doi.org/10.1007/s11897-023-00608-y.</Citation></Reference><Reference><Citation>K. H. Kuck, A. Schaumann, L. Eckardt, et al., &#x201c;Catheter Ablation of Stable Ventricular Tachycardia Before Defibrillator Implantation in Patients With Coronary Heart Disease (VTACH): A Multicentre Randomised Controlled Trial,&#x201d; Lancet 375 (2010): 31&#x2013;40, https://doi.org/10.1016/S0140-6736(09)61755-4.</Citation></Reference><Reference><Citation>P. Santangeli, D. Muser, E. S. Zado, et al., &#x201c;Acute Hemodynamic Decompensation During Catheter Ablation of Scar&#x2010;Related Ventricular Tachycardia: Incidence, Predictors, and Impact on Mortality,&#x201d; Circulation: Arrhythmia and Electrophysiology 8 (2015): 68&#x2013;75, https://doi.org/10.1161/CIRCEP.114.002155.</Citation></Reference><Reference><Citation>M. Ghannam, N. Christian&#x2010;Miller, J. Liang, and A. Deshmukh, &#x201c;Ventricular Tachycardia Ablation in Patients With Severely Decreased Left Ventricular Ejection Fraction,&#x201d; Journal of Cardiovascular Electrophysiology (2025). In press.</Citation></Reference><Reference><Citation>N. V. K. Pothineni, A. Enriquez, R. Kumareswaran, et al., &#x201c;Outcomes of a PAINESD Score&#x2010;Guided Multidisciplinary Management Approach for Patients With Ventricular Tachycardia Storm and Advanced Heart Failure: A Pilot Study,&#x201d; Heart Rhythm 20 (2023): 134&#x2013;139, https://doi.org/10.1016/j.hrthm.2022.08.037.</Citation></Reference><Reference><Citation>W. S. Tzou, R. Tung, D. S. Frankel, et al., &#x201c;Ventricular Tachycardia Ablation in Severe Heart Failure: An International Ventricular Tachycardia Ablation Center Collaboration Analysis,&#x201d; Circulation: Arrhythmia and Electrophysiology 10 (2017): e004494, https://doi.org/10.1161/CIRCEP.116.004494.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40601382</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-0293</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Jul</Month><Day>02</Day></PubDate></JournalIssue><Title>Critical care medicine</Title><ISOAbbreviation>Crit Care Med</ISOAbbreviation></Journal><ArticleTitle>Association Between Initial Left Ventricular Systolic Dysfunction and Clinical Outcome in Sepsis: A Multicenter Cohort Study.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1097/CCM.0000000000006771</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To investigate the association between the severities of left ventricular (LV) systolic dysfunction and clinical outcomes in patients with sepsis, with a particular focus on in-hospital mortality.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Multicenter cohort study.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">Nineteen tertiary or university-affiliated hospitals in South Korea.</AbstractText><AbstractText Label="PATIENTS" NlmCategory="METHODS">A total of 2274 adult patients with sepsis or septic shock underwent echocardiographic examination within 24 hours of sepsis recognition.</AbstractText><AbstractText Label="INTERVENTIONS" NlmCategory="METHODS">None.</AbstractText><AbstractText Label="MEASUREMENTS AND MAIN RESULTS" NlmCategory="RESULTS">Patients were stratified by left ventricular ejection fraction (LVEF) into three groups: normal (&gt; 50%, n = 1803), mild-to-moderate dysfunction (30-50%, n = 356), and severe dysfunction (&lt; 30%, n = 115). In-hospital mortality is significantly associated with LV dysfunction severity (normal: 25.73%, mild-to-moderate: 29.49%, severe: 40.00%; p = 0.023). After propensity score matching using three different methodologies, severe LV dysfunction remained independently associated with increased in-hospital mortality (adjusted odds ratio [OR] 1.81; 95% CI, 1.09-3.03). This effect was more pronounced in patients without preexisting cardiovascular disease (CVD) (OR 1.84; 95% CI, 1.08-3.13) and those with bacteremia (OR 2.20; 95% CI, 1.5-3.22). Cardiopulmonary arrest rates increased significantly with dysfunction severity (normal: 2.11%, mild-to-moderate: 3.93%, severe: 10.43%; p &lt; 0.001), while other ICU complications showed no significant differences.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Severe LV systolic dysfunction (LVEF &lt; 30%) is associated with significantly increased in-hospital mortality in sepsis patients, particularly in those with bacteremia and without preexisting CVD. These findings highlight the importance of early cardiac function assessment in sepsis and suggest that infection status and underlying cardiovascular health modify the relationship between LV dysfunction and clinical outcome.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the Society of Critical Care Medicine and Wolters Kluwer Health, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nam</LastName><ForeName>Hyunseung</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Critical Care Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cha</LastName><ForeName>Ji Hyun</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Department of Critical Care Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Ki Hong</ForeName><Initials>KH</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Medicine, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chung</LastName><ForeName>Chi Ryang</ForeName><Initials>CR</Initials><AffiliationInfo><Affiliation>Department of Critical Care Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Jeong Hoon</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Department of Critical Care Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Cardiology, Department of Medicine, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suh</LastName><ForeName>Gee Young</ForeName><Initials>GY</Initials><AffiliationInfo><Affiliation>Department of Critical Care Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Sunghoon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pulmonary, Allergy and Critical Care Medicine, Hallym University Sacred Heart Hospital, Anyang, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lim</LastName><ForeName>Chae-Man</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ko</LastName><ForeName>Ryoung-Eun</ForeName><Initials>RE</Initials><Identifier Source="ORCID">0000-0003-4945-5623</Identifier><AffiliationInfo><Affiliation>Department of Critical Care Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Korean Sepsis Alliance (KSA) Investigators</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Crit Care Med</MedlineTA><NlmUniqueID>0355501</NlmUniqueID><ISSNLinking>0090-3493</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">bacteremia</Keyword><Keyword MajorTopicYN="N">cardiomyopathy</Keyword><Keyword MajorTopicYN="N">ejection fraction</Keyword><Keyword MajorTopicYN="N">left ventricular dysfunction</Keyword><Keyword MajorTopicYN="N">mortality</Keyword><Keyword MajorTopicYN="N">sepsis</Keyword></KeywordList><CoiStatement>Drs. Suh and Ko received support for article research from the Korean Disease Control and Prevention Agency. Dr. Park received support for article research from the Korean Ministry of Health. The remaining authors have disclosed that they do not have any potential conflicts of interest.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Suh</LastName><ForeName>Gee Young</ForeName><Initials>GY</Initials><AffiliationInfo><Affiliation>Department of Critical Care Medicine, Samsung Medical Center.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Ko</LastName><ForeName>Ryoung-Eun</ForeName><Initials>RE</Initials><AffiliationInfo><Affiliation>Department of Critical Care Medicine, Samsung Medical Center.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Kim</LastName><ForeName>Won-Young</ForeName><Initials>WY</Initials><AffiliationInfo><Affiliation>Department of Emergency Medicine, Asan Medical Center.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Park</LastName><ForeName>Sunghoon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Pulmonology and Critical Care Medicine, Pyeongchon Sacred Heart Hospital.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Lee</LastName><ForeName>Yeon Joo</ForeName><Initials>YJ</Initials><AffiliationInfo><Affiliation>Division of Pulmonology and Critical Care Medicine, Seoul National University Bundang Hospital.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Lee</LastName><ForeName>Hong Yeul</ForeName><Initials>HY</Initials><AffiliationInfo><Affiliation>Department of Critical Care Medicine, Seoul National University Hospital.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Lim</LastName><ForeName>Sung Yoon</ForeName><Initials>SY</Initials><AffiliationInfo><Affiliation>Division of Pulmonology and Critical Care Medicine, Seoul National University Bundang Hospital.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Cho</LastName><ForeName>Woo Hyun</ForeName><Initials>WH</Initials><AffiliationInfo><Affiliation>Division of Pulmonology and Critical Care Medicine, Pusan National University Yangsan Hospital.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Hyun</LastName><ForeName>Dong-Gon</ForeName><Initials>DG</Initials><AffiliationInfo><Affiliation>Department of Emergency Medicine, Asan Medical Center.</Affiliation></AffiliationInfo></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>2</Day><Hour>12</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>2</Day><Hour>12</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>2</Day><Hour>11</Hour><Minute>54</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40601382</ArticleId><ArticleId IdType="doi">10.1097/CCM.0000000000006771</ArticleId><ArticleId IdType="pii">00003246-990000000-00555</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Singer M, Deutschman CS, Seymour CW, et al.: The third international consensus definitions for sepsis and septic shock (SEPSIS-3). JAMA 2016; 315:801&#x2013;810</Citation></Reference><Reference><Citation>Beesley SJ, Weber G, Sarge T, et al.: Septic cardiomyopathy. Crit Care Med 2018; 46:625&#x2013;634</Citation></Reference><Reference><Citation>Parker MM, Shelhamer JH, Bacharach SL, et al.: Profound but reversible myocardial depression in patients with septic shock. Ann Intern Med 1984; 100:483&#x2013;490</Citation></Reference><Reference><Citation>Pulido JN, Afessa B, Masaki M, et al.: Clinical spectrum, frequency, and significance of myocardial dysfunction in severe sepsis and septic shock. Mayo Clin Proc 2012; 87:620&#x2013;628</Citation></Reference><Reference><Citation>Sevilla Berrios RA, O&#x2019;Horo JC, Velagapudi V, et al.: Correlation of left ventricular systolic dysfunction determined by low ejection fraction and 30-day mortality in patients with severe sepsis and septic shock: A systematic review and meta-analysis. J Crit Care 2014; 29:495&#x2013;499</Citation></Reference><Reference><Citation>Huang SJ, Nalos M, McLean AS: Is early ventricular dysfunction or dilatation associated with lower mortality rate in adult severe sepsis and septic shock? A meta-analysis. Crit Care 2013; 17:R96</Citation></Reference><Reference><Citation>Martin L, Derwall M, Al Zoubi S, et al.: The septic heart: Current understanding of molecular mechanisms and clinical implications. Chest 2019; 155:427&#x2013;437</Citation></Reference><Reference><Citation>Pruszczyk A, Zawadka M, Andruszkiewicz P, et al.: Mortality in patients with septic cardiomyopathy identified by longitudinal strain by speckle tracking echocardiography: An updated systematic review and meta-analysis with trial sequential analysis. Anaesth Crit Care Pain Med 2024; 43:101339</Citation></Reference><Reference><Citation>Kim S, Lee J-D, Kim BK, et al.: Association between left ventricular systolic dysfunction and mortality in patients with septic shock. J Korean Med Sci 2020; 35:e24</Citation></Reference><Reference><Citation>Forner J, Weidner K, Rusnak J, et al.: Prognostic impact of left compared to right heart function in sepsis and septic shock. ASAIO J 2024; 70:502&#x2013;509</Citation></Reference><Reference><Citation>Park S, Jeon K, Oh DK, et al.; Korean Sepsis Alliance (KSA) Study Group: Normothermia in patients with sepsis who present to emergency departments is associated with low compliance with sepsis bundles and increased in-hospital mortality rate. Crit Care Med 2020; 48:1462&#x2013;1470</Citation></Reference><Reference><Citation>Im Y, Kang D, Ko RE, et al.: Time-to-antibiotics and clinical outcomes in patients with sepsis and septic shock: A prospective nationwide multicenter cohort study. Crit Care 2022; 26:19</Citation></Reference><Reference><Citation>Cecconi M, Backer DD, Antonelli M, et al.: Consensus on circulatory shock and hemodynamic monitoring. Task force of the European Society of Intensive Care Medicine. Intensive Care Med 2014; 40:1795&#x2013;1815</Citation></Reference><Reference><Citation>Yan X, Li Y, Liu J, et al.: Serial changes in left ventricular myocardial deformation in sepsis or septic shock using three-dimensional and two-dimensional speckle tracking echocardiography. Front Cardiovasc Med 2022; 9:925367</Citation></Reference><Reference><Citation>Ng PY, Sin WC, Ng AKY, et al.: Speckle tracking echocardiography in patients with septic shock: A case control study (SPECKSS). Crit Care 2016; 20:145</Citation></Reference><Reference><Citation>Boissier F, Razazi K, Seemann A, et al.: Left ventricular systolic dysfunction during septic shock: The role of loading conditions. Intensive Care Med 2017; 43:633&#x2013;642</Citation></Reference><Reference><Citation>Cour M, Klouche K, Souweine B, et al.; RECO-Sepsis Trial Investigators: Remote ischemic conditioning in septic shock: The reco-sepsis randomized clinical trial. Intensive Care Med 2022; 48:1563&#x2013;1572</Citation></Reference><Reference><Citation>Kloner RA, Shi J, Dai W, et al.: Remote ischemic conditioning in acute myocardial infarction and shock states. J Cardiovasc Pharmacol Ther 2019; 25:103&#x2013;109</Citation></Reference><Reference><Citation>Tomai F, Crea F, Chiariello L, et al.: Ischemic preconditioning in humans. Circulation 1999; 100:559&#x2013;563</Citation></Reference><Reference><Citation>Mosevoll KA, Skrede S, Markussen DL, et al.: Inflammatory mediator profiles differ in sepsis patients with and without bacteremia. Front Immunol 2018; 9:691</Citation></Reference><Reference><Citation>Paladugu B, Kumar A, Parrillo JE, et al.: Bacterial DNA and RNA induce rat cardiac myocyte contraction depression in vitro. Shock 2004; 21:364&#x2013;369</Citation></Reference><Reference><Citation>Antonucci E, Fiaccadori E, Donadello K, et al.: Myocardial depression in sepsis: From pathogenesis to clinical manifestations and treatment. J Crit Care 2014; 29:500&#x2013;511</Citation></Reference><Reference><Citation>Vieillard-Baron A, Caille V, Charron C, et al.: Actual incidence of global left ventricular hypokinesia in adult septic shock. Crit Care Med 2008; 36:1701&#x2013;1706</Citation></Reference><Reference><Citation>Sato R, Kuriyama A, Takada T, et al.: Prevalence and risk factors of sepsis-induced cardiomyopathy: A retrospective cohort study. Medicine (Baltim) 2016; 95:e5031</Citation></Reference><Reference><Citation>Nu&#xdf;baum BL, McCook O, Hartmann C, et al.: Left ventricular function during porcine-resuscitated septic shock with pre-existing atherosclerosis. Intensive Care Med Exp 2016; 4:14</Citation></Reference><Reference><Citation>Chotalia M, Ali M, Hebballi R, et al.: Hyperdynamic left ventricular ejection fraction in icu patients with sepsis. Crit Care Med 2022; 50:770&#x2013;779</Citation></Reference><Reference><Citation>Dugar S, Sato R, Chawla S, et al.: Is left ventricular systolic dysfunction associated with increased mortality among patients with sepsis and septic shock? Chest 2023; 163:1437&#x2013;1447</Citation></Reference><Reference><Citation>Vallabhajosyula S, Kumar M, Pandompatam G, et al.: Prognostic impact of isolated right ventricular dysfunction in sepsis and septic shock: An 8-year historical cohort study. Ann Intensive Care 2017; 7:94</Citation></Reference><Reference><Citation>Gonzalez C, Begot E, Dalmay F, et al.: Prognostic impact of left ventricular diastolic function in patients with septic shock. Ann Intensive Care 2016; 6:36</Citation></Reference><Reference><Citation>Rolando G, Espinoza ED, Avid E, et al.: Prognostic value of ventricular diastolic dysfunction in patients with severe sepsis and septic shock. Rev Bras Ter Intensiva 2015; 27:333&#x2013;339</Citation></Reference><Reference><Citation>Lin YM, Lee MC, Toh HS, et al.: Association of sepsis-induced cardiomyopathy and mortality: A systematic review and meta-analysis. Ann Intensive Care 2022; 12:112</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40444607</PMID><DateCompleted><Year>2025</Year><Month>05</Month><Day>30</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2284-0729</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>5</Issue><PubDate><Year>2025</Year><Month>May</Month></PubDate></JournalIssue><Title>European review for medical and pharmacological sciences</Title><ISOAbbreviation>Eur Rev Med Pharmacol Sci</ISOAbbreviation></Journal><ArticleTitle>Dapagliflozin enhances systolic and diastolic function in concordance with clinical response in patients with left ventricular dysfunction.</ArticleTitle><Pagination><StartPage>231</StartPage><EndPage>247</EndPage><MedlinePgn>231-247</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.26355/eurrev_202505_37222</ELocationID><ELocationID EIdType="pii" ValidYN="Y">37222</ELocationID><Abstract><AbstractText Label="UNLABELLED">OBJECTIVE: Sodium-glucose co-transporter-2 (SGLT2) inhibitors have reshaped heart failure (HF) management. However, evidence regarding their effects on cardiac structure, particularly for dapagliflozin, remains inconsistent. This study evaluates dapagliflozin's impact on echocardiographic parameters and its concordance with clinical response. MATERIALS AND METHODS: A prospective, randomized controlled study included HF patients with left ventricular (LV) dysfunction, divided into dapagliflozin-treated and dapagliflozin-na&#xef;ve groups. Echocardiography and speckle-tracking strain analysis were conducted at baseline and six months. The primary outcome was the change in indexed LV mass. Secondary outcomes included LV function, volumes, dimensions, functional mitral regurgitation, global longitudinal strain (GLS), diastolic function, right ventricular (RV) function, and clinical response assessed using the Kansas City Cardiomyopathy Questionnaire (KCCQ) score. RESULTS: Among 240 participants, 160 received dapagliflozin in addition to guideline-directed medical therapy, while 80 were dapagliflozin-na&#xef;ve. Adjusted regression analysis showed significant improvements in LV mass index (-43.51 g/m&#xb2;, 95% CI: -59.4 to -27.5, p &lt; 0.0001), end-systolic volume (-29.45 mL, 95% CI: -43.9 to -14.9, p &lt; 0.0001), and end-diastolic volume (-29.44 mL, 95% CI: -47.9 to -10.9, p = 0.0021). Improvements were also observed in LV ejection fraction (5.15%, 95% CI: 2.84 to 7.45, p &lt; 0.0001), GLS (-1.99%, 95% CI: -2.87 to -1.11, p &lt; 0.0001), E/A ratio (-0.56, 95% CI: -1.01 to -0.10, p = 0.016), effective regurgitant orifice area (EROA) (-0.18 cm&#xb2;, 95% CI: -0.28 to -0.081, p = 0.0006), tricuspid annular plane systolic excursion (TAPSE) (0.38 cm, 95% CI: 0.15 to 0.62, p = 0.0024), and composite clinical outcome (HR 0.65, 95% CI: 0.43-0.98, p = 0.043). LVEF, GLS, E/A ratio, TAPSE, inferior vena cava diameter, and left atrial area correlated with clinical response. CONCLUSIONS: Dapagliflozin emerges as a potential therapy for patients with left ventricular dysfunction, enhancing LV systolic function and diastolic performance, alongside a favorable clinical response. Future studies with more extensive assessment of right ventricular function and longer follow-up are warranted.</AbstractText><AbstractText Label="GRAPHICAL ABSTRACT" NlmCategory="UNASSIGNED">https://www.europeanreview.org/wp/wp-content/uploads/abstract.jpg.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Abou Warda</LastName><ForeName>A E</ForeName><Initials>AE</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacy, Faculty of Pharmacy, October 6 University, Giza, Egypt. asdalananzi@ju.edu.sa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duarte</LastName><ForeName>J D</ForeName><Initials>JD</Initials></Author><Author ValidYN="Y"><LastName>Nabil Salem</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Salem</LastName><ForeName>H F</ForeName><Initials>HF</Initials></Author><Author ValidYN="Y"><LastName>Moharram</LastName><ForeName>A N</ForeName><Initials>AN</Initials></Author><Author ValidYN="Y"><LastName>Alanazi</LastName><ForeName>A S</ForeName><Initials>AS</Initials></Author><Author ValidYN="Y"><LastName>Alzarea</LastName><ForeName>A I</ForeName><Initials>AI</Initials></Author><Author ValidYN="Y"><LastName>Alsahli</LastName><ForeName>T G</ForeName><Initials>TG</Initials></Author><Author ValidYN="Y"><LastName>Sultan</LastName><ForeName>H</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Alrashdi</LastName><ForeName>M A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Altebainawi</LastName><ForeName>A F</ForeName><Initials>AF</Initials></Author><Author ValidYN="Y"><LastName>Emil Ibrahim</LastName><ForeName>B</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Ibrahim Alnahrawi</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Kamel Megalaa</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Zarif</LastName><ForeName>B</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Sarhan</LastName><ForeName>R M</ForeName><Initials>RM</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Italy</Country><MedlineTA>Eur Rev Med Pharmacol Sci</MedlineTA><NlmUniqueID>9717360</NlmUniqueID><ISSNLinking>1128-3602</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005960">Glucosides</NameOfSubstance></Chemical><Chemical><RegistryNumber>1ULL0QJ8UC</RegistryNumber><NameOfSubstance UI="C529054">dapagliflozin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001559">Benzhydryl Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000077203">Sodium-Glucose Transporter 2 Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005960" MajorTopicYN="Y">Glucosides</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001559" MajorTopicYN="Y">Benzhydryl Compounds</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018487" MajorTopicYN="Y">Ventricular Dysfunction, Left</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003971" MajorTopicYN="N">Diastole</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013599" MajorTopicYN="N">Systole</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077203" MajorTopicYN="Y">Sodium-Glucose Transporter 2 Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004452" MajorTopicYN="N">Echocardiography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006333" MajorTopicYN="Y">Heart Failure</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016277" MajorTopicYN="N">Ventricular Function, Left</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>5</Month><Day>30</Day><Hour>18</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>5</Month><Day>30</Day><Hour>18</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>5</Month><Day>30</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40444607</ArticleId><ArticleId IdType="doi">10.26355/eurrev_202505_37222</ArticleId><ArticleId IdType="pii">37222</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40564694</PMID><DateRevised><Year>2025</Year><Month>06</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2227-9067</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>6</Issue><PubDate><Year>2025</Year><Month>Jun</Month><Day>06</Day></PubDate></JournalIssue><Title>Children (Basel, Switzerland)</Title><ISOAbbreviation>Children (Basel)</ISOAbbreviation></Journal><ArticleTitle>The Role of Global Longitudinal Strain in Detecting Early Left Ventricular Dysfunction in Pediatric Bicuspid Aortic Valve Patients.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">736</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/children12060736</ELocationID><Abstract><AbstractText>Global longitudinal strain (GLS), assessed via speckle tracking echocardiography (STE), is increasingly recognized as a sensitive and early indicator of left ventricular (LV) dysfunction in pediatric patients with bicuspid aortic valve (BAV) [...].</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mashali</LastName><ForeName>Mohammed A</ForeName><Initials>MA</Initials><Identifier Source="ORCID">0000-0003-3264-5623</Identifier><AffiliationInfo><Affiliation>Department of Physiology and Cell Biology, Dorothy M. Davis Heart and Lung Research Institute, College of Medicine, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Surgery, Faculty of Veterinary Medicine, Damanhour University, Damanhour 22514, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Desch&#xea;nes</LastName><ForeName>Isabelle</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Physiology and Cell Biology, Dorothy M. Davis Heart and Lung Research Institute, College of Medicine, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leier</LastName><ForeName>Carl V</ForeName><Initials>CV</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Division of Cardiovascular Medicine, College of Medicine, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saad</LastName><ForeName>Nancy S</ForeName><Initials>NS</Initials><Identifier Source="ORCID">0000-0002-5194-7515</Identifier><AffiliationInfo><Affiliation>Department of Physiology and Cell Biology, Dorothy M. Davis Heart and Lung Research Institute, College of Medicine, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmacology and Toxicology, Faculty of Pharmacy, Helwan University, Cairo 11795, Egypt.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>06</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Children (Basel)</MedlineTA><NlmUniqueID>101648936</NlmUniqueID><ISSNLinking>2227-9067</ISSNLinking></MedlineJournalInfo><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>5</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>5</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>6</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>6</Month><Day>26</Day><Hour>6</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>6</Month><Day>26</Day><Hour>6</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>6</Month><Day>26</Day><Hour>1</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>6</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40564694</ArticleId><ArticleId IdType="pmc">PMC12191610</ArticleId><ArticleId IdType="doi">10.3390/children12060736</ArticleId><ArticleId IdType="pii">children12060736</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>F&#x103;g&#x103;r&#x103;&#x219;an A., Ghiragosian-Rusu S.-E., Ghiragosian C., Gozar L., Suteu C., Toma D., Al-Akel F.C., Cucerea M. Speckle strain analysis of left ventricular dysfunction in paediatric patients with bicuspid aortic valve&#x2014;A pilot study. Children. 2024;11:1514. doi: 10.3390/children11121514.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/children11121514</ArticleId><ArticleId IdType="pmc">PMC11674767</ArticleId><ArticleId IdType="pubmed">39767943</ArticleId></ArticleIdList></Reference><Reference><Citation>Kusner J.J., Brown J.Y., Gleason T.G., Edelman E.R. The natural history of bicuspid aortic valve disease. Struct. Heart. 2023;7:100119. doi: 10.1016/j.shj.2022.100119.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.shj.2022.100119</ArticleId><ArticleId IdType="pmc">PMC10236785</ArticleId><ArticleId IdType="pubmed">37275583</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson V., Petrini J., Caidahl K., Eriksson M.J., Liska J., Eriksson P., Franco-Cereceda A. Bicuspid aortic valve leaflet morphology in relation to aortic root morphology: A study of 300 patients undergoing open-heart surgery. Eur. J. Cardiothorac. Surg. 2011;40:e118&#x2013;e124. doi: 10.1016/j.ejcts.2011.04.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejcts.2011.04.014</ArticleId><ArticleId IdType="pubmed">21620721</ArticleId></ArticleIdList></Reference><Reference><Citation>Mubarik A., Sharma S., Law M.A. &#x201c;Bicuspid aortic valve (archived).&#x201d; In Statpearls [Internet] StatPearls; Publishing; Treasure Island, FL, USA: 2023.</Citation><ArticleIdList><ArticleId IdType="pubmed">30480953</ArticleId></ArticleIdList></Reference><Reference><Citation>Michelena H.I., Desjardins V.A., Avierinos J.-F., Russo A., Nkomo V.T., Sundt T.M., Pellikka P.A., Tajik A.J., Enriquez-Sarano M. Natural history of asymptomatic patients with normally functioning or minimally dysfunctional bicuspid aortic valve in the community. Circulation. 2008;117:2776&#x2013;2784. doi: 10.1161/CIRCULATIONAHA.107.740878.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.107.740878</ArticleId><ArticleId IdType="pmc">PMC2878133</ArticleId><ArticleId IdType="pubmed">18506017</ArticleId></ArticleIdList></Reference><Reference><Citation>Vancheri F., Longo G., Henein M.Y. Left ventricular ejection fraction: Clinical, pathophysiological, and technical limitations. Front. Cardiovasc. Med. 2024;11:1340708. doi: 10.3389/fcvm.2024.1340708.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2024.1340708</ArticleId><ArticleId IdType="pmc">PMC10879419</ArticleId><ArticleId IdType="pubmed">38385136</ArticleId></ArticleIdList></Reference><Reference><Citation>Smiseth O.A., Torp H., Opdahl A., Haugaa K.H., Urheim S. Myocardial strain imaging: How useful is it in clinical decision making? Eur. Heart J. 2016;37:1196&#x2013;1207. doi: 10.1093/eurheartj/ehv529.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehv529</ArticleId><ArticleId IdType="pmc">PMC4830908</ArticleId><ArticleId IdType="pubmed">26508168</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu R., Ding Z., Li H., Shi J., Cheng L., Xu H., Wu J., Zou Y. Identification of early cardiac dysfunction and heterogeneity after pressure and volume overload in mice by high-frequency echocardiographic strain imaging. Front. Cardiovasc. Med. 2023;9:1071249. doi: 10.3389/fcvm.2022.1071249.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2022.1071249</ArticleId><ArticleId IdType="pmc">PMC9880208</ArticleId><ArticleId IdType="pubmed">36712248</ArticleId></ArticleIdList></Reference><Reference><Citation>Brady B., King G., Murphy R.T., Walsh D. Myocardial strain: A clinical review. Ir. J. Med. Sci. 2023;192:1649&#x2013;1656. doi: 10.1007/s11845-022-03210-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11845-022-03210-8</ArticleId><ArticleId IdType="pmc">PMC9666989</ArticleId><ArticleId IdType="pubmed">36380189</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh J.K., Park J.-H. Role of strain echocardiography in patients with hypertension. Clin. Hypertens. 2022;28:6. doi: 10.1186/s40885-021-00186-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40885-021-00186-y</ArticleId><ArticleId IdType="pmc">PMC8845306</ArticleId><ArticleId IdType="pubmed">35164856</ArticleId></ArticleIdList></Reference><Reference><Citation>Pagourelias E.D., Mirea O., Duchenne J., Van Cleemput J., Delforge M., Bogaert J., Kuznetsova T., Voigt J.-U. Echo parameters for differential diagnosis in cardiac amyloidosis: A head-to-head comparison of deformation and nondeformation parameters. Circ. Cardiovasc. Imaging. 2017;10:e005588. doi: 10.1161/CIRCIMAGING.116.005588.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCIMAGING.116.005588</ArticleId><ArticleId IdType="pubmed">28298286</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagata Y., Bertrand P.B., Baliyan V., Kochav J., Kagan R.D., Ujka K., Alfraidi H., van Kampen A., Morningstar J.E., Dal-Bianco J.P. Abnormal mechanics relate to myocardial fibrosis and ventricular arrhythmias in patients with mitral valve prolapse. Circ. Cardiovasc. Imaging. 2023;16:e014963. doi: 10.1161/CIRCIMAGING.122.014963.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCIMAGING.122.014963</ArticleId><ArticleId IdType="pmc">PMC10108844</ArticleId><ArticleId IdType="pubmed">37071717</ArticleId></ArticleIdList></Reference><Reference><Citation>Voigt J.-U., Cvijic M. 2-and 3-dimensional myocardial strain in cardiac health and disease. JACC Cardiovasc. Imaging. 2019;12:1849&#x2013;1863. doi: 10.1016/j.jcmg.2019.01.044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcmg.2019.01.044</ArticleId><ArticleId IdType="pubmed">31488253</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu S., Laghzali O., Shalikar S., Rusu M.-C., Carrier L., Niendorf T., Ku M.-C. Cardiac mri strain as an early indicator of myocardial dysfunction in hypertrophic cardiomyopathy. Int. J. Mol. Sci. 2025;26:1407. doi: 10.3390/ijms26041407.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms26041407</ArticleId><ArticleId IdType="pmc">PMC11855820</ArticleId><ArticleId IdType="pubmed">40003877</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang J.-W., Song H.G., Yang D.H., Baek S., Kim D.-H., Song J.-M., Kang D.-H., Lim T.-H., Song J.-K. Association between bicuspid aortic valve phenotype and patterns of valvular dysfunction and bicuspid aortopathy: Comprehensive evaluation using mdct and echocardiography. JACC Cardiovasc. Imaging. 2013;6:150&#x2013;161. doi: 10.1016/j.jcmg.2012.11.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcmg.2012.11.007</ArticleId><ArticleId IdType="pubmed">23489528</ArticleId></ArticleIdList></Reference><Reference><Citation>Michelena H.I. Speaking a common language: The international consensus on bicuspid aortic valve nomenclature and classification. Ann. Cardiothorac. Surg. 2022;11:402. doi: 10.21037/acs-2022-bav-24.</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/acs-2022-bav-24</ArticleId><ArticleId IdType="pmc">PMC9357966</ArticleId><ArticleId IdType="pubmed">35958544</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">40448135</PMID><DateRevised><Year>2025</Year><Month>06</Month><Day>02</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1475-2840</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>May</Month><Day>30</Day></PubDate></JournalIssue><Title>Cardiovascular diabetology</Title><ISOAbbreviation>Cardiovasc Diabetol</ISOAbbreviation></Journal><ArticleTitle>Effects of dapagliflozin on the progression of left ventricular dysfunction in type 2 diabetes mellitus: a randomized controlled trial.</ArticleTitle><Pagination><StartPage>232</StartPage><MedlinePgn>232</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">232</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12933-025-02796-4</ELocationID><Abstract><AbstractText Label="BACKGROUND">Screening for HF may identify asymptomatic abnormalities of LV structure or function, described as stage B heart failure (SBHF) in asymptomatic patients with type 2 diabetes mellitus (T2DM). Sodium-glucose transport protein-2 (SGLT2) inhibitors are associated with reduction of overt HF in T2DM, but the mechanism of their effect in SBHF remains obscure. We sought to assess the response of cardiac function and exercise capacity to dapagliflozin vs placebo in T2DM with stage B HF.</AbstractText><AbstractText Label="METHODS">The LEAVE-DM (Limiting the progression of Echocardiographically-Assessed left VEntricular dysfunction in Diabetes Mellitus) trial assessed echocardiography and 6-min walk (6MWD) in 262 people with well-controlled T2DM (age 73&#x2009;&#xb1;&#x2009;7&#xa0;years; 159 women). Those with LVD (n&#x2009;=&#x2009;139) were randomized 1:1 to dapagliflozin 10&#xa0;mg/day or placebo. Follow-up was undertaken at 6 and 24&#xa0;months and the primary endpoint was global longitudinal strain (GLS).</AbstractText><AbstractText Label="RESULTS">Within the randomized group with LV dysfunction, dapagliflozin was associated with reduction of LA volume index (&#x2212;&#x2009;2.0&#x2009;&#xb1;&#x2009;9.0 vs. 0.03&#x2009;&#xb1;&#x2009;8.6, <i>p</i>&#x2009;=&#x2009;0.002), and average E/e&#x2032; (&#x2212;&#x2009;0.1&#x2009;&#xb1;&#x2009;2.4 vs. 0.7&#x2009;&#xb1;&#x2009;2.4, <i>p</i>&#x2009;&lt;&#x2009;0.001), and improved LA reservoir strain (1.8&#x2009;&#xb1;&#x2009;4.0 vs. &#x2212;&#x2009;0.2&#x2009;&#xb1;&#x2009;4.0, <i>p</i>&#x2009;=&#x2009;0.02) from baseline to 6&#xa0;months follow-up. There was an improvement in exercise capacity on dapagliflozin at 6&#xa0;months follow-up (&#x394;6MWD 17&#x2009;&#xb1;&#x2009;46 vs. 2&#x2009;&#xb1;&#x2009;73&#xa0;m, <i>p</i>&#x2009;=&#x2009;0.001). However, although abnormal GLS (&lt;&#x2009;16%) was less common at 6&#xa0;months follow-up (41% vs. 49%, <i>p</i>&#x2009;=&#x2009;0.03), there was no difference in &#x394;GLS from baseline to 6&#xa0;months between dapagliflozin and placebo (<i>p</i>&#x2009;=&#x2009;0.18). There were no significant differences between 6 and 24&#xa0;months.</AbstractText><AbstractText Label="CONCLUSIONS">Dapagliflozin showed improvements in diastolic function, atrial function and exercise capacity in in patients with T2DM and SBHF, but no change in GLS. <i>Trial Registration</i>: ACTRN12619001393145 at Australia and New Zealand Clinical Trials registry (https://www.anzctr.org.au/).</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Marwick</LastName><ForeName>Thomas H</ForeName><Initials>TH</Initials><AffiliationInfo><Affiliation>Baker Heart and Diabetes Institute, 75 Commercial Road, Melbourne, VIC, 3004, Australia. tom.marwick@baker.edu.au.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Western Health, Melbourne, Australia. tom.marwick@baker.edu.au.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Menzies Institute for Medical Research, Hobart, Australia. tom.marwick@baker.edu.au.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Halabi</LastName><ForeName>Amera</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Baker Heart and Diabetes Institute, 75 Commercial Road, Melbourne, VIC, 3004, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Western Health, Melbourne, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soh</LastName><ForeName>Cheng Hwee</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>Baker Heart and Diabetes Institute, 75 Commercial Road, Melbourne, VIC, 3004, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Curtin</LastName><ForeName>Annie</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Baker Heart and Diabetes Institute, 75 Commercial Road, Melbourne, VIC, 3004, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sherrif</LastName><ForeName>Ashleigh-Georgia</ForeName><Initials>AG</Initials><AffiliationInfo><Affiliation>Baker Heart and Diabetes Institute, 75 Commercial Road, Melbourne, VIC, 3004, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Azad</LastName><ForeName>Atro</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Baker Heart and Diabetes Institute, 75 Commercial Road, Melbourne, VIC, 3004, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wright</LastName><ForeName>Leah</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Baker Heart and Diabetes Institute, 75 Commercial Road, Melbourne, VIC, 3004, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ANZCTR</DataBankName><AccessionNumberList><AccessionNumber>ACTRN12619001393145</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>ESR-19-20042</GrantID><Agency>Astra Zeneca</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>05</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Cardiovasc Diabetol</MedlineTA><NlmUniqueID>101147637</NlmUniqueID><ISSNLinking>1475-2840</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Dapagliflozin</Keyword><Keyword MajorTopicYN="N">Diabetic cardiomyopathy</Keyword><Keyword MajorTopicYN="N">Diastolic dysfunction</Keyword><Keyword MajorTopicYN="N">Systolic dysfunction</Keyword></KeywordList><CoiStatement>Declarations. Competing interests: The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>4</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>5</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>5</Month><Day>31</Day><Hour>0</Hour><Minute>36</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>5</Month><Day>31</Day><Hour>0</Hour><Minute>36</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>5</Month><Day>30</Day><Hour>23</Hour><Minute>49</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>5</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40448135</ArticleId><ArticleId IdType="pmc">PMC12125862</ArticleId><ArticleId IdType="doi">10.1186/s12933-025-02796-4</ArticleId><ArticleId IdType="pii">10.1186/s12933-025-02796-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Pop-Busui R, Januzzi JL, Bruemmer D, Butalia S, Green JB, Horton WB, Knight C, Levi M, Rasouli N, Richardson CR. Heart failure: an underappreciated complication of diabetes a consensus report of the American Diabetes Association. Diabetes Care. 2022;45:1670&#x2013;90. 10.2337/dci22-0014.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9726978</ArticleId><ArticleId IdType="pubmed">35796765</ArticleId></ArticleIdList></Reference><Reference><Citation>Pandey A, Vaduganathan M, Patel KV, Ayers C, Ballantyne CM, Kosiborod MN, Carnethon M, DeFilippi C, McGuire DK, Khan SS, et al. Biomarker-based risk prediction of incident heart failure in pre-diabetes and diabetes. JACC Heart Fail. 2021;9:215&#x2013;23. 10.1016/j.jchf.2020.10.013.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11229674</ArticleId><ArticleId IdType="pubmed">33422434</ArticleId></ArticleIdList></Reference><Reference><Citation>Sacre JW, Wong C, Chan YK, Carrington MJ, Stewart S, Kingwell BA. Left ventricular dysfunction and exercise capacity trajectory: implications for subclinical heart failure staging criteria. JACC Cardiovasc Imaging. 2019;12:798&#x2013;806. 10.1016/j.jcmg.2017.10.023.</Citation><ArticleIdList><ArticleId IdType="pubmed">29454775</ArticleId></ArticleIdList></Reference><Reference><Citation>Young KA, Scott CG, Rodeheffer RJ, Chen HH. Progression of preclinical heart failure: a description of stage A and B heart failure in a community population. Circ Cardiovasc Qual Outcomes. 2021;14:e007216. 10.1161/CIRCOUTCOMES.120.007216.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8137558</ArticleId><ArticleId IdType="pubmed">33951931</ArticleId></ArticleIdList></Reference><Reference><Citation>McClelland S, Zhou S, O&#x2019;Connell E, Gallagher J, Ryan F, Watson CJ, Ledwidge M, McDonald K. New-onset heart failure in the STOP-HF programme. Natriuretic peptide defines and tracks risk and enables earlier diagnosis of heart failure. Eur J Heart Fail. 2020;22:378&#x2013;80. 10.1002/ejhf.1661.</Citation><ArticleIdList><ArticleId IdType="pubmed">31908097</ArticleId></ArticleIdList></Reference><Reference><Citation>Seferovic P, Farmakis D, Bayes-Genis A, Ben Gal T, Bohm M, Chioncel O, Ferrari R, Filippatos G, Hill L, Jankowska E, et al. Biomarkers for the prediction of heart failure and cardiovascular events in patients with type 2 diabetes: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2022;24:1162&#x2013;70. 10.1002/ejhf.2575.</Citation><ArticleIdList><ArticleId IdType="pubmed">35703329</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Yang H, Huynh Q, Nolan M, Negishi K, Marwick TH. Diagnosis of nonischemic stage B heart failure in type 2 diabetes mellitus: optimal parameters for prediction of heart failure. JACC Cardiovasc Imaging. 2018;11:1390&#x2013;400. 10.1016/j.jcmg.2018.03.015.</Citation><ArticleIdList><ArticleId IdType="pubmed">29778859</ArticleId></ArticleIdList></Reference><Reference><Citation>Huelsmann M, Neuhold S, Resl M, Strunk G, Brath H, Francesconi C, Adlbrecht C, Prager R, Luger A, Pacher R, Clodi M. PONTIAC (NT-proBNP selected prevention of cardiac events in a population of diabetic patients without a history of cardiac disease): a prospective randomized controlled trial. J Am Coll Cardiol. 2013;62:1365&#x2013;72. 10.1016/j.jacc.2013.05.069.</Citation><ArticleIdList><ArticleId IdType="pubmed">23810874</ArticleId></ArticleIdList></Reference><Reference><Citation>Ledwidge M, Gallagher J, Conlon C, Tallon E, O&#x2019;Connell E, Dawkins I, Watson C, O&#x2019;Hanlon R, Bermingham M, Patle A, et al. Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial. JAMA. 2013;310:66&#x2013;74. 10.1001/jama.2013.7588.</Citation><ArticleIdList><ArticleId IdType="pubmed">23821090</ArticleId></ArticleIdList></Reference><Reference><Citation>Marwick TH, Ritchie R, Shaw JE, Kaye D. Implications of underlying mechanisms for the recognition and management of diabetic cardiomyopathy. J Am Coll Cardiol. 2018;71:339&#x2013;51. 10.1016/j.jacc.2017.11.019.</Citation><ArticleIdList><ArticleId IdType="pubmed">29348027</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med. 2001;33:337&#x2013;43. 10.3109/07853890109002087.</Citation><ArticleIdList><ArticleId IdType="pubmed">11491192</ArticleId></ArticleIdList></Reference><Reference><Citation>Hlatky MA, Boineau RE, Higginbotham MB, Lee KL, Mark DB, Califf RM, Cobb FR, Pryor DB. A brief self-administered questionnaire to determine functional capacity (the duke activity status index). Am J Cardiol. 1989;64:651&#x2013;4. 10.1016/0002-9149(89)90496-7.</Citation><ArticleIdList><ArticleId IdType="pubmed">2782256</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitchell C, Rahko PS, Blauwet LA, Canaday B, Finstuen JA, Foster MC, Horton K, Ogunyankin KO, Palma RA, Velazquez EJ. Guidelines for Performing a comprehensive transthoracic echocardiographic examination in adults: recommendations from the American Society of Echocardiography. J Am Soc Echocardiogr. 2019;32:1&#x2013;64. 10.1016/j.echo.2018.06.004.</Citation><ArticleIdList><ArticleId IdType="pubmed">30282592</ArticleId></ArticleIdList></Reference><Reference><Citation>Flachskampf FA, Blankstein R, Grayburn PA, Kramer CM, Kwong RYK, Marwick TH, Nagel E, Sengupta PP, Zoghbi WA, Chandrashekhar Y. Global longitudinal shortening: a positive step towards reducing confusion surrounding global longitudinal strain. JACC Cardiovasc Imaging. 2019;12:1566&#x2013;7. 10.1016/j.jcmg.2019.03.032.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7561032</ArticleId><ArticleId IdType="pubmed">31395245</ArticleId></ArticleIdList></Reference><Reference><Citation>Ernande L, Audureau E, Jellis CL, Bergerot C, Henegar C, Sawaki D, Czibik G, Volpi C, Canoui-Poitrine F, Thibault H, et al. Clinical implications of echocardiographic phenotypes of patients with diabetes mellitus. J Am Coll Cardiol. 2017;70:1704&#x2013;16. 10.1016/j.jacc.2017.07.792.</Citation><ArticleIdList><ArticleId IdType="pubmed">28958326</ArticleId></ArticleIdList></Reference><Reference><Citation>Anon. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166:111&#x2013;117.</Citation><ArticleIdList><ArticleId IdType="pubmed">12091180</ArticleId></ArticleIdList></Reference><Reference><Citation>Casanova C, Celli BR, Barria P, Casas A, Cote C, de Torres JP, Jardim J, Lopez MV, Marin JM, Montes de Oca M, et al. The 6-min walk distance in healthy subjects: reference standards from seven countries. Eur Respir J. 2011;37:150.</Citation><ArticleIdList><ArticleId IdType="pubmed">20525717</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang H, Negishi K, Wang Y, Nolan M, Saito M, Marwick TH. Echocardiographic screening for non-ischaemic stage B heart failure in the community. Eur J Heart Fail. 2016;18:1331&#x2013;9. 10.1002/ejhf.643.</Citation><ArticleIdList><ArticleId IdType="pubmed">27813300</ArticleId></ArticleIdList></Reference><Reference><Citation>Kosmala W, Jellis CL, Marwick TH. Exercise limitation associated with asymptomatic left ventricular impairment: analogy with stage B heart failure. J Am Coll Cardiol. 2015;65:257&#x2013;66. 10.1016/j.jacc.2014.10.044.</Citation><ArticleIdList><ArticleId IdType="pubmed">25533754</ArticleId></ArticleIdList></Reference><Reference><Citation>Ostrominski JW, Vaduganathan M. Chapter 2: clinical and mechanistic potential of sodium-glucose co-transporter 2 (SGLT2) inhibitors in heart failure with preserved ejection fraction. Am J Med. 2024;137:S9&#x2013;24. 10.1016/j.amjmed.2023.04.035.</Citation><ArticleIdList><ArticleId IdType="pubmed">37160196</ArticleId></ArticleIdList></Reference><Reference><Citation>Kosmala W, Przewlocka-Kosmala M, Sharman JE, Schultz MG, Marwick TH. Stability of left ventricular longitudinal and circumferential deformation over time and standard loading conditions. Eur Heart J Cardiovasc Imaging. 2017;18:1001&#x2013;7. 10.1093/ehjci/jew135.</Citation><ArticleIdList><ArticleId IdType="pubmed">27369851</ArticleId></ArticleIdList></Reference><Reference><Citation>Hundertmark MJ, Adler A, Antoniades C, Coleman R, Griffin JL, Holman RR, Lamlum H, Lee J, Massey D, Miller J, et al. Assessment of cardiac energy metabolism, function, and physiology in patients with heart failure taking empagliflozin: the randomized, Controlled EMPA-VISION trial. Circulation. 2023;147:1654&#x2013;69. 10.1161/CIRCULATIONAHA.122.062021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10212585</ArticleId><ArticleId IdType="pubmed">37070436</ArticleId></ArticleIdList></Reference><Reference><Citation>Soh CH, Wright L, Baumann A, Seidel B, Yu C, Nolan M, Mylius T, Marwick TH, Echo investigators in Tasmania WNSWNVWAWQ, Northern Territory A. Use of artificial intelligence-guided echocardiography to detect cardiac dysfunction and heart valve disease in rural and remote areas: rationale and design of the AGILE-echo trial. Am Heart J. 2024;277:11&#x2013;9. 10.1016/j.ahj.2024.08.004.</Citation><ArticleIdList><ArticleId IdType="pubmed">39128659</ArticleId></ArticleIdList></Reference><Reference><Citation>Negishi T, Negishi K, Thavendiranathan P, Cho GY, Popescu BA, Vinereanu D, Kurosawa K, Penicka M, Marwick TH, Investigators S. Effect of experience and training on the concordance and precision of strain measurements. JACC Cardiovasc Imaging. 2017;10:518&#x2013;22. 10.1016/j.jcmg.2016.06.012.</Citation><ArticleIdList><ArticleId IdType="pubmed">27743951</ArticleId></ArticleIdList></Reference><Reference><Citation>Potter E, Huynh Q, Haji K, Wong C, Yang H, Wright L, Marwick TH. Use of clinical and echocardiographic evaluation to assess the risk of heart failure. JACC Heart Fail. 2024;12:275&#x2013;86. 10.1016/j.jchf.2023.06.014.</Citation><ArticleIdList><ArticleId IdType="pubmed">37498272</ArticleId></ArticleIdList></Reference><Reference><Citation>Soh CH, de Sa AGC, Potter E, Halabi A, Ascher DB, Marwick TH. Use of the energy waveform electrocardiogram to detect subclinical left ventricular dysfunction in patients with type 2 diabetes mellitus. Cardiovasc Diabetol. 2024;23:91. 10.1186/s12933-024-02141-1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10918872</ArticleId><ArticleId IdType="pubmed">38448993</ArticleId></ArticleIdList></Reference><Reference><Citation>McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, Burri H, Butler J, Celutkiene J, Chioncel O, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42:3599&#x2013;726. 10.1093/eurheartj/ehab368.</Citation><ArticleIdList><ArticleId IdType="pubmed">34447992</ArticleId></ArticleIdList></Reference><Reference><Citation>Kosmala W, Rojek A, Przewlocka-Kosmala M, Wright L, Mysiak A, Marwick TH. Effect of aldosterone antagonism on exercise tolerance in heart failure with preserved ejection fraction. J Am Coll Cardiol. 2016;68:1823&#x2013;34. 10.1016/j.jacc.2016.07.763.</Citation><ArticleIdList><ArticleId IdType="pubmed">27765184</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang H, Negishi K, Wang Y, Nolan M, Marwick TH. Imaging-guided cardioprotective treatment in a community elderly population of stage B heart failure. JACC Cardiovasc Imaging. 2017;10:217&#x2013;26. 10.1016/j.jcmg.2016.11.015.</Citation><ArticleIdList><ArticleId IdType="pubmed">28279368</ArticleId></ArticleIdList></Reference><Reference><Citation>Potter E, Stephenson G, Harris J, Wright L, Marwick TH. Screening-guided spironolactone treatment of subclinical left ventricular dysfunction for heart failure prevention in at-risk patients. Eur J Heart Fail. 2022;24:620&#x2013;30. 10.1002/ejhf.2428.</Citation><ArticleIdList><ArticleId IdType="pubmed">35014128</ArticleId></ArticleIdList></Reference><Reference><Citation>Kosmala W, Przewlocka-Kosmala M, Szczepanik-Osadnik H, Mysiak A, O&#x2019;Moore-Sullivan T, Marwick TH. A randomized study of the beneficial effects of aldosterone antagonism on LV function, structure, and fibrosis markers in metabolic syndrome. JACC Cardiovasc Imaging. 2011;4:1239&#x2013;49. 10.1016/j.jcmg.2011.08.014.</Citation><ArticleIdList><ArticleId IdType="pubmed">22172779</ArticleId></ArticleIdList></Reference><Reference><Citation>Halabi A, Sen J, Huynh Q, Marwick TH. Metformin treatment in heart failure with preserved ejection fraction: a systematic review and meta-regression analysis. Cardiovasc Diabetol. 2020;19:124. 10.1186/s12933-020-01100-w.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7409497</ArticleId><ArticleId IdType="pubmed">32758236</ArticleId></ArticleIdList></Reference><Reference><Citation>Talha KM, Anker SD, Butler J. SGLT-2 inhibitors in heart failure: a review of current evidence. Int J Heart Fail. 2023;5:82&#x2013;90. 10.36628/ijhf.2022.0030.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10172076</ArticleId><ArticleId IdType="pubmed">37180562</ArticleId></ArticleIdList></Reference><Reference><Citation>Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2022;79:e263&#x2013;421. 10.1016/j.jacc.2021.12.012.</Citation><ArticleIdList><ArticleId IdType="pubmed">35379503</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380:347&#x2013;57. 10.1056/NEJMoa1812389.</Citation><ArticleIdList><ArticleId IdType="pubmed">30415602</ArticleId></ArticleIdList></Reference><Reference><Citation>Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117&#x2013;28. 10.1056/NEJMoa1504720.</Citation><ArticleIdList><ArticleId IdType="pubmed">26378978</ArticleId></ArticleIdList></Reference><Reference><Citation>McMurray JJV, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Belohlavek J, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381:1995&#x2013;2008. 10.1056/NEJMoa1911303.</Citation><ArticleIdList><ArticleId IdType="pubmed">31535829</ArticleId></ArticleIdList></Reference><Reference><Citation>Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, Januzzi J, Verma S, Tsutsui H, Brueckmann M, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383:1413&#x2013;24. 10.1056/NEJMoa2022190.</Citation><ArticleIdList><ArticleId IdType="pubmed">32865377</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Martinez F, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387:1089&#x2013;98. 10.1056/NEJMoa2206286.</Citation><ArticleIdList><ArticleId IdType="pubmed">36027570</ArticleId></ArticleIdList></Reference><Reference><Citation>Theofilis P, Antonopoulos AS, Katsimichas T, Oikonomou E, Siasos G, Aggeli C, Tsioufis K, Tousoulis D. The impact of SGLT2 inhibition on imaging markers of cardiac function: a systematic review and meta-analysis. Pharmacol Res. 2022;180:106243. 10.1016/j.phrs.2022.106243.</Citation><ArticleIdList><ArticleId IdType="pubmed">35523389</ArticleId></ArticleIdList></Reference><Reference><Citation>Hwang IC, Cho GY, Yoon YE, Park JJ, Park JB, Lee SP, Kim HK, Kim YJ, Sohn DW. Different effects of SGLT2 inhibitors according to the presence and types of heart failure in type 2 diabetic patients. Cardiovasc Diabetol. 2020;19:69. 10.1186/s12933-020-01042-3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7254690</ArticleId><ArticleId IdType="pubmed">32466760</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu YW, Zhao XM, Wang YH, Zhou Q, Huang Y, Zhai M, Zhang J. Effect of sodium-glucose cotransporter 2 inhibitors on cardiac structure and function in type 2 diabetes mellitus patients with or without chronic heart failure: a meta-analysis. Cardiovasc Diabetol. 2021;20:25. 10.1186/s12933-020-01209-y.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7836497</ArticleId><ArticleId IdType="pubmed">33494751</ArticleId></ArticleIdList></Reference><Reference><Citation>Nesti L, Pugliese NR, Sciuto P, et al. Effect of empagliflozin on left ventricular contractility and peak oxygen uptake in subjects with type 2 diabetes without heart disease: results of the EMPA-HEART trial. Cardiovasc Diabetol. 2022;21:181. 10.1186/s12933-022-01618-1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9467417</ArticleId><ArticleId IdType="pubmed">36096863</ArticleId></ArticleIdList></Reference><Reference><Citation>Nesti L, Pugliese NR, Sciuto P, Natali A. Type 2 diabetes and reduced exercise tolerance: a review of the literature through an integrated physiology approach. Cardiovasc Diabetol. 2020;19:134. 10.1186/s12933-020-01109-1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7487838</ArticleId><ArticleId IdType="pubmed">32891175</ArticleId></ArticleIdList></Reference><Reference><Citation>Troosters T, Gosselink R, Decramer M. Six minute walking distance in healthy elderly subjects. Eur Respir J. 1999;14:270&#x2013;4. 10.1034/j.1399-3003.1999.14b06.x.</Citation><ArticleIdList><ArticleId IdType="pubmed">10515400</ArticleId></ArticleIdList></Reference><Reference><Citation>Jain SS, Cohen DJ, Zhang Z, Uriel N, Sayer G, Lindenfeld J, Abraham WT, Mack MJ, Stone GW, Arnold SV. Defining a clinically important change in 6-minute walk distance in patients with heart failure and mitral valve disease. Circ Heart Fail. 2021;14:e007564. 10.1161/CIRCHEARTFAILURE.120.007564.</Citation><ArticleIdList><ArticleId IdType="pubmed">33663234</ArticleId></ArticleIdList></Reference><Reference><Citation>Shoemaker MJ, Curtis AB, Vangsnes E, Dickinson MG. Clinically meaningful change estimates for the six-minute walk test and daily activity in individuals with chronic heart failure. Cardiopulm Phys Ther J. 2013;24:21&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3751711</ArticleId><ArticleId IdType="pubmed">23997688</ArticleId></ArticleIdList></Reference><Reference><Citation>Nesti L, Pugliese NR, Sciuto P, De Biase N, Mazzola M, Fabiani I, Trico D, Masi S, Natali A. Mechanisms of reduced peak oxygen consumption in subjects with uncomplicated type 2 diabetes. Cardiovasc Diabetol. 2021;20:124. 10.1186/s12933-021-01314-6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8218418</ArticleId><ArticleId IdType="pubmed">34158062</ArticleId></ArticleIdList></Reference><Reference><Citation>Deboeck G, Van Muylem A, Vachiery JL, Naeije R. Physiological response to the 6-minute walk test in chronic heart failure patients versus healthy control subjects. Eur J Prev Cardiol. 2014;21:997&#x2013;1003. 10.1177/2047487313482283.</Citation><ArticleIdList><ArticleId IdType="pubmed">23513011</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40367000</PMID><DateCompleted><Year>2025</Year><Month>05</Month><Day>15</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1678-4170</ISSN><JournalIssue CitedMedium="Internet"><Volume>122</Volume><Issue>4</Issue><PubDate><Year>2025</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Arquivos brasileiros de cardiologia</Title><ISOAbbreviation>Arq Bras Cardiol</ISOAbbreviation></Journal><ArticleTitle>The Effect of Coronary Artery Bypass Graft Surgery on Contractile Function and Symptoms in Patients with Left Ventricular Dysfunction.</ArticleTitle><Pagination><StartPage>e20240486</StartPage><MedlinePgn>e20240486</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e20240486</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.36660/abc.20240486</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0066-782X2025000400304</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The degree of left ventricular (LV) dysfunction is an independent risk factor for poor outcomes in patients with chronic coronary syndrome. Coronary artery bypass graft (CABG) is the standard care for the management of ischemic heart failure to improve symptoms and prognosis. However, the predictors of improvement are still uncertain.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To assess the effect of myocardial revascularization on LV function and symptoms in patients with CCS and reduced left ventricular ejection fraction (LVEF), as well as to identify the improvement predictors.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We retrospectively analyzed the data and clinical status of 136 consecutive patients with LVEF&lt;50% that underwent CABG. During clinical follow-up echocardiographic LV function was reassessed at the short-term (3.6 months) and long-term (30.8 months), and compared to baseline.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Mean pre-operative LVEF was 40.9 &#xb1; 8.6% and wall motion score index (WMSI) was 1.99 &#xb1; 0.36, both improving at long-term to 48.1 &#xb1; 15.0% (p&lt;0.001) and 1.75 &#xb1; 0.49 (p&lt;0.001), respectively. We observed that 55.7% of the patients presented an improvement of LVEF&#x2265;10% and 58.1% in WMSI &#x2265;10%. Univariate logistic regression analysis revealed that cerebrovascular disease was the only variable to be predictor of LVEF improvement. At the end of follow-up, we observed a reduction in the rate of patients in functional class III/IV when compared to baseline (65.4 vs. 10.3% - p&lt;0.001).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Patients with CCS and reduced LVEF undergoing CABG experienced improvement in both LV contractile function and size, with beneficial response in functional class.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bassan</LastName><ForeName>Fernando</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-0179-4661</Identifier><AffiliationInfo><Affiliation>Instituto Nacional de Cardiologia, Rio de Janeiro, RJ - Brasil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Esporcatte</LastName><ForeName>Roberto</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Universidade do Estado do Rio de Janeiro - Doen&#xe7;as do T&#xf3;rax, Rio de Janeiro, RJ - Brasil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Correia</LastName><ForeName>Marcelo Goulart</ForeName><Initials>MG</Initials><Identifier Source="ORCID">0000-0002-3446-5741</Identifier></Author><Author ValidYN="Y"><LastName>Guina</LastName><ForeName>Octavio Drummond</ForeName><Initials>OD</Initials><Identifier Source="ORCID">0000-0001-6277-5985</Identifier><AffiliationInfo><Affiliation>Instituto Nacional de Cardiologia, Rio de Janeiro, RJ - Brasil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weigert</LastName><ForeName>Guilherme de Souza</ForeName><Initials>GS</Initials><AffiliationInfo><Affiliation>Instituto Nacional de Cardiologia, Rio de Janeiro, RJ - Brasil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oliveira</LastName><ForeName>Gracielle Christine do Nascimento</ForeName><Initials>GCDN</Initials><AffiliationInfo><Affiliation>Instituto Nacional de Cardiologia, Rio de Janeiro, RJ - Brasil.</Affiliation></AffiliationInfo></Author></AuthorList><Language>por</Language><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>O Efeito da Cirurgia de Revasculariza&#xe7;&#xe3;o Mioc&#xe1;rdica na Fun&#xe7;&#xe3;o Contr&#xe1;til e Sintomas em Pacientes com Disfun&#xe7;&#xe3;o Ventricular Esquerda.</VernacularTitle></Article><MedlineJournalInfo><Country>Brazil</Country><MedlineTA>Arq Bras Cardiol</MedlineTA><NlmUniqueID>0421031</NlmUniqueID><ISSNLinking>0066-782X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001026" MajorTopicYN="Y">Coronary Artery Bypass</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018487" MajorTopicYN="Y">Ventricular Dysfunction, Left</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013318" MajorTopicYN="N">Stroke Volume</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009200" MajorTopicYN="Y">Myocardial Contraction</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016277" MajorTopicYN="N">Ventricular Function, Left</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004452" MajorTopicYN="N">Echocardiography</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="por"><AbstractText Label="FUNDAMENTO" NlmCategory="OBJECTIVE">O grau de disfun&#xe7;&#xe3;o do ventr&#xed;culo esquerdo (VE) &#xe9; um fator de risco independente para piores desfechos em pacientes com s&#xed;ndrome coronariana cr&#xf4;nica (SCC). A cirurgia de revasculariza&#xe7;&#xe3;o mioc&#xe1;rdica (CRVM) &#xe9; a estrat&#xe9;gia terap&#xea;utica padr&#xe3;o na insufici&#xea;ncia card&#xed;aca isqu&#xea;mica para melhorar os sintomas e o progn&#xf3;stico. No entanto, os preditores de melhora ainda s&#xe3;o incertos.</AbstractText><AbstractText Label="OBJETIVOS" NlmCategory="OBJECTIVE">Avaliar o efeito da revasculariza&#xe7;&#xe3;o mioc&#xe1;rdica sobre a fun&#xe7;&#xe3;o do VE e sintomas em pacientes com SCC e fra&#xe7;&#xe3;o de eje&#xe7;&#xe3;o do ventr&#xed;culo esquerdo (FEVE) reduzida, e identificar os preditores de melhora.</AbstractText><AbstractText Label="M&#xc9;TODOS" NlmCategory="UNASSIGNED">Analisamos, retrospectivamente, dados e condi&#xe7;&#xe3;o cl&#xed;nica de 136 pacientes consecutivos com FEVE &lt;50%, submetidos &#xe0; CRVM. Durante o acompanhamento ecocardiogr&#xe1;fico, a fun&#xe7;&#xe3;o do VE foi reavaliada no curto (3,6 meses) e longo prazo (30,8 meses), e comparada com os dados basais.</AbstractText><AbstractText Label="RESULTADOS" NlmCategory="RESULTS">A FEVE m&#xe9;dia no pr&#xe9;-operat&#xf3;rio foi 40,9 &#xb1; 8,6% e a m&#xe9;dia do escore do &#xed;ndice de motilidade (WMSI) foi 1,99 &#xb1; 0,36, ambos melhorando no longo prazo para 48,1 &#xb1; 15,0% (p&lt;0,001) e 1,75 &#xb1; 0,49 (p&lt;0,001), respectivamente. Observamos que 55,7% dos pacientes apresentaram uma melhora na FEVE &#x2265;10% e 58,1% no WMSI &#x2265;10%. A an&#xe1;lise de regress&#xe3;o log&#xed;stica revelou que a doen&#xe7;a cerebrovascular foi a &#xfa;nica vari&#xe1;vel preditora de melhora na FEVE. No final do acompanhamento, observamos uma redu&#xe7;&#xe3;o na taxa de pacientes em classe funcional III/IV em compara&#xe7;&#xe3;o ao basal (65,4 vs. 10,3% - p&lt;0,001).</AbstractText><AbstractText Label="CONCLUS&#xd5;ES" NlmCategory="UNASSIGNED">Pacientes com SCC e FEVE reduzida, submetidos &#xe0; CRVM apresentaram melhora na fun&#xe7;&#xe3;o contr&#xe1;til e no tamanho do VE, com resposta ben&#xe9;fica sobre a classe funcional.</AbstractText></OtherAbstract><OtherAbstract Type="Publisher" Language="eng"><AbstractText Label="BACKGROUND">The degree of left ventricular (LV) dysfunction is an independent risk factor for poor outcomes in patients with chronic coronary syndrome. Coronary artery bypass graft (CABG) is the standard care for the management of ischemic heart failure to improve symptoms and prognosis. However, the predictors of improvement are still uncertain.</AbstractText><AbstractText Label="OBJECTIVE">To assess the effect of myocardial revascularization on LV function and symptoms in patients with CCS and reduced left ventricular ejection fraction (LVEF), as well as to identify the improvement predictors.</AbstractText><AbstractText Label="METHODS">We retrospectively analyzed the data and clinical status of 136 consecutive patients with LVEF&lt;50% that underwent CABG. During clinical follow-up echocardiographic LV function was reassessed at the short-term (3.6 months) and long-term (30.8 months), and compared to baseline.</AbstractText><AbstractText Label="RESULTS">Mean pre-operative LVEF was 40.9 &#xb1; 8.6% and wall motion score index (WMSI) was 1.99 &#xb1; 0.36, both improving at long-term to 48.1 &#xb1; 15.0% (p&lt;0.001) and 1.75 &#xb1; 0.49 (p&lt;0.001), respectively. We observed that 55.7% of the patients presented an improvement of LVEF&#x2265;10% and 58.1% in WMSI &#x2265;10%. Univariate logistic regression analysis revealed that cerebrovascular disease was the only variable to be predictor of LVEF improvement. At the end of follow-up, we observed a reduction in the rate of patients in functional class III/IV when compared to baseline (65.4 vs. 10.3% - p&lt;0.001).</AbstractText><AbstractText Label="CONCLUSIONS">Patients with CCS and reduced LVEF undergoing CABG experienced improvement in both LV contractile function and size, with beneficial response in functional class.</AbstractText></OtherAbstract><CoiStatement><b>Potencial conflito de interesse:</b> N&#xe3;o h&#xe1; conflito com o presente artigo</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>1</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>5</Month><Day>15</Day><Hour>12</Hour><Minute>36</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>5</Month><Day>14</Day><Hour>19</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>5</Month><Day>14</Day><Hour>13</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>4</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40367000</ArticleId><ArticleId IdType="pmc">PMC12107766</ArticleId><ArticleId IdType="doi">10.36660/abc.20240486</ArticleId><ArticleId IdType="pii">S0066-782X2025000400304</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wong M, Staszewsky L, Latini R, Barlera S, Glazer R, Aknay N, et al. Severity of Left Ventricular Remodeling Defines Outcomes and Response to Therapy in Heart Failure: Valsartan Heart Failure Trial (Val-HeFT) Echocardiographic Data. J Am Coll Cardiol. 2004;43(11):2022&#x2013;2027. doi: 10.1016/j.jacc.2003.12.053.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2003.12.053</ArticleId><ArticleId IdType="pubmed">15172407</ArticleId></ArticleIdList></Reference><Reference><Citation>Topkara VK, Cheema FH, Kesavaramanujam S, Mercando ML, Cheema AF, Namerow PB, et al. Coronary Artery Bypass Grafting in Patients with Low Ejection Fraction. Circulation. 2005;112(9) Suppl:I344&#x2013;I350. doi: 10.1161/CIRCULATIONAHA.104.526277.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.104.526277</ArticleId><ArticleId IdType="pubmed">16159844</ArticleId></ArticleIdList></Reference><Reference><Citation>Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, et al. Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update from the GBD 2019 Study. J Am Coll Cardiol. 2020;76(25):2982&#x2013;3021. doi: 10.1016/j.jacc.2020.11.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2020.11.010</ArticleId><ArticleId IdType="pmc">PMC7755038</ArticleId><ArticleId IdType="pubmed">33309175</ArticleId></ArticleIdList></Reference><Reference><Citation>Felker GM, Shaw LK, O'Connor CM. A Standardized Definition of Ischemic Cardiomyopathy for Use in Clinical Research. J Am Coll Cardiol. 2002;39(2):210&#x2013;218. doi: 10.1016/s0735-1097(01)01738-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0735-1097(01)01738-7</ArticleId><ArticleId IdType="pubmed">11788209</ArticleId></ArticleIdList></Reference><Reference><Citation>Breathett K, Allen LA, Udelson J, Davis G, Bristow M. Changes in Left Ventricular Ejection Fraction Predict Survival and Hospitalization in Heart Failure with Reduced Ejection Fraction. Circ Heart Fail. 2016;9(10):e002962. doi: 10.1161/CIRCHEARTFAILURE.115.002962.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCHEARTFAILURE.115.002962</ArticleId><ArticleId IdType="pmc">PMC5082710</ArticleId><ArticleId IdType="pubmed">27656000</ArticleId></ArticleIdList></Reference><Reference><Citation>Panza JA, Ellis AM, Al-Khalidi HR, Holly TA, Berman DS, Oh JK, et al. Myocardial Viability and Long-Term Outcomes in Ischemic Cardiomyopathy. N Engl J Med. 2019;381(8):739&#x2013;748. doi: 10.1056/NEJMoa1807365.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1807365</ArticleId><ArticleId IdType="pmc">PMC6814246</ArticleId><ArticleId IdType="pubmed">31433921</ArticleId></ArticleIdList></Reference><Reference><Citation>Panza JA, Holly TA, Asch FM, She L, Pellikka PA, Velazquez EJ, et al. Inducible Myocardial Ischemia and Outcomes in Patients with Coronary Artery Disease and Left Ventricular Dysfunction. J Am Coll Cardiol. 2013;61(18):1860&#x2013;1870. doi: 10.1016/j.jacc.2013.02.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2013.02.014</ArticleId><ArticleId IdType="pmc">PMC3755503</ArticleId><ArticleId IdType="pubmed">23500234</ArticleId></ArticleIdList></Reference><Reference><Citation>Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, et al. Third Universal Definition of Myocardial Infarction. Eur Heart J. 2012;33(20):2551&#x2013;2567. doi: 10.1093/eurheartj/ehs184.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehs184</ArticleId><ArticleId IdType="pubmed">22922414</ArticleId></ArticleIdList></Reference><Reference><Citation>Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015;28(1):1&#x2013;39. doi: 10.1016/j.echo.2014.10.003. e14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.echo.2014.10.003</ArticleId><ArticleId IdType="pubmed">25559473</ArticleId></ArticleIdList></Reference><Reference><Citation>Bax JJ, Schinkel AFL, Boersma E, Elhendy A, Rizzello V, Maat A, et al. Extensive Left Ventricular Remodeling does Not Allow Viable Myocardium to Improve in Left Ventricular Ejection Fraction after Revascularization and is Associated with Worse Long-Term Prognosis. Circulation. 2004;110(11) Suppl 1:II18&#x2013;II22. doi: 10.1161/01.CIR.0000138195.33452.b0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.CIR.0000138195.33452.b0</ArticleId><ArticleId IdType="pubmed">15364832</ArticleId></ArticleIdList></Reference><Reference><Citation>Bax JJ, Maddahi J, Poldermans D, Elhendy A, Schinkel A, Boersma E, et al. Preoperative Comparison of Different Noninvasive Strategies for Predicting Improvement in Left Ventricular Function after Coronary Artery Bypass Grafting. Am J Cardiol. 2003;92(1):1&#x2013;4. doi: 10.1016/s0002-9149(03)00454-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0002-9149(03)00454-5</ArticleId><ArticleId IdType="pubmed">12842235</ArticleId></ArticleIdList></Reference><Reference><Citation>Carluccio E, Biagioli P, Alunni G, Murrone A, Giombolini C, Ragni T, et al. Patients with Hibernating Myocardium Show Altered Left Ventricular Volumes and Shape, Which Revert after Revascularization: Evidence that Dyssynergy Might Directly Induce Cardiac Remodeling. J Am Coll Cardiol. 2006;47(5):969&#x2013;977. doi: 10.1016/j.jacc.2005.09.064.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2005.09.064</ArticleId><ArticleId IdType="pubmed">16516079</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S, Borah BJ, Cheng S, Li S, Zheng Z, Gu X, et al. Diabetes Associated with Greater Ejection Fraction Improvement after Revascularization in Patients with Reduced Ejection Fraction. 751474Front Cardiovasc Med. 2021;8 doi: 10.3389/fcvm.2021.751474.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2021.751474</ArticleId><ArticleId IdType="pmc">PMC8502963</ArticleId><ArticleId IdType="pubmed">34646874</ArticleId></ArticleIdList></Reference><Reference><Citation>Velagaleti RS, Vetter J, Parker R, Kurgansky KE, Sun YV, Djousse L, et al. Change in Left Ventricular Ejection Fraction with Coronary Artery Revascularization and Subsequent Risk for Adverse Cardiovascular Outcomes. Circ Cardiovasc Interv. 2022;15(4):e011284. doi: 10.1161/CIRCINTERVENTIONS.121.011284.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCINTERVENTIONS.121.011284</ArticleId><ArticleId IdType="pmc">PMC10103079</ArticleId><ArticleId IdType="pubmed">35411780</ArticleId></ArticleIdList></Reference><Reference><Citation>Metra M, Nodari S, Parrinello G, Giubbini R, Manca C, Dei Cas L. Marked Improvement in Left Ventricular Ejection Fraction During Long-Term Beta-Blockade in Patients with Chronic Heart Failure: Clinical Correlates and Prognostic Significance. Am Heart J. 2003;145(2):292&#x2013;299. doi: 10.1067/mhj.2003.105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1067/mhj.2003.105</ArticleId><ArticleId IdType="pubmed">12595847</ArticleId></ArticleIdList></Reference><Reference><Citation>Khattar RS, Senior R, Soman P, van der Does R, Lahiri A. Regression of Left Ventricular Remodeling in Chronic Heart Failure: Comparative and Combined Effects of Captopril and Carvedilol. Am Heart J. 2001;142(4):704&#x2013;713. doi: 10.1067/mhj.2001.116768.</Citation><ArticleIdList><ArticleId IdType="doi">10.1067/mhj.2001.116768</ArticleId><ArticleId IdType="pubmed">11579363</ArticleId></ArticleIdList></Reference><Reference><Citation>Lozonschi L, Kohmoto T, Osaki S, Oliveira NC, Dhingra R, Akhter SA, et al. Coronary Bypass in Left Ventricular Dysfunction and Differential Cardiac Recovery. Asian Cardiovasc Thorac Ann. 2017;25(9):586&#x2013;593. doi: 10.1177/0218492317744472.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0218492317744472</ArticleId><ArticleId IdType="pubmed">29153000</ArticleId></ArticleIdList></Reference><Reference><Citation>Byty&#xe7;i I, Shenouda R, Wester P, Henein MY. Carotid Atherosclerosis in Predicting Coronary Artery Disease: A Systematic Review and Meta-Analysis. Arterioscler Thromb Vasc Biol. 2021;41(4):e224&#x2013;e237. doi: 10.1161/ATVBAHA.120.315747.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/ATVBAHA.120.315747</ArticleId><ArticleId IdType="pubmed">33626907</ArticleId></ArticleIdList></Reference><Reference><Citation>Kallikazaros I, Tsioufis C, Sideris S, Stefanadis C, Toutouzas P. Carotid Artery Disease as a Marker for the Presence of Severe Coronary Artery Disease in Patients Evaluated for Chest Pain. Stroke. 1999;30(5):1002&#x2013;1007. doi: 10.1161/01.str.30.5.1002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.str.30.5.1002</ArticleId><ArticleId IdType="pubmed">10229735</ArticleId></ArticleIdList></Reference><Reference><Citation>Serruys PW, Morice M-C, Kappetein AP, Colombo A, Holmes DR, Mack MJ, et al. Percutaneous Coronary Intervention versus Coronary-Artery Bypass Grafting for Severe Coronary Artery Disease. N Engl J Med. 2009;360(10):961&#x2013;972. doi: 10.1056/NEJMoa0804626.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa0804626</ArticleId><ArticleId IdType="pubmed">19228612</ArticleId></ArticleIdList></Reference><Reference><Citation>Velazquez EJ, Lee KL, Jones RH, Al-Khalidi HR, Hill JA, Panza JA, et al. Coronary-Artery Bypass Surgery in Patients with Ischemic Cardiomyopathy. N Engl J Med. 2016;374(16):1511&#x2013;1520. doi: 10.1056/NEJMoa1602001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1602001</ArticleId><ArticleId IdType="pmc">PMC4938005</ArticleId><ArticleId IdType="pubmed">27040723</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Z, Zhuang X, Liu M, Jian B, Fu G, Liao X, et al. Left Ventricular Volume Change and Long-Term Outcomes in Ischaemic Cardiomyopathy with or without Surgical Revascularisation: A Post-Hoc Analysis of a Randomised Controlled Trial. 101626EClinicalMedicine. 2022;53 doi: 10.1016/j.eclinm.2022.101626.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2022.101626</ArticleId><ArticleId IdType="pmc">PMC9433601</ArticleId><ArticleId IdType="pubmed">36060518</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40754261</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>12</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-1570</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Aug</Month><Day>05</Day></PubDate></JournalIssue><Title>Resuscitation</Title><ISOAbbreviation>Resuscitation</ISOAbbreviation></Journal><ArticleTitle>Systemic administration of allogeneic mesenchymal stem cells attenuates post-resuscitation left ventricular dysfunction in a porcine model of cardiac arrest.</ArticleTitle><Pagination><StartPage>110744</StartPage><MedlinePgn>110744</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.resuscitation.2025.110744</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0300-9572(25)00256-4</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Based on evidence that a systemic inflammatory response exacerbates multi-organ injury after resuscitation from cardiac arrest (CA), we tested the efficacy of allogeneic mesenchymal stem cell (MSC) administration early after return of spontaneous circulation (ROSC) in a porcine model of CA.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Swine (n&#xa0;=&#xa0;33) were subjected to 10-min CA followed by mechanical CPR with defibrillation and intravenous epinephrine (EPI; 0.015&#xa0;mg/kg). Animals that achieved ROSC (n&#xa0;=&#xa0;19) were blindly randomized to intraventricular saline (n&#xa0;=&#xa0;9) or allogeneic bone marrow-derived MSCs (55&#xa0;&#xb1;&#xa0;2&#xa0;&#xd7;&#xa0;10<sup>6</sup>; n&#xa0;=&#xa0;10) 30-min post-ROSC. Intravenous EPI was given during the post-ROSC period as needed to maintain MAP&#xa0;&#x2265;&#xa0;60&#xa0;mmHg. Echocardiography, hemodynamic analysis, and serial blood sampling were performed for 4-hours post-ROSC, at which time the heart and brain were collected for post-mortem analysis of inflammation and injury.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Compared with saline-treated controls, MSC-treated animals exhibited improved post-ROSC LV function and lower cTnI levels, indicative of reduced myocardial injury. By design, both groups had a similar post-ROSC blood pressure and cardiac output, but the saline group required significantly more EPI. Allogeneic MSCs also decreased plasma reactive oxygen species and tended to attenuate the post-ROSC rise in circulating IL-6.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Early post-ROSC delivery of allogeneic MSCs attenuates LV dysfunction and reduces the need for pharmacologic hemodynamic support after CA in swine, suggesting that systemic MSC administration may be an effective strategy to improve patient outcomes after resuscitation from CA.</AbstractText><CopyrightInformation>Published by Elsevier B.V.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nsumbu</LastName><ForeName>Dorcas</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>The VA WNY Healthcare System and the Departments of Physiology &amp; Biophysics and Medicine of the State University of New York at Buffalo, Buffalo, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rolland</LastName><ForeName>Tyler J</ForeName><Initials>TJ</Initials><AffiliationInfo><Affiliation>The VA WNY Healthcare System and the Departments of Physiology &amp; Biophysics and Medicine of the State University of New York at Buffalo, Buffalo, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tajlil</LastName><ForeName>Arezou</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>The VA WNY Healthcare System and the Departments of Physiology &amp; Biophysics and Medicine of the State University of New York at Buffalo, Buffalo, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahmed</LastName><ForeName>Donia W</ForeName><Initials>DW</Initials><AffiliationInfo><Affiliation>The VA WNY Healthcare System and the Departments of Physiology &amp; Biophysics and Medicine of the State University of New York at Buffalo, Buffalo, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Young</LastName><ForeName>Rebeccah F</ForeName><Initials>RF</Initials><AffiliationInfo><Affiliation>The VA WNY Healthcare System and the Departments of Physiology &amp; Biophysics and Medicine of the State University of New York at Buffalo, Buffalo, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Palka</LastName><ForeName>Beth A</ForeName><Initials>BA</Initials><AffiliationInfo><Affiliation>The VA WNY Healthcare System and the Departments of Physiology &amp; Biophysics and Medicine of the State University of New York at Buffalo, Buffalo, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weil</LastName><ForeName>Brian R</ForeName><Initials>BR</Initials><AffiliationInfo><Affiliation>The VA WNY Healthcare System and the Departments of Physiology &amp; Biophysics and Medicine of the State University of New York at Buffalo, Buffalo, NY, USA. Electronic address: bweil@buffalo.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>Ireland</Country><MedlineTA>Resuscitation</MedlineTA><NlmUniqueID>0332173</NlmUniqueID><ISSNLinking>0300-9572</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Allogeneic Stem Cells</Keyword><Keyword MajorTopicYN="N">Cardiac Arrest</Keyword><Keyword MajorTopicYN="N">Inflammation</Keyword><Keyword MajorTopicYN="N">Ischemic Injury</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>5</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>7</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>4</Day><Hour>0</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>4</Day><Hour>0</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>3</Day><Hour>19</Hour><Minute>41</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40754261</ArticleId><ArticleId IdType="doi">10.1016/j.resuscitation.2025.110744</ArticleId><ArticleId IdType="pii">S0300-9572(25)00256-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40475305</PMID><DateRevised><Year>2025</Year><Month>06</Month><Day>07</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2514-2119</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>6</Issue><PubDate><Year>2025</Year><Month>Jun</Month></PubDate></JournalIssue><Title>European heart journal. Case reports</Title><ISOAbbreviation>Eur Heart J Case Rep</ISOAbbreviation></Journal><ArticleTitle>Treat-and-repair strategy for atrial septal defect with left ventricular systolic dysfunction: a case report of cardiac resynchronization therapy responder.</ArticleTitle><Pagination><StartPage>ytaf258</StartPage><MedlinePgn>ytaf258</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">ytaf258</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/ehjcr/ytaf258</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">The treatment strategy for closing atrial septal defect (ASD) in patients with left ventricular (LV) dysfunction remains to be elucidated. Current guidelines recommend a balloon occlusion test to determine whether the ASD should be closed, fenestrated, or not.</AbstractText><AbstractText Label="CASE SUMMARY" NlmCategory="UNASSIGNED">A 56-year-old man was referred to our hospital for secundum ASD with LV dysfunction. He was diagnosed with non-ischaemic cardiomyopathy with LV ejection fraction of 24%. A secundum ASD with a diameter of 18&#x2005;mm also existed, with a pulmonary blood flow to systemic blood flow ratio over 2.0. Initially, ASD closure was deemed challenging because the occlusion test resulted in abrupt elevation of the left atrial pressure. The patient had been implanted cardiac resynchronization therapy (CRT) with a defibrillator for a left bundle branch block by the referring physician; however, the LV lead was positioned at the anterior interventricular vein. Since he was a non-responder for CRT, the LV lead was repositioned to the left posterior vein at our hospital. The patient's haemodynamic status improved after CRT optimization and medical therapy. Eventually, repeated occlusion tests allowed for successful transcatheter ASD closure.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="UNASSIGNED">This case demonstrates a novel treat-and-repair strategy for patients with ASD and LV systolic dysfunction. Although initial evaluation precluded ASD closure, CRT optimization and medical therapy for heart failure improved the haemodynamic status and facilitated ASD closure.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2025. Published by Oxford University Press on behalf of the European Society of Cardiology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kinjo</LastName><ForeName>Takahiko</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0003-4363-0259</Identifier><AffiliationInfo><Affiliation>Department of Cardiology and Nephrology, Hirosaki University Graduate School of Medicine, 5 Zaifu-cho, Hirosaki, 036-8562, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yokoyama</LastName><ForeName>Hiroaki</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0001-6452-6413</Identifier><AffiliationInfo><Affiliation>Department of the Stroke and Cerebrovascular Medicine, Hirosaki University Graduate School of Medicine, 5 Zaifu-cho, Hirosaki, 036-8562, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sasaki</LastName><ForeName>Shingo</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-9866-2325</Identifier><AffiliationInfo><Affiliation>Department of Cardiology and Nephrology, Hirosaki University Graduate School of Medicine, 5 Zaifu-cho, Hirosaki, 036-8562, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Advanced Management of Cardiac Arrhythmias, Hirosaki University Graduate School of Medicine, Hirosaki, 036-8562, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiac Remote Management System, Hirosaki University Graduate School of Medicine, Hirosaki, 036-8562, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nishizaki</LastName><ForeName>Kimitaka</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0003-4597-1508</Identifier><AffiliationInfo><Affiliation>Department of Cardiology and Nephrology, Hirosaki University Graduate School of Medicine, 5 Zaifu-cho, Hirosaki, 036-8562, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tomita</LastName><ForeName>Hirofumi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Cardiology and Nephrology, Hirosaki University Graduate School of Medicine, 5 Zaifu-cho, Hirosaki, 036-8562, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of the Stroke and Cerebrovascular Medicine, Hirosaki University Graduate School of Medicine, 5 Zaifu-cho, Hirosaki, 036-8562, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Advanced Management of Cardiac Arrhythmias, Hirosaki University Graduate School of Medicine, Hirosaki, 036-8562, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiac Remote Management System, Hirosaki University Graduate School of Medicine, Hirosaki, 036-8562, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>05</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur Heart J Case Rep</MedlineTA><NlmUniqueID>101730741</NlmUniqueID><ISSNLinking>2514-2119</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Angiotensin receptor blocker-neprilysin inhibitor</Keyword><Keyword MajorTopicYN="N">Atrial septal defect</Keyword><Keyword MajorTopicYN="N">Cardiac resynchronization therapy</Keyword><Keyword MajorTopicYN="N">Case report</Keyword><Keyword MajorTopicYN="N">Left ventricular dysfunction</Keyword></KeywordList><CoiStatement>Conflict of interest: S.S. received a research grant from Boston Scientific Japan Co., Ltd. and is a concurrent associate professor of the Department of Advanced Management of Cardiac Arrhythmias, which is an endowment Department supported by Medtronic Japan Co., Ltd., Japan Lifeline Co., Ltd, and Fukuda Denshi Kita-Tohoku Hanbai Co., Ltd. S.S. is also a concurrent associate professor of the Department of Cardiac Remote Management System, which is an endowment Department supported by BIOTRONIK Japan Co., Ltd. H.T. is a concurrent professor of the Department of Advanced Management of Cardiac Arrhythmias, and the Department of Cardiac Remote Management System. H.T. also received a research grant from Abbott Medical Japan LLC. and Boston Scientific Japan Co., Ltd. Other authors have no relevant disclosures.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>11</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>3</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>5</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>6</Month><Day>6</Day><Hour>6</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>6</Month><Day>6</Day><Hour>6</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>6</Month><Day>6</Day><Hour>5</Hour><Minute>11</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>5</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40475305</ArticleId><ArticleId IdType="pmc">PMC12138885</ArticleId><ArticleId IdType="doi">10.1093/ehjcr/ytaf258</ArticleId><ArticleId IdType="pii">ytaf258</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Baumgartner &#xa0;H, De Backer &#xa0;J, Babu-Narayan &#xa0;SV, Budts &#xa0;W, Chessa &#xa0;M, Diller &#xa0;GP, et al. &#xa0;2020 ESC guidelines for the management of adult congenital heart disease. Eur Heart J &#xa0;2021;42:563&#x2013;645.</Citation><ArticleIdList><ArticleId IdType="pubmed">32860028</ArticleId></ArticleIdList></Reference><Reference><Citation>Nyboe &#xa0;C, Karunanithi &#xa0;Z, Nielsen-Kudsk &#xa0;JE, Hjortdal &#xa0;VE. Long-term mortality in patients with atrial septal defect: a nationwide cohort-study. Eur Heart J &#xa0;2018;39:993&#x2013;998.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6037065</ArticleId><ArticleId IdType="pubmed">29211856</ArticleId></ArticleIdList></Reference><Reference><Citation>Du &#xa0;ZD, Hijazi &#xa0;ZM, Kleinman &#xa0;CS, Silverman &#xa0;NH, Larntz &#xa0;K. Comparison between transcatheter and surgical closure of secundum atrial septal defect in children and adults: results of a multicenter nonrandomized trial. J Am Coll Cardiol &#xa0;2002;39:1836&#x2013;1844.</Citation><ArticleIdList><ArticleId IdType="pubmed">12039500</ArticleId></ArticleIdList></Reference><Reference><Citation>Masura &#xa0;J, Gavora &#xa0;P, Podnar &#xa0;T. Long-term outcome of transcatheter secundum-type atrial septal defect closure using amplatzer septal occluders. J Am Coll Cardiol &#xa0;2005;45:505&#x2013;507.</Citation><ArticleIdList><ArticleId IdType="pubmed">15708695</ArticleId></ArticleIdList></Reference><Reference><Citation>Kotowycz &#xa0;MA, Therrien &#xa0;J, Ionescu-Ittu &#xa0;R, Owens &#xa0;CG, Pilote &#xa0;L, Martucci &#xa0;G, et al. &#xa0;Long-term outcomes after surgical versus transcatheter closure of atrial septal defects in adults. JACC Cardiovasc Interv &#xa0;2013;6:497&#x2013;503.</Citation><ArticleIdList><ArticleId IdType="pubmed">23602461</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomai &#xa0;F, Gaspardone &#xa0;A, Papa &#xa0;M, Polisca &#xa0;P. Acute left ventricular failure after transcatheter closure of a secundum atrial septal defect in a patient with coronary artery disease: a critical reappraisal. Catheter Cardiovasc Interv &#xa0;2002;55:97&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">11793503</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomai &#xa0;F, And&#xf2; &#xa0;G, De Paulis &#xa0;R, Chiariello &#xa0;L. Real-time evaluation of the haemodynamic effects of atrial septal defect closure in adults with left ventricular dysfunction. Catheter Cardiovasc Interv &#xa0;2005;64:124&#x2013;126.</Citation><ArticleIdList><ArticleId IdType="pubmed">15619277</ArticleId></ArticleIdList></Reference><Reference><Citation>Oakley &#xa0;L, Foley &#xa0;S, Cox &#xa0;J, Seidensticker &#xa0;D. An adult with a sinus venosus atrial septal defect and dilated cardiomyopathy. BMJ Case Rep &#xa0;2014;2014:bcr2013201306.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4039816</ArticleId><ArticleId IdType="pubmed">24855073</ArticleId></ArticleIdList></Reference><Reference><Citation>Tadros &#xa0;VX, Asgar &#xa0;AW. Atrial septal defect closure with left ventricular dysfunction. EuroIntervention &#xa0;2016;12:X13&#x2013;X17.</Citation><ArticleIdList><ArticleId IdType="pubmed">27174105</ArticleId></ArticleIdList></Reference><Reference><Citation>Akagi &#xa0;T. Current concept of transcatheter closure of atrial septal defect in adults. J Cardiol &#xa0;2015;65:17&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">25308548</ArticleId></ArticleIdList></Reference><Reference><Citation>Lapidot &#xa0;D, Rav-Acha &#xa0;M, Bdolah-Abram &#xa0;T, Farkash &#xa0;R, Glikson &#xa0;M, Hasin &#xa0;T. QRS narrowing following CRT implantation: predictors, dynamics, and association with improved long-term outcome. J Clin Med &#xa0;2022;11:1279.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8911497</ArticleId><ArticleId IdType="pubmed">35268370</ArticleId></ArticleIdList></Reference><Reference><Citation>Zanon &#xa0;F, Baracca &#xa0;E, Pastore &#xa0;G, Fraccaro &#xa0;C, Roncon &#xa0;L, Aggio &#xa0;S, et al. &#xa0;Determination of the longest intrapatient left ventricular electrical delay may predict acute haemodynamic improvement in patients after cardiac resynchronization therapy. Circ Arrhythm Electrophysiol &#xa0;2014;7:377&#x2013;383.</Citation><ArticleIdList><ArticleId IdType="pubmed">24668162</ArticleId></ArticleIdList></Reference><Reference><Citation>Pitzalis &#xa0;MV, Iacoviello &#xa0;M, Romito &#xa0;R, Massari &#xa0;F, Rizzon &#xa0;B, Luzzi &#xa0;G, et al. &#xa0;Cardiac resynchronization therapy tailored by echocardiographic evaluation of ventricular asynchrony. J Am Coll Cardiol &#xa0;2002;40:1615&#x2013;1622.</Citation><ArticleIdList><ArticleId IdType="pubmed">12427414</ArticleId></ArticleIdList></Reference><Reference><Citation>Khairy &#xa0;P, Landzberg &#xa0;MJ, Gatzoulis &#xa0;MA, Mercier &#xa0;LA, Fernandes &#xa0;SM, C&#xf4;t&#xe9; &#xa0;JM, et al. &#xa0;Transvenous pacing leads and systemic thromboemboli in patients with intracardiac shunts. Circulation &#xa0;2006;113:2391&#x2013;2397.</Citation><ArticleIdList><ArticleId IdType="pubmed">16702467</ArticleId></ArticleIdList></Reference><Reference><Citation>Khairy &#xa0;P, Van Hare &#xa0;GF, Balaji &#xa0;S, Berul &#xa0;CI, Cecchin &#xa0;F, Cohen &#xa0;MI, et al. &#xa0;PACES/HRS expert consensus statement on the recognition and management of arrhythmias in adult congenital heart disease. Can J Cardiol &#xa0;2014;30:e1&#x2013;e63.</Citation><ArticleIdList><ArticleId IdType="pubmed">25262867</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40548407</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>10</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1470-8736</ISSN><JournalIssue CitedMedium="Internet"><Volume>139</Volume><Issue>12</Issue><PubDate><Year>2025</Year><Month>Jun</Month><Day>23</Day></PubDate></JournalIssue><Title>Clinical science (London, England : 1979)</Title><ISOAbbreviation>Clin Sci (Lond)</ISOAbbreviation></Journal><ArticleTitle>Retraction: Balancing mitochondrial dynamics via increasing mitochondrial fusion attenuates infarct size and left ventricular dysfunction in rats with cardiac ischemia/reperfusion injury.</ArticleTitle><Pagination><StartPage>739</StartPage><MedlinePgn>739</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">CS20190014_RET</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1042/CS20190014_RET</ELocationID><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016440">Retraction Notice</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>06</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Clin Sci (Lond)</MedlineTA><NlmUniqueID>7905731</NlmUniqueID><ISSNLinking>0143-5221</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="RetractionOf"><RefSource>Clin Sci (Lond). 2019 Feb 12;133(3):497-513. doi: 10.1042/CS20190014.</RefSource><PMID Version="1">30705107</PMID></CommentsCorrections></CommentsCorrectionsList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>6</Month><Day>24</Day><Hour>10</Hour><Minute>52</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>6</Month><Day>24</Day><Hour>10</Hour><Minute>51</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>6</Month><Day>23</Day><Hour>6</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>6</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40548407</ArticleId><ArticleId IdType="pmc">PMC12236171</ArticleId><ArticleId IdType="doi">10.1042/CS20190014_RET</ArticleId><ArticleId IdType="pii">236209</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40486316</PMID><DateRevised><Year>2025</Year><Month>06</Month><Day>11</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2168-8184</ISSN><JournalIssue CitedMedium="Print"><Volume>17</Volume><Issue>5</Issue><PubDate><Year>2025</Year><Month>May</Month></PubDate></JournalIssue><Title>Cureus</Title><ISOAbbreviation>Cureus</ISOAbbreviation></Journal><ArticleTitle>A Case Report of Pericardial Constriction and Left Ventricular Dysfunction in a Breast Cancer Survivor: Late Cardiotoxicity From Radiotherapy or 5-Fluorouracil.</ArticleTitle><Pagination><StartPage>e83682</StartPage><MedlinePgn>e83682</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e83682</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.7759/cureus.83682</ELocationID><Abstract><AbstractText>Cardiotoxicity from oncologic treatments, including radiotherapy and fluoropyrimidine-based chemotherapy, can manifest years later, leading to pericardial constriction and left ventricular dysfunction in cancer survivors. We report the case of a 53-year-old breast cancer survivor, treated with surgery, radiotherapy (&gt;25 Gy), and 5-fluorouracil (5-FU) chemotherapy in 2015, who remained cancer-free until a pleural recurrence in 2024, managed with pleurodesis and capecitabine. Six months later, she developed cardiac tamponade requiring pericardial drainage. Transthoracic echocardiography showed a preserved left ventricular ejection fraction (LVEF) (60%), and concurrent subclavian vein thrombosis led to anticoagulation. By early 2025, she developed left ventricular dysfunction (LVEF 45%) with exertional dyspnea classified as New York Heart Association (NYHA) class III.&#xa0;NT-proBNP levels were elevated. Coronary disease was excluded. Cardiac magnetic resonance imaging (MRI) revealed evolving constrictive pericarditis, moderate dysfunction (global longitudinal strain (GLS)-13.5%), biatrial enlargement, and bilateral pleural effusion. Right heart catheterization confirmed adiastole with a deep plateau pattern. This case highlights a rare late-onset pericardial constriction and ventricular dysfunction in a breast cancer survivor, potentially linked to prior oncologic treatments. These findings underscore the importance of long-term cardiovascular monitoring in cancer survivors.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025, Berhil et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Berhil</LastName><ForeName>Taha</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Cardiology, Mohammed VI University Hospital Center, Tangier, MAR.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lahnaoui</LastName><ForeName>Fadoua</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Cardiology, Mohammed VI University Hospital Center, Tangier, MAR.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>El Boussaadani</LastName><ForeName>Badre</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Cardiology, Abdelmalek Essaadi University, Tangier, MAR.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ech-Chenbouli</LastName><ForeName>Amine</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Cardiology, Abdelmalek Essaadi University, Tangier, MAR.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raissouni</LastName><ForeName>Zainab</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Cardiology, Abdelmalek Essaadi University, Tangier, MAR.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>05</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cureus</MedlineTA><NlmUniqueID>101596737</NlmUniqueID><ISSNLinking>2168-8184</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">5-fu chemotherapy</Keyword><Keyword MajorTopicYN="N">cardiotoxicity</Keyword><Keyword MajorTopicYN="N">constrictive pericarditis</Keyword><Keyword MajorTopicYN="N">left ventricular dysfunction</Keyword><Keyword MajorTopicYN="N">long-term cardiovascular monitoring</Keyword><Keyword MajorTopicYN="N">radiotherapy-induced cardiac injury</Keyword></KeywordList><CoiStatement>Human subjects: Consent for treatment and open access publication was obtained or waived by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>5</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>6</Month><Day>9</Day><Hour>12</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>6</Month><Day>9</Day><Hour>12</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>6</Month><Day>9</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>5</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40486316</ArticleId><ArticleId IdType="pmc">PMC12143941</ArticleId><ArticleId IdType="doi">10.7759/cureus.83682</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Radiation-induced heart disease: a clinical update. Yusuf SW, Sami S, Daher IN. https://onlinelibrary.wiley.com/doi/full/10.4061/2011/317659. Cardiol Res Pract. 2011:317659.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3051159</ArticleId><ArticleId IdType="pubmed">21403872</ArticleId></ArticleIdList></Reference><Reference><Citation>Risk of ischemic heart disease in women after radiotherapy for breast cancer. Darby SC, Ewertz M, McGale P, et al. N Engl J Med. 2013;368:987&#x2013;998.</Citation><ArticleIdList><ArticleId IdType="pubmed">23484825</ArticleId></ArticleIdList></Reference><Reference><Citation>2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for practice guidelines: the task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC) Zamorano JL, Lancellotti P, Rodriguez Mu&#xf1;oz D, et al. Eur Heart J. 2016;37:2768&#x2013;2801.</Citation><ArticleIdList><ArticleId IdType="pubmed">27567406</ArticleId></ArticleIdList></Reference><Reference><Citation>Experimental radiation-induced heart disease. I. Light microscopic studies. Fajardo LF, Stewart JR. https://pubmed.ncbi.nlm.nih.gov/5443637/ Am J Pathol. 1970;59:299&#x2013;316.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2032869</ArticleId><ArticleId IdType="pubmed">5443637</ArticleId></ArticleIdList></Reference><Reference><Citation>Radiation-induced heart disease: systemic disorders in heart disease. Heidenreich PA, Kapoor JR. https://heart.bmj.com/content/95/3/252. Heart. 2009;95:252&#x2013;258.</Citation><ArticleIdList><ArticleId IdType="pubmed">19144884</ArticleId></ArticleIdList></Reference><Reference><Citation>Late cardiotoxicity after treatment for Hodgkin lymphoma. Aleman BM, van den Belt-Dusebout AW, De Bruin ML, et al.  https://ashpublications.org/blood/article/109/5/1878/23311/Late-cardiotoxicity-after-treatment-for-Hodgkin. Blood. 2007;109:1878&#x2013;1886.</Citation><ArticleIdList><ArticleId IdType="pubmed">17119114</ArticleId></ArticleIdList></Reference><Reference><Citation>Incidence and risk markers of 5-fluorouracil and capecitabine cardiotoxicity in patients with colorectal cancer. Dyhl-Polk A, Vaage-Nilsen M, Schou M, et al. Acta Oncol. 2020;59:475&#x2013;483.</Citation><ArticleIdList><ArticleId IdType="pubmed">31931649</ArticleId></ArticleIdList></Reference><Reference><Citation>5-fluorouracil and cardiotoxicity: a review. Sara JD, Kaur J, Khodadadi R, et al. Ther Adv Med Oncol. 2018;10:1758835918780140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6024329</ArticleId><ArticleId IdType="pubmed">29977352</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardiovascular toxic effects of targeted cancer therapies. Moslehi JJ. N Engl J Med. 2016;375:1457&#x2013;1467.</Citation><ArticleIdList><ArticleId IdType="pubmed">27732808</ArticleId></ArticleIdList></Reference><Reference><Citation>5-fluorouracil induced takotsubo cardiomyopathy complicated by left ventricular thrombosis. Kumar D, Warsha F, Mehta A, Deepak V, Jawad W. Cureus. 2021;13:0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8060147</ArticleId><ArticleId IdType="pubmed">33898135</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40795781</PMID><DateCompleted><Year>2025</Year><Month>08</Month><Day>22</Day></DateCompleted><DateRevised><Year>2025</Year><Month>08</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2753-670X</ISSN><JournalIssue CitedMedium="Internet"><Volume>40</Volume><Issue>8</Issue><PubDate><Year>2025</Year><Month>Aug</Month><Day>05</Day></PubDate></JournalIssue><Title>Interdisciplinary cardiovascular and thoracic surgery</Title><ISOAbbreviation>Interdiscip Cardiovasc Thorac Surg</ISOAbbreviation></Journal><ArticleTitle>Free Margin Running Suture Repair for Bileaflet Mitral Valve Prolapse in Patients with Left Ventricular Dysfunction: A Mid-term Follow-up Study.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">ivaf187</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/icvts/ivaf187</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Repairing severe mitral regurgitation (MR) in patients with degenerative bileaflet prolapse and reduced left ventricular ejection fraction (LVrEF) is challenging. The Free Margin Running Suture (FMRS) technique offers a non-resectional approach, but mid-term data are limited.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We analysed 28 patients with bileaflet degenerative MR and LVrEF (&#x2264;40%) undergoing FMRS. Primary outcomes were mid-term survival and MR recurrence; secondary outcomes included LVEF, in-hospital complications, transmitral gradient, coaptation length, and mitral valve orifice area.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Mean age was 59.3&#x2009;&#xb1;&#x2009;12.8 years; 69.4% were male. No perioperative deaths; 1 patient required ECMO. Mean aortic cross-clamp time was 47&#x2009;&#xb1;&#x2009;18.6 min. Over 4.7 years, survival was 100%, with 1 case of moderate MR recurrence. At follow-up, LVEF improved to 43.04&#x2009;&#xb1;&#x2009;2.26 (P&#x2009;&lt;&#x2009;0.001), and all patients were NYHA I-II.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">FMRS is a minimally invasive, reproducible technique providing durable repair, symptomatic improvement, and excellent mid-term survival.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2025. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Agnino</LastName><ForeName>Alfonso</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Robotic and Minimally Invasive Cardiac Surgery, HUMANITAS Gavazzeni-Castelli, Bergamo, 24125, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D'Errico Ramirez</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-5565-0519</Identifier><AffiliationInfo><Affiliation>Division of Thoracic and Cardiovascular Surgery, CHU Reims, Rue du General Koenig, Reims, 51100, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parrinello</LastName><ForeName>Matteo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Robotic and Minimally Invasive Cardiac Surgery, HUMANITAS Gavazzeni-Castelli, Bergamo, 24125, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Muccio</LastName><ForeName>Salvatore</ForeName><Initials>S</Initials><Identifier Source="ORCID">0009-0002-6349-0273</Identifier><AffiliationInfo><Affiliation>Division of Thoracic and Cardiovascular Surgery, CHU Reims, Rue du General Koenig, Reims, 51100, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anselmi</LastName><ForeName>Amedeo</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Thoracic and Cardiovascular Surgery, Pontchaillou University Hospital, Rennes, 35000, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruggieri</LastName><ForeName>Vito Giovanni</ForeName><Initials>VG</Initials><AffiliationInfo><Affiliation>Division of Thoracic and Cardiovascular Surgery, CHU Reims, Rue du General Koenig, Reims, 51100, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>URCA, Universit&#xe9; de Reims Champagne Ardenne, Reims, 51100, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>University Hospital of Reims</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Interdiscip Cardiovasc Thorac Surg</MedlineTA><NlmUniqueID>9918540787006676</NlmUniqueID><ISSNLinking>2753-670X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008945" MajorTopicYN="Y">Mitral Valve Prolapse</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008944" MajorTopicYN="Y">Mitral Valve Insufficiency</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013536" MajorTopicYN="Y">Suture Techniques</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018487" MajorTopicYN="Y">Ventricular Dysfunction, Left</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016277" MajorTopicYN="Y">Ventricular Function, Left</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013318" MajorTopicYN="N">Stroke Volume</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008943" MajorTopicYN="Y">Mitral Valve</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058386" MajorTopicYN="Y">Mitral Valve Annuloplasty</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020127" MajorTopicYN="N">Recovery of Function</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">free margin running suture technique</Keyword><Keyword MajorTopicYN="N">left ventricular dysfunction</Keyword><Keyword MajorTopicYN="N">mitral valve repair</Keyword><Keyword MajorTopicYN="N">robotic mitral valve repair</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>5</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>7</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>13</Day><Hour>0</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>23</Day><Hour>8</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>12</Day><Hour>18</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40795781</ArticleId><ArticleId IdType="doi">10.1093/icvts/ivaf187</ArticleId><ArticleId IdType="pii">8229572</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40421517</PMID><DateRevised><Year>2025</Year><Month>05</Month><Day>27</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2150-136X</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>May</Month><Day>27</Day></PubDate></JournalIssue><Title>World journal for pediatric &amp; congenital heart surgery</Title><ISOAbbreviation>World J Pediatr Congenit Heart Surg</ISOAbbreviation></Journal><ArticleTitle>Outcomes After Surgery for Isolated Rheumatic Aortic Valve Disease in the Young: Preoperative Left Ventricular Dysfunction is a Risk Factor for Increased Mortality.</ArticleTitle><Pagination><StartPage>21501351251339390</StartPage><MedlinePgn>21501351251339390</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/21501351251339390</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">To improve understanding of indications and outcomes for cardiac surgery for rheumatic aortic valvular disease in the young.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Single institution retrospective cohort aged&#x2009;&lt;&#x2009;18 years with rheumatic heart disease who underwent surgery for isolated rheumatic aortic valve disease between 2000 and 2019. Baseline, intermediate follow-up, and late follow-up data were collected. Left ventricular (LV) dysfunction defined as LV ejection fraction&#x2009;&lt;&#x2009;55% or LV shortening fraction&#x2009;&lt;&#x2009;27%.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Thirty-nine patients who were 8 to 18 years of age were included (median age 14 years), weighing 27 to 157 kg (median 78 kg) with follow up of 2 to 15 years (median 7 years). Index operations were valve repair 6 of 39 (15%), valve replacement 33 of 39 (84%) with homograft (n&#x2009;=&#x2009;20), and mechanical valve (13). The 30-day mortality was zero. Overall mortality was 8 of 39 (20%); 17 of 39 (43%) underwent reoperation. At intermediate and late follow up, 27% (7/26) and 53% (18/34) had persistent dysfunction, respectively. Baseline LV dysfunction increased the risk of death (hazard ratio 13.3 [1.52-115.5], <i>P</i>&#x2009;=&#x2009;.003), which increased adjusting for higher body surface area (BSA). All those with baseline weight&#x2009;&gt;&#x2009;105 kg either died or had LV dysfunction at late follow up (<i>P</i>&#x2009;=&#x2009;.001). Freedom from late valve-related complications at 5, 10, and 15 years was 72%, 31%, and 23%, respectively.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Preoperative LV dysfunction is associated with an increased risk of death for pediatric patients undergoing isolated rheumatic aortic valve surgery. This risk increases further, adjusting for BSA. There was a high rate of reoperations and late complications.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hardefeldt</LastName><ForeName>Hilary A</ForeName><Initials>HA</Initials><AffiliationInfo><Affiliation>Queensland Paediatric Cardiac Service, Queensland Children's Hospital, Brisbane, Queensland, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kiyokawa</LastName><ForeName>Steven</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Green Lane Paediatric and Congenital Cardiac Services, Starship Children's Hospital, Health New Zealand - Te Whatu Ora, Te Toka Tumai Auckland, Auckland, New Zealand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gentles</LastName><ForeName>Thomas L</ForeName><Initials>TL</Initials><AffiliationInfo><Affiliation>Green Lane Paediatric and Congenital Cardiac Services, Starship Children's Hospital, Health New Zealand - Te Whatu Ora, Te Toka Tumai Auckland, Auckland, New Zealand.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Paediatrics, Child and Youth Health, University of Auckland, Auckland, New Zealand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iyengar</LastName><ForeName>Ajay J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Green Lane Paediatric and Congenital Cardiac Services, Starship Children's Hospital, Health New Zealand - Te Whatu Ora, Te Toka Tumai Auckland, Auckland, New Zealand.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Surgery, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand.</Affiliation><Identifier Source="RINGGOLD">1415</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mitchelson</LastName><ForeName>Bryan</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Paediatrics, Child and Youth Health, University of Auckland, Auckland, New Zealand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Han</LastName><ForeName>Dug Yeo</ForeName><Initials>DY</Initials><AffiliationInfo><Affiliation>Starship Research and Innovation Office, Starship Children's Hospital, Health New Zealand - Te Whatu Ora, Te Toka Tumai Auckland, Auckland, New Zealand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Finucane</LastName><ForeName>Kirsten</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Green Lane Paediatric and Congenital Cardiac Services, Starship Children's Hospital, Health New Zealand - Te Whatu Ora, Te Toka Tumai Auckland, Auckland, New Zealand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wilson</LastName><ForeName>Nigel J</ForeName><Initials>NJ</Initials><Identifier Source="ORCID">0000-0002-0551-4655</Identifier><AffiliationInfo><Affiliation>Green Lane Paediatric and Congenital Cardiac Services, Starship Children's Hospital, Health New Zealand - Te Whatu Ora, Te Toka Tumai Auckland, Auckland, New Zealand.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Paediatrics, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand.</Affiliation><Identifier Source="RINGGOLD">1415</Identifier></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>05</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>World J Pediatr Congenit Heart Surg</MedlineTA><NlmUniqueID>101518415</NlmUniqueID><ISSNLinking>2150-1351</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">aortic valve</Keyword><Keyword MajorTopicYN="N">pediatric</Keyword><Keyword MajorTopicYN="N">rheumatic</Keyword><Keyword MajorTopicYN="N">surgery</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>5</Month><Day>27</Day><Hour>6</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>5</Month><Day>27</Day><Hour>6</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>5</Month><Day>27</Day><Hour>4</Hour><Minute>53</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40421517</ArticleId><ArticleId IdType="doi">10.1177/21501351251339390</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40634538</PMID><DateCompleted><Year>2025</Year><Month>07</Month><Day>09</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>12</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Jul</Month><Day>09</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Prognostic impacts of left ventricular strain in hemodialytic patients with preserved left ventricular systolic function.</ArticleTitle><Pagination><StartPage>24723</StartPage><MedlinePgn>24723</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">24723</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-025-97569-0</ELocationID><Abstract><AbstractText>Left ventricular dysfunction is a known risk factor for morbidity and mortality in hemodialysis patients. The prognostic value of left ventricular global longitudinal strain (LV GLS) among those with preserved left ventricular ejection fraction (LVEF) remains uncertain. Subjects with end-stage renal disease initiated hemodialysis at Taipei Veteran General Hospital between 2015 and 2018 were registered. All participants received annually echocardiographic studies thereafter. Left ventricular end-systolic volume (LVESV), end-diastolic volume (LVEDV) and internal diameter in systole (LVIDs), LVEF, and LV GLS were measured. A LV GLS of &gt; - 15.9% was defined as reduced LV GLS. Clinical outcomes of mortality and hospitalization for heart failure (HHF) were followed. A total of 319 patients with preserved LVEF (66.3&#x2009;&#xb1;&#x2009;15.1 years, 48.6% men) were recruited in the study. Subjects with reduced LV GLS had more coronary artery disease (CAD), higher LVESV and LVIDs, but were similar in age, gender, co-morbidities, biochemistries and other echocardiographic parameters as the counterpart. Both CAD [(odds ratio (OR) and 95% confidence intervals (CIs): 1.669, 1.023-2.724], and LVESV (OR per-1 mL and 95% CIs: 1.073, 1.004-1.146) were independent determinants of reduced LV GLS. Kaplan-Meier analysis indicated that patients with reduced LV GLS had a significantly lower event-free survival rate compared to those with preserved GLS. The multivariate Cox regression analysis further demonstrated LV GLS as a significant predictor of adverse clinical events (hazard ratio per-1% and 95% CIs: 1.055, 1.002-1.110) after accounting for age, gender, and diabetes. Among the hemodialysis patients with preserved LVEF, LV GLS but not the conventional left ventricular functional indices were associated with long-term mortality and HHF. CAD could be a modifiable risk factor among the subjects with reduced LV GLS.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fu</LastName><ForeName>Yi-Tsang</ForeName><Initials>YT</Initials><AffiliationInfo><Affiliation>Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tseng</LastName><ForeName>Chih-Hsueh</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Emergency and Critical Care Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Wei-Min</ForeName><Initials>WM</Initials><AffiliationInfo><Affiliation>Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Kinmen Hospital, Ministry of Health and Welfare, Jinhu, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Wen-Chung</ForeName><Initials>WC</Initials><AffiliationInfo><Affiliation>Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Hao-Min</ForeName><Initials>HM</Initials><AffiliationInfo><Affiliation>Department of Medical Education, Taipei Veterans General Hospital, Taipei, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cardiovascular Research Center, National Yang Ming Chiao Tung University, Taipei, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chiang</LastName><ForeName>Chern-En</ForeName><Initials>CE</Initials><AffiliationInfo><Affiliation>General Clinical Research Center, Taipei Veterans General Hospital, Taipei, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cardiovascular Research Center, National Yang Ming Chiao Tung University, Taipei, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Chen-Huan</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>Department of Medical Education, Taipei Veterans General Hospital, Taipei, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cardiovascular Research Center, National Yang Ming Chiao Tung University, Taipei, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sung</LastName><ForeName>Shih-Hsien</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>General Clinical Research Center, Taipei Veterans General Hospital, Taipei, Taiwan. mr.sungsh@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cardiovascular Research Center, National Yang Ming Chiao Tung University, Taipei, Taiwan. mr.sungsh@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan. mr.sungsh@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Emergency and Critical Care Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan. mr.sungsh@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, National Yang Ming Chiao Tung University, No. 155, Sec. 2, Linong Street, Beitou District, 112, Taipei, Taiwan. mr.sungsh@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Chih-Ching</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan. lincc2@vghtpe.gov.tw.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan. lincc2@vghtpe.gov.tw.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, National Yang Ming Chiao Tung University, No. 155, Sec. 2, Linong Street, Beitou District, 112, Taipei, Taiwan. lincc2@vghtpe.gov.tw.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006435" MajorTopicYN="Y">Renal Dialysis</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007676" MajorTopicYN="Y">Kidney Failure, Chronic</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018487" MajorTopicYN="Y">Ventricular Dysfunction, Left</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004452" MajorTopicYN="N">Echocardiography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016277" MajorTopicYN="Y">Ventricular Function, Left</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013318" MajorTopicYN="N">Stroke Volume</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006352" MajorTopicYN="N">Heart Ventricles</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006333" MajorTopicYN="N">Heart Failure</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013599" MajorTopicYN="N">Systole</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">All-cause mortality</Keyword><Keyword MajorTopicYN="N">Hemodialysis</Keyword><Keyword MajorTopicYN="N">Hospitalization for heart failure</Keyword><Keyword MajorTopicYN="N">Left ventricular end-systolic volume</Keyword><Keyword MajorTopicYN="N">Left ventricular global longitudinal strain</Keyword><Keyword MajorTopicYN="N">Preserved left ventricular ejection fraction</Keyword></KeywordList><CoiStatement>Competing interests: The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>11</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>4</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>10</Day><Hour>0</Hour><Minute>36</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>10</Day><Hour>0</Hour><Minute>35</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>9</Day><Hour>23</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>7</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40634538</ArticleId><ArticleId IdType="pmc">PMC12241372</ArticleId><ArticleId IdType="doi">10.1038/s41598-025-97569-0</ArticleId><ArticleId IdType="pii">10.1038/s41598-025-97569-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Foley, R. N., Parfrey, P. S. &amp; Sarnak, M. J. Epidemiology of cardiovascular disease in chronic renal disease. <i>J. Am. Soc. Nephrol.: JASN</i>. <b>9</b>(12 Suppl), S16&#x2013;23 (1998).
</Citation><ArticleIdList><ArticleId IdType="pubmed">11443763</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, A. Y. M. et al. Sudden cardiac death in end-stage renal disease patients: a 5-year prospective analysis. <i>Hypertension</i><b>56</b>(2), 210&#x2013;216 (2010).
</Citation><ArticleIdList><ArticleId IdType="pubmed">20606110</ArticleId></ArticleIdList></Reference><Reference><Citation>Foley, R. N. et al. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. <i>Kidney Int.</i><b>47</b>(1), 186&#x2013;192 (1995).
</Citation><ArticleIdList><ArticleId IdType="pubmed">7731145</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada, S. et al. Prognostic value of reduced left ventricular ejection fraction at start of Hemodialysis therapy on cardiovascular and all-cause mortality in end-stage renal disease patients. <i>Clin. J. Am. Soc. Nephrology: CJASN</i>. <b>5</b>(10), 1793 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2974379</ArticleId><ArticleId IdType="pubmed">20595691</ArticleId></ArticleIdList></Reference><Reference><Citation>Stallworthy, E. J. et al. Do echocardiographic parameters predict mortality in patients with end-stage renal disease? <i>Transplantation</i><b>95</b>(10), 1225&#x2013;1232 (2013).
</Citation><ArticleIdList><ArticleId IdType="pubmed">23542473</ArticleId></ArticleIdList></Reference><Reference><Citation>Curtis, J. P. et al. The association of left ventricular ejection fraction, mortality, and cause of death in stable outpatients with heart failure. <i>J. Am. Coll. Cardiol.</i><b>42</b>(4), 736&#x2013;742 (2003).
</Citation><ArticleIdList><ArticleId IdType="pubmed">12932612</ArticleId></ArticleIdList></Reference><Reference><Citation>Marwick, T. H. Methods used for the assessment of LV systolic function: common currency or tower of babel?? <i>Heart</i><b>99</b>(15), 1078&#x2013;1086 (2013).
</Citation><ArticleIdList><ArticleId IdType="pubmed">23376947</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim, H. K. et al. Assessment of left ventricular rotation and torsion with two-dimensional speckle tracking echocardiography. <i>J. Am. Soc. Echocardiogr.</i><b>20</b>(1), 45&#x2013;53 (2007).
</Citation><ArticleIdList><ArticleId IdType="pubmed">17218201</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, Y. W. et al. Left ventricular systolic strain in chronic kidney disease and Hemodialysis patients. <i>Am. J. Nephrol.</i><b>33</b>(1), 84&#x2013;90 (2011).
</Citation><ArticleIdList><ArticleId IdType="pubmed">21178338</ArticleId></ArticleIdList></Reference><Reference><Citation>Amundsen, B. H. et al. Noninvasive myocardial strain measurement by speckle tracking echocardiography: validation against sonomicrometry and tagged magnetic resonance imaging. <i>J. Am. Coll. Cardiol.</i><b>47</b>(4), 789&#x2013;793 (2006).
</Citation><ArticleIdList><ArticleId IdType="pubmed">16487846</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho, G. Y. et al. Global 2-dimensional strain as a new prognosticator in patients with heart failure. <i>J. Am. Coll. Cardiol.</i><b>54</b>(7), 618&#x2013;624 (2009).
</Citation><ArticleIdList><ArticleId IdType="pubmed">19660692</ArticleId></ArticleIdList></Reference><Reference><Citation>Stanton, T., Leano, R. &amp; Marwick, T. H. Prediction of all-cause mortality from global longitudinal speckle strain: comparison with ejection fraction and wall motion scoring. <i>Circ. Cardiovasc. Imaging</i>. <b>2</b>(5), 356&#x2013;364 (2009).
</Citation><ArticleIdList><ArticleId IdType="pubmed">19808623</ArticleId></ArticleIdList></Reference><Reference><Citation>Lang, R. M. et al. Recommendations for chamber quantification: a report from the American society of echocardiography&#x2019;s guidelines and standards committee and the chamber quantification writing group, developed in conjunction with the European association of echocardiography, a branch of the European society of cardiology. <i>J. Am. Soc. Echocardiogr.</i><b>18</b>(12), 1440&#x2013;1463 (2005).
</Citation><ArticleIdList><ArticleId IdType="pubmed">16376782</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagueh, S. F. et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American society of echocardiography and the European association of cardiovascular imaging. <i>Eur. J. Echocardiogr.</i><b>17</b>(12), 1321&#x2013;1360 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27422899</ArticleId></ArticleIdList></Reference><Reference><Citation>Negishi, K. et al. Practical guidance in echocardiographic assessment of global longitudinal strain. <i>JACC: Cardiovasc. Imaging</i>. <b>8</b>(4), 489&#x2013;492 (2015).
</Citation><ArticleIdList><ArticleId IdType="pubmed">25129519</ArticleId></ArticleIdList></Reference><Reference><Citation>DeVore, A. D. et al. Impaired left ventricular global longitudinal strain in patients with heart failure with preserved ejection fraction: insights from the RELAX trial. <i>Eur. J. Heart Fail.</i><b>19</b>(7), 893&#x2013;900 (2017).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5511088</ArticleId><ArticleId IdType="pubmed">28194841</ArticleId></ArticleIdList></Reference><Reference><Citation>Yingchoncharoen, T. et al. Normal ranges of left ventricular strain: a meta-analysis. <i>J. Am. Soc. Echocardiogr.</i><b>26</b>(2), 185&#x2013;191 (2013).
</Citation><ArticleIdList><ArticleId IdType="pubmed">23218891</ArticleId></ArticleIdList></Reference><Reference><Citation>Krishnasamy, R. et al. The association between left ventricular global longitudinal strain, renal impairment and all-cause mortality. <i>Nephrol. Dialysis Transplant.</i><b>29</b>(6), 1218&#x2013;1225 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24516227</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, Y. W. et al. Association of left ventricular longitudinal strain with mortality among stable Hemodialysis patients with preserved left ventricular ejection fraction. <i>Clin. J. Am. Soc. Nephrol.: CJASN</i><b>8</b>(9), 1564 (2013).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3805079</ArticleId><ArticleId IdType="pubmed">23704303</ArticleId></ArticleIdList></Reference><Reference><Citation>Aoki, J. et al. Clinical and pathologic characteristics of dilated cardiomyopathy in Hemodialysis patients. <i>Kidney Int.</i><b>67</b>(1), 333&#x2013;340 (2005).
</Citation><ArticleIdList><ArticleId IdType="pubmed">15610259</ArticleId></ArticleIdList></Reference><Reference><Citation>Kramann, R. et al. Speckle tracking echocardiography detects uremic cardiomyopathy early and predicts cardiovascular mortality in ESRD. <i>J. Am. Soc. Nephrol. JASN</i>. <b>25</b>(10), 2351 (2014).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4178432</ArticleId><ArticleId IdType="pubmed">24700873</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu, C. K. et al. High inferior Vena Cava diameter with high left ventricular end systolic diameter as a risk factor for major adverse cardiovascular events, cardiovascular and overall mortality among chronic Hemodialysis patients. <i>J. Clin. Med.</i><b>11</b>(18), 5485 (2022).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9503705</ArticleId><ArticleId IdType="pubmed">36143131</ArticleId></ArticleIdList></Reference><Reference><Citation>Burkhoff, D., Mirsky, I. &amp; Suga, H. Assessment of systolic and diastolic ventricular properties via pressure-volume analysis: a guide for clinical, translational, and basic researchers. <i>Am. J. Physiol. Heart Circ. Physiol.</i><b>289</b>(2), H501&#x2013;H512 (2005).
</Citation><ArticleIdList><ArticleId IdType="pubmed">16014610</ArticleId></ArticleIdList></Reference><Reference><Citation>Konstam, M. A. Systolic and diastolic dysfunction in heart failure? Time for a new paradigm. <i>J. Card. Fail.</i><b>9</b>(1), 1&#x2013;3 (2003).
</Citation><ArticleIdList><ArticleId IdType="pubmed">12612866</ArticleId></ArticleIdList></Reference><Reference><Citation>Maurer, M. S., Rumbarger, L. E. K. &amp; King, D. L. Ventricular volume and length in hypertensive diastolic heart failure. <i>J. Am. Soc. Echocardiogr.</i><b>18</b>(10), 1051&#x2013;1057 (2005).
</Citation><ArticleIdList><ArticleId IdType="pubmed">16198882</ArticleId></ArticleIdList></Reference><Reference><Citation>Sagawa, K. et al. End-systolic pressure/volume ratio: a new index of ventricular contractility. <i>Am. J. Cardiol.</i><b>40</b>(5), 748&#x2013;753 (1977).
</Citation><ArticleIdList><ArticleId IdType="pubmed">920611</ArticleId></ArticleIdList></Reference><Reference><Citation>Suga, H., Kitabatake, A. &amp; Sagawa, K. End-systolic pressure determines stroke volume from fixed end-diastolic volume in the isolated canine left ventricle under a constant contractile state. <i>Circul. Res.</i><b>44</b>(2), 238&#x2013;249 (1979).</Citation><ArticleIdList><ArticleId IdType="pubmed">761306</ArticleId></ArticleIdList></Reference><Reference><Citation>Eckardt, K. U. et al. Left ventricular geometry predicts cardiovascular outcomes associated with anemia correction in CKD. <i>J. Am. Soc. Nephrology: JASN</i>. <b>20</b>(12), 2651 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2794228</ArticleId><ArticleId IdType="pubmed">19850955</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu, I. W. et al. Ventricular function and all-cause mortality in chronic kidney disease patients with angiographic coronary artery disease. <i>JN J. Nephrol.</i><b>23</b>(2), 181 (2010).
</Citation><ArticleIdList><ArticleId IdType="pubmed">20119930</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen, R. et al. Left ventricular myocardial function in Hemodialysis and nondialysis uremia patients: a three-dimensional speckle-tracking echocardiography study. <i>PLoS One</i><b>9</b>(6), e100265 (2014).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4069011</ArticleId><ArticleId IdType="pubmed">24959903</ArticleId></ArticleIdList></Reference><Reference><Citation>Leibowitz, D. Left ventricular hypertrophy and chronic renal insufficiency in the elderly. <i>Cardiorenal. Med.</i><b>4</b>(3&#x2013;4), 168&#x2013;175 (2014).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4299265</ArticleId><ArticleId IdType="pubmed">25737681</ArticleId></ArticleIdList></Reference><Reference><Citation>Abraham, T. P. et al. Diastolic dysfunction in Familial hypertrophic cardiomyopathy Transgenic model mice. <i>Cardiovascular. Res.</i><b>82</b>(1), 84&#x2013;92 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2721639</ArticleId><ArticleId IdType="pubmed">19150977</ArticleId></ArticleIdList></Reference><Reference><Citation>Lombardi, R. et al. Myocardial collagen turnover in hypertrophic cardiomyopathy. <i>Circulation</i><b>108</b>(12), 1455&#x2013;1460 (2003).
</Citation><ArticleIdList><ArticleId IdType="pubmed">12952838</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, Y. C. et al. Preclinical systolic and diastolic dysfunctions in metabolically healthy and unhealthy obese individuals. <i>Circulation: Heart Fail.</i><b>8</b>(5), 897&#x2013;904 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4573845</ArticleId><ArticleId IdType="pubmed">26175540</ArticleId></ArticleIdList></Reference><Reference><Citation>Reant, P. et al. Experimental validation of circumferential, longitudinal, and radial 2-dimensional strain during Dobutamine stress echocardiography in ischemic conditions. <i>J. Am. Coll. Cardiol.</i><b>51</b>(2), 149&#x2013;157 (2008).
</Citation><ArticleIdList><ArticleId IdType="pubmed">18191740</ArticleId></ArticleIdList></Reference><Reference><Citation>Weidemann, F. et al. Myocardial function defined by strain rate and strain during alterations in inotropic States and heart rate. <i>Am. J. Physiol. Heart Circ. Physiol.</i><b>283</b>(2), H792&#x2013;H799 (2002).
</Citation><ArticleIdList><ArticleId IdType="pubmed">12124229</ArticleId></ArticleIdList></Reference><Reference><Citation>Marwick, T. H. Measurement of strain and strain rate by echocardiography: ready for prime time? <i>J. Am. Coll. Cardiol.</i><b>47</b>(7), 1313&#x2013;1327 (2006).
</Citation><ArticleIdList><ArticleId IdType="pubmed">16580516</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40421705</PMID><DateCompleted><Year>2025</Year><Month>08</Month><Day>11</Day></DateCompleted><DateRevised><Year>2025</Year><Month>08</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1522-726X</ISSN><JournalIssue CitedMedium="Internet"><Volume>106</Volume><Issue>2</Issue><PubDate><Year>2025</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography &amp; Interventions</Title><ISOAbbreviation>Catheter Cardiovasc Interv</ISOAbbreviation></Journal><ArticleTitle>Transcatheter Edge to Edge Repair as a Bridge to Recovery in Patient With Severe Mitral Regurgitation, Advanced Left Ventricular Dysfunction and ECMO Support: A Case Report.</ArticleTitle><Pagination><StartPage>903</StartPage><EndPage>907</EndPage><MedlinePgn>903-907</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/ccd.31642</ELocationID><Abstract><AbstractText>Currently, there is limited evidence supporting the use of transcatheter edge-to-edge mitral valve repair for mitral regurgitation in patients with cardiogenic shock. Moreover, the evidence is even scarcer when considering the application of this intervention in the context of mechanical circulatory support. Here, we present a successful case of a MitraClip implantation as a bridge to recovery in a young patient with cardiogenic shock secondary to acute organic mitral valve regurgitation and severe left ventricular dysfunction that required ECMO support. A detailed description of the procedure is provided.</AbstractText><CopyrightInformation>&#xa9; 2025 Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Licciardi</LastName><ForeName>Marco</ForeName><Initials>M</Initials><Identifier Source="ORCID">0009-0006-3024-2176</Identifier><AffiliationInfo><Affiliation>Department of Interventional Cardiology, Azienda Ospedaliera Brotzu, Cagliari, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanna</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Interventional Cardiology, Azienda Ospedaliera Brotzu, Cagliari, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Melis</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Azienda Ospedaliera Brotzu, Cagliari, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Loi</LastName><ForeName>Bruno</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Interventional Cardiology, Azienda Ospedaliera Brotzu, Cagliari, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>The authors received no specific funding for this work.</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>05</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Catheter Cardiovasc Interv</MedlineTA><NlmUniqueID>100884139</NlmUniqueID><ISSNLinking>1522-1946</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008944" MajorTopicYN="Y">Mitral Valve Insufficiency</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015199" MajorTopicYN="Y">Extracorporeal Membrane Oxygenation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018487" MajorTopicYN="Y">Ventricular Dysfunction, Left</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="Y">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006328" MajorTopicYN="Y">Cardiac Catheterization</DescriptorName><QualifierName UI="Q000295" MajorTopicYN="N">instrumentation</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019918" MajorTopicYN="Y">Heart Valve Prosthesis Implantation</DescriptorName><QualifierName UI="Q000295" MajorTopicYN="N">instrumentation</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020127" MajorTopicYN="N">Recovery of Function</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016277" MajorTopicYN="Y">Ventricular Function, Left</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008943" MajorTopicYN="Y">Mitral Valve</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006350" MajorTopicYN="N">Heart Valve Prosthesis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011474" MajorTopicYN="N">Prosthesis Design</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017548" MajorTopicYN="N">Echocardiography, Transesophageal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">MitraClip</Keyword><Keyword MajorTopicYN="N">cardiogenic shock</Keyword><Keyword MajorTopicYN="N">extracorporeal membrane oxygenation</Keyword><Keyword MajorTopicYN="N">mitral regurgitation</Keyword><Keyword MajorTopicYN="N">transcatheter edge&#x2010;to&#x2010;edge mitral valve repair</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>4</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>2</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>5</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>11</Day><Hour>6</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>5</Month><Day>27</Day><Hour>12</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>5</Month><Day>27</Day><Hour>6</Hour><Minute>52</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40421705</ArticleId><ArticleId IdType="doi">10.1002/ccd.31642</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>D. Sef, T. Kabir, N. J. Lees, and U. Stock, &#x201c;Valvular Complications Following the Impella Device Implantation,&#x201d; Journal of Cardiac Surgery 36, no. 3 (March 2021): 1062&#x2013;1066, https://doi.org/10.1111/jocs.15303.</Citation></Reference><Reference><Citation>C. A. Pivato, G. Ferrante, M. Briani, J. Sanz Sanchez, B. Reimers, and P. Pagnotta, &#x201c;MitraClip Treatment for Severe Mitral Regurgitation Due to Chordae Rupture Following Impella CP Support in a Patient With Severe Aortic Stenosis,&#x201d; Cardiovascular Revascularization Medicine 28S (July 2021): 118&#x2013;120, https://doi.org/10.1016/j.carrev.2020.08.027.</Citation></Reference><Reference><Citation>R. Est&#xe9;vez&#x2010;Loureiro, M. Shuvy, M. Taramasso, et al., &#x201c;Use of MitraClip for Mitral Valve Repair in Patients With Acute Mitral Regurgitation Following Acute Myocardial Infarction: Effect of Cardiogenic Shock on Outcomes (IREMMI Registry),&#x201d; Catheterization and Cardiovascular Interventions 97, no. 6 (2021; 1): 1259&#x2013;1267, https://doi.org/10.1002/ccd.29552.</Citation></Reference><Reference><Citation>R. Estevez&#x2010;Loureiro, M. Adamo, D. Arzamendi, et al., &#x201c;Transcatheter Mitral Valve Repair in Patients With Acute Myocardial Infarction: Insights From the European Registry of MitraClip in Acute Mitral Regurgitation Following an Acute Myocardial Infarction (EREMMI),&#x201d; Eurointervention 15, no. 14 (2020): 1248&#x2013;1250, https://doi.org/10.4244/EIJ-D-19-00653.</Citation></Reference><Reference><Citation>C. Godino, A. Munaf&#xf2;, A. Scotti, et al., &#x201c;MitraClip in Secondary Mitral regurgitation as a Bridge to Heart Transplantation: 1&#x2010;year Outcomes From the International MitraBridge Registry,&#x201d; The Journal of Heart and Lung Transplantation 39, no. 12 (December 2020): 1353&#x2013;1362, https://doi.org/10.1016/j.healun.2020.09.005.</Citation></Reference><Reference><Citation>T. Saito, T. Kuno, H. A. Ueyama, et al., &#x201c;Transcatheter Edge&#x2010;to&#x2010;Edge Mitral Valve Repair for Mitral Regurgitation in Patients With Cardiogenic Shock: A Systematic Review and Meta&#x2010;Analysis,&#x201d; Catheterization and Cardiovascular Interventions 103, no. 2 (February 2024): 340&#x2013;347, https://doi.org/10.1002/ccd.30944.</Citation></Reference><Reference><Citation>C. Fraccaro, N. Karam, H. M&#xf6;llmann, et al., &#x201c;Transcatheter Interventions for Left&#x2010;Sided Valvular Heart Disease Complicated by Cardiogenic Shock: A Consensus Statement From the European Association of Percutaneous Cardiovascular Interventions (EAPCI) in Collaboration With the Association for Acute Cardiovascular Care (ACVC) and the ESC Working Group on Cardiovascular Surgery,&#x201d; EuroIntervention: Journal of EuroPCR in collaboration With the Working Group on Interventional Cardiology of the European Society of Cardiology 19, no. 8 (2023): 634&#x2013;651, https://doi.org/10.4244/EIJ-D-23-00473.</Citation></Reference><Reference><Citation>D. L. Staudacher, C. Bode, and T. Wengenmayer, &#x201c;Severe Mitral Regurgitation Requiring ECMO Therapy Treated by Interventional Valve Reconstruction Using the MitraClip,&#x201d; Catheterization and Cardiovascular Interventions 85, no. 1 (2015): 170&#x2013;175, https://doi.org/10.1002/ccd.25332.</Citation></Reference><Reference><Citation>I. Mizote, J. Schirmer, and U. Sch&#xe4;fer, &#x201c;A Case of Successful Mitraclip Implantation in a Patient Having a Large Coaptation Gap under Extracorporeal Membrane Oxygenation (ECMO),&#x201d; Catheterization and Cardiovascular Interventions 91, no. 4 (2018): 827&#x2013;830, https://doi.org/10.1002/ccd.26691.</Citation></Reference><Reference><Citation>M. O. Schmiady, S. Winnik, D. Bettex, and R. Aser, &#x201c;Mitraclip Procedure as Bridge to Left Ventricular Assist Device: Enable Extracorporeal Membrane Oxygenation Weaning and Reduce Perioperative Risk,&#x201d; Perfusion 38, no. 3 (2023): 651&#x2013;653, https://doi.org/10.1177/02676591211065251.</Citation></Reference><Reference><Citation>I. Muraca, M. Pennesi, N. Carrabba, et al., &#x201c;Percutaneous Left Ventricular Advanced Support for &#x2018;Protected&#x2019; Complex High&#x2010;Risk Transcatheter Mitral Valve Repair: A Case Series,&#x201d; European Heart Journal&#x2014;Case Reports 4, no. 3 (2020): 1&#x2013;7, https://doi.org/10.1093/ehjcr/ytaa066.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40780427</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1874-1754</ISSN><JournalIssue CitedMedium="Internet"><Volume>440</Volume><PubDate><Year>2025</Year><Month>Aug</Month><Day>06</Day></PubDate></JournalIssue><Title>International journal of cardiology</Title><ISOAbbreviation>Int J Cardiol</ISOAbbreviation></Journal><ArticleTitle>Impact of metabolic dysfunction-associated fatty liver disease on left ventricular function and myocardial strain in patients with ASTEMI: Insights from a 3.0-T cardiac magnetic resonance study.</ArticleTitle><Pagination><StartPage>133709</StartPage><MedlinePgn>133709</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ijcard.2025.133709</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0167-5273(25)00752-1</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Metabolic dysfunction-associated fatty liver disease (MAFLD) is linked to adverse cardiovascular outcomes in patients with acute ST-segment elevation myocardial infarction (ASTEMI). Nonetheless, its impact on left ventricular dysfunction and myocardial strain in this population is yet to be elucidated. Therefore, this study aimed to determine the effect of MAFLD on left ventricular function and strain parameters in patients with ASTEMI using cardiac magnetic resonance (CMR).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This retrospective study included 318 patients with ASTEMI (113 MAFLD and 205 non-MAFLD) undergoing CMR and non-enhanced computed tomography. Left ventricular function, global radial strain (GRS), global circumferential strain (GCS), and global longitudinal strain (GLS) were compared between the two groups. Univariate and multivariate linear regression analyses were performed to examine the effect of MAFLD on left ventricular function and global strain in patients with ASTEMI.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Patients with MAFLD demonstrated significantly lower left ventricular ejection fraction (LVEF) (53.35&#xa0;% vs. 59.64&#xa0;%, P&#xa0;&lt;&#xa0;0.001), left ventricular global function index (LVGFI) (27.24 vs. 29.23, P&#xa0;=&#xa0;0.006), and reduced absolute values of global strain in all three directions (GRS: 16.90&#xa0;% vs. 18.80&#xa0;%; GCS: 11.90&#xa0;% vs. 12.90&#xa0;%; GLS: 8.80&#xa0;% vs. 10.90&#xa0;%; all P&#xa0;&lt;&#xa0;0.001). Multivariate analysis confirmed that MAFLD was an independent predictor of LVEF (&#x3b2;&#xa0;=&#xa0;-0.112, P&#xa0;=&#xa0;0.028), LVGFI (&#x3b2;&#xa0;=&#xa0;- 0.109, P&#xa0;=&#xa0;0.034), and multidirectional strain parameters (GRS, GCS, and GLS) (all P&#xa0;&lt;&#xa0;0.05). Moreover, increased MAFLD severity was correlated with a numerical deterioration in both left ventricular function parameters and global strain values.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">MAFLD independently exacerbates left ventricular dysfunction and myocardial deformation in patients with ASTEMI, emphasizing its role in postinfarction risk stratification and management.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025. Published by Elsevier B.V.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Sha</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Radiology, Beijing Anzhen Hospital, Capital Medical University, No. 2 Anzhen Road, Chaoyang District, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bo</LastName><ForeName>Kairui</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Radiology, Beijing Anzhen Hospital, Capital Medical University, No. 2 Anzhen Road, Chaoyang District, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Wenshan</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Radiology, Yidu Central Hospital of Shandong Second Medical University, Qingzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Weibo</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Radiology, Beijing Anzhen Hospital, Capital Medical University, No. 2 Anzhen Road, Chaoyang District, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Hong</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Radiology, Sanya Central Hosptial, Hainan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Hui</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Radiology, Beijing Anzhen Hospital, Capital Medical University, No. 2 Anzhen Road, Chaoyang District, Beijing, China. Electronic address: hugeren@126.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Lei</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Radiology, Beijing Anzhen Hospital, Capital Medical University, No. 2 Anzhen Road, Chaoyang District, Beijing, China. Electronic address: leixu2001@hotmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Int J Cardiol</MedlineTA><NlmUniqueID>8200291</NlmUniqueID><ISSNLinking>0167-5273</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Acute ST-segment elevation myocardial infarction</Keyword><Keyword MajorTopicYN="N">Cardiovascular magnetic resonance</Keyword><Keyword MajorTopicYN="N">Left ventricular dysfunction</Keyword><Keyword MajorTopicYN="N">Metabolic dysfunction-associated fatty liver disease</Keyword><Keyword MajorTopicYN="N">Strain</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare that the study was conducted without any commercial or financial relationships construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>4</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>7</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>9</Day><Hour>13</Hour><Minute>48</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>9</Day><Hour>13</Hour><Minute>48</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>8</Day><Hour>19</Hour><Minute>50</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40780427</ArticleId><ArticleId IdType="doi">10.1016/j.ijcard.2025.133709</ArticleId><ArticleId IdType="pii">S0167-5273(25)00752-1</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40411336</PMID><DateCompleted><Year>2025</Year><Month>05</Month><Day>24</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>31</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1752-8984</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>3</Issue><PubDate><Year>2025</Year><Season>May-Jun</Season></PubDate></JournalIssue><Title>Diabetes &amp; vascular disease research</Title><ISOAbbreviation>Diab Vasc Dis Res</ISOAbbreviation></Journal><ArticleTitle>Early detection of ventricular dysfunction in LADA using novel tissue Doppler parameters: A case-control study.</ArticleTitle><Pagination><StartPage>14791641251346268</StartPage><MedlinePgn>14791641251346268</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">14791641251346268</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1177/14791641251346268</ELocationID><Abstract><AbstractText>Introduction &amp; ObjectiveLatent autoimmune diabetes mellitus (LADA), a heterogeneous disease, is much more common in society than thought. Although it has been claimed that LADA is similar to type 2 diabetes mellitus (T2DM) from a cardiovascular perspective, there is no clear consensus. In this context, the objective of this study is to assess subclinical dysfunction in the left and right ventricles in patients with LADA using novel tissue Doppler imaging (TDI) parameters.Materials &amp;MethodsThe sample of this observational case-control study consisted of 57 consecutive patients aged between 30 and 70 years who applied to the endocrinology and metabolism outpatient clinics, were diagnosed with LADA, and were referred to the cardiology clinic for echocardiographic (ECHO) evaluation. The control group consisted of 60 healthy volunteers. Participants' demographic and clinical characteristics and laboratory findings were recorded. All participants underwent ECHO using conventional ECHO and TDI. Subclinical left ventricular dysfunction was assessed using the myocardial performance index (MPI) and isovolumic myocardial acceleration (IVA).ResultsThere were no significant differences between the patient and control groups in terms of conventional ECHO parameters. The left ventricular (LV) MPI was significantly higher in the patient group than in the control group (0.54 &#xb1; 0.11 vs 0.47 &#xb1; 0.07, <i>p =</i> 0.008). There was no significant difference between the groups in right ventricular (RV) MPI (0.49 &#xb1; 0.10 vs 0.46 &#xb1; 0.70, <i>p =</i> 0.217). IVA was decreased in both ventricles (IVA mitral: 3.03 &#xb1; 1.44 vs 3.78 &#xb1; 1.66, <i>p =</i> 0.008 and IVA tricuspid: 2.67 &#xb1; 0.88 vs 3.42 &#xb1; 0.97, <i>p =</i> 0.034). Both LV IVA and RV IVA were found to be significantly correlated with glutamic acid decarboxylase antibodies' (GADA) levels in the negative direction (R = -0.290, <i>p =</i> 0.005 and R = -0.340, <i>p =</i> 0.001).ConclusionsIt was observed that LADA negatively affected the systolic and diastolic functions of both ventricles, with its effect being more pronounced in the left ventricle. Glycemic control and autoantibody titers were found to be correlated with TDI parameters, emphasizing their relevance in assessing cardiac dysfunction.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Oksen</LastName><ForeName>Dogac</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0003-4548-9543</Identifier><AffiliationInfo><Affiliation>Department of Cardiology, Altinbas University, Istanbul, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aslan</LastName><ForeName>Muzaffer</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Siirt University, Siirt, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yavuz</LastName><ForeName>Yunus Emre</ForeName><Initials>YE</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Siirt University, Siirt, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaynak</LastName><ForeName>Cagdas</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Siirt University, Siirt, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tekin</LastName><ForeName>Esra Erturk</ForeName><Initials>EE</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, Mersin City Hospital, The Health Science University, Mersin, Turkey.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>05</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Diab Vasc Dis Res</MedlineTA><NlmUniqueID>101234011</NlmUniqueID><ISSNLinking>1479-1641</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D042241" MajorTopicYN="N">Early Diagnosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018487" MajorTopicYN="Y">Ventricular Dysfunction, Left</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016277" MajorTopicYN="Y">Ventricular Function, Left</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016278" MajorTopicYN="Y">Ventricular Function, Right</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018497" MajorTopicYN="Y">Ventricular Dysfunction, Right</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015150" MajorTopicYN="Y">Echocardiography, Doppler</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058070" MajorTopicYN="N">Asymptomatic Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058065" MajorTopicYN="Y">Diabetic Cardiomyopathies</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">diastolic dysfunction</Keyword><Keyword MajorTopicYN="N">isovolumic myocardial acceleration</Keyword><Keyword MajorTopicYN="N">latent autoimmune diabetes mellitus</Keyword><Keyword MajorTopicYN="N">myocardial performance index</Keyword><Keyword MajorTopicYN="N">subclinical myocardial dysfunction</Keyword></KeywordList><CoiStatement>Declaration of conflicting interestsThe authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>5</Month><Day>25</Day><Hour>0</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>5</Month><Day>25</Day><Hour>0</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>5</Month><Day>24</Day><Hour>5</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>5</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40411336</ArticleId><ArticleId IdType="pmc">PMC12103687</ArticleId><ArticleId IdType="doi">10.1177/14791641251346268</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ramu D, Ramaswamy S, Rao S, et al. The worldwide prevalence of latent autoimmune diabetes of adults among adult-onset diabetic individuals: a systematic review and meta-analysis. Endocrine 2023; 82(1): 28&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">37428296</ArticleId></ArticleIdList></Reference><Reference><Citation>Maddaloni E, Coleman RL, Pozzilli P, et al. Long-term risk of cardiovascular disease in individuals with latent autoimmune diabetes in adults (UKPDS 85). Diabetes Obes Metab 2019; 21(9): 2115&#x2013;2122.</Citation><ArticleIdList><ArticleId IdType="pubmed">31099472</ArticleId></ArticleIdList></Reference><Reference><Citation>de Ferranti SD, de Boer IH, Fonseca V, et al. Type 1 diabetes mellitus and cardiovascular disease: a scientific statement from the American Heart Association and American Diabetes Association. Circulation 2014; 130(13): 1110&#x2013;1130.</Citation><ArticleIdList><ArticleId IdType="pubmed">25114208</ArticleId></ArticleIdList></Reference><Reference><Citation>Maddaloni E, Lessan N, Al Tikriti A, et al. Latent autoimmune diabetes in adults in the United Arab Emirates: clinical features and factors related to insulin-requirement. PLoS One 2015; 10(8): e0131837.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4529198</ArticleId><ArticleId IdType="pubmed">26252955</ArticleId></ArticleIdList></Reference><Reference><Citation>Kul S, Dursun &#x130;, Ayhan S, et al. Presystolic wave is associated with subclinical left ventricular dysfunction assessed by myocardial performance index in type 2 diabetes mellitus. Arq Bras Cardiol 2019; 113(2): 207&#x2013;215.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6777877</ArticleId><ArticleId IdType="pubmed">31365600</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho JE, Lyass A, Lee DS, et al. Predictors of new-onset heart failure: differences in preserved versus reduced ejection fraction. Circ Heart Fail 2013; 6(2): 279&#x2013;286.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3705220</ArticleId><ArticleId IdType="pubmed">23271790</ArticleId></ArticleIdList></Reference><Reference><Citation>Suran D, Sinkovic A, Naji F. Tissue Doppler imaging is a sensitive echocardiographic technique to detect subclinical systolic and diastolic dysfunction of both ventricles in type 1 diabetes mellitus. BMC Cardiovasc Disord 2016; 16: 72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4840968</ArticleId><ArticleId IdType="pubmed">27102111</ArticleId></ArticleIdList></Reference><Reference><Citation>Tei C, Ling LH, Hodge DO, et al. New index of combined systolic and diastolic myocardial performance: a simple and reproducible measure of cardiac function--a study in normals and dilated cardiomyopathy. J Cardiol 1995; 26(6): 357&#x2013;366.</Citation><ArticleIdList><ArticleId IdType="pubmed">8558414</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xf8;ller JE, S&#xf8;ndergaard E, Poulsen SH, et al. The Doppler echocardiographic myocardial performance index predicts left-ventricular dilation and cardiac death after myocardial infarction. Cardiology 2001; 95(2): 105&#x2013;111.</Citation><ArticleIdList><ArticleId IdType="pubmed">11423716</ArticleId></ArticleIdList></Reference><Reference><Citation>Ert&#xfc;rk M, &#xd6;ner E, Kalkan AK, et al. The role of isovolumic acceleration in predicting subclinical right and left ventricular systolic dysfunction in patient with metabolic syndrome. Anatol J Cardiol 2015; 15(1): 42&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5336897</ArticleId><ArticleId IdType="pubmed">25179884</ArticleId></ArticleIdList></Reference><Reference><Citation>American Diabetes Association . Diagnosis and classification of diabetes mellitus. Diabetes Care 2014; 37(Suppl 1): S81&#x2013;S90.</Citation><ArticleIdList><ArticleId IdType="pubmed">24357215</ArticleId></ArticleIdList></Reference><Reference><Citation>Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2015; 16(1): 1&#x2013;39.e14.</Citation><ArticleIdList><ArticleId IdType="pubmed">25559473</ArticleId></ArticleIdList></Reference><Reference><Citation>Qui&#xf1;ones MA, Otto CM, Stoddard M, et al. Recommendations for quantification of Doppler echocardiography: a report from the Doppler quantification task force of the nomenclature and standards committee of the American society of echocardiography. J Am Soc Echocardiogr 2002; 15(2): 167&#x2013;184.</Citation><ArticleIdList><ArticleId IdType="pubmed">11836492</ArticleId></ArticleIdList></Reference><Reference><Citation>Isomaa B, Almgren P, Henricsson M, et al. Chronic complications in patients with slowly progressing autoimmune type 1 diabetes (LADA). Diabetes Care 1999; 22(8): 1347&#x2013;1353.</Citation><ArticleIdList><ArticleId IdType="pubmed">10480781</ArticleId></ArticleIdList></Reference><Reference><Citation>Hern&#xe1;ndez M, L&#xf3;pez C, Real J, et al. Preclinical carotid atherosclerosis in patients with latent autoimmune diabetes in adults (LADA), type 2 diabetes and classical type 1 diabetes. Cardiovasc Diabetol 2017; 16(1): 94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5532780</ArticleId><ArticleId IdType="pubmed">28750634</ArticleId></ArticleIdList></Reference><Reference><Citation>Rijal P, Kumar B, Barnwal S, et al. Subclinical right ventricular dysfunction in patients with asymptomatic type 2 diabetes mellitus: a cross-sectional study. Indian Heart J 2023; 75(6): 451&#x2013;456.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10774569</ArticleId><ArticleId IdType="pubmed">37863394</ArticleId></ArticleIdList></Reference><Reference><Citation>Karakurt O, Oztekin S, Yaz&#x131;han N, et al. Impaired right ventricular functions in metabolic syndrome patients with preserved left ventricular ejection fraction. Turk Kardiyol Dern Ars 2011; 39(7): 549&#x2013;556.</Citation><ArticleIdList><ArticleId IdType="pubmed">21983764</ArticleId></ArticleIdList></Reference><Reference><Citation>Margulescu AD, Thomas DE, Ingram TE, et al. Can isovolumic acceleration be used in clinical practice to estimate ventricular contractile function? Reproducibility and regional variation of a new noninvasive index. J Am Soc Echocardiogr 2010; 23(4): 423&#x2013;431.</Citation><ArticleIdList><ArticleId IdType="pubmed">20202789</ArticleId></ArticleIdList></Reference><Reference><Citation>Tayyareci Y, Yurdakul S, Tayyareci G, et al. Impact of myocardial acceleration during isovolumic contraction in evaluating subclinical right ventricular systolic dysfunction in type 2 diabetes mellitus patients. Echocardiography 2010; 27(10): 1211&#x2013;1218.</Citation><ArticleIdList><ArticleId IdType="pubmed">20584066</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40597382</PMID><DateCompleted><Year>2025</Year><Month>07</Month><Day>02</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>04</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2047-783X</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Jul</Month><Day>01</Day></PubDate></JournalIssue><Title>European journal of medical research</Title><ISOAbbreviation>Eur J Med Res</ISOAbbreviation></Journal><ArticleTitle>Development of an electrocardiographic prediction model for outflow tract idiopathic premature ventricular contraction with decreased left ventricular ejection fraction.</ArticleTitle><Pagination><StartPage>532</StartPage><MedlinePgn>532</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">532</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s40001-025-02790-2</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The incidence of premature ventricular contraction (PVC) can be as high as 70% to 75% in general population. Even in the absence of any underlying heart disease, isolated ventricular premature contractions (IPVCs) can still lead to cardiac structural remodeling and impaired heart function during long-term follow-up. Currently, there is a lack of predictive models to assess the risk of idiopathic PVCs associated with left ventricular dysfunction, leading to over or under treatment for IPVC.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To develop an electrocardiographic prediction model of IPVC with decreased left ventricular ejection fraction (LVEF).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A retrospective analysis of 419 patients first diagnosed with idiopathic outflow tract PVC from January 2020 to December 2023 was performed. The cohort was randomly divided into training and validation sets in a 7:3 ratio. A nomogram predictive model was constructed based on multifactorial logistic regression analysis. Model discrimination was assessed using ROC curve and AUC, while calibration was evaluated with the Hosmer-Lemeshow test. Decision curve analysis (DCA) assessed clinical applicability, and net reclassification improvement (NRI) along with integrated discrimination improvement (IDI) indices were calculated to assess additional predictive value compared with traditional PVC burden.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">No significant differences in baseline data were observed between the training and validation sets (P&#x2009;&gt;&#x2009;0.05). The Nomogram prediction model involving PVC burden, PVC bigeminy, and SDNN&#x2009;&#x2264;&#x2009;80&#xa0;ms. The model showed good discrimination both in the training and validation set, with AUC of 0.912 (95% CI 0.872-0.951) and 0.894 (95% CI: 0.803-0.985), respectively. Calibration curve indicated good agreement between predicted probability and actual incidence in both datasets with Hosmer and Lemeshow goodness-of-fit (GOF) test of &#x3c7;<sup>2</sup>&#x2009;=&#x2009;9.832, P&#x2009;=&#x2009;0.277 and &#x3c7;<sup>2</sup>&#x2009;=&#x2009;5.935, P&#x2009;=&#x2009;0.654. DCA also showed good application value. Compared with PVC burden alone, the model showed superior predictive performance with NRI of 0.851 (95%CI 0.624-1.078; P&#x2009;&lt;&#x2009;0.001) and IDI of 0.152 (95%CI 0.094-0.209; P&#x2009;&lt;&#x2009;0.001).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The ECG prediction model for IPVC with decreased LVEF developed in this study is highly effective and easy to implement. Due to the accessible nature of Holter data, this model provides valuable insights for assessing IPVC prior to clinical decision-making regarding treatment.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Liao</LastName><ForeName>Pinliang</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Center for Circadian Metabolism and Cardiovascular Disease, Southwest Hospital, Army Medical University, Chongqing, 400038, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Cai</LastName><ForeName>Xiaolian</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Center for Circadian Metabolism and Cardiovascular Disease, Southwest Hospital, Army Medical University, Chongqing, 400038, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Wen</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Institute of Respiratory Diseases, Department of Pulmonary and Critical Care Medicine, Xinqiao Hospital, Third Military Medical University(Army Medical University), Chongqing, 400037, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ou</LastName><ForeName>Min</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Center for Circadian Metabolism and Cardiovascular Disease, Southwest Hospital, Army Medical University, Chongqing, 400038, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ren</LastName><ForeName>Heling</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Center for Circadian Metabolism and Cardiovascular Disease, Southwest Hospital, Army Medical University, Chongqing, 400038, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shu</LastName><ForeName>Maoqin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Center for Circadian Metabolism and Cardiovascular Disease, Southwest Hospital, Army Medical University, Chongqing, 400038, China. shumaoqin@tmmu.edu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>2024GGXM001</GrantID><Agency>Science-Health Joint Medical Scientific Research Major Project of Chongqing , China</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur J Med Res</MedlineTA><NlmUniqueID>9517857</NlmUniqueID><ISSNLinking>0949-2321</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018879" MajorTopicYN="Y">Ventricular Premature Complexes</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004562" MajorTopicYN="Y">Electrocardiography</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013318" MajorTopicYN="Y">Stroke Volume</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018487" MajorTopicYN="Y">Ventricular Dysfunction, Left</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049451" MajorTopicYN="N">Nomograms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012372" MajorTopicYN="N">ROC Curve</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Decreased LVEF</Keyword><Keyword MajorTopicYN="N">IPVC</Keyword><Keyword MajorTopicYN="N">PVC bigeminy</Keyword><Keyword MajorTopicYN="N">PVC burden</Keyword><Keyword MajorTopicYN="N">SDNN</Keyword></KeywordList><CoiStatement>Declarations. Ethics approval and consent to participate: The study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of the First Affiliated Hospital of Army Medical University [Grant No. (B) KY2022165]. This is a retrospective clinical study where the ethics committee exempted patients from informed consent, and all identifiable patient information has been blurred. Competing interests: The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>2</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>6</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>2</Day><Hour>12</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>2</Day><Hour>6</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>2</Day><Hour>4</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>7</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40597382</ArticleId><ArticleId IdType="pmc">PMC12211209</ArticleId><ArticleId IdType="doi">10.1186/s40001-025-02790-2</ArticleId><ArticleId IdType="pii">10.1186/s40001-025-02790-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lee AKY, Andrade J, Hawkins NM, et al. Outcomes of untreated frequent premature ventricular complexes with normal left ventricular function. Heart. 2019;105(18):1408&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">31142596</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou CR, He Q, Ding YC, et al. Myocardial work in idiopathic premature ventricular contractions: assessing left ventricular function and prognosis. J Clin Ultrasound. 2024;52:1346.</Citation><ArticleIdList><ArticleId IdType="pubmed">39223778</ArticleId></ArticleIdList></Reference><Reference><Citation>Shanmugam N, Chua TP, Ward D. Frequent&#x2019; ventricular bigeminy&#x2013;a reversible cause of dilated cardiomyopathy How frequent is &#x201c;frequent&#x201d;? Eur J Heart Fail. 2006;8(8):869&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">16714145</ArticleId></ArticleIdList></Reference><Reference><Citation>Lavalle C, Mariani MV, Piro A, et al. Electrocardiographic features, mapping and ablation of idiopathic outflow tract ventricular arrhythmias. J Interv Card Electrophysiol. 2020;57(2):207&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">31650457</ArticleId></ArticleIdList></Reference><Reference><Citation>Lang RM, Badano LP, Mor-Avi V. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American society of echocardiography and the European association of, cardiovascular imaging. Eur Heart J Cardiovasc Imag. 2015;17(4):412.</Citation><ArticleIdList><ArticleId IdType="pubmed">26983884</ArticleId></ArticleIdList></Reference><Reference><Citation>Baman TS, Lange DC, Ilg KJ, et al. Relationship between burden of premature ventricular complexes and left ventricular function. Heart Rhythm. 2010;7(7):865&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">20348027</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasdemir C, Ulucan C, Yavuzgil O, et al. Tachycardia-induced cardiomyopathy in patients with idiopathic ventricular arrhythmias: the incidence, clinical and electrophysiologic characteristics, and the predictors. J Cardiovasc Electrophysiol. 2011;22(6):663&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">21235667</ArticleId></ArticleIdList></Reference><Reference><Citation>del Carpio MF, Syed FF, Noheria A, et al. Characteristics of premature ventricular complexes as correlates of reduced left ventricular systolic function: study of the burden, duration, coupling interval, morphology and site of origin of PVCs. J Cardiovasc Electrophysiol. 2011;22(7):791&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">21332870</ArticleId></ArticleIdList></Reference><Reference><Citation>Yokokawa M, Kim HM, Good E, et al. Impact of QRS duration of frequent premature ventricular complexes on the development of cardiomyopathy. Heart Rhythm. 2012;9(9):1460&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">22542704</ArticleId></ArticleIdList></Reference><Reference><Citation>Walters TE, Rahmutula D, Szilagyi J, et al. Left ventricular dyssynchrony predicts the cardiomyopathy associated with premature ventricular contractions. J Am Coll Cardiol. 2018;72(23):2870&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">30522650</ArticleId></ArticleIdList></Reference><Reference><Citation>Walters TE, Szilagyi J, Alhede C, et al. Dyssynchrony and fibrosis persist after resolution of cardiomyopathy in a swine premature ventricular contraction model. JACC Clin Electrophysiol. 2020;6(11):1367&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">33121665</ArticleId></ArticleIdList></Reference><Reference><Citation>He W, Lu Z, Bao M, et al. Autonomic involvement in idiopathic premature ventricular contractions. Clin Res Cardiol. 2013;102(5):361&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">23386255</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Eltit JM, Kaszala K, et al. Cellular mechanism of premature ventricular contraction-induced cardiomyopathy. Heart Rhythm. 2014;11(11):2064&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4252777</ArticleId><ArticleId IdType="pubmed">25046857</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin YS, Chang TH, Ho WC, et al. Sarcomeres morphology and Z-Line arrangement disarray induced by ventricular premature contractions through the Rac2/Cofilin pathway. Int J Mol Sci. 2020;22(20):11244.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8541677</ArticleId><ArticleId IdType="pubmed">34681906</ArticleId></ArticleIdList></Reference><Reference><Citation>Torrado J, Kowlgi GN, Ramirez RJ, et al. Eccentric hypertrophy in an animal model of mid- and long-term premature ventricular contraction-induced cardiomyopathy. Heart Rhythm O2. 2021;2(1):80&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8183810</ArticleId><ArticleId IdType="pubmed">34113908</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan AY, Elharrif K, Cardona-Guarache R, et al. Persistent proarrhythmic neural remodeling despite recovery from premature ventricular contraction-induced cardiomyopathy. J Am Coll Cardiol. 2020;75(1):1&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7006705</ArticleId><ArticleId IdType="pubmed">31918815</ArticleId></ArticleIdList></Reference><Reference><Citation>Arshi B, Geurts S, Tilly MJ, et al. Heart rate variability is associated with left ventricular systolic, diastolic function and incident heart failure in the general population. BMC Med. 2022;20(1):91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8862241</ArticleId><ArticleId IdType="pubmed">35189879</ArticleId></ArticleIdList></Reference><Reference><Citation>Baig M, Moafi-Madani M, Qureshi R, et al. Heart rate variability and the risk of heart failure and its subtypes in post-menopausal women: the women&#x2019;s health Initiative study. PLoS ONE. 2022;17(10): e0276585.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9595519</ArticleId><ArticleId IdType="pubmed">36282885</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomes BFO, Benchimol-Barbosa PR, Nadal J. Predictive model of all-cause death in patients with heart failure using heart rate variability. Arq Bras Cardiol. 2023;120(11): e20220379.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10763696</ArticleId><ArticleId IdType="pubmed">38126484</ArticleId></ArticleIdList></Reference><Reference><Citation>Moses JC, Adibi S, Angelova M, et al. Time-domain heart rate variability features for automatic congestive heart failure prediction. ESC Heart Fail. 2024;11(1):378&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10804149</ArticleId><ArticleId IdType="pubmed">38009405</ArticleId></ArticleIdList></Reference><Reference><Citation>Lampert J, Vaid A, whang W, et al. A novel ECG-based deep learning algorithm to predict cardiomyopathy in patients with premature ventricular complexes. JACC Clin Electrophysiol. 2023;9(8):1437&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">37480862</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee YH, Zhong L, Roger VL, et al. Frequency, origin, and outcome of ventricular premature complexes in patients with or without heart diseases. Am J Cardiol. 2014;114(9):1373&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">25205629</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawamura M, Badhwar N, Vedantham V, et al. Coupling interval dispersion and body mass index are independent predictors of idiopathic premature ventricular complex-induced cardiomyopathy. J Cardiovasc Electrophysiol. 2014;25(7):756&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">24612052</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadron Blaye-Felice M, Hamon D, Sacher F, et al. Premature ventricular contraction-induced cardiomyopathy: related clinical and electrophysiologic parameters. Heart Rhythm. 2016;13(1):103&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">26296327</ArticleId></ArticleIdList></Reference><Reference><Citation>Yokokawa M, Kim HM, Good E, et al. Relation of symptoms and symptom duration to premature ventricular complex-induced cardiomyopathy. Heart Rhythm. 2012;9(1):92&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">21855522</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40384378</PMID><DateRevised><Year>2025</Year><Month>05</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1467-1107</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>May</Month><Day>19</Day></PubDate></JournalIssue><Title>Cardiology in the young</Title><ISOAbbreviation>Cardiol Young</ISOAbbreviation></Journal><ArticleTitle>Endoscopic visualisation in the surgical repair of an aorto-left ventricular tunnel in a neonate.</ArticleTitle><Pagination><StartPage>1</StartPage><EndPage>2</EndPage><MedlinePgn>1-2</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1017/S1047951125001982</ELocationID><Abstract><AbstractText>Aorto-left ventricular tunnel is a rare congenital cardiac anomaly characterised by an extracardiac channel connecting the ascending aorta directly to the left ventricle. Surgical repair in neonates poses significant challenges due to the diminutive size and close proximity of critical structures such as the aortic valve and coronary ostia. We report the case of a neonate with an aorto-left ventricular tunnel, mild left ventricular dysfunction, and mild aortic insufficiency who underwent successful surgical repair on the sixth day of life. Following cardiopulmonary bypass initiation and cardioplegic arrest, the ascending aorta was transected for direct visualisation. A 5-mm 0&#xb0; rigid endoscope was employed intraoperatively, providing high-resolution magnification of the aortic valve, right coronary artery, and tunnel anatomy. The tunnel was closed using an autologous pericardial patch, ensuring preservation of the coronary ostium and aortic valve integrity. Postoperative echocardiography demonstrated good left ventricular function, trivial aortic insufficiency, and no residual shunt. The use of rigid endoscopy significantly enhanced the safety and precision of the repair by allowing accurate anatomical delineation and facilitating patch placement. This case highlights the importance of detailed visualisation in neonatal aorto-left ventricular tunnel repair and underscores the utility of rigid endoscopic technology in complex congenital heart surgery. Endoscopic assistance not only aids intraoperative decision-making but also serves as a valuable tool for surgical education and postoperative review.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yoneyama</LastName><ForeName>Fumiya</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0001-6862-0087</Identifier><AffiliationInfo><Affiliation>Congenital Heart Surgery, Texas Children's Hospital, Baylor College of Medicine, Houston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brenes</LastName><ForeName>Javier</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Congenital Heart Surgery, Texas Children's Hospital, Baylor College of Medicine, Houston, TX, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>05</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Cardiol Young</MedlineTA><NlmUniqueID>9200019</NlmUniqueID><ISSNLinking>1047-9511</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Aorto&#x2013;left ventricular tunnel</Keyword><Keyword MajorTopicYN="N">endoscopic visualisation</Keyword><Keyword MajorTopicYN="N">neonatal repair</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>5</Month><Day>19</Day><Hour>6</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>5</Month><Day>19</Day><Hour>6</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>5</Month><Day>19</Day><Hour>4</Hour><Minute>43</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40384378</ArticleId><ArticleId IdType="doi">10.1017/S1047951125001982</ArticleId><ArticleId IdType="pii">S1047951125001982</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40578266</PMID><DateCompleted><Year>2025</Year><Month>08</Month><Day>06</Day></DateCompleted><DateRevised><Year>2025</Year><Month>08</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2213-1787</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>8</Issue><PubDate><Year>2025</Year><Month>Aug</Month></PubDate></JournalIssue><Title>JACC. Heart failure</Title><ISOAbbreviation>JACC Heart Fail</ISOAbbreviation></Journal><ArticleTitle>Patterns of Left Ventricular Regional Wall Motion Abnormalities After Brain Death and Their Clinical Significance.</ArticleTitle><Pagination><StartPage>102511</StartPage><MedlinePgn>102511</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jchf.2025.102511</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2213-1779(25)00438-X</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Left ventricular dysfunction is common in potential heart donors after brain death, but specific regional wall motion abnormality (RWMA) patterns in this population have not been well described.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">This study aims to define and characterize RWMA patterns in potential heart donors after brain death by using a machine learning algorithm.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The Donor Heart Study enrolled 4,333 potential heart donors after brain death. All had a transthoracic echocardiogram (TTE) including RWMA assessment, with each segment analyzed for WMS (Wall Motion Score). Those with any RWMA (ie, any WMS &gt;1) were classified using k-means clustering, and each cluster's associations with donor clinical characteristics, heart use, and recipient survival were assessed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The final analytical cohort included 913 initial TTEs. We identified 4 unique RWMA phenotypes: focal basal septal (FBS) (n = 500), basal and midventricular (n = 311), apical (n = 66), and global hypokinesis (n = 36). These phenotypes exhibited similar donor characteristics but differed in troponin, N-terminal pro-B-type natriuretic peptide levels (both lowest in FBS), and left ventricular ejection fraction (LVEF) (highest in FBS). On subsequent TTEs (performed in 314 donors with any RWMA), all phenotypes demonstrated significant improvement in LVEF. The FBS phenotype had the highest donor heart acceptance for transplantation (68%). Of the hearts accepted for transplantation, there were no significant differences by RWMA phenotype in recipient survival.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Left ventricular dysfunction after brain death exhibits distinct RWMA phenotypes, which differ in terms of selected biomarkers and LVEF, but not in recipient survival of the hearts accepted for transplantation.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Alex J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Department of Medicine, Kaiser Permanente San Francisco Medical Center, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wayda</LastName><ForeName>Brian J</ForeName><Initials>BJ</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Shiqi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Quantitative Sciences Unit, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weng</LastName><ForeName>Yingjie</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Quantitative Sciences Unit, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khush</LastName><ForeName>Kiran K</ForeName><Initials>KK</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zaroff</LastName><ForeName>Jonathan G</ForeName><Initials>JG</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Kaiser Permanente San Francisco Medical Center, San Francisco, California, USA; Division of Research, Kaiser Permanente Northern California, Oakland, California, USA. Electronic address: jonathan.g.zaroff@kp.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 HL125303</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001085</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>06</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JACC Heart Fail</MedlineTA><NlmUniqueID>101598241</NlmUniqueID><ISSNLinking>2213-1779</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001926" MajorTopicYN="Y">Brain Death</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018487" MajorTopicYN="Y">Ventricular Dysfunction, Left</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004452" MajorTopicYN="N">Echocardiography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016027" MajorTopicYN="Y">Heart Transplantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013318" MajorTopicYN="N">Stroke Volume</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014019" MajorTopicYN="Y">Tissue Donors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006352" MajorTopicYN="Y">Heart Ventricles</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069550" MajorTopicYN="N">Machine Learning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016277" MajorTopicYN="N">Ventricular Function, Left</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000092522" MajorTopicYN="N">Clinical Relevance</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">donor heart</Keyword><Keyword MajorTopicYN="N">left ventricular dysfunction</Keyword><Keyword MajorTopicYN="N">machine learning</Keyword><Keyword MajorTopicYN="N">outcomes</Keyword><Keyword MajorTopicYN="N">regional wall motion abnormality</Keyword></KeywordList><CoiStatement>Funding Support and Author Disclosures This study was funded by the National Institutes of Health (NIH)/National Heart, Lung, and Blood Institute (R01 HL125303). The Stanford REDCap platform (http://redcap.stanford.edu) was developed and operated by the Stanford Medicine Research Information Technology team. The REDCap platform services at Stanford are subsidized by the Stanford School of Medicine Research Office, the National Center for Research Resources, and the National Center for Advancing Translational Sciences, NIH, through grant UL1 TR001085. The data reported here have been supplied by the Donor Management Goals Advisory Group. The interpretation and reporting of these data are the responsibility of the authors and in no way should be seen as an official policy of or interpretation by the Donor Management Goals Advisory Group. The authors have reported that they have no relationships relevant to the contents of this paper to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>3</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>3</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2026</Year><Month>6</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>7</Day><Hour>0</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>6</Month><Day>28</Day><Hour>0</Hour><Minute>39</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>6</Month><Day>27</Day><Hour>18</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40578266</ArticleId><ArticleId IdType="mid">NIHMS2093440</ArticleId><ArticleId IdType="pmc">PMC12341468</ArticleId><ArticleId IdType="doi">10.1016/j.jchf.2025.102511</ArticleId><ArticleId IdType="pii">S2213-1779(25)00438-X</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Khush KK, Malinoski D, Luikart H, et al. Left Ventricular Dysfunction Associated With Brain Death: Results From the Donor Heart Study. Circulation. 2023;148(10):822&#x2013;833. doi: 10.1161/CIRCULATIONAHA.122.063400</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.122.063400</ArticleId><ArticleId IdType="pmc">PMC10529108</ArticleId><ArticleId IdType="pubmed">37465972</ArticleId></ArticleIdList></Reference><Reference><Citation>Tryon D, Hasaniya NW, Jabo B, Razzouk AJ, Bailey LL, Rabkin DG. Effect of left ventricular dysfunction on utilization of donor hearts. J Heart Lung Transplant. 2018;37(3):349&#x2013;357. doi: 10.1016/j.healun.2017.07.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.healun.2017.07.015</ArticleId><ArticleId IdType="pubmed">28797760</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaroff JG, Babcock WD, Shiboski SC. The impact of left ventricular dysfunction on cardiac donor transplant rates. J Heart Lung Transplant. 2003;22(3):334&#x2013;337. doi: 10.1016/s1053-2498(02)00554-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1053-2498(02)00554-5</ArticleId><ArticleId IdType="pubmed">12633701</ArticleId></ArticleIdList></Reference><Reference><Citation>Samuels MA. Neurogenic heart disease: a unifying hypothesis. Am J Cardiol. 1987;60(18):15J&#x2013;19J. doi: 10.1016/0002-9149(87)90678-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0002-9149(87)90678-3</ArticleId><ArticleId IdType="pubmed">3321964</ArticleId></ArticleIdList></Reference><Reference><Citation>Masuda T, Sato K, Yamamoto S, et al. Sympathetic nervous activity and myocardial damage immediately after subarachnoid hemorrhage in a unique animal model. Stroke. 2002;33(6):1671&#x2013;1676. doi: 10.1161/01.str.0000016327.74392.02</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.str.0000016327.74392.02</ArticleId><ArticleId IdType="pubmed">12053010</ArticleId></ArticleIdList></Reference><Reference><Citation>Hachinski VC, Smith KE, Silver MD, Gibson CJ, Ciriello J. Acute myocardial and plasma catecholamine changes in experimental stroke. Stroke. 1986;17(3):387&#x2013;390. doi: 10.1161/01.str.17.3.387</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.str.17.3.387</ArticleId><ArticleId IdType="pubmed">3715933</ArticleId></ArticleIdList></Reference><Reference><Citation>Drislane FW, Samuels MA, Kozakewich H, Schoen FJ, Strunk RC. Myocardial contraction band lesions in patients with fatal asthma: possible neurocardiologic mechanisms. Am Rev Respir Dis. 1987;135(2):498&#x2013;501. doi: 10.1164/arrd.1987.135.2.498</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/arrd.1987.135.2.498</ArticleId><ArticleId IdType="pubmed">3813210</ArticleId></ArticleIdList></Reference><Reference><Citation>Banki NM, Kopelnik A, Dae MW, et al. Acute neurocardiogenic injury after subarachnoid hemorrhage. Circulation. 2005;112(21):3314&#x2013;3319. doi: 10.1161/CIRCULATIONAHA.105.558239</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.105.558239</ArticleId><ArticleId IdType="pubmed">16286583</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaroff JG, Rordorf GA, Ogilvy CS, Picard MH. Regional patterns of left ventricular systolic dysfunction after subarachnoid hemorrhage: evidence for neurally mediated cardiac injury. J Am Soc Echocardiogr. 2000;13(8):774&#x2013;779. doi: 10.1067/mje.2000.105763</Citation><ArticleIdList><ArticleId IdType="doi">10.1067/mje.2000.105763</ArticleId><ArticleId IdType="pubmed">10936822</ArticleId></ArticleIdList></Reference><Reference><Citation>Khush K, Kopelnik A, Tung P, et al. Age and aneurysm position predict patterns of left ventricular dysfunction after subarachnoid hemorrhage. J Am Soc Echocardiogr. 2005;18(2):168&#x2013;174. doi: 10.1016/j.echo.2004.08.045</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.echo.2004.08.045</ArticleId><ArticleId IdType="pubmed">15682055</ArticleId></ArticleIdList></Reference><Reference><Citation>Banki N, Kopelnik A, Tung P, et al. Prospective analysis of prevalence, distribution, and rate of recovery of left ventricular systolic dysfunction in patients with subarachnoid hemorrhage. J Neurosurg. 2006;105(1):15&#x2013;20. doi: 10.3171/jns.2006.105.1.15</Citation><ArticleIdList><ArticleId IdType="doi">10.3171/jns.2006.105.1.15</ArticleId><ArticleId IdType="pubmed">16871878</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohamedali B, Bhat G, Zelinger A. Frequency and pattern of left ventricular dysfunction in potential heart donors: implications regarding use of dysfunctional hearts for successful transplantation. J Am Coll Cardiol. 2012;60(3):235&#x2013;236. doi: 10.1016/j.jacc.2012.04.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2012.04.016</ArticleId><ArticleId IdType="pubmed">22789890</ArticleId></ArticleIdList></Reference><Reference><Citation>Madan S, Sims DB, Vlismas P, et al. Cardiac Transplantation Using Hearts With Transient Dysfunction: Role of Takotsubo-Like Phenotype. Ann Thorac Surg. 2020;110(1):76&#x2013;84. doi: 10.1016/j.athoracsur.2019.09.101</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.athoracsur.2019.09.101</ArticleId><ArticleId IdType="pubmed">31816283</ArticleId></ArticleIdList></Reference><Reference><Citation>Pierpont GL, DeMaster EG, Reynolds S, Pederson J, Cohn JN. Ventricular myocardial catecholamines in primates. J Lab Clin Med. 1985;106(2):205&#x2013;210.</Citation><ArticleIdList><ArticleId IdType="pubmed">4020248</ArticleId></ArticleIdList></Reference><Reference><Citation>Kline RC, Swanson DP, Wieland DM, et al. Myocardial imaging in man with I-123 meta-iodobenzylguanidine. J Nucl Med. 1981;22(2):129&#x2013;132.</Citation><ArticleIdList><ArticleId IdType="pubmed">7463156</ArticleId></ArticleIdList></Reference><Reference><Citation>Schiller NB, Shah PM, Crawford M, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr. 1989;2(5):358&#x2013;367. doi: 10.1016/s0894-7317(89)80014-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0894-7317(89)80014-8</ArticleId><ArticleId IdType="pubmed">2698218</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen J Statistical Power Analysis for the Behavioral Sciences. 2nd ed. Hillsdale, NJ: Lawrence Erlbaum; 1988.</Citation></Reference><Reference><Citation>Mori H, Ishikawa S, Kojima S, et al. Increased responsiveness of left ventricular apical myocardium to adrenergic stimuli. Cardiovasc Res. 1993;27(2):192&#x2013;198. doi: 10.1093/cvr/27.2.192</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cvr/27.2.192</ArticleId><ArticleId IdType="pubmed">8386061</ArticleId></ArticleIdList></Reference><Reference><Citation>Paur H, Wright PT, Sikkel MB, et al. High levels of circulating epinephrine trigger apical cardiodepression in a &#x3b2;2-adrenergic receptor/Gi-dependent manner: a new model of Takotsubo cardiomyopathy. Circulation. 2012;126(6):697&#x2013;706. doi: 10.1161/CIRCULATIONAHA.112.111591</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.112.111591</ArticleId><ArticleId IdType="pmc">PMC4890655</ArticleId><ArticleId IdType="pubmed">22732314</ArticleId></ArticleIdList></Reference><Reference><Citation>Jolly SS, d&#x2019;Entremont MA, Lee SF, et al. Colchicine in Acute Myocardial Infarction. N Engl J Med. Published online November 17, 2024. doi: 10.1056/NEJMoa2405922</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2405922</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsuchihashi K, Ueshima K, Uchida T, et al. Transient left ventricular apical ballooning without coronary artery stenosis: a novel heart syndrome mimicking acute myocardial infarction. Angina Pectoris-Myocardial Infarction Investigations in Japan. J Am Coll Cardiol. 2001;38(1):11&#x2013;18. doi: 10.1016/s0735-1097(01)01316-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0735-1097(01)01316-x</ArticleId><ArticleId IdType="pubmed">11451258</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacob WA, Van Bogaert A, De Groodt-Lasseel MH. Myocardial ultrastructure and haemodynamic reactions during experimental subarachnoid haemorrhage. J Mol Cell Cardiol. 1972;4(4):287&#x2013;298. doi: 10.1016/0022-2828(72)90076-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0022-2828(72)90076-4</ArticleId><ArticleId IdType="pubmed">5052586</ArticleId></ArticleIdList></Reference><Reference><Citation>Samuels MA. The brain-heart connection. Circulation. 2007;116(1):77&#x2013;84. doi: 10.1161/CIRCULATIONAHA.106.678995</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.106.678995</ArticleId><ArticleId IdType="pubmed">17606855</ArticleId></ArticleIdList></Reference><Reference><Citation>Watts RP, Thom O, Fraser JF. Inflammatory signalling associated with brain dead organ donation: from brain injury to brain stem death and posttransplant ischaemia reperfusion injury. J Transplant. 2013;2013:521369. doi: 10.1155/2013/521369</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2013/521369</ArticleId><ArticleId IdType="pmc">PMC3649190</ArticleId><ArticleId IdType="pubmed">23691272</ArticleId></ArticleIdList></Reference><Reference><Citation>Meldrum DR. Tumor necrosis factor in the heart. Am J Physiol. 1998;274(3):R577&#x2013;R595. doi: 10.1152/ajpregu.1998.274.3.R577</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpregu.1998.274.3.R577</ArticleId><ArticleId IdType="pubmed">9530222</ArticleId></ArticleIdList></Reference><Reference><Citation>Su JH, Luo MY, Liang N, et al. Interleukin-6: A Novel Target for Cardio-Cerebrovascular Diseases. Front Pharmacol. 2021;12:745061. Published 2021 Aug 24. doi: 10.3389/fphar.2021.745061</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2021.745061</ArticleId><ArticleId IdType="pmc">PMC8421530</ArticleId><ArticleId IdType="pubmed">34504432</ArticleId></ArticleIdList></Reference><Reference><Citation>Jain R, Kransdorf EP, Cowger J, Jeevanandam V, Kobashigawa JA. Donor Selection for Heart Transplantation in 2024. JACC Heart Fail. Published online November 8, 2024. doi: 10.1016/j.jchf.2024.09.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jchf.2024.09.016</ArticleId><ArticleId IdType="pmc">PMC12085803</ArticleId><ArticleId IdType="pubmed">39570235</ArticleId></ArticleIdList></Reference><Reference><Citation>Siaghy EM, Halejcio-Delophont P, Devaux Y, et al. Protective effects of labetalol on myocardial contractile function in brain-dead pigs. Transplant Proc. 1998;30(6):2842&#x2013;2843. doi: 10.1016/s0041-1345(98)00833-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0041-1345(98)00833-1</ArticleId><ArticleId IdType="pubmed">9745589</ArticleId></ArticleIdList></Reference><Reference><Citation>Audibert G, Charpentier C, Seguin-Devaux C, et al. Improvement of donor myocardial function after treatment of autonomic storm during brain death. Transplantation. 2006;82(8):1031&#x2013;1036. doi: 10.1097/01.tp.0000235825.97538.d5</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.tp.0000235825.97538.d5</ArticleId><ArticleId IdType="pubmed">17060850</ArticleId></ArticleIdList></Reference><Reference><Citation>Kotloff RM, Blosser S, Fulda GJ, et al. Management of the Potential Organ Donor in the ICU: Society of Critical Care Medicine/American College of Chest Physicians/Association of Organ Procurement Organizations Consensus Statement. Crit Care Med. 2015;43(6):1291&#x2013;1325. doi: 10.1097/CCM.0000000000000958</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0000000000000958</ArticleId><ArticleId IdType="pubmed">25978154</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosendale JD, Kauffman HM, McBride MA, et al. Hormonal resuscitation yields more transplanted hearts, with improved early function. Transplantation. 2003;75(8):1336&#x2013;1341. doi: 10.1097/01.TP.0000062839.58826.6D</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.TP.0000062839.58826.6D</ArticleId><ArticleId IdType="pubmed">12717226</ArticleId></ArticleIdList></Reference><Reference><Citation>Khush KK, Nguyen J, Goldstein BA, McGlothlin DP, Zaroff JG. Reliability of transthoracic echocardiogram interpretation in potential adult heart transplant donors. J Heart Lung Transplant. 2015;34(2):266&#x2013;269. doi: 10.1016/j.healun.2014.09.046</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.healun.2014.09.046</ArticleId><ArticleId IdType="pmc">PMC4423611</ArticleId><ArticleId IdType="pubmed">25434522</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40615203</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>04</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2666-0849</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>17</Issue><PubDate><Year>2025</Year><Month>Jul</Month><Day>02</Day></PubDate></JournalIssue><Title>JACC. Case reports</Title><ISOAbbreviation>JACC Case Rep</ISOAbbreviation></Journal><ArticleTitle>Treating Concomitant Advanced Heart Failure and Advanced Cancer With Left Ventricular Assist Device, Surgery, and Biologics.</ArticleTitle><Pagination><StartPage>103875</StartPage><MedlinePgn>103875</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jaccas.2025.103875</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2666-0849(25)00653-9</ELocationID><Abstract><AbstractText>The diagnosis of cancer in the context of evaluation for advanced heart failure therapies represents a psychosocial and therapeutic challenge. We present a case report of a patient with breast cancer diagnosed during heart transplantation evaluation. A 63-year-old female presented with anterior ST-segment elevation myocardial infarction and severe left ventricular dysfunction 2 months prior. She was readmitted because of heart failure decompensation and diagnosed with inotrope-dependent stage D heart failure. Routine pre-heart transplantation evaluation diagnosed Stage IIIb breast cancer. She underwent left ventricular assist device (LVAD) implantation, neoadjuvant chemo-immunotherapy, mastectomy, adjuvant radiation, and adjuvant immunotherapy. Three years after LVAD implantation, she is at home with cancer in remission. There are no direct guidelines for the management of active cancer in the setting of advanced heart failure. Multidisciplinary teams should rapidly evaluate patients with cancer and advanced heart failure to plan life-saving cardiac and oncologic therapies. The treatment of cancer in LVAD patients is an important area for future expansion of guidelines.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Campbell</LastName><ForeName>Blake</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Cleveland Clinic, Cleveland, Ohio, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Agdamag</LastName><ForeName>Arianne Clare</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Heart, Vascular and Thoracic Institute, Division of Heart Failure and Transplant, Cleveland Clinic, Cleveland, Ohio, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moore</LastName><ForeName>Halle C F</ForeName><Initials>HCF</Initials><AffiliationInfo><Affiliation>Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alvarez</LastName><ForeName>Paulino</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Heart, Vascular and Thoracic Institute, Division of Heart Failure and Transplant, Cleveland Clinic, Cleveland, Ohio, USA. Electronic address: alvarep3@ccf.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>JACC Case Rep</MedlineTA><NlmUniqueID>101757292</NlmUniqueID><ISSNLinking>2666-0849</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cancer</Keyword><Keyword MajorTopicYN="N">cardiac assist devices</Keyword><Keyword MajorTopicYN="N">echocardiography</Keyword><Keyword MajorTopicYN="N">reduced ejection fraction</Keyword><Keyword MajorTopicYN="N">systolic heart failure</Keyword></KeywordList><CoiStatement>Funding Support and Author Disclosures The authors have reported that they have no relationships relevant to the contents of this paper to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>1</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>2</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>2</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>5</Day><Hour>0</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>5</Day><Hour>0</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>4</Day><Hour>20</Hour><Minute>56</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40615203</ArticleId><ArticleId IdType="doi">10.1016/j.jaccas.2025.103875</ArticleId><ArticleId IdType="pii">S2666-0849(25)00653-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40385581</PMID><DateRevised><Year>2025</Year><Month>05</Month><Day>20</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2296-858X</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><PubDate><Year>2025</Year></PubDate></JournalIssue><Title>Frontiers in medicine</Title><ISOAbbreviation>Front Med (Lausanne)</ISOAbbreviation></Journal><ArticleTitle>Myocardial impairment in rheumatoid arthritis patients with normal left ventricular function: findings from speckle tracking echocardiography.</ArticleTitle><Pagination><StartPage>1530622</StartPage><MedlinePgn>1530622</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1530622</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fmed.2025.1530622</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Rheumatoid arthritis (RA) is a chronic inflammatory condition recognized for elevating cardiovascular morbidity and mortality, even in the absence of overt cardiovascular symptoms. Traditional echocardiogram frequently overlooks early myocardial failure, necessitating more sensitive imaging modalities, such as speckle tracking echocardiography (STE), to effectively diagnose subclinical left ventricular systolic dysfunction (LVSD). Timely identification of cardiac involvement is essential for reducing long-term cardiovascular risks in people with rheumatoid arthritis.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="UNASSIGNED">This study sought to (i) determine if STE can identify subclinical myocardial dysfunction in RA Patients with normal left ventricular function as assessed by transthoracic echocardiography and (ii) identify clinical and biological factors linked to this extra-articular manifestation.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">A total of 36 RA patients and 36 matching healthy controls were included. All subjects underwent standard transthoracic echocardiogram and speckle tracking STE to evaluate left ventricular function. Global longitudinal strain (GLS) was employed to identify subclinical left ventricular systolic dysfunction, with a GLS threshold of &#x2264;&#x202f;-&#x202f;18% signifying LVSD. Clinical and biochemical variables, such as hemoglobin concentrations, diabetes mellitus, and disease activity (DAS28-CRP), were evaluated to determine their correlation with compromised myocardial strain.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">RA patients had a significantly diminished GLS compared to healthy controls (18.99&#x202f;&#xb1;&#x202f;2.81% vs. 20.42&#x202f;&#xb1;&#x202f;1.33%, <i>p</i>&#x202f;=&#x202f;0.015), notwithstanding a normal left ventricular ejection fraction (LVEF). Subclinical LVSD was detected in 33% of RA patients, but none of the control subjects exhibited this condition. Anemia was identified as the most significant independent predictor of diminished GLS (OR: 11.39, 95% CI: 1.57-82.89, <i>p</i>&#x202f;=&#x202f;0.016), although diabetes mellitus and age exhibited associations with myocardial strain in univariate analysis. No substantial correlations were identified between GLS and disease activity (DAS28-CRP) or immunological markers (RF, anti-CCP).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">STE identified subclinical LVSD in a significant number of RA patients with normal LVEF, emphasizing its effectiveness in early cardiovascular risk assessment. Hemoglobin levels were a crucial predictor of subclinical LVSD, highlighting the necessity of thorough cardiovascular risk evaluations in RA, especially for individuals with anemia or other concomitant conditions. Incorporating STE into standard assessments may facilitate early interventions and enhance long-term cardiovascular outcomes for patients with RA.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 Dhahri, Houaida, Dergaa, Ben Ammar, Ceylan, Ben Abderrazek, Fenniche, Chenik, Fehri, Muntean and Gharsallah.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dhahri</LastName><ForeName>Rim</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Rheumatology Department, Military Hospital of Tunis, Faculty of Medicine of Tunis, University Tunis El Manar, Tunis, Tunisia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Houaida</LastName><ForeName>Mahfoudhi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Military Hospital of Tunis, Faculty of Medicine of Tunis, University Tunis El Manar, Tunis, Tunisia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dergaa</LastName><ForeName>Ismail</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>High Institute of Sport and Physical Education of Ksar Said, University of Manouba, Manouba, Tunisia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ben Ammar</LastName><ForeName>Lobna</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Rheumatology Department, Military Hospital of Tunis, Faculty of Medicine of Tunis, University Tunis El Manar, Tunis, Tunisia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ceylan</LastName><ForeName>Halil &#x130;brahim</ForeName><Initials>H&#x130;</Initials><AffiliationInfo><Affiliation>Physical Education of Sports Teaching Department, Faculty of Sports Sciences, Ataturk University, Erzurum, T&#xfc;rkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ben Abderrazek</LastName><ForeName>Youssef</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Rheumatology Department, Military Hospital of Tunis, Faculty of Medicine of Tunis, University Tunis El Manar, Tunis, Tunisia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fenniche</LastName><ForeName>Insaf</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Rheumatology Department, Military Hospital of Tunis, Faculty of Medicine of Tunis, University Tunis El Manar, Tunis, Tunisia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chenik</LastName><ForeName>Sarra</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Military Hospital of Tunis, Faculty of Medicine of Tunis, University Tunis El Manar, Tunis, Tunisia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fehri</LastName><ForeName>Wafa</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Military Hospital of Tunis, Faculty of Medicine of Tunis, University Tunis El Manar, Tunis, Tunisia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Muntean</LastName><ForeName>Raul Ioan</ForeName><Initials>RI</Initials><AffiliationInfo><Affiliation>Department of Physical Education and Sport, Faculty of Law and Social Sciences, University "1 Decembrie 1918" of Alba Iulia, Alba Iulia, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gharsallah</LastName><ForeName>Im&#xe8;ne</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Rheumatology Department, Military Hospital of Tunis, Faculty of Medicine of Tunis, University Tunis El Manar, Tunis, Tunisia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>05</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Med (Lausanne)</MedlineTA><NlmUniqueID>101648047</NlmUniqueID><ISSNLinking>2296-858X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">anemia</Keyword><Keyword MajorTopicYN="N">cardiac function</Keyword><Keyword MajorTopicYN="N">cardiovascular comorbidities</Keyword><Keyword MajorTopicYN="N">diabetes mellitus</Keyword><Keyword MajorTopicYN="N">hemodynamic monitoring</Keyword><Keyword MajorTopicYN="N">inflammatory biomarkers</Keyword><Keyword MajorTopicYN="N">left ventricular dysfunction</Keyword><Keyword MajorTopicYN="N">rheumatoid heart disease</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>11</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>4</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>5</Month><Day>19</Day><Hour>12</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>5</Month><Day>19</Day><Hour>12</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>5</Month><Day>19</Day><Hour>6</Hour><Minute>14</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>5</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40385581</ArticleId><ArticleId IdType="pmc">PMC12081369</ArticleId><ArticleId IdType="doi">10.3389/fmed.2025.1530622</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. (2011) 365:2205&#x2013;19. doi: 10.1056/NEJMra1004965, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1004965</ArticleId><ArticleId IdType="pubmed">22150039</ArticleId></ArticleIdList></Reference><Reference><Citation>Cojocaru M, Cojocaru IM, Silosi I, Vrabie CD, Tanasescu R. Extra-articular manifestations in rheumatoid arthritis. Maedica. (2010) 5:286&#x2013;91. PMID:</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3152850</ArticleId><ArticleId IdType="pubmed">21977172</ArticleId></ArticleIdList></Reference><Reference><Citation>Khalid U, Egeberg A, Ahlehoff O, Lane D, Gislason GH, Lip GYH, et al. . Incident heart failure in patients with rheumatoid arthritis: a Nationwide cohort study. J Am Heart Assoc. (2018) 7:e00722. doi: 10.1161/JAHA.117.007227, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/JAHA.117.007227</ArticleId><ArticleId IdType="pmc">PMC5850154</ArticleId><ArticleId IdType="pubmed">29352092</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis JM, 3rd, Roger VL, Crowson CS, Kremers HM, Therneau TM, Gabriel SE. The presentation and outcome of heart failure in patients with rheumatoid arthritis differs from that in the general population. Arthritis Rheum. (2008) 58:2603&#x2013;11. doi: 10.1002/art.23798, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.23798</ArticleId><ArticleId IdType="pmc">PMC2631416</ArticleId><ArticleId IdType="pubmed">18759286</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindhardsen J, Ahlehoff O, Gislason GH, Madsen OR, Olesen JB, Torp-Pedersen C, et al. . The risk of myocardial infarction in rheumatoid arthritis and diabetes mellitus: a Danish nationwide cohort study. Ann Rheum Dis. (2011) 70:929&#x2013;34. doi: 10.1136/ard.2010.143396, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2010.143396</ArticleId><ArticleId IdType="pubmed">21389043</ArticleId></ArticleIdList></Reference><Reference><Citation>Mavrogeni S, Dimitroulas T, Gabriel S, Sfikakis PP, Pohost GM, Kitas GD. Why currently used diagnostic techniques for heart failure in rheumatoid arthritis are not enough: the challenge of cardiovascular magnetic resonance imaging. Rev Cardiovasc Med. (2014) 15:320&#x2013;31. doi: 10.3909/ricm0724, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3909/ricm0724</ArticleId><ArticleId IdType="pubmed">25662926</ArticleId></ArticleIdList></Reference><Reference><Citation>Bansal M, Kasliwal RR. How do I do it? Speckle-tracking echocardiography. Indian Heart J. (2013) 65:117&#x2013;23. doi: 10.1016/j.ihj.2012.12.004, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ihj.2012.12.004</ArticleId><ArticleId IdType="pmc">PMC3860973</ArticleId><ArticleId IdType="pubmed">23438628</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexandre A, S&#xe1;-Couto D, Brand&#xe3;o M, Cabral S, Fonseca T, Costa RQ, et al. . Subclinical left ventricular dysfunction in rheumatoid arthritis: findings from the prospective Porto-RA cohort. Clin Res Cardiol. (2024). doi: 10.1007/s00392-024-02548-6, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00392-024-02548-6</ArticleId><ArticleId IdType="pubmed">39347795</ArticleId></ArticleIdList></Reference><Reference><Citation>Bedekovi&#x107; D, Bo&#x161;njak I, Bili&#x107;-&#x106;ur&#x10d;i&#x107; I, Kirner D, &#x160;ari&#x107; S, Novak S. Risk for cardiovascular disease development in rheumatoid arthritis. BMC Cardiovasc Disord. (2024) 24:291. doi: 10.1186/s12872-024-03963-3, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12872-024-03963-3</ArticleId><ArticleId IdType="pmc">PMC11149346</ArticleId><ArticleId IdType="pubmed">38834973</ArticleId></ArticleIdList></Reference><Reference><Citation>Oskuyl AE. The heart and cardiovascular manifestations in rheumatoid arthritis. Rheumatology. (2006) 45:iv4&#x2013;7. doi: 10.1093/rheumatology/kel313, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kel313</ArticleId><ArticleId IdType="pubmed">16980723</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagueh SF, Smiseth OA, Appleton CP, Byrd BF, III, Dokainish H, Edvardsen T, et al. . Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. (2016) 29:277&#x2013;314. doi: 10.1016/j.echo.2016.01.011, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.echo.2016.01.011</ArticleId><ArticleId IdType="pubmed">27037982</ArticleId></ArticleIdList></Reference><Reference><Citation>Maradit-Kremers H, Crowson CS, Nicola PJ, Ballman KV, Roger VL, Jacobsen SJ, et al. . Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum. (2005) 52:402&#x2013;11. doi: 10.1002/art.20853, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.20853</ArticleId><ArticleId IdType="pubmed">15693010</ArticleId></ArticleIdList></Reference><Reference><Citation>Corrao S, Argano C, Pistone G, Messina S, Calvo L, Perticone F. Rheumatoid arthritis affects left ventricular mass: systematic review and meta-analysis. Eur J Intern Med. (2015) 26:259&#x2013;67. doi: 10.1016/j.ejim.2015.02.008, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejim.2015.02.008</ArticleId><ArticleId IdType="pubmed">25753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Aslam F, Bandeali SJ, Khan NA, Alam M. Diastolic dysfunction in rheumatoid arthritis: a meta-analysis and systematic review. Arthritis Care Res. (2013) 65:534&#x2013;43. doi: 10.1002/acr.21861, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.21861</ArticleId><ArticleId IdType="pubmed">23002032</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikonomidis I, Tzortzis S, Lekakis J, Paraskevaidis I, Andreadou I, Nikolaou M, et al. . Lowering interleukin-1 activity with anakinra improves myocardial deformation in rheumatoid arthritis. Heart. (2009) 95:1502&#x2013;7. doi: 10.1136/hrt.2009.168971, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/hrt.2009.168971</ArticleId><ArticleId IdType="pubmed">19482847</ArticleId></ArticleIdList></Reference><Reference><Citation>Cioffi G, Viapiana O, Ognibeni F, Dalbeni A, Giollo A, Gatti D, et al. . Prognostic role of subclinical left ventricular systolic dysfunction evaluated by speckle-tracking echocardiography in rheumatoid arthritis. J Am Soc Echocardiogr. (2017) 30:602&#x2013;11. doi: 10.1016/j.echo.2017.02.001, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.echo.2017.02.001</ArticleId><ArticleId IdType="pubmed">28391000</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Q, Shen J, Liu Y, Luo R, Tan B, Li G. Assessment of left ventricular systolic function in patients with iron deficiency anemia by three-dimensional speckle-tracking echocardiography. Anatol J Cardiol. (2017) 18:194&#x2013;9. doi: 10.14744/AnatolJCardiol.2017.7694, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.14744/AnatolJCardiol.2017.7694</ArticleId><ArticleId IdType="pmc">PMC5689050</ArticleId><ArticleId IdType="pubmed">28639946</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xf6;ller B, Everts-Graber J, Florentinus S, Li Y, Kupper H, Finckh A. Low hemoglobin and radiographic damage progression in early rheumatoid arthritis: secondary analysis from a phase III trial. Arthritis Care Res. (2018) 70:861&#x2013;8. doi: 10.1002/acr.23427, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.23427</ArticleId><ArticleId IdType="pubmed">28950430</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xf6;ller B, Scherer A, F&#xf6;rger F, Villiger PM, Finckh A. Swiss clinical quality management program for rheumatic diseases. Anaemia may add information to standardised disease activity assessment to predict radiographic damage in rheumatoid arthritis: a prospective cohort study. Ann Rheum Dis. (2014) 73:691&#x2013;6. doi: 10.1136/annrheumdis-2012-202709, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2012-202709</ArticleId><ArticleId IdType="pmc">PMC3963599</ArticleId><ArticleId IdType="pubmed">23505235</ArticleId></ArticleIdList></Reference><Reference><Citation>van Steenbergen HW, van Nies JA, van der Helm-van Mil AH. Anaemia to predict radiographic progression in rheumatoid arthritis. Ann Rheum Dis. (2013) 72:e16. doi: 10.1136/annrheumdis-2013-203718, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2013-203718</ArticleId><ArticleId IdType="pubmed">23625976</ArticleId></ArticleIdList></Reference><Reference><Citation>Fine NM, Crowson CS, Lin G, Oh JK, Villarraga HR, Gabriel SE. Evaluation of myocardial function in patients with rheumatoid arthritis using strain imaging by speckle-tracking echocardiography. Ann Rheum Dis. (2014) 73:1833&#x2013;9. doi: 10.1136/annrheumdis-2013-203314, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2013-203314</ArticleId><ArticleId IdType="pmc">PMC3895498</ArticleId><ArticleId IdType="pubmed">23873875</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanvivadhanakul P, Buakhamsri A. Disease activity is associated with LV dysfunction in rheumatoid arthritis patients without clinical cardiovascular disease. Adv Rheumatol. (2019) 59:56. doi: 10.1186/s42358-019-0100-x, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s42358-019-0100-x</ArticleId><ArticleId IdType="pubmed">31843000</ArticleId></ArticleIdList></Reference><Reference><Citation>Dergaa I, Saad HB, Glenn JM, Aissa MB, Taheri M, Swed S, et al. . A thorough examination of ChatGPT-3.5 potential applications in medical writing: a preliminary study. Medicine. (2024) 103:e39757. doi: 10.1097/MD.0000000000039757, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000039757</ArticleId><ArticleId IdType="pmc">PMC11460921</ArticleId><ArticleId IdType="pubmed">39465713</ArticleId></ArticleIdList></Reference><Reference><Citation>Dergaa I, Fekih-Romdhane F, Glenn JM, Fessi MS, Chamari K, Dhahbi W, et al. . Moving beyond the stigma: understanding and overcoming the resistance to the acceptance and adoption of artificial intelligence chatbots. New Asian J Med. (2023) 1:29&#x2013;36. doi: 10.61838/kman.najm.1.2.4</Citation><ArticleIdList><ArticleId IdType="doi">10.61838/kman.najm.1.2.4</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40428267</PMID><DateRevised><Year>2025</Year><Month>05</Month><Day>31</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2075-4418</ISSN><JournalIssue CitedMedium="Print"><Volume>15</Volume><Issue>10</Issue><PubDate><Year>2025</Year><Month>May</Month><Day>17</Day></PubDate></JournalIssue><Title>Diagnostics (Basel, Switzerland)</Title><ISOAbbreviation>Diagnostics (Basel)</ISOAbbreviation></Journal><ArticleTitle>Risk Factors Influencing Right and Left Ventricular Variables Assessed with Gated Cadmium-Zinc-Telluride Equilibrium Radionuclide Angiocardiography in Oncology Patients.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1274</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/diagnostics15101274</ELocationID><Abstract><AbstractText><b>Background</b>: Left ventricular ejection fraction remains the primary focus in cardiac monitoring for oncology patients undergoing potentially cardiotoxic chemotherapy, while right ventricular function is seldom examined. This study evaluates how established risk factors for left ventricular dysfunction affect right ventricular function. <b>Methods</b>: This retrospective cohort study included 1770 patients undergoing cadmium-zinc-telluride equilibrium radionuclide angiocardiography before chemotherapy. Patients were categorized based on risk factors for left ventricular dysfunction-diabetes (DM), atrial fibrillation (AF), coronary heart disease (CHD), and previous oncological therapy-and compared to controls using independent <i>t</i>-tests. <b>Results</b>: Patients with previous oncological therapy exhibited a significantly lower right ventricular end-diastolic volume (RVEDV) (mean difference: -4.4 mL/m<sup>2</sup>, 95% CI: -6.1 to -2.7, <i>p</i> &lt; 0.001), lower right ventricular end-systolic volume (RVESV) (-2.3 mL/m<sup>2</sup>, 95% CI: -3.4 to -1.2, <i>p</i> &lt; 0.001), and lower right ventricular stroke volume (RVSV) (-2.1 mL/m<sup>2</sup>, 95% CI: -3 to -1.2, <i>p</i> &lt; 0.001). In patients with CHD, there was a higher right ventricular ejection fraction (RVEF) (3.0 mL/m<sup>2</sup>, 95% CI: 0.8 to 5.2, <i>p</i> &lt; 0.01), whereas patients with DM had lower RVEDV (-5.1 mL/m<sup>2</sup>, 95% CI: -9.2 to -1, <i>p</i> &lt; 0.05) and RVESV (-3.0 mL/m<sup>2</sup>, 95% CI: -5.5 to -0.4, <i>p</i> &lt; 0.05). No ventricular variables differed from the control group among patients with AF. <b>Conclusions</b>: Risk factors known to affect the left ventricle also impacted the right ventricle, with the exception of AF.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Monsson</LastName><ForeName>Olav</ForeName><Initials>O</Initials><Identifier Source="ORCID">0000-0003-2413-0179</Identifier><AffiliationInfo><Affiliation>Department of Nuclear Medicine, Herlev og Gentofte Hospital, 2730 Herlev, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology, Odense University Hospital, 5000 Odense, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Unit of Radiology, Department of Clinical Research, University of Southern Denmark, 5000 Odense, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nielsen</LastName><ForeName>Marc</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-7722-7655</Identifier><AffiliationInfo><Affiliation>Department of Nuclear Medicine, Herlev og Gentofte Hospital, 2730 Herlev, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>K&#xfc;mler</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Complications Research, Steno Diabetes Center Copenhagen, 2730 Herlev, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiology, Herlev-Gentofte Hospital, 2730 Herlev, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Medicine, Copenhagen University, 2200 Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haarmark</LastName><ForeName>Christian</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-3786-4737</Identifier><AffiliationInfo><Affiliation>Department of Nuclear Medicine, Herlev og Gentofte Hospital, 2730 Herlev, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Medicine, Copenhagen University, 2200 Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zerahn</LastName><ForeName>Bo</ForeName><Initials>B</Initials><Identifier Source="ORCID">0009-0004-0103-6950</Identifier><AffiliationInfo><Affiliation>Department of Nuclear Medicine, Herlev og Gentofte Hospital, 2730 Herlev, Denmark.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>05</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Diagnostics (Basel)</MedlineTA><NlmUniqueID>101658402</NlmUniqueID><ISSNLinking>2075-4418</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CZT SPECT</Keyword><Keyword MajorTopicYN="N">cardiac function</Keyword><Keyword MajorTopicYN="N">equilibrium radionuclide angiography</Keyword><Keyword MajorTopicYN="N">left ventricular ejection fraction</Keyword><Keyword MajorTopicYN="N">right ventricular ejection fraction</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>4</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>5</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>5</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>5</Month><Day>28</Day><Hour>6</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>5</Month><Day>28</Day><Hour>6</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>5</Month><Day>28</Day><Hour>1</Hour><Minute>14</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>5</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40428267</ArticleId><ArticleId IdType="pmc">PMC12110102</ArticleId><ArticleId IdType="doi">10.3390/diagnostics15101274</ArticleId><ArticleId IdType="pii">diagnostics15101274</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Jones N.R., Hobbs F.R., Taylor C.J. Prognosis following a diagnosis of heart failure and the role of primary care: A review of the literature. BJGP Open. 2017;1:bjgpopen17X101013. doi: 10.3399/bjgpopen17X101013.</Citation><ArticleIdList><ArticleId IdType="doi">10.3399/bjgpopen17X101013</ArticleId><ArticleId IdType="pmc">PMC6169931</ArticleId><ArticleId IdType="pubmed">30564675</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyon A.R., L&#xf3;pez-Fern&#xe1;ndez T., Couch L.S., Asteggiano R., Aznar M.C., Bergler-Klein J., Boriani G., Cardinale D., Cordoba R., Cosyns B., et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS) Eur. Heart J. 2022;43:4229&#x2013;4361. doi: 10.1093/eurheartj/ehac244.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehac244</ArticleId><ArticleId IdType="pubmed">36017568</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrmann J. Adverse cardiac effects of cancer therapies: Cardiotoxicity and arrhythmia. Nat. Rev. Cardiol. 2020;17:474&#x2013;502. doi: 10.1038/s41569-020-0348-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41569-020-0348-1</ArticleId><ArticleId IdType="pmc">PMC8782611</ArticleId><ArticleId IdType="pubmed">32231332</ArticleId></ArticleIdList></Reference><Reference><Citation>Kossaify A. Echocardiographic Assessment of the Right Ventricle, from the Conventional Approach to Speckle Tracking and Three-Dimensional Imaging, and Insights into the &#x201c;Right Way&#x201d; to Explore the Forgotten Chamber. Clin. Med. Insights Cardiol. 2015;9:65&#x2013;75. doi: 10.4137/CMC.S27462.</Citation><ArticleIdList><ArticleId IdType="doi">10.4137/CMC.S27462</ArticleId><ArticleId IdType="pmc">PMC4493918</ArticleId><ArticleId IdType="pubmed">26244034</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer P., Filippatos G.S., Ahmed M.I., Iskandrian A.E., Bittner V., Perry G.J., White M., Aban I.B., Mujib M., Dell&#x2019;Italia L.J., et al. Effects of Right Ventricular Ejection Fraction on Outcomes in Chronic Systolic Heart Failure. Circulation. 2010;121:252&#x2013;258. doi: 10.1161/CIRCULATIONAHA.109.887570.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.109.887570</ArticleId><ArticleId IdType="pmc">PMC2877272</ArticleId><ArticleId IdType="pubmed">20048206</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanz J., S&#xe1;nchez-Quintana D., Bossone E., Bogaard H.J., Naeije R. Anatomy, Function, and Dysfunction of the Right Ventricle. J. Am. Coll. Cardiol. 2019;73:1463&#x2013;1482. doi: 10.1016/j.jacc.2018.12.076.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2018.12.076</ArticleId><ArticleId IdType="pubmed">30922478</ArticleId></ArticleIdList></Reference><Reference><Citation>Seo Y., Ishizu T., Ieda M., Ohte N. Right ventricular three-dimensional echocardiography: The current status and future perspectives. J. Echocardiogr. 2020;18:149&#x2013;159. doi: 10.1007/s12574-020-00468-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12574-020-00468-8</ArticleId><ArticleId IdType="pubmed">32239383</ArticleId></ArticleIdList></Reference><Reference><Citation>Kartas A., Samaras A., Akrivos E., Vrana E., Papazoglou A.S., Moysidis D.V., Papanastasiou A., Baroutidou A., Botis M., Liampas E., et al. &#x3a4;he association of heart failure across left ventricular ejection fraction with mortality in atrial fibrillation. ESC Heart Fail. 2021;8:3189&#x2013;3197. doi: 10.1002/ehf2.13440.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ehf2.13440</ArticleId><ArticleId IdType="pmc">PMC8318411</ArticleId><ArticleId IdType="pubmed">34080782</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoon G.J., Telli M.L., Kao D.P., Matsuda K.Y., Carlson R.W., Witteles R.M. Left Ventricular Dysfunction in Patients Receiving Cardiotoxic Cancer Therapies. J. Am. Coll. Cardiol. 2010;56:1644&#x2013;1650. doi: 10.1016/j.jacc.2010.07.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2010.07.023</ArticleId><ArticleId IdType="pmc">PMC3835691</ArticleId><ArticleId IdType="pubmed">21050974</ArticleId></ArticleIdList></Reference><Reference><Citation>Hendriks T., Van Dijk R., Alsabaan N.A., Van Der Harst P. Active Tobacco Smoking Impairs Cardiac Systolic Function. Sci. Rep. 2020;10:6608. doi: 10.1038/s41598-020-63509-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-63509-3</ArticleId><ArticleId IdType="pmc">PMC7171181</ArticleId><ArticleId IdType="pubmed">32313023</ArticleId></ArticleIdList></Reference><Reference><Citation>Siddiqui A.J., Holzmann M.J. Association between reduced left ventricular ejection fraction following non-ST-segment elevation myocardial infarction and long-term mortality in patients of advanced age. Int. J. Cardiol. 2019;296:15&#x2013;20. doi: 10.1016/j.ijcard.2019.07.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijcard.2019.07.019</ArticleId><ArticleId IdType="pubmed">31327520</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehl N.F., K&#xfc;hne M., Brinkert M., M&#xfc;ller-Brand J., Zellweger M.J. Diabetes reduces left ventricular ejection fraction-irrespective of presence and extent of coronary artery disease. Eur. J. Endocrinol. 2011;165:945&#x2013;951. doi: 10.1530/EJE-11-0687.</Citation><ArticleIdList><ArticleId IdType="doi">10.1530/EJE-11-0687</ArticleId><ArticleId IdType="pubmed">21903896</ArticleId></ArticleIdList></Reference><Reference><Citation>Hesse B., Lindhardt T.B., Acampa W., Anagnostopoulos C., Ballinger J., Bax J.J., Edenbrandt L., Flotats A., Germano G., Stopar T.G., et al. EANM/ESC guidelines for radionuclide imaging of cardiac function. Eur. J. Nucl. Med. Mol. Imaging. 2008;35:851&#x2013;885. doi: 10.1007/s00259-007-0694-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-007-0694-9</ArticleId><ArticleId IdType="pubmed">18224320</ArticleId></ArticleIdList></Reference><Reference><Citation>Jensen M.M., Schmidt U., Huang C., Zerahn B. Gated tomographic radionuclide angiography using cadmium-zinc-telluride detector gamma camera; comparison to traditional gamma cameras. J. Nucl. Cardiol. 2014;21:384&#x2013;396. doi: 10.1007/s12350-013-9844-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12350-013-9844-6</ArticleId><ArticleId IdType="pubmed">24366823</ArticleId></ArticleIdList></Reference><Reference><Citation>Duvall W.L., Guma-Demers K.A., George T., Henzlova M.J. Radiation reduction and faster acquisition times with SPECT gated blood pool scans using a high-efficiency cardiac SPECT camera. J. Nucl. Cardiol. 2016;23:1128&#x2013;1138. doi: 10.1007/s12350-015-0214-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12350-015-0214-4</ArticleId><ArticleId IdType="pubmed">26231888</ArticleId></ArticleIdList></Reference><Reference><Citation>Jensen M.M., Haase C., Zerahn B. Interstudy repeatability of left and right ventricular volume estimations by serial-gated tomographic radionuclide angiographies using a cadmium-zinc-telluride detector gamma camera. Clin. Physiol. Funct. Imaging. 2015;35:418&#x2013;424. doi: 10.1111/cpf.12178.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cpf.12178</ArticleId><ArticleId IdType="pubmed">24980073</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansen M.N., Haarmark C., Kristensen B., Zerahn B. An Algorithm for Individual Dosage in Cadmium&#x2013;Zinc&#x2013;Telluride SPECT-Gated Radionuclide Angiography. Diagnostics. 2021;11:2268. doi: 10.3390/diagnostics11122268.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/diagnostics11122268</ArticleId><ArticleId IdType="pmc">PMC8700612</ArticleId><ArticleId IdType="pubmed">34943505</ArticleId></ArticleIdList></Reference><Reference><Citation>Haarmark C., Haase C., Jensen M.M., Zerahn B. Pre-chemotherapy values for left and right ventricular volumes and ejection fraction by gated tomographic radionuclide angiography using a cadmium-zinc-telluride detector gamma camera. J. Nucl. Cardiol. 2016;23:87&#x2013;97. doi: 10.1007/s12350-015-0177-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12350-015-0177-5</ArticleId><ArticleId IdType="pubmed">26338424</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansen N.L., Haarmark C., Zerahn B. Ventricular peak emptying and filling rates measured by gated tomographic radionuclide angiography using a cadmium&#x2013;zinc&#x2013;telluride SPECT camera in chemotherapy-na&#xef;ve cancer patients. J. Nucl. Cardiol. 2020;27:1193&#x2013;1201. doi: 10.1007/s12350-019-01756-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12350-019-01756-2</ArticleId><ArticleId IdType="pubmed">31127488</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawel-Boehm N., Hetzel S.J., Ambale-Venkatesh B., Captur G., Francois C.J., Jerosch-Herold M., Salerno M., Teague S.D., Valsangiacomo-Buechel E., van der Geest R.J., et al. Reference ranges (&#x201c;normal values&#x201d;) for cardiovascular magnetic resonance (CMR) in adults and children: 2020 update. J. Cardiovasc. Magn. Reson. 2020;22:87. doi: 10.1186/s12968-020-00683-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12968-020-00683-3</ArticleId><ArticleId IdType="pmc">PMC7734766</ArticleId><ArticleId IdType="pubmed">33308262</ArticleId></ArticleIdList></Reference><Reference><Citation>Theetha Kariyanna P., Kumar A., Jayarangaiah A., Shetty M., Chowdhury Y., Das S., Jayarangaiah A. Chemotherapy induced right ventricular cardiomyopathy; a systematic review and meta-analysis. Front. Cardiovasc. Med. 2023;10:1103941. doi: 10.3389/fcvm.2023.1103941.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2023.1103941</ArticleId><ArticleId IdType="pmc">PMC10434797</ArticleId><ArticleId IdType="pubmed">37600030</ArticleId></ArticleIdList></Reference><Reference><Citation>Grover S., Leong D.P., Chakrabarty A., Joerg L., Kotasek D., Cheong K., Joshi R., Joseph M.X., DePasquale C., Koczwara B., et al. Left and right ventricular effects of anthracycline and trastuzumab chemotherapy: A prospective study using novel cardiac imaging and biochemical markers. Int. J. Cardiol. 2013;168:5465&#x2013;5467. doi: 10.1016/j.ijcard.2013.07.246.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijcard.2013.07.246</ArticleId><ArticleId IdType="pubmed">24090744</ArticleId></ArticleIdList></Reference><Reference><Citation>Tadic M., Baudisch A., Ha&#xdf;feld S., Heinzel F., Cuspidi C., Burkhardt F., Escher F., Attanasio P., Pieske B., Genger M. Right ventricular function and mechanics in chemotherapy- and radiotherapy-na&#xef;ve cancer patients. Int. J. Cardiovasc. Imaging. 2018;34:1581&#x2013;1587. doi: 10.1007/s10554-018-1379-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10554-018-1379-0</ArticleId><ArticleId IdType="pubmed">29799062</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanindi A., Demirci U., Tacoy G., Buyukberber S., Alsancak Y., Coskun U., Yalcin R., Benekli M. Assessment of right ventricular functions during cancer chemotherapy. Eur. J. Echocardiogr. 2011;12:834&#x2013;840. doi: 10.1093/ejechocard/jer142.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ejechocard/jer142</ArticleId><ArticleId IdType="pubmed">21880609</ArticleId></ArticleIdList></Reference><Reference><Citation>Piper S.E., McDonagh T.A. Chemotherapy-related Cardiomyopathy. Eur. Cardiol. Rev. 2015;10:19&#x2013;24. doi: 10.15420/ecr.2015.10.01.19.</Citation><ArticleIdList><ArticleId IdType="doi">10.15420/ecr.2015.10.01.19</ArticleId><ArticleId IdType="pmc">PMC6159418</ArticleId><ArticleId IdType="pubmed">30310418</ArticleId></ArticleIdList></Reference><Reference><Citation>Parmentier S., Melin J.A., Piret L., Beckers C. Assessment of left ventricular diastolic function in patients receiving anthracycline therapy. Eur. J. Nucl. Med. 1988;13:563&#x2013;567. doi: 10.1007/BF02574768.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF02574768</ArticleId><ArticleId IdType="pubmed">3162416</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawut S.M., Lima J.A.C., Barr R.G., Chahal H., Jain A., Tandri H., Praestgaard A., Bagiella E., Kizer J.R., Johnson W.C., et al. Sex and Race Differences in Right Ventricular Structure and Function: The Multi-Ethnic Study of Atherosclerosis&#x2013;Right Ventricle Study. Circulation. 2011;123:2542&#x2013;2551. doi: 10.1161/CIRCULATIONAHA.110.985515.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.110.985515</ArticleId><ArticleId IdType="pmc">PMC3111939</ArticleId><ArticleId IdType="pubmed">21646505</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker L.A., Buttrick P.M. The Right Ventricle: Biologic Insights and Response to Disease: Updated. Curr. Cardiol. Rev. 2013;9:73&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3584309</ArticleId><ArticleId IdType="pubmed">23092273</ArticleId></ArticleIdList></Reference><Reference><Citation>Maggioni A.P., Dahlstr&#xf6;m U., Filippatos G., Chioncel O., Leiro M.C., Drozdz J., Fruhwald F., Gullestad L., Logeart D., Fabbri G., et al. EURObservational Research Programme: Regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot) Eur. J. Heart Fail. 2013;15:808&#x2013;817. doi: 10.1093/eurjhf/hft050.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurjhf/hft050</ArticleId><ArticleId IdType="pubmed">23537547</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy S.P., Ibrahim N.E., Januzzi J.L. Heart Failure With Reduced Ejection Fraction: A Review. JAMA. 2020;324:488&#x2013;504. doi: 10.1001/jama.2020.10262.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.10262</ArticleId><ArticleId IdType="pubmed">32749493</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldstein J.A. Right heart ischemia: Pathophysiology, natural history, and clinical management. Prog. Cardiovasc. Dis. 1998;40:325&#x2013;341. doi: 10.1016/S0033-0620(98)80051-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0033-0620(98)80051-0</ArticleId><ArticleId IdType="pubmed">9449958</ArticleId></ArticleIdList></Reference><Reference><Citation>Lahm T., Douglas I.S., Archer S.L., Bogaard H.J., Chesler N.C., Haddad F., Hemnes A.R., Kawut S.M., Kline J.A., Kolb T.M., et al. Assessment of Right Ventricular Function in the Research Setting: Knowledge Gaps and Pathways Forward. An Official American Thoracic Society Research Statement. Am. J. Respir. Crit. Care Med. 2018;198:e15&#x2013;e43. doi: 10.1164/rccm.201806-1160ST.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.201806-1160ST</ArticleId><ArticleId IdType="pmc">PMC6835085</ArticleId><ArticleId IdType="pubmed">30109950</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Wolferen S.A., Marcus J.T., Boonstra A., Marques K.M.J., Bronzwaer J.G.F., Spreeuwenberg M.D., Postmus P.E., Vonk-Noordegraaf A. Prognostic value of right ventricular mass, volume, and function in idiopathic pulmonary arterial hypertension. Eur. Heart J. 2007;28:1250&#x2013;1257. doi: 10.1093/eurheartj/ehl477.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehl477</ArticleId><ArticleId IdType="pubmed">17242010</ArticleId></ArticleIdList></Reference><Reference><Citation>Widya R.L., Van Der Meer R.W., Smit J.W.A., Rijzewijk L.J., Diamant M., Bax J.J., de Roos A., Lamb H.J. Right Ventricular Involvement in Diabetic Cardiomyopathy. Diabetes Care. 2013;36:457&#x2013;462. doi: 10.2337/dc12-0474.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc12-0474</ArticleId><ArticleId IdType="pmc">PMC3554276</ArticleId><ArticleId IdType="pubmed">23139371</ArticleId></ArticleIdList></Reference><Reference><Citation>Apert A., Canu M., Jankowski A., Riou L., Broisat A., Charlon C., Augier C., Boignard A., Leenhardt J., Salvat M., et al. Comparison of Cadmium Zinc Telluride ECG-gated SPECT equilibrium radionuclide angiocardiography to magnetic resonance imaging to measure right ventricular volumes and ejection fraction in patients with cardiomyopathy. J. Nucl. Cardiol. 2022;29:1647&#x2013;1656. doi: 10.1007/s12350-021-02653-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12350-021-02653-3</ArticleId><ArticleId IdType="pubmed">33988809</ArticleId></ArticleIdList></Reference><Reference><Citation>Triposkiadis F., Xanthopoulos A., Bargiota A., Kitai T., Katsiki N., Farmakis D., Skoularigis J., Starling R.C., Iliodromitis E. Diabetes Mellitus and Heart Failure. J. Clin. Med. 2021;10:3682. doi: 10.3390/jcm10163682.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm10163682</ArticleId><ArticleId IdType="pmc">PMC8396967</ArticleId><ArticleId IdType="pubmed">34441977</ArticleId></ArticleIdList></Reference><Reference><Citation>Mgbemena O., Zhang Y., Velarde G. Role of Diabetes Mellitus in Heart Failure With Preserved Ejection Fraction: A Review Article.  [(accessed on 5 June 2024)];Cureus. 2021 13:e19398. doi: 10.7759/cureus.19398. Available online:  https://www.cureus.com/articles/75988-role-of-diabetes-mellitus-in-heart-failure-with-preserved-ejection-fraction-a-review-article.</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.19398</ArticleId><ArticleId IdType="pmc">PMC8654084</ArticleId><ArticleId IdType="pubmed">34926000</ArticleId></ArticleIdList></Reference><Reference><Citation>Abudureyimu M., Luo X., Wang X., Sowers J.R., Wang W., Ge J., Ren J., Zhang Y. Heart failure with preserved ejection fraction (HFpEF) in type 2 diabetes mellitus: From pathophysiology to therapeutics. J. Mol. Cell Biol. 2022;14:mjac028. doi: 10.1093/jmcb/mjac028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jmcb/mjac028</ArticleId><ArticleId IdType="pmc">PMC9465638</ArticleId><ArticleId IdType="pubmed">35511596</ArticleId></ArticleIdList></Reference><Reference><Citation>Alpert J.S., Petersen P., Godtfredsen J. Atrial Fibrillation: Natural History, Complications, and Management. Annu. Rev. Med. 1988;39:41&#x2013;52. doi: 10.1146/annurev.me.39.020188.000353.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.me.39.020188.000353</ArticleId><ArticleId IdType="pubmed">3285783</ArticleId></ArticleIdList></Reference><Reference><Citation>Marcusohn E., Kobo O., Postnikov M., Epstein D., Agmon Y., Gepstein L., Hellman Y., Zukermann R. Left Ventricular Systolic Dysfunction Due to Atrial Fibrillation: Clinical and Echocardiographic Predictors. Card. Fail. Rev. 2021;7:e16. doi: 10.15420/cfr.2021.17.</Citation><ArticleIdList><ArticleId IdType="doi">10.15420/cfr.2021.17</ArticleId><ArticleId IdType="pmc">PMC8674700</ArticleId><ArticleId IdType="pubmed">34950506</ArticleId></ArticleIdList></Reference><Reference><Citation>Kerr A.J., Williams M.J.A., Stewart R.A.H. Ventricular rate and beat-to-beat variation of stroke volume in atrial fibrillation. Am. J. Cardiol. 2001;87:1116&#x2013;1119. doi: 10.1016/S0002-9149(01)01475-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0002-9149(01)01475-8</ArticleId><ArticleId IdType="pubmed">11348616</ArticleId></ArticleIdList></Reference><Reference><Citation>Grau M., Barr R.G., Lima J.A., Hoffman E.A., Bluemke D.A., Carr J.J., Chahal H., Enright P.L., Jain A., Prince M.R., et al. Percent Emphysema and Right Ventricular Structure and Function. Chest. 2013;144:136&#x2013;144. doi: 10.1378/chest.12-1779.</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.12-1779</ArticleId><ArticleId IdType="pmc">PMC3704233</ArticleId><ArticleId IdType="pubmed">23450302</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40384403</PMID><DateCompleted><Year>2025</Year><Month>05</Month><Day>19</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1525-6049</ISSN><JournalIssue CitedMedium="Internet"><Volume>47</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Renal failure</Title><ISOAbbreviation>Ren Fail</ISOAbbreviation></Journal><ArticleTitle>The combination of left ventricular ejection fraction and end-diastolic diameter and outcomes in peritoneal dialysis patients: a multicenter retrospective study.</ArticleTitle><Pagination><StartPage>2497493</StartPage><MedlinePgn>2497493</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">2497493</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1080/0886022X.2025.2497493</ELocationID><Abstract><AbstractText>End-stage renal disease (ESRD) is often complicated by left ventricular dysfunction, which is associated with a poor prognosis. This study aims to investigate the association between baseline left ventricular ejection fraction (LVEF) plus left ventricular end-diastolic diameter (LVEDD) with outcomes in peritoneal dialysis (PD) patients. In this multicenter retrospective study, 1,511 incident Chinese patients on PD between 1 January 2005 and 31 December 2021 were enrolled. Restricted cubic splines (RCS) were used to explore the non-linear associations between LVEF+LVEDD and the risk of mortality. Parametric models for interval-censored survival-time data (stintreg) were used to examine the association between LVEF+LVEDD quartiles and the outcomes. During 6,451.11 person-years of follow-up [median 4.81 (IQR 3.61-6.81) years], 247 (17.8%) patients died, including 88 cardiovascular deaths. RCS showed a U-shaped association between LVEF+LVEDD and the risks of all-cause and CV mortality. According to the quartiles, the optimal range of LVEF+LVEDD associated with the lowest risk of all-cause and CV mortality was 103-107, which was set as the reference range. Both higher (&#x2265;115) and lower (&lt;103) levels of LVEF+LVEDD were associated with increased risks of all-cause mortality (hazard ratio [HR] 2.20, 95% confidence interval [CI] 1.58-3.07; HR 1.68, 95% CI 1.19-2.36) and cardiovascular mortality (HR 2.51, 95% CI 1.33-4.75; HR 1.86, 95% CI 0.96-3.61). Low and high levels of baseline LVEF+LVEDD were associated with increased risks of all-cause and cardiovascular mortality in PD patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>You</LastName><ForeName>Jiayin</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-5815-0640</Identifier><AffiliationInfo><Affiliation>Department of Nephrology, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Su</LastName><ForeName>Ning</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-2799-133X</Identifier><AffiliationInfo><Affiliation>Department of Nephrology, The Sixth Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feng</LastName><ForeName>Xiaoran</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Nephrology, Jiujiang No.1 People's Hospital, Jiujiang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peng</LastName><ForeName>Fenfen</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Nephrology, Zhujiang Hospital, Southern Medical University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Qingdong</ForeName><Initials>Q</Initials><Identifier Source="ORCID">0000-0001-8755-7968</Identifier><AffiliationInfo><Affiliation>Department of Nephrology, Jiangmen Central Hospital, Jiangmen, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhan</LastName><ForeName>Xiaojiang</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Nephrology, The First Affiliated Hospital of Nanchang University, Nanchang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wen</LastName><ForeName>Yueqiang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Nephrology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xiaoyang</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Nephrology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tian</LastName><ForeName>Na</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Nephrology, General Hospital of Ningxia Medical University, Yinchuan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Xianfeng</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Nephrology, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Niansong</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Nephrology, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>05</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Ren Fail</MedlineTA><NlmUniqueID>8701128</NlmUniqueID><ISSNLinking>0886-022X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010530" MajorTopicYN="Y">Peritoneal Dialysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013318" MajorTopicYN="Y">Stroke Volume</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007676" MajorTopicYN="Y">Kidney Failure, Chronic</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018487" MajorTopicYN="Y">Ventricular Dysfunction, Left</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002681" MajorTopicYN="N" Type="Geographic">China</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006352" MajorTopicYN="Y">Heart Ventricles</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016277" MajorTopicYN="N">Ventricular Function, Left</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Left ventricular ejection fraction</Keyword><Keyword MajorTopicYN="N">left ventricular end-diastolic diameter</Keyword><Keyword MajorTopicYN="N">mortality</Keyword><Keyword MajorTopicYN="N">peritoneal dialysis</Keyword></KeywordList><CoiStatement>No potential conflict of interest was reported by the author(s).</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>5</Month><Day>19</Day><Hour>6</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>5</Month><Day>19</Day><Hour>6</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>5</Month><Day>19</Day><Hour>4</Hour><Minute>53</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>5</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40384403</ArticleId><ArticleId IdType="pmc">PMC12090317</ArticleId><ArticleId IdType="doi">10.1080/0886022X.2025.2497493</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Di Lullo L, Gorini A, Russo D, et al. . Left ventricular hypertrophy in chronic kidney disease patients: from pathophysiology to treatment. Cardiorenal Med. 2015;5(4):254&#x2013;266. doi: 10.1159/000435838.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000435838</ArticleId><ArticleId IdType="pmc">PMC4662296</ArticleId><ArticleId IdType="pubmed">26648942</ArticleId></ArticleIdList></Reference><Reference><Citation>Zoccali C, Mallamaci F, Adamczak M, et al. . Cardiovascular complications in chronic kidney disease: a review from the European Renal and Cardiovascular Medicine Working Group of the European Renal Association. Cardiovasc Res. 2023;119(11):2017&#x2013;2032. doi: 10.1093/cvr/cvad083.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cvr/cvad083</ArticleId><ArticleId IdType="pmc">PMC10478756</ArticleId><ArticleId IdType="pubmed">37249051</ArticleId></ArticleIdList></Reference><Reference><Citation>Naito K, Anzai T, Yoshikawa T, et al. . Impact of chronic kidney disease on postinfarction inflammation, oxidative stress, and left ventricular remodeling. J Card Fail. 2008;14(10):831&#x2013;838. doi: 10.1016/j.cardfail.2008.07.233.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cardfail.2008.07.233</ArticleId><ArticleId IdType="pubmed">19041046</ArticleId></ArticleIdList></Reference><Reference><Citation>Fatema K, Hirono O, Takeishi Y, et al. . Hemodialysis improves myocardial interstitial edema and left ventricular diastolic function in patients with end-stage renal disease: noninvasive assessment by ultrasonic tissue characterization. Heart Vessels. 2002;16(6):227&#x2013;231. doi: 10.1007/s003800200029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s003800200029</ArticleId><ArticleId IdType="pubmed">12382031</ArticleId></ArticleIdList></Reference><Reference><Citation>Velasquez MT, Centron P, Barrows I, et al. . Gut microbiota and cardiovascular uremic toxicities. Toxins. 2018;10(7):287. doi: 10.3390/toxins10070287.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/toxins10070287</ArticleId><ArticleId IdType="pmc">PMC6071268</ArticleId><ArticleId IdType="pubmed">29997362</ArticleId></ArticleIdList></Reference><Reference><Citation>Li PK-T, Chow KM, Van de Luijtgaarden MWM, et al. . Changes in the worldwide epidemiology of peritoneal dialysis. Nat Rev Nephrol. 2017;13(2):90&#x2013;103. doi: 10.1038/nrneph.2016.181.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneph.2016.181</ArticleId><ArticleId IdType="pubmed">28029154</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng CH, Ong ZH, Sran HK, et al. . Comparison of cardiovascular mortality in hemodialysis versus peritoneal dialysis. Int Urol Nephrol. 2021;53(7):1363&#x2013;1371. doi: 10.1007/s11255-020-02683-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11255-020-02683-9</ArticleId><ArticleId IdType="pubmed">33113084</ArticleId></ArticleIdList></Reference><Reference><Citation>Foley RN, Curtis BM, Randell EW, et al. . Left ventricular hypertrophy in new hemodialysis patients without symptomatic cardiac disease. Clin J Am Soc Nephrol. 2010;5(5):805&#x2013;813. doi: 10.2215/CJN.07761109.</Citation><ArticleIdList><ArticleId IdType="doi">10.2215/CJN.07761109</ArticleId><ArticleId IdType="pmc">PMC2863966</ArticleId><ArticleId IdType="pubmed">20378644</ArticleId></ArticleIdList></Reference><Reference><Citation>Arcari L, Camastra G, Ciolina F, et al. . T(1) and T(2) mapping in uremic cardiomyopathy: an update. Card Fail Rev. 2022;8:e02.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8790724</ArticleId><ArticleId IdType="pubmed">35111336</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Dai S, Ge X, et al. . Prognostic values of left ventricular mass index progression in incident peritoneal dialysis patients: a prospective cohort study. BMC Nephrol. 2022;23(1):200. doi: 10.1186/s12882-022-02831-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12882-022-02831-6</ArticleId><ArticleId IdType="pmc">PMC9158358</ArticleId><ArticleId IdType="pubmed">35641920</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang AY, Wang M, Lam CW, et al. . Heart failure with preserved or reduced ejection fraction in patients treated with peritoneal dialysis. Am J Kidney Dis. 2013;61(6):975&#x2013;983. doi: 10.1053/j.ajkd.2012.12.030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.ajkd.2012.12.030</ArticleId><ArticleId IdType="pubmed">23474006</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye M, Li J, Liu Y, et al. . Serum prealbumin and echocardiography parameters predict mortality in peritoneal dialysis patients. Kidney Blood Press Res. 2020;45(5):671&#x2013;685. doi: 10.1159/000507331.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000507331</ArticleId><ArticleId IdType="pubmed">32998138</ArticleId></ArticleIdList></Reference><Reference><Citation>Thein PM, Mirzaee S, Cameron JD, et al. . Left ventricular contractile reserve as a determinant of adverse clinical outcomes: a systematic review. Intern Med J. 2022;52(2):186&#x2013;197. doi: 10.1111/imj.14995.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imj.14995</ArticleId><ArticleId IdType="pubmed">35015318</ArticleId></ArticleIdList></Reference><Reference><Citation>Wehner GJ, Jing L, Haggerty CM, et al. . Routinely reported ejection fraction and mortality in clinical practice: where does the nadir of risk lie? Eur Heart J. 2020;41(12):1249&#x2013;1257. doi: 10.1093/eurheartj/ehz550.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehz550</ArticleId><ArticleId IdType="pmc">PMC8204658</ArticleId><ArticleId IdType="pubmed">31386109</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou L, Wang X, Zhan X, et al. . Serum chloride and mortality in patients on continuous ambulatory peritoneal dialysis: a multi-center retrospective study. EClinicalMedicine. 2021;41:101133. doi: 10.1016/j.eclinm.2021.101133.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2021.101133</ArticleId><ArticleId IdType="pmc">PMC8452795</ArticleId><ArticleId IdType="pubmed">34585124</ArticleId></ArticleIdList></Reference><Reference><Citation>Lang RM, Badano LP, Mor-Avi V, et al. . Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2015;16(3):233&#x2013;270. doi: 10.1093/ehjci/jev014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ehjci/jev014</ArticleId><ArticleId IdType="pubmed">25712077</ArticleId></ArticleIdList></Reference><Reference><Citation>Zipes DP, Camm AJ, Borggrefe M, et al. . ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). J Am Coll Cardiol. 2006;48(5):e247&#x2013;346.</Citation><ArticleIdList><ArticleId IdType="pubmed">16949478</ArticleId></ArticleIdList></Reference><Reference><Citation>Bello AK, Okpechi IG, Osman MA, et al. . Epidemiology of peritoneal dialysis outcomes. Nat Rev Nephrol. 2022;18(12):779&#x2013;793. doi: 10.1038/s41581-022-00623-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41581-022-00623-7</ArticleId><ArticleId IdType="pmc">PMC9483482</ArticleId><ArticleId IdType="pubmed">36114414</ArticleId></ArticleIdList></Reference><Reference><Citation>Foley RN, Parfrey PS, Sarnak MJ.. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 1998;32(5 Suppl 3):S112&#x2013;S119. doi: 10.1053/ajkd.1998.v32.pm9820470.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/ajkd.1998.v32.pm9820470</ArticleId><ArticleId IdType="pubmed">9820470</ArticleId></ArticleIdList></Reference><Reference><Citation>Banshodani M, Kawanishi H, Moriishi M, et al. . Association between dialysis modality and cardiovascular diseases: a comparison between peritoneal dialysis and hemodialysis. Blood Purif. 2020;49(3):302&#x2013;309. doi: 10.1159/000504040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000504040</ArticleId><ArticleId IdType="pubmed">31851981</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Huang G, Ma X, et al. . A retrospective study of baseline peritoneal transport character and left ventricular hypertrophy in incident peritoneal dialysis patients: interrelationship and prognostic impacts. Ren Fail. 2022;44(1):2073&#x2013;2084.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9848238</ArticleId><ArticleId IdType="pubmed">36645038</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomura M, Hamasaki Y, Komaru Y, et al. . Prognostic significance of concentric left ventricular hypertrophy at peritoneal dialysis initiation. BMC Nephrol. 2021;22(1):135. doi: 10.1186/s12882-021-02321-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12882-021-02321-1</ArticleId><ArticleId IdType="pmc">PMC8052641</ArticleId><ArticleId IdType="pubmed">33863299</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu C-K, Lee J-K, Wu Y-F, et al. . Left ventricular diastolic dysfunction in peritoneal dialysis: a forgotten risk factor. Medicine. 2015;94(20):e819. doi: 10.1097/MD.0000000000000819.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000000819</ArticleId><ArticleId IdType="pmc">PMC4602859</ArticleId><ArticleId IdType="pubmed">25997054</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Y, Zhang D, Hu X, et al. . A longitudinal study of cardiac structure and function using echocardiography in patients undergoing peritoneal dialysis. BMC Nephrol. 2021;22(1):342. doi: 10.1186/s12882-021-02535-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12882-021-02535-3</ArticleId><ArticleId IdType="pmc">PMC8520263</ArticleId><ArticleId IdType="pubmed">34656084</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi F, Feng S, Zhu J, et al. . Left ventricular strain and dyssynchrony in young and middle-aged peritoneal dialysis patients and healthy controls: a case-matched study. Cardiorenal Med. 2018;8(4):271&#x2013;284. doi: 10.1159/000490395.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000490395</ArticleId><ArticleId IdType="pmc">PMC6477487</ArticleId><ArticleId IdType="pubmed">30045025</ArticleId></ArticleIdList></Reference><Reference><Citation>de Bie MK, Ajmone Marsan N, Gaasbeek A, et al. . Left ventricular diastolic dysfunction in dialysis patients assessed by novel speckle tracking strain rate analysis: prevalence and determinants. Int J Nephrol. 2012;2012:963504&#x2013;963507. doi: 10.1155/2012/963504.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2012/963504</ArticleId><ArticleId IdType="pmc">PMC3357524</ArticleId><ArticleId IdType="pubmed">22649726</ArticleId></ArticleIdList></Reference><Reference><Citation>Antlanger M, Aschauer S, Kopecky C, et al. . Heart failure with preserved and reduced ejection fraction in hemodialysis patients: prevalence, disease prediction and prognosis. Kidney Blood Press Res. 2017;42(1):165&#x2013;176. doi: 10.1159/000473868.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000473868</ArticleId><ArticleId IdType="pubmed">28395286</ArticleId></ArticleIdList></Reference><Reference><Citation>Saran R, Robinson B, Abbott KC, et al. . US renal data system 2018 annual data report: epidemiology of kidney disease in the United States. Am J Kidney Dis. 2019;73(3 Suppl 1):A7&#x2013;a8. doi: 10.1053/j.ajkd.2019.01.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.ajkd.2019.01.001</ArticleId><ArticleId IdType="pmc">PMC6620109</ArticleId><ArticleId IdType="pubmed">30798791</ArticleId></ArticleIdList></Reference><Reference><Citation>Katz AM. Ernest Henry Starling, his predecessors, and the "Law of the Heart". Circulation. 2002;106(23):2986&#x2013;2992. doi: 10.1161/01.cir.0000040594.96123.55.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.cir.0000040594.96123.55</ArticleId><ArticleId IdType="pubmed">12460884</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Rourke MF. Starling&#x2019;s law of the heart: an appraisal 70 years on. Aust N Z J Med. 1984;14(6):879&#x2013;887. doi: 10.1111/j.1445-5994.1984.tb03800.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1445-5994.1984.tb03800.x</ArticleId><ArticleId IdType="pubmed">6398055</ArticleId></ArticleIdList></Reference><Reference><Citation>Peverill RE. Understanding preload and preload reserve within the conceptual framework of a limited range of possible left ventricular end-diastolic volumes. Adv Physiol Educ. 2020;44(3):414&#x2013;422. doi: 10.1152/advan.00043.2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/advan.00043.2020</ArticleId><ArticleId IdType="pubmed">32697153</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40748416</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1875-8312</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Aug</Month><Day>01</Day></PubDate></JournalIssue><Title>The international journal of cardiovascular imaging</Title><ISOAbbreviation>Int J Cardiovasc Imaging</ISOAbbreviation></Journal><ArticleTitle>Heart-Brain axis: is microvascular dysfunction the link between stroke and Takotsubo syndrome?</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1007/s10554-025-03477-9</ELocationID><Abstract><AbstractText>Takotsubo syndrome (TS) is characterized by transient left ventricular dysfunction, often triggered by psychological or physiological stress. Increasing evidence highlights the critical role of the brain-heart axis in TS, with small blood vessels acting as central mediators. Recent data indicate a significant association between TS and cerebrovascular events, particularly ischemic stroke. Studies show that the incidence of stroke in TS patients is 1-2% per patient-year, which may occur during the acute phase or later due to ongoing autonomic and microvascular dysfunction. This underscores the shared mechanisms of microvascular impairment between the heart and brain in TS. Imaging techniques are essential for detecting microvascular abnormalities in both the heart and brain, providing valuable insights into the interconnected nature of microvascular dysfunction across the heart-brain axis. The aim of this review is to investigate the potential shared pathophysiological mechanisms that link TS and stroke, with a specific emphasis on microvascular dysfunction as a common factor. By examining the role of the heart-brain axis in both conditions and emphasizing the crucial role of advanced imaging techniques, this review seeks to clarify how microvascular abnormalities can simultaneously affect the cardiovascular and cerebrovascular systems. Additionally, it provides insights into the clinical implications of these findings, highlighting the importance of viewing TS and stroke as interconnected conditions within a shared pathological framework. Understanding these mechanisms may not only improve early detection but also pave the way for novel therapeutic strategies targeting both cardiac and cerebral microvascular health, potentially enhancing outcomes for TS patients.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cau</LastName><ForeName>Riccardo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Radiology, Azienda Ospedaliero-Universitaria (A.O.U.) di Cagliari, Polo di Monserrato s.s. 554 Monserrato, Cagliari, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Cagliari, Cagliari, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Porcu</LastName><ForeName>Michele</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Radiology, Azienda Ospedaliero-Universitaria (A.O.U.) di Cagliari, Polo di Monserrato s.s. 554 Monserrato, Cagliari, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suri</LastName><ForeName>Jasjit S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Department of ECE, Idaho State University, Pocatello, ID, 83209, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of CE, Graphics Era Deemed to be University, Dehradun, 248002, India.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University Center for Research &amp; Development, Chandigarh University, Mohali, India.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Symbiosis Institute of Technology, Nagpur Campus, Symbiosis International (Deemed University), Pune, India.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Stroke Diagnostic and Monitoring Division AtheroPoint&#x2122;, Roseville, CA, 95661, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cademartiri</LastName><ForeName>Filippo</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>IRCCS SYNLAB SDN, Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mossa-Basha</LastName><ForeName>Mahmud</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Vascular Imaging Lab, Department of Radiology, University of Washington, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saba</LastName><ForeName>Luca</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Radiology, Azienda Ospedaliero-Universitaria (A.O.U.) di Cagliari, Polo di Monserrato s.s. 554 Monserrato, Cagliari, Italy. lucasaba@tiscali.it.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Cagliari, Cagliari, Italy. lucasaba@tiscali.it.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Int J Cardiovasc Imaging</MedlineTA><NlmUniqueID>100969716</NlmUniqueID><ISSNLinking>1569-5794</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cerebrovascular diseases</Keyword><Keyword MajorTopicYN="N">Microvascular dysfunction</Keyword><Keyword MajorTopicYN="N">Stroke</Keyword><Keyword MajorTopicYN="N">Takotsubo syndrome</Keyword></KeywordList><CoiStatement>Declarations. Competing interests: The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>4</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>1</Day><Hour>12</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>1</Day><Hour>12</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>1</Day><Hour>11</Hour><Minute>16</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40748416</ArticleId><ArticleId IdType="doi">10.1007/s10554-025-03477-9</ArticleId><ArticleId IdType="pii">10.1007/s10554-025-03477-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ono R, Falc&#xe3;o LM (2016) Takotsubo cardiomyopathy systematic review: pathophysiologic process, clinical presentation and diagnostic approach to Takotsubo cardiomyopathy. Int J Cardiol 209:196&#x2013;205</Citation></Reference><Reference><Citation>Lyon AR, Citro R, Schneider B, Morel O, Ghadri JR, Templin C et al (2021) Pathophysiology of Takotsubo Syndrome: JACC State-of-the-Art Review. J Am Coll Cardiol [Internet]. ;77:902&#x2013;21. Available from: https://www.sciencedirect.com/science/article/pii/S073510972038133X</Citation></Reference><Reference><Citation>Lyon AR, Bossone E, Schneider B, Sechtem U, Citro R, Underwood SR et al (2016) Current state of knowledge on Takotsubo syndrome: a position statement from the taskforce on Takotsubo syndrome of the heart failure association of the European society of cardiology. Eur J Heart Fail 18:8&#x2013;27</Citation></Reference><Reference><Citation>Ghadri J-R, Wittstein IS, Prasad A, Sharkey S, Dote K, Akashi YJ et al (2018) International expert consensus document on Takotsubo syndrome (Part II): diagnostic workup, outcome, and management. Eur Heart J 39:2047&#x2013;2062</Citation></Reference><Reference><Citation>Ghadri J-R, Wittstein IS, Prasad A, Sharkey S, Dote K, Akashi YJ et al (2018) International expert consensus document on Takotsubo syndrome (Part I): clinical characteristics, diagnostic criteria, and pathophysiology. Eur Heart J 39:2032&#x2013;2046</Citation></Reference><Reference><Citation>Templin C, Ghadri JR, Diekmann J, Napp LC, Bataiosu DR, Jaguszewski M et al (2015) Clinical features and outcomes of Takotsubo (Stress) cardiomyopathy. N Engl J Med 373:929&#x2013;938</Citation></Reference><Reference><Citation>Francesco P, Vincenzo P, Giuseppe P, Gaetano T, Giulio S, Carlo G et al (2019) Long-Term Prognosis and Outcome Predictors in Takotsubo Syndrome. JACC Heart Fail [Internet]. ;7:143&#x2013;54. Available from: https://doi.org/10.1016/j.jchf.2018.10.009</Citation></Reference><Reference><Citation>Isaak A, Bratz J, Kravchenko D, Mesropyan N, Eckardt I, Bischoff LM et al (2023) A novel and simple cardiac magnetic resonance score (PE2RT) predicts outcome in takotsubo syndrome. Eur Radiol [Internet]. ; Available from: https://doi.org/10.1007/s00330-023-09543-x</Citation></Reference><Reference><Citation>Cau R, Palmisano A, Suri JS, Pisu F, Esposito A, Saba L (2024) Prognostic role of cardiovascular magnetic resonance in Takotsubo syndrome: A systematic review. Eur J Radiol [Internet]. ;177. Available from: https://doi.org/10.1016/j.ejrad.2024.111576</Citation></Reference><Reference><Citation>Jessen N, Andersen JA, Tayal B, &#xd8;stergaard L, Andersen MP, Schmidt M et al (2023) Takotsubo syndrome and stroke risk: A nationwide register-based study. Int J Cardiol [Internet]. ;392:131283. Available from: https://www.sciencedirect.com/science/article/pii/S0167527323011622</Citation></Reference><Reference><Citation>Morris NA, Chen ML, Adejumo OL, Murthy SB, Kamel H, Merkler AE (2020) Stroke Risk Following Takotsubo Cardiomyopathy. Neurohospitalist [Internet]. ;10:277&#x2013;80. Available from: https://doi.org/10.1177/1941874420931230</Citation></Reference><Reference><Citation>Zia A, Silliman S (2016) Vascular Territories of Ischemic Stroke in Associated Takotsubo Cardiomyopathy (P1.221). Neurology [Internet]. ;86:P1.221. Available from: https://doi.org/10.1212/WNL.86.16_supplement.P1.221</Citation></Reference><Reference><Citation>Jung J-M, Kim J-G, Kim J, Bin, Cho K-H, Yu S, Oh K et al (2016) Takotsubo-Like Myocardial Dysfunction in Ischemic Stroke. Stroke [Internet]. ;47:2729&#x2013;36. Available from: https://doi.org/10.1161/STROKEAHA.116.014304</Citation></Reference><Reference><Citation>Cammann VL, Scheitz JF, von Rennenberg R, J&#xe4;ncke L, Nolte CH, Szawan KA et al (2021) Clinical correlates and prognostic impact of neurologic disorders in Takotsubo syndrome. Sci Rep [Internet]. ;11:23555. Available from: https://doi.org/10.1038/s41598-021-01496-9</Citation></Reference><Reference><Citation>Brazdil V, Kala P, Hudec M, Poloczek M, Kanovsky J, Stipal R et al (2022) The role of central autonomic nervous system dysfunction in Takotsubo syndrome: a systematic review. Clinical Autonomic Research. Springer Science and Business Media Deutschland GmbH; pp. 9&#x2013;17</Citation></Reference><Reference><Citation>Wang X, Pei J, Hu X, Clemente-Su&#xe1;rez VJ (2020) The Brain-Heart Connection in Takotsubo Syndrome: The Central Nervous System, Sympathetic Nervous System, and Catecholamine Overload. Cardiol Res Pract. ;2020</Citation></Reference><Reference><Citation>Testai FD, Gorelick PB, Chuang P-Y, Dai X, Furie KL, Gottesman RF et al (2024) Cardiac Contributions to Brain Health: A Scientific Statement From the American Heart Association. Stroke [Internet]. ; Available from: https://www.ahajournals.org/doi/ https://doi.org/10.1161/STR.0000000000000476</Citation></Reference><Reference><Citation>Bradley CP, Berry C (2023) Microvascular arterial disease of the brain and the heart: A shared pathogenesis. QJM: an international journal of medicine. Oxford University Press, pp 829&#x2013;834</Citation></Reference><Reference><Citation>Thomas JE, Rooke ED, Kvale WF (1966) The Neurologist&#x2019;s Experience With Pheochromocytoma: A Review of 100 Cases. JAMA [Internet]. ;197:754&#x2013;8. Available from: https://doi.org/10.1001/jama.1966.03110100062014</Citation></Reference><Reference><Citation>Davel AP, Brum PC, Rossoni LV (2014) Isoproterenol Induces Vascular Oxidative Stress and Endothelial Dysfunction via a Gi&#x3b1;-Coupled &#x3b2;2-Adrenoceptor Signaling Pathway. PLoS One [Internet]. ;9:e91877-. Available from: https://doi.org/10.1371/journal.pone.0091877</Citation></Reference><Reference><Citation>Higashi Y, Sasaki S, Nakagawa K, Kimura M, Sasaki S, Noma K et al (2002) Excess Norepinephrine Impairs Both Endothelium-Dependent and -Independent Vasodilation in Patients With Pheochromocytoma. Hypertension [Internet]. ;39:513&#x2013;8. Available from: https://doi.org/10.1161/hy02t2.102820</Citation></Reference><Reference><Citation>Pelliccia F, H&#xe4;nsel M, Wegener S, Camici PG (2023) Concomitant Takotsubo syndrome and stroke: two separate disorders or do they share a common aetiology? Eur J Prev Cardiol [Internet]. ;zwad323. Available from: https://doi.org/10.1093/eurjpc/zwad323</Citation></Reference><Reference><Citation>Crea F, Montone RA, Rinaldi R (2022) Pathophysiology of Coronary Microvascular Dysfunction. Circ J [Internet]. [cited 2025 Jun 23];86:1319&#x2013;28. Available from: https://pubmed.ncbi.nlm.nih.gov/34759123/</Citation></Reference><Reference><Citation>Hillier E, Covone J, Fischer K, Chen HY, Hafyane T, Friedrich MG (2023) Microvascular Dysfunction as a Possible Link Between Heart Failure and Cognitive Dysfunction. Circ Heart Fail [Internet]. [cited 2025 Jun 23];16:E010117. Available from: https://www.ahajournals.org/doi/ https://doi.org/10.1161/CIRCHEARTFAILURE.122.010117</Citation></Reference><Reference><Citation>Tonet E, Pompei G, Faragasso E, Cossu A, Pavasini R, Passarini G et al (2021) Coronary microvascular dysfunction: Pet, cmr and ct assessment. J Clin Med. MDPI</Citation></Reference><Reference><Citation>Thomas MA, Hazany S, Ellingson BM, Hu P, Nguyen K-L (2020) Pathophysiology, classification, and MRI parallels in microvascular disease of the heart and brain. Microcirculation [Internet]. ;27:e12648. Available from: https://doi.org/10.1111/micc.12648</Citation></Reference><Reference><Citation>Cau R, Masala S, Manelli L, Porcu M, Scaglione M, D&#x2019;Angelo T et al (2024) Cardiovascular Magnetic Resonance Imaging of Takotsubo Syndrome: Evolving Diagnostic and Prognostic Perspectives. Echocardiography. p. e15949</Citation></Reference><Reference><Citation>Akashi YJ, Goldstein DS, Barbara G, Ueyama T (2008) Takotsubo cardiomyopathy a new form of acute, reversible heart failure. Circulation 118:2754&#x2013;2762</Citation></Reference><Reference><Citation>Cau R, Loewe C, Cherchi V, Porcu M, Ciet P, Suri JS et al (2022) Atrial impairment as a marker in discriminating between Takotsubo and acute myocarditis using cardiac magnetic resonance. J Thorac Imaging 37:W78&#x2013;84</Citation></Reference><Reference><Citation>Cau R, Bassareo P, Cademartiri F, Cadeddu C, Balestrieri A, Mannelli L et al (2023) Epicardial fat volume assessed with cardiac magnetic resonance imaging in patients with Takotsubo cardiomyopathy. Eur J Radiol 160:110706</Citation></Reference><Reference><Citation>Cau R, Bassareo P, Deidda M, Caredda G, Suri JS, Pontone G et al (2021) Could CMR Tissue-Tracking and Parametric Mapping Distinguish Between Takotsubo Syndrome and Acute Myocarditis? A Pilot Study. Acad Radiol [Internet]. ; Available from: http://www.sciencedirect.com/science/article/pii/S1076633221000155</Citation></Reference><Reference><Citation>Cau R, Pisu F, Porcu M, Cademartiri F, Montisci R, Bassareo P, Muscogiuri G, Amadu A, Sironi S, Esposito A, Suri JS, Saba L (2023) Machine learning approach in diagnosing Takotsubo cardiomyopathy: the role of the combined evaluation of atrial and ventricular strain, and parametric mapping. Int J Cardiol 373:124&#x2013;133. https://doi.org/10.1016/j.ijcard.2022.11.021</Citation></Reference><Reference><Citation>Cau R, Muscogiuri G, Pisu F, Gatti M, Velthuis B, Loewe C, Cademartiri F, Pontone G, Montisci R, Guglielmo M, Sironi S, Esposito A, Francone M, Dacher N, Peebles C, Bastarrika G, Salgado R, Saba L (2023) Exploring the evolution in prognostic capabiLity of multisequence cardiac magnetic resonance in patients affected by Takotsubo cardiomyopathy based on machine learning analysis: design and rationale of the EVOLUTION Study. J Thorac Imaging. https://doi.org/10.1097/RTI.0000000000000709</Citation></Reference><Reference><Citation>Scudiero F, Arcari L, Cacciotti L, De Vito E, Marcucci R, Passaseo I et al (2020) Prognostic relevance of GRACE risk score in Takotsubo syndrome. Eur Heart J Acute Cardiovasc Care [Internet]. ;9:721&#x2013;8. Available from: https://doi.org/10.1177/2048872619882363</Citation></Reference><Reference><Citation>Ghadri JR, Cammann VL, Jurisic S, Seifert B, Napp LC, Diekmann J et al (2017) A novel clinical score (InterTAK diagnostic Score) to differentiate Takotsubo syndrome from acute coronary syndrome: results from the international Takotsubo registry. Eur J Heart Fail 19:1036&#x2013;1042</Citation></Reference><Reference><Citation>Thomas S, Charlotte E, Stefanie D, Steffen D, Gerhard S, Holger T et al (2015) Prevalence and Clinical Significance of Life-Threatening Arrhythmias in Takotsubo Cardiomyopathy. J Am Coll Cardiol [Internet]. ;65:2148&#x2013;50. Available from: https://doi.org/10.1016/j.jacc.2015.02.062</Citation></Reference><Reference><Citation>Sclafani M, Arcari L, Russo D, Tini G, Limite LR, Cacciotti L et al (2021) Long-term management of Takotsubo syndrome: a not-so-benign condition. RCM 22:597&#x2013;611</Citation></Reference><Reference><Citation>El-Battrawy I, Santoro F, Stiermaier T, M&#xf6;ller C, Guastafierro F, Novo G et al (2019) Incidence and Clinical Impact of Recurrent Takotsubo Syndrome: Results From the GEIST Registry. J Am Heart Assoc [Internet]. ;8:e010753. Available from: https://doi.org/10.1161/JAHA.118.010753</Citation></Reference><Reference><Citation>Stiermaier T, Busch K, Lange T, P&#xe4;tz T, Meusel M, Backhaus SJ et al (2020) Prognostic value of different CMR-Based techniques to assess left ventricular myocardial strain in Takotsubo syndrome. J Clin Med 9:3882</Citation></Reference><Reference><Citation>Cau R, Bassareo P, Caredda G, Suri JS, Esposito A, Saba L (2022) Atrial strain by feature-tracking cardiac magnetic resonance imaging in Takotsubo cardiomyopathy features, feasibility, and reproducibility. Can Assoc Radiol J 73(3):573&#x2013;580. https://doi.org/10.1177/08465371211042497</Citation></Reference><Reference><Citation>Arcari L, Cacciotti L, Limite LR, Russo D, Sclafani M, Semeraro R et al (2021) Clinical characteristics of patients with takotsubo syndrome recurrence: An observational study with long-term follow-up. Int J Cardiol [Internet]. ;329:23&#x2013;7. Available from: https://doi.org/10.1016/j.ijcard.2020.12.047</Citation></Reference><Reference><Citation>El-Battrawy I, Santoro F, Stiermaier T, M&#xf6;ller C, Guastafierro F, Novo G et al (2021) Incidence and clinical impact of right ventricular involvement (Biventricular Ballooning) in Takotsubo syndrome: results from the GEIST registry. Chest 160:1433&#x2013;1441</Citation></Reference><Reference><Citation>Ekenb&#xe4;ck C, Nickander J, Jokhaji F, Tornvall P, Engblom H, Spaak J et al (2023) Coronary microvascular dysfunction in Takotsubo syndrome and associations with left ventricular function. ESC Heart Fail [Internet]. ;10:2395&#x2013;405. Available from: https://doi.org/10.1002/ehf2.14394</Citation></Reference><Reference><Citation>Shetrit A, Freund O, Banai A, Amar Shamir R, Avivi I, Zornitzki L et al (2024) Coronary microvascular dysfunction in patients with Takotsubo syndrome. Heart &amp; Lung [Internet]. ;68:46&#x2013;51. Available from: https://www.sciencedirect.com/science/article/pii/S0147956324001146</Citation></Reference><Reference><Citation>Meimoun P, Malaquin D, Sayah S, Benali T, Luycx-Bore A, Levy F et al (2008) The coronary flow reserve is transiently impaired in tako-tsubo cardiomyopathy: a prospective study using serial doppler transthoracic echocardiography. J Am Soc Echocardiogr 21:72&#x2013;77</Citation></Reference><Reference><Citation>Rivero F, Cuesta J, Garc&#xed;a-Guimaraes M, Bastante T, Alvarado T, Antu&#xf1;a P et al (2017) Time-related microcirculatory dysfunction in patients with Takotsubo cardiomyopathy. JAMA Cardiol 2:699&#x2013;700</Citation></Reference><Reference><Citation>Galiuto L, De Caterina AR, Porfidia A, Paraggio L, Barchetta S, Locorotondo G et al (2010) Reversible coronary microvascular dysfunction: a common pathogenetic mechanism in apical ballooning or Tako-Tsubo syndrome. Eur Heart J 31:1319&#x2013;1327</Citation></Reference><Reference><Citation>Haghi D, Roehm S, Hamm K, Harder N, Suselbeck T, Borggrefe M et al (2010) Takotsubo Cardiomyopathy Is Not Due to Plaque Rupture: An Intravascular Ultrasound Study. Clin Cardiol [Internet]. ;33:307&#x2013;10. Available from: https://doi.org/10.1002/clc.20747</Citation></Reference><Reference><Citation>Fiol M, Carrillo A, Rodriguez A, Herrero J, Garc&#xed;a-Niebla J (2012) Left ventricular ballooning syndrome due to vasospasm of the middle portion of the left anterior descending coronary artery. Cardiol J 19:314&#x2013;316</Citation></Reference><Reference><Citation>Dong F, Yin L, Sisakian H, Hakobyan T, Jeong LS, Joshi H et al (2023) Takotsubo syndrome is a coronary microvascular disease: experimental evidence. Eur Heart J [Internet]. ;44:2244&#x2013;53. Available from: https://doi.org/10.1093/eurheartj/ehad274</Citation></Reference><Reference><Citation>Rehan R, Yong A, Ng M, Weaver J, Puranik R (2023) Coronary microvascular dysfunction: A review of recent progress and clinical implications. Front Cardiovasc Med [Internet]. ;10. Available from: https://www.frontiersin.org/journals/cardiovascular-medicine/articles/ https://doi.org/10.3389/fcvm.2023.1111721</Citation></Reference><Reference><Citation>Vrints C, Andreotti F, Koskinas KC, Rossello X, Adamo M, Ainslie J et al (2024) 2024 ESC Guidelines for the management of chronic coronary syndromes: Developed by the task force for the management of chronic coronary syndromes of the European Society of Cardiology (ESC) Endorsed by the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J [Internet]. ;45:3415&#x2013;537. Available from: https://doi.org/10.1093/eurheartj/ehae177</Citation></Reference><Reference><Citation>Wei K, Skyba DM, Firschke C, Jayaweera AR, Lindner JR, Kaul S (1997) Interactions Between Microbubbles and Ultrasound: In Vitro and In Vivo Observations. J Am Coll Cardiol [Internet]. ;29:1081&#x2013;8. Available from: https://www.sciencedirect.com/science/article/pii/S0735109797000296</Citation></Reference><Reference><Citation>Vogel R, Inderm&#xfc;hle A, Reinhardt J, Meier P, Siegrist PT, Namdar M et al (2005) The quantification of absolute myocardial perfusion in humans by contrast echocardiography: Algorithm and validation. J Am Coll Cardiol [Internet]. ;45:754&#x2013;62. Available from: https://www.sciencedirect.com/science/article/pii/S0735109704024180</Citation></Reference><Reference><Citation>Vegsundv&#xe5;g J, Holte E, Wiseth R, Hegbom K, Hole T (2011) Coronary Flow Velocity Reserve in the Three Main Coronary Arteries Assessed with Transthoracic Doppler: A Comparative Study with Quantitative Coronary Angiography. Journal of the American Society of Echocardiography [Internet]. ;24:758&#x2013;67. Available from: https://doi.org/10.1016/j.echo.2011.03.010</Citation></Reference><Reference><Citation>Danad I, Szymonifka J, Schulman-Marcus J, Min JK (2016) Static and dynamic assessment of myocardial perfusion by computed tomography. Eur Heart J Cardiovasc Imaging [Internet]. ;17:836&#x2013;44. Available from: https://doi.org/10.1093/ehjci/jew044</Citation></Reference><Reference><Citation>Sliwicka O, Sechopoulos I, Baggiano A, Pontone G, Nijveldt R, Habets J (2023) Dynamic myocardial CT perfusion imaging&#x2014;state of the art. Eur Radiol [Internet]. ;33:5509&#x2013;25. Available from: https://doi.org/10.1007/s00330-023-09550-y</Citation></Reference><Reference><Citation>Rajiah P, Cummings KW, Williamson E, Young PM (2022) CT Fractional Flow Reserve: A Practical Guide to Application, Interpretation, and Problem Solving. RadioGraphics [Internet]. ;42:340&#x2013;58. Available from: https://doi.org/10.1148/rg.210097</Citation></Reference><Reference><Citation>C MR, M BJ, Michael S (2020) M KC. Cardiovascular Imaging Techniques to Assess Microvascular Dysfunction. JACC Cardiovasc Imaging [Internet]. ;13:1577&#x2013;90. Available from: https://doi.org/10.1016/j.jcmg.2019.09.006</Citation></Reference><Reference><Citation>Xie L, Cai X, Guo Y, Yu L, Li X, Fu C et al (2024) Novel implementation of cardiac magnetic resonance first-pass perfusion imaging for semi-quantitatively evaluating microvascular dysfunction in paediatric patients with Duchenne muscular dystrophy. British Journal of Radiology [Internet]. ;97:249&#x2013;57. Available from: https://doi.org/10.1093/bjr/tqad016</Citation></Reference><Reference><Citation>Yang M-X, Li Q-L, Wang D-Q, Ye L, Li K-M, Lin X-J et al (2022) Myocardial microvascular function assessed by CMR first-pass perfusion in patients treated with chemotherapy for gynecologic malignancies. Eur Radiol 32:6850&#x2013;6858</Citation></Reference><Reference><Citation>Sara JD, Widmer RJ, Matsuzawa Y, Lennon RJ, Lerman LO, Lerman A (2015) Prevalence of Coronary Microvascular Dysfunction Among Patients With Chest Pain and Nonobstructive Coronary Artery Disease. JACC Cardiovasc Interv [Internet]. ;8:1445&#x2013;53. Available from: https://www.sciencedirect.com/science/article/pii/S1936879815009863</Citation></Reference><Reference><Citation>Ong P, Safdar B, Seitz A, Hubert A, Beltrame JF, Prescott E (2020) Diagnosis of coronary microvascular dysfunction in the clinic. Cardiovasc Res [Internet]. ;116:841&#x2013;55. Available from: https://doi.org/10.1093/cvr/cvz339</Citation></Reference><Reference><Citation>Fearon WF, Kobayashi Y (2017) Invasive Assessment of the Coronary Microvasculature. Circ Cardiovasc Interv [Internet]. ;10:e005361. Available from: https://doi.org/10.1161/CIRCINTERVENTIONS.117.005361</Citation></Reference><Reference><Citation>Wardlaw JM, Smith EE, Biessels GJ, Cordonnier C, Fazekas F, Frayne R et al (2013) Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol [Internet]. ;12:822&#x2013;38. Available from: https://doi.org/10.1016/S1474-4422(13)70124-8</Citation></Reference><Reference><Citation>Staals J, Makin SDJ, Doubal FN, Dennis MS, Wardlaw JM (2014) Stroke subtype, vascular risk factors, and total MRI brain small-vessel disease burden. Neurology [Internet]. ;83:1228&#x2013;34. Available from: https://doi.org/10.1212/WNL.0000000000000837</Citation></Reference><Reference><Citation>Huijts M, Duits A, Van Oostenbrugge RJ, Kroon AA, De Leeuw PW, Staals J (2013) Accumulation of MRI Markers of Cerebral Small Vessel Disease is Associated with Decreased Cognitive Function. A Study in First-Ever Lacunar Stroke and Hypertensive Patients. Front Aging Neurosci [Internet]. ;5. Available from: https://www.frontiersin.org/journals/aging-neuroscience/articles/ https://doi.org/10.3389/fnagi.2013.00072</Citation></Reference><Reference><Citation>Fan Y, Xu Y, Shen M, Guo H, Zhang Z (2021) Total Cerebral Small Vessel Disease Burden on MRI Correlates With Cognitive Impairment in Outpatients With Amnestic Disorders. Front Neurol [Internet]. ;12. Available from: https://www.frontiersin.org/journals/neurology/articles/ https://doi.org/10.3389/fneur.2021.747115</Citation></Reference><Reference><Citation>van Sloten TT, Sedaghat S, Carnethon MR, Launer LJ, Stehouwer CDA (2020) Cerebral microvascular complications of type 2 diabetes: stroke, cognitive dysfunction, and depression. Lancet Diabetes Endocrinol [Internet]. ;8:325&#x2013;36. Available from: https://doi.org/10.1016/S2213-8587(19)30405-X</Citation></Reference><Reference><Citation>Agarwal N, Carare RO (2021) Cerebral Vessels: An Overview of Anatomy, Physiology, and Role in the Drainage of Fluids and Solutes. Front Neurol [Internet]. ;11. Available from: https://www.frontiersin.org/journals/neurology/articles/ https://doi.org/10.3389/fneur.2020.611485</Citation></Reference><Reference><Citation>Rubinov M, Sporns O (2010) Complex network measures of brain connectivity: Uses and interpretations. Neuroimage [Internet]. ;52:1059&#x2013;69. Available from: https://www.sciencedirect.com/science/article/pii/S105381190901074X</Citation></Reference><Reference><Citation>Winklewski PJ, Sabisz A, Naumczyk P, Jodzio K, Szurowska E, Szarmach A (2018) Understanding the Physiopathology Behind Axial and Radial Diffusivity Changes&#x2014;What Do We Know? Front Neurol [Internet]. ;9. Available from: https://www.frontiersin.org/journals/neurology/articles/ https://doi.org/10.3389/fneur.2018.00092</Citation></Reference><Reference><Citation>Alexander AL, Lee JE, Lazar M, Field AS (2007) Diffusion Tensor Imaging of the Brain. Neurotherapeutics [Internet]. ;4:316&#x2013;29. Available from: https://www.sciencedirect.com/science/article/pii/S1878747923006530</Citation></Reference><Reference><Citation>Chang EH, Argyelan M, Aggarwal M, Chandon T-SS, Karlsgodt KH, Mori S et al (2017) The role of myelination in measures of white matter integrity: Combination of diffusion tensor imaging and two-photon microscopy of CLARITY intact brains. Neuroimage [Internet]. ;147:253&#x2013;61. Available from: https://www.sciencedirect.com/science/article/pii/S1053811916306863</Citation></Reference><Reference><Citation>Budde MD, Xie M, Cross AH, Song S-K (2009) Axial Diffusivity Is the Primary Correlate of Axonal Injury in the Experimental Autoimmune Encephalomyelitis Spinal Cord: A Quantitative Pixelwise Analysis. The Journal of Neuroscience [Internet]. ;29:2805. Available from: http://www.jneurosci.org/content/29/9/2805.abstract</Citation></Reference><Reference><Citation>van den Brink H, Doubal FN, Duering M (2022) Advanced MRI in cerebral small vessel disease. International Journal of Stroke [Internet]. ;18:28&#x2013;35. Available from: https://doi.org/10.1177/17474930221091879</Citation></Reference><Reference><Citation>Sleight E, Stringer MS, Clancy U, Arteaga C, Jaime Garcia D, Hewins W et al (2023) Cerebrovascular Reactivity in Patients With Small Vessel Disease: A Cross-Sectional Study. Stroke [Internet]. ;54:2776&#x2013;84. Available from: https://doi.org/10.1161/STROKEAHA.123.042656</Citation></Reference><Reference><Citation>Cogswell PM, Fan AP (2023) Multimodal comparisons of QSM and PET in neurodegeneration and aging. Neuroimage [Internet]. ;273:120068. Available from: https://www.sciencedirect.com/science/article/pii/S1053811923002148</Citation></Reference><Reference><Citation>Li H, Jacob MA, Cai M, Duering M, Chamberland M, Norris DG et al (2023) Regional cortical thinning, demyelination and iron loss in cerebral small vessel disease. Brain [Internet]. ;146:4659&#x2013;73. Available from: https://doi.org/10.1093/brain/awad220</Citation></Reference><Reference><Citation>Mejia-Renteria H, Travieso A, Mat&#xed;as-Guiu JA, Yus M, Espejo-Paeres C, Finocchiaro F et al (2023) Coronary microvascular dysfunction is associated with impaired cognitive function: the Cerebral-Coronary Connection study (C3 study). Eur Heart J [Internet]. ;44:113&#x2013;25. Available from: https://doi.org/10.1093/eurheartj/ehac521</Citation></Reference><Reference><Citation>Mazini B, Dietz M, Mar&#xe9;chal B, Corredor-Jerez R, Prior JO, Dunet V (2023) Interrelation between cardiac and brain small-vessel disease: a pilot quantitative PET and MRI study. Eur J Hybrid Imaging [Internet]. ;7:20. Available from: https://doi.org/10.1186/s41824-023-00180-7</Citation></Reference><Reference><Citation>Berry C, Sidik N, Pereira AC, Ford TJ, Touyz RM, Kaski J et al (2019) Small-Vessel Disease in the Heart and Brain: Current Knowledge, Unmet Therapeutic Need, and Future Directions. J Am Heart Assoc [Internet]. ;8:e011104. Available from: https://doi.org/10.1161/JAHA.118.011104</Citation></Reference><Reference><Citation>Templin C, H&#xe4;nggi J, Klein C, Topka MS, Hiestand T, Levinson RA et al (2019) Altered limbic and autonomic processing supports brain-heart axis in Takotsubo syndrome. Eur Heart J [Internet]. ;40:1183&#x2013;7. Available from: https://doi.org/10.1093/eurheartj/ehz068</Citation></Reference><Reference><Citation>M&#xfc;nzel T, Templin C, Cammann VL, Hahad O (2021) Takotsubo Syndrome: Impact of endothelial dysfunction and oxidative stress. Free Radic Biol Med [Internet]. ;169:216&#x2013;23. Available from: https://www.sciencedirect.com/science/article/pii/S0891584921001933</Citation></Reference><Reference><Citation>Fan X, Yang G, Yang Z, Uhlig S, Sattler K, Bieback K et al (2024) Catecholamine induces endothelial dysfunction via Angiotensin II and intermediate conductance calcium activated potassium channel. Biomedicine &amp; Pharmacotherapy [Internet]. ;177:116928. Available from: https://www.sciencedirect.com/science/article/pii/S0753332224008126</Citation></Reference><Reference><Citation>Lin PC, Hsu J, Te, Chung CM, Chang ST (2007) Pheochromocytoma with Hypertension, Stroke, and Cardiomyopathy Case Reports</Citation></Reference><Reference><Citation>Fegley MW, Duarte-Chavez R, Agrawal S, Singh A, Longo S, Nanda S (2016) Stroke in pheochromocytoma: A novel mechanism. Int J Acad Med [Internet]. ;2. Available from: https://journals.lww.com/ijam/fulltext/2016/02020/stroke_in_pheochromocytoma__a_novel_mechanism.12.aspx</Citation></Reference><Reference><Citation>SEMENAS E, SHARMA HS (2014) WIKLUND L. Adrenaline increases blood-brain-barrier permeability after haemorrhagic cardiac arrest in immature pigs. Acta Anaesthesiol Scand [Internet]. ;58:620&#x2013;9. Available from: https://doi.org/10.1111/aas.12293</Citation></Reference><Reference><Citation>Thompson CS, Hakim AM (2009) Living Beyond Our Physiological Means. Stroke [Internet]. ;40:e322&#x2013;30. Available from: https://doi.org/10.1161/STROKEAHA.108.542266</Citation></Reference><Reference><Citation>Farrall AJ, Wardlaw JM (2009) Blood&#x2013;brain barrier: Ageing and microvascular disease&#x2013; systematic review and meta-analysis. Neurobiol Aging [Internet]. ;30:337&#x2013;52. Available from: https://www.sciencedirect.com/science/article/pii/S0197458007002904</Citation></Reference><Reference><Citation>Knottnerus ILH, Ten Cate H, Lodder J, Kessels F, van Oostenbrugge RJ (2009) Endothelial Dysfunction in Lacunar Stroke: A Systematic Review. Cerebrovascular Diseases [Internet]. ;27:519&#x2013;26. Available from: https://doi.org/10.1159/000212672</Citation></Reference><Reference><Citation>Lyon AR, Rees PSC, Prasad S, Poole-Wilson PA, Harding SE (2008) Stress (Takotsubo) cardiomyopathy&#x2014;a novel pathophysiological hypothesis to explain catecholamine-induced acute myocardial stunning. Nat Clin Pract Cardiovasc Med [Internet]. ;5:22&#x2013;9. Available from: https://doi.org/10.1038/ncpcardio1066</Citation></Reference><Reference><Citation>Erhart DK, Ludolph AC, Althaus K (2023) RCVS: by clinicians for clinicians&#x2014;a narrative review. J Neurol [Internet]. ;270:673&#x2013;88. Available from: https://doi.org/10.1007/s00415-022-11425-z</Citation></Reference><Reference><Citation>Schweiger V, Gilhofer T, Fang R, Candreva A, Seifert B, Di Vece D et al (2023) Coronary microvascular dysfunction in Takotsubo syndrome: an analysis using angiography-derived index of microcirculatory resistance. Clinical Research in Cardiology [Internet]. ; Available from: https://doi.org/10.1007/s00392-023-02329-7</Citation></Reference><Reference><Citation>Sans-Rosell&#xf3; J, Fern&#xe1;ndez-Peregrina E, Duran-Cambra A, Carreras-Mora J, Sionis A, &#xc1;lvarez-Garc&#xed;a J et al (2022) Prognostic Value of Microvascular Resistance at Rest in Patients With Takotsubo Syndrome. JACC Cardiovasc Imaging [Internet]. ;15:1784&#x2013;95. Available from: https://www.sciencedirect.com/science/article/pii/S1936878X22002340</Citation></Reference><Reference><Citation>Appunni S, Rubens M, Ramamoorthy V, Saxena A, McGranaghan P, Veledar E (2022) Stroke Genomics: Current Knowledge, Clinical Applications and Future Possibilities. Brain Sci [Internet]. [cited 2025 Jun 23];12:302. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC8946102/</Citation></Reference><Reference><Citation>Meschia JF (2020) Effects of genetic variants on stroke risk. Stroke 51:736&#x2013;741</Citation></Reference><Reference><Citation>Harshfield EL, Sands CJ, Tuladhar AM, De Leeuw FE, Lewis MR, Markus HS (2022) Metabolomic profiling in small vessel disease identifies multiple associations with disease severity. Brain [Internet]. [cited 2025 Jun 23];145:2461. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC9337813/</Citation></Reference><Reference><Citation>Lu Y, Wang Y, Xin Q, Yuan R, Chen K, Chu J et al Metabolic and Proteomic Profiling of Coronary Microvascular Dysfunction: Insights from Rat Models. Biomolecules [Internet]. 2024 [cited 2025 Jun 23];14:1305. Available from: https://www.mdpi.com/2218-273X/14/10/1305/htm</Citation></Reference><Reference><Citation>Akasaka T, Hokimoto S, Sueta D, Tabata N, Sakamoto K, Yamamoto E et al (2016) Sex differences in the impact of CYP2C19 polymorphisms and low-grade inflammation on coronary microvascular disorder. Am J Physiol Heart Circ Physiol 310:H1494&#x2013;H1500</Citation></Reference><Reference><Citation>Wayne N, Singamneni VS, Venkatesh R, Cherlin T, Verma SS, Guerraty MA (2025) Genetic Insights Into Coronary Microvascular Disease. Microcirculation [Internet]. [cited 2025 Jun 23];32. Available from: https://pubmed.ncbi.nlm.nih.gov/39755372/</Citation></Reference><Reference><Citation>van Assen M, Muscogiuri G, Caruso D, Lee SJ, Laghi A, De Cecco CN (2020) Artificial intelligence in cardiac radiology. Radiologia Medica [Internet]. ;125:1186&#x2013;99. Available from: https://doi.org/10.1007/s11547-020-01277-w</Citation></Reference><Reference><Citation>Cau R, Pisu F, Suri JS, Montisci R, Gatti M, Mannelli L, Gong X, Saba L (2024) Artificial intelligence in the differential diagnosis of cardiomyopathy phenotypes. Diagnostics (Basel) 14(2):156. https://doi.org/10.3390/diagnostics14020156</Citation></Reference><Reference><Citation>Cau R, Pisu F, Suri JS, Mannelli L, Scaglione M, Masala S et al (2023) Artificial Intelligence Applications in Cardiovascular Magnetic Resonance Imaging: Are We on the Path to Avoiding the Administration of Contrast Media? Diagnostics</Citation></Reference><Reference><Citation>Dey D, Slomka PJ, Leeson P, Comaniciu D, Shrestha S, Sengupta PP et al (2019) Artificial Intelligence in Cardiovascular Imaging: JACC State-of-the-Art Review. J Am Coll Cardiol. Elsevier USA; pp. 1317&#x2013;35</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40763459</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1876-035X</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>11</Issue><PubDate><Year>2025</Year><Month>Jul</Month><Day>31</Day></PubDate></JournalIssue><Title>Journal of infection and public health</Title><ISOAbbreviation>J Infect Public Health</ISOAbbreviation></Journal><ArticleTitle>Severe circulatory failure caused by acute cardiac dysfunction in a young man with leptospirosis living in a slum of Rome, Italy (REV JI-PH-D-24-01876R3).</ArticleTitle><Pagination><StartPage>102915</StartPage><MedlinePgn>102915</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jiph.2025.102915</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1876-0341(25)00264-3</ELocationID><Abstract><AbstractText>Leptospirosis may cause severe disease characterized by acute kidney injury, hepatic failure, or multiorgan dysfunction, including cardiac manifestations. The incidence and severity of cardiac involvement in leptospirosis are underreported and poorly understood. Moreover, left ventricular dysfunction is considered a rare complication in seen in leptospirosis cases. We present a case of leptospirosis in a 19-year-old male, living in a slum in Rome-Italy, without a previous cardiovascular history, who developed septic shock, and severe non-ischemic left ventricular systolic dysfunction following leptospirosis infection. In this setting, the patient developed KDIGO stage 3 acute kidney injury and acute circulatory failure, and requiring high dose norepinephrine and dobutamine. Empiric wide-spectrum antibiotic therapy with Piperacillin-Tazobactam was started early after the recognition of sepsis, and was deemed appropriate after the serological confirmation of leptospirosis. Patient's clinical condition progressively improved and he was discharged after 21 days of hospital stay (6 of those were in the intensive care unit), with full organ function recovery. To conclude, this case report supports the need for preventive public health interventions aiming to reduce the burden of environmentally transmitted life-threatening infectious diseases, including leptospirosis, by promoting sanitation and infrastructures, in order to prevent unequal health outcomes.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 The Author(s). Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cutuli</LastName><ForeName>Salvatore Lucio</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>Department of Emergency, Intensive Care Medicine and Anesthesia, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy; Department of Basic Biotechnology Sciences, Intensive and Perioperative Clinics, Universit&#xe0; Cattolica del Sacro Cuore, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rizzo</LastName><ForeName>Fabiana</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Istituto Superiore di Sanit&#xe0;, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Pascale</LastName><ForeName>Gennaro</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Emergency, Intensive Care Medicine and Anesthesia, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy; Department of Basic Biotechnology Sciences, Intensive and Perioperative Clinics, Universit&#xe0; Cattolica del Sacro Cuore, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Costantini</LastName><ForeName>Silvia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Istituto Superiore di Sanit&#xe0;, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marella</LastName><ForeName>Anna Maria</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Istituto Superiore di Sanit&#xe0;, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Antonelli</LastName><ForeName>Massimo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Emergency, Intensive Care Medicine and Anesthesia, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy; Department of Basic Biotechnology Sciences, Intensive and Perioperative Clinics, Universit&#xe0; Cattolica del Sacro Cuore, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ciervo</LastName><ForeName>Alessandra</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Istituto Superiore di Sanit&#xe0;, Rome, Italy. Electronic address: alessandra.ciervo@iss.it.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Infect Public Health</MedlineTA><NlmUniqueID>101487384</NlmUniqueID><ISSNLinking>1876-0341</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Acute cardiac dysfunction</Keyword><Keyword MajorTopicYN="N">Leptospirosis</Keyword><Keyword MajorTopicYN="N">Septic shock</Keyword><Keyword MajorTopicYN="N">Serovars</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors declare that they have no conflict of interests with this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>12</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>7</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>6</Day><Hour>0</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>6</Day><Hour>0</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>5</Day><Hour>18</Hour><Minute>7</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40763459</ArticleId><ArticleId IdType="doi">10.1016/j.jiph.2025.102915</ArticleId><ArticleId IdType="pii">S1876-0341(25)00264-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40424674</PMID><DateRevised><Year>2025</Year><Month>06</Month><Day>27</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2772-963X</ISSN><JournalIssue CitedMedium="Internet"><Volume>4</Volume><Issue>6 Pt 1</Issue><PubDate><Year>2025</Year><Month>Jun</Month></PubDate></JournalIssue><Title>JACC. Advances</Title><ISOAbbreviation>JACC Adv</ISOAbbreviation></Journal><ArticleTitle>Association of Tricuspid Regurgitation With Mortality in Heart Failure With Left-Sided Heart Disease.</ArticleTitle><Pagination><StartPage>101832</StartPage><MedlinePgn>101832</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">101832</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jacadv.2025.101832</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2772-963X(25)00251-0</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Left-sided heart disease is the leading etiology of tricuspid regurgitation (TR) in heart failure (HF); however, the association between different HF phenotypes and the adverse effects of TR remains unclear.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">The authors aimed to elucidate the association between TR and outcomes across the subtypes of left-sided heart disease in patients hospitalized for HF.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We analyzed data from the multicenter West Tokyo Heart Failure registry between January 2006 and December 2021. Moderate or severe mitral or aortic valve disease was defined as left-sided valve dysfunction (LVD). Patients with congenital heart disease, secondary cardiomyopathy, systemic conditions related to HF, or those with incomplete datasets were excluded. Using a multivariable Cox hazard model, the survival effect of TR on mortality in patients with LVD was examined.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Overall, 3,040 presented with LVD (median age, 80 years; 45.9% female), and 2,438 had no LVD (median age, 74 years; 27.8% female). The prevalence of moderate and severe TR was 27.6% and 6.5% in patients with LVD and 9.2% and 1.5% in those without LVD, respectively. The adjusted HRs of moderate and severe TR for mortality were 1.25 (95% CI: 1.03-1.52) and 1.72 (95% CI: 1.30-2.29) in those with LVD, respectively, and 2.15 (95% CI: 1.62-2.84) and 3.09 (95% CI: 1.87-5.09) in those without LVD, respectively. Significant interactions between the subtypes were observed (P = 0.005).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">TR severity stratified mortality after acute decompensated HF better in patients without LVD than in those with LVD.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kitamura</LastName><ForeName>Mitsunobu</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Sakakibara Heart Institute, Tokyo, Japan. Electronic address: mitsunobu.kitamura123@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amami</LastName><ForeName>Kazuaki</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Sakakibara Heart Institute, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yaguchi</LastName><ForeName>Tomoyuki</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Sakakibara Heart Institute, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Okabe</LastName><ForeName>Kouya</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Sakakibara Heart Institute, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shiraishi</LastName><ForeName>Yasuyuki</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Keio University School of Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakamaru</LastName><ForeName>Ryo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Kyorin University School of Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nagatomo</LastName><ForeName>Yuji</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Cardiology, National Defense Medical College, Saitama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goda</LastName><ForeName>Ayumi</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Kyorin University School of Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nomoto</LastName><ForeName>Michiru</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Saitama University International Medical Hospital, Saitama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mizuno</LastName><ForeName>Atsushi</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Cardiology St Luke's International Hospital, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sakamoto</LastName><ForeName>Munehisa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cardiology, National Hospital Organization Tokyo Medical Center, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ichihara</LastName><ForeName>Yumiko K</ForeName><Initials>YK</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Tokyo Saiseikai Central Hospital, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kohno</LastName><ForeName>Takashi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Kyorin University School of Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kohsaka</LastName><ForeName>Shun</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Keio University School of Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoshikawa</LastName><ForeName>Tsutomu</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Sakakibara Heart Institute, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>West Tokyo Heart Failure Registry Investigators</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>05</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JACC Adv</MedlineTA><NlmUniqueID>9918419284106676</NlmUniqueID><ISSNLinking>2772-963X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cohort study</Keyword><Keyword MajorTopicYN="N">heart failure</Keyword><Keyword MajorTopicYN="N">left ventricular dysfunction</Keyword><Keyword MajorTopicYN="N">tricuspid regurgitation</Keyword><Keyword MajorTopicYN="N">valvular heart disease</Keyword></KeywordList><CoiStatement>Funding support and author disclosures This study was supported by the Japan Society for the Promotion of Science, a Grant-in-Aid for Science Research (23K07591, 24K11303, 23K07584, 21K08142, 21K08064, 20K08482, 20K08408, 20H03915), a Health Labour Sciences Research Grant (14528506), the Sakakibara Clinical Research Grants for Promotion of Sciences (2012-2024), and a grant from the Japan Agency for Medical Research and Development (201439013C). The authors have reported that they have no relationships relevant to the contents of this paper to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>10</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>4</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>4</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>5</Month><Day>27</Day><Hour>18</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>5</Month><Day>27</Day><Hour>18</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>5</Month><Day>27</Day><Hour>18</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>5</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40424674</ArticleId><ArticleId IdType="pmc">PMC12155599</ArticleId><ArticleId IdType="doi">10.1016/j.jacadv.2025.101832</ArticleId><ArticleId IdType="pii">S2772-963X(25)00251-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Nath J., Foster E., Heidenreich P.A. Impact of tricuspid regurgitation on long-term survival. J Am Coll Cardiol. 2004;43:405&#x2013;409.</Citation><ArticleIdList><ArticleId IdType="pubmed">15013122</ArticleId></ArticleIdList></Reference><Reference><Citation>Topilsky Y., Nkomo V.T., Vatury O., et al. Clinical outcome of isolated tricuspid regurgitation. JACC Cardiovasc Imaging. 2014;7:1185&#x2013;1194.</Citation><ArticleIdList><ArticleId IdType="pubmed">25440592</ArticleId></ArticleIdList></Reference><Reference><Citation>Schlotter F., Dietz M.F., Stolz L., et al. Atrial functional tricuspid regurgitation: novel definition and impact on prognosis. Circ Cardiovasc Interv. 2022;15</Citation><ArticleIdList><ArticleId IdType="pubmed">36126130</ArticleId></ArticleIdList></Reference><Reference><Citation>Galloo X., Dietz M.F., Fortuni F., et al. Prognostic implications of atrial vs. ventricular functional tricuspid regurgitation. Eur Heart J Cardiovasc Imaging. 2023;24:733&#x2013;741.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10437306</ArticleId><ArticleId IdType="pubmed">36762683</ArticleId></ArticleIdList></Reference><Reference><Citation>Konstam M.A., Kiernan M.S., Bernstein D., et al. Evaluation and management of right-sided heart failure: a scientific statement from the American Heart Association. Circulation. 2018;137:e578&#x2013;e622.</Citation><ArticleIdList><ArticleId IdType="pubmed">29650544</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehr M., Karam N., Taramasso M., et al. Combined tricuspid and mitral versus isolated mitral valve repair for severe MR and TR: an analysis from the TriValve and TRAMI registries. JACC Cardiovasc Interv. 2020;13:543&#x2013;550.</Citation><ArticleIdList><ArticleId IdType="pubmed">31954679</ArticleId></ArticleIdList></Reference><Reference><Citation>Gammie J.S., Chu M.W.A., Falk V., et al. Concomitant tricuspid repair in patients with degenerative mitral regurgitation. N Engl J Med. 2022;386:327&#x2013;339.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8796794</ArticleId><ArticleId IdType="pubmed">34767705</ArticleId></ArticleIdList></Reference><Reference><Citation>Sorajja P., Whisenant B., Hamid N., et al. Transcatheter repair for patients with tricuspid regurgitation. N Engl J Med. 2023;388:1833&#x2013;1842.</Citation><ArticleIdList><ArticleId IdType="pubmed">36876753</ArticleId></ArticleIdList></Reference><Reference><Citation>Otto C.M., Nishimura R.A., Bonow R.O., et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. Circulation. 2021;143:e72&#x2013;e227.</Citation><ArticleIdList><ArticleId IdType="pubmed">33332150</ArticleId></ArticleIdList></Reference><Reference><Citation>Baumgartner H., Falk V., Bax J.J., et al. 2017 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J. 2017;38:2739&#x2013;2791.</Citation><ArticleIdList><ArticleId IdType="pubmed">28886619</ArticleId></ArticleIdList></Reference><Reference><Citation>Axtell A.L., Bhambhani V., Moonsamy P., et al. Surgery does not improve survival in patients with isolated severe tricuspid regurgitation. J Am Coll Cardiol. 2019;74:715&#x2013;725.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8890054</ArticleId><ArticleId IdType="pubmed">31071413</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitamura M., Kresoja K.P., Balata M., et al. Health status after transcatheter tricuspid valve repair in patients with functional tricuspid regurgitation. JACC Cardiovasc Interv. 2021;14:2545&#x2013;2556.</Citation><ArticleIdList><ArticleId IdType="pubmed">34887048</ArticleId></ArticleIdList></Reference><Reference><Citation>Akita K., Kohno T., Kohsaka S., et al. Current use of guideline-based medical therapy in elderly patients admitted with acute heart failure with reduced ejection fraction and its impact on event-free survival. Int J Cardiol. 2017;235:162&#x2013;168.</Citation><ArticleIdList><ArticleId IdType="pubmed">28259550</ArticleId></ArticleIdList></Reference><Reference><Citation>Higuchi S., Kohsaka S., Shiraishi Y., et al. Association of renin-angiotensin system inhibitors with long-term outcomes in patients with systolic heart failure and moderate-to-severe kidney function impairment. Eur J Intern Med. 2019;62:58&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">30737061</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito M., Maeda D., Matsue Y., et al. Association between class of foundational medication for heart failure and prognosis in heart failure with reduced/mildly reduced ejection fraction. Sci Rep. 2022;12</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9534994</ArticleId><ArticleId IdType="pubmed">36198895</ArticleId></ArticleIdList></Reference><Reference><Citation>Ichihara Y.K., Shiraishi Y., Kohsaka S., et al. Association of pre-hospital precipitating factors with short- and long-term outcomes of acute heart failure patients: a report from the WET-HF2 registry. Int J Cardiol. 2023;389</Citation><ArticleIdList><ArticleId IdType="pubmed">37437664</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamaru R., Shiraishi Y., Kohno T., et al. Treatment patterns and trajectories in patients after acute heart failure hospitalization. ESC Heart Fail. 2023;11(2):692&#x2013;701.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10966272</ArticleId><ArticleId IdType="pubmed">38098210</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamaru R., Shiraishi Y., Niimi N., et al. Phenotyping of elderly patients with heart failure focused on noncardiac conditions: a latent class analysis from a multicenter registry of patients hospitalized with heart failure. J Am Heart Assoc. 2023;12</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9973643</ArticleId><ArticleId IdType="pubmed">36695300</ArticleId></ArticleIdList></Reference><Reference><Citation>Bozkurt B., Coats A.J.S., Tsutsui H., et al. Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the universal definition of heart failure: endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association. Eur J Heart Fail. 2021;23:352&#x2013;380.</Citation><ArticleIdList><ArticleId IdType="pubmed">33605000</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitchell C., Rahko P.S., Blauwet L.A., et al. Guidelines for performing a comprehensive transthoracic echocardiographic examination in adults: recommendations from the American Society of Echocardiography. J Am Soc Echocardiogr. 2019;32:1&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">30282592</ArticleId></ArticleIdList></Reference><Reference><Citation>Zoghbi W.A., Adams D., Bonow R.O., et al. Recommendations for noninvasive evaluation of native valvular regurgitation: a report from the American Society of Echocardiography developed in collaboration with the society for cardiovascular magnetic resonance. J Am Soc Echocardiogr. 2017;30:303&#x2013;371.</Citation><ArticleIdList><ArticleId IdType="pubmed">28314623</ArticleId></ArticleIdList></Reference><Reference><Citation>Shiran A., Sagie A. Tricuspid regurgitation in mitral valve disease incidence, prognostic implications, mechanism, and management. J Am Coll Cardiol. 2009;53:401&#x2013;408.</Citation><ArticleIdList><ArticleId IdType="pubmed">19179197</ArticleId></ArticleIdList></Reference><Reference><Citation>Essayagh B., Antoine C., Benfari G., et al. Functional tricuspid regurgitation of degenerative mitral valve disease: a crucial determinant of survival. Eur Heart J. 2020;41:1918&#x2013;1929.</Citation><ArticleIdList><ArticleId IdType="pubmed">32300779</ArticleId></ArticleIdList></Reference><Reference><Citation>Amano M., Izumi C., Taniguchi T., et al. Impact of concomitant tricuspid regurgitation on long-term outcomes in severe aortic stenosis. Eur Heart J Cardiovasc Imaging. 2019;20:353&#x2013;360.</Citation><ArticleIdList><ArticleId IdType="pubmed">30085068</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindman B.R., Maniar H.S., Jaber W.A., et al. Effect of tricuspid regurgitation and the right heart on survival after transcatheter aortic valve replacement: insights from the Placement of Aortic Transcatheter Valves II inoperable cohort. Circ Cardiovasc Interv. 2015;8:e002073. doi: 10.1161/CIRCINTERVENTIONS.114.002073.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCINTERVENTIONS.114.002073</ArticleId><ArticleId IdType="pmc">PMC4438083</ArticleId><ArticleId IdType="pubmed">25855679</ArticleId></ArticleIdList></Reference><Reference><Citation>Hahn R.T., Asch F., Weissman N.J., et al. Impact of tricuspid regurgitation on clinical outcomes: the COAPT trial. J Am Coll Cardiol. 2020;76:1305&#x2013;1314.</Citation><ArticleIdList><ArticleId IdType="pubmed">32912445</ArticleId></ArticleIdList></Reference><Reference><Citation>Cocianni D., Stolfo D., Perotto M., et al. Association of tricuspid regurgitation with outcome in acute heart failure. Circ Cardiovasc Imaging. 2023;16:566&#x2013;576.</Citation><ArticleIdList><ArticleId IdType="pubmed">37381900</ArticleId></ArticleIdList></Reference><Reference><Citation>Sagie A., Schwammenthal E., Newell J.B., et al. Significant tricuspid regurgitation is a marker for adverse outcome in patients undergoing percutaneous balloon mitral valvuloplasty. J Am Coll Cardiol. 1994;24:696&#x2013;702.</Citation><ArticleIdList><ArticleId IdType="pubmed">8077541</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohno Y., Attizzani G.F., Capodanno D., et al. Association of tricuspid regurgitation with clinical and echocardiographic outcomes after percutaneous mitral valve repair with the MitraClip System: 30-day and 12-month follow-up from the GRASP Registry. Eur Heart J Cardiovasc Imaging. 2014;15:1246&#x2013;1255.</Citation><ArticleIdList><ArticleId IdType="pubmed">24939944</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura R.A., Otto C.M., Bonow R.O., et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. J Am Coll Cardiol. 2014;63:e57&#x2013;e185.</Citation><ArticleIdList><ArticleId IdType="pubmed">24603191</ArticleId></ArticleIdList></Reference><Reference><Citation>Adamo M., Pagnesi M., Ghizzoni G., et al. Evolution of tricuspid regurgitation after transcatheter edge-to-edge mitral valve repair for secondary mitral regurgitation and its impact on mortality. Eur J Heart Fail. 2022;24:2175&#x2013;2184.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10086984</ArticleId><ArticleId IdType="pubmed">36482160</ArticleId></ArticleIdList></Reference><Reference><Citation>Hahn R.T., Lawlor M.K., Davidson C.J., et al. Tricuspid valve academic research consortium definitions for tricuspid regurgitation and trial endpoints. J Am Coll Cardiol. 2023;82:1711&#x2013;1735.</Citation><ArticleIdList><ArticleId IdType="pubmed">37804294</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsunaga A., Duran C.M. Progression of tricuspid regurgitation after repaired functional ischemic mitral regurgitation. Circulation. 2005;112:I453&#x2013;I457.</Citation><ArticleIdList><ArticleId IdType="pubmed">16159862</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40618685</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>06</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1768-3181</ISSN><JournalIssue CitedMedium="Internet"><Volume>74</Volume><Issue>6</Issue><PubDate><Year>2025</Year><Month>Jul</Month><Day>05</Day></PubDate></JournalIssue><Title>Annales de cardiologie et d'angeiologie</Title><ISOAbbreviation>Ann Cardiol Angeiol (Paris)</ISOAbbreviation></Journal><ArticleTitle>[Successive complications in takotsubo cardiomyopathy - pulmonary edema to cardiogenic shock acute to ventricular arrhythmia : A case report].</ArticleTitle><Pagination><StartPage>101903</StartPage><MedlinePgn>101903</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ancard.2025.101903</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0003-3928(25)00042-3</ELocationID><Abstract><AbstractText>Takotsubo syndrome (TTS), also known as "stress cardiomyopathy", manifests as transient left ventricular dysfunction and shares similarities with acute coronary syndrome (ACS). Although often considered benign, it has mortality rates and complications (cardiogenic shock, arrhythmias, etc.) close to those of ACS. This article reports on a clinical case of Takotsubo syndrome in a 70-year-old female patient who presented a series of complications. This serves as a reminder of the need for intensive follow-up during the acute phase.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 Elsevier Masson SAS. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fran&#xe7;ois</LastName><ForeName>Alexia</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>D&#xe9;partement de cardiologie, Cliniques universitaires Saint-Luc, Bruxelles, Belgique. Electronic address: alx.francois@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ngena</LastName><ForeName>Eddy Ngando</ForeName><Initials>EN</Initials><AffiliationInfo><Affiliation>Service de cardiologie, Cliniques de l'Europe, Bruxelles, Belgique.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Der Haert</LastName><ForeName>Laurence</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Service de cardiologie, Cliniques de l'Europe, Bruxelles, Belgique.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haine</LastName><ForeName>Emmanuel</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Service de cardiologie, Cliniques de l'Europe, Bruxelles, Belgique.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bunzi</LastName><ForeName>Linda Kubangumusu</ForeName><Initials>LK</Initials><AffiliationInfo><Affiliation>Service de cardiologie, Cliniques de l'Europe, Bruxelles, Belgique.</Affiliation></AffiliationInfo></Author></AuthorList><Language>fre</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Complications successives dans le syndrome de takotsubo &#x2013; de l'oed&#xe8;me pulmonaire au choc cardiog&#xe9;nique aigu &#xe0; l'arythmie ventriculaire : un rapport de cas.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Ann Cardiol Angeiol (Paris)</MedlineTA><NlmUniqueID>0142167</NlmUniqueID><ISSNLinking>0003-3928</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cardiomyopathie</Keyword><Keyword MajorTopicYN="N">Cardiomyopathy</Keyword><Keyword MajorTopicYN="N">Dysfonction ventriculaire gauche</Keyword><Keyword MajorTopicYN="N">Left ventricular dysfunction</Keyword><Keyword MajorTopicYN="N">Oed&#xe8;me cardiaque</Keyword><Keyword MajorTopicYN="N">Pulmonary oedema</Keyword><Keyword MajorTopicYN="N">Syndrome de Tako-Tsubo</Keyword><Keyword MajorTopicYN="N">Tachycardie ventriculaire</Keyword><Keyword MajorTopicYN="N">Takotsubo syndrome</Keyword><Keyword MajorTopicYN="N">Ventricular arrythmia</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>2</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>5</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>7</Day><Hour>0</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>7</Day><Hour>0</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>6</Day><Hour>18</Hour><Minute>9</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40618685</ArticleId><ArticleId IdType="doi">10.1016/j.ancard.2025.101903</ArticleId><ArticleId IdType="pii">S0003-3928(25)00042-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40655066</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>16</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2168-8184</ISSN><JournalIssue CitedMedium="Print"><Volume>17</Volume><Issue>7</Issue><PubDate><Year>2025</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Cureus</Title><ISOAbbreviation>Cureus</ISOAbbreviation></Journal><ArticleTitle>Anomalous Origin of the Left Coronary Artery From the Right Pulmonary Artery (ALCARPA): A Case Report.</ArticleTitle><Pagination><StartPage>e87762</StartPage><MedlinePgn>e87762</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e87762</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.7759/cureus.87762</ELocationID><Abstract><AbstractText>Although the congenitally anomalous left coronary artery (LCA) is a rare condition, it can give rise to a most rare case, which is an anomalous LCA from the right pulmonary artery (RPA) (ALCARPA). If left untreated, ALCARPA results in myocardial territories receiving low-pressure, oxygen-poor blood. A male infant aged eight months exhibited signs of respiratory distress, poor feeding, and precordial activity. The diagnosis of ALCARPA is usually considered in infants with otherwise unexplained left ventricular dysfunction or mitral valve regurgitation.&#xa0;Imaging studies, including computed tomography angiography and echocardiography, showed a markedly dilated right coronary artery and a dilated left ventricle, confirming ALCARPA. Using autologous pericardium treated with glutaraldehyde, the abnormal LCA was directly anastomosed to the&#xa0;aorta. Postoperative recovery was uneventful, with elective inotropic support provided. To prevent fatal arrhythmias and myocardial ischemia, prompt diagnosis and surgical creation of a dual-coronary system are essential.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025, Talwar et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Talwar</LastName><ForeName>Sachin</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Cardiothoracic and Vascular Surgery, All India Institute of Medical Sciences, New Delhi, IND.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sharma</LastName><ForeName>Srikant</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Cardiothoracic and Vascular Surgery, The Mission Hospital, Durgapur, IND.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Siddharth</LastName><ForeName>Bharat</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Cardiovascular Surgery, Aster Ramesh Hospitals, Guntur, IND.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bhende</LastName><ForeName>Vishal V</ForeName><Initials>VV</Initials><AffiliationInfo><Affiliation>Pediatric Cardiac Surgery, Bhanubhai and Madhuben Patel Cardiac Centre, Shree Krishna Hospital, Bhaikaka University, Anand, IND.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cureus</MedlineTA><NlmUniqueID>101596737</NlmUniqueID><ISSNLinking>2168-8184</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">anomalous left coronary artery from the right pulmonary artery (alcarpa)</Keyword><Keyword MajorTopicYN="N">congenital heart disease</Keyword><Keyword MajorTopicYN="N">coronary vessel anomalies</Keyword><Keyword MajorTopicYN="N">intramural coronary artery course</Keyword><Keyword MajorTopicYN="N">myocardial ischemia</Keyword></KeywordList><CoiStatement>Human subjects: Consent for treatment and open access publication was obtained or waived by all participants in this study. Institutional Ethics Committee (IEC-2) of the H.M. Patel Centre for Medical Care and Education in Anand, Gujarat issued approval Approval No. IEC/BU/2025/Cr.10/73/2025, dated 21/02/2025. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>14</Day><Hour>12</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>14</Day><Hour>12</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>14</Day><Hour>7</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>7</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40655066</ArticleId><ArticleId IdType="pmc">PMC12254896</ArticleId><ArticleId IdType="doi">10.7759/cureus.87762</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Anomalous origin of the left coronary artery from the right pulmonary artery with intramural aortic trajectory. Clinicosurgical diagnostic implications. Atik E, Barbero-Marcial M, Tanamati C, Kajita L, Ebaid M, Jatene A. Arq Bras Cardiol. 1999;73:181&#x2013;190.</Citation><ArticleIdList><ArticleId IdType="pubmed">10752187</ArticleId></ArticleIdList></Reference><Reference><Citation>Congenital anomalies of the coronary arteries: report of an unusual case associated with cardiac hypertrophy. Bland EF, White PD, Garland J. https://doi.org/10.1016/S0002-8703(33)90140-4 Am Heart J. 1933;8:787&#x2013;801.</Citation></Reference><Reference><Citation>The direction of blood flow in coronary arteries arising from the pulmonary trunk. Edwards JE. Circulation. 1964;29:163&#x2013;166.</Citation><ArticleIdList><ArticleId IdType="pubmed">14119382</ArticleId></ArticleIdList></Reference><Reference><Citation>Two cases of an abnormal coronary artery of the heart arising from the pulmonary artery: with some remarks upon the effect of this anomaly in producing cirsoid dilatation of the vessels. Brooks HS. https://pubmed.ncbi.nlm.nih.gov/17231608/ J Anat Physiol. 1885;20:26&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1288534</ArticleId><ArticleId IdType="pubmed">17231608</ArticleId></ArticleIdList></Reference><Reference><Citation>ALCAPA presents in an adult with exercise intolerance but preserved cardiac function. Liu Y, Miller BW. https://pmc.ncbi.nlm.nih.gov/articles/PMC4007788/ Case Rep Cardiol. 2012;2012:471759.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4007788</ArticleId><ArticleId IdType="pubmed">24826255</ArticleId></ArticleIdList></Reference><Reference><Citation>Origin of the left coronary artery from the right pulmonary artery. Tanaka SA, Takanashi Y, Nagatsu M, et al. Ann Thorac Surg. 1996;61:986&#x2013;988.</Citation><ArticleIdList><ArticleId IdType="pubmed">8619732</ArticleId></ArticleIdList></Reference><Reference><Citation>Anomalous origin of the left coronary artery from the pulmonary artery: collective review of surgical therapy. Dodge-Khatami A, Mavroudis C, Backer CL. Ann Thorac Surg. 2002;74:946&#x2013;955.</Citation><ArticleIdList><ArticleId IdType="pubmed">12238882</ArticleId></ArticleIdList></Reference><Reference><Citation>Double-outlet right ventricle (tetralogy of Fallot type) associated with anomalous origin of the left coronary artery from the right pulmonary artery: report of successful total repair in a 2-month-old infant. Bitar FF, Kveselis DA, Smith FC, Byrum CJ, Quaegebeur JM. Pediatr Cardiol. 1998;19:361&#x2013;362.</Citation><ArticleIdList><ArticleId IdType="pubmed">9636264</ArticleId></ArticleIdList></Reference><Reference><Citation>Differentiating anomalous left main coronary artery originating from the pulmonary artery in infants from myocarditis and dilated cardiomyopathy by electrocardiogram. Johnsrude CL, Perry JC, Cecchin F, et al. Am J Cardiol. 1995;75:71&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">7801869</ArticleId></ArticleIdList></Reference><Reference><Citation>Malignant ventricular arrhythmias revealing anomalous origin of the left coronary artery from the pulmonary artery in two adults. Frapier JM, Leclercq F, Bodino M, Chaptal PA. Eur J Cardiothorac Surg. 1999;15:539&#x2013;541.</Citation><ArticleIdList><ArticleId IdType="pubmed">10371138</ArticleId></ArticleIdList></Reference><Reference><Citation>Anomalous left main coronary artery arising from the pulmonary artery in an adult: treatment by internal mammary artery grafting. Chan RK, Hare DL, Buxton BF. J Thorac Cardiovasc Surg. 1995;109:393&#x2013;394.</Citation><ArticleIdList><ArticleId IdType="pubmed">7853894</ArticleId></ArticleIdList></Reference><Reference><Citation>Anomalous origin of the left coronary artery from the pulmonary artery: a new method of surgical repair. Neches WH, Mathews RA, Park SC, Lenox CC, Zuberbuhler JR, Siewers RD, Bahnson HT. Circulation. 1974;50:582&#x2013;587.</Citation><ArticleIdList><ArticleId IdType="pubmed">4277998</ArticleId></ArticleIdList></Reference><Reference><Citation>New surgical method for repair of anomalous left coronary artery from pulmonary artery. Takeuchi S, Imamura H, Katsumoto K, et al.  https://pubmed.ncbi.nlm.nih.gov/449387/ J Thorac Cardiovasc Surg. 1979;78:7&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">449387</ArticleId></ArticleIdList></Reference><Reference><Citation>Management of anomalous left coronary artery from the pulmonary artery. Arciniegas E, Farooki ZQ, Hakimi M, Green EW. https://pubmed.ncbi.nlm.nih.gov/6967375/ Circulation. 1980;62:0&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">6967375</ArticleId></ArticleIdList></Reference><Reference><Citation>Atresia of the left main coronary artery: repair with left internal mammary artery bypass. Fortune RL, Baron PJ, Fitzgerald JW. https://pubmed.ncbi.nlm.nih.gov/3496498/ J Thorac Cardiovasc Surg. 1987;94:150&#x2013;151.</Citation><ArticleIdList><ArticleId IdType="pubmed">3496498</ArticleId></ArticleIdList></Reference><Reference><Citation>Successful repair of non-facing sinus ALCAPA associated with left-sided cardiomegaly using Takeuchi technique. Bhende VV, Sharma TS, Majmudar HP, Pathan SR, Mehta DV. Cureus. 2021;13:0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8476186</ArticleId><ArticleId IdType="pubmed">34603874</ArticleId></ArticleIdList></Reference><Reference><Citation>Anomalous origin of the left coronary artery from the right pulmonary artery. Farouk A, Zahka K, Siwik E, Golden A, Karimi M, Uddin M, Hennein HA. J Card Surg. 2009;24:49&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">19120675</ArticleId></ArticleIdList></Reference><Reference><Citation>Anomalous origin of the left coronary artery from the pulmonary artery. New operative technique. Tashiro T, Todo K, Haruta Y, Yasunaga H, Nagata M, Nakamura M. https://pubmed.ncbi.nlm.nih.gov/8412268/ J Thorac Cardiovasc Surg. 1993;106:718&#x2013;722.</Citation><ArticleIdList><ArticleId IdType="pubmed">8412268</ArticleId></ArticleIdList></Reference><Reference><Citation>Diagnosis and operation for anomalous circumflex coronary artery. Ueyama K, Ramchandani M, Beall AC Jr, Jones JW. Ann Thorac Surg. 1997;63:377&#x2013;381.</Citation><ArticleIdList><ArticleId IdType="pubmed">9033304</ArticleId></ArticleIdList></Reference><Reference><Citation>Anomalous origin of single coronary artery from pulmonary artery: serendipitous diagnosis and successful surgical treatment. Shetty RS, Thareen JK, Ramaiah AK, Narayan R, Das JK, Chandrashekariah MM. World J Pediatr Congenit Heart Surg. 2015;6:108&#x2013;110.</Citation><ArticleIdList><ArticleId IdType="pubmed">25548355</ArticleId></ArticleIdList></Reference><Reference><Citation>Anomalous right coronary artery from pulmonary artery in aortopulmonary window. Kaushik PK, Dhabe V, Majhi L, Kaskar A, Paanwala H. Indian J Thorac Cardiovasc Surg. 2022;38:415&#x2013;417.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9218030</ArticleId><ArticleId IdType="pubmed">35756565</ArticleId></ArticleIdList></Reference><Reference><Citation>Anomalous left coronary artery origin from the nonfacing sinus of pulmonary artery - Successful repair of a rare entity. George A, Pavithran S, Sivakumar K, Agarwal R. Ann Pediatr Cardiol. 2024;17:288&#x2013;291.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11651400</ArticleId><ArticleId IdType="pubmed">39698430</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40612172</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>05</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">3050-2225</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><PubDate><Year>2025</Year><Season>Jan-Dec</Season></PubDate></JournalIssue><Title>Sage open pediatrics</Title><ISOAbbreviation>Sage Open Pediatr</ISOAbbreviation></Journal><ArticleTitle>Incessant Ventricular Tachycardia in Infant With Structurally Normal Heart: Is it Truly Benign or a Old Wives' Tale.</ArticleTitle><Pagination><StartPage>30502225251319869</StartPage><MedlinePgn>30502225251319869</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">30502225251319869</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1177/30502225251319869</ELocationID><Abstract><AbstractText>Idiopathic ventricular tachycardia (VT) is a rare form of arrhythmia in neonates that can be life-threatening prompting its timely diagnosis and importance of treatment to avoid serious complications, that is; heart failure. We describe a neonate with an incessant idiopathic ventricular tachycardia presented with heart failure and severe left ventricular dysfunction. This infant presented with poor feeding, irritability, increase work of breathing, and heartbeat of 260/min. The electrocardiogram (ECG) showed wide complex tachycardia and the echocardiogram showed a structurally normal heart with dilated cardiomyopathy. The clinical signs and chest X-ray changes were consistent with cardiac failure but preserved peripheral perfusion. This presentation, the sustained VT and the global cardiac failure makes the treatment challenging; therefore, early diagnosis of incessant VT in neonate is important for better prognosis.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2025.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mohsin</LastName><ForeName>Muhammad</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>National institute of cardiovascular diseases, Karachi, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sangi</LastName><ForeName>Rumana</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-0160-7133</Identifier><AffiliationInfo><Affiliation>Aga Khan University Hospital, Karachi Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sheikh</LastName><ForeName>Abdul Sattar</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>National institute of cardiovascular diseases, Karachi, Pakistan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>04</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sage Open Pediatr</MedlineTA><NlmUniqueID>9919052035406676</NlmUniqueID><ISSNLinking>3050-2225</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Idiopathic ventricular tachycardia</Keyword><Keyword MajorTopicYN="N">heart failure</Keyword><Keyword MajorTopicYN="N">neonate</Keyword><Keyword MajorTopicYN="N">normal heart</Keyword></KeywordList><CoiStatement>The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>1</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>1</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>4</Day><Hour>6</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>4</Day><Hour>6</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>4</Day><Hour>4</Hour><Minute>58</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>4</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40612172</ArticleId><ArticleId IdType="pmc">PMC12220836</ArticleId><ArticleId IdType="doi">10.1177/30502225251319869</ArticleId><ArticleId IdType="pii">10.1177_30502225251319869</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ban JE. Neonatal arrhythmias: diagnosis, treatment, and clinical outcome. Korean J Pediatr. 2017;60(11):344-352. doi: 10.3345/kjp.2017.60.11.344</Citation><ArticleIdList><ArticleId IdType="doi">10.3345/kjp.2017.60.11.344</ArticleId><ArticleId IdType="pmc">PMC5725339</ArticleId><ArticleId IdType="pubmed">29234357</ArticleId></ArticleIdList></Reference><Reference><Citation>De Rosa G, Butera G, Chessa M, et al. Outcome of newborns with asymptomatic monomorphic ventricular arrhythmia. Arch Dis Child Fetal Neonatal Ed. 2006;91(6):F419-F422. doi: 10.1136/adc.2005.092932</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/adc.2005.092932</ArticleId><ArticleId IdType="pmc">PMC2672755</ArticleId><ArticleId IdType="pubmed">16820390</ArticleId></ArticleIdList></Reference><Reference><Citation>Levin MD, Stephens P, Tanel RE, Vetter VL, Rhodes LA. Ventricular tachycardia in infants with structurally normal heart: a benign disorder. Cardiol Young. 2010;20(6):641-647. doi: 10.1017/S1047951110000867</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S1047951110000867</ArticleId><ArticleId IdType="pmc">PMC3751393</ArticleId><ArticleId IdType="pubmed">20723269</ArticleId></ArticleIdList></Reference><Reference><Citation>El Joueid N, Touma Boulos M, Abou Jaoude S, Daou L. Ventricular tachycardia in an infant without congenital anomaly: a case report. Cardiol Res. 2020;11(1):61-65. doi: 10.14740/cr1005</Citation><ArticleIdList><ArticleId IdType="doi">10.14740/cr1005</ArticleId><ArticleId IdType="pmc">PMC7011923</ArticleId><ArticleId IdType="pubmed">32095198</ArticleId></ArticleIdList></Reference><Reference><Citation>Crosson JE, Callans DJ, Bradley DJ, et al. PACES/HRS expert consensus statement on the evaluation and management of ventricular arrhythmias in the child with a structurally normal heart. Heart Rhythm. 2014;11(9):e55-e78. doi: 10.1016/j.hrthm.2014.05.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.hrthm.2014.05.010</ArticleId><ArticleId IdType="pubmed">24814375</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen H, Raman D, Dean C, Salvo R, Achamallah N. Incessant ventricular tachycardia in the setting of septic shock treated with bilateral stellate ganglion block. J Am Coll Cardiol. 2019;73(9):2464. doi: 10.1016/S0735-1097(19)33070-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0735-1097(19)33070-0</ArticleId></ArticleIdList></Reference><Reference><Citation>
Vetter VL.
Ventricular arrhythmias in patients with congenital heart disease. In: Greenspon AJ, Waxman HL, eds. Contemporary management of ventricular arrhythmias. Cardiovasc Clin. 1992;22(1):255-273. https://pubmed.ncbi.nlm.nih.gov/1728429/
</Citation><ArticleIdList><ArticleId IdType="pubmed">1728429</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanisch D. Pediatric arrhythmias. J Pediatr Nurs. 2001;16(5):351-362. doi: 10.1053/jpdn.2001.26571</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/jpdn.2001.26571</ArticleId><ArticleId IdType="pubmed">11598867</ArticleId></ArticleIdList></Reference><Reference><Citation>Perry JC. Ventricular tachycardia in neonates. Pacing Clin Electrophysiol. 1997;20(8):2061-2064. doi: 10.1111/j.1540-8159.1997.tb03628.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1540-8159.1997.tb03628.x</ArticleId><ArticleId IdType="pubmed">9272509</ArticleId></ArticleIdList></Reference><Reference><Citation>Case CL, Gillette PC, Crawford FA. Cardiac rhabdomyomas causing supraventricular and lethal ventricnlar arrhythmias in an infant. Am Heart J. 1991;122(5):1484-1486. doi: 10.1016/0002-8703(91)90600-m</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0002-8703(91)90600-m</ArticleId><ArticleId IdType="pubmed">1951021</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen NM, Azam M, Dunne KP, Walsh KP. Idiopathic ventricular tachycardia in a newborn: immediate response to lidocaine. Pediatr Cardiol. 2011;32(5):706-707. doi: 10.1007/s00246-011-9947-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00246-011-9947-2</ArticleId><ArticleId IdType="pubmed">21547492</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis AM, Gow RM, McCrindle BW, Hamilton RM. Clinical spectrum, therapeutic management, and follow-up of ventricular tachycardia in infants and young children. Am Heart J. 1996;131(1):186-191. doi: 10.1016/s0002-8703(96)90068-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0002-8703(96)90068-x</ArticleId><ArticleId IdType="pubmed">8554007</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfammatter JP, Paul T. Working Group on Dysrhythmias and Electrophysiology of the Association for European Pediatric Cardiology. Idiopathic ventricular tachycardia in infancy and childhood: a multicenter study on clinical profile and outcome. J Am Coll Cardiol. 1999;33(7):2067-2072. doi: 10.1016/s0735-1097(99)00105-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0735-1097(99)00105-9</ArticleId><ArticleId IdType="pubmed">10362215</ArticleId></ArticleIdList></Reference><Reference><Citation>Escudero CA, Tan RBM, Beach CM, Dalal AS, LaPage MJ, Hill AC. Approach to wide complex tachycardia in paediatric patients. CJC Pediatr Congenit Heart Dis. 2022;1(2):60-73. doi: 10.1016/j.cjcpc.2022.02.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cjcpc.2022.02.003</ArticleId><ArticleId IdType="pmc">PMC10642107</ArticleId><ArticleId IdType="pubmed">37969244</ArticleId></ArticleIdList></Reference><Reference><Citation>Maghrabi K, Uzun O, Kirsh JA, Balaji S, Von Bergen NH, Sanatani S. Cardiovascular collapse with intravenous amiodarone in children: a multi-center retrospectivecohort study. Pediatr Cardiol. 2019;40(5):925-933. doi: 10.1007/s00246-019-02090-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00246-019-02090-7</ArticleId><ArticleId IdType="pubmed">30929065</ArticleId></ArticleIdList></Reference><Reference><Citation>Saul JP, Scott WA, Brown S, et al. Intravenous amiodarone for incessant tachyarrhythmias in children: a randomized, double-blind, antiarrhythmic drug trial. Circulation. 2005;29(22):3470-3477. doi: 10.1161/CIRCULATIONAHA.105.534149</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.105.534149</ArticleId><ArticleId IdType="pubmed">16316969</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasdemir C, Yuksel A, Camli D, et al. Late gadolinium enhancement CMR in patients with tachycardia-induced cardiomyopathy caused by idiopathic ventricular arrhythmias. Pacing Clin Electrophysiol. 2012;35(4):465-470.</Citation><ArticleIdList><ArticleId IdType="pubmed">22303908</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiu SN, Wu WL, Lu CW, et al. Primary ventricular tachycardia in paediatric population in a tertiary centre. Arch Dis Child. 2017;102(12):1137-1142. doi: 10.1136/archdischild-2016-312418</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/archdischild-2016-312418</ArticleId><ArticleId IdType="pubmed">28821499</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40726609</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>31</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2514-2119</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>7</Issue><PubDate><Year>2025</Year><Month>Jul</Month></PubDate></JournalIssue><Title>European heart journal. Case reports</Title><ISOAbbreviation>Eur Heart J Case Rep</ISOAbbreviation></Journal><ArticleTitle>Coronary steal from an anomalous circumflex artery diagnosed 25 years after ventricular septal defect closure: a case report.</ArticleTitle><Pagination><StartPage>ytaf325</StartPage><MedlinePgn>ytaf325</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">ytaf325</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/ehjcr/ytaf325</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Association of anomalous origin of a coronary artery arising from pulmonary artery (PA) with other congenital heart defects, such as ventricular septal defects (VSDs), is uncommon. In such cases, coronary anomalies may be overlooked and underdiagnosed.</AbstractText><AbstractText Label="CASE SUMMARY" NlmCategory="UNASSIGNED">We report a case of late diagnosis of a circumflex coronary artery arising from the right PA, 25 years after VSD-closure during infancy with a complicated post-operative course with severe left ventricular dysfunction. Eventually being discharged, she remained asymptomatic until reaching adulthood, when she developed atypical chest pain during moderate exertion initially with no further investigation being performed. The patient further developed palpitations and underwent a CT-scan, showing an anomalous circumflex artery arising from the right PA. Surgical circumflex artery re-implantation was performed and the symptoms have resolved.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="UNASSIGNED">This case report highlights the unique pathophysiology of coronary artery steal when arising from the PA. Severe ventricular dysfunction, frequently occurring post-operatively after VSD-closure is usually related to increased afterload. However, other causes should not be neglected especially if function does not improve. Long-term follow-up is therefore mandatory for patients diagnosed with congenital heart disease, even after supposedly simple defects.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2025. Published by Oxford University Press on behalf of the European Society of Cardiology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Provost</LastName><ForeName>Bastien</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0002-5385-673X</Identifier><AffiliationInfo><Affiliation>Department of Congenital Heart Diseases, Reference Center for Complex Congenital Cardiac Disease M3C, Marie Lannelongue Hospital, 133 Avenue de la R&#xe9;sistance, Plessis-Robinson 92350, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Cardiovascular Surgery, The Labatt Family Heart Center, The Hospital of Sick Children, Toronto, ON M5G 1X8, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weixler</LastName><ForeName>Viktoria</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Surgery, The Labatt Family Heart Center, The Hospital of Sick Children, Toronto, ON M5G 1X8, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fournier</LastName><ForeName>Emmanuelle</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Congenital Heart Diseases, Reference Center for Complex Congenital Cardiac Disease M3C, Marie Lannelongue Hospital, 133 Avenue de la R&#xe9;sistance, Plessis-Robinson 92350, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Richard</LastName><ForeName>Adelaide</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pediatric Cardiology, H&#xf4;pital Priv&#xe9; de La Louvi&#xe8;re, Lille 59800, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Belli</LastName><ForeName>Emre</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0001-8326-6610</Identifier><AffiliationInfo><Affiliation>Department of Congenital Heart Diseases, Reference Center for Complex Congenital Cardiac Disease M3C, Marie Lannelongue Hospital, 133 Avenue de la R&#xe9;sistance, Plessis-Robinson 92350, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur Heart J Case Rep</MedlineTA><NlmUniqueID>101730741</NlmUniqueID><ISSNLinking>2514-2119</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Case report</Keyword><Keyword MajorTopicYN="N">Congenital heart disease</Keyword><Keyword MajorTopicYN="N">Coronary artery anomaly</Keyword></KeywordList><CoiStatement>Conflict of interest. None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>11</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>3</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>29</Day><Hour>6</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>29</Day><Hour>6</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>29</Day><Hour>5</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>7</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40726609</ArticleId><ArticleId IdType="pmc">PMC12301549</ArticleId><ArticleId IdType="doi">10.1093/ehjcr/ytaf325</ArticleId><ArticleId IdType="pii">ytaf325</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Naimo &#xa0;PS, Fricke &#xa0;TA, d&#x2019;Udekem &#xa0;Y, Cochrane &#xa0;AD, Bullock &#xa0;A, Robertson &#xa0;T, et al. &#xa0;Surgical intervention for anomalous origin of left coronary artery from the pulmonary artery in children: a long-term follow-up. Ann Thorac Surg &#xa0;2016;101:1842&#x2013;1848.</Citation><ArticleIdList><ArticleId IdType="pubmed">26897320</ArticleId></ArticleIdList></Reference><Reference><Citation>Ben Ali &#xa0;W, Metton &#xa0;O, Roubertie &#xa0;F, Pouard &#xa0;P, Sidi &#xa0;D, Raisky &#xa0;O, et al. &#xa0;Anomalous origin of the left coronary artery from the pulmonary artery: late results with special attention to the mitral valve&#x22c6;. Eur J Cardiothorac Surg &#xa0;2009;36:244&#x2013;249.</Citation><ArticleIdList><ArticleId IdType="pubmed">19372048</ArticleId></ArticleIdList></Reference><Reference><Citation>Bunton &#xa0;R, Jonas &#xa0;RA, Lang &#xa0;P, Rein &#xa0;AJ, Castaneda &#xa0;AR. Anomalous origin of left coronary artery from pulmonary artery. Ligation versus establishment of a two coronary artery system. J Thorac Cardiovasc Surg &#xa0;1987;93:103&#x2013;108.</Citation><ArticleIdList><ArticleId IdType="pubmed">3796022</ArticleId></ArticleIdList></Reference><Reference><Citation>Baumgartner &#xa0;H, De Backer &#xa0;J, Babu-Narayan &#xa0;SV, Budts &#xa0;W, Chessa &#xa0;M, Diller &#xa0;GP, et al. &#xa0;2020 ESC guidelines for the management of adult congenital heart disease. Eur Heart J &#xa0;2021;42:563&#x2013;645.</Citation><ArticleIdList><ArticleId IdType="pubmed">32860028</ArticleId></ArticleIdList></Reference><Reference><Citation>Sekelyk &#xa0;R, Mykychak &#xa0;Y, Fedevych &#xa0;O, Yemets &#xa0;I. Anomalous origin of circumflex coronary artery from right pulmonary artery associated with coarctation of the aorta: a case report of surgical treatment. World J Pediatr Congenit Heart Surg &#xa0;2014;5:97&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">24403364</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia &#xa0;CM, Chandler &#xa0;J, Russell &#xa0;R. Anomalous left circumflex coronary artery from the right pulmonary artery: first adult case report. Am Heart J &#xa0;1992;123:526&#x2013;528.</Citation><ArticleIdList><ArticleId IdType="pubmed">1736592</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40418612</PMID><DateRevised><Year>2025</Year><Month>05</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1558-254X</ISSN><JournalIssue CitedMedium="Internet"><Volume>PP</Volume><PubDate><Year>2025</Year><Month>May</Month><Day>26</Day></PubDate></JournalIssue><Title>IEEE transactions on medical imaging</Title><ISOAbbreviation>IEEE Trans Med Imaging</ISOAbbreviation></Journal><ArticleTitle>Segmentation of the Left Ventricle and Its Pathologies for Acute Myocardial Infarction After Reperfusion in LGE-CMR Images.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1109/TMI.2025.3573706</ELocationID><Abstract><AbstractText>Due to the association with higher incidence of left ventricular dysfunction and complications, segmentation of left ventricle and related pathological tissues: microvascular obstruction and myocardial infarction from late gadolinium enhancement cardiac magnetic resonance images is crucially important. However, lack of datasets, diverse shapes and locations, extreme imbalanced class, severe intensity distribution overlapping are the main challenges. We first release a late gadolinium enhancement cardiac magnetic resonance benchmark dataset LGE-LVP containing 140 patients with left ventricle myocardial infarction and concomitant microvascular obstruction. Then, a progressive deep learning model LVPSegNet is proposed to segment the left ventricle and its pathologies via adaptive region of interest extraction, sample augmentation, curriculum learning, and multiple receptive field fusion in dealing with the challenges. Comprehensive comparisons with state-of-the-art models on the internal and external datasets demonstrate that the proposed model performs the best on both geometric and clinical metrics and it most closely matched the clinician's performance. Overall, the released LGE-LVP dataset alongside the LVPSegNet we proposed offer a practical solution for automated left ventricular and its pathologies segmentation by providing data support and facilitating effective segmentation. The dataset and source codes will be released via https://github.com/DFLAG-NEU/LVPSegNet.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Shulin</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Chongwen</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Feng</LastName><ForeName>Chaolu</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Bian</LastName><ForeName>Zijian</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Dai</LastName><ForeName>Yisi</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Lian-Ming</ForeName><Initials>LM</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>05</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>IEEE Trans Med Imaging</MedlineTA><NlmUniqueID>8310780</NlmUniqueID><ISSNLinking>0278-0062</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>5</Month><Day>26</Day><Hour>18</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>5</Month><Day>26</Day><Hour>18</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>5</Month><Day>26</Day><Hour>12</Hour><Minute>24</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40418612</ArticleId><ArticleId IdType="doi">10.1109/TMI.2025.3573706</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40351450</PMID><DateRevised><Year>2025</Year><Month>05</Month><Day>13</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2514-2119</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>5</Issue><PubDate><Year>2025</Year><Month>May</Month></PubDate></JournalIssue><Title>European heart journal. Case reports</Title><ISOAbbreviation>Eur Heart J Case Rep</ISOAbbreviation></Journal><ArticleTitle>Late post-operative cardiogenic shock from left main coronary compression in tetralogy of Fallot with absent pulmonary valve: a case report.</ArticleTitle><Pagination><StartPage>ytaf190</StartPage><MedlinePgn>ytaf190</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">ytaf190</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/ehjcr/ytaf190</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Extrinsic left main coronary artery (LMCA) compression is well described in patients with severe pulmonary dilatation secondary to atrial septal defect, idiopathic pulmonary artery hypertension, and eisenmengerized patent ductus arteriosus. An inferiorly displaced origin of LMCA closer to the left coronary sinus and a dilated pulmonary artery (PA) trunk twice as much as aortic trunk increases risk of extrinsic compression. Such patients are prone to left ventricular ischaemia, malignant ventricular arrhythmia, and sudden cardiac death.</AbstractText><AbstractText Label="CASE SUMMARY" NlmCategory="UNASSIGNED">A 20-year-old girl presented with gradually worsening exertional dyspnoea for the last 5 years was diagnosed to have tetralogy of Fallot with absent pulmonary valve (TOF-APV). After undergoing intra-cardiac repair with bioprosthetic pulmonary valve implantation, she developed a broad complex right bundle branch block with right precordial Q waves (qRBBB), new-onset left ventricular dysfunction, acute decompensated heart failure, and elevated serum cardiac enzymes. Coronary angiogram and intravascular ultrasound examination showed a critically narrowed slit-like LMCA ostium. Percutaneous stenting of LMCA saw resolution of qRBBB and improvement in left ventricle function, after which patient stabilized and could be weaned off ventilatory support.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="UNASSIGNED">Left main coronary artery compression after surgical pulmonary valve replacement in TOF-APV occurring few days after the operation may pose diagnostic and therapeutic challenges. Exact mechanism for post-operative compression is not known. It can be hypothesized that the ionotropic agents used in post-operative period, or change in the geometric relationships of pulmonary artery and LMCA due to pulmonary valve implantation, brought out the compression. A case for prophylactic PA size reduction can be made to avoid the possibility of LMCA compression.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2025. Published by Oxford University Press on behalf of the European Society of Cardiology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kothari</LastName><ForeName>Shyam S</ForeName><Initials>SS</Initials><Identifier Source="ORCID">0000-0002-4463-5433</Identifier><AffiliationInfo><Affiliation>Department of Cardiology, U. N. Mehta Institute of Cardiology and Research Centre (UNMICRC), Civil Hospital Campus, Asarwa, Ahmedabad, Gujarat 380016, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sharma</LastName><ForeName>Vishal</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Cardiology, U. N. Mehta Institute of Cardiology and Research Centre (UNMICRC), Civil Hospital Campus, Asarwa, Ahmedabad, Gujarat 380016, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patel</LastName><ForeName>Kartik</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Thoracic Surgery, U. N. Mehta Institute of Cardiology and Research Centre (UNMICRC), Civil Hospital Campus, Asarwa, Ahmedabad 380016, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thakut</LastName><ForeName>Gowtham</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Thoracic Surgery, U. N. Mehta Institute of Cardiology and Research Centre (UNMICRC), Civil Hospital Campus, Asarwa, Ahmedabad 380016, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parikh</LastName><ForeName>Rujuta</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0003-0686-9586</Identifier><AffiliationInfo><Affiliation>Department of Cardiology, U. N. Mehta Institute of Cardiology and Research Centre (UNMICRC), Civil Hospital Campus, Asarwa, Ahmedabad, Gujarat 380016, India.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>04</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur Heart J Case Rep</MedlineTA><NlmUniqueID>101730741</NlmUniqueID><ISSNLinking>2514-2119</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Case report</Keyword><Keyword MajorTopicYN="N">LMCA compression</Keyword><Keyword MajorTopicYN="N">LMCA stenting</Keyword><Keyword MajorTopicYN="N">PA dilatation</Keyword><Keyword MajorTopicYN="N">Post-operative complication</Keyword><Keyword MajorTopicYN="N">Tetralogy of Fallot</Keyword></KeywordList><CoiStatement>Conflict of interest. None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>10</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>1</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>4</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>5</Month><Day>12</Day><Hour>11</Hour><Minute>14</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>5</Month><Day>12</Day><Hour>11</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>5</Month><Day>12</Day><Hour>5</Hour><Minute>55</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>4</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40351450</ArticleId><ArticleId IdType="pmc">PMC12063075</ArticleId><ArticleId IdType="doi">10.1093/ehjcr/ytaf190</ArticleId><ArticleId IdType="pii">ytaf190</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gali&#xe8; &#xa0;N, Saia &#xa0;F, Palazzini &#xa0;M, Manes &#xa0;A, Russo &#xa0;V, Bacchi Reggiani &#xa0;ML, et al. &#xa0;Left main coronary artery compression in patients with pulmonary arterial hypertension and angina. J Am Coll Cardiol &#xa0;2017;69:2808&#x2013;2817.</Citation><ArticleIdList><ArticleId IdType="pubmed">28595696</ArticleId></ArticleIdList></Reference><Reference><Citation>Badea &#xa0;R, Dorobantu &#xa0;DM, Sharabiani &#xa0;MTA, Predescu &#xa0;LM, Coman &#xa0;IM, Ginghina &#xa0;C. Left main coronary artery compression by dilated pulmonary artery in pulmonary arterial hypertension: a systematic review and meta-analysis. Clin Res Cardiol &#xa0;2022;111:816&#x2013;826.</Citation><ArticleIdList><ArticleId IdType="pubmed">35290496</ArticleId></ArticleIdList></Reference><Reference><Citation>Labin &#xa0;JE, Saggar &#xa0;R, Yang &#xa0;EH, Lluri &#xa0;G, Sayah &#xa0;D, Channick &#xa0;R, et al. &#xa0;Left main coronary artery compression in pulmonary hypertension. Catheter Cardiovasc Interv &#xa0;2021;97:E956&#x2013;E966.</Citation><ArticleIdList><ArticleId IdType="pubmed">33241630</ArticleId></ArticleIdList></Reference><Reference><Citation>Akagi &#xa0;S, Nakamura &#xa0;K, Sarashina &#xa0;T, Ejiri &#xa0;K, Kasahara &#xa0;S, Ito &#xa0;H. Progression of pulmonary artery dilatation in patients with pulmonary hypertension coexisting with a pulmonary artery aneurysm. J Cardiol &#xa0;2018;71:517&#x2013;522.</Citation><ArticleIdList><ArticleId IdType="pubmed">29246394</ArticleId></ArticleIdList></Reference><Reference><Citation>Daskalopoulos &#xa0;DA, Edwards &#xa0;WD, Driscoll &#xa0;DJ, Danielson &#xa0;GK, Puga &#xa0;FJ. Coronary artery compression with fatal myocardial ischemia: a rare complication of valved extracardiac conduits in children with congenital heart disease. J Thorac Cardiovasc Surg &#xa0;1983;85:546&#x2013;551.</Citation><ArticleIdList><ArticleId IdType="pubmed">6834874</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris &#xa0;JP, Stewart &#xa0;S, Anderson &#xa0;V, Mitchell &#xa0;ML, Manning &#xa0;JA. Coronary artery injury by a valved external conduit. Ann Thorac Surg &#xa0;1981;31:271&#x2013;273.</Citation><ArticleIdList><ArticleId IdType="pubmed">7212824</ArticleId></ArticleIdList></Reference><Reference><Citation>Morray &#xa0;BH, McElhinney &#xa0;DB, Cheatham &#xa0;JP, Zahn &#xa0;EM, Berman &#xa0;DP, Sullivan &#xa0;PM, et al. &#xa0;Risk of coronary artery compression among patients referred for transcatheter pulmonary valve implantation: a multicenter experience. Circ Cardiovasc Interv &#xa0;2013;6:535&#x2013;542.</Citation><ArticleIdList><ArticleId IdType="pubmed">24065444</ArticleId></ArticleIdList></Reference><Reference><Citation>Saia &#xa0;F, Dall&#x2019;Ara &#xa0;G, Marzocchi &#xa0;A, Dardi &#xa0;F, Palazzini &#xa0;M, Manes &#xa0;A, et al. &#xa0;Left main coronary artery extrinsic compression in patients with pulmonary arterial hypertension: technical insights and long-term clinical outcomes after stenting. J Am Coll Cardiol Intv &#xa0;2019;12:319&#x2013;321.</Citation><ArticleIdList><ArticleId IdType="pubmed">30732740</ArticleId></ArticleIdList></Reference><Reference><Citation>Edginton &#xa0;S, D&#x2019;Arsigny &#xa0;CL, McLellan &#xa0;C, Archer &#xa0;SL. Left main coronary artery compression in pulmonary arterial hypertension: percutaneous treatment to improve symptoms. CJC Open &#xa0;2020;3:690&#x2013;692.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8134911</ArticleId><ArticleId IdType="pubmed">34027375</ArticleId></ArticleIdList></Reference><Reference><Citation>Buszman &#xa0;PE, Buszman &#xa0;PP, Banasiewicz-Szkr&#xf3;bka &#xa0;I, Milewski &#xa0;KP, &#x17b;urakowski &#xa0;A, Orlik &#xa0;B, et al. &#xa0;Left main stenting in comparison with surgical revascularization: 10-year outcomes of the (left main coronary artery stenting) LE MANS trial. JACC Cardiovasc Interv &#xa0;2016;9:318&#x2013;327.</Citation><ArticleIdList><ArticleId IdType="pubmed">26892080</ArticleId></ArticleIdList></Reference><Reference><Citation>Velazquez Martin &#xa0;M, Montero Cabezas &#xa0;JM, Huertas &#xa0;S, Nuche &#xa0;J, Albarr&#xe1;n &#xa0;A, Delgado &#xa0;JF, et al. &#xa0;Clinical relevance of adding intravascular ultrasound to coronary angiography for the diagnosis of extrinsic left main coronary artery compression by a pulmonary artery aneurysm in pulmonary hypertension. Catheter Cardiovasc Interv &#xa0;2021;98:691&#x2013;700.</Citation><ArticleIdList><ArticleId IdType="pubmed">32790221</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40629892</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2150-136X</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Jul</Month><Day>09</Day></PubDate></JournalIssue><Title>World journal for pediatric &amp; congenital heart surgery</Title><ISOAbbreviation>World J Pediatr Congenit Heart Surg</ISOAbbreviation></Journal><ArticleTitle>Off-Pump Coronary Artery Bypass Grafting for Congenital Left Main Coronary Artery Stenosis in a Six-Month-Old Infant: A Novel Approach.</ArticleTitle><Pagination><StartPage>21501351251330841</StartPage><MedlinePgn>21501351251330841</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/21501351251330841</ELocationID><Abstract><AbstractText>We report a case of congenital left main coronary artery stenosis surgically treated at our center in a six-month-old patient using an off-pump coronary artery bypass grafting (CABG) approach. The infant presented with respiratory distress, feeding difficulties, and diaphoresis and was diagnosed with dilated cardiomyopathy with severe left ventricular dysfunction. Diagnostic imaging with computed tomography (CT) angiography and coronary angiography identified severe stenosis (&gt;90%) of the left main coronary artery with normal right-sided coronary anatomy. A left internal thoracic artery to left anterior descending coronary artery anastomosis was performed using off-pump CABG, a novel intervention in an infant with congenital left main coronary artery stenosis. Postoperative recovery was smooth and three-year follow-up demonstrated normal development with significant improvement in left ventricular function (ejection fraction 55%). To our knowledge, this case represents the first successful application of off-pump CABG in an infant with congenital left main coronary artery stenosis, marking a pioneering step in pediatric cardiac surgery.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Daga</LastName><ForeName>Manoj Kumar</ForeName><Initials>MK</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic and Vascular Surgery, BM Birla Heart Research Centre, Kolkata, India.</Affiliation><Identifier Source="RINGGOLD">75612</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kumar</LastName><ForeName>Nitish</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-9700-298X</Identifier><AffiliationInfo><Affiliation>Department of Cardiothoracic and Vascular Surgery, BM Birla Heart Research Centre, Kolkata, India.</Affiliation><Identifier Source="RINGGOLD">75612</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mandal</LastName><ForeName>Subhendu</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Paediatric Cardiology, BM Birla Heart Hospital, Kolkata, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Das</LastName><ForeName>Gaur Hari</ForeName><Initials>GH</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic and Vascular Surgery, BM Birla Heart Research Centre, Kolkata, India.</Affiliation><Identifier Source="RINGGOLD">75612</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Das</LastName><ForeName>Pravir Kumar</ForeName><Initials>PK</Initials><AffiliationInfo><Affiliation>Department of Cardiac Anaesthesia, BM Birla Heart Research Centre, Kolkata, India.</Affiliation><Identifier Source="RINGGOLD">75612</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Agarwal</LastName><ForeName>Anurag</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic and Vascular Surgery, BM Birla Heart Research Centre, Kolkata, India.</Affiliation><Identifier Source="RINGGOLD">75612</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghosh</LastName><ForeName>Madhurima</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Paediatric Cardiology, BM Birla Heart Hospital, Kolkata, India.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>World J Pediatr Congenit Heart Surg</MedlineTA><NlmUniqueID>101518415</NlmUniqueID><ISSNLinking>2150-1351</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>9</Day><Hour>6</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>9</Day><Hour>6</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>9</Day><Hour>3</Hour><Minute>53</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40629892</ArticleId><ArticleId IdType="doi">10.1177/21501351251330841</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40719608</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1365-2362</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Jul</Month><Day>28</Day></PubDate></JournalIssue><Title>European journal of clinical investigation</Title><ISOAbbreviation>Eur J Clin Invest</ISOAbbreviation></Journal><ArticleTitle>Parvovirus B19-associated myocarditis in children: A systematic review of clinical features, management and outcomes.</ArticleTitle><Pagination><StartPage>e70102</StartPage><MedlinePgn>e70102</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/eci.70102</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Parvovirus B19 (PVB19) has emerged as a relevant etiologic agent of paediatric myocarditis, particularly during recent epidemiological surges in Europe and the United States. Despite increasing recognition, current knowledge remains fragmented, and standardised diagnostic and therapeutic strategies are lacking.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We conducted a systematic review of the literature up to May 2025, including 40 studies encompassing 53 individual case reports, 107 patients from registry-based cohorts, and 4 tissue-based investigations.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Clinical presentation was frequently fulminant, with cardiogenic shock, severe left ventricular dysfunction, and need for mechanical circulatory support in up to 47% of cases. Mortality rates ranged from 10% to 30%, with heart transplantation rates varying between 5% and 42% across cohorts. Diagnosis relied primarily on blood polymerase chain reaction (PCR), while serology showed limited diagnostic utility. Histological confirmation via endomyocardial biopsy (EMB) was variably applied across studies, and myocardial viral load quantification was reported in only one study. Case series and cohort studies confirmed early age of onset (median 16-24 months), respiratory or gastrointestinal prodromes, and poor outcomes in fulminant presentations. Tissue-based studies revealed high myocardial PVB19 loads in acute myocarditis, particularly in infants, but also demonstrated viral persistence in asymptomatic individuals, complicating causal inference. Immunomodulatory therapy was administered in up to 58% of cases, although its clinical impact remains uncertain due to heterogeneity in treatment protocols. No antiviral treatments have been evaluated to date.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">These findings highlight the need for standardised diagnostic criteria incorporating PCR, serology, imaging, and, where appropriate, EMB and viral load assessment. Given recent epidemiologic surges and high morbidity, prospective multicentre studies and surveillance efforts are urgently required to refine clinical algorithms and improve outcomes in paediatric PVB19 myocarditis.</AbstractText><CopyrightInformation>&#xa9; 2025 The Author(s). European Journal of Clinical Investigation published by John Wiley &amp; Sons Ltd on behalf of Stichting European Society for Clinical Investigation Journal Foundation.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Veronese</LastName><ForeName>Giacomo</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-6257-729X</Identifier><AffiliationInfo><Affiliation>Pediatric Intensive Care Unit, ASST Papa Giovanni XXIII, Bergamo, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, Heart and Vascular Centre, Maastricht University Medical Centre, Maastricht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Colombo</LastName><ForeName>Giada</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>De Gasperis Cardio Center, Niguarda Hospital, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garascia</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>De Gasperis Cardio Center, Niguarda Hospital, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Adorisio</LastName><ForeName>Rachele</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Heart Failure, Transplant and Mechanical Assist Device Unit, IRCCS Bambino Ges&#xf9; Children's Hospital, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bonanomi</LastName><ForeName>Ezio</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Pediatric Intensive Care Unit, ASST Papa Giovanni XXIII, Bergamo, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ammirati</LastName><ForeName>Enrico</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>De Gasperis Cardio Center, Niguarda Hospital, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Milan-Bicocca, School of Medicine and Surgery, Monza, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur J Clin Invest</MedlineTA><NlmUniqueID>0245331</NlmUniqueID><ISSNLinking>0014-2972</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cardiogenic shock</Keyword><Keyword MajorTopicYN="N">paediatric myocarditis</Keyword><Keyword MajorTopicYN="N">parvovirus B19</Keyword><Keyword MajorTopicYN="N">viral myocarditis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>6</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>18</Hour><Minute>59</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>18</Hour><Minute>59</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>10</Hour><Minute>2</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40719608</ArticleId><ArticleId IdType="doi">10.1111/eci.70102</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Ammirati E, Moslehi JJ. Diagnosis and treatment of acute myocarditis: a review. JAMA. 2023;329(13):1098&#x2010;1113.</Citation></Reference><Reference><Citation>Mahrholdt H, Wagner A, Deluigi CC, et&#xa0;al. Presentation, patterns of myocardial damage, and clinical course of viral myocarditis. Circulation. 2006;114(15):1581&#x2010;1590.</Citation></Reference><Reference><Citation>Kindermann I, Barth C, Mahfoud F, et&#xa0;al. Update on myocarditis. J Am Coll Cardiol. 2012;59(9):779&#x2010;792.</Citation></Reference><Reference><Citation>Feldstein LR, Rose EB, Horwitz SM, et&#xa0;al. Multisystem inflammatory syndrome in U.S. children and adolescents. N Engl J Med. 2020;383(4):334&#x2010;346.</Citation></Reference><Reference><Citation>Kracalik I, Oster ME, Broder KR, et&#xa0;al. Outcomes at least 90&#x2009;days since onset of myocarditis after mRNA COVID&#x2010;19 vaccination in adolescents and young adults in the USA: a follow&#x2010;up surveillance study. Lancet Child Adolesc Health. 2022;6(11):788&#x2010;798.</Citation></Reference><Reference><Citation>Truong DT, Dionne A, Muniz JC, McHugh KE, Portman MA, Lambert LM. Clinically suspected myocarditis temporally related to COVID&#x2010;19 vaccination in adolescents and Young adults. Circulation. 2021;145:345&#x2010;356.</Citation></Reference><Reference><Citation>Freund MW, Kleinveld G, Krediet TG, van Loon AM, Verboon&#x2010;Maciolek MA. Prognosis for neonates with enterovirus myocarditis. Arch Dis Child Fetal Neonatal Ed. 2010;95(3):F206&#x2010;F212.</Citation></Reference><Reference><Citation>Young NS, Brown KE. Parvovirus B19. N Engl J Med. 2004;350(6):586&#x2010;597.</Citation></Reference><Reference><Citation>Heegaard ED, Brown KE. Human parvovirus B19. Clin Microbiol Rev. 2002;15(3):485&#x2010;505.</Citation></Reference><Reference><Citation>Simms RA, Liebling RE, Patel RR, et&#xa0;al. Management and outcome of pregnancies with parvovirus B19 infection over seven years in a tertiary fetal medicine unit. Fetal Diagn Ther. 2009;25(4):373&#x2010;378.</Citation></Reference><Reference><Citation>Rogo LD, Mokhtari&#x2010;Azad T, Kabir MH, Rezaei F. Human parvovirus B19: a review. Acta Virol. 2014;58(3):199&#x2010;213.</Citation></Reference><Reference><Citation>Landry ML. Parvovirus B19. Microbiol Spectr. 2016;4(3):1&#x2010;13.</Citation></Reference><Reference><Citation>Bock CT, Klingel K, Kandolf R. Human parvovirus B19&#x2010;associated myocarditis. N Engl J Med. 2010;362(13):1248&#x2010;1249.</Citation></Reference><Reference><Citation>Molina KM, Garcia X, Denfield SW, et&#xa0;al. Parvovirus B19 myocarditis causes significant morbidity and mortality in children. Pediatr Cardiol. 2013;34(2):390&#x2010;397.</Citation></Reference><Reference><Citation>d'Humi&#xe8;res C, Fouillet A, Verdurme L, et&#xa0;al. An unusual outbreak of parvovirus B19 infections, France, 2023 to 2024. Euro Surveill. 2024;29(25):2400339.</Citation></Reference><Reference><Citation>Rubin R. What to know about the recent rise in parvovirus B19 infections. JAMA. 2024;332:1226&#x2010;1227.</Citation></Reference><Reference><Citation>Alfego D, Hernandez&#x2010;Romieu AC, Briggs&#x2010;Hagen M, et&#xa0;al. Detection of increased activity of human parvovirus B19 using commercial laboratory testing of clinical samples and source plasma donor pools &#x2010; United States, 2024. MMWR Morb Mortal Wkly Rep. 2024;73(47):1076&#x2010;1081.</Citation></Reference><Reference><Citation>Yee MEM, Kalmus GG, Patel AP, Payne JN, Tang A, Gee BE. Notes from the field: increase in diagnoses of human parvovirus B19&#x2010;associated aplastic crises in children and adolescents with sickle cell disease&#x2014;Atlanta, Georgia, December 14, 2023&#x2010;September 30, 2024. MMWR Morb Mortal Wkly Rep. 2024;73(47):1090&#x2010;1091.</Citation></Reference><Reference><Citation>European Centre for Disease Prevention and Control (ECDC). Risks posed by the reported increased circulation of human parvovirus B19 in the EU/EEA &#x2013; 17 April 2024. ECDC; 2024. https://www.ecdc.europa.eu/en/publications&#x2010;data/risks&#x2010;posed&#x2010;reported&#x2010;increased&#x2010;circulation&#x2010;human&#x2010;parvovirus&#x2010;b19&#x2010;eueea</Citation></Reference><Reference><Citation>Centers for Disease Control and Prevention (CDC). Increase in Pediatric Cases of Severe Acute Illness Potentially Associated with Human Parvovirus B19 Infection &#x2014; United States, May 2024. CDC Health Alert Network (HAN); 2024. HAN Archive Number: 00514. https://www.cdc.gov/han/2024/han00514.html</Citation></Reference><Reference><Citation>Tonon M, Panaite SA, Gentili D, et&#xa0;al. Retrospective and prospective surveillance and clinical presentation of parvovirus B19 in Veneto, Italy, 2024. Microorganisms. 2025;13(2):430.</Citation></Reference><Reference><Citation>Ranno S, Russo C, Colagrossi L, et&#xa0;al. Parvovirus B19 rebound. J Med Virol. 2025;97(5):e70380.</Citation></Reference><Reference><Citation>Poeta M, Moracas C, Cal&#xf2; Carducci FI, et&#xa0;al. Outbreak of paediatric myocarditis associated with parvovirus B19 infection in Italy, January to October 2024. Euro Surveill. 2024;29(48):2400746.</Citation></Reference><Reference><Citation>Russell N, Hatcher J, Best T, et&#xa0;al. Severe parvovirus B19&#x2010;associated myocarditis in children in the post&#x2010;COVID&#x2010;19 era: a multicenter observational cohort study. Open Forum Infect Dis. 2025;12(5):ofaf224.</Citation></Reference><Reference><Citation>Drazner MH, Bozkurt B, Cooper LT, et&#xa0;al. 2024 ACC expert consensus decision pathway on strategies and criteria for the diagnosis and Management of Myocarditis: a report of the American College of Cardiology Solution set Oversight Committee. J Am Coll Cardiol. 2025;85(4):391&#x2010;431.</Citation></Reference><Reference><Citation>Law YM, Lal AK, Chen S, et&#xa0;al. Diagnosis and Management of Myocarditis in children: a scientific Statement from the American Heart Association. Circulation. 2021;144(6):e123&#x2010;e135.</Citation></Reference><Reference><Citation>Joanna Briggs Institute. Checklist for case reports. The Joanna Briggs Institute; 2017. https://jbi.global/critical&#x2010;appraisal&#x2010;tools</Citation></Reference><Reference><Citation>Vigneswaran TV, Brown JR, Breuer J, Burch M. Parvovirus B19 myocarditis in children: an observational study. Arch Dis Child. 2016;101(2):177&#x2010;180.</Citation></Reference><Reference><Citation>Esmel&#x2010;Vilomara R, Dolader P, Izquierdo&#x2010;Blasco J, et&#xa0;al. Parvovirus B19 myocarditis in children: a diagnostic and therapeutic approach. Eur J Pediatr. 2022;181(5):2045&#x2010;2053.</Citation></Reference><Reference><Citation>Gran F, Dolader P, Juzga&#x2010;Corrales DC, et&#xa0;al. Interferon&#x2010;beta and corticosteroid therapy for parvovirus B19 myocarditis in children. Int J Cardiol. 2025;434:133337.</Citation></Reference><Reference><Citation>Esmel&#x2010;Vilomara R, Dolader P, Melendo S, Ros&#xe9;s&#x2010;Noguer F, Gran F. High specificity electrocardiogram patterns for parvovirus B19 myocarditis in children: bridging electrocardiogram findings to aetiological diagnosis. Cardiol Young. 2025;35(5):1&#x2010;1027.</Citation></Reference><Reference><Citation>Canales Siguero D, Garc&#xed;a&#x2010;Mu&#xf1;oz C, Mart&#xed;nez de la Torre F, Ferrari Piquero JM, Granados Ru&#xed;z MA. Paediatric viral myocarditis successfully treated with interferon beta&#x2010;1b and corticoids. J Clin Pharm Ther. 2021;46(3):862&#x2010;864.</Citation></Reference><Reference><Citation>Jain P, Jain A, Khan DN, Kumar M. Human parvovirus B19 associated dilated cardiomyopathy. BMJ Case Rep. 2013;2013:bcr2013010410.</Citation></Reference><Reference><Citation>Dina J, Villedieu F, Labombarda F, et&#xa0;al. Childhood myocarditis and parvovirus B19 genotypes. J Clin Virol. 2011;50(1):61&#x2010;64.</Citation></Reference><Reference><Citation>Hu HY, Wei SY, Huang WH, Pan CH. Fatal parvovirus B19 infections: a report of two autopsy cases. Int J Legal Med. 2019;133(2):553&#x2010;560.</Citation></Reference><Reference><Citation>Koehl B, Oualha M, Lesage F, et&#xa0;al. Fatal parvovirus B19 myocarditis in children and possible dysimmune mechanism. Pediatr Infect Dis J. 2012;31(4):418&#x2010;421.</Citation></Reference><Reference><Citation>Nigro G, Bastianon V, Colloridi V, et&#xa0;al. Human parvovirus B19 infection in infancy associated with acute and chronic lymphocytic myocarditis and high cytokine levels: report of 3 cases and review. Clin Infect Dis. 2000;31(1):65&#x2010;69.</Citation></Reference><Reference><Citation>Munro K, Croxson MC, Thomas S, Wilson NJ. Three cases of myocarditis in childhood associated with human parvovirus (B19 virus). Pediatr Cardiol. 2003;24(5):473&#x2010;475.</Citation></Reference><Reference><Citation>Enders G, D&#xf6;tsch J, Bauer J, et&#xa0;al. Life&#x2010;threatening parvovirus B19&#x2010;associated myocarditis and cardiac transplantation as possible therapy: two case reports. Clin Infect Dis. 1998;26(2):355&#x2010;358.</Citation></Reference><Reference><Citation>Beghetti M, Gervaix A, Haenggeli CA, Berner M, Rimensberger PC. Myocarditis associated with parvovirus B19 infection in two siblings with merosin&#x2010;deficient congenital muscular dystrophy. Eur J Pediatr. 2000;159(1&#x2013;2):135&#x2010;136.</Citation></Reference><Reference><Citation>McMahon CJ, Murchan H, Prendiville T, Burch M. Parvovirus B19 infection associated with dilated cardiomyopathy in patients with previous anthracycline exposure. Pediatr Cardiol. 2007;28(5):394&#x2010;395.</Citation></Reference><Reference><Citation>Amabile N, Fraisse A, Bouvenot J, Chetaille P, Ovaert C. Outcome of acute fulminant myocarditis in children. Heart. 2006;92(9):1269&#x2010;1273.</Citation></Reference><Reference><Citation>Simpson KE, Storch GA, Lee CK, et&#xa0;al. High frequency of detection by PCR of viral nucleic acid in the blood of infants presenting with clinical myocarditis. Pediatr Cardiol. 2016;37(2):399&#x2010;404.</Citation></Reference><Reference><Citation>Saleh M, Sajwany S. Intravenous immunoglobulins in the management of parvovirus B19&#x2010;induced fulminant myocarditis: case report. Int J Clin Cardiol. 2017;4:094. doi:10.23937/2378-2951/1410094</Citation></Reference><Reference><Citation>Wahjudi T, Nitsch A, Sperhake JP, Hoeger PH. Fulminant parvovirus B19 myocarditis in infants &#x2010;report of three post&#x2010;pandemic cases. Eur J Clin Microbiol Infect Dis. 2025;44(5):1239&#x2010;1243.</Citation></Reference><Reference><Citation>Ferro V, Pisani M, Marotta R, et&#xa0;al. Severe outcomes from suspected human parvovirus B19 infection in immunocompetent children: the need for timely recognition. J Med Virol. 2025;97(4):e70324.</Citation></Reference><Reference><Citation>Izquierdo&#x2010;Blasco J, Salcedo Allende MT, Codina Grau MG, Gran F, Mart&#xed;nez S&#xe1;ez E, Balcells J. Parvovirus B19 myocarditis: looking beyond the heart. Pediatr Dev Pathol. 2020;23(2):158&#x2010;162.</Citation></Reference><Reference><Citation>Adda J, Machado S, Eberst E, Roubille C, Macia JC, Roubille F. Parvovirus B19 infection and acute myocarditis. Intern Med. 2010;49(1):79.</Citation></Reference><Reference><Citation>Veronese G, Nonini S, Bottiroli M, et&#xa0;al. A case of parvovirus B19&#x2010;associated fulminant myocarditis in an infant successfully treated with immunosuppressive therapy. J Cardiovasc Med (Hagerstown). 2022;23(10):697&#x2010;699.</Citation></Reference><Reference><Citation>Papadogiannakis N, Tolfvenstam T, Fischler B, Norbeck O, Broliden K. Active, fulminant, lethal myocarditis associated with parvovirus B19 infection in an infant. Clin Infect Dis. 2002;35(9):1027&#x2010;1031.</Citation></Reference><Reference><Citation>Butin M, Mekki Y, Phan A, et&#xa0;al. Successful immunotherapy in life&#x2010;threatening parvovirus B19 infection in a child. Pediatr Infect Dis J. 2013;32(7):789&#x2010;792.</Citation></Reference><Reference><Citation>Murry CE, Jerome KR, Reichenbach DD. Fatal parvovirus myocarditis in a 5&#x2010;year&#x2010;old girl. Hum Pathol. 2001;32(3):342&#x2010;345.</Citation></Reference><Reference><Citation>Dina J, Vabret A, Rambaud C, et&#xa0;al. Fulminant myocarditis associated with parvovirus B19 infection in a child. J Clin Virol. 2008;42(1):70&#x2010;71.</Citation></Reference><Reference><Citation>Krishnamurti L, Lanford L, Munoz R. Life threatening parvovirus B19 and herpes simplex virus associated acute myocardial dysfunction in a child with homozygous sickle cell disease. Pediatr Blood Cancer. 2007;49(7):1019&#x2010;1021.</Citation></Reference><Reference><Citation>Rohayem J, Dinger J, Fischer R, Klingel K, Kandolf R, Rethwilm A. Fatal myocarditis associated with acute parvovirus B19 and human herpesvirus 6 coinfection. J Clin Microbiol. 2001;39(12):4585&#x2010;4587.</Citation></Reference><Reference><Citation>Zack F, Klingel K, Kandolf R, Wegener R. Sudden cardiac death in a 5&#x2010;year&#x2010;old girl associated with parvovirus B19 infection. Forensic Sci Int. 2005;155(1):13&#x2010;17.</Citation></Reference><Reference><Citation>O'Connell MJ, Duff DF, Hayes RM. Non&#x2010;invasive investigation and management of aortic saddle embolus in a 7&#x2010;month&#x2010;old infant. Cardiovasc Intervent Radiol. 2002;25(1):74&#x2010;75.</Citation></Reference><Reference><Citation>Floyd A, Lal A, Molina K, Puchalski M, Miller D, May L. When lightning strikes twice in pediatrics: case report and review of recurrent myocarditis. Pediatrics. 2018;141(3):e20164096.</Citation></Reference><Reference><Citation>Spartalis M, Tzatzaki E, Spartalis E, Damaskos C, Mavrogeni S, Voudris V. Parvovirus B19 myocarditis of fulminant evolution. Cardiol Res. 2017;8(4):172&#x2010;175.</Citation></Reference><Reference><Citation>Ajmi H, Chemli J, Trabelsi A, et&#xa0;al. Acute myocarditis associated with parvovirus B19 infection in a child. Pediatr Infect Dis J. 2015;7:53&#x2010;55. doi:10.1016/j.pid.2015.02.001</Citation></Reference><Reference><Citation>Schowengerdt KO, Ni J, Denfield SW, et&#xa0;al. Association of parvovirus B19 genome in children with myocarditis and cardiac allograft rejection: diagnosis using the polymerase chain reaction. Circulation. 1997;96(10):3549&#x2010;3554.</Citation></Reference><Reference><Citation>Pelzl L, Mantino S, Sauter M, Manuylova T, Vogel U, Klingel K. Lymphocytic myocarditis in children with parvovirus B19 infection: pathological and molecular insights. Biomedicine. 2024;12(8):1909.</Citation></Reference><Reference><Citation>Gagliardi MG, Fierabracci A, Pilati M, et&#xa0;al. The impact of specific viruses on clinical outcome in children presenting with acute heart failure. Int J Mol Sci. 2016;17(4):486.</Citation></Reference><Reference><Citation>Nielsen TS, Hansen J, Nielsen LP, Baandrup UT, Banner J. The presence of enterovirus, adenovirus, and parvovirus B19 in myocardial tissue samples from autopsies: an evaluation of their frequencies in deceased individuals with myocarditis and in non&#x2010;inflamed control hearts. Forensic Sci Med Pathol. 2014;10(3):344&#x2010;350.</Citation></Reference><Reference><Citation>Keramari S, Poutoglidis A, Chatzis S, Keramaris M, Savopoulos C, Kaiafa G. Parvovirus B19&#x2010;associated myocarditis: a literature review of pediatric cases. Cureus. 2022;14(1):e21726.</Citation></Reference><Reference><Citation>Canter CE, Simpson KE. Diagnosis and treatment of myocarditis in children in the current era. Circulation. 2014;129(1):115&#x2010;128.</Citation></Reference><Reference><Citation>K&#xfc;hl U, Schultheiss HP. Myocarditis in children. Heart Fail Clin. 2010;6(4):483&#x2010;496. viii&#x2010;ix.</Citation></Reference><Reference><Citation>Werner B, Ro&#x17c;nowska&#x2010;W&#xf3;jtowicz A, Puchalski M. Diagnosis and Management of Pediatric Myocarditis. Pediatr Infect Dis J. 2025;44(3):e95&#x2010;e98.</Citation></Reference><Reference><Citation>Arola A, Pikkarainen E, Sipil&#xe4; JO, Pyk&#xe4;ri J, Rautava P, Kyt&#xf6; V. Occurrence and features of childhood myocarditis: a Nationwide study in Finland. J Am Heart Assoc. 2017;6(11):e005306.</Citation></Reference><Reference><Citation>Ghelani SJ, Spaeder MC, Pastor W, Spurney CF, Klugman D. Demographics, trends, and outcomes in pediatric acute myocarditis in the United States, 2006 to 2011. Circ Cardiovasc Qual Outcomes. 2012;5(5):622&#x2010;627.</Citation></Reference><Reference><Citation>Butts RJ, Boyle GJ, Deshpande SR, et&#xa0;al. Characteristics of clinically diagnosed pediatric myocarditis in a contemporary multi&#x2010;center cohort. Pediatr Cardiol. 2017;38(6):1175&#x2010;1182.</Citation></Reference><Reference><Citation>Foerster SR, Canter CE, Cinar A, et&#xa0;al. Ventricular remodeling and survival are more favorable for myocarditis than for idiopathic dilated cardiomyopathy in childhood: an outcomes study from the pediatric cardiomyopathy registry. Circ Heart Fail. 2010;3(6):689&#x2010;697.</Citation></Reference><Reference><Citation>Messroghli DR, Pickardt T, Fischer M, et&#xa0;al. Toward evidence&#x2010;based diagnosis of myocarditis in children and adolescents: rationale, design, and first baseline data of MYKKE, a multicenter registry and study platform. Am Heart J. 2017;187:133&#x2010;144.</Citation></Reference><Reference><Citation>Gutierrez Sanchez LH, Shiau H, Baker JM, et&#xa0;al. A case series of children with acute hepatitis and human adenovirus infection. N Engl J Med. 2022;387(7):620&#x2010;630.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40710834</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>31</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2571-841X</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>2</Issue><PubDate><Year>2025</Year><Month>Apr</Month><Day>02</Day></PubDate></JournalIssue><Title>Reports (MDPI)</Title><ISOAbbreviation>Reports (MDPI)</ISOAbbreviation></Journal><ArticleTitle>Shock and Awe: The Tactical Trade-Offs of Impella<sup>&#xae;</sup> Versus Intra-Aortic Balloon Pump in Takotsubo Cardiomyopathy.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">43</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/reports8020043</ELocationID><Abstract><AbstractText><b>Background and Clinical Significance:</b> Takotsubo cardiomyopathy (TCM), an acute stress-induced left ventricular dysfunction, stems from catecholaminergic surges leading to transient myocyte stunning, calcium overload, and microvascular dysregulation. Although most cases resolve spontaneously, roughly 10% deteriorate into fulminant cardiogenic shock, warranting mechanical circulatory support (MCS). Impella<sup>&#xae;</sup> provides direct transvalvular LV unloading but carries elevated risks of hemolysis, vascular compromise, and thrombogenicity. Conversely, the intra-aortic balloon pump (IABP) enhances diastolic coronary perfusion and marginally reduces afterload via counterpulsation, albeit with less potent LV decompression. Optimal MCS selection in TCM-associated shock therefore hinges on balancing hemodynamic benefits against procedural morbidity. <b>Case Presentation:</b> A 72-year-old female with coronary artery disease, paroxysmal atrial fibrillation (status post-left atrial appendage occlusion), and stage 3 chronic kidney disease presented with anterior ST-segment elevations (V2-V4) and troponin I &gt;1000 ng/L, progressing rapidly to cardiogenic shock and respiratory failure. Coronary angiography revealed mild luminal irregularities, while echocardiography demonstrated severely reduced ejection fraction (5-10%) with characteristic apical ballooning. Refractory elevations in pulmonary capillary wedge pressure, despite escalating inotropes and vasopressors, prompted IABP insertion for partial LV offloading. Over one week, her ejection fraction improved to 35%, facilitating weaning from pressor support, extubation, and discharge on guideline-directed medical therapy. <b>Conclusions:</b> In TCM complicated by shock, meticulous MCS selection is paramount. Although Impella confers more robust unloading, heightened device-related complications may be unjustified in a largely reversible disease. IABP can sufficiently stabilize hemodynamics, enable myocardial recovery, and mitigate morbidity, underscoring the importance of individualized decision-making in TCM-related shock. Importantly, no trial has shown that MCS confers a proven long-term mortality benefit beyond initial hemodynamic rescue.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Saraf</LastName><ForeName>Ajay</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Internal Medicine Residency, Boonshoft School of Medicine, Wright State University, Dayton, OH 45435, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goyal</LastName><ForeName>Amit</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Cardiovascular Medicine, Premier Heart Institute, Boonshoft School of Medicine, Wright State University, Dayton, OH 45435, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>04</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Reports (MDPI)</MedlineTA><NlmUniqueID>101757880</NlmUniqueID><ISSNLinking>2571-841X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Impella</Keyword><Keyword MajorTopicYN="N">cardiogenic shock</Keyword><Keyword MajorTopicYN="N">intra-aortic balloon pump</Keyword><Keyword MajorTopicYN="N">mechanical circulatory support</Keyword><Keyword MajorTopicYN="N">stress-induced cardiomyopathy</Keyword><Keyword MajorTopicYN="N">takotsubo cardiomyopathy</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>1</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>3</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>3</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>12</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>12</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>9</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>4</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40710834</ArticleId><ArticleId IdType="pmc">PMC12197009</ArticleId><ArticleId IdType="doi">10.3390/reports8020043</ArticleId><ArticleId IdType="pii">reports8020043</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Templin C., Ghadri J.R., Diekmann J., Napp L.C., Bataiosu D.R., Jaguszewski M., Cammann V.L., Sarcon A., Geyer V., Neumann C.A., et al. Clinical features and outcomes of Takotsubo (stress) cardiomyopathy. N. Engl. J. Med. 2015;373:929&#x2013;938. doi: 10.1056/NEJMoa1406761.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1406761</ArticleId><ArticleId IdType="pubmed">26332547</ArticleId></ArticleIdList></Reference><Reference><Citation>Wittstein I.S., Thiemann D.R., Lima J.A.C., Baughman K.L., Schulman S.P., Gerstenblith G., Wu K.C., Rade J.J., Bivalacqua T.J., Champion H.C. Neurohumoral features of myocardial stunning due to sudden emotional stress. N. Engl. J. Med. 2005;352:539&#x2013;548. doi: 10.1056/NEJMoa043046.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa043046</ArticleId><ArticleId IdType="pubmed">15703419</ArticleId></ArticleIdList></Reference><Reference><Citation>Syed M., Khan M.Z., Osman M., Alharbi A., Khan M.U., Munir M.B., Balla S. Comparison of outcomes in patients with Takotsubo syndrome with versus without cardiogenic shock. Am. J. Cardiol. 2020;136:24&#x2013;31. doi: 10.1161/JAHA.123.030819.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/JAHA.123.030819</ArticleId><ArticleId IdType="pmc">PMC8375056</ArticleId><ArticleId IdType="pubmed">32941812</ArticleId></ArticleIdList></Reference><Reference><Citation>Santoro F., N&#xfa;&#xf1;ez Gil I.J., Stiermaier T., El-Battrawy I., Moeller C., Guerra F., Novo G., Arcari L., Musumeci B., Cacciotti L., et al. Impact of intra-aortic balloon counterpulsation on all-cause mortality among patients with Takotsubo syndrome complicated by cardiogenic shock: Results from the German-Italian-Spanish (GEIST) registry. Eur. Heart J. Open. 2023;3:oead003. doi: 10.1093/ehjopen/oead003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ehjopen/oead003</ArticleId><ArticleId IdType="pmc">PMC9921723</ArticleId><ArticleId IdType="pubmed">36789137</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed M., Bano S., Asif M., Sidra F.N., Ram M., Bibi S. Impella vs intra-aortic balloon pump in patients with acute myocardial infarction complicated with cardiogenic shock: An updated systematic review and meta-analysis; Proceedings of the International Student Research Conference (ISRC&#x2019;24); Karachi, Pakistan. 7&#x2013;8 September 2024;</Citation><ArticleIdList><ArticleId IdType="doi">10.4081/cardio.2025.61</ArticleId></ArticleIdList></Reference><Reference><Citation>Thiele H., Zeymer U., Neumann F.J., Ferenc M., Olbrich H.G., Hausleiter J., De Waha A., Richardt G., Hennersdorf M., Empen K., et al. Intra-aortic balloon counterpulsation in acute myocardial infarction complicated by cardiogenic shock (IABP-SHOCK II): Final 12 month results of a randomized, open-label trial. Lancet. 2013;382:1638&#x2013;1645. doi: 10.1016/S0140-6736(13)61783-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(13)61783-3</ArticleId><ArticleId IdType="pubmed">24011548</ArticleId></ArticleIdList></Reference><Reference><Citation>Teruhiko I. Clinical implication of intra-aortic balloon pumping in patients with Takotsubo syndrome and cardiogenic shock. Eur. Heart J. Open. 2023;3:oead050. doi: 10.1093/ehjopen/oead050.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ehjopen/oead050</ArticleId><ArticleId IdType="pmc">PMC10243834</ArticleId><ArticleId IdType="pubmed">37288073</ArticleId></ArticleIdList></Reference><Reference><Citation>Napp L.C., Westenfeld R., M&#xf8;ller J.E., Pappalardo F., Ibrahim K., Bonello L., Wilkins C., Pershad A., Mannino S.F., Schreiber T.L., et al. Impella mechanical circulatory support for Takotsubo syndrome with shock: A retrospective multicenter analysis. Cardiovasc. Revasc. Med. 2022;40:113&#x2013;119. doi: 10.1016/j.carrev.2021.11.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.carrev.2021.11.018</ArticleId><ArticleId IdType="pubmed">34916157</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40703891</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>28</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">0300-1652</ISSN><JournalIssue CitedMedium="Print"><Volume>66</Volume><Issue>2</Issue><PubDate><Year>2025</Year><Season>Mar-Apr</Season></PubDate></JournalIssue><Title>Nigerian medical journal : journal of the Nigeria Medical Association</Title><ISOAbbreviation>Niger Med J</ISOAbbreviation></Journal><ArticleTitle>Coarctation of the Aorta Presenting as Haemorrhagic Stroke in a 3-Year-Old Boy- A Case Report.</ArticleTitle><Pagination><StartPage>799</StartPage><EndPage>804</EndPage><MedlinePgn>799-804</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.71480/nmj.v66i2.710</ELocationID><Abstract><AbstractText>Coarctation of the aorta is an obstructive form of congenital heart defects that presents with upper limb hypertension. If untreated, Coarctation of the aorta can lead to left ventricular dysfunction and cerebral vasculopathy. Missed diagnosis due to its subtle presentation is common with attendant complications. This is a case report of an apparently healthy 3-year-old boy who lapsed into a coma after a trivial fall. He had upper limb hypertension and the pulses in the lower limbs were barely palpable. Brain computed tomography (CT) revealed non-traumatic haemorrhagic stroke and echocardiography showed severe left ventricular hypertrophy and severe coarctation of the aorta. Coarctation of the aorta can manifest as chronic upper limb hypertension in children with complicated non-traumatic haemorrhagic stroke. Routine blood pressure measurement in young children can serve as a screening tool for early diagnosis of the condition.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 Nigerian Medical Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Abolodje</LastName><ForeName>Efe</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Paediatrics, Delta State University Teaching Hospital, Oghara, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Campbell</LastName><ForeName>Francis Chukwuebuka</ForeName><Initials>FC</Initials><AffiliationInfo><Affiliation>Department of Surgery, Delta State University Teaching Hospital, Oghara, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Etumudor</LastName><ForeName>Stellamaris Nwanneka</ForeName><Initials>SN</Initials><AffiliationInfo><Affiliation>Department of Paediatrics, Delta State University Teaching Hospital, Oghara, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ejumudo</LastName><ForeName>Fred Ofakpo</ForeName><Initials>FO</Initials><AffiliationInfo><Affiliation>Department of Surgery, Delta State University Teaching Hospital, Oghara, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ovili</LastName><ForeName>Chukwuemeke</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Paediatrics, Delta State University Teaching Hospital, Oghara, Nigeria.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>06</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>Nigeria</Country><MedlineTA>Niger Med J</MedlineTA><NlmUniqueID>0315137</NlmUniqueID><ISSNLinking>0300-1652</ISSNLinking></MedlineJournalInfo></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>24</Day><Hour>6</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>24</Day><Hour>6</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>24</Day><Hour>5</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>6</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40703891</ArticleId><ArticleId IdType="pmc">PMC12280325</ArticleId><ArticleId IdType="doi">10.71480/nmj.v66i2.710</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rao PS. Should balloon angioplasty be used instead of surgery for native aortic coarctation? Br Heart J. 1995. Dec. 74(6):578-9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC484108</ArticleId><ArticleId IdType="pubmed">8541158</ArticleId></ArticleIdList></Reference><Reference><Citation>Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM, et al. Heart Disease and Stroke Statistics&#x2014;2011 Update. A Report from the American Heart Association. Circulation. 2011;123: e18&#x2013;e209</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4418670</ArticleId><ArticleId IdType="pubmed">21160056</ArticleId></ArticleIdList></Reference><Reference><Citation>Rawanduzy CA, Earl E, Mayer G, Lucke-Wold B. Paediatric Stroke: A Review of Common Etiologies and Management Strategies. Biomedicines. 2022. Dec 20;11(1):2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9856134</ArticleId><ArticleId IdType="pubmed">36672510</ArticleId></ArticleIdList></Reference><Reference><Citation>Jordan LC, Hillis AE. Challenges in the diagnosis and treatment of paediatric stroke. Nat Rev Neurol. 2011. Apr;7(4):199-208.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3383861</ArticleId><ArticleId IdType="pubmed">21386815</ArticleId></ArticleIdList></Reference><Reference><Citation>Gebremariam SA, Yang HS. Types, Risk Profiles, and Outcomes of Stroke Patients in a Tertiary Teaching Hospital in northern Ethiopia. ENeurological Sci. 2016; 3:41&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5803092</ArticleId><ArticleId IdType="pubmed">29430535</ArticleId></ArticleIdList></Reference><Reference><Citation>George IO, Frank-Briggs AI. Stroke in Nigerian Children with Sickle Cell Anaemia. Journal of Public Health and Epidemiology. 2011; 3(9): 407-409</Citation></Reference><Reference><Citation>Beslow LA, Licht DJ, Smith SE, Storm PB, Heuer GG, Zimmerman RA et al. Predictors of outcome in childhood intracerebral haemorrhage: a prospective consecutive cohort study. Stroke; a journal of cerebral circulation. 2010; 41:313&#x2013;318.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2821039</ArticleId><ArticleId IdType="pubmed">20019325</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollist M, Au K, Morgan L, Shetty PA, Rane R, Hollist A, et al. Paediatric Stroke: Overview and Recent Updates. Aging Dis. 2021. Jul 1;12(4):1043-1055.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8219494</ArticleId><ArticleId IdType="pubmed">34221548</ArticleId></ArticleIdList></Reference><Reference><Citation>Raza S, Aggarwal S, Jenkins P, Kharabish A, Anwer S, Cullington D, et al. Coarctation of the Aorta: Diagnosis and Management. Diagnostics (Basel). 2023;13(13):1-18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10340190</ArticleId><ArticleId IdType="pubmed">37443581</ArticleId></ArticleIdList></Reference><Reference><Citation>Opio J, Kiguli-Malwadde E, Byanyima RK. Coarctation of aorta presenting as acute haemorrhagic stroke in a 14-year-old. A case report. Afr Health Sci. 2008. Dec;8(4):256-8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2887012</ArticleId><ArticleId IdType="pubmed">20589134</ArticleId></ArticleIdList></Reference><Reference><Citation>Unnithan AKA, Das JM, Mehta P. Haemorrhagic Stroke. [Updated 2023May 8]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK559173/</Citation></Reference><Reference><Citation>Doumbia AK, Coulibaly O, Diall HG, Demb&#xe9;l&#xe9; G, Hamadassaliha A, Mangara FS, et al. Haemorrhagic Stroke: About a Paediatric Case. Open Journal of Paediatrics. 2021; 11:804-809.</Citation></Reference><Reference><Citation>Arvin M, Siavash KA, Hamid Reza R, Forod S. Cerebral Infarction Following Correction of Aortic Coarctation Surgery in Children, Journal of Comprehensive Paediatrics, 13, 1, (2022).</Citation></Reference><Reference><Citation>Mehwald PS, Dittrich S, Grohmann J, Bley T, Kececioglu D. Coarctation of the aorta presenting as cerebral haemorrhage. INSIGHTS. 2005;146: 293</Citation><ArticleIdList><ArticleId IdType="pubmed">15689929</ArticleId></ArticleIdList></Reference><Reference><Citation>Opio J, Kiguli-Malwadde E, Byanyima RK. Coarctation of aorta presenting as acute haemorrhagic stroke in a 14-year-old. A case report. Afr Health Sci. 2008. Dec;8(4):256-8</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2887012</ArticleId><ArticleId IdType="pubmed">20589134</ArticleId></ArticleIdList></Reference><Reference><Citation>Baykan A, Argun M, Ozyurt A, Pamuk&#xe7;u O, Uz&#xfc;m K, Nar&#x131;n N. Hypertension associated with coarctation of the aorta revisited: case-based update from experience of three children. Case Rep Pediatr. 2013; 2013:716438.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3777203</ArticleId><ArticleId IdType="pubmed">24093067</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh V, Prasad K, Singh PK, Singh D, Chaudhary BK, Bhattnagar R. A rare presentation of Coarctation of the aorta as haemorrhagic stroke in a 22-year-old male: a case report. National Journal of Medical Research. 2020; 10:57-59</Citation></Reference><Reference><Citation>Jordan LC, Kleinman JT, Hillis AE. Intracerebral haemorrhage volume predicts poor neurologic outcome in children. Stroke. 2009. May;40(5):1666-71</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2830068</ArticleId><ArticleId IdType="pubmed">19286576</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40672529</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>19</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2574-0954</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>3</Issue><PubDate><Year>2025</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Cardiovascular endocrinology &amp; metabolism</Title><ISOAbbreviation>Cardiovasc Endocrinol Metab</ISOAbbreviation></Journal><ArticleTitle>Utilizing natriuretic peptides for predicting heart failure risk following myocardial infarction.</ArticleTitle><Pagination><StartPage>e00338</StartPage><MedlinePgn>e00338</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e00338</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1097/XCE.0000000000000338</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">In Mongolia, ischemic heart disease, specifically acute myocardial infarction (AMI), is a significant etiology of chronic heart failure (HF). Therefore, early recognition of the risk of HF following AMI is critically important for improving patient management. This study aimed to assess the N-terminal pro-B-type natriuretic peptide (NT-proBNP) as an early detection and prognosis of asymptomatic left ventricular (LV) dysfunction following AMI.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">Patients diagnosed with AMI and in the absence of symptoms or signs of HF were prospectively included. Clinical and echocardiographic data were collected at baseline, and NT-proBNP levels were measured at admission and discharge. Patients were divided into four distinct groups based on NT-proBNP level quartiles. The study endpoint was de-novo HF at 6 months after AMI.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">A total of 120 patients with a mean age of 56.0&#x2005;&#xb1;&#x2005;9.2 years and 80.8% (<i>N</i>&#x2005;=&#x2005;97) men were included. Higher NT-proBNP levels were associated with elevated GRACE score and diabetes, both at admission and predischarge. Additionally, higher NT-proBNP levels at admission were associated with delayed hospital presentation, whereas higher NT-proBNP levels at predischarge were associated with reduced LV global longitudinal strain. Furthermore, NT-proBNP level at predischarge was significantly associated with the development of HF 6 months after AMI, with a threshold value of 1410 pg/ml.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">Incorporation of NT-proBNP measurement before discharge in AMI patients could enhance risk stratification, thereby supporting its integration into routine clinical evaluation for more efficient patient management.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 The Author(s). Published by Wolters Kluwer Health, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ulziisaikhan</LastName><ForeName>Ganchimeg</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>National Cardiovascular Center, The Third State Central Hospital.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Departments of Cardiology.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khurelbaatar</LastName><ForeName>Mungun-Ulzii</ForeName><Initials>MU</Initials><AffiliationInfo><Affiliation>National Cardiovascular Center, The Third State Central Hospital.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khorloo</LastName><ForeName>Chingerel</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Departments of Cardiology.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khasag</LastName><ForeName>Altaisaikhan</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Endocrinology, Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Unurjargal</LastName><ForeName>Tsolmon</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Departments of Cardiology.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cardiovasc Endocrinol Metab</MedlineTA><NlmUniqueID>101730894</NlmUniqueID><ISSNLinking>2574-0954</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">acute myocardial infarction</Keyword><Keyword MajorTopicYN="N">early detection</Keyword><Keyword MajorTopicYN="N">heart failure</Keyword><Keyword MajorTopicYN="N">left ventricular dysfunction</Keyword><Keyword MajorTopicYN="N">natriuretic peptide levels</Keyword></KeywordList><CoiStatement>There are no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>2</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>6</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>17</Day><Hour>6</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>17</Day><Hour>6</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>17</Day><Hour>5</Hour><Minute>36</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>7</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40672529</ArticleId><ArticleId IdType="pmc">PMC12266924</ArticleId><ArticleId IdType="doi">10.1097/XCE.0000000000000338</ArticleId><ArticleId IdType="pii">CAEN-D-25-00012</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Health Indicators
2023. doi:https://hdc.gov.mn/media/files/last_eruul%20mendiin%20uzuulelt%202023_english_laast-8.13_8lAJzIZ.pdf.</Citation></Reference><Reference><Citation>Enkh-Oyun T, Kotani K, Swanson E. Ischemic heart disease among the general Mongolian population: a review of epidemiological studies. Int Health 2016; 8:13&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">26647395</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahit MC, Kochar A, Granger CB. Post-myocardial infarction heart failure. JACC Heart Fail 2018; 6:179&#x2013;186.</Citation><ArticleIdList><ArticleId IdType="pubmed">29496021</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Bijl P, Abou R, Goedemans L, Gersh BJ, Holmes DR, Jr, Ajmone Marsan N, et al. Left ventricular post-infarct remodeling: implications for systolic function improvement and outcomes in the modern era. JACC Heart Fail 2020; 8:131&#x2013;140.</Citation><ArticleIdList><ArticleId IdType="pubmed">31838030</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulziisaikhan G, Tsogbadrakh O, Namsrainaidan B, Norpil B, Dagva M, Sim D. Clinical characteristics and management of hospitalized patients with heart failure, results from Mongolia. Eur Heart J 2017; 19(Suppl. S1):S246.</Citation></Reference><Reference><Citation>Desta L, Jernberg T, L&#xf6;fman I, Hofman-Bang C, Hagerman I, Spaak J, Persson H. Incidence, temporal trends, and prognostic impact of heart failure complicating acute myocardial infarction. The SWEDEHEART Registry (Swedish Web-System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies): a study of 199,851 patients admitted with index acute myocardial infarctions, 1996 to 2008. JACC Heart Fail 2015; 3:234&#x2013;242.</Citation><ArticleIdList><ArticleId IdType="pubmed">25742760</ArticleId></ArticleIdList></Reference><Reference><Citation>Hwang SY, Kim SH, Uhm IA, Shin JH, Lim YH. Prognostic implications for patients after myocardial infarction: an integrative literature review and in-depth interviews with patients and experts. BMC Cardiovasc Disord 2022; 22:348.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9344648</ArticleId><ArticleId IdType="pubmed">35918641</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaggin HK, Januzzi JL. The past, the present, and the future of natriuretic peptides in the diagnosis of heart failure. Eur Heart J Suppl 2018; 20:G11&#x2013;G20.</Citation></Reference><Reference><Citation>McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B&#xf6;hm M, et al. ; ESC Scientific Document Group. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021; 42:3599&#x2013;3726.</Citation><ArticleIdList><ArticleId IdType="pubmed">34447992</ArticleId></ArticleIdList></Reference><Reference><Citation>Buyanjargal Ya, Davaakhuu N, Choijiljav G, Tsognemekh B, Dandar E, Dagdan B, et al. Mongolian acute myocardial infarction management guideline
2019. https://moh.gov.mn/uploads/files/943a7882c19b824f49ee11d86de5c7476762dbb1.pdf.</Citation></Reference><Reference><Citation>Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, et al. ; ESC Scientific Document Group. 2023 ESC guidelines for the management of acute coronary syndromes. Eur Heart J 2023; 44:3720&#x2013;3826.</Citation><ArticleIdList><ArticleId IdType="pubmed">37622654</ArticleId></ArticleIdList></Reference><Reference><Citation>Weber M, Hamm C. Role of B-type natriuretic peptide (BNP) and NT-proBNP in clinical routine. Heart 2006; 92:843&#x2013;849.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1860679</ArticleId><ArticleId IdType="pubmed">16698841</ArticleId></ArticleIdList></Reference><Reference><Citation>Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2015; 16:233&#x2013;270.</Citation><ArticleIdList><ArticleId IdType="pubmed">25712077</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang H, Wright L, Negishi T, Negishi K, Liu J, Marwick TH. Research to practice: assessment of left ventricular global longitudinal strain for surveillance of cancer chemotherapeutic-related cardiac dysfunction. JACC. Cardiovascular imaging 2018; 11:1196&#x2013;1201.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7570450</ArticleId><ArticleId IdType="pubmed">30092974</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim HN, Januzzi JL. Natriuretic peptide testing in heart failure. Circulation 2011; 123:2015&#x2013;2019.</Citation><ArticleIdList><ArticleId IdType="pubmed">21555724</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanderheyden M, Bartunek, Claeys G, Manoharan G, Beckers JF, Ide L. Head to head comparison of N-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in patients with/without left ventricular systolic dysfunction. Clin Biochem 2006; 39:640&#x2013;645.</Citation><ArticleIdList><ArticleId IdType="pubmed">16516185</ArticleId></ArticleIdList></Reference><Reference><Citation>Kotecha D, Flather MD, Atar D, Collins P, Pepper J, Jenkins E, et al. ; Alternative Risk Markers in Coronary Artery Disease (ARM-CAD) Study. B-type natriuretic peptide trumps other prognostic markers in patients assessed for coronary disease. Alternative risk markers in coronary artery disease (ARM-CAD) study. BMC Med 2019; 17:72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6448253</ArticleId><ArticleId IdType="pubmed">30943979</ArticleId></ArticleIdList></Reference><Reference><Citation>Kragelund C, Gronning B, Kober L, Hildebrandt P, Steffensen R. N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Engl J Med 2005; 352:666&#x2013;675.</Citation><ArticleIdList><ArticleId IdType="pubmed">15716560</ArticleId></ArticleIdList></Reference><Reference><Citation>Goetze JP, Gore A, M&#xf8;ller CH, Steinbr&#xfc;chel DA, Rehfeld JF, Nielsen LB. Acute myocardial hypoxia increases BNP gene expression. FASEB J 2004; 18:1928&#x2013;1930.</Citation><ArticleIdList><ArticleId IdType="pubmed">15576492</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu L, Qian W, Li W, Liu J, He H, Li G, et al. The severity of coronary artery disease and reversible ischemia revealed by N-terminal pro-brain natriuretic peptide in patients with unstable angina and preserved left ventricular function. Peptides 2014; 52:143&#x2013;148.</Citation><ArticleIdList><ArticleId IdType="pubmed">24412773</ArticleId></ArticleIdList></Reference><Reference><Citation>Omland T. Clinical and laboratory diagnostics of cardiovascular disease: focus on natriuretic peptides and cardiac ischemia. Scand J Clin Lab Invest 2005; 65(Suppl 240):18&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">16112956</ArticleId></ArticleIdList></Reference><Reference><Citation>Peacock WF. Time to treatment and acute coronary syndromes: bridging the gap in rapid decision making. Rev Cardiovasc Med 2010; 11(Suppl 2):S45&#x2013;S50.</Citation><ArticleIdList><ArticleId IdType="pubmed">20700102</ArticleId></ArticleIdList></Reference><Reference><Citation>Melendo-Viu M, Abu-Assia E, Manzano-Fern&#xe1;ndezb S, Flores-Blancob PJ, Cambronero-S&#xe1;nchezb F, P&#xe9;rez DD, et al. Incidence, prognosis and predictors of heart failure after acute myocardial infarction. CardioClinics 2020; 55:8&#x2013;14.</Citation></Reference><Reference><Citation>Heeschen C, Hamm CW, Mitrovic V, Lantelme N, White HD; Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Investigators. N-Terminal Pro&#x2013;B-Type Natriuretic peptide levels for dynamic risk stratification of patients with acute coronary syndromes. Circulation 2004; 110:3206&#x2013;3212.</Citation><ArticleIdList><ArticleId IdType="pubmed">15533869</ArticleId></ArticleIdList></Reference><Reference><Citation>Eurlings LW, Sanders-van Wijk S, van Kraaij DJ, van Kimmenade R, Meeder JG, et al. Risk stratification with the use of serial N-Terminal Pro&#x2013;B-type natriuretic peptide measurements during admission and early after discharge in heart failure patients: post hoc analysis of the prima study. J Card Fail 2014; 20:881&#x2013;890.</Citation><ArticleIdList><ArticleId IdType="pubmed">25175696</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyon AR, L&#xf3;pez-Fern&#xe1;ndez T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al. ; ESC Scientific Document Group. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J 2022; 43:4229&#x2013;4361.</Citation><ArticleIdList><ArticleId IdType="pubmed">36017568</ArticleId></ArticleIdList></Reference><Reference><Citation>Otani K, Higa Y, Kitano T, Nabeshima Y, Takeuchi M. Prediction of cardiac events using fully automated GLS and BNP titers in patients with known or suspected heart failure. PLoS One 2020; 15:e0234294.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7295200</ArticleId><ArticleId IdType="pubmed">32542005</ArticleId></ArticleIdList></Reference><Reference><Citation>Ersb&#xf8;ll M, Valeur N, Mogensen UM, Andersen M, Greibe R, M&#xf8;ller JE, et al. Global left ventricular longitudinal strain is closely associated with increased neurohormonal activation after acute myocardial infarction in patients with both reduced and preserved ejection fraction: a two-dimensional speckle tracking study. Eur J Heart Fail 2012; 14:1121&#x2013;1129.</Citation><ArticleIdList><ArticleId IdType="pubmed">22753861</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40672900</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>19</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2048-0040</ISSN><JournalIssue CitedMedium="Print"><Volume>14</Volume><PubDate><Year>2025</Year><Season>Jan-Dec</Season></PubDate></JournalIssue><Title>JRSM cardiovascular disease</Title><ISOAbbreviation>JRSM Cardiovasc Dis</ISOAbbreviation></Journal><ArticleTitle>Pregnancy and breastfeeding in the mother with cardiomyopathy.</ArticleTitle><Pagination><StartPage>20480040251352901</StartPage><MedlinePgn>20480040251352901</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">20480040251352901</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1177/20480040251352901</ELocationID><Abstract><AbstractText>Cardiomyopathies are diseases of the heart muscle, characterised by structural and functional abnormalities of the myocardium that are not caused by ischemia, valvular problems or congenital heart disease. They are responsible for one-third of pregnancy-related cardiovascular deaths. A woman may enter pregnancy with a pre-existing diagnosis, or the cardiomyopathy may emerge or develop de novo during pregnancy. The most common cardiomyopathies encountered in pregnancy are dilated cardiomyopathy, hypertrophic cardiomyopathy and peripartum cardiomyopathy. All cardiomyopathies can be complicated by clinical heart failure, arrhythmia and thromboembolic events. Pregnancy may be poorly tolerated in women with dilated cardiomyopathy. New York Heart Association Class (NYHA) III/IV symptoms, and severe left ventricular dysfunction are the main determinants of adverse maternal outcomes. Peripartum cardiomyopathy is a diagnosis of exclusion with symptom onset towards the end of pregnancy, or within a few months following delivery. The management of heart failure and arrhythmias is based upon established guidelines, tailored for the unique considerations of pregnancy. Contemporary data suggests that recovery in cardiac function by 12 months is approximately 60-70% for the peripartum group. Maternal cardiovascular risk can be determined using specific risk-predictive scores. All patients with cardiomyopathy who wish to consider pregnancy should be offered individualized pre-conception and contraceptive counselling by a multidisciplinary team. This article reviews the management of women with cardiomyopathy during pregnancy and breastfeeding, focusing on the essential role of the multidisciplinary team at every stage of pregnancy and postpartum period to improve the maternal, fetal, and neonatal outcomes.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2025.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Coldea</LastName><ForeName>Bianca Maria</ForeName><Initials>BM</Initials><Identifier Source="ORCID">0009-0009-8193-8693</Identifier><AffiliationInfo><Affiliation>Department of Cardiology, Addenbrooke's Hospital, Cambridge, UK.</Affiliation><Identifier Source="RINGGOLD">89744</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Middleton</LastName><ForeName>Lucille</ForeName><Initials>L</Initials><Identifier Source="ORCID">0009-0002-8483-2535</Identifier><AffiliationInfo><Affiliation>University of Nottingham, Nottingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aiken</LastName><ForeName>Catherine</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-6510-5626</Identifier><AffiliationInfo><Affiliation>Department of Obstetrics and Gynaecology, The Rosie Hospital, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bhagra</LastName><ForeName>Catriona J</ForeName><Initials>CJ</Initials><Identifier Source="ORCID">0000-0002-3960-9273</Identifier><AffiliationInfo><Affiliation>Department of Cardiology, Addenbrooke's Hospital, Cambridge, UK.</Affiliation><Identifier Source="RINGGOLD">89744</Identifier></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>JRSM Cardiovasc Dis</MedlineTA><NlmUniqueID>101598607</NlmUniqueID><ISSNLinking>2048-0040</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cardiomyopathy</Keyword><Keyword MajorTopicYN="N">heart failure in pregnancy</Keyword><Keyword MajorTopicYN="N">pre-conception counselling</Keyword><Keyword MajorTopicYN="N">pregnancy and heart conditions</Keyword></KeywordList><CoiStatement>The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>11</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>5</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>5</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>17</Day><Hour>6</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>17</Day><Hour>6</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>17</Day><Hour>5</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>7</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40672900</ArticleId><ArticleId IdType="pmc">PMC12264410</ArticleId><ArticleId IdType="doi">10.1177/20480040251352901</ArticleId><ArticleId IdType="pii">10.1177_20480040251352901</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Knight M, Bunch K, Felker A, et al. (eds.) Saving Lives, Improving Mothers&#x2019; Care Core Report &#x2013; Lessons learned to inform maternity care from the UK and Ireland Confidential Enquiries into Maternal Deaths and Morbidity 2019-21. Oxford: National Perinatal Epidemiology Unit, University of Oxford, 2023. On behalf of MBRRACE-UK.</Citation></Reference><Reference><Citation>Centers for Disease Control and Prevention. Pregnancy mortality surveillance system. https://www.cdc.gov/maternal-mortality/php/pregnancy-mortality-surveillance/index.html, 2024. Accessed: 2024-08-13.</Citation></Reference><Reference><Citation>Knight M, Bunch K, Tuffnell D, et al. (eds.) Saving Lives, Improving Mothers&#x2019; Care- Lessons learned to inform maternity care from the UK and Ireland Confidential Enquiries into Maternal Deaths and Morbidity 2015-17. Oxford: National Perinatal Epidemiology Unit, University of Oxford, 2019, pp.5&#x2013;44. On behalf of MBRRACE-UK.</Citation></Reference><Reference><Citation>Mehta LS, Warnes CA, Bradley E, et al. Cardiovascular considerations in caring for pregnant patients: a scientific statement from the American Heart Association. Circulation 2020; 141: 884&#x2013;897.</Citation><ArticleIdList><ArticleId IdType="pubmed">32362133</ArticleId></ArticleIdList></Reference><Reference><Citation>Arbelo E, Protonotarios A, Gimeno JR, et al. ESC Guidelines for the management of cardiomyopathies. Eur Heart J 2023; 44: 3503&#x2013;3626.</Citation><ArticleIdList><ArticleId IdType="pubmed">37622657</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis MB, Arany Z, McNamara DM, et al. Peripartum cardiomyopathy. J Am Coll Cardiol 2020; 75: 207&#x2013;221.</Citation><ArticleIdList><ArticleId IdType="pubmed">31948651</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruys TPE, Roos-Hesselink JW, Hall R, et al. Heart failure in pregnant women with cardiac disease: data from the ROPAC. Heart 2014; 100: 231&#x2013;238.</Citation><ArticleIdList><ArticleId IdType="pubmed">24293523</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis MB, Arendt K, Bello NA, et al. Team-Based care of women with cardiovascular disease from Pre-conception through pregnancy and postpartum. J Am Coll Cardiol 2021; 77: 1763&#x2013;1777.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8238394</ArticleId><ArticleId IdType="pubmed">33832604</ArticleId></ArticleIdList></Reference><Reference><Citation>Silversides CK, Grewal J, Mason J, et al. Pregnancy outcomes in women with heart disease. J Am Coll Cardiol 2018; 71: 2419&#x2013;2430.</Citation><ArticleIdList><ArticleId IdType="pubmed">29793631</ArticleId></ArticleIdList></Reference><Reference><Citation>Roos-Hesselink JW. The Task Force for the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC), 2018.</Citation></Reference><Reference><Citation>Park K, Bairey Merz CN, Bello NA, et al. Management of women with acquired cardiovascular disease from Pre-conception through pregnancy and postpartum. J Am Coll Cardiol 2021; 77: 1799&#x2013;1812.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8061780</ArticleId><ArticleId IdType="pubmed">33832606</ArticleId></ArticleIdList></Reference><Reference><Citation>McDonagh T, Metra M, Adamo M, et al. 
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the heart failure association (HFA) of the ESC. Eur Heart J, 2021; 42: 3599&#x2013;3726, August 2021. eprint: https://academic.oup.com/eurheartj/article-pdf/42/36/3599/40594787/ehab368.pdf.
</Citation></Reference><Reference><Citation>Meah VL, Cockcroft JR, Backx K, et al. Cardiac output and related haemodynamics during pregnancy: a series of meta-analyses. Heart 2016; 102: 518&#x2013;526.</Citation><ArticleIdList><ArticleId IdType="pubmed">26794234</ArticleId></ArticleIdList></Reference><Reference><Citation>Bauersachs J, Konig T, Van Der Meer P, et al. Pathophysiology, diagnosis and management of peripartum cardiomyopathy: a position statement from the heart failure association of the European Society of Cardiology study group on peripartum cardiomyopathy. Eur J Heart Fail 2019; 21: 827&#x2013;843.</Citation><ArticleIdList><ArticleId IdType="pubmed">31243866</ArticleId></ArticleIdList></Reference><Reference><Citation>Schaufelberger M. Cardiomyopathy and pregnancy. Heart 2019; 105: 1543&#x2013;1551.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6839719</ArticleId><ArticleId IdType="pubmed">31308064</ArticleId></ArticleIdList></Reference><Reference><Citation>Grewal J, Siu SC, Ross HJ, et al. Pregnancy outcomes in women with dilated cardiomyopathy. J Am Coll Cardiol 2009; 55: 45&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">20117363</ArticleId></ArticleIdList></Reference><Reference><Citation>Grewal J, Siu SC, Lee T, et al. Impact of Beta-blockers on birth weight in a high-risk cohort of pregnant women with CVD. J Am Coll Cardiol 2020; 75: 2751&#x2013;2752.</Citation><ArticleIdList><ArticleId IdType="pubmed">32466893</ArticleId></ArticleIdList></Reference><Reference><Citation>Sliwa K, Petrie MC, Hilfiker-Kleiner D, et al. Long-term prognosis, subsequent pregnancy, contraception and overall management of peripartum cardiomyopathy: practical guidance paper from the heart failure association of the European Society of Cardiology study group on peripartum cardiomyopathy. Eur J Heart Fail 2018; 20: 951&#x2013;962.</Citation><ArticleIdList><ArticleId IdType="pubmed">29578284</ArticleId></ArticleIdList></Reference><Reference><Citation>Goli R, Li J, Brandimarto J, et al. Genetic and phenotypic landscape of peripartum cardiomyopathy. Circulation 2021; 143: 1852&#x2013;1862.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8113098</ArticleId><ArticleId IdType="pubmed">33874732</ArticleId></ArticleIdList></Reference><Reference><Citation>Sliwa K, Petrie MC, Van Der Meer P, et al. Clinical presentation, management, and 6-month outcomes in women with peripartum cardiomyopathy: an ESC EORP registry. Eur Heart J 2020; 41: 3787&#x2013;3797.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7846090</ArticleId><ArticleId IdType="pubmed">32840318</ArticleId></ArticleIdList></Reference><Reference><Citation>Goland S, Modi K, Bitar F, et al. Clinical profile and predictors of complications in peripartum cardiomyopathy. J Card Fail 2009; 15: 645&#x2013;650.</Citation><ArticleIdList><ArticleId IdType="pubmed">19786252</ArticleId></ArticleIdList></Reference><Reference><Citation>McNamara DM, Elkayam U, Alharethi R, et al. Clinical outcomes for peripartum cardiomyopathy in North America. J Am Coll Cardiol 2015; 66: 905&#x2013;914.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5645077</ArticleId><ArticleId IdType="pubmed">26293760</ArticleId></ArticleIdList></Reference><Reference><Citation>Sliwa K, Mebazaa A, Hilfiker-Kleiner D, et al. Clinical characteristics of patients from the worldwide registry on peripartum cardiomyopathy research programme in conjunction with the heart failure association of the European Society of Cardiology study group on PPCM. Eur J Heart Fail 2017; 19: 1131&#x2013;1141.</Citation><ArticleIdList><ArticleId IdType="pubmed">28271625</ArticleId></ArticleIdList></Reference><Reference><Citation>Goland S, Van Hagen I, Elbaz-Greener G, et al. Pregnancy in women with hypertrophic cardiomyopathy: data from the European Society of Cardiology initiated registry of pregnancy and cardiac disease (ROPAC). Eur Heart J 2017; 38: 2683&#x2013;2690.</Citation><ArticleIdList><ArticleId IdType="pubmed">28934836</ArticleId></ArticleIdList></Reference><Reference><Citation>Schinkel AF. Pregnancy in women with hypertrophic cardiomyopathy. Cardiol Rev 2014; 22: 217&#x2013;222.</Citation><ArticleIdList><ArticleId IdType="pubmed">25093741</ArticleId></ArticleIdList></Reference><Reference><Citation>Hodes AR, Tichnell C, Te Riele ASJM, et al. Pregnancy course and outcomes in women with arrhythmogenic right ventricular cardiomyopathy. Heart 2016; 102: 303&#x2013;312.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4752646</ArticleId><ArticleId IdType="pubmed">26719359</ArticleId></ArticleIdList></Reference><Reference><Citation>Briller JE, Mogos MF, Muchira JM, et al. Pregnancy associated heart failure with preserved ejection fraction: risk factors and maternal morbidity. J Card Fail 2021; 27: 143&#x2013;152.</Citation><ArticleIdList><ArticleId IdType="pubmed">33388469</ArticleId></ArticleIdList></Reference><Reference><Citation>Ueda Y, Kamiya CA, Nakanishi A, et al. Cardiomyopathy phenotypes and pregnancy outcomes with left ventricular noncompaction cardiomyopathy: three cases and a literature review. Int Heart J 2018; 59: 862&#x2013;867.</Citation><ArticleIdList><ArticleId IdType="pubmed">29794382</ArticleId></ArticleIdList></Reference><Reference><Citation>Falconi S, Okimi A, Wesley S, et al. The concentration of maternal sacubitril/valsartan transferred into human milk is negligible. Front Public Health 2024; 12: 1389513.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11150817</ArticleId><ArticleId IdType="pubmed">38841677</ArticleId></ArticleIdList></Reference><Reference><Citation>Muller DRP, Stenvers DJ, Malekzadeh A, et al. Effects of GLP-1 agonists and SGLT2 inhibitors during pregnancy and lactation on offspring outcomes: a systematic review of the evidence. Front Endocrinol (Lausanne) 2023; 14: 1215356.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10597691</ArticleId><ArticleId IdType="pubmed">37881498</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40673582</PMID><DateCompleted><Year>2025</Year><Month>08</Month><Day>06</Day></DateCompleted><DateRevised><Year>2025</Year><Month>08</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2047-9980</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>15</Issue><PubDate><Year>2025</Year><Month>Aug</Month><Day>05</Day></PubDate></JournalIssue><Title>Journal of the American Heart Association</Title><ISOAbbreviation>J Am Heart Assoc</ISOAbbreviation></Journal><ArticleTitle>Association of Cognitive Impairment With Evolution of Heart Failure.</ArticleTitle><Pagination><StartPage>e039697</StartPage><MedlinePgn>e039697</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1161/JAHA.124.039697</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">While many studies have suggested that heart failure (HF) may lead to cognitive impairment, our understanding about this relationship is limited. This study investigated the association of cognitive function with HF risk factors and how cognitive impairment may impact the development of incident clinical HF in people with subclinical HF.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">People with either preclinical (at risk and asymptomatic, n=814) or clinical (symptomatic, n=1152) HF were recruited from communities, clinics, and hospitals in 5 Australian states (Victoria, New South Wales, South Australia, Tasmania, and Queensland). Cognitive impairment was measured with the Montreal Cognitive Assessment (MOCA &lt;26). Left ventricular dysfunction was assessed as global longitudinal strain (&lt;16%). Patients with preclinical HF were followed up for 45&#xb1;13&#x2009;months for incident clinical HF or death.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Baseline MOCA was independently associated with age, HF stage, diabetes, atrial fibrillation, chronic lung disease, cerebrovascular disease, global longitudinal strain, left atrial volume index, and left ventricular filling pressure. Cognitive impairment significantly increased the associations of age (interaction <i>P</i>&lt;0.001), comorbidity index (interaction&lt;0.001), and global longitudinal strain (interaction <i>P</i>=0.042) with clinical HF. Of patients with preclinical HF at baseline, 71 (9%) developed clinical HF and 87 (11%) died within the follow-up period. In time-to-event analysis of participants with preclinical HF, those with either cognitive impairment or left ventricular dysfunction had double the risk of developing clinical HF, compared with those with normal cognition and left ventricular function. Those with concomitant cognitive impairment and left ventricular dysfunction had a 4-fold greater risk of developing HF (subdistribution hazard ratio, 4.01 [95% CI, 2.39-6.76]).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Cognitive impairment is associated with increased risk of incident clinical HF, independent of cardiac function and other HF risk factors.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Huynh</LastName><ForeName>Quan</ForeName><Initials>Q</Initials><Identifier Source="ORCID">0000-0003-1368-5160</Identifier><AffiliationInfo><Affiliation>Baker Heart and Diabetes Research Institute Melbourne Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Menzies Institute for Medical Research University of Tasmania Hobart Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haji</LastName><ForeName>Kawa</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Baker Heart and Diabetes Research Institute Melbourne Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DePasquale</LastName><ForeName>Carmine G</ForeName><Initials>CG</Initials><Identifier Source="ORCID">0000-0001-5025-6117</Identifier><AffiliationInfo><Affiliation>Cardiac Services Flinders Medical Centre Adelaide Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hare</LastName><ForeName>James L</ForeName><Initials>JL</Initials><Identifier Source="ORCID">0000-0001-6438-1867</Identifier><AffiliationInfo><Affiliation>Baker Heart and Diabetes Research Institute Melbourne Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leung</LastName><ForeName>Dominic</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-5626-7236</Identifier><AffiliationInfo><Affiliation>Faculty of Medicine University of New South Wales Sydney Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stanton</LastName><ForeName>Tony</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>School of Medicine University of Queensland Brisbane Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marwick</LastName><ForeName>Thomas H</ForeName><Initials>TH</Initials><Identifier Source="ORCID">0000-0001-9065-0899</Identifier><AffiliationInfo><Affiliation>Baker Heart and Diabetes Research Institute Melbourne Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Menzies Institute for Medical Research University of Tasmania Hobart Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Am Heart Assoc</MedlineTA><NlmUniqueID>101580524</NlmUniqueID><ISSNLinking>2047-9980</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001315" MajorTopicYN="N" Type="Geographic">Australia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="Y">Cognition</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="Y">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006333" MajorTopicYN="Y">Heart Failure</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018487" MajorTopicYN="N">Ventricular Dysfunction, Left</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016277" MajorTopicYN="N">Ventricular Function, Left</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cardiac dysfunction</Keyword><Keyword MajorTopicYN="N">cognition</Keyword><Keyword MajorTopicYN="N">heart failure</Keyword><Keyword MajorTopicYN="N">outcomes</Keyword><Keyword MajorTopicYN="N">postdischarge</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>6</Day><Hour>6</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>17</Day><Hour>12</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>17</Day><Hour>8</Hour><Minute>26</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40673582</ArticleId><ArticleId IdType="doi">10.1161/JAHA.124.039697</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40692989</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0970-9134</ISSN><JournalIssue CitedMedium="Print"><Volume>41</Volume><Issue>8</Issue><PubDate><Year>2025</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Indian journal of thoracic and cardiovascular surgery</Title><ISOAbbreviation>Indian J Thorac Cardiovasc Surg</ISOAbbreviation></Journal><ArticleTitle>E-CPR: coming back to life.</ArticleTitle><Pagination><StartPage>1033</StartPage><EndPage>1035</EndPage><MedlinePgn>1033-1035</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s12055-025-01905-y</ELocationID><Abstract><AbstractText>Extracorporeal cardiopulmonary resuscitation (E-CPR) employs rapid venoarterial extracorporeal membrane oxygenation (VA-ECMO) during cardiopulmonary resuscitation (CPR) to restore perfusion. This case involves a 3.5-month-old girl with anomalous left coronary artery from the pulmonary artery (ALCAPA), severe left ventricular dysfunction, and moderate mitral regurgitation. After surgical correction, she experienced cardiac arrest post-extubation. Conventional CPR failed, and E-CPR was initiated after 70&#xa0;min. Hemodynamic stability and end-organ function were maintained during 72&#xa0;h and 45&#xa0;min on ECMO. Post-decannulation, she showed significant recovery, normal neurological status, and improved cardiac function. At 6&#xa0;months post discharge, her left ventricular function was normalized.</AbstractText><CopyrightInformation>&#xa9; Indian Association of Cardiovascular-Thoracic Surgeons 2025. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Das</LastName><ForeName>Shubhadeep</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-1996-2800</Identifier><AffiliationInfo><Affiliation>Pediatric Cardiac Intensive Care Unit, Narayana Superspeciality Hospital, Howrah, West Bengal India.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Kolkata, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Das</LastName><ForeName>Debasis</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Depertment of Cardiac Surgery, Narayana Superspeciality Hospital, Howrah, West Bengal India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dutta</LastName><ForeName>Nilanjan</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Depertment of Cardiac Surgery, NH Narayana Superspeciality Hospital, Howrah, West Bengal India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sharma</LastName><ForeName>Manish Kumar</ForeName><Initials>MK</Initials><AffiliationInfo><Affiliation>Depertment of Cardiac Anesthesiology, NH Narayana Superspeciality Hospital, Howrah, West Bengal India.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>02</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>India</Country><MedlineTA>Indian J Thorac Cardiovasc Surg</MedlineTA><NlmUniqueID>8700105</NlmUniqueID><ISSNLinking>0970-9134</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALCAPA</Keyword><Keyword MajorTopicYN="N">E-CPR</Keyword><Keyword MajorTopicYN="N">ECMO</Keyword></KeywordList><CoiStatement>Conflict of interestThere is no conflict of interest among the authors.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>9</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>1</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>1</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2026</Year><Month>8</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>22</Day><Hour>6</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>22</Day><Hour>6</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>22</Day><Hour>4</Hour><Minute>44</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40692989</ArticleId><ArticleId IdType="pmc">PMC12276148</ArticleId><ArticleId IdType="doi">10.1007/s12055-025-01905-y</ArticleId><ArticleId IdType="pii">1905</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Conrad SA, Rycus PT. Extracorporeal membrane oxygenation for refractory cardiac arrest. Ann Card Anaesth. 2017;20:S4&#x2013;10. 10.4103/0971-9784.197790.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5299827</ArticleId><ArticleId IdType="pubmed">28074817</ArticleId></ArticleIdList></Reference><Reference><Citation>Lasa JJ, Rogers RS, Localio R, Shults J, Raymond T, Gaies M, et al. extracorporeal cardiopulmonary resuscitation (E-CPR) during pediatric in-hospital cardiopulmonary arrest is associated with improved survival to discharge: a report from the American Heart Association&#x2019;s Get With The Guidelines-Resuscitation (GWTG-R) Registry. Circulation. 2016;133:165&#x2013;76. 10.1161/CIRCULATIONAHA.115.016082.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4814337</ArticleId><ArticleId IdType="pubmed">26635402</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer-Macaulay C, Rosen D. Paediatric extracorporeal membrane oxygenation and extracorporeal cardiopulmonary resuscitation. BJA Educ. 2018;18:153&#x2013;7. 10.1016/j.bjae.2017.12.003.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7807934</ArticleId><ArticleId IdType="pubmed">33456826</ArticleId></ArticleIdList></Reference><Reference><Citation>Duff JP, Topjian AA, Berg MD, Chan M, Haskell SE, Joyner BL Jr, et al. American Heart Association focused update on pediatric advanced life support: an update to the American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care.&#xa0;Circulation. 2019;140:e904&#x2013;14. 10.1161/CIR.0000000000000731.</Citation><ArticleIdList><ArticleId IdType="pubmed">31722551</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujji Y, Kasahara S, Kanki K, Mitsui H, Ishino K, Sano S. Successful Intra-postoperative extracorporeal circulatory support with atrial communication for treatment of anomalous left coronary artery from the pulmonary artery: a case report. Acta Med Okayama. 2007;61:41&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">17332841</ArticleId></ArticleIdList></Reference><Reference><Citation>Chauhan S, Malik M, Malik V, Chauhan Y, Kiran U, Bisoi AK. Extracorporeal membrane oxygenation after pediatric cardiac surgery: a 10 year experience. Ann Card Anaesth. 2011;14:19&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">21196670</ArticleId></ArticleIdList></Reference><Reference><Citation>Selected abstracts presented at the annual conference of the paediatric cardiac society of India 2012. Development of the AIIMS integrated CPB&#x2013;ECMO. Ann Pediatr Cardiol. 2013;6:105&#x2013;8.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40697207</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>25</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1878-5409</ISSN><JournalIssue CitedMedium="Internet"><Volume>32</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Journal of cardiology cases</Title><ISOAbbreviation>J Cardiol Cases</ISOAbbreviation></Journal><ArticleTitle>A case of heart failure due to multiple late complications after repair of tetralogy of Fallot in adulthood.</ArticleTitle><Pagination><StartPage>23</StartPage><EndPage>26</EndPage><MedlinePgn>23-26</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jccase.2025.03.010</ELocationID><Abstract><AbstractText Label="UNLABELLED">The prognosis of tetralogy of Fallot (TOF) has improved in recent years, but complications in the late postoperative period remain a serious problem. These complications, combined with specific hemodynamic and structural abnormalities, make it difficult to determine the optimal treatment plan. A man in his early 60s had been diagnosed with TOF in his early teens; he had undergone ventricular septal defect closure and right ventricular outflow tract repair in his mid-20s. Approximately 40&#x202f;years after surgery, he was referred to our hospital because of worsening heart failure due to moderate aortic regurgitation with left ventricular dysfunction caused by a residual ventricular septal defect, marked continuous right ventricular dilation and dysfunction, and severe pulmonary and tricuspid regurgitation. The patient had clearly missed the optimal time for surgery and had a high surgical risk score. After the patient had been provided sufficient information regarding treatment and risks, he underwent pulmonary and aortic valve replacement, tricuspid annuloplasty, and shunt closure. No obvious perioperative complications were observed, and the heart failure had remained stable for 4&#x202f;years following reoperation. We report this complicated case of TOF repaired in adulthood with marked biventricular remodeling, associated with a residual shunt and progression of valvular disease.</AbstractText><AbstractText Label="LEARNING OBJECTIVE" NlmCategory="UNASSIGNED">Surgical interventions for the multiple complications that occur during the long-term course after TOF repair, particularly in the context of right ventricular remodeling, may be associated with risks. In the field of adult congenital heart disease, rather than applying a single cut-off to determine the optimal timing for intervention, clinicians should consider factors such as the patients' age, sex, and other individual characteristics, paying particular attention to the hemodynamic status.</AbstractText><CopyrightInformation>&#xa9; 2025 Japanese College of Cardiology. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Goten</LastName><ForeName>Chiaki</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Kanazawa University, Kanazawa, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Usui</LastName><ForeName>Soichiro</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Kanazawa University, Kanazawa, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takatori</LastName><ForeName>Osamu</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Tonami General Hospital, Tonami, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sakata</LastName><ForeName>Kenji</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Kanazawa University, Kanazawa, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murata</LastName><ForeName>Akira</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Thoracic, Cardiovascular and General Surgery, Kanazawa University, Kanazawa, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takemura</LastName><ForeName>Hirofumi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Thoracic, Cardiovascular and General Surgery, Kanazawa University, Kanazawa, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takamura</LastName><ForeName>Masayuki</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Kanazawa University, Kanazawa, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>04</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>Japan</Country><MedlineTA>J Cardiol Cases</MedlineTA><NlmUniqueID>101549579</NlmUniqueID><ISSNLinking>1878-5409</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Pulmonic regurgitation</Keyword><Keyword MajorTopicYN="N">Residual ventricular septal defect</Keyword><Keyword MajorTopicYN="N">Right ventricular end-diastolic volume index</Keyword><Keyword MajorTopicYN="N">Tetralogy of Fallot</Keyword></KeywordList><CoiStatement>The authors declare that they have no conflict of interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>3</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>3</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>23</Day><Hour>11</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>23</Day><Hour>11</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>23</Day><Hour>4</Hour><Minute>53</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>4</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40697207</ArticleId><ArticleId IdType="pmc">PMC12277615</ArticleId><ArticleId IdType="doi">10.1016/j.jccase.2025.03.010</ArticleId><ArticleId IdType="pii">S1878-5409(25)00029-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cuypers J.A., Menting M.E., Konings E.E., Opic P., Utens E.M., Helbing W.A., et al. Unnatural history of tetralogy of Fallot: prospective follow-up of 40 years after surgical correction. Circulation. 2014;130:1944&#x2013;1953.</Citation><ArticleIdList><ArticleId IdType="pubmed">25341442</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizuno A., Niwa K., Matsuo K., Kawada M., Miyazaki A., Mori Y., et al. Survey of reoperation indications in tetralogy of Fallot in Japan. Circ J. 2013;77:2942&#x2013;2947.</Citation><ArticleIdList><ArticleId IdType="pubmed">24042321</ArticleId></ArticleIdList></Reference><Reference><Citation>Gatzoulis M.A., Balaji S., Webber S.A., Siu S.C., Hokanson J.S., Poile C., et al. Risk factors for arrhythmia and sudden cardiac death late after repair of tetralogy of Fallot: a multicentre study. Lancet. 2000;356:975&#x2013;981.</Citation><ArticleIdList><ArticleId IdType="pubmed">11041398</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghonim S., Gatzoulis M.A., Ernst S., Li W., Moon J.C., Smith G.C., et al. Predicting survival in repaired tetralogy of Fallot: a lesion-specific and personalized approach. JACC Cardiovasc Imaging. 2022;15:257&#x2013;268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8821017</ArticleId><ArticleId IdType="pubmed">34656466</ArticleId></ArticleIdList></Reference><Reference><Citation>Oosterhof T., van Straten A., Vliegen H.W., Meijboom F.J., van Dijk A.P., Spijkerboer A.M., et al. Preoperative thresholds for pulmonary valve replacement in patients with corrected tetralogy of Fallot using cardiovascular magnetic resonance. Circulation. 2007;116:545&#x2013;551.</Citation><ArticleIdList><ArticleId IdType="pubmed">17620511</ArticleId></ArticleIdList></Reference><Reference><Citation>Therrien J., Provost Y., Merchant N., Williams W., Colman J., Webb G. Optimal timing for pulmonary valve replacement in adults after tetralogy of Fallot repair. Am J Cardiol. 2005;95:779&#x2013;782.</Citation><ArticleIdList><ArticleId IdType="pubmed">15757612</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40697203</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>25</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1878-5409</ISSN><JournalIssue CitedMedium="Internet"><Volume>32</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Journal of cardiology cases</Title><ISOAbbreviation>J Cardiol Cases</ISOAbbreviation></Journal><ArticleTitle>A case of congenital type 1 long QT syndrome which developed electrical storm with myocarditis.</ArticleTitle><Pagination><StartPage>27</StartPage><EndPage>30</EndPage><MedlinePgn>27-30</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jccase.2025.03.009</ELocationID><Abstract><AbstractText Label="UNLABELLED">This case report presents a 39-year-old woman with congenital type 1 long QT syndrome (LQT1) who was transported to the hospital after syncope. She had no previous history of syncope or ventricular fibrillation, but had a family history of LQT1 without sudden death. On arrival, she had regained consciousness with stable vital signs, although she reported cold symptoms starting a week previously. An electrocardiogram showed a prolonged QTc interval of 618&#x202f;ms, and echocardiography revealed severe left ventricular dysfunction with an ejection fraction (EF) of approximately 15&#x202f;%. She suddenly developed torsades de pointes and lost consciousness again, progressing to an electrical storm requiring repeated defibrillation. Emergency coronary angiography showed no stenosis, and right heart catheterization revealed hemodynamic parameters consistent with Forrester classification III. A myocardial biopsy from the right ventricular septum was performed due to suspected myocarditis. Treatment included sedation, mechanical ventilation, catecholamines, and intra-aortic balloon pump, stabilizing her hemodynamics. Pathological findings confirmed inflammatory cell infiltration in the myocardium. Her EF returned to normal within approximately two weeks. This report discusses an unusual case of electrical storm in LQT1 triggered by myocarditis, with a full recovery achieved.</AbstractText><AbstractText Label="LEARNING OBJECTIVE" NlmCategory="UNASSIGNED">This case emphasizes that careful management is required for patients with type 1 long QT (LQT1) syndrome. Despite guideline-based management, this case developed an electrical storm triggered by myocarditis as a cardiac event. This case suggests the need to re-evaluate the implantable cardioverter defibrillator implantation criteria for high-risk LQT1 cases.</AbstractText><CopyrightInformation>&#xa9; 2025 Japanese College of Cardiology. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yamada</LastName><ForeName>Shugo</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Cardiology, International University of Health and Welfare Hospital, Tochigi, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ikeda</LastName><ForeName>Shohei</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Cardiology, International University of Health and Welfare Hospital, Tochigi, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sato</LastName><ForeName>Koichi</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Cardiology, International University of Health and Welfare Hospital, Tochigi, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shinozaki</LastName><ForeName>Mariko</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cardiology, International University of Health and Welfare Hospital, Tochigi, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miki</LastName><ForeName>Keita</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Cardiology, International University of Health and Welfare Hospital, Tochigi, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hirano</LastName><ForeName>Michinori</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cardiology, International University of Health and Welfare Hospital, Tochigi, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fukuda</LastName><ForeName>Koji</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Cardiology, International University of Health and Welfare Hospital, Tochigi, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takeda</LastName><ForeName>Morihiko</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cardiology, International University of Health and Welfare Hospital, Tochigi, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>04</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>Japan</Country><MedlineTA>J Cardiol Cases</MedlineTA><NlmUniqueID>101549579</NlmUniqueID><ISSNLinking>1878-5409</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Electrical storm</Keyword><Keyword MajorTopicYN="N">Long QT syndrome</Keyword><Keyword MajorTopicYN="N">Myocarditis</Keyword></KeywordList><CoiStatement>The authors declare that there is no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>11</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>3</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>3</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>23</Day><Hour>11</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>23</Day><Hour>11</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>23</Day><Hour>4</Hour><Minute>53</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>4</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40697203</ArticleId><ArticleId IdType="pmc">PMC12277598</ArticleId><ArticleId IdType="doi">10.1016/j.jccase.2025.03.009</ArticleId><ArticleId IdType="pii">S1878-5409(25)00028-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wilde A.A.M., Amin A.S., Postema P.G. Diagnosis, management and therapeutic strategies for congenital long QT syndrome. Heart. 2022;108:332&#x2013;338.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8862104</ArticleId><ArticleId IdType="pubmed">34039680</ArticleId></ArticleIdList></Reference><Reference><Citation>Napolitano C., Priori S.G., Schwartz P.J., Bloise R., Ronchetti E., Nastoli J., Bottelli G., Cerrone M., Leonardi S. Genetic testing in the long QT syndrome: development and validation of an efficient approach to genotyping in clinical practice. JAMA. 2005;294:2975&#x2013;2980.</Citation><ArticleIdList><ArticleId IdType="pubmed">16414944</ArticleId></ArticleIdList></Reference><Reference><Citation>Moss A.J., Shimizu W., Wilde A.A., Towbin J.A., Zareba W., Robinson J.L., Qi M., Vincent G.M., Ackerman M.J., Kaufman E.S., Hofman N., Seth R., Kamakura S., Miyamoto Y., Goldenberg I., et al. Clinical aspects of type-1 long-QT syndrome by location, coding type, and biophysical function of mutations involving the KCNQ1 gene. Circulation. 2007;115:2481&#x2013;2489.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3332528</ArticleId><ArticleId IdType="pubmed">17470695</ArticleId></ArticleIdList></Reference><Reference><Citation>Takase B., Ikeda T., Shimizu W., Abe H., Aiba T., Chinushi M., Koba S., Kusano K., Niwano S., Takahashi N., Takatsuki S., Tanno K., Watanabe E., Yoshioka K., Kurita Y., et al. JCS/JHRS 2022 Guideline on diagnosis and risk assessment of arrhythmia. Circ J. 2024;88:1509&#x2013;1595.</Citation><ArticleIdList><ArticleId IdType="pubmed">37690816</ArticleId></ArticleIdList></Reference><Reference><Citation>Priori S.G., Schwartz P.J., Napolitano C., Bloise R., Ronchetti E., Grillo M., Vicentini A., Spazzolini C., Nastoli J., Bottelli G., Folli R., Cappelletti D. Risk stratification in the long-QT syndrome. N Engl J Med. 2003;348:1866&#x2013;1874.</Citation><ArticleIdList><ArticleId IdType="pubmed">12736279</ArticleId></ArticleIdList></Reference><Reference><Citation>Ukena C., Mahfoud F., Kindermann I., Kandolf R., Kindermann M., B&#xf6;hm M. Prognostic electrocardiographic parameters in patients with suspected myocarditis. Eur J Heart Fail. 2011;13:398&#x2013;405.</Citation><ArticleIdList><ArticleId IdType="pubmed">21239404</ArticleId></ArticleIdList></Reference><Reference><Citation>Hung Y., Lin W.H., Lin C.S., Cheng S.M., Tsai T.N., Yang S.P., Lin W.Y. The prognostic role of QTc interval in acute myocarditis. Acta Cardiol Sin. 2016;32:223&#x2013;230.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4816921</ArticleId><ArticleId IdType="pubmed">27122953</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40697957</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>25</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2589-5370</ISSN><JournalIssue CitedMedium="Internet"><Volume>86</Volume><PubDate><Year>2025</Year><Month>Aug</Month></PubDate></JournalIssue><Title>EClinicalMedicine</Title><ISOAbbreviation>EClinicalMedicine</ISOAbbreviation></Journal><ArticleTitle>Contemporary medical therapy, sex-specific characteristics, and outcomes of patients with non-ischemic cardiomyopathy: a prespecified interim analysis of the BIO-LIBRA study.</ArticleTitle><Pagination><StartPage>103337</StartPage><MedlinePgn>103337</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">103337</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.eclinm.2025.103337</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Contemporary data on characteristics, medical therapy, and outcomes in non-ischemic cardiomyopathy (NICM) with implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy defibrillator (CRT-D) are lacking, and the role of sex remains unexplored due to historical low enrollment of females in device trials. The purpose of this pre-specified interim analysis of the BIO-LIBRA study was to assess characteristics, medical therapy, and ventricular tachyarrhythmias (VT/VF) or mortality at 12 months in NICM patients with ICD or CRT-D, by sex.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">In this multicenter, prospective, registry study, we recruited patients with primary prevention ICD or CRT-Ds with Home Monitoring&#xae;, aiming for 40% female enrollment, utilizing specific recruitment tools. Patients were assessed for the primary endpoint of device-treated VT or VF every 6 months. This study is registered with ClinicalTrials.gov (NCT03884608).</AbstractText><AbstractText Label="FINDINGS" NlmCategory="UNASSIGNED">From May 9, 2019 to October 1, 2021, we enrolled 1000 patients, including 475 (47.5%) females, 30.4% non-white, and 9.2% Hispanic/Latino patients. Beta-blockers were prescribed in 92%, ACE-Inhibitor/ARB in 80%, ARNI in 39%, and SGLT2 in 6% at enrollment with increase in SGLT2 use over time. Diuretics were more frequently prescribed in females. Females had a 52% lower risk of VT/VF or death as compared to men through 12 months (HR = 0.49, 95% CI: 0.31-0.78, p = 0.003), driven by a 54% lower risk of VT/VF (HR = 0.46, 95% CI: 0.25-0.85, p = 0.003), even after adjustments for LVEF or QRS duration. No significant differences were reported by ICD vs. CRT-D.</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="UNASSIGNED">In a contemporary cohort of patients with NICM and ICD/CRT-D, we report an increased enrollment of females and minorities, an increase in the use of novel guideline-directed medical therapy (GDMT) over time, and a lower risk of ventricular arrhythmias or death in females as compared to men at one year.</AbstractText><AbstractText Label="FUNDING" NlmCategory="UNASSIGNED">BIOTRONIK Inc.</AbstractText><CopyrightInformation>&#xa9; 2025 Published by Elsevier Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kutyifa</LastName><ForeName>Valentina</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Clinical Cardiovascular Research Center, University of Rochester, Medical Center, Rochester, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Di Biase</LastName><ForeName>Luigi</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Montefiore Medical Center, Bronx, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prasad</LastName><ForeName>Karthik Venkatesh</ForeName><Initials>KV</Initials><AffiliationInfo><Affiliation>Cardiology Associates Research, Tupelo, MS, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Torres</LastName><ForeName>Vilma</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>University of Florida, Gainesville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hesselson</LastName><ForeName>Aaron</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>University of Kentucky, Lexington, KY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McCotter</LastName><ForeName>Craig J</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>Baptist Health, Lexington, KY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harris</LastName><ForeName>Gregory</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Heart Rhythm Associates, Greenville, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cox</LastName><ForeName>Karlene</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>BIOTRONIK Inc., Lake Oswego, OR, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schleede</LastName><ForeName>Susan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Clinical Cardiovascular Research Center, University of Rochester, Medical Center, Rochester, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heist</LastName><ForeName>E Kevin</ForeName><Initials>EK</Initials><AffiliationInfo><Affiliation>Massachusetts General Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McNitt</LastName><ForeName>Scott</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Clinical Cardiovascular Research Center, University of Rochester, Medical Center, Rochester, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brown</LastName><ForeName>Mary W</ForeName><Initials>MW</Initials><AffiliationInfo><Affiliation>Clinical Cardiovascular Research Center, University of Rochester, Medical Center, Rochester, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Crystal</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>BIOTRONIK Inc., Lake Oswego, OR, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beck</LastName><ForeName>Christopher A</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>Clinical Cardiovascular Research Center, University of Rochester, Medical Center, Rochester, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poole</LastName><ForeName>Jeanne</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>University of Washington, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>BIO-LIBRA Investigators</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT03884608</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>EClinicalMedicine</MedlineTA><NlmUniqueID>101733727</NlmUniqueID><ISSNLinking>2589-5370</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cardiac resynchronization therapy</Keyword><Keyword MajorTopicYN="N">Implantable cardioverter defibrillator</Keyword><Keyword MajorTopicYN="N">Left ventricular dysfunction</Keyword><Keyword MajorTopicYN="N">Sex differences</Keyword><Keyword MajorTopicYN="N">Ventricular tachyarrhythmias</Keyword></KeywordList><CoiStatement>Valentina Kutyifa MD, PhD: research grants from Boston Scientific, BIOTRONIK, NIH, Spire Inc., speaker fee from Medtronic, Abbott Medical, consultant fees from Medtronic, Abbott Medical, Biotronik, PIVATAL NIH trial DSMB, AHA CSSP committee. Luigi Di Biase MD, PhD: consultant for Medtronic, Abbott Medical, Biotronik, Zoll, Boston Scientific, Baylis, Zoll, Biosense Webster, Stereotaxis, I rhythm, Zoll, Atricure and has received speaker honoraria/travel from Medtronic, Abbott Medical, Biotronik, Zoll, Boston Scientific, Baylis, Zoll, Biosense Webster, Stereotaxis, I rhythm, Zoll, Atricure and travel support from Medtronic, Abbott Medical, Biotronik, Zoll, Boston Scientific, Baylis, Zoll, Biosense Webster, Stereotaxis, I rhythm, Zoll, Atricure. Karthik Venkatesh Prasad MD: none. Vilma Torres MD: received consultant fees from Biotronik. Aaron Hesselson MD: payment or honoraria from Medtronic and Abbott. Craig J. McCotter MD: none. Gregory Harris MD: received speaker honoraria/travel from Biotronik. Karlene Cox BS&#x2013;employee of Biotronik Inc. Susan Schleede MS: none. Kevin Heist MD, PhD: consultant: Biotronik, Boston Scientific, and HRS Membership Committee Chair. Scott McNitt MS: none. Mary W. Brown MS: none. Crystal Miller MS&#x2013;employee of Biotronik Inc. Christopher A. Beck PhD: grants from Boston Scientific, BIOTRONIK, NIH. Jeanne Poole MD&#x2013;Research contracts direct to institution from: Biotronik, Boston Scientific, AtriCure, Kestra Medical.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Di Biase</LastName><ForeName>Luigi</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Prasad</LastName><ForeName>Karthik</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Frazier</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Torres</LastName><ForeName>Vilma</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ellison</LastName><ForeName>Kristin</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dukes</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Han</LastName><ForeName>Jihn</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gerczuk</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tomassoni</LastName><ForeName>Gery</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sellers</LastName><ForeName>Matthew</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mela</LastName><ForeName>Theofanie</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mountantonakis</LastName><ForeName>Stavros</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mountantonakis</LastName></Investigator><Investigator ValidYN="Y"><LastName>Frain</LastName><ForeName>Bryan</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pokharel</LastName><ForeName>Parash</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rajsheker</LastName><ForeName>Srinivas</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thomas</LastName><ForeName>George</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brunson</LastName><ForeName>J Matt</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kahaly</LastName><ForeName>Omar</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnston</LastName><ForeName>Samuel</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Garcia</LastName><ForeName>Luis</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Latchamsetty</LastName><ForeName>Rakesh</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Huang</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aziz</LastName><ForeName>Zaid</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rodak</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Samii</LastName><ForeName>Soraya</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hobson</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saxonhouse</LastName><ForeName>Sherry</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shah</LastName><ForeName>Vipul</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Manyam</LastName><ForeName>Harish</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Robichaux</LastName><ForeName>Robert P</ForeName><Initials>RP</Initials><Suffix>Jr</Suffix></Investigator><Investigator ValidYN="Y"><LastName>Pierce</LastName><ForeName>Christopher</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vest</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ngo</LastName><ForeName>Christian</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yarnoz</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bradford</LastName><ForeName>Natalie</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nekkanti</LastName><ForeName>Rajasekhar</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vloka</LastName><ForeName>Margot</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Srivatsa</LastName><ForeName>Uma</ForeName><Initials>U</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bomma</LastName><ForeName>Chandra</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Awad</LastName><ForeName>Khaled</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Iwai</LastName><ForeName>Sei</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rowan</LastName><ForeName>Shane</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sevensma</LastName><ForeName>Matthew</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Drucker</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Okabe</LastName><ForeName>Toshimasa</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ochoa</LastName><ForeName>Anthony</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Feldman</LastName><ForeName>Leon</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Turitto</LastName><ForeName>Gioia</ForeName><Initials>G</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>1</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>6</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>6</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>23</Day><Hour>11</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>23</Day><Hour>11</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>23</Day><Hour>5</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>7</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40697957</ArticleId><ArticleId IdType="pmc">PMC12281065</ArticleId><ArticleId IdType="doi">10.1016/j.eclinm.2025.103337</ArticleId><ArticleId IdType="pii">S2589-5370(25)00269-X</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Epstein A.E., DiMarco J.P., Ellenbogen K.A., et al. 2012 ACCF/AHA/HRS focused update incorporated into the ACCF/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines and the heart rhythm society. J Am Coll Cardiol. 2013;61:e6&#x2013;e75.</Citation><ArticleIdList><ArticleId IdType="pubmed">23265327</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Khatib S.M., Stevenson W.G., Ackerman M.J., et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: executive summary: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the heart rhythm society. Heart Rhythm. 2018;15(10):e73&#x2013;e189. doi: 10.1016/j.hrthm.2017.10.036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.hrthm.2017.10.036</ArticleId><ArticleId IdType="pubmed">29097319</ArticleId></ArticleIdList></Reference><Reference><Citation>Yancy C.W., Jessup M., Bozkurt B., et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013;128:1810&#x2013;1852.</Citation><ArticleIdList><ArticleId IdType="pubmed">23741057</ArticleId></ArticleIdList></Reference><Reference><Citation>Tracy C.M., Epstein A.E., Darbar D., et al. 2012 ACCF/AHA/HRS focused update of the 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Thorac Cardiovasc Surg. 2012;144:e127&#x2013;e145.</Citation><ArticleIdList><ArticleId IdType="pubmed">23140976</ArticleId></ArticleIdList></Reference><Reference><Citation>Epstein A.E., DiMarco J.P., Ellenbogen K.A., et al. ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology/American heart association task force on practice guidelines (writing committee to revise the ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices) developed in collaboration with the American association for thoracic surgery and society of thoracic surgeons. J Am Coll Cardiol. 2008;51:e1&#x2013;e62.</Citation><ArticleIdList><ArticleId IdType="pubmed">18498951</ArticleId></ArticleIdList></Reference><Reference><Citation>Kober L., Thune J.J., Nielsen J.C., et al. Defibrillator implantation in patients with nonischemic systolic heart failure. N Engl J Med. 2016;375:1221&#x2013;1230.</Citation><ArticleIdList><ArticleId IdType="pubmed">27571011</ArticleId></ArticleIdList></Reference><Reference><Citation>Moss A.J., Zareba W., Hall W.J., et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346:877&#x2013;883.</Citation><ArticleIdList><ArticleId IdType="pubmed">11907286</ArticleId></ArticleIdList></Reference><Reference><Citation>Bardy G.H., Lee K.L., Mark D.B., et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352:225&#x2013;237.</Citation><ArticleIdList><ArticleId IdType="pubmed">15659722</ArticleId></ArticleIdList></Reference><Reference><Citation>Herz N.D., Engeda J., Zusterzeel R., et al. Sex differences in device therapy for heart failure: utilization, outcomes, and adverse events. J Wom Health. 2015;24:261&#x2013;271.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4808287</ArticleId><ArticleId IdType="pubmed">25793483</ArticleId></ArticleIdList></Reference><Reference><Citation>Michos E.D., Reddy T.K., Gulati M., et al. Improving the enrollment of women and racially/ethnically diverse populations in cardiovascular clinical trials: an ASPC practice statement. Am J Prev Cardiol. 2021;8</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8408620</ArticleId><ArticleId IdType="pubmed">34485967</ArticleId></ArticleIdList></Reference><Reference><Citation>Segan L.T.K. Gender equity in the EP field: time to ignite the spark. EP Lab Digest. 2022</Citation></Reference><Reference><Citation>Lau E.S., Hayes S.N., Volgman A.S., Lindley K., Pepine C.J., Wood M.J. Does patient-physician gender concordance influence patient perceptions or outcomes? J Am Coll Cardiol. 2021;77:1135&#x2013;1138.</Citation><ArticleIdList><ArticleId IdType="pubmed">33632488</ArticleId></ArticleIdList></Reference><Reference><Citation>Kutyifa V., Brown M.W., Beck C.A., et al. AnaLysIs of Both sex and device specific factoRs on outcomes in pAtients with non-ischemic cardiomyopathy (BIO-LIBRA): design and clinical protocol. Heart Rhythm O2. 2020;1:376&#x2013;384.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8183973</ArticleId><ArticleId IdType="pubmed">34113895</ArticleId></ArticleIdList></Reference><Reference><Citation>Yancy C.W., Jessup M., Bozkurt B., et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the heart failure society of America. J Am Coll Cardiol. 2017;70:776&#x2013;803.</Citation><ArticleIdList><ArticleId IdType="pubmed">28461007</ArticleId></ArticleIdList></Reference><Reference><Citation>Ouellet G., Huang D.T., Moss A.J., et al. Effect of cardiac resynchronization therapy on the risk of first and recurrent ventricular tachyarrhythmic events in MADIT-CRT. J Am Coll Cardiol. 2012;60:1809&#x2013;1816.</Citation><ArticleIdList><ArticleId IdType="pubmed">23040580</ArticleId></ArticleIdList></Reference><Reference><Citation>Barsheshet A., Brenyo A., Goldenberg I., Moss A.J. Sex-related differences in patients' responses to heart failure therapy. Nat Rev Cardiol. 2012;9:234&#x2013;242.</Citation><ArticleIdList><ArticleId IdType="pubmed">22330611</ArticleId></ArticleIdList></Reference><Reference><Citation>Russo A.M., Poole J.E., Mark D.B., et al. Primary prevention with defibrillator therapy in women: results from the sudden cardiac death in heart failure trial. J Cardiovasc Electrophysiol. 2008;19:720&#x2013;724.</Citation><ArticleIdList><ArticleId IdType="pubmed">18373605</ArticleId></ArticleIdList></Reference><Reference><Citation>Barra S., Providencia R., Boveda S., et al. Do women benefit equally as men from the primary prevention implantable cardioverter-defibrillator? Europace. 2018;20(6):897&#x2013;901. doi: 10.1093/europace/eux203.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/europace/eux203</ArticleId><ArticleId IdType="pubmed">29016772</ArticleId></ArticleIdList></Reference><Reference><Citation>Gillis A.M. Atrial fibrillation and ventricular arrhythmias: sex differences in electrophysiology, epidemiology, clinical presentation, and clinical outcomes. Circulation. 2017;135:593&#x2013;608.</Citation><ArticleIdList><ArticleId IdType="pubmed">28153995</ArticleId></ArticleIdList></Reference><Reference><Citation>Russo A.M., Stamato N.J., Lehmann M.H., et al. Influence of gender on arrhythmia characteristics and outcome in the multicenter UnSustained tachycardia trial. J Cardiovasc Electrophysiol. 2004;15:993&#x2013;998.</Citation><ArticleIdList><ArticleId IdType="pubmed">15363069</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen L., Jhund P.S., Petrie M.C., et al. Declining risk of sudden death in heart failure. N Engl J Med. 2017;377:41&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">28679089</ArticleId></ArticleIdList></Reference><Reference><Citation>Escobar-Lopez L., Ochoa J.P., Mirelis J.G., et al. Association of genetic variants with outcomes in patients with nonischemic dilated cardiomyopathy. J Am Coll Cardiol. 2021;78:1682&#x2013;1699.</Citation><ArticleIdList><ArticleId IdType="pubmed">34674813</ArticleId></ArticleIdList></Reference><Reference><Citation>Di-Marco A., Brown P.F., Claver E., et al. Ventricular arrhythmias and sudden death in nonischemic dilated cardiomyopathy: matter of sex or scar? J Card Fail. 2022;28:1278&#x2013;1286.</Citation><ArticleIdList><ArticleId IdType="pubmed">35176484</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirelis J.G., Escobar-Lopez L., Ochoa J.P., et al. Combination of late gadolinium enhancement and genotype improves prediction of prognosis in non-ischaemic dilated cardiomyopathy. Eur J Heart Fail. 2022;24:1183&#x2013;1196.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9546008</ArticleId><ArticleId IdType="pubmed">35485241</ArticleId></ArticleIdList></Reference><Reference><Citation>Poole J.E., Johnson G.W., Hellkamp A.S., et al. Prognostic importance of defibrillator shocks in patients with heart failure. N Engl J Med. 2008;359:1009&#x2013;1017.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2922510</ArticleId><ArticleId IdType="pubmed">18768944</ArticleId></ArticleIdList></Reference><Reference><Citation>Packer D.L., Prutkin J.M., Hellkamp A.S., et al. Impact of implantable cardioverter-defibrillator, amiodarone, and placebo on the mode of death in stable patients with heart failure: analysis from the sudden cardiac death in heart failure trial. Circulation. 2009;120:2170&#x2013;2176.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2922511</ArticleId><ArticleId IdType="pubmed">19917887</ArticleId></ArticleIdList></Reference><Reference><Citation>Arshad A., Moss A.J., Foster E., et al. Cardiac resynchronization therapy is more effective in women than in men: the MADIT-CRT (multicenter automatic defibrillator implantation trial with cardiac resynchronization therapy) trial. J Am Coll Cardiol. 2011;57:813&#x2013;820.</Citation><ArticleIdList><ArticleId IdType="pubmed">21310317</ArticleId></ArticleIdList></Reference><Reference><Citation>Tompkins C.M., Kutyifa V., Arshad A., et al. Sex differences in device therapies for ventricular arrhythmias or death in the multicenter automatic defibrillator implantation trial with cardiac resynchronization therapy (MADIT-CRT) trial. J Cardiovasc Electrophysiol. 2015;26:862&#x2013;871.</Citation><ArticleIdList><ArticleId IdType="pubmed">25929699</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldenberg I., Erath J.W., Russo A.M., et al. Sex differences in arrhythmic burden with the wearable cardioverter-defibrillator. Heart Rhythm. 2021;18:404&#x2013;410.</Citation><ArticleIdList><ArticleId IdType="pubmed">33248269</ArticleId></ArticleIdList></Reference><Reference><Citation>Heidenreich P.A., Bozkurt B., Aguilar D., et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines. Circulation. 2022;145:e876&#x2013;e894.</Citation><ArticleIdList><ArticleId IdType="pubmed">35363500</ArticleId></ArticleIdList></Reference><Reference><Citation>Heidenreich P.A., Bozkurt B., Aguilar D., et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines. J Am Coll Cardiol. 2022;79:1757&#x2013;1780.</Citation><ArticleIdList><ArticleId IdType="pubmed">35379504</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40698376</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>25</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2666-6685</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><PubDate><Year>2025</Year><Month>Sep</Month></PubDate></JournalIssue><Title>International journal of cardiology. Congenital heart disease</Title><ISOAbbreviation>Int J Cardiol Congenit Heart Dis</ISOAbbreviation></Journal><ArticleTitle>Late diagnosis of severe aortic coarctation in a 65-year-old endurance athlete: Insights into exercise physiology and collateral compensation.</ArticleTitle><Pagination><StartPage>100606</StartPage><MedlinePgn>100606</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">100606</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ijcchd.2025.100606</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Coarctation of the aorta (CoA) is a relatively rare congenital narrowing of the distal aortic arch to proximal descending thoracic aorta, usually diagnosed in infancy or early childhood with upper extremity hypertension as a typical finding. Late detection in asymptomatic, physically active older adults is rare and can be clinically significant.</AbstractText><AbstractText Label="CASE PRESENTATION" NlmCategory="UNASSIGNED">We present the case of a 65-year-old lifelong endurance athlete found to have transient severe left ventricular (LV) systolic dysfunction after completing a marathon. Stress testing revealed a hypertensive response, prompting cardiac MRI, which detected a new severe juxta-ductal CoA with collateralization. The patient underwent successful endovascular stenting with improved blood pressure response and stabilization of LV function.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">This case underscores the importance of thorough cardiovascular assessment in older athletes and highlights the impact of lifelong exercise in compensating for congenital defects like CoA.</AbstractText><CopyrightInformation>&#xa9; 2025 The Authors.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sharma</LastName><ForeName>Arundhati</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Mayo Clinic, 13400 E, Shea Blvd, Scottsdale, AZ, 85259, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sharma</LastName><ForeName>Anubhuti</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Mayo Clinic, 13400 E, Shea Blvd, Scottsdale, AZ, 85259, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chaliki</LastName><ForeName>Kalyan</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>The University of Arizona College of Medicine - Phoenix, 475 N 5th St, Phoenix, AZ, 85004, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fernandes</LastName><ForeName>Marco Antonio</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Loyola Marymount University, Loyola Marymount University Dr, Los Angeles, CA, 90045, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marcotte</LastName><ForeName>Francois</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Mayo Clinic, 13400 E, Shea Blvd, Scottsdale, AZ, 85259, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reddy</LastName><ForeName>Satyajit</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Mayo Clinic, 13400 E, Shea Blvd, Scottsdale, AZ, 85259, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>06</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Int J Cardiol Congenit Heart Dis</MedlineTA><NlmUniqueID>9918367981006676</NlmUniqueID><ISSNLinking>2666-6685</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Coarctation of aorta</Keyword><Keyword MajorTopicYN="N">Exertional hypertension</Keyword><Keyword MajorTopicYN="N">Left ventricular dysfunction</Keyword></KeywordList><CoiStatement>The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>6</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>6</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>6</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>23</Day><Hour>11</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>23</Day><Hour>11</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>23</Day><Hour>5</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>6</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40698376</ArticleId><ArticleId IdType="pmc">PMC12281131</ArticleId><ArticleId IdType="doi">10.1016/j.ijcchd.2025.100606</ArticleId><ArticleId IdType="pii">S2666-6685(25)00042-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Strafford M.A., Griffiths S.P., Gerson W.M. Coarctation of the aorta: a study in delayed detection. Pediatrics. 1982;69(2):159&#x2013;163.</Citation><ArticleIdList><ArticleId IdType="pubmed">7058089</ArticleId></ArticleIdList></Reference><Reference><Citation>Grech V. Diagnostic and surgical trends, and epidemiology of coarctation of the aorta in a population-based study. Int J Cardiol. 1999;68(2):197&#x2013;202. doi: 10.1016/s0167-5273(98)00352-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0167-5273(98)00352-0</ArticleId><ArticleId IdType="pubmed">10189008</ArticleId></ArticleIdList></Reference><Reference><Citation>Celik S., Izgi C., Cevik C. Asymptomatic severe aortic coarctation in an 80-year-old man. Texas Heart Institute journal. 2004;31(4):429&#x2013;431.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC548248</ArticleId><ArticleId IdType="pubmed">15745298</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel Y., Jilani M.I., Cho K. Coarctation of the aorta presenting in a 79-year-old male. Thorac Cardiovasc Surg. 1998;46(3):158&#x2013;160. doi: 10.1055/s-2007-1010216.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-2007-1010216</ArticleId><ArticleId IdType="pubmed">9714494</ArticleId></ArticleIdList></Reference><Reference><Citation>Cicek D., Haberal C., Ozkan S., Muderrisoglu H. A severe coarctation of aorta in a 52-year-old male: a case report. Int J Med Sci. 2010;7(6):340&#x2013;341. doi: 10.7150/ijms.7.340.</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/ijms.7.340</ArticleId><ArticleId IdType="pmc">PMC2962261</ArticleId><ArticleId IdType="pubmed">20975843</ArticleId></ArticleIdList></Reference><Reference><Citation>Convens C., Vermeersch P., Paelinck B., Van den Heuvel P., Van den Branden F. Aortic coarctation: a rare and unexpected cause of secondary arterial hypertension in the elderly. Catheter Cardiovasc Diagn. 1996;39(1):71&#x2013;74. doi: 10.1002/(SICI)1097-0304(199609)39:1&lt;71::AID-CCD15&gt;3.0.CO;2-R.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1097-0304(199609)39:1&lt;71::AID-CCD15&gt;3.0.CO;2-R</ArticleId><ArticleId IdType="pubmed">8874951</ArticleId></ArticleIdList></Reference><Reference><Citation>Mir&#xf3; O., Jim&#xe9;nez S., Gonz&#xe1;lez J., De Caralt T.M., Ordi J. Highly effective compensatory mechanisms in a 76-year-old man with a coarctation of the aorta. Cardiology. 1999;92(4):284&#x2013;286. doi: 10.1159/000006989.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000006989</ArticleId><ArticleId IdType="pubmed">10844392</ArticleId></ArticleIdList></Reference><Reference><Citation>Meller S.M., Fahey J.T., Setaro J.F., Forrest J.K. Multi-drug-resistant hypertension caused by severe aortic coarctation presenting in late adulthood. J Clin Hypertens. 2015;17(4):313&#x2013;316. doi: 10.1111/jch.12495.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jch.12495</ArticleId><ArticleId IdType="pmc">PMC8032136</ArticleId><ArticleId IdType="pubmed">25644790</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo W., Li J., Huang X., Cai X. Late diagnosis of coarctation of the aorta in a 44-year-old male: a case report. BMC Cardiovasc Disord. 2020;20(1):470. doi: 10.1186/s12872-020-01753-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12872-020-01753-1</ArticleId><ArticleId IdType="pmc">PMC7607745</ArticleId><ArticleId IdType="pubmed">33143642</ArticleId></ArticleIdList></Reference><Reference><Citation>Liberthson R.R., Pennington D.G., Jacobs M.L., Daggett W.M. Coarctation of the aorta: review of 234 patients and clarification of management problems. Am J Cardiol. 1979;43(4):835&#x2013;840. doi: 10.1016/0002-9149(79)90086-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0002-9149(79)90086-9</ArticleId><ArticleId IdType="pubmed">425922</ArticleId></ArticleIdList></Reference><Reference><Citation>Campbell M. Natural history of coarctation of the aorta. Br Heart J. 1970;32(5):633&#x2013;640. doi: 10.1136/hrt.32.5.633.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/hrt.32.5.633</ArticleId><ArticleId IdType="pmc">PMC487385</ArticleId><ArticleId IdType="pubmed">5470045</ArticleId></ArticleIdList></Reference><Reference><Citation>Nickolay T., Nichols S., Ingle L., Hoye A. Exercise training as a mediator for enhancing coronary collateral circulation: a review of the evidence. Curr Cardiol Rev. 2020;16(3):212&#x2013;220. doi: 10.2174/1573403X15666190819144336.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1573403X15666190819144336</ArticleId><ArticleId IdType="pmc">PMC7536817</ArticleId><ArticleId IdType="pubmed">31424373</ArticleId></ArticleIdList></Reference><Reference><Citation>Roos-Hesselink J.W., Sch&#xf6;lzel B.E., Heijdra R.J., Spitaels S.E., Meijboom F.J., Boersma E., Bogers A.J., Simoons M.L. Aortic valve and aortic arch pathology after coarctation repair. Heart (British Cardiac Society) 2003;89(9):1074&#x2013;1077. doi: 10.1136/heart.89.9.1074.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/heart.89.9.1074</ArticleId><ArticleId IdType="pmc">PMC1767804</ArticleId><ArticleId IdType="pubmed">12923033</ArticleId></ArticleIdList></Reference><Reference><Citation>Tessler I., Albuisson J., Goudot G., et al. Bicuspid aortic valve: genetic and clinical insights. Aorta (Stamford) 2021;9(4):139&#x2013;146. doi: 10.1055/s-0041-1730294.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0041-1730294</ArticleId><ArticleId IdType="pmc">PMC8642070</ArticleId><ArticleId IdType="pubmed">34861740</ArticleId></ArticleIdList></Reference><Reference><Citation>Alkashkari W., Albugami S., Hijazi Z.M. Management of Coarctation of the aorta in adult patients: state of the art. Korean circulation journal. 2019;49(4):298&#x2013;313. doi: 10.4070/kcj.2018.0433.</Citation><ArticleIdList><ArticleId IdType="doi">10.4070/kcj.2018.0433</ArticleId><ArticleId IdType="pmc">PMC6428953</ArticleId><ArticleId IdType="pubmed">30895757</ArticleId></ArticleIdList></Reference><Reference><Citation>Isselbacher E.M., Preventza O., Hamilton Black Iii J., Augoustides J.G., Beck A.W., Bolen M.A., Braverman A.C., Bray B.E., Brown-Zimmerman M.M., Chen E.P., Collins T.J., DeAnda A., Jr., Fanola C.L., Girardi L.N., Hicks C.W., Hui D.S., Jones W.S., Kalahasti V., Kim K.M.&#x2026;Woo Y.J. 2022 ACC/AHA guideline for the diagnosis and management of aortic disease: a report of the American heart association/American college of cardiology joint committee on clinical practice guidelines. J Am Coll Cardiol. 2022;80(24):e223&#x2013;e393. doi: 10.1016/j.jacc.2022.08.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2022.08.004</ArticleId><ArticleId IdType="pmc">PMC9860464</ArticleId><ArticleId IdType="pubmed">36334952</ArticleId></ArticleIdList></Reference><Reference><Citation>Baumgartner H., De Backer J., Babu-Narayan S.V., Budts W., Chessa M., Diller G.P., Lung B., Kluin J., Lang I.M., Meijboom F., Moons P., Mulder B.J.M., Oechslin E., Roos-Hesselink J.W., Schwerzmann M., Sondergaard L., Zeppenfeld K., ESC Scientific Document Group 2020 ESC guidelines for the management of adult congenital heart disease. Eur Heart J. 2021;42(6):563&#x2013;645. doi: 10.1093/eurheartj/ehaa554.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehaa554</ArticleId><ArticleId IdType="pubmed">32860028</ArticleId></ArticleIdList></Reference><Reference><Citation>Shih M.C., Tholpady A., Kramer C.M., Sydnor M.K., Hagspiel K.D. Surgical and endovascular repair of aortic coarctation: normal findings and appearance of complications on CT angiography and MR angiography. AJR Am J Roentgenol. 2006;187(3):W302&#x2013;W312. doi: 10.2214/AJR.05.0424.</Citation><ArticleIdList><ArticleId IdType="doi">10.2214/AJR.05.0424</ArticleId><ArticleId IdType="pubmed">16928909</ArticleId></ArticleIdList></Reference><Reference><Citation>Macdonald S., Thomas S.M., Cleveland T.J., Gaines P.A. Angioplasty or stenting in adult coarctation of the aorta? A retrospective single center analysis over a decade. Cardiovasc Interv Radiol. 2003;26(4):357&#x2013;364. doi: 10.1007/s00270-003-2709-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00270-003-2709-7</ArticleId><ArticleId IdType="pubmed">14667117</ArticleId></ArticleIdList></Reference><Reference><Citation>Dikmen N., Ozcinar E., Eyileten Z., Hasde A.I., Yazicioglu L., Kaya B., Uysalel A. Comparative analysis of surgical and endovascular approaches for isolated aortic coarctation repair across age groups: outcomes and long-term efficacy. J Clin Med. 2024;13(19):5814. doi: 10.3390/jcm13195814.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm13195814</ArticleId><ArticleId IdType="pmc">PMC11477021</ArticleId><ArticleId IdType="pubmed">39407874</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40746649</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>03</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2772-6096</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><PubDate><Year>2025</Year><Month>Sep</Month></PubDate></JournalIssue><Title>BJA open</Title><ISOAbbreviation>BJA Open</ISOAbbreviation></Journal><ArticleTitle>Peripartum takotsubo cardiomyopathy after an emergency Caesarean delivery-diagnosis and specialist management.</ArticleTitle><Pagination><StartPage>100478</StartPage><MedlinePgn>100478</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">100478</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.bjao.2025.100478</ELocationID><Abstract><AbstractText>We report the case of a 32-yr-old primiparous patient who underwent an emergency Caesarean delivery and subsequently developed peripartum takotsubo cardiomyopathy necessitating transfer to a tertiary referral critical care unit and the heart failure service. Takotsubo cardiomyopathy, also called stress cardiomyopathy, is a form of left ventricular dysfunction with distinct wall motion abnormalities in the absence of coronary artery disease. It is considered extremely rare in the peripartum period, most commonly presenting in postmenopausal women with increased myocardial sensitivity to excess circulating catecholamines as a potential role in the pathogenesis. In the peripartum period, the physiological cardiovascular adaptations of pregnancy superimposed on psychosocial stressors is the assumed pathogenesis. Unexplained dyspnoea in the peripartum period should prompt early transthoracic echocardiography and specialist critical care and heart failure team input, where appropriate. This case highlights the need to consider rare cardiac causes of acute dyspnoea and demonstrates the value of point-of-care transthoracic ultrasound for prompt bedside assessment, aiding diagnosis and management. Clinical, echocardiographic, and radiological features can aid differentiating takotsubo cardiomyopathy from other differential diagnoses. Specialist multidisciplinary teams comprised of obstetricians, anaesthetists, intensivists, cardiologists, and specialist services, such as lactation and psychology services, should be available to care for these patients and a holistic approach needs to be adopted to counsel and address the psychological sequelae after such a diagnosis and appropriately plan for future pregnancies.</AbstractText><CopyrightInformation>&#xa9; 2025 The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Murphy</LastName><ForeName>Cathriona</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Anaesthesiology, The Rotunda Hospital, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Edgeworth</LastName><ForeName>Deirdre</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Intensive Care Medicine and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giblin</LastName><ForeName>Gerard</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Mater Misericordiae University Hospital, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kearsley</LastName><ForeName>Rosemarie</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Consultant Anaesthetist, The Rotunda Hospital, Dublin, Ireland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>RCSI University of Medicine and Health Sciences, Dublin, Ireland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BJA Open</MedlineTA><NlmUniqueID>9918419157906676</NlmUniqueID><ISSNLinking>2772-6096</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">maternal critical care</Keyword><Keyword MajorTopicYN="N">maternal morbidity</Keyword><Keyword MajorTopicYN="N">point-of-care ultrasound</Keyword><Keyword MajorTopicYN="N">pregnancy</Keyword><Keyword MajorTopicYN="N">takotsubo cardiomyopathy</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>1</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>6</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>1</Day><Hour>11</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>1</Day><Hour>11</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>1</Day><Hour>5</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>7</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40746649</ArticleId><ArticleId IdType="pmc">PMC12311578</ArticleId><ArticleId IdType="doi">10.1016/j.bjao.2025.100478</ArticleId><ArticleId IdType="pii">S2772-6096(25)00102-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ghadri J.R., Cammann V.L., Jurisic S., et al. A novel clinical score (InterTAK Diagnostic Score) to differentiate takotsubo syndrome from acute coronary syndrome: results from the International Takotsubo Registry. Eur J Heart Fail. 2017;19:1036&#x2013;1042.</Citation><ArticleIdList><ArticleId IdType="pubmed">27928880</ArticleId></ArticleIdList></Reference><Reference><Citation>Felker Allison, Patel Roshni, Kotnis Rohit, Kenyon Sara, Knight Marian., editors. Lessons learned to inform maternity care from the UK and Ireland Confidential Enquiries into Maternal Deaths and Morbidity 2020-22. National Perinatal Epidemiology Unit, University of Oxford; Oxford: 2024. on behalf of MBRRACE-UK. Saving Lives, Improving Mothers&#x2019; Care Compiled Report.</Citation></Reference><Reference><Citation>Templin C., Ghadri J.R., Diekmann J., et al. Clinical features and outcomes of takotsubo (stress) cardiomyopathy. N Engl J Med. 2015;373:929&#x2013;938.</Citation><ArticleIdList><ArticleId IdType="pubmed">26332547</ArticleId></ArticleIdList></Reference><Reference><Citation>Vazirani R., Blanco-Ponce E., Almendro Delia M., et al. Peripartum takotsubo cardiomyopathy: a review and insights from a national registry. J Cardiovasc Dev Dis. 2024;11:37.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10889154</ArticleId><ArticleId IdType="pubmed">38392251</ArticleId></ArticleIdList></Reference><Reference><Citation>Kandah F., Deol T., Dhruva P., Chandler Z., Musa T., Velarde G. A case of postpartum takotsubo (Stress) cardiomyopathy. Case Rep Cardiol. 2022;2022</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9371808</ArticleId><ArticleId IdType="pubmed">35967747</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyd B., Solh T. Takotsubo cardiomyopathy: review of broken heart syndrome. JAAPA. 2020;33:24&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pubmed">32039951</ArticleId></ArticleIdList></Reference><Reference><Citation>Muller O., Roguelov C., Pascale P. A basal variant form of the transient &#x2018;midventricular&#x2019; and &#x2018;apical&#x2019; ballooning syndrome. QJM Int J Med. 2007;100:738&#x2013;739.</Citation><ArticleIdList><ArticleId IdType="pubmed">17971394</ArticleId></ArticleIdList></Reference><Reference><Citation>Hern&#xe1;ndez-Guajardo D.A., Sol&#xed;s J.G., Flores-Ram&#xed;rez R., Carrizales-Sep&#xfa;lveda E.F. Failing in reverse: a case report of reverse Takotsubo syndrome complicating peripartum. Eur Heart J Case Rep. 2023;7</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10597320</ArticleId><ArticleId IdType="pubmed">37881355</ArticleId></ArticleIdList></Reference><Reference><Citation>Minatoguchi M., Itakura A., Takagi E., Nishibayashi M., Kikuchi M., Ishihara O. Takotsubo cardiomyopathy after cesarean: a case report and published work review of pregnancy-related cases. J Obstet Gynaecol Res. 2014;40:1534&#x2013;1539.</Citation><ArticleIdList><ArticleId IdType="pubmed">24888912</ArticleId></ArticleIdList></Reference><Reference><Citation>Conradi P.M., van Loon R.B., Handoko M.L. Dynamic left ventricular outflow tract obstruction in Takotsubo cardiomyopathy resulting in cardiogenic shock. BMJ Case Rep. 2021;14</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7993169</ArticleId><ArticleId IdType="pubmed">33762278</ArticleId></ArticleIdList></Reference><Reference><Citation>Amsterdam E.A., Wenger N.K., Brindis R.G., et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes. J Am Coll Cardiol. 2014;64:e139&#x2013;e228.</Citation><ArticleIdList><ArticleId IdType="pubmed">25260718</ArticleId></ArticleIdList></Reference><Reference><Citation>Arbelo E., Protonotarios A., Gimeno J.R., et al. 2023 ESC guidelines for the management of cardiomyopathies: developed by the task force on the management of cardiomyopathies of the European Society of Cardiology (ESC) Eur Heart J. 2023;44:3503&#x2013;3626.</Citation><ArticleIdList><ArticleId IdType="pubmed">37622657</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyon A.R., Bossone E., Schneider B., et al. Current state of knowledge on Takotsubo syndrome: a Position Statement from the Taskforce on Takotsubo Syndrome of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2016;18:8&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">26548803</ArticleId></ArticleIdList></Reference><Reference><Citation>Santoro F., Stiermaier T., Tarantino N., et al. Left ventricular thrombi in Takotsubo syndrome: incidence, predictors, and management: results from the GEIST (German Italian Stress Cardiomyopathy) Registry. J Am Heart Assoc. 2017;6</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5779019</ArticleId><ArticleId IdType="pubmed">29203578</ArticleId></ArticleIdList></Reference><Reference><Citation>Pollock W., Rose L., Dennis C.-L. Pregnant and postpartum admissions to the intensive care unit: a systematic review. Intensive Care Med. 2010;36:1465&#x2013;1474.</Citation><ArticleIdList><ArticleId IdType="pubmed">20631987</ArticleId></ArticleIdList></Reference><Reference><Citation>Garg H., Singh S., Ramachandran R., Trikha A. Takotsubo cardiomyopathy in pregnancy: a focused review. J Obstet Anaesth Crit Care. 2023;13:142&#x2013;159.</Citation></Reference><Reference><Citation>Citro R., Bellino M., Minichino F., Di Vece D., Ferraioli D., Petta R. Subsequent safe pregnancy with Cesarean delivery in a patient with a history of peripartum takotsubo syndrome complicated by cardiogenic shock. J Cardiovasc Echogr. 2017;27:114&#x2013;117.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5516443</ArticleId><ArticleId IdType="pubmed">28758066</ArticleId></ArticleIdList></Reference><Reference><Citation>Horsch A., Garthus-Niegel S., Ayers S., et al. Childbirth-related posttraumatic stress disorder: definition, risk factors, pathophysiology, diagnosis, prevention, and treatment. Am J Obstet Gynecol. 2024;230:S1116&#x2013;S1127.</Citation><ArticleIdList><ArticleId IdType="pubmed">38233316</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40746980</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">2198-7793</ISSN><JournalIssue CitedMedium="Print"><Volume>11</Volume><Issue>1</Issue><PubDate><Year>2025</Year></PubDate></JournalIssue><Title>Surgical case reports</Title><ISOAbbreviation>Surg Case Rep</ISOAbbreviation></Journal><ArticleTitle>Successful Use of Extracorporeal LVAD for Cardiogenic Shock with Aortic Valve Regurgitation as Bridge to Surgery.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">25-0343</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.70352/scrj.cr.25-0343</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Intra-aortic balloon pumping (IABP), Impella, and veno-arterial extracorporeal membrane oxygenation (VA-ECMO) are common percutaneous devices used to manage hemodynamic instability in patients with cardiogenic shock. These devices play a critical role in providing circulatory support. However, they may fail to achieve sufficient left ventricular unloading in patients with aortic valve regurgitation (AR), potentially complicating treatment strategies. In such challenging cases, an extracorporeal left ventricular assist device (LVAD) may serve as an effective alternative solution.</AbstractText><AbstractText Label="CASE PRESENTATION" NlmCategory="METHODS">A 61-year-old man presented with heart failure and cardiogenic shock, further complicated by AR. Despite intensive inotropic therapy, his condition deteriorated, leading to significant hepatic and renal dysfunction. Echocardiography revealed left ventricular dysfunction with an ejection fraction of 23.5%, as well as moderate aortic, mitral, and tricuspid valve regurgitation. Initial management with VA-ECMO proved inadequate, necessitating the implantation of an extracorporeal LVAD. This intervention resulted in marked improvements in hemodynamics and multi-organ function. Subsequently, the patient underwent successful surgical procedures, including aortic valve replacement, mitral and tricuspid annuloplasty, and pulmonary vein isolation. He was discharged on day 51.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This case highlights the challenges in managing cardiogenic shock with AR, where conventional devices like IABP, Impella, and VA-ECMO may exacerbate the condition. The use of an extracorporeal LVAD provided effective left ventricular unloading, enabling successful preoperative optimization and surgery. This case supports the utility of LVAD as a bridge to surgery in patients with cardiogenic shock and AR, suggesting a need for further research into optimal management strategies in such complex cases.</AbstractText><CopyrightInformation>&#xa9; 2025 The Author(s). Published by Japan Surgical Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Taguchi</LastName><ForeName>Takura</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, University of Osaka Graduate School of Medicine, Suita, Osaka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kawamura</LastName><ForeName>Takuji</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, University of Osaka Graduate School of Medicine, Suita, Osaka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoshioka</LastName><ForeName>Daisuke</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, University of Osaka Graduate School of Medicine, Suita, Osaka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saito</LastName><ForeName>Shunsuke</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, University of Osaka Graduate School of Medicine, Suita, Osaka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kawamura</LastName><ForeName>Ai</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, University of Osaka Graduate School of Medicine, Suita, Osaka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Misumi</LastName><ForeName>Yusuke</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, University of Osaka Graduate School of Medicine, Suita, Osaka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miyagawa</LastName><ForeName>Shigeru</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, University of Osaka Graduate School of Medicine, Suita, Osaka, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>Japan</Country><MedlineTA>Surg Case Rep</MedlineTA><NlmUniqueID>101662125</NlmUniqueID><ISSNLinking>2198-7793</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">aortic valve regurgitation</Keyword><Keyword MajorTopicYN="N">cardiogenic shock</Keyword><Keyword MajorTopicYN="N">case report</Keyword><Keyword MajorTopicYN="N">extracorporeal left ventricular assist device</Keyword></KeywordList><CoiStatement>The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>6</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>1</Day><Hour>11</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>1</Day><Hour>11</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>1</Day><Hour>5</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>7</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40746980</ArticleId><ArticleId IdType="pmc">PMC12310382</ArticleId><ArticleId IdType="doi">10.70352/scrj.cr.25-0343</ArticleId><ArticleId IdType="pii">scrj.cr.25-0343</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Telukuntla KS, Estep JD. Acute mechanical circulatory support for cardiogenic shock. Methodist DeBakey Cardiovasc J 2020; 16: 27&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7137625</ArticleId><ArticleId IdType="pubmed">32280415</ArticleId></ArticleIdList></Reference><Reference><Citation>Sidebotham D, Allen S, McGeorge A, et al. Catastrophic left heart distension following initiation of venoarterial extracorporeal membrane oxygenation in a patient with mild aortic regurgitation. Anaesth Intensive Care 2012; 40: 568&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">22577936</ArticleId></ArticleIdList></Reference><Reference><Citation>Pesarini G, Lunardi M, Piccoli A, et al. Effectiveness and safety of transcatheter aortic valve implantation in patients with pure aortic regurgitation and advanced heart failure. Am J Cardiol 2018; 121: 642&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">29329825</ArticleId></ArticleIdList></Reference><Reference><Citation>Achkouty G, Amabile N, Zannis K, et al. Transcatheter aortic valve replacement for severe aortic regurgitation with acute refractory cardiogenic shock. Can J Cardiol 2018; 34: 342.e5&#x2013;42.e7.</Citation><ArticleIdList><ArticleId IdType="pubmed">29475537</ArticleId></ArticleIdList></Reference><Reference><Citation>Park H, Yang JH, Ahn JM, et al. Early left atrial venting versus conventional treatment for left ventricular decompression during venoarterial extracorporeal membrane oxygenation support: the EVOLVE-ECMO randomized clinical trial. Eur J Heart Fail 2023; 25: 2037&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">37642192</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiang M, Gonzalez PE, Basir B, et al. Left atrial venoarterial extracorporeal membrane oxygenation for acute aortic regurgitation and cardiogenic shock. JACC Case Rep 2022; 4: 276&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8897074</ArticleId><ArticleId IdType="pubmed">35257102</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40759534</PMID><DateCompleted><Year>2025</Year><Month>08</Month><Day>04</Day></DateCompleted><DateRevised><Year>2025</Year><Month>08</Month><Day>07</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2053-3624</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>2</Issue><PubDate><Year>2025</Year><Month>Aug</Month><Day>04</Day></PubDate></JournalIssue><Title>Open heart</Title><ISOAbbreviation>Open Heart</ISOAbbreviation></Journal><ArticleTitle>Cardiac structure and function in anabolic-androgenic steroid users: a 16-year follow-up study.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e003376</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/openhrt-2025-003376</ELocationID><Abstract><AbstractText Label="BACKGROUND AND AIM" NlmCategory="OBJECTIVE">Long-term data on cardiac changes in anabolic-androgenic steroid (AAS) users are lacking. The aim of this study was to explore the effects of AAS on cardiac structure and function during long-term follow-up.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In this prospective cohort study, AAS users and strength-trained non-users were included and examined at two time points with echocardiography and coronary CT angiography. AAS use and non-use were verified by blood and urine analyses.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A cohort of 32 AAS users (median age 33 years) and 13 non-users (median age 34 years) were followed for a median of 16 (IQR, 15-17) and 13 (7-15) years, respectively. At baseline, AAS users had been taking AAS for a median of 5-10 years. At follow-up, 15 had discontinued AAS, while 17 remained continued users. At baseline, AAS users presented with larger left ventricular mass (LVM) (266&#x2009;g (213-319) vs 215&#x2009;g (196-217), p&lt;0.01), and lower left ventricular ejection fraction (LVEF) (49% (44-53) vs 53% (51-56), p=0.05), compared with non-users. At follow-up, LVM in discontinued users was reduced and similar to the non-users, while continued users still had larger LVM. LVEF remained significantly impaired in continued users versus non-users (p&lt;0.01). In discontinued users, LVEF seemed to improve over time. The median change in LVEF over time differed significantly between continued and discontinued AAS users (-2 (-6 to 2) vs 3 (1 to 8), p&lt;0.01). Despite higher cardiac troponin T levels in AAS users, coronary artery disease prevalence did not differ between groups.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Long-term AAS use was associated with myocardial remodelling and left ventricular dysfunction. In AAS users who discontinued use during follow-up, left ventricular remodelling and systolic function seemed to improve, even after more than a decade of AAS use.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fyksen</LastName><ForeName>Tea S&#xe6;tereng</ForeName><Initials>TS</Initials><Identifier Source="ORCID">0000-0003-0315-4120</Identifier><AffiliationInfo><Affiliation>Institute of Clinical Medicine, University of Oslo, Oslo, Norway t.s.fyksen@medisin.uio.no.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiology, Oslo University Hospital Ullev&#xe5;l, Oslo University Hospital, Oslo, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gravning</LastName><ForeName>J&#xf8;rgen</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute of Clinical Medicine, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiology, Oslo University Hospital Ullev&#xe5;l, Oslo University Hospital, Oslo, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosseb&#xf8;</LastName><ForeName>Anne</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Oslo University Hospital Ullev&#xe5;l, Oslo University Hospital, Oslo, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vanberg</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Oslo University Hospital Ullev&#xe5;l, Oslo University Hospital, Oslo, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gr&#xf8;tta</LastName><ForeName>Ole J&#xf8;rgen</ForeName><Initials>OJ</Initials><AffiliationInfo><Affiliation>Department of Radiology, Oslo University Hospital Ullev&#xe5;l, Oslo University Hospital, Oslo, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Atar</LastName><ForeName>Dan</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0003-1513-8793</Identifier><AffiliationInfo><Affiliation>Institute of Clinical Medicine, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiology, Oslo University Hospital Ullev&#xe5;l, Oslo University Hospital, Oslo, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Halvorsen</LastName><ForeName>Sigrun</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute of Clinical Medicine, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiology, Oslo University Hospital Ullev&#xe5;l, Oslo University Hospital, Oslo, Oslo, Norway.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Open Heart</MedlineTA><NlmUniqueID>101631219</NlmUniqueID><ISSNLinking>2053-3624</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D045930">Anabolic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000728">Androgens</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016277" MajorTopicYN="Y">Ventricular Function, Left</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045930" MajorTopicYN="Y">Anabolic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004452" MajorTopicYN="N">Echocardiography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013318" MajorTopicYN="Y">Stroke Volume</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020257" MajorTopicYN="Y">Ventricular Remodeling</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072226" MajorTopicYN="N">Computed Tomography Angiography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017023" MajorTopicYN="N">Coronary Angiography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006352" MajorTopicYN="Y">Heart Ventricles</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000728" MajorTopicYN="Y">Androgens</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cardiomyopathies</Keyword><Keyword MajorTopicYN="N">Coronary Artery Disease</Keyword><Keyword MajorTopicYN="N">Risk Factors</Keyword></KeywordList><CoiStatement>Competing interests: None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>4</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>5</Day><Hour>0</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>5</Day><Hour>0</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>4</Day><Hour>21</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>8</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40759534</ArticleId><ArticleId IdType="pmc">PMC12323528</ArticleId><ArticleId IdType="doi">10.1136/openhrt-2025-003376</ArticleId><ArticleId IdType="pii">openhrt-2025-003376</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kanayama G, Pope HG., Jr History and epidemiology of anabolic androgens in athletes and non-athletes. Mol Cell Endocrinol. 2018;464:4&#x2013;13. doi: 10.1016/j.mce.2017.02.039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mce.2017.02.039</ArticleId><ArticleId IdType="pubmed">28245998</ArticleId></ArticleIdList></Reference><Reference><Citation>Ip EJ, Lu DH, Barnett MJ, et al. Psychological and physical impact of anabolic-androgenic steroid dependence. Pharmacotherapy. 2012;32:910&#x2013;9. doi: 10.1002/j.1875-9114.2012.01123.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/j.1875-9114.2012.01123</ArticleId><ArticleId IdType="pubmed">23033230</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdullah R, Bj&#xf8;rnebekk A, Hauger LE, et al. Severe biventricular cardiomyopathy in both current and former long-term users of anabolic&#x2013;androgenic steroids. Eur J Prev Cardiol. 2024;31:599&#x2013;608. doi: 10.1093/eurjpc/zwad362.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurjpc/zwad362</ArticleId><ArticleId IdType="pubmed">37992194</ArticleId></ArticleIdList></Reference><Reference><Citation>Baggish AL, Weiner RB, Kanayama G, et al. Cardiovascular Toxicity of Illicit Anabolic-Androgenic Steroid Use. Circulation. 2017;135:1991&#x2013;2002. doi: 10.1161/CIRCULATIONAHA.116.026945.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.116.026945</ArticleId><ArticleId IdType="pmc">PMC5614517</ArticleId><ArticleId IdType="pubmed">28533317</ArticleId></ArticleIdList></Reference><Reference><Citation>Fyksen TS, Vanberg P, Gjesdal K, et al. Cardiovascular phenotype of long-term anabolic-androgenic steroid abusers compared with strength-trained athletes. Scand J Med Sci Sports. 2022;32:1170&#x2013;81. doi: 10.1111/sms.14172.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/sms.14172</ArticleId><ArticleId IdType="pmc">PMC9540672</ArticleId><ArticleId IdType="pubmed">35460300</ArticleId></ArticleIdList></Reference><Reference><Citation>Rasmussen JJ, Schou M, Madsen PL, et al. Cardiac systolic dysfunction in past illicit users of anabolic androgenic steroids. Am Heart J. 2018;203:49&#x2013;56. doi: 10.1016/j.ahj.2018.06.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ahj.2018.06.010</ArticleId><ArticleId IdType="pubmed">30015068</ArticleId></ArticleIdList></Reference><Reference><Citation>Windfeld-Mathiasen J, Heerfordt IM, Dalhoff KP, et al. Cardiovascular Disease in Anabolic Androgenic Steroid Users. Circulation. 2025;151:828&#x2013;34. doi: 10.1161/CIRCULATIONAHA.124.071117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.124.071117</ArticleId><ArticleId IdType="pubmed">39945117</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanberg P, Atar D. Androgenic anabolic steroid abuse and the cardiovascular system. Handb Exp Pharmacol. 2010;2010:411&#x2013;57. doi: 10.1007/978-3-540-79088-4_18.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-540-79088-4_18</ArticleId><ArticleId IdType="pubmed">20020375</ArticleId></ArticleIdList></Reference><Reference><Citation>Marsh JD, Lehmann MH, Ritchie RH, et al. Androgen receptors mediate hypertrophy in cardiac myocytes. Circulation. 1998;98:256&#x2013;61. doi: 10.1161/01.cir.98.3.256.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.cir.98.3.256</ArticleId><ArticleId IdType="pubmed">9697826</ArticleId></ArticleIdList></Reference><Reference><Citation>Du Bois D, Bois EF. A formula to estimate the approximate surface area if height and weight be known. Nutrition. 1916;5:503&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">2520314</ArticleId></ArticleIdList></Reference><Reference><Citation>Christou GA, Christou MA, &#x17d;iberna L, et al. Indirect clinical markers for the detection of anabolic steroid abuse beyond the conventional doping control in athletes. Eur J Sport Sci. 2019;19:1276&#x2013;86. doi: 10.1080/17461391.2019.1587522.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17461391.2019.1587522</ArticleId><ArticleId IdType="pubmed">30880613</ArticleId></ArticleIdList></Reference><Reference><Citation>Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015;28:1&#x2013;39. doi: 10.1016/j.echo.2014.10.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.echo.2014.10.003</ArticleId><ArticleId IdType="pubmed">25559473</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagueh SF, Smiseth OA, Appleton CP, et al. Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2016;29:277&#x2013;314. doi: 10.1016/j.echo.2016.01.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.echo.2016.01.011</ArticleId><ArticleId IdType="pubmed">27037982</ArticleId></ArticleIdList></Reference><Reference><Citation>Devereux RB, Alonso DR, Lutas EM, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol. 1986;57:450&#x2013;8. doi: 10.1016/0002-9149(86)90771-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0002-9149(86)90771-x</ArticleId><ArticleId IdType="pubmed">2936235</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson S, Ring L, Oxborough D, et al. The assessment of left ventricular diastolic function: guidance and recommendations from the British Society of Echocardiography. Echo Res Pract. 2024;11:16. doi: 10.1186/s44156-024-00051-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s44156-024-00051-2</ArticleId><ArticleId IdType="pmc">PMC11145885</ArticleId><ArticleId IdType="pubmed">38825710</ArticleId></ArticleIdList></Reference><Reference><Citation>Smit DL, Voogel AJ, den Heijer M, et al. Anabolic Androgenic Steroids Induce Reversible Left Ventricular Hypertrophy and Cardiac Dysfunction. Echocardiography Results of the HAARLEM Study. Front Reprod Health . 2021;3:732318. doi: 10.3389/frph.2021.732318.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/frph.2021.732318</ArticleId><ArticleId IdType="pmc">PMC9580689</ArticleId><ArticleId IdType="pubmed">36304014</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammoud S, van den Bemt BJF, Jaber A, et al. Chronic anabolic androgenic steroid administration reduces global longitudinal strain among off-cycle bodybuilders. Int J Cardiol. 2023;381:153&#x2013;60. doi: 10.1016/j.ijcard.2023.03.057.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijcard.2023.03.057</ArticleId><ArticleId IdType="pubmed">37003371</ArticleId></ArticleIdList></Reference><Reference><Citation>Christou MA, Christou PA, Markozannes G, et al. Effects of Anabolic Androgenic Steroids on the Reproductive System of Athletes and Recreational Users: A Systematic Review and Meta-Analysis. Sports Med. 2017;47:1869&#x2013;83. doi: 10.1007/s40279-017-0709-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40279-017-0709-z</ArticleId><ArticleId IdType="pubmed">28258581</ArticleId></ArticleIdList></Reference><Reference><Citation>Rasmussen JJ, Selmer C, &#xd8;stergren PB, et al. Former Abusers of Anabolic Androgenic Steroids Exhibit Decreased Testosterone Levels and Hypogonadal Symptoms Years after Cessation: A Case-Control Study. PLoS One. 2016;11:e0161208. doi: 10.1371/journal.pone.0161208.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0161208</ArticleId><ArticleId IdType="pmc">PMC4988681</ArticleId><ArticleId IdType="pubmed">27532478</ArticleId></ArticleIdList></Reference><Reference><Citation>Bulut Y, Rasmussen JJ, Brandt-Jacobsen N, et al. Coronary Microvascular Dysfunction Years After Cessation of Anabolic Androgenic Steroid Use. JAMA Netw Open . 2024;7:e2451013. doi: 10.1001/jamanetworkopen.2024.51013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2024.51013</ArticleId><ArticleId IdType="pmc">PMC11650407</ArticleId><ArticleId IdType="pubmed">39680410</ArticleId></ArticleIdList></Reference><Reference><Citation>Fineschi V, Baroldi G, Monciotti F, et al. Anabolic steroid abuse and cardiac sudden death: a pathologic study. Arch Pathol Lab Med. 2001;125:253&#x2013;5. doi: 10.5858/2001-125-0253-ASAACS.</Citation><ArticleIdList><ArticleId IdType="doi">10.5858/2001-125-0253-ASAACS</ArticleId><ArticleId IdType="pubmed">11175645</ArticleId></ArticleIdList></Reference><Reference><Citation>Fadah K, Gopi G, Lingireddy A, et al. Anabolic androgenic steroids and cardiomyopathy: an update. Front Cardiovasc Med. 2023;10:1214374. doi: 10.3389/fcvm.2023.1214374.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2023.1214374</ArticleId><ArticleId IdType="pmc">PMC10412093</ArticleId><ArticleId IdType="pubmed">37564909</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang S, M&#xfc;nster A-MB, Gram J, et al. Anabolic Androgenic Steroid Abuse: The Effects on Thrombosis Risk, Coagulation, and Fibrinolysis. Semin Thromb Hemost. 2018;44:734&#x2013;46. doi: 10.1055/s-0038-1670639.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0038-1670639</ArticleId><ArticleId IdType="pubmed">30267392</ArticleId></ArticleIdList></Reference><Reference><Citation>Tungesvik HM, Bj&#xf8;rnebekk A, Hisdal J. Impaired vascular function among young users of anabolic-androgenic steroids. Sci Rep. 2024;14:19201. doi: 10.1038/s41598-024-70110-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-024-70110-5</ArticleId><ArticleId IdType="pmc">PMC11333575</ArticleId><ArticleId IdType="pubmed">39160232</ArticleId></ArticleIdList></Reference><Reference><Citation>Gregersen I, Scarth ME, Abdullah R, et al. Elevated interleukin 8 and matrix metalloproteinase 9 levels are associated with myocardial pathology in users of anabolic-androgenic steroids. Eur J Prev Cardiol. 2024;31:1469&#x2013;76. doi: 10.1093/eurjpc/zwae126.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurjpc/zwae126</ArticleId><ArticleId IdType="pubmed">38573232</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40782646</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1768-3181</ISSN><JournalIssue CitedMedium="Internet"><Volume>74</Volume><Issue>4</Issue><PubDate><Year>2025</Year><Month>Aug</Month><Day>08</Day></PubDate></JournalIssue><Title>Annales de cardiologie et d'angeiologie</Title><ISOAbbreviation>Ann Cardiol Angeiol (Paris)</ISOAbbreviation></Journal><ArticleTitle>[Coronary revascularization in diabetic patient : which approach to choose ?].</ArticleTitle><Pagination><StartPage>101918</StartPage><MedlinePgn>101918</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ancard.2025.101918</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0003-3928(25)00057-5</ELocationID><Abstract><AbstractText>Diabetes constitutes a major risk factor for coronary artery disease, with often diffuse, calcified, and complex lesions, making the revascularization strategy particularly challenging. We report two clinical cases illustrating contrasting approaches in diabetic patients presenting with multivessel coronary disease. The first case involves a complex coronary angioplasty in the setting of acute coronary syndrome, guided by intracoronary imaging, highlighting the value of this modality in ostial left main lesions. The second case describes surgical revascularization in a stable patient with extensive coronary artery disease and left ventricular dysfunction, demonstrating the superiority of coronary artery bypass grafting in this context. These observations illustrate the importance of a personalized and multidisciplinary approach, based on current guidelines and the patient's anatomical and clinical characteristics. The advent of modern revascularization techniques and the anticipated results of the ANDAMAN study could soon redefine the standards of care for these high-risk patients.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 Elsevier Masson SAS. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Benamer</LastName><ForeName>Mehdi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Universit&#xe9; Paris-Cit&#xe9;, Department of Cardiology, University Hospital of Lariboisiere, (Assistance Publique des H&#xf4;pitaux de Paris, AP-HP), 75010, Paris, France; Inserm MASCOT - UMRS 942, University Hospital of Lariboisiere, 75010, Paris, France; MIRACL.ai laboratory, Multimodality Imaging for Research and Artificial Intelligence Core Laboratory, University Hospital of Lariboisiere (AP-HP), 75010, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Henry</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Universit&#xe9; Paris-Cit&#xe9;, Department of Cardiology, University Hospital of Lariboisiere, (Assistance Publique des H&#xf4;pitaux de Paris, AP-HP), 75010, Paris, France; Inserm MASCOT - UMRS 942, University Hospital of Lariboisiere, 75010, Paris, France; MIRACL.ai laboratory, Multimodality Imaging for Research and Artificial Intelligence Core Laboratory, University Hospital of Lariboisiere (AP-HP), 75010, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dillinger</LastName><ForeName>Jean Guillaume</ForeName><Initials>JG</Initials><AffiliationInfo><Affiliation>Universit&#xe9; Paris-Cit&#xe9;, Department of Cardiology, University Hospital of Lariboisiere, (Assistance Publique des H&#xf4;pitaux de Paris, AP-HP), 75010, Paris, France; Inserm MASCOT - UMRS 942, University Hospital of Lariboisiere, 75010, Paris, France; MIRACL.ai laboratory, Multimodality Imaging for Research and Artificial Intelligence Core Laboratory, University Hospital of Lariboisiere (AP-HP), 75010, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lequipar</LastName><ForeName>Antoine</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Universit&#xe9; Paris-Cit&#xe9;, Department of Cardiology, University Hospital of Lariboisiere, (Assistance Publique des H&#xf4;pitaux de Paris, AP-HP), 75010, Paris, France; Inserm MASCOT - UMRS 942, University Hospital of Lariboisiere, 75010, Paris, France; MIRACL.ai laboratory, Multimodality Imaging for Research and Artificial Intelligence Core Laboratory, University Hospital of Lariboisiere (AP-HP), 75010, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pezel</LastName><ForeName>Th&#xe9;o</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Universit&#xe9; Paris-Cit&#xe9;, Department of Cardiology, University Hospital of Lariboisiere, (Assistance Publique des H&#xf4;pitaux de Paris, AP-HP), 75010, Paris, France; Inserm MASCOT - UMRS 942, University Hospital of Lariboisiere, 75010, Paris, France; MIRACL.ai laboratory, Multimodality Imaging for Research and Artificial Intelligence Core Laboratory, University Hospital of Lariboisiere (AP-HP), 75010, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lafont</LastName><ForeName>Alexandre</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Universit&#xe9; Paris-Cit&#xe9;, Department of Cardiology, University Hospital of Lariboisiere, (Assistance Publique des H&#xf4;pitaux de Paris, AP-HP), 75010, Paris, France; Inserm MASCOT - UMRS 942, University Hospital of Lariboisiere, 75010, Paris, France; MIRACL.ai laboratory, Multimodality Imaging for Research and Artificial Intelligence Core Laboratory, University Hospital of Lariboisiere (AP-HP), 75010, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gall</LastName><ForeName>Emmanuel</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Universit&#xe9; Paris-Cit&#xe9;, Department of Cardiology, University Hospital of Lariboisiere, (Assistance Publique des H&#xf4;pitaux de Paris, AP-HP), 75010, Paris, France; Inserm MASCOT - UMRS 942, University Hospital of Lariboisiere, 75010, Paris, France; MIRACL.ai laboratory, Multimodality Imaging for Research and Artificial Intelligence Core Laboratory, University Hospital of Lariboisiere (AP-HP), 75010, Paris, France. Electronic address: emmanuel.gall@aphp.fr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>fre</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>La revascularisation coronaire chez le patient diab&#xe9;tique : que choisir ?</VernacularTitle><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Ann Cardiol Angeiol (Paris)</MedlineTA><NlmUniqueID>0142167</NlmUniqueID><ISSNLinking>0003-3928</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Angioplasties coronaires</Keyword><Keyword MajorTopicYN="N">Coronary angioplasty</Keyword><Keyword MajorTopicYN="N">Coronary artery bypass grafting</Keyword><Keyword MajorTopicYN="N">Coronary revascularization</Keyword><Keyword MajorTopicYN="N">Diabetes</Keyword><Keyword MajorTopicYN="N">Diab&#xe8;te</Keyword><Keyword MajorTopicYN="N">Maladie multitronculaire</Keyword><Keyword MajorTopicYN="N">Multivessel disease</Keyword><Keyword MajorTopicYN="N">Pontage aorto-coronaire</Keyword><Keyword MajorTopicYN="N">Revascularisation coronaire</Keyword></KeywordList><CoiStatement>D&#xe9;claration de liens d'int&#xe9;r&#xea;ts Les auteurs d&#xe9;clarent n&#x2019;avoir aucun lien d&#x2019;int&#xe9;r&#xea;t en relation avec cet article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>6</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>10</Day><Hour>6</Hour><Minute>16</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>10</Day><Hour>6</Hour><Minute>16</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>9</Day><Hour>18</Hour><Minute>14</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40782646</ArticleId><ArticleId IdType="doi">10.1016/j.ancard.2025.101918</ArticleId><ArticleId IdType="pii">S0003-3928(25)00057-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle>
<PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">40846350</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>22</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2666-0849</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>24</Issue><PubDate><Year>2025</Year><Month>Aug</Month><Day>20</Day></PubDate></JournalIssue><Title>JACC. Case reports</Title><ISOAbbreviation>JACC Case Rep</ISOAbbreviation></Journal><ArticleTitle>Iron Overload Cardiomyopathy in Myelodysplastic Syndrome: A Fatal Outcome After 20 Years of Chronic Transfusions.</ArticleTitle><Pagination><StartPage>104667</StartPage><MedlinePgn>104667</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jaccas.2025.104667</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2666-0849(25)01447-0</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Iron overload cardiomyopathy (IOC) results from excess iron accumulation in the myocardium, usually because of genetic disorders or secondary hemochromatosis by multiple blood transfusions.</AbstractText><AbstractText Label="CASE SUMMARY" NlmCategory="METHODS">A 42-year-old man with refractory heart failure was referred to our hospital. He had a history of myelodysplastic syndrome, requiring 112 U of blood transfusions over 16 years. Severe left ventricular dysfunction, elevated ferritin levels, and myocardial iron deposition confirmed by endomyocardial biopsy led to the diagnosis of IOC. Despite intensive management, the patient was discharged after death.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">Early IOC typically starts with asymptomatic diastolic dysfunction. Noninvasive modalities (eg, N-terminal pro-B-type natriuretic peptide, T2-star magnetic resonance imaging) are crucial for early detection. Iron chelation therapy may reverse cardiac dysfunction in the early phase but is less effective in advanced phases, highlighting the need for timely intervention.</AbstractText><AbstractText Label="TAKE-HOME MESSAGE" NlmCategory="CONCLUSIONS">Early detection, cardiac monitoring, and close collaboration between hematologists and cardiologists are essential to prevent IOC progression.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hayashida</LastName><ForeName>Miyu</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Department of Internal Medicine, Kurume University School of Medicine, Kurume, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nohara</LastName><ForeName>Shoichiro</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Department of Internal Medicine, Kurume University School of Medicine, Kurume, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yamakawa</LastName><ForeName>Rei</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Department of Internal Medicine, Kurume University School of Medicine, Kurume, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nishikido</LastName><ForeName>Aya</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Department of Internal Medicine, Kurume University School of Medicine, Kurume, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matsushima</LastName><ForeName>Yoshihisa</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Department of Internal Medicine, Kurume University School of Medicine, Kurume, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yanai</LastName><ForeName>Toshiyuki</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Department of Internal Medicine, Kurume University School of Medicine, Kurume, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ishimatsu</LastName><ForeName>Takashi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Department of Internal Medicine, Kurume University School of Medicine, Kurume, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Otsuka</LastName><ForeName>Maki</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Department of Internal Medicine, Kurume University School of Medicine, Kurume, Japan. Electronic address: ohtsuka_maki@kurume-u.ac.jp.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fukumoto</LastName><ForeName>Yoshihiro</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Department of Internal Medicine, Kurume University School of Medicine, Kurume, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>JACC Case Rep</MedlineTA><NlmUniqueID>101757292</NlmUniqueID><ISSNLinking>2666-0849</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cardiomyopathy</Keyword><Keyword MajorTopicYN="N">hemochromatosis</Keyword><Keyword MajorTopicYN="N">iron overload</Keyword><Keyword MajorTopicYN="N">myelodysplastic syndrome</Keyword><Keyword MajorTopicYN="N">transfusion-related complications</Keyword></KeywordList><CoiStatement>Funding Support and Author Disclosures The authors have reported that they have no relationships relevant to the contents of this paper to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>23</Day><Hour>0</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>23</Day><Hour>0</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>5</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>6</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>6</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>20</Hour><Minute>55</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40846350</ArticleId><ArticleId IdType="doi">10.1016/j.jaccas.2025.104667</ArticleId><ArticleId IdType="pii">S2666-0849(25)01447-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40747449</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>03</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2755-9637</ISSN><JournalIssue CitedMedium="Internet"><Volume>3</Volume><Issue>2</Issue><PubDate><Year>2025</Year><Month>Jul</Month></PubDate></JournalIssue><Title>European heart journal. Imaging methods and practice</Title><ISOAbbreviation>Eur Heart J Imaging Methods Pract</ISOAbbreviation></Journal><ArticleTitle>Haemodynamic implications of cardiovascular magnetic resonance pulmonary capillary wedge pressure in acute myocardial infarction.</ArticleTitle><Pagination><StartPage>qyaf086</StartPage><MedlinePgn>qyaf086</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">qyaf086</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/ehjimp/qyaf086</ELocationID><Abstract><AbstractText Label="AIMS" NlmCategory="UNASSIGNED">Cardiovascular magnetic resonance (CMR)-derived pulmonary capillary wedge pressure (PCWP) has demonstrated diagnostic and prognostic utility in heart failure patients. However, its clinical value in acute myocardial infarction (AMI) remains undetermined. This study investigates the relationship between CMR-derived PCWP, myocardial injury, and left ventricular (LV) remodelling in re-perfused acute ST-elevation myocardial infarction (STEMI).</AbstractText><AbstractText Label="METHODS AND RESULTS" NlmCategory="UNASSIGNED">Sixty-nine patients with STEMI underwent CMR within 48 h and at 3&#x2005;months. PCWP was estimated using the sex-specific equation: CMR PCWP: 5.7591 + (0.07505 &#xd7; left atrial volume) [0.05289 &#xd7; left ventricular mass (LVM)] - (1.9927 &#xd7; sex) [female = 0; male = 1], where LAV is left atrial volume (mL) and LVM is left ventricular mass (g). LV remodelling was assessed via changes in LV end-diastolic volume (LVEDV) and ejection fraction (LVEF). Patients with high CMR PCWP (&#x2265;18&#x2005;mmHg) exhibited greater myocardial scar burden (28.5% vs. 17.2%, <i>P</i> = 0.0008) and microvascular obstruction (7.6% vs. 2.5%, <i>P</i> &lt; 0.0001). They also had higher acute LVEDV (193.7 &#xb1; 39.7 vs. 158.0 &#xb1; 29.5&#x2005;mL, <i>P</i> &lt; 0.0001) and lower LVEF (41.4 &#xb1; 10.4% vs. 48.5 &#xb1; 9.2%, <i>P</i> = 0.0066). At follow-up, higher baseline CMR PCWP was associated with greater LV remodelling (<i>P</i> &lt; 0.0001) and persistently reduced LVEF (45.4 &#xb1; 10.2% vs. 55.0 &#xb1; 10.3%, <i>P</i> = 0.0005). Regression analysis confirmed baseline PCWP as an independent predictor of follow-up LVEF (<i>P</i> = 0.0036).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">CMR-derived PCWP may be a valuable biomarker in STEMI, identifying patients at risk of adverse remodelling and LV dysfunction. Its integration into clinical practice may enhance risk stratification and guide targeted therapies.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2025. Published by Oxford University Press on behalf of the European Society of Cardiology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Garg</LastName><ForeName>Pankaj</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-5483-169X</Identifier><AffiliationInfo><Affiliation>The Bob Champion Research &amp; Education Building, Rosalind Franklin Road, University of East Anglia, Norwich NR4 7UQ, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cardiology Department, Colney Lane, Norfolk and Norwich University Teaching Hospitals, Norwich NR4 7UY, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bana</LastName><ForeName>Aradhai</ForeName><Initials>A</Initials><Identifier Source="ORCID">0009-0005-3984-5005</Identifier><AffiliationInfo><Affiliation>The Bob Champion Research &amp; Education Building, Rosalind Franklin Road, University of East Anglia, Norwich NR4 7UQ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matthews</LastName><ForeName>Gareth</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0001-8353-4806</Identifier><AffiliationInfo><Affiliation>The Bob Champion Research &amp; Education Building, Rosalind Franklin Road, University of East Anglia, Norwich NR4 7UQ, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cardiology Department, Colney Lane, Norfolk and Norwich University Teaching Hospitals, Norwich NR4 7UY, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bali</LastName><ForeName>Tiya</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>The Bob Champion Research &amp; Education Building, Rosalind Franklin Road, University of East Anglia, Norwich NR4 7UQ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Rui</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>The Bob Champion Research &amp; Education Building, Rosalind Franklin Road, University of East Anglia, Norwich NR4 7UQ, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cardiology Department, Colney Lane, Norfolk and Norwich University Teaching Hospitals, Norwich NR4 7UY, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mehmood</LastName><ForeName>Zia</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>The Bob Champion Research &amp; Education Building, Rosalind Franklin Road, University of East Anglia, Norwich NR4 7UQ, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cardiology Department, Colney Lane, Norfolk and Norwich University Teaching Hospitals, Norwich NR4 7UY, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhong</LastName><ForeName>Liang</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>SingHealth Building, Outram Road, National Heart Centre Singapore 169608, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van der Geest</LastName><ForeName>Rob J</ForeName><Initials>RJ</Initials><Identifier Source="ORCID">0000-0002-9084-5597</Identifier><AffiliationInfo><Affiliation>Division of Image Processing, Leiden University Medical Center, Leiden, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Plein</LastName><ForeName>Sven</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-0997-4384</Identifier><AffiliationInfo><Affiliation>The Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Woodhouse Lane, Leeds LS2 9JT, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Greenwood</LastName><ForeName>John P</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>The Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Woodhouse Lane, Leeds LS2 9JT, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Baker Heart and Diabetes Institute, 99 Commercial Rd, Melbourne VIC 3004, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Swoboda</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>The Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Woodhouse Lane, Leeds LS2 9JT, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur Heart J Imaging Methods Pract</MedlineTA><NlmUniqueID>9918697088006676</NlmUniqueID><ISSNLinking>2755-9637</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ST elevation myocardial infarction</Keyword><Keyword MajorTopicYN="N">follow-up studies</Keyword><Keyword MajorTopicYN="N">heart atria</Keyword><Keyword MajorTopicYN="N">heart failure</Keyword><Keyword MajorTopicYN="N">humans</Keyword><Keyword MajorTopicYN="N">left ventricular dysfunction</Keyword><Keyword MajorTopicYN="N">prognosis</Keyword></KeywordList><CoiStatement>Conflict of interest: P.G. is a clinical advisor for Pie Medical Imaging and Medis Medical Imaging and consults for Anteris Technologies and Edward Lifesciences. All other authors have no conflicts of interest to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>4</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>6</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>1</Day><Hour>11</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>1</Day><Hour>11</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>1</Day><Hour>5</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>7</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40747449</ArticleId><ArticleId IdType="pmc">PMC12311366</ArticleId><ArticleId IdType="doi">10.1093/ehjimp/qyaf086</ArticleId><ArticleId IdType="pii">qyaf086</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chenzbraun &#xa0;A, Keren &#xa0;A, Stern &#xa0;S. Doppler echocardiographic patterns of left ventricular filling in patients early after acute myocardial infarction. Am J Cardiol &#xa0;1992;70:711&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">1519519</ArticleId></ArticleIdList></Reference><Reference><Citation>Kapur &#xa0;NK, O&#x2019;Neill &#xa0;WW. Left ventricular end-diastolic pressure in acute myocardial infarction: a loaded target in need of unloading. Catheter Cardiovasc Interv &#xa0;2019;93:910&#x2013;1.</Citation><ArticleIdList><ArticleId IdType="pubmed">30953413</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Herck &#xa0;PL, Carlier &#xa0;SG, Claeys &#xa0;MJ, Haine &#xa0;SE, Gorissen &#xa0;P, Miljoen &#xa0;H &#xa0;et al. &#xa0;Coronary microvascular dysfunction after myocardial infarction: increased coronary zero flow pressure both in the infarcted and in the remote myocardium is mainly related to left ventricular filling pressure. Heart Br Card Soc &#xa0;2007;93:1231&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2000925</ArticleId><ArticleId IdType="pubmed">17395671</ArticleId></ArticleIdList></Reference><Reference><Citation>Flaherty &#xa0;JT. Role of nitrates in acute myocardial infarction. Am J Cardiol &#xa0;1992;70:73B&#x2013;81B.</Citation><ArticleIdList><ArticleId IdType="pubmed">1529929</ArticleId></ArticleIdList></Reference><Reference><Citation>Garg &#xa0;P, Gosling &#xa0;R, Swoboda &#xa0;P, Jones &#xa0;R, Rothman &#xa0;A, Wild &#xa0;JM &#xa0;et al. &#xa0;Cardiac magnetic resonance identifies raised left ventricular filling pressure: prognostic implications. Eur Heart J &#xa0;2022;43:2511&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9259376</ArticleId><ArticleId IdType="pubmed">35512290</ArticleId></ArticleIdList></Reference><Reference><Citation>Backhaus &#xa0;SJ, Schulz &#xa0;A, Lange &#xa0;T, Evertz &#xa0;R, Kowallick &#xa0;JT, Hasenfu&#xdf; &#xa0;G &#xa0;et al. &#xa0;Rest and exercise-stress estimated pulmonary capillary wedge pressure using real-time free-breathing cardiovascular magnetic resonance imaging. J Cardiovasc Magn Reson &#xa0;2024;26:101032.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10950869</ArticleId><ArticleId IdType="pubmed">38431079</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomson &#xa0;RJ, Grafton-Clarke &#xa0;C, Matthews &#xa0;G, Swoboda &#xa0;PP, Swift &#xa0;AJ, Frangi &#xa0;A &#xa0;et al. &#xa0;Risk factors for raised left ventricular filling pressure by cardiovascular magnetic resonance: prognostic insights. ESC Heart Fail &#xa0;2024;11:4148&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11631267</ArticleId><ArticleId IdType="pubmed">39132877</ArticleId></ArticleIdList></Reference><Reference><Citation>Garg &#xa0;P, van der Geest &#xa0;RJ, Swoboda &#xa0;PP, Crandon &#xa0;S, Fent &#xa0;GJ, Foley &#xa0;JRJ &#xa0;et al. &#xa0;Left ventricular thrombus formation in myocardial infarction is associated with altered left ventricular blood flow energetics. Eur Heart J Cardiovasc Imaging &#xa0;2019;20:108&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6302263</ArticleId><ArticleId IdType="pubmed">30137274</ArticleId></ArticleIdList></Reference><Reference><Citation>Demirkiran &#xa0;A, Hassell &#xa0;MECJ, Garg &#xa0;P, Elbaz &#xa0;MSM, Delewi &#xa0;R, Greenwood &#xa0;JP &#xa0;et al. &#xa0;Left ventricular four-dimensional blood flow distribution, energetics, and vorticity in chronic myocardial infarction patients with/without left ventricular thrombus. Eur J Radiol &#xa0;2022;150:110233.</Citation><ArticleIdList><ArticleId IdType="pubmed">35278980</ArticleId></ArticleIdList></Reference><Reference><Citation>Ibanez &#xa0;B, James &#xa0;S, Agewall &#xa0;S, Antunes &#xa0;MJ, Bucciarelli-Ducci &#xa0;C, Bueno &#xa0;H &#xa0;et al. &#xa0;2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J &#xa0;2018;39:119&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">28886621</ArticleId></ArticleIdList></Reference><Reference><Citation>Garg &#xa0;P, Grafton-Clarke &#xa0;C, Matthews &#xa0;G, Swoboda &#xa0;P, Zhong &#xa0;L, Aung &#xa0;N &#xa0;et al. &#xa0;Sex-specific cardiac magnetic resonance pulmonary capillary wedge pressure. Eur Heart J Open &#xa0;2024;4:oeae038.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11095051</ArticleId><ArticleId IdType="pubmed">38751456</ArticleId></ArticleIdList></Reference><Reference><Citation>Haslak &#xa0;F, Yildiz &#xa0;M, Adrovic &#xa0;A, Sahin &#xa0;S, Koker &#xa0;O, Aliyeva &#xa0;A &#xa0;et al. &#xa0;Management of childhood-onset autoinflammatory diseases during the COVID-19 pandemic. Rheumatol Int &#xa0;2020;40:1423&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7355083</ArticleId><ArticleId IdType="pubmed">32661928</ArticleId></ArticleIdList></Reference><Reference><Citation>Sugimoto &#xa0;T, Dohi &#xa0;K, Tanabe &#xa0;M, Watanabe &#xa0;K, Sugiura &#xa0;E, Nakamori &#xa0;S &#xa0;et al. &#xa0;Echocardiographic estimation of pulmonary capillary wedge pressure using the combination of diastolic annular and mitral inflow velocities. J Echocardiogr &#xa0;2013;11:1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3611026</ArticleId><ArticleId IdType="pubmed">23555178</ArticleId></ArticleIdList></Reference><Reference><Citation>Guzzetti &#xa0;S, La Rovere &#xa0;MT, Pinna &#xa0;GD, Maestri &#xa0;R, Borroni &#xa0;E, Porta &#xa0;A &#xa0;et al. &#xa0;Different spectral components of 24 h heart rate variability are related to different modes of death in chronic heart failure. Eur Heart J &#xa0;2005;26:357&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">15618038</ArticleId></ArticleIdList></Reference><Reference><Citation>Aalders &#xa0;M, Kok &#xa0;W. Comparison of hemodynamic factors predicting prognosis in heart failure: a systematic review. J Clin Med &#xa0;2019;8:1757.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6832156</ArticleId><ArticleId IdType="pubmed">31652650</ArticleId></ArticleIdList></Reference><Reference><Citation>Planer &#xa0;D, Mehran &#xa0;R, Witzenbichler &#xa0;B, Guagliumi &#xa0;G, Peruga &#xa0;JZ, Brodie &#xa0;BR &#xa0;et al. &#xa0;Prognostic utility of left ventricular end-diastolic pressure in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Am J Cardiol &#xa0;2011;108:1068&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">21798494</ArticleId></ArticleIdList></Reference><Reference><Citation>Bagai &#xa0;A, Armstrong &#xa0;PW, Stebbins &#xa0;A, Mahaffey &#xa0;KW, Hochman &#xa0;JS, Weaver &#xa0;WD &#xa0;et al. &#xa0;Prognostic implications of left ventricular end-diastolic pressure during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: findings from the Assessment of Pexelizumab in Acute Myocardial Infarction study. Am Heart J &#xa0;2013;166:913&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">24176448</ArticleId></ArticleIdList></Reference><Reference><Citation>Marc &#xa0;MC, Iancu &#xa0;AC, Ober &#xa0;CD, Homorodean &#xa0;C, B&#xe3;l&#xe3;nescu &#xa0;&#x15e;, Sitar &#xa0;AV &#xa0;et al. &#xa0;Pre-revascularization coronary wedge pressure as marker of adverse long-term left ventricular remodelling in patients with acute ST-segment elevation myocardial infarction. Sci Rep &#xa0;2018;8:1897.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5789971</ArticleId><ArticleId IdType="pubmed">29382891</ArticleId></ArticleIdList></Reference><Reference><Citation>Zagrosek &#xa0;A, Wassmuth &#xa0;R, Abdel-Aty &#xa0;H, Rudolph &#xa0;A, Dietz &#xa0;R, Schulz-Menger &#xa0;J. Relation between myocardial edema and myocardial mass during the acute and convalescent phase of myocarditis&#x2014;a CMR study. J Cardiovasc Magn Reson &#xa0;2008;10:19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2396625</ArticleId><ArticleId IdType="pubmed">18447954</ArticleId></ArticleIdList></Reference><Reference><Citation>Dregoesc &#xa0;MI, Iancu &#xa0;AC, Ober &#xa0;CD, Homorodean &#xa0;C, B&#xe3;l&#xe3;nescu &#xa0;&#x15e;, Bolboac&#xe3; &#xa0;S. In ST-segment elevation myocardial infarction, the echocardiographic parameters of microvascular obstruction are not associated with left ventricular remodeling at five years of follow-up. Echocardiography &#xa0;2019;36:1103&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">31116460</ArticleId></ArticleIdList></Reference><Reference><Citation>Saklecha &#xa0;A, Kapoor &#xa0;A, Sahu &#xa0;A, Khanna &#xa0;R, Kumar &#xa0;S, Garg &#xa0;N &#xa0;et al. &#xa0;Is indexed left atrial volume (LAVi) in Indian patients with acute coronary syndrome (ACS) undergoing revascularization a predictor of cardiovascular outcomes? &#xa0;Ann Card Anaesth &#xa0;2022;25:19&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8865354</ArticleId><ArticleId IdType="pubmed">35075016</ArticleId></ArticleIdList></Reference><Reference><Citation>De Luca &#xa0;G, Parodi &#xa0;G, Sciagr&#xe0; &#xa0;R, Bellandi &#xa0;B, Verdoia &#xa0;M, Vergara &#xa0;R &#xa0;et al. &#xa0;Relation of gender to infarct size in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty. Am J Cardiol &#xa0;2013;111:936&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">23332594</ArticleId></ArticleIdList></Reference><Reference><Citation>Krefting &#xa0;J, Graesser &#xa0;C, Novacek &#xa0;S, Voll &#xa0;F, Moggio &#xa0;A, Krueger &#xa0;N &#xa0;et al. &#xa0;Sex-specific outcomes in myocardial infarction: a dual-cohort analysis using clinical and real-world data. Clin Res Cardiol &#xa0;2025.</Citation><ArticleIdList><ArticleId IdType="pubmed">40111442</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40845017</PMID><DateCompleted><Year>2025</Year><Month>08</Month><Day>22</Day></DateCompleted><DateRevised><Year>2025</Year><Month>08</Month><Day>22</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>8</Issue><PubDate><Year>2025</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>Application of transthoracic echocardiography to assess the dynamic evolution of early cardiac damage induced by abdominal aorta-inferior vena cava fistula in female rats with chronic renal failure.</ArticleTitle><Pagination><StartPage>e0324951</StartPage><MedlinePgn>e0324951</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0324951</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Left ventricular dysfunction (LVD) frequently occurs in patients with chronic renal failure (CRF) who have an arteriovenous fistula (AVF). In a rat model of CRF with AVF, we assessed the utility of transthoracic echocardiography for the early detection of LVD and examined the associated pathological damage.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Forty female rats that had successfully established a CRF model were divided into three groups: the CRF group (n&#x2009;=&#x2009;13), the sham group (n&#x2009;=&#x2009;13), and the AVF group (n&#x2009;=&#x2009;14). The AVF was established (labeled as T0). Renal function and myocardial enzyme parameters were measured at T0, the 4th week (labeled as T1), and the 6th week (labeled as T2). The parameters of echocardiography were measured with an animal ultrasound device (Vevo 3100). The early diastolic peak flow velocity (E) was divided by the mitral valve's E wave deceleration time (DT), to calculate the E/DT ratio. TOMTEC image analysis software was utilized to analyze the LV's global longitudinal strain (GLS) and global circumferential strain (GCS). At each time point, three rats from each group were euthanized, and the left ventricular pathological tissues were collected for HE and Masson staining.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">(1) At T1, the AVF group had no significant difference in GLS, although GCS and the E/DT ratio increased. At T2, the AVF showed lower GLS and GCS and a higher E/DT ratio. (2) Significant alterations were observed in AVF group tissues stained with HE and Masson at T1 and T2.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This study found that pathological damage to the left ventricular myocardium persisted after the rat model was established. Unlike traditional echocardiography measurements, GLS, GCS, and the E/DT ratio can detect dynamic changes in left ventricular function.</AbstractText><CopyrightInformation>Copyright: &#xa9; 2025 Zhang et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yiran</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0009-0003-1099-1004</Identifier><AffiliationInfo><Affiliation>Department of Medical Ultrasound, The First Affiliated Hospital of Shandong First Medical University &amp; Shandong Provincial Qianfoshan Hospital, Jinan, Shandong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Lizhou</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Medical Ultrasound, The First Affiliated Hospital of Shandong First Medical University &amp; Shandong Provincial Qianfoshan Hospital, Jinan, Shandong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>Liming</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Nephrology, The First Affiliated Hospital of Shandong First Medical University &amp; Shandong provincial Qianfoshan Hospital, Shandong institute of Nephrology, Jinan, Shandong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Kuan</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Clinical Medical Institute, Xinjiang Medical University, Urumqi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kong</LastName><ForeName>Xianglei</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Nephrology, The First Affiliated Hospital of Shandong First Medical University &amp; Shandong provincial Qianfoshan Hospital, Shandong institute of Nephrology, Jinan, Shandong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Haiyan</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0003-3607-731X</Identifier><AffiliationInfo><Affiliation>Department of Medical Ultrasound, The First Affiliated Hospital of Shandong First Medical University &amp; Shandong Provincial Qianfoshan Hospital, Jinan, Shandong, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004452" MajorTopicYN="Y">Echocardiography</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007676" MajorTopicYN="Y">Kidney Failure, Chronic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018487" MajorTopicYN="Y">Ventricular Dysfunction, Left</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014682" MajorTopicYN="Y">Vena Cava, Inferior</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001012" MajorTopicYN="Y">Aorta, Abdominal</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001164" MajorTopicYN="Y">Arteriovenous Fistula</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>20</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>20</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>11</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>5</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>13</Hour><Minute>43</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40845017</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0324951</ArticleId><ArticleId IdType="pii">PONE-D-24-47138</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40828180</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1861-0692</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Aug</Month><Day>19</Day></PubDate></JournalIssue><Title>Clinical research in cardiology : official journal of the German Cardiac Society</Title><ISOAbbreviation>Clin Res Cardiol</ISOAbbreviation></Journal><ArticleTitle>Bedside echocardiography in patients with suspected acute myocardial infarction without ST elevation.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00392-025-02724-2</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Guidelines recommend using echocardiography in addition to high-sensitivity cardiac troponin (hs-cTn)-based assessment in patients with suspected acute myocardial infarction (MI), although data on its diagnostic and prognostic value is limited.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Patients presenting with suspected MI without ST elevation to a tertiary center were enrolled. Final diagnoses were adjudicated by two cardiologists. Trained cardiology fellows conducted and interpreted bedside echocardiography in the emergency department as standard of care. Diagnostic performance measures (negative and positive predictive values [NPV, PPV] [95% confidence intervals]) to rule-in or rule-out MI were compared for patients with and without any pathological finding (any wall-motion abnormalities [WMA] or systolic&#xa0;left ventricular dysfunction) in patients assigned to the observe group by a 0/1-hs-cTnI-algorithm. Cox regression analysis was&#xa0;conducted to investigate the association of pathological findings with all-cause&#xa0;death.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Overall, 2779 patients with available echocardiography were included (median age 63&#xa0;years, 366 [13.2%] with MI, 2158 [77.6%] with data on WMA, median follow-up 5.2&#xa0;years). The PPV to identify MI using bedside echocardiography&#xa0;in the observe group was low (PPV 8.9 [6.3, 12.5]), and the NPV was 95.6 [93.9, 96.9]. After adjustment for relevant covariates, patients with any compared to no pathological finding &#xa0;were at increased risk for all-cause death during follow-up (HR 1.36 [1.06, 1.74], p&#x2009;=&#x2009;0.014).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In this observational study, it could not be shown that bedside echocardiography&#xa0;in the context of suspected acute MI without ST elevation substantially improves diagnostic accuracy beyond hs-cTn-based diagnostic protocols to identify MI in patients assigned to the observe zone. However, findings on echocardiography&#xa0;helped to identify high-risk patients. More prospective evidence on the use of bedside echocardiography&#xa0;is needed&#xa0;to increase the body of evidence. Trial registration ClinicalTrials.gov Identifier: NCT02355457.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Haller</LastName><ForeName>Paul Michael</ForeName><Initials>PM</Initials><Identifier Source="ORCID">0000-0002-7714-4446</Identifier><AffiliationInfo><Affiliation>Department of Cardiology, University Heart and Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. p.haller@uke.de.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Cardiovascular Research (DZHK), Partner Site Hamburg/Kiel/L&#xfc;beck, Hamburg, Germany. p.haller@uke.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schock</LastName><ForeName>Alina</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Cardiology, University Heart and Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kellner</LastName><ForeName>Caroline</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Cardiology, University Heart and Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lehmacher</LastName><ForeName>Jonas</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Cardiology, University Heart and Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Toprak</LastName><ForeName>Bet&#xfc;l</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Cardiology, University Heart and Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Cardiovascular Research (DZHK), Partner Site Hamburg/Kiel/L&#xfc;beck, Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hartikainen</LastName><ForeName>Tau Sarra</ForeName><Initials>TS</Initials><AffiliationInfo><Affiliation>Department of Cardiology, University Heart Center Freiburg Bad Krotzingen, Bad Krotzingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kiss</LastName><ForeName>Kira Marie</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>Department of Cardiology, University Heart and Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alhaou</LastName><ForeName>Gheas</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Cardiology, University Heart and Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peifer</LastName><ForeName>Kristin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Cardiology, University Heart and Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Twerenbold</LastName><ForeName>Raphael</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Cardiology, University Heart and Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Cardiovascular Research (DZHK), Partner Site Hamburg/Kiel/L&#xfc;beck, Hamburg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University Center of Cardiovascular Science, University Heart and Vascular Center Hamburg, Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zeller</LastName><ForeName>Tanja</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Cardiology, University Heart and Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Cardiovascular Research (DZHK), Partner Site Hamburg/Kiel/L&#xfc;beck, Hamburg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University Center of Cardiovascular Science, University Heart and Vascular Center Hamburg, Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Westermann</LastName><ForeName>Dirk</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Cardiology, University Heart and Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Cardiovascular Research (DZHK), Partner Site Hamburg/Kiel/L&#xfc;beck, Hamburg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiology, University Heart Center Freiburg Bad Krotzingen, Bad Krotzingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Neumann</LastName><ForeName>Johannes Tobias</ForeName><Initials>JT</Initials><AffiliationInfo><Affiliation>Department of Cardiology, University Heart and Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Cardiovascular Research (DZHK), Partner Site Hamburg/Kiel/L&#xfc;beck, Hamburg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>S&#xf6;rensen</LastName><ForeName>Nils Arne</ForeName><Initials>NA</Initials><AffiliationInfo><Affiliation>Department of Cardiology, University Heart and Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. n.soerensen@uke.de.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Cardiovascular Research (DZHK), Partner Site Hamburg/Kiel/L&#xfc;beck, Hamburg, Germany. n.soerensen@uke.de.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT02355457</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Clin Res Cardiol</MedlineTA><NlmUniqueID>101264123</NlmUniqueID><ISSNLinking>1861-0684</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Acute myocardial infarction</Keyword><Keyword MajorTopicYN="N">Echocardiography</Keyword><Keyword MajorTopicYN="N">High-sensitivity cardiac troponin</Keyword><Keyword MajorTopicYN="N">TTE</Keyword></KeywordList><CoiStatement>Declarations. Conflict of interest: PMH received travel grants from the German Center of Cardiovascular Research (DZHK) and is supported by a grant of the Faculty of Medicine, University of Hamburg, and by a grant of the German Foundation for Heart Research, and the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) &#x2013;10086/1-1. DW reports personal fees from Bayer, Boehringer-Ingelheim, Berlin Chemie, Astra Zeneca, Biotronik, and Novartis. RT reports research support from the Swiss National Science Foundation (Grant No P300PB_167803), the Swiss Heart Foundation, the Swiss Society of Cardiology, the Cardiovascular Research Foundation Basel, and speaker honoraria/consulting honoraria from Abbott, Amgen, Astra Zeneca, Roche, Siemens, Singulex, and Thermo Fisher. TZ was supported by the German Centre for Cardiovascular Research (FKZ 81Z1710101 and FKZ 81Z0710102). NS received funding grants by the German Heart Foundation and the German Research Foundation. JTN reports speaker honoraria/consulting honoraria from Abbott,&#xa0;PHC, Roche and Siemens. NAS reports speaker honoraria from Siemens. JTN, RT, and TZ are listed as co-inventors of an international patent on the use of a computing device to estimate the probability of myocardial infarction (International Publication Number WO2022043229A1) as well as co-founders and shareholders of the ART-EMIS Hamburg GmbH. All other authors report no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>2</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>19</Day><Hour>12</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>19</Day><Hour>12</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>19</Day><Hour>11</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40828180</ArticleId><ArticleId IdType="doi">10.1007/s00392-025-02724-2</ArticleId><ArticleId IdType="pii">10.1007/s00392-025-02724-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Collet JP, Thiele H, Barbato E et al (2021) 2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 42(14):1289&#x2013;1367. https://doi.org/10.1093/eurheartj/ehaa575</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehaa575</ArticleId><ArticleId IdType="pubmed">32860058</ArticleId></ArticleIdList></Reference><Reference><Citation>Westermann D, Neumann JT, S&#xf6;rensen NA, Blankenberg S (2017) High-sensitivity assays for troponin in patients with cardiac disease. Nat Rev Cardiol 14(8):472&#x2013;483. https://doi.org/10.1038/nrcardio.2017.48</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrcardio.2017.48</ArticleId><ArticleId IdType="pubmed">28383022</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann JT, Sorensen NA, Schwemer T et al (2016) Diagnosis of myocardial infarction using a high-sensitivity troponin I 1-hour algorithm. JAMA Cardiol 1(4):397&#x2013;404. https://doi.org/10.1001/jamacardio.2016.0695</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamacardio.2016.0695</ArticleId><ArticleId IdType="pubmed">27438315</ArticleId></ArticleIdList></Reference><Reference><Citation>Sorensen NA, Gossling A, Neumann JT et al (2021) Diagnostic validation of a high-sensitivity cardiac troponin I assay. Clin Chem 9:1230&#x2013;1239. https://doi.org/10.1093/clinchem/hvab070</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/clinchem/hvab070</ArticleId></ArticleIdList></Reference><Reference><Citation>Twerenbold R, Costabel JP, Nestelberger T et al (2019) Outcome of applying the ESC 0/1-hour algorithm in patients with suspected myocardial infarction. J Am Coll Cardiol 74(4):483&#x2013;494. https://doi.org/10.1016/j.jacc.2019.05.046</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2019.05.046</ArticleId><ArticleId IdType="pubmed">31345421</ArticleId></ArticleIdList></Reference><Reference><Citation>Writing C, Kontos MC, de Lemos JA et al (2022) 2022 ACC expert consensus decision pathway on the evaluation and disposition of acute chest pain in the emergency department: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol 80(20):1925&#x2013;1960. https://doi.org/10.1016/j.jacc.2022.08.750</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2022.08.750</ArticleId></ArticleIdList></Reference><Reference><Citation>Nestelberger T, Boeddinghaus J, Lopez Ayala P et al (2021) Utility of echocardiography in patients with suspected acute myocardial infarction and left bundle-branch block. J Am Heart Assoc 10(18):e021262. https://doi.org/10.1161/JAHA.121.021262</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/JAHA.121.021262</ArticleId><ArticleId IdType="pubmed">34514839</ArticleId><ArticleId IdType="pmc">8649530</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartikainen TS, Sorensen NA, Haller PM et al (2020) Clinical application of the 4th universal definition of myocardial infarction. Eur Heart J 41(23):2209&#x2013;2216. https://doi.org/10.1093/eurheartj/ehaa035</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehaa035</ArticleId><ArticleId IdType="pubmed">32077925</ArticleId></ArticleIdList></Reference><Reference><Citation>Haller PM, Boeddinghaus J, Neumann JT et al (2020) Performance of the ESC 0/1-h and 0/3-h algorithm for the rapid identification of myocardial infarction without ST-elevation in patients with diabetes. Diabetes Care 43(2):460&#x2013;467. https://doi.org/10.2337/dc19-1327</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc19-1327</ArticleId><ArticleId IdType="pubmed">31843947</ArticleId></ArticleIdList></Reference><Reference><Citation>Haller PM, Neumann JT, S&#xf6;rensen NA et al (2021) The association of anaemia and high-sensitivity cardiac troponin and its effect on diagnosing myocardial infarction. European Heart Journal. Acute Cardiovascular Care 10(10):1187&#x2013;1196. https://doi.org/10.1093/ehjacc/zuab066</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ehjacc/zuab066</ArticleId><ArticleId IdType="pubmed">34350455</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xf6;rensen NA, Neumann JT, Ojeda F et al (2021) Differences in measurement of high-sensitivity troponin in an on-demand and batch-wise setting. European Heart Journal. Acute Cardiovascular Care 10(3):302&#x2013;309. https://doi.org/10.1177/2048872620924198</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2048872620924198</ArticleId><ArticleId IdType="pubmed">32700543</ArticleId></ArticleIdList></Reference><Reference><Citation>Haller PM, Sorensen NA, Hartikainen TS, et al. Rising and falling high-sensitivity cardiac troponin in diagnostic algorithms for patients with suspected myocardial infarction. J Am Heart Assoc. May 9 2023:e027166. https://doi.org/10.1161/JAHA.122.027166</Citation></Reference><Reference><Citation>Roffi M, Patrono C, Collet JP et al (2016) 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: task force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 37(3):267&#x2013;315. https://doi.org/10.1093/eurheartj/ehv320</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehv320</ArticleId><ArticleId IdType="pubmed">26320110</ArticleId></ArticleIdList></Reference><Reference><Citation>Thygesen K, Alpert JS, Jaffe AS et al (2019) Fourth universal definition of myocardial infarction (2018). Eur Heart J 40(3):237&#x2013;269. https://doi.org/10.1093/eurheartj/ehy462</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehy462</ArticleId><ArticleId IdType="pubmed">30165617</ArticleId></ArticleIdList></Reference><Reference><Citation>R: A language and environment for statistical computing. R foundatin for Statistical Computing, Vienna, Austria.; 2020. http://www.R-project.org/ .</Citation></Reference><Reference><Citation>Lopez-Ayala P, Nestelberger T, Boeddinghaus J et al (2021) Novel criteria for the observe-zone of the ESC 0/1h-hs-cTnT algorithm. Circulation 144(10):773&#x2013;787. https://doi.org/10.1161/circulationaha.120.052982</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/circulationaha.120.052982</ArticleId><ArticleId IdType="pubmed">34376064</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40543348</PMID><DateRevised><Year>2025</Year><Month>06</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1036-7314</ISSN><JournalIssue CitedMedium="Internet"><Volume>38</Volume><Issue>5</Issue><PubDate><Year>2025</Year><Month>Jun</Month><Day>20</Day></PubDate></JournalIssue><Title>Australian critical care : official journal of the Confederation of Australian Critical Care Nurses</Title><ISOAbbreviation>Aust Crit Care</ISOAbbreviation></Journal><ArticleTitle>Identification of Takotsubo syndrome in intensive care units: A scoping review.</ArticleTitle><Pagination><StartPage>101269</StartPage><MedlinePgn>101269</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.aucc.2025.101269</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1036-7314(25)00099-2</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">The objective of this scoping review was to evaluate existing evidence on assessment and screening tools for Takotsubo syndrome (TTS) with a focus on understanding whether a clinical pathway tailored for intensive care unit (ICU) patients is warranted, given the high risk and complex presentation of Takotsubo syndrome in critically ill populations.</AbstractText><AbstractText Label="REVIEW METHODS AND DATA SOURCES" NlmCategory="METHODS">This review followed the framework of Arksey and O'Malley. Searches spanned 10 databases, including MEDLINE, EMBASE, and CINAHL, plus grey literature, covering English-language studies on adults. The search strategy included Medical Subject Headings terms, keywords, Boolean operators, and truncations. We organised citations with EndNote (Clarivate Analytics, Philadelphia, PA, USA) and screened studies using Covidence, with eligibility confirmed by consensus.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Thirty-two studies met the inclusion criteria, with publications ranging from 1990 to June 2024. Fourteen studies assessed electrocardiographic features to distinguish TTS from other cardiac conditions; 11 studies examined biomarkers with the potential for early detection of TTS. Five studies assessed echocardiographic markers for identifying transient left ventricular dysfunction associated with TTS. Two scoring systems, the International Takotsubo score and Platelets and Thrombosis in Sheba score, show potential for TTS diagnosis but lack validation specific to the ICU, limiting clinical utility. This review found that integrating distinctive electrocardiographic patterns and elevated biomarker ratios could provide valuable early indicators of TTS in intensive care settings. Echocardiographic parameters, including contrast imaging and wall motion score indices, could further support differentiation of TTS from other acute myocardial conditions in critically ill patients.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This review highlights gaps in ICU-specific TTS assessment practices, suggesting that developing a tailored clinical pathway, followed by validation, could support early recognition and management of TTS in ICU settings, enabling timely intervention and enhancing patient outcomes.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 The Author(s). Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Visvanathan</LastName><ForeName>Vicky</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Clinical &amp; Health Sciences, University of South Australia, Adelaide, South Australia, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jayasekara</LastName><ForeName>Rasika</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Clinical &amp; Health Sciences, University of South Australia, Adelaide, South Australia, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Howard</LastName><ForeName>Matylda</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Clinical &amp; Health Sciences, University of South Australia, Adelaide, South Australia, Australia. Electronic address: Matylda.howard@unisa.edu.au.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>06</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Australia</Country><MedlineTA>Aust Crit Care</MedlineTA><NlmUniqueID>9207852</NlmUniqueID><ISSNLinking>1036-7314</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Clinical protocols</Keyword><Keyword MajorTopicYN="N">Critical care</Keyword><Keyword MajorTopicYN="N">Intensive care units</Keyword><Keyword MajorTopicYN="N">Nursing assessment</Keyword><Keyword MajorTopicYN="N">Takotsubo cardiomyopathy</Keyword></KeywordList><CoiStatement>Conflict of interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>11</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>4</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>5</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>6</Month><Day>22</Day><Hour>6</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>6</Month><Day>22</Day><Hour>6</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>6</Month><Day>21</Day><Hour>18</Hour><Minute>8</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40543348</ArticleId><ArticleId IdType="doi">10.1016/j.aucc.2025.101269</ArticleId><ArticleId IdType="pii">S1036-7314(25)00099-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40572675</PMID><DateCompleted><Year>2025</Year><Month>06</Month><Day>27</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1648-9144</ISSN><JournalIssue CitedMedium="Internet"><Volume>61</Volume><Issue>6</Issue><PubDate><Year>2025</Year><Month>May</Month><Day>27</Day></PubDate></JournalIssue><Title>Medicina (Kaunas, Lithuania)</Title><ISOAbbreviation>Medicina (Kaunas)</ISOAbbreviation></Journal><ArticleTitle>The Triglyceride-Glucose Index, a Marker of Insulin Resistance, Is Associated with the Myocardial Performance Index in Asymptomatic Subjects.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">987</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/medicina61060987</ELocationID><Abstract><AbstractText><i>Background and Objectives</i>: The myocardial performance index (MPI) is a diagnostic tool that assesses both the systolic and diastolic function of ventricles. The MPI provides a comprehensive view of the overall efficiency of the heart's pumping ability, making it a valuable tool for detecting early signs of heart dysfunction, even in the absence of overt symptoms. In this regard, we aimed to explore the relationship between the triglyceride-glucose (TyG) index and subclinical heart failure (HF), as well as its correlation with the MPI, in asymptomatic patients visiting a routine cardiology outpatient clinic. The study specifically excluded individuals with known diabetes, hypertension, and HF, focusing instead on those who had undergone 12 h fasting blood glucose (FBG) and triglyceride (TG) tests. <i>Materials and Methods</i>: The study included 125 patients with FBG, TG, total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) data after the exclusion criteria were applied. <i>Results</i>: When asymptomatic patients were categorized as MPI normal or MPI (+) subjects, significant differences were found between the groups in terms of body mass index (BMI), metabolic syndrome (MetS) components, and serum TG values. Pearson correlation analysis revealed a significant and positive correlation between the MPI and TyG index (r = 0.358, <i>p</i> &lt; 0.001). Regression analysis was used to determine the effective parameters in subclinical left ventricular dysfunction (SCLVD). In univariate regression analysis, obesity, the presence of MetS, serum TG, and the TyG index were identified as risk factors. In multivariate regression analysis, the TyG index was found to be the independent risk factor. <i>Conclusions</i>: The positive association found between the MPI and TyG index suggests a link with metabolic disorders and myocardial performance. Obesity, the presence of MetS, serum TG, and the TyG index were identified as risk factors for SCLVD in asymptomatic patients. Notably, the TyG index was identified as an independent risk factor for SCLVD, highlighting its potential role in the early identification and risk stratification of individuals at risk for cardiac dysfunction. These findings suggest that monitoring the TyG index could provide valuable insights into subclinical heart dysfunction, particularly in patients with metabolic abnormalities.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nas</LastName><ForeName>Necip</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Medical Faculty, Siirt University, 56100 Siirt, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aslan</LastName><ForeName>Muzaffer</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Medical Faculty, Siirt University, 56100 Siirt, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saglik</LastName><ForeName>Semih</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-4224-9272</Identifier><AffiliationInfo><Affiliation>Department of Radiology, Siirt Training and Research Hospital, 56000 Siirt, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Uzun</LastName><ForeName>Hafize</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-1347-8498</Identifier><AffiliationInfo><Affiliation>Department of Medical Biochemistry, Faculty of Medicine, Istanbul Atlas University, 34403 Istanbul, Turkey.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>05</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Medicina (Kaunas)</MedlineTA><NlmUniqueID>9425208</NlmUniqueID><ISSNLinking>1010-660X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014280">Triglycerides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001786">Blood Glucose</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014280" MajorTopicYN="Y">Triglycerides</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007333" MajorTopicYN="Y">Insulin Resistance</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001786" MajorTopicYN="Y">Blood Glucose</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006333" MajorTopicYN="N">Heart Failure</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058070" MajorTopicYN="N">Asymptomatic Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015992" MajorTopicYN="N">Body Mass Index</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">asymptomatic subjects</Keyword><Keyword MajorTopicYN="N">metabolic syndrome</Keyword><Keyword MajorTopicYN="N">myocardial performance index</Keyword><Keyword MajorTopicYN="N">subclinical left heart failure</Keyword><Keyword MajorTopicYN="N">triglyceride&#x2013;glucose index</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>4</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>5</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>5</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>6</Month><Day>27</Day><Hour>6</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>6</Month><Day>27</Day><Hour>6</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>6</Month><Day>27</Day><Hour>1</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>5</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40572675</ArticleId><ArticleId IdType="pmc">PMC12195194</ArticleId><ArticleId IdType="doi">10.3390/medicina61060987</ArticleId><ArticleId IdType="pii">medicina61060987</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Artola Arita V., Beigrezaei S., Franco O.H. Risk factors for cardiovascular disease: The known unknown. Eur. J. Prev. Cardiol. 2024;31:e106&#x2013;e107. doi: 10.1093/eurjpc/zwad392.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurjpc/zwad392</ArticleId><ArticleId IdType="pubmed">38099566</ArticleId></ArticleIdList></Reference><Reference><Citation>GBD 2019 Diseases and Injuries Collaborators Global burden of 369 diseases and injuries in 204 countries and territories, 1990&#x2013;2019: A systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396:1204&#x2013;1222. doi: 10.1016/S0140-6736(20)30925-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30925-9</ArticleId><ArticleId IdType="pmc">PMC7567026</ArticleId><ArticleId IdType="pubmed">33069326</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaduganathan M., Mensah G.A., Turco J.V., Fuster V., Roth G.A. The global burden of cardiovascular diseases and risk: A compass for future health. J. Am. Coll. Cardiol. 2022;80:2361&#x2013;2371. doi: 10.1016/j.jacc.2022.11.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2022.11.005</ArticleId><ArticleId IdType="pubmed">36368511</ArticleId></ArticleIdList></Reference><Reference><Citation>Yusuf S., Joseph P., Rangarajan S., Islam S., Mente A., Hystad P., Brauer M., Kutty V.R., Gupta R., Wielgosz A., et al. Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): A prospective cohort study. Lancet. 2020;395:795&#x2013;808. doi: 10.1016/S0140-6736(19)32008-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(19)32008-2</ArticleId><ArticleId IdType="pmc">PMC8006904</ArticleId><ArticleId IdType="pubmed">31492503</ArticleId></ArticleIdList></Reference><Reference><Citation>Tei C., Ling L.H., Hodge D.O., Bailey K.R., Oh J.K., Rodeheffer R.J., Tajik A.J., Seward J.B. New index of combined systolic and diastolic myocardial performance: A simple and reproducible measure of cardiac function&#x2014;A study in normals and dilated cardiomyopathy. J. Cardiol. 1995;26:357&#x2013;366.</Citation><ArticleIdList><ArticleId IdType="pubmed">8558414</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization . WHO Guidelines on Physical Activity and Sedentary Behaviour. World Health Organization; Geneva, Switzerland: 2020.</Citation></Reference><Reference><Citation>Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection Evaluation And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III) JAMA. 2001;285:2486&#x2013;2497. doi: 10.1001/jama.285.19.2486.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.285.19.2486</ArticleId><ArticleId IdType="pubmed">11368702</ArticleId></ArticleIdList></Reference><Reference><Citation>Lang R.M., Badano L.P., Mor-Avi V., Afilalo J., Armstrong A., Ernande L., Flachskampf F.A., Foster E., Goldstein S.A., Kuznetsova T., et al. Recommendations for cardiac chamber quantification by echocardiography in adults: An update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur. Heart J. Cardiovasc. Imaging. 2015;16:233&#x2013;271. doi: 10.1093/ehjci/jev014. Erratum in Eur. Heart J. Cardiovasc. Imaging 2016, 17, 412.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ehjci/jev014</ArticleId><ArticleId IdType="pubmed">25712077</ArticleId></ArticleIdList></Reference><Reference><Citation>Harjai K.J., Scott L., Vivekananthan K., Nunez E., Edupuganti R. The Tei index: A new prognostic index for patients with symptomatic heart failure. J. Am. Soc. Echocardiogr. 2002;15:864&#x2013;868. doi: 10.1067/mje.2002.120892.</Citation><ArticleIdList><ArticleId IdType="doi">10.1067/mje.2002.120892</ArticleId><ArticleId IdType="pubmed">12221401</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheung M.M., Smallhorn J.F., Redington A.N., Vogel M. The effects of changes in loading conditions and modulation of inotropic state on the myocardial performance index: Comparison with conductance catheter measurements. Eur. Heart J. 2004;25:2238&#x2013;2242. doi: 10.1016/j.ehj.2004.07.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ehj.2004.07.034</ArticleId><ArticleId IdType="pubmed">15589642</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagueh S.F., Smiseth O.A., Appleton C.P., Byrd B.F., 3rd, Dokainish H., Edvardsen T., Flachskampf F.A., Gillebert T.C., Klein A.L., Lancellotti P., et al. Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J. Am. Soc. Echocardiogr. 2016;29:277&#x2013;314. doi: 10.1016/j.echo.2016.01.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.echo.2016.01.011</ArticleId><ArticleId IdType="pubmed">27037982</ArticleId></ArticleIdList></Reference><Reference><Citation>Moller J.E., Sondergaard E., Poulsen S.H., Egstrup K. The Doppler echocardiographic myocardial performance index predicts left ventricular dilatation and cardiac death after myocardial infarction. Cardiyology. 2001;95:105&#x2013;111. doi: 10.1159/000047355.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000047355</ArticleId><ArticleId IdType="pubmed">11423716</ArticleId></ArticleIdList></Reference><Reference><Citation>Takasaki K., Otsuji Y., Yoshifuku S., Kuwahara E., Yuasa T., El Rahim A.E.R.A., Matsukida K., Kumanohoso T., Toyonaga K., Kisanuki A., et al. Noninvasive estimation of impaired hemodynamics for patients with acute myocardial infarction by Tei index. J. Am. Soc. Echocardiogr. 2004;17:615&#x2013;621. doi: 10.1016/j.echo.2004.02.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.echo.2004.02.020</ArticleId><ArticleId IdType="pubmed">15163931</ArticleId></ArticleIdList></Reference><Reference><Citation>Spencer K.T., Kirkpatrick J.N., Mor-Avi V., Decara J.M., Lang R.M. Age dependency of the Tei index of myocardial performance. J. Am. Soc. Echocardiogr. 2004;17:350&#x2013;352. doi: 10.1016/j.echo.2004.01.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.echo.2004.01.003</ArticleId><ArticleId IdType="pubmed">15044869</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnl&#xf6;v J., Ingelsson E., Ris&#xe9;rus U., Andr&#xe9;n B., Lind L. Myocardial performance index, a Doppler-derived index of global left ventricular function, predicts congestive heart failure in elderly men. Eur. Heart J. 2004;25:2220&#x2013;2225. doi: 10.1016/j.ehj.2004.10.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ehj.2004.10.021</ArticleId><ArticleId IdType="pubmed">15589639</ArticleId></ArticleIdList></Reference><Reference><Citation>Karvounis H.I., Papadopoulos C.E., Zaglavara T.A., Nouskas I.G., Gemitzis K.D., Parharidis G.E., Louridas G.E. Evidence of left ventricular dysfunction in asymptomatic elderly patients with non-insulin-dependent diabetes mellitus. Angiology. 2004;55:549&#x2013;555. doi: 10.1177/000331970405500511.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/000331970405500511</ArticleId><ArticleId IdType="pubmed">15378118</ArticleId></ArticleIdList></Reference><Reference><Citation>Orem C., K&#xfc;&#xe7;&#xfc;kosmano&#x11f;lu M., Hacihasano&#x11f;lu A., Yilmaz R., Kasap H., Erdo&#x11f;an T., Kaplan &#x15e;., &#xc7;elik &#x15e;. Association of Doppler-derived myocardial performance index with albuminuria in patients with diabetes. J. Am. Soc. Echocardiogr. 2004;17:1185&#x2013;1190. doi: 10.1016/j.echo.2004.07.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.echo.2004.07.006</ArticleId><ArticleId IdType="pubmed">15502795</ArticleId></ArticleIdList></Reference><Reference><Citation>K&#x131;l&#x131;&#xe7; R., Aslan M., Nas N., G&#xfc;zel T. Relationship between presystolic wave and subclinical left ventricular dysfunction as assessed by myocardial performance index in patients with metabolic syndrome. Int. J. Cardiovasc. Imaging. 2023;39:2175&#x2013;2182. doi: 10.1007/s10554-023-02929-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10554-023-02929-4</ArticleId><ArticleId IdType="pubmed">37594699</ArticleId></ArticleIdList></Reference><Reference><Citation>Voulgari C., Moyssakis I., Papazafiropoulou A., Perrea D., Kyriaki D., Katsilambros N., Tentolouris N. The impact of metabolic syndrome on left ventricular myocardial performance. Diabetes Metab. Res. Rev. 2010;26:121&#x2013;127. doi: 10.1002/dmrr.1063.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/dmrr.1063</ArticleId><ArticleId IdType="pubmed">20131336</ArticleId></ArticleIdList></Reference><Reference><Citation>Sreenivasa Kumar M.L., Rajasekhar D., Vanajakshamma V., Latheef K. Impact of metabolic syndrome on global left ventricular function: As evaluated by the myocardial performance index. J. Saudi Heart Assoc. 2014;26:145&#x2013;151. doi: 10.1016/j.jsha.2014.03.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsha.2014.03.003</ArticleId><ArticleId IdType="pmc">PMC4062761</ArticleId><ArticleId IdType="pubmed">24954987</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao Q., Zhou D., Li Y., Wang Y., Xu S.C., Zhao X.H. The Triglyceride-Glucose Index Predicts Coronary Artery Disease Severity and Cardiovascular Outcomes in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome. Dis. Markers. 2019;2019:6891537. doi: 10.1155/2019/6891537.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2019/6891537</ArticleId><ArticleId IdType="pmc">PMC6594265</ArticleId><ArticleId IdType="pubmed">31281548</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Z., Gong H., Kan F., Ji N. Association between the triglyceride glucose (TyG) index and the risk of acute kidney injury in critically ill patients with heart failure: Analysis of the MIMIC-IV database. Cardiovasc. Diabetol. 2023;22:232. doi: 10.1186/s12933-023-01971-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12933-023-01971-9</ArticleId><ArticleId IdType="pmc">PMC10472684</ArticleId><ArticleId IdType="pubmed">37653418</ArticleId></ArticleIdList></Reference><Reference><Citation>Khalaji A., Behnoush A.H., Khanmohammadi S., Mardasi K.G., Sharifkashani S., Sahebkar A., Vinciguerra C., Cannavo A. Triglyceride-glucose index and heart failure: A systematic review and meta-analysis. Cardiovasc. Diabetol. 2023;22:244. doi: 10.1186/s12933-023-01973-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12933-023-01973-7</ArticleId><ArticleId IdType="pmc">PMC10486123</ArticleId><ArticleId IdType="pubmed">37679763</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang F., Hou X. Association between the triglyceride glucose index and heart failure: NHANES 2007&#x2013;2018. Front. Endocrinol. 2024;14:1322445. doi: 10.3389/fendo.2023.1322445.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fendo.2023.1322445</ArticleId><ArticleId IdType="pmc">PMC10839084</ArticleId><ArticleId IdType="pubmed">38317716</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X., Chan J.S.K., Guan B., Peng S., Wu X., Lu X., Zhou J., Hui J.M.H., Lee Y.H.A., Satti D.I., et al. Triglyceride-glucose index and the risk of heart failure: Evidence from two large cohorts and a mendelian randomization analysis. Cardiovasc. Diabetol. 2022;21:229. doi: 10.1186/s12933-022-01658-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12933-022-01658-7</ArticleId><ArticleId IdType="pmc">PMC9635212</ArticleId><ArticleId IdType="pubmed">36329456</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng H., Chen G., Wu K., Wu W., Huang Z., Wang X., Chen Z., Cai Z., Cai Z., Lan Y., et al. Relationship between cumulative exposure to triglyceride-glucose index and heart failure: A prospective cohort study. Cardiovasc. Diabetol. 2023;22:239. doi: 10.1186/s12933-023-01967-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12933-023-01967-5</ArticleId><ArticleId IdType="pmc">PMC10476374</ArticleId><ArticleId IdType="pubmed">37667253</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Q., Yang J., Tang H., Guo Z., Dong W., Wang Y., Meng X., Zhang K., Wang W., Shao C., et al. High triglyceride-glucose (TyG) index is associated with poor prognosis of heart failure with preserved ejection fraction. Cardiovasc. Diabetol. 2023;22:263. doi: 10.1186/s12933-023-02001-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12933-023-02001-4</ArticleId><ArticleId IdType="pmc">PMC10541699</ArticleId><ArticleId IdType="pubmed">37775762</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang R., Wang Z., Chen J., Bao X., Xu N., Guo S., Gu R., Wang W., Wei Z., Wang L. Prognostic value of triglyceride glucose (TyG) index in patients with acute decompensated heart failure. Cardiovasc. Diabetol. 2022;21:88. doi: 10.1186/s12933-022-01507-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12933-022-01507-7</ArticleId><ArticleId IdType="pmc">PMC9158138</ArticleId><ArticleId IdType="pubmed">35641978</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang S., Shi X., Liu W., Wang Z., Li R., Xu X., Wang C., Li L., Wang R., Xu T. Association between triglyceride glucose-body mass index and heart failure in subjects with diabetes mellitus or prediabetes mellitus: A cross-sectional study. Front. Endocrinol. 2023;14:1294909. doi: 10.3389/fendo.2023.1294909.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fendo.2023.1294909</ArticleId><ArticleId IdType="pmc">PMC10655238</ArticleId><ArticleId IdType="pubmed">38027163</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang Y., Shen J., Lyu L. Value of the triglyceride-glucose index and related parameters in heart failure patients. Front. Cardiovasc. Med. 2024;11:1397907. doi: 10.3389/fcvm.2024.1397907.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2024.1397907</ArticleId><ArticleId IdType="pmc">PMC11291214</ArticleId><ArticleId IdType="pubmed">39091358</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang R., Lin Y., Ye X., Zhong X., Xie P., Li M., Zhuang X., Liao X. Triglyceride-glucose index in the development of heart failure and left ventricular dysfunction: Analysis of the ARIC study. Eur. J. Prev. Cardiol. 2022;29:1531&#x2013;1541. doi: 10.1093/eurjpc/zwac058.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurjpc/zwac058</ArticleId><ArticleId IdType="pubmed">35512245</ArticleId></ArticleIdList></Reference><Reference><Citation>Oksen D., Aslan M. Impact of oxidative stress on myocardial performance in patients with diabetes: A focus on subclinical left ventricular dysfunction. BMJ Open Diabetes Res. Care. 2024;12:e004153. doi: 10.1136/bmjdrc-2024-004153.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjdrc-2024-004153</ArticleId><ArticleId IdType="pmc">PMC11184181</ArticleId><ArticleId IdType="pubmed">38886070</ArticleId></ArticleIdList></Reference><Reference><Citation>Aky&#xfc;z A.R., Turan T., G&#xfc;rbak &#x130;., Korkmaz L., A&#x11f;a&#xe7; M.T., &#xc7;elik &#x15e;. The relationship between presystolic wave and subclinical left ventricular dysfunction in asymptomatic hypertensive patients. Blood Press. Monit. 2016;21:277&#x2013;281. doi: 10.1097/MBP.0000000000000199.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MBP.0000000000000199</ArticleId><ArticleId IdType="pubmed">27223102</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40566099</PMID><DateRevised><Year>2025</Year><Month>06</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2077-0383</ISSN><JournalIssue CitedMedium="Print"><Volume>14</Volume><Issue>12</Issue><PubDate><Year>2025</Year><Month>Jun</Month><Day>18</Day></PubDate></JournalIssue><Title>Journal of clinical medicine</Title><ISOAbbreviation>J Clin Med</ISOAbbreviation></Journal><ArticleTitle>Cardio-Oncology and Multi-Imaging Modalities.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">4353</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/jcm14124353</ELocationID><Abstract><AbstractText>Early detection and the rise of targeted cancer treatment have led to increased overall survival and decreased mortality among cancer patients. As the cancer survivor population ages, there is an increased risk for cardiovascular disease due to pre-existing comorbidities, deconditioning during therapy, or the natural progression of aging. Furthermore, with emerging oncologic therapies, there is an increased recognition of their potential cardiovascular toxicities. Indeed, heart disease is the leading cause of death in cancer survivors, which may reflect upon both the success of novel oncologic therapies and their potential cardiovascular toxicities. This recognition has driven the development of cardio-oncology, a multi-disciplinary field that involves collaboration between hematologists, oncologists, and cardiologists to screen, prevent, and manage cardiovascular disease in cancer patients and cancer survivors. The field focuses on early cardiovascular detection and prevention for these patients before, during, and after their oncologic treatment. As oncologic therapies evolve and our knowledge of short- and long-term adverse cardiovascular effects grows, it is critical for physicians to identify those at risk for increased morbidity and mortality, while also balancing the importance of their oncologic treatment plan. Multimodality cardiac imaging is the crux of the diagnosis and surveillance of these patients within cardio-oncology, and includes echocardiography, nuclear, computed tomography (CT), and cardiac magnetic resonance (CMR). Cardiac imaging is essential to establish the baseline function and assess various cardiotoxicities, including left ventricular dysfunction, heart failure, atherosclerosis, vascular injury, and arrhythmias. This review will discuss common oncologic therapies and their cardiotoxic profiles, the cardiac multimodality imaging modalities used in cardio-oncology, and the various approaches for the diagnosis and surveillance of this population.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Christine M</ForeName><Initials>CM</Initials><Identifier Source="ORCID">0000-0001-8732-5307</Identifier><AffiliationInfo><Affiliation>Division of Cardiology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY 10461, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lerman</LastName><ForeName>Ben</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY 10461, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Contreras Yametti</LastName><ForeName>Felipe</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0003-0799-4805</Identifier><AffiliationInfo><Affiliation>Division of Cardiology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY 10461, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garcia</LastName><ForeName>Mario</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY 10461, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Slipczuk</LastName><ForeName>Leandro</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0003-3091-3735</Identifier><AffiliationInfo><Affiliation>Division of Cardiology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY 10461, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schenone</LastName><ForeName>Aldo L</ForeName><Initials>AL</Initials><Identifier Source="ORCID">0000-0002-1554-4188</Identifier><AffiliationInfo><Affiliation>Division of Cardiology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY 10461, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Lili</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY 10461, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gongora</LastName><ForeName>Carlos A</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY 10461, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>06</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>J Clin Med</MedlineTA><NlmUniqueID>101606588</NlmUniqueID><ISSNLinking>2077-0383</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cardio-oncology</Keyword><Keyword MajorTopicYN="N">multi-modality imaging</Keyword></KeywordList><CoiStatement>The authors have no conflicts of interest to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>4</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>6</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>6</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>6</Month><Day>26</Day><Hour>6</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>6</Month><Day>26</Day><Hour>6</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>6</Month><Day>26</Day><Hour>1</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>6</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40566099</ArticleId><ArticleId IdType="pmc">PMC12194156</ArticleId><ArticleId IdType="doi">10.3390/jcm14124353</ArticleId><ArticleId IdType="pii">jcm14124353</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lenneman C.G., Sawyer D.B. Cardio-Oncology: An Update on Cardiotoxicity of Cancer-Related Treatment. Circ. Res. 2016;118:1008&#x2013;1020. doi: 10.1161/CIRCRESAHA.115.303633.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.115.303633</ArticleId><ArticleId IdType="pubmed">26987914</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrmann J., Lenihan D., Armenian S., Barac A., Blaes A., Cardinale D., Carver J., Dent S., Ky B., Lyon A.R., et al. Defining Cardiovascular Toxicities of Cancer Therapies: An International Cardio-Oncology Society (IC-OS) Consensus Statement. Eur. Heart J. 2022;43:280&#x2013;299. doi: 10.1093/eurheartj/ehab674.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehab674</ArticleId><ArticleId IdType="pmc">PMC8803367</ArticleId><ArticleId IdType="pubmed">34904661</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrmann J., Lerman A., Sandhu N.P., Villarraga H.R., Mulvagh S.L., Kohli M. Evaluation and Management of Patients with Heart Disease and Cancer: Cardio-Oncology. Mayo Clin. Proc. 2014;89:1287&#x2013;1306. doi: 10.1016/j.mayocp.2014.05.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mayocp.2014.05.013</ArticleId><ArticleId IdType="pmc">PMC4258909</ArticleId><ArticleId IdType="pubmed">25192616</ArticleId></ArticleIdList></Reference><Reference><Citation>Baldassarre L.A., Ganatra S., Lopez-Mattei J., Yang E.H., Zaha V.G., Wong T.C., Ayoub C., DeCara J.M., Dent S., Deswal A., et al. Advances in Multimodality Imaging in Cardio-Oncology: JACC State-of-the-Art Review. J. Am. Coll. Cardiol. 2022;80:1560&#x2013;1578. doi: 10.1016/j.jacc.2022.08.743.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2022.08.743</ArticleId><ArticleId IdType="pubmed">36229093</ArticleId></ArticleIdList></Reference><Reference><Citation>Camilli M., Cipolla C.M., Dent S., Minotti G., Cardinale D.M. Anthracycline Cardiotoxicity in Adult Cancer Patients: JACC: CardioOncology State-of-the-Art Review. JACC CardioOncol. 2024;6:655&#x2013;677. doi: 10.1016/j.jaccao.2024.07.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaccao.2024.07.016</ArticleId><ArticleId IdType="pmc">PMC11520218</ArticleId><ArticleId IdType="pubmed">39479333</ArticleId></ArticleIdList></Reference><Reference><Citation>Dempsey N., Rosenthal A., Dabas N., Kropotova Y., Lippman M., Bishopric N.H. Trastuzumab-Induced Cardiotoxicity: A Review of Clinical Risk Factors, Pharmacologic Prevention, and Cardiotoxicity of Other HER2-Directed Therapies. Breast Cancer Res. Treat. 2021;188:21&#x2013;36. doi: 10.1007/s10549-021-06280-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10549-021-06280-x</ArticleId><ArticleId IdType="pubmed">34115243</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Q., Bai B., Tian C., Li D., Yu H., Song B., Li B., Chu X. The Molecular Mechanisms of Cardiotoxicity Induced by HER2, VEGF, and Tyrosine Kinase Inhibitors: An Updated Review. Cardiovasc. Drugs Ther. 2022;36:511&#x2013;524. doi: 10.1007/s10557-021-07181-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10557-021-07181-3</ArticleId><ArticleId IdType="pubmed">33847848</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyon A.R., Lopez-Fernandez T., Couch L.S., Asteggiano R., Aznar M.C., Bergler-Klein J., Boriani G., Cardinale D., Cordoba R., Cosyns B., et al. 2022 ESC Guidelines on Cardio-Oncology Developed in Collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS) Eur. Heart J. 2022;43:4229&#x2013;4361. doi: 10.1093/eurheartj/ehac244.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehac244</ArticleId><ArticleId IdType="pubmed">36017568</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahmood S.S., Fradley M.G., Cohen J.V., Nohria A., Reynolds K.L., Heinzerling L.M., Sullivan R.J., Damrongwatanasuk R., Chen C.L., Gupta D., et al. Myocarditis in Patients Treated with Immune Checkpoint Inhibitors. J. Am. Coll. Cardiol. 2018;71:1755&#x2013;1764. doi: 10.1016/j.jacc.2018.02.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2018.02.037</ArticleId><ArticleId IdType="pmc">PMC6196725</ArticleId><ArticleId IdType="pubmed">29567210</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L., Awadalla M., Mahmood S.S., Nohria A., Hassan M.Z.O., Thuny F., Zlotoff D.A., Murphy S.P., Stone J.R., Golden D.L.A., et al. Cardiovascular Magnetic Resonance in Immune Checkpoint Inhibitor-Associated Myocarditis. Eur. Heart J. 2020;41:1733&#x2013;1743. doi: 10.1093/eurheartj/ehaa051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehaa051</ArticleId><ArticleId IdType="pmc">PMC7205467</ArticleId><ArticleId IdType="pubmed">32112560</ArticleId></ArticleIdList></Reference><Reference><Citation>Frascaro F., Bianchi N., Sanguettoli F., Marchini F., Meossi S., Zanarelli L., Tonet E., Serenelli M., Guardigli G., Campo G., et al. Immune Checkpoint Inhibitors-Associated Myocarditis: Diagnosis, Treatment and Current Status on Rechallenge. J. Clin. Med. 2023;12:7737. doi: 10.3390/jcm12247737.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm12247737</ArticleId><ArticleId IdType="pmc">PMC10744238</ArticleId><ArticleId IdType="pubmed">38137806</ArticleId></ArticleIdList></Reference><Reference><Citation>Brahmer J.R., Abu-Sbeih H., Ascierto P.A., Brufsky J., Cappelli L.C., Cortazar F.B., Gerber D.E., Hamad L., Hansen E., Johnson D.B., et al. Society for Immunotherapy of Cancer (SITC) Clinical Practice Guideline on Immune Checkpoint Inhibitor-Related Adverse Events. J. Immunother. Cancer. 2021;9:e002435. doi: 10.1136/jitc-2021-002435.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jitc-2021-002435</ArticleId><ArticleId IdType="pmc">PMC8237720</ArticleId><ArticleId IdType="pubmed">34172516</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonaca M.P., Olenchock B.A., Salem J.E., Wiviott S.D., Ederhy S., Cohen A., Stewart G.C., Choueiri T.K., Di Carli M., Allenbach Y., et al. Myocarditis in the Setting of Cancer Therapeutics: Proposed Case Definitions for Emerging Clinical Syndromes in Cardio-Oncology. Circulation. 2019;140:80&#x2013;91. doi: 10.1161/CIRCULATIONAHA.118.034497.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.118.034497</ArticleId><ArticleId IdType="pmc">PMC6779326</ArticleId><ArticleId IdType="pubmed">31390169</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrmann J. Adverse Cardiac Effects of Cancer Therapies: Cardiotoxicity and Arrhythmia. Nat. Rev. Cardiol. 2020;17:474&#x2013;502. doi: 10.1038/s41569-020-0348-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41569-020-0348-1</ArticleId><ArticleId IdType="pmc">PMC8782611</ArticleId><ArticleId IdType="pubmed">32231332</ArticleId></ArticleIdList></Reference><Reference><Citation>Fradley M.G., Beckie T.M., Brown S.A., Cheng R.K., Dent S.F., Nohria A., Patton K.K., Singh J.P., Olshansky B. Recognition, Prevention, and Management of Arrhythmias and Autonomic Disorders in Cardio-Oncology: A Scientific Statement from the American Heart Association. Circulation. 2021;144:e41&#x2013;e55. doi: 10.1161/CIR.0000000000000986.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIR.0000000000000986</ArticleId><ArticleId IdType="pmc">PMC8992663</ArticleId><ArticleId IdType="pubmed">34134525</ArticleId></ArticleIdList></Reference><Reference><Citation>Touyz R.M., Herrmann J. Cardiotoxicity with Vascular Endothelial Growth Factor Inhibitor Therapy. NPJ Precis. Oncol. 2018;2:13. doi: 10.1038/s41698-018-0056-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41698-018-0056-z</ArticleId><ArticleId IdType="pmc">PMC5988734</ArticleId><ArticleId IdType="pubmed">30202791</ArticleId></ArticleIdList></Reference><Reference><Citation>Li W., Cornell R.F., Lenihan D., Slosky D., Jagasia M., Piazza G., Moslehi J. Cardiovascular Complications of Novel Multiple Myeloma Treatments. Circulation. 2016;133:908&#x2013;912. doi: 10.1161/CIRCULATIONAHA.115.018351.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.115.018351</ArticleId><ArticleId IdType="pubmed">26927008</ArticleId></ArticleIdList></Reference><Reference><Citation>More L.A., Lane S., Asnani A. 5-FU Cardiotoxicity: Vasospasm, Myocarditis, and Sudden Death. Curr. Cardiol. Rep. 2021;23:17. doi: 10.1007/s11886-021-01441-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11886-021-01441-2</ArticleId><ArticleId IdType="pubmed">33537861</ArticleId></ArticleIdList></Reference><Reference><Citation>Ell P., Martin J.M., Cehic D.A., Ngo D.T.M., Sverdlov A.L. Cardiotoxicity of Radiation Therapy: Mechanisms, Management, and Mitigation. Curr. Treat. Options Oncol. 2021;22:70. doi: 10.1007/s11864-021-00868-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11864-021-00868-7</ArticleId><ArticleId IdType="pubmed">34110500</ArticleId></ArticleIdList></Reference><Reference><Citation>Giza D.E., Boccalandro F., Lopez-Mattei J., Iliescu G., Karimzad K., Kim P., Iliescu C. Ischemic Heart Disease: Special Considerations in Cardio-Oncology. Curr. Treat. Options Cardiovasc. Med. 2017;19:37. doi: 10.1007/s11936-017-0535-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11936-017-0535-5</ArticleId><ArticleId IdType="pubmed">28425056</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobson R., Ghosh A.K., Ky B., Marwick T., Stout M., Harkness A., Steeds R., Robinson S., Oxborough D., Adlam D., et al. BSE and BCOS Guideline for Transthoracic Echocardiographic Assessment of Adult Cancer Patients Receiving Anthracyclines and/or Trastuzumab. JACC CardioOncol. 2021;3:1&#x2013;16. doi: 10.1016/j.jaccao.2021.01.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaccao.2021.01.011</ArticleId><ArticleId IdType="pmc">PMC8352267</ArticleId><ArticleId IdType="pubmed">34396303</ArticleId></ArticleIdList></Reference><Reference><Citation>Sartorio A., Cristin L., Pont C.D., Farzaneh-Far A., Romano S. Global Longitudinal Strain as an Early Marker of Cardiac Damage after Cardiotoxic Medications, a State of the Art Review. Prog. Cardiovasc. Dis. 2025;89:92&#x2013;101. doi: 10.1016/j.pcad.2025.01.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pcad.2025.01.001</ArticleId><ArticleId IdType="pubmed">39798593</ArticleId></ArticleIdList></Reference><Reference><Citation>Thavendiranathan P., Poulin F., Lim K.D., Plana J.C., Woo A., Marwick T.H. Use of Myocardial Strain Imaging by Echocardiography for the Early Detection of Cardiotoxicity in Patients during and after Cancer Chemotherapy: A Systematic Review. J. Am. Coll. Cardiol. 2014;63:2751&#x2013;2768. doi: 10.1016/j.jacc.2014.01.073.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2014.01.073</ArticleId><ArticleId IdType="pubmed">24703918</ArticleId></ArticleIdList></Reference><Reference><Citation>Oikonomou E.K., Kokkinidis D.G., Kampaktsis P.N., Amir E.A., Marwick T.H., Gupta D., Thavendiranathan P. Assessment of Prognostic Value of Left Ventricular Global Longitudinal Strain for Early Prediction of Chemotherapy-Induced Cardiotoxicity: A Systematic Review and Meta-Analysis. JAMA Cardiol. 2019;4:1007&#x2013;1018. doi: 10.1001/jamacardio.2019.2952.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamacardio.2019.2952</ArticleId><ArticleId IdType="pmc">PMC6705141</ArticleId><ArticleId IdType="pubmed">31433450</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J.E., Barac A., Thavendiranathan P., Scherrer-Crosbie M. Strain Imaging in Cardio-Oncology. JACC CardioOncol. 2020;2:677&#x2013;689. doi: 10.1016/j.jaccao.2020.10.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaccao.2020.10.011</ArticleId><ArticleId IdType="pmc">PMC8352045</ArticleId><ArticleId IdType="pubmed">34396282</ArticleId></ArticleIdList></Reference><Reference><Citation>Nazir M.S., Okafor J., Murphy T., Andres M.S., Ramalingham S., Rosen S.D., Chiribiri A., Plein S., Prasad S., Mohiaddin R., et al. Echocardiography versus Cardiac MRI for Measurement of Left Ventricular Ejection Fraction in Individuals with Cancer and Suspected Cardiotoxicity. Radiol. Cardiothorac. Imaging. 2024;6:e230048. doi: 10.1148/ryct.230048.</Citation><ArticleIdList><ArticleId IdType="doi">10.1148/ryct.230048</ArticleId><ArticleId IdType="pmc">PMC10912891</ArticleId><ArticleId IdType="pubmed">38206164</ArticleId></ArticleIdList></Reference><Reference><Citation>Lorenzo-Esteller L., Ramos-Polo R., Pons Riverola A., Morillas H., Berdejo J., Pernas S., Pomares H., Asiain L., Garay A., Martinez Perez E., et al. Pericardial Disease in Patients with Cancer: Clinical Insights on Diagnosis and Treatment. Cancers. 2024;16:3466. doi: 10.3390/cancers16203466.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers16203466</ArticleId><ArticleId IdType="pmc">PMC11505731</ArticleId><ArticleId IdType="pubmed">39456560</ArticleId></ArticleIdList></Reference><Reference><Citation>Yalta K., Yilmaztepe M., Zorkun C. Left Ventricular Dysfunction in the Setting of Takotsubo Cardiomyopathy: A Review of Clinical Patterns and Practical Implications. Card. Fail. Rev. 2018;4:14&#x2013;20. doi: 10.15420/cfr.2018:24:2.</Citation><ArticleIdList><ArticleId IdType="doi">10.15420/cfr.2018:24:2</ArticleId><ArticleId IdType="pmc">PMC5971666</ArticleId><ArticleId IdType="pubmed">29892470</ArticleId></ArticleIdList></Reference><Reference><Citation>Addison D., Neilan T.G., Barac A., Scherrer-Crosbie M., Okwuosa T.M., Plana J.C., Reding K.W., Taqueti V.R., Yang E.H., Zaha V.G., et al. Cardiovascular Imaging in Contemporary Cardio-Oncology: A Scientific Statement from the American Heart Association. Circulation. 2023;148:1271&#x2013;1286. doi: 10.1161/CIR.0000000000001174.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIR.0000000000001174</ArticleId><ArticleId IdType="pubmed">37732422</ArticleId></ArticleIdList></Reference><Reference><Citation>Thavendiranathan P., Zhang L., Zafar A., Drobni Z.D., Mahmood S.S., Cabral M., Awadalla M., Nohria A., Zlotoff D.A., Thuny F., et al. Myocardial T1 and T2 Mapping by Magnetic Resonance in Patients with Immune Checkpoint Inhibitor-Associated Myocarditis. J. Am. Coll. Cardiol. 2021;77:1503&#x2013;1516. doi: 10.1016/j.jacc.2021.01.050.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2021.01.050</ArticleId><ArticleId IdType="pmc">PMC8442989</ArticleId><ArticleId IdType="pubmed">33766256</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreira V.M., Schulz-Menger J., Holmvang G., Kramer C.M., Carbone I., Sechtem U., Kindermann I., Gutberlet M., Cooper L.T., Liu P., et al. Cardiovascular Magnetic Resonance in Nonischemic Myocardial Inflammation. J. Am. Coll. Cardiol. 2018;72:3158&#x2013;3176. doi: 10.1016/j.jacc.2018.09.072.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2018.09.072</ArticleId><ArticleId IdType="pubmed">30545455</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang T.K.M., Jellis C.L., Cremer P.C., Bolen M.A., Flamm S.D., Klein A.L. Cardiac Magnetic Resonance Imaging Techniques and Applications for Pericardial Diseases. Circ. Cardiovasc. Imaging. 2022;15:e014283. doi: 10.1161/CIRCIMAGING.122.014283.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCIMAGING.122.014283</ArticleId><ArticleId IdType="pubmed">35861978</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Mattei J.C., Yang E.H., Ferencik M., Baldassarre L.A., Dent S., Budoff M.J. Cardiac Computed Tomography in Cardio-Oncology. JACC CardioOncol. 2021;3:635&#x2013;649. doi: 10.1016/j.jaccao.2021.09.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaccao.2021.09.010</ArticleId><ArticleId IdType="pmc">PMC8702811</ArticleId><ArticleId IdType="pubmed">34988472</ArticleId></ArticleIdList></Reference><Reference><Citation>Erthal F., Premaratne M., Yam Y., Chen L., Lamba J., Keenan M., Haddad T., Pharasi K., Anand S., Beanlands R.S., et al. Appropriate Use Criteria for Cardiac Computed Tomography: Does Computed Tomography Have Incremental Value in All Appropriate Use Criteria Categories? J. Thorac. Imaging. 2018;33:132&#x2013;137. doi: 10.1097/RTI.0000000000000297.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/RTI.0000000000000297</ArticleId><ArticleId IdType="pubmed">28914747</ArticleId></ArticleIdList></Reference><Reference><Citation>Milazzo V., Cosentino N., Campodonico J., Lucci C., Cardinale D., Cipolla C.M., Marenzi G. Characteristics, Management, and Outcomes of Acute Coronary Syndrome Patients with Cancer. J. Clin. Med. 2020;9:3642. doi: 10.3390/jcm9113642.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm9113642</ArticleId><ArticleId IdType="pmc">PMC7696544</ArticleId><ArticleId IdType="pubmed">33198355</ArticleId></ArticleIdList></Reference><Reference><Citation>Driessen R.S., Danad I., Stuijfzand W.J., Raijmakers P.G., Schumacher S.P., Van Diemen P.A., Leipsic J.A., Knuuti J., Underwood S.R., Van De Ven P.M., et al. Comparison of Coronary Computed Tomography Angiography, Fractional Flow Reserve, and Perfusion Imaging for Ischemia Diagnosis. J. Am. Coll. Cardiol. 2019;73:161&#x2013;173. doi: 10.1016/j.jacc.2018.10.056.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2018.10.056</ArticleId><ArticleId IdType="pubmed">30654888</ArticleId></ArticleIdList></Reference><Reference><Citation>Tyebally S., Chen D., Bhattacharyya S., Mughrabi A., Hussain Z., Manisty C., Westwood M., Ghosh A.K., Guha A. Cardiac Tumors. JACC CardioOncol. 2020;2:293&#x2013;311. doi: 10.1016/j.jaccao.2020.05.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaccao.2020.05.009</ArticleId><ArticleId IdType="pmc">PMC8352246</ArticleId><ArticleId IdType="pubmed">34396236</ArticleId></ArticleIdList></Reference><Reference><Citation>Angeli F., Bodega F., Bergamaschi L., Armillotta M., Amicone S., Canton L., Fedele D., Suma N., Cavallo D., Fo&#xe0; A., et al. Multimodality Imaging in the Diagnostic Work-Up of Patients with Cardiac Masses. JACC CardioOncol. 2024;6:847&#x2013;862. doi: 10.1016/j.jaccao.2024.09.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaccao.2024.09.006</ArticleId><ArticleId IdType="pmc">PMC11711820</ArticleId><ArticleId IdType="pubmed">39801632</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang K.W., Finkelman B.S., Gulati G., Narayan H.K., Upshaw J., Narayan V., Plappert T., Englefield V., Smith A.M., Zhang C., et al. Abnormalities in 3-Dimensional Left Ventricular Mechanics with Anthracycline Chemotherapy Are Associated with Systolic and Diastolic Dysfunction. JACC Cardiovasc. Imaging. 2018;11:1059&#x2013;1068. doi: 10.1016/j.jcmg.2018.01.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcmg.2018.01.015</ArticleId><ArticleId IdType="pmc">PMC6417916</ArticleId><ArticleId IdType="pubmed">29550306</ArticleId></ArticleIdList></Reference><Reference><Citation>Camilli M., Ferdinandy P., Salvatorelli E., Menna P., Minotti G. Anthracyclines, Diastolic Dysfunction and the Road to Heart Failure in Cancer Survivors: An Untold Story. Prog. Cardiovasc. Dis. 2024;86:38&#x2013;47. doi: 10.1016/j.pcad.2024.07.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pcad.2024.07.002</ArticleId><ArticleId IdType="pubmed">39025347</ArticleId></ArticleIdList></Reference><Reference><Citation>Sawyer D.B., Zuppinger C., Miller T.A., Eppenberger H.M., Suter T.M. Modulation of Anthracycline-Induced Myofibrillar Disarray in Rat Ventricular Myocytes by Neuregulin-1beta and Anti-erbB2: Potential Mechanism for Trastuzumab-Induced Cardiotoxicity. Circulation. 2002;105:1551&#x2013;1554. doi: 10.1161/01.CIR.0000013839.41224.1C.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.CIR.0000013839.41224.1C</ArticleId><ArticleId IdType="pubmed">11927521</ArticleId></ArticleIdList></Reference><Reference><Citation>Georgiopoulos G., Makris N., Laina A., Theodorakakou F., Briasoulis A., Trougakos I.P., Dimopoulos M.A., Kastritis E., Stamatelopoulos K. Cardiovascular Toxicity of Proteasome Inhibitors: Underlying Mechanisms and Management Strategies: JACC: CardioOncology State-of-the-Art Review. JACC CardioOncol. 2023;5:1&#x2013;21. doi: 10.1016/j.jaccao.2022.12.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaccao.2022.12.005</ArticleId><ArticleId IdType="pmc">PMC9982226</ArticleId><ArticleId IdType="pubmed">36875897</ArticleId></ArticleIdList></Reference><Reference><Citation>Senechal I., Andres M.S., Tong J., Ramalingam S., Nazir M.S., Rosen S.D., Young K., Idaikkadar P., Larkin J., Lyon A.R. Risk Stratification, Screening and Treatment of BRAF/MEK Inhibitors-Associated Cardiotoxicity. Curr. Oncol. Rep. 2024;26:1431&#x2013;1441. doi: 10.1007/s11912-024-01599-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11912-024-01599-2</ArticleId><ArticleId IdType="pubmed">39316222</ArticleId></ArticleIdList></Reference><Reference><Citation>Mincu R.I., Mahabadi A.A., Michel L., Mrotzek S.M., Schadendorf D., Rassaf T., Totzeck M. Cardiovascular Adverse Events Associated with BRAF and MEK Inhibitors: A Systematic Review and Meta-Analysis. JAMA Netw. Open. 2019;2:e198890. doi: 10.1001/jamanetworkopen.2019.8890.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2019.8890</ArticleId><ArticleId IdType="pmc">PMC6692687</ArticleId><ArticleId IdType="pubmed">31397860</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu T.F., Rupnick M.A., Kerkela R., Dallabrida S.M., Zurakowski D., Nguyen L., Woulfe K., Pravda E., Cassiola F., Desai J., et al. Cardiotoxicity Associated with Tyrosine Kinase Inhibitor Sunitinib. Lancet. 2007;370:2011&#x2013;2019. doi: 10.1016/S0140-6736(07)61865-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(07)61865-0</ArticleId><ArticleId IdType="pmc">PMC2643085</ArticleId><ArticleId IdType="pubmed">18083403</ArticleId></ArticleIdList></Reference><Reference><Citation>Santoni M., Guerra F., Conti A., Lucarelli A., Rinaldi S., Belvederesi L., Capucci A., Berardi R. Incidence and Risk of Cardiotoxicity in Cancer Patients Treated with Targeted Therapies. Cancer Treat Rev. 2017;59:123&#x2013;131. doi: 10.1016/j.ctrv.2017.07.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ctrv.2017.07.006</ArticleId><ArticleId IdType="pubmed">28818671</ArticleId></ArticleIdList></Reference><Reference><Citation>Webster R.M. The Immune Checkpoint Inhibitors: Where Are We Now? Nat Rev Drug Discov. 2014;13:883&#x2013;884. doi: 10.1038/nrd4476.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd4476</ArticleId><ArticleId IdType="pubmed">25345674</ArticleId></ArticleIdList></Reference><Reference><Citation>Sterner R.C., Sterner R.M. CAR-T Cell Therapy: Current Limitations and Potential Strategies. Blood Cancer J. 2021;11:69. doi: 10.1038/s41408-021-00459-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41408-021-00459-7</ArticleId><ArticleId IdType="pmc">PMC8024391</ArticleId><ArticleId IdType="pubmed">33824268</ArticleId></ArticleIdList></Reference><Reference><Citation>Lefebvre B., Kang Y., Smith A.M., Frey N.V., Carver J.R., Scherrer-Crosbie M. Cardiovascular Effects of CAR T Cell Therapy: A Retrospective Study. JACC CardioOncol. 2020;2:193&#x2013;203. doi: 10.1016/j.jaccao.2020.04.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaccao.2020.04.012</ArticleId><ArticleId IdType="pmc">PMC7413146</ArticleId><ArticleId IdType="pubmed">32776016</ArticleId></ArticleIdList></Reference><Reference><Citation>Bayraktar U.D., Bashir Q., Qazilbash M., Champlin R.E., Ciurea S.O. Fifty Years of Melphalan Use in Hematopoietic Stem Cell Transplantation. Biol. Blood Marrow Transplant. 2013;19:344&#x2013;356. doi: 10.1016/j.bbmt.2012.08.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbmt.2012.08.011</ArticleId><ArticleId IdType="pmc">PMC4337224</ArticleId><ArticleId IdType="pubmed">22922522</ArticleId></ArticleIdList></Reference><Reference><Citation>Feliz V., Saiyad S., Ramarao S.M., Khan H., Leonelli F., Guglin M. Melphalan-Induced Supraventricular Tachycardia: Incidence and Risk Factors. Clin. Cardiol. 2011;34:356&#x2013;359. doi: 10.1002/clc.20904.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/clc.20904</ArticleId><ArticleId IdType="pmc">PMC6652479</ArticleId><ArticleId IdType="pubmed">21538392</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhesi S., Chu M.P., Blevins G., Paterson I., Larratt L., Oudit G.Y., Kim D.H. Cyclophosphamide-Induced Cardiomyopathy: A Case Report, Review, and Recommendations for Management. J. Investig. Med. High Impact Case Rep. 2013;1:2324709613480346. doi: 10.1177/2324709613480346.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2324709613480346</ArticleId><ArticleId IdType="pmc">PMC4528786</ArticleId><ArticleId IdType="pubmed">26425570</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamphuis J.A.M., Linschoten M., Cramer M.J., Gort E.H., van Rhenen A., Asselbergs F.W., Doevendans P.A., Teske A.J. Cancer Therapy-Related Cardiac Dysfunction of Nonanthracycline Chemotherapeutics: What Is the Evidence? JACC CardioOncol. 2019;1:280&#x2013;290. doi: 10.1016/j.jaccao.2019.09.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaccao.2019.09.007</ArticleId><ArticleId IdType="pmc">PMC8352330</ArticleId><ArticleId IdType="pubmed">34396190</ArticleId></ArticleIdList></Reference><Reference><Citation>Gongora C.A. Are Sodium-Glucose Cotransporter-2 Inhibitors the Cherry on Top of Cardio-Oncology Care? Cardiovasc. Drugs Ther. 2024:1&#x2013;8. doi: 10.1007/s10557-024-07604-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10557-024-07604-x</ArticleId><ArticleId IdType="pubmed">38958827</ArticleId></ArticleIdList></Reference><Reference><Citation>Gongora C.A., Drobni Z.D., Quinaglia Araujo Costa Silva T., Zafar A., Gong J., Zlotoff D.A., Gilman H.K., Hartmann S.E., Sama S., Nikolaidou S., et al. Sodium-Glucose Co-Transporter-2 Inhibitors and Cardiac Outcomes Among Patients Treated with Anthracyclines. J. Am. Coll. Cardiol. Heart Fail. 2022;10:559&#x2013;567. doi: 10.1016/j.jchf.2022.03.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jchf.2022.03.006</ArticleId><ArticleId IdType="pmc">PMC9638993</ArticleId><ArticleId IdType="pubmed">35902159</ArticleId></ArticleIdList></Reference><Reference><Citation>Maamari D.J., Biddinger K.J., Jurgens S.J., R&#xe4;m&#xf6; J.T., Zheng A., Hayes D., Gongora C.A., Choi S.H., Arany Z., Thavendiranathan P., et al. Polygenic Susceptibility to Dilated Cardiomyopathy Underlies Peripartum, Alcohol-Induced, and Cancer Therapy-Related Cardiomyopathies. medRxiv. 2025 doi: 10.1101/2025.02.17.25321705.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2025.02.17.25321705</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40558663</PMID><DateRevised><Year>2025</Year><Month>06</Month><Day>27</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2308-3425</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>6</Issue><PubDate><Year>2025</Year><Month>Jun</Month><Day>14</Day></PubDate></JournalIssue><Title>Journal of cardiovascular development and disease</Title><ISOAbbreviation>J Cardiovasc Dev Dis</ISOAbbreviation></Journal><ArticleTitle>Severe Myocardial Involvement and Persistent Supraventricular Arrhythmia in a Premature Infant Due to Enterovirus Infection: Case Report and Literature Review.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">228</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/jcdd12060228</ELocationID><Abstract><AbstractText>Enterovirus (EV) infections in neonates can be transmitted vertically or horizontally, with symptoms ranging from mild to severe, including myocarditis, meningoencephalitis, and hepatitis. Neonates with EV-induced myocarditis may present severe cardiovascular disease with sudden onset of arrhythmia. Neonatal arrhythmias, particularly in low birth weight or critically ill infants, can impair cardiac function and worsen outcomes. EV targets cardiomyocyte receptors, inducing apoptosis pathways and triggering cardiac conduction disturbances. We present an extremely low-birth-weight preterm infant (GW 27 + 6) who developed EV-induced myocarditis, complicated with a sudden onset of supraventricular tachycardia (SVT), pericardial effusion and bi-atrial enlargement. Despite multi-agent regimen, including propranolol, flecainide, and amiodarone, the infant showed persistent junctional rhythm until seven months of age, later transitioning to atrial rhythm with stable cardiac function. A review of previously published rhythm disturbances due to EV-induced myocarditis is presented. Newborns with EV-induced arrhythmia may require a multi-modal treatment such as a multi-agent medical regimen or, in severe non-responsive cases, an electrophysiological approach. EV infections may cause long-term cardiovascular comorbidities (such as left ventricular dysfunction or mitral valve regurgitation), necessitating continuous monitoring through echocardiography and ECG. Collaboration between neonatologists and pediatric cardiologists is crucial for effective treatment and follow-up.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Montobbio</LastName><ForeName>Carolina</ForeName><Initials>C</Initials><Identifier Source="ORCID">0009-0009-0341-6750</Identifier><AffiliationInfo><Affiliation>Neonatal Intensive Care Unit, Department of Maternal and Neonatal Health, IRCCS Istituto Giannina Gaslini, 16147 Genoa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Conte</LastName><ForeName>Alessio</ForeName><Initials>A</Initials><Identifier Source="ORCID">0009-0006-5781-3178</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Mother and Child Health, School of Medical and Pharmaceuticals, University of Genoa, 16132 Genoa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Calandrino</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-2710-1798</Identifier><AffiliationInfo><Affiliation>Neonatal Intensive Care Unit, Department of Maternal and Neonatal Health, IRCCS Istituto Giannina Gaslini, 16147 Genoa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pepe</LastName><ForeName>Alessia</ForeName><Initials>A</Initials><Identifier Source="ORCID">0009-0008-0043-8666</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Mother and Child Health, School of Medical and Pharmaceuticals, University of Genoa, 16132 Genoa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vinci</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0003-3693-1555</Identifier><AffiliationInfo><Affiliation>Neonatal Intensive Care Unit, Department of Maternal and Neonatal Health, IRCCS Istituto Giannina Gaslini, 16147 Genoa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Siboldi</LastName><ForeName>Alessandra</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Pediatric Cardiology Department, IRCCS Istituto Giannina Gaslini, 16147 Genoa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Formigari</LastName><ForeName>Roberto</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-6745-8783</Identifier><AffiliationInfo><Affiliation>Pediatric Cardiology Department, IRCCS Istituto Giannina Gaslini, 16147 Genoa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramenghi</LastName><ForeName>Luca Antonio</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Neonatal Intensive Care Unit, Department of Maternal and Neonatal Health, IRCCS Istituto Giannina Gaslini, 16147 Genoa, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Mother and Child Health, School of Medical and Pharmaceuticals, University of Genoa, 16132 Genoa, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>UAUT (2022_258_0)</GrantID><Agency>IRCCS Istituto Giannina Gaslini</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>06</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>J Cardiovasc Dev Dis</MedlineTA><NlmUniqueID>101651414</NlmUniqueID><ISSNLinking>2308-3425</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ELBW</Keyword><Keyword MajorTopicYN="N">arrhythmia</Keyword><Keyword MajorTopicYN="N">enterovirus</Keyword><Keyword MajorTopicYN="N">myocarditis</Keyword><Keyword MajorTopicYN="N">preterm</Keyword><Keyword MajorTopicYN="N">supraventricular tachycardia</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>5</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>6</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>6</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>6</Month><Day>25</Day><Hour>12</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>6</Month><Day>25</Day><Hour>12</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>6</Month><Day>25</Day><Hour>9</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>6</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40558663</ArticleId><ArticleId IdType="pmc">PMC12193909</ArticleId><ArticleId IdType="doi">10.3390/jcdd12060228</ArticleId><ArticleId IdType="pii">jcdd12060228</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Simpson K.E., Hulse E., Carlson K. Atrial Tachyarrhythmias in Neonatal Enterovirus Myocarditis. Pediatr. Cardiol. 2009;30:827&#x2013;830. doi: 10.1007/s00246-009-9398-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00246-009-9398-1</ArticleId><ArticleId IdType="pubmed">19294461</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang M., Wang H., Tang J., He Y., Xiong T., Li W., Qu Y., Mu D. Clinical characteristics of severe neonatal enterovirus infection: A systematic review. BMC Pediatr. 2021;21:127. doi: 10.1186/s12887-021-02599-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12887-021-02599-y</ArticleId><ArticleId IdType="pmc">PMC7958388</ArticleId><ArticleId IdType="pubmed">33722228</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu J.C., Koay K.W., Ramers C.B., Milazzo A.S., Carolina N. Neonate with Coxsackie B1 Infection, Cardiomyopathy and Arrhythmias. J. Natl. Med. Assoc. 2005;97:1028&#x2013;1030.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2569309</ArticleId><ArticleId IdType="pubmed">16080674</ArticleId></ArticleIdList></Reference><Reference><Citation>Madden K., Thiagarajan R.R., Rycus P.T., Rajagopal S.K. Survival of neonates with enteroviral myocarditis requiring extracorporeal membrane oxygenation. Pediatr. Crit. Care Med. 2011;12:314&#x2013;318. doi: 10.1097/PCC.0b013e3181e8b44b.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PCC.0b013e3181e8b44b</ArticleId><ArticleId IdType="pubmed">20625340</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaudhry-Waterman N., Nashed L., Chidester R., Nalewanski A., Bastawrous D., Busch H., Jeong H., Baker R., Donnelly K., Cohen M. A Prospective Evaluation of Arrhythmias in a Large Tertiary Neonatal Intensive Care Unit. Pediatr. Cardiol. 2023;44:1319&#x2013;1326. doi: 10.1007/s00246-022-03046-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00246-022-03046-0</ArticleId><ArticleId IdType="pubmed">36418551</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaeggi E., &#xd6;hman A. Fetal and Neonatal Arrhythmias. Clin. Perinatol. 2016;43:99&#x2013;112. doi: 10.1016/j.clp.2015.11.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clp.2015.11.007</ArticleId><ArticleId IdType="pubmed">26876124</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruder D., Weber R., Gass M., Balmer C., Cavigelli-Brunner A. Antiarrhythmic Medication in Neonates and Infants with Supraventricular Tachycardia. Pediatr. Cardiol. 2022;43:1311&#x2013;1318. doi: 10.1007/s00246-022-02853-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00246-022-02853-9</ArticleId><ArticleId IdType="pmc">PMC9293794</ArticleId><ArticleId IdType="pubmed">35258638</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang K.T., Potts J.E., Radbill A.E., La Page M.J., Papagiannis J., Garnreiter J.M., Kubus P., Kantoch M.J., Von Bergen N.H., Fournier A., et al. Permanent junctional reciprocating tachycardia in children: A multicenter experience. Heart Rhythm. 2014;11:1426&#x2013;1432. doi: 10.1016/j.hrthm.2014.04.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.hrthm.2014.04.033</ArticleId><ArticleId IdType="pubmed">24769425</ArticleId></ArticleIdList></Reference><Reference><Citation>Aydo&#x11f;an S., Fettah N.D., Tu&#x11f;cu A.U., Koyuncu E., Yolda&#x15f; T., Zenciro&#x11f;lu A. Supraventricular tachycardia after respiratory syncytial virus infection in a newborn. Bayl. Univ. Med. Cent. Proc. 2022;35:705&#x2013;706. doi: 10.1080/08998280.2022.2086788.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/08998280.2022.2086788</ArticleId><ArticleId IdType="pmc">PMC9373735</ArticleId><ArticleId IdType="pubmed">35991716</ArticleId></ArticleIdList></Reference><Reference><Citation>Radaelli M., Keller C.P.T.L., Franca H., Mehrotra K. Mycoplasma myocarditis presenting with sustained SVT and acute heart failure without signs of myocardiocytolysis and extra-cardiac disease. Clin. Case Rep. 2024;12:e8851. doi: 10.1002/ccr3.8851.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ccr3.8851</ArticleId><ArticleId IdType="pmc">PMC11077204</ArticleId><ArticleId IdType="pubmed">38721564</ArticleId></ArticleIdList></Reference><Reference><Citation>Muehlenbachs A., Bhatnagar J., Zaki S.R. Tissue tropism, pathology and pathogenesis of enterovirus infection. J. Pathol. 2015;235:217&#x2013;228. doi: 10.1002/path.4438.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/path.4438</ArticleId><ArticleId IdType="pubmed">25211036</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaaloul I., Riabi S., Evans M., Hunter T., Huber S., Aouni M. Postmortem diagnosis of infectious heart diseases: A mystifying cause of Sudden Infant Death. Forensic Sci. Int. 2016;262:166&#x2013;172. doi: 10.1016/j.forsciint.2016.03.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.forsciint.2016.03.002</ArticleId><ArticleId IdType="pmc">PMC4838494</ArticleId><ArticleId IdType="pubmed">27016640</ArticleId></ArticleIdList></Reference><Reference><Citation>Neagu O., Rodr&#xed;guez A.F., Callon D., Andr&#xe9;oletti L., Cohen M.C. Myocarditis Presenting as Sudden Death in Infants and Children: A Single Centre Analysis by ESGFOR Study Group. Pediatr. Dev. Pathol. 2021;24:327&#x2013;336. doi: 10.1177/10935266211007262.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/10935266211007262</ArticleId><ArticleId IdType="pubmed">33872111</ArticleId></ArticleIdList></Reference><Reference><Citation>Grangeot-Keros L., Broyer M., Briand E., Gut J.P., Turkogl&#xfc; S., Chretien P., Emilie D., Dussaix E., Lazizi Y., Dehan M. Enterovirus in sudden unexpected deaths in infants. Pediatr. Infect. Dis. J. 1996;15:123&#x2013;128. doi: 10.1097/00006454-199602000-00007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00006454-199602000-00007</ArticleId><ArticleId IdType="pubmed">8822284</ArticleId></ArticleIdList></Reference><Reference><Citation>Laitinen O.H., Svedin E., Kapell S., Nurminen A., Hyt&#xf6;nen V.P., Flodstr&#xf6;m-Tullberg M. Enteroviral proteases: Structure, host interactions and pathogenicity: Pathogenicity of enteroviral proteases. Rev. Med. Virol. 2016;26:251&#x2013;267. doi: 10.1002/rmv.1883.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.1883</ArticleId><ArticleId IdType="pmc">PMC7169145</ArticleId><ArticleId IdType="pubmed">27145174</ArticleId></ArticleIdList></Reference><Reference><Citation>Venteo L., Bourlet T., Renois F., Douche-Aourik F., Mosnier J.-F., Lorain De La Grand Maison G., Pluot M., Pozzetto B., Andreoletti L. Enterovirus-related activation of the cardiomyocyte mitochondrial apoptotic pathway in patients with acute myocarditis. Eur. Heart J. 2010;31:728&#x2013;736. doi: 10.1093/eurheartj/ehp489.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehp489</ArticleId><ArticleId IdType="pubmed">19933281</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouin A., Gretteau P.-A., Wehbe M., Renois F., N&#x2019;Guyen Y., L&#xe9;v&#xea;que N., Vu M.N., Tracy S., Chapman N.M., Bruneval P., et al. Enterovirus Persistence in Cardiac Cells of Patients With Idiopathic Dilated Cardiomyopathy Is Linked to 5&#x2019; Terminal Genomic RNA-Deleted Viral Populations With Viral-Encoded Proteinase Activities. Circulation. 2019;139:2326&#x2013;2338. doi: 10.1161/CIRCULATIONAHA.118.035966.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.118.035966</ArticleId><ArticleId IdType="pmc">PMC6517084</ArticleId><ArticleId IdType="pubmed">30755025</ArticleId></ArticleIdList></Reference><Reference><Citation>Aretz H.T., Billingham M.E., Edwards W.D., Factor S.M., Fallon J.T., Fenoglio J.J., Olsen E.G., Schoen F.J. Myocarditis. A histopathologic definition and classification. Am. J. Cardiovasc. Pathol. 1987;1:3&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">3455232</ArticleId></ArticleIdList></Reference><Reference><Citation>Law Y.M., Lal A.K., Chen S., &#x10c;ih&#xe1;kov&#xe1; D., Cooper L.T., Deshpande S., Godown J., Grosse-Wortmann L., Robinson J.D., Towbin J.A., et al. Diagnosis and Management of Myocarditis in Children: A Scientific Statement from the American Heart Association. Circulation. 2021;144:6. doi: 10.1161/CIR.0000000000001001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIR.0000000000001001</ArticleId><ArticleId IdType="pubmed">34229446</ArticleId></ArticleIdList></Reference><Reference><Citation>Batra A.S., Silka M.J., Borquez A., Cuneo B., Dechert B., Jaeggi E., Kannankeril P.J., Tabulov C., Tisdale J.E., Wolfe D., et al. Pharmacological Management of Cardiac Arrhythmias in the Fetal and Neonatal Periods: A Scientific Statement From the American Heart Association. Circulation. 2024;149:e937&#x2013;e952. doi: 10.1161/CIR.0000000000001206.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIR.0000000000001206</ArticleId><ArticleId IdType="pubmed">38314551</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim Y.T., Kim Y.H., Kwon J.E. Effective Control of Supraventricular Tachycardia in Neonates May Requires Combination Pharmacologic Therapy. JCM. 2022;11:3279. doi: 10.3390/jcm11123279.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm11123279</ArticleId><ArticleId IdType="pmc">PMC9224806</ArticleId><ArticleId IdType="pubmed">35743350</ArticleId></ArticleIdList></Reference><Reference><Citation>Aljohani O.A., Herrick N.L., Borquez A.A., Shepard S., Wieler M.E., Perry J.C., Williams M.R. Antiarrhythmic Treatment Duration and Tachycardia Recurrence in Infants with Supraventricular Tachycardia. Pediatr. Cardiol. 2021;42:716&#x2013;720. doi: 10.1007/s00246-020-02534-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00246-020-02534-5</ArticleId><ArticleId IdType="pubmed">33416921</ArticleId></ArticleIdList></Reference><Reference><Citation>Mecarini F., Comitini F., Bardanzellu F., Neroni P., Fanos V. Neonatal supraventricular tachycardia and necrotizing enterocolitis: Case report and literature review. Ital. J. Pediatr. 2020;46:117. doi: 10.1186/s13052-020-00876-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13052-020-00876-7</ArticleId><ArticleId IdType="pmc">PMC7448440</ArticleId><ArticleId IdType="pubmed">32843076</ArticleId></ArticleIdList></Reference><Reference><Citation>Freund M.W., Kleinveld G., Krediet T.G., Van Loon A.M., Verboon-Maciolek M.A. Prognosis for neonates with enterovirus myocarditis. Arch. Dis. Child.&#x2014;Fetal Neonatal Ed. 2010;95:F206&#x2013;F212. doi: 10.1136/adc.2009.165183.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/adc.2009.165183</ArticleId><ArticleId IdType="pubmed">20444813</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah S.S., Hellenbrand W.E., Gallagher P.G. Atrial Flutter Complicating Neonatal Coxsackie B2 Myocarditis. Pediatr. Cardiol. 1998;19:185&#x2013;186. doi: 10.1007/s002469900277.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s002469900277</ArticleId><ArticleId IdType="pubmed">9565516</ArticleId></ArticleIdList></Reference><Reference><Citation>Giampetruzzi S., Sirico D., Mainini N., Meneghelli M., Valerio E., Salvadori S., Di Salvo G. Neonatal Enterovirus-Associated Myocarditis in Dizygotic Twins: Myocardial Longitudinal Strain Pattern Analysis. Children. 2024;11:506. doi: 10.3390/children11050506.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/children11050506</ArticleId><ArticleId IdType="pmc">PMC11120217</ArticleId><ArticleId IdType="pubmed">38790501</ArticleId></ArticleIdList></Reference><Reference><Citation>Drew J.H. Echo 11 virus outbreak in a nursery associated with myocarditis. J. Paediatr. Child. Health. 1973;9:90&#x2013;95. doi: 10.1111/j.1440-1754.1973.tb01856.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1440-1754.1973.tb01856.x</ArticleId><ArticleId IdType="pubmed">4718801</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee S.R., Ko S.Y., Yoon S.Y., Lee Y.K., Shin S.M. Early Detection and Successful Treatment of Vertically Transmitted Fulminant Enteroviral Infection Associated with Various Forms of Arrhythmia and Severe Hepatitis with Coagulopathy. Pediatr. Infect. Vaccine. 2019;26:199. doi: 10.14776/piv.2019.26.e16.</Citation><ArticleIdList><ArticleId IdType="doi">10.14776/piv.2019.26.e16</ArticleId></ArticleIdList></Reference><Reference><Citation>Banjac L., Nikcevi&#x107; D., Vujosevi&#x107; D., Raoni&#x107; J., Banjac G. Tachycardia in a newborn with enterovirus infection. Acta Clin. Croat. 2014;53:102&#x2013;106.</Citation><ArticleIdList><ArticleId IdType="pubmed">24974673</ArticleId></ArticleIdList></Reference><Reference><Citation>Weickmann J., Gebauer R.A., Paech C. Junctional ectopic tachycardia in neonatal enterovirus myocarditis. Clin. Case Rep. 2020;8:987&#x2013;990. doi: 10.1002/ccr3.2796.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ccr3.2796</ArticleId><ArticleId IdType="pmc">PMC7303854</ArticleId><ArticleId IdType="pubmed">32577248</ArticleId></ArticleIdList></Reference><Reference><Citation>Yokota Y., Wada M. Accelerated ventricular rhythm associated with myocarditis in a neonate. Pediatr. Cardiol. 1989;10:178. doi: 10.1007/BF02081686.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF02081686</ArticleId><ArticleId IdType="pubmed">2798196</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40585675</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>02</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2168-8184</ISSN><JournalIssue CitedMedium="Print"><Volume>17</Volume><Issue>5</Issue><PubDate><Year>2025</Year><Month>May</Month></PubDate></JournalIssue><Title>Cureus</Title><ISOAbbreviation>Cureus</ISOAbbreviation></Journal><ArticleTitle>A Case of Takotsubo Cardiomyopathy Triggered by Human Metapneumovirus.</ArticleTitle><Pagination><StartPage>e84977</StartPage><MedlinePgn>e84977</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e84977</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.7759/cureus.84977</ELocationID><Abstract><AbstractText>Takotsubo cardiomyopathy (TC) is a transient, left ventricular dysfunction and apical ballooning that is commonly associated with emotional or physical triggers; however, it is not a known complication of infection with human metapneumovirus (HMPV). This case report describes a 59-year-old woman with a history of anxiety, depression, seizure disorder, fibromyalgia, and chronic obstructive pulmonary disease, who initially presented to the emergency department with pneumonia and sepsis. A sputum polymerase chain reaction (PCR) was positive for HMPV. The following day after admission, the patient developed acute chest pain, increased troponin that peaked at 12.29 ng/L, and ST-segment elevation in L1, V2-V6 on ECG. Subsequent cardiac catheterization revealed normal coronary arteries, and an echocardiogram showed left ventricular systolic dysfunction with apical ballooning and an ejection fraction of 15%, consistent with a diagnosis of TC. To the best of our knowledge, this is the first reported case of TC in an adult secondary to infection with HMPV and thus marks an important contribution to the current knowledge of HMPV complications.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025, Kongala et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kongala</LastName><ForeName>Brittani P</ForeName><Initials>BP</Initials><AffiliationInfo><Affiliation>College of Medicine, Florida State University College of Medicine, Tallahassee, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bhattarai</LastName><ForeName>Mahesh</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Internal Medicine, Tallahassee Memorial Hospital/Florida State University, Tallahassee, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ammar</LastName><ForeName>Hussam</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Internal Medicine, Tallahassee Memorial Hospital/Florida State University, Tallahassee, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>05</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cureus</MedlineTA><NlmUniqueID>101596737</NlmUniqueID><ISSNLinking>2168-8184</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">broken-heart syndrome</Keyword><Keyword MajorTopicYN="N">human metapneumovirus (hmpv)</Keyword><Keyword MajorTopicYN="N">intensive care unit stay</Keyword><Keyword MajorTopicYN="N">reversible cardiomyopathy</Keyword><Keyword MajorTopicYN="N">severe sepsis</Keyword><Keyword MajorTopicYN="N">tako-tsubo cardiomyopathy</Keyword></KeywordList><CoiStatement>Human subjects: Consent for treatment and open access publication was obtained or waived by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>5</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>1</Day><Hour>4</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>1</Day><Hour>4</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>6</Month><Day>30</Day><Hour>6</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>5</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40585675</ArticleId><ArticleId IdType="pmc">PMC12204640</ArticleId><ArticleId IdType="doi">10.7759/cureus.84977</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Clinical features and outcomes of Takotsubo (stress) cardiomyopathy. Templin C, Ghadri JR, Diekmann J, et al. N Engl J Med. 2015;373:929&#x2013;938.</Citation><ArticleIdList><ArticleId IdType="pubmed">26332547</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato HT, Uchida T, Dote K, Ishihara M. Clinical Aspect of Myocardial Injury: From Ischemia to Heart Failure [Book in Japanese] Tokyo, Japan: Kagakuhyoronsha Publishing; 1990. Tako-tsubo-like left ventricular dysfunction due to multivessel coronary spasm; pp. 56&#x2013;64.</Citation></Reference><Reference><Citation>Stress cardiomyopathy diagnosis and&#xa0;treatment: JACC state-of-the-art review. Medina de Chazal H, Del Buono MG, Keyser-Marcus L, Ma L, Moeller FG, Berrocal D, Abbate A. J Am Coll Cardiol. 2018;72:1955&#x2013;1971.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7058348</ArticleId><ArticleId IdType="pubmed">30309474</ArticleId></ArticleIdList></Reference><Reference><Citation>International expert consensus document on Takotsubo syndrome (part I): clinical characteristics, diagnostic criteria, and pathophysiology. Ghadri JR, Wittstein IS, Prasad A, et al. Eur Heart J. 2018;39:2032&#x2013;2046.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5991216</ArticleId><ArticleId IdType="pubmed">29850871</ArticleId></ArticleIdList></Reference><Reference><Citation>Takotsubo cardiomyopathy: a brief review. Amin HZ, Amin LZ, Pradipta A. J Med Life. 2020;13:3&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7175432</ArticleId><ArticleId IdType="pubmed">32341693</ArticleId></ArticleIdList></Reference><Reference><Citation>Clinical characteristics and outcomes in takotsubo syndrome -review of insights from the InterTAK Registry. Kato K, Di Vece D, Kitagawa M, et al. J Cardiol. 2025;85:263&#x2013;267.</Citation><ArticleIdList><ArticleId IdType="pubmed">39892867</ArticleId></ArticleIdList></Reference><Reference><Citation>The many faces of takotsubo syndrome: a review. Ahmed T, Lodhi SH, Haigh PJ, Sorrell VL. Curr Probl Cardiol. 2024;49:102421.</Citation><ArticleIdList><ArticleId IdType="pubmed">38253114</ArticleId></ArticleIdList></Reference><Reference><Citation>Takotsubo syndrome: pathophysiology, emerging concepts, and clinical implications. Singh T, Khan H, Gamble DT, Scally C, Newby DE, Dawson D. Circulation. 2022;145:1002&#x2013;1019.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7612566</ArticleId><ArticleId IdType="pubmed">35344411</ArticleId></ArticleIdList></Reference><Reference><Citation>Clinical problem-solving. A change of heart. Tsai TT, Nallamothu BK, Prasad A, Saint S, Bates ER. N Engl J Med. 2009;361:1010&#x2013;1016.</Citation><ArticleIdList><ArticleId IdType="pubmed">19726776</ArticleId></ArticleIdList></Reference><Reference><Citation>Sepsis-related cardiomyopathy: not an easy task for ICU physicians. Zhang H, Liu D. J Intensive Med. 2022;2:257&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9923957</ArticleId><ArticleId IdType="pubmed">36788939</ArticleId></ArticleIdList></Reference><Reference><Citation>Tako-Tsubo cardiomyopathy in severe sepsis: nationwide trends, predictors, and outcomes. Vallabhajosyula S, Deshmukh AJ, Kashani K, Prasad A, Sakhuja A. J Am Heart Assoc. 2018;7:0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6222948</ArticleId><ArticleId IdType="pubmed">30371194</ArticleId></ArticleIdList></Reference><Reference><Citation>Burkholderia cepacia complex bacteria: a feared contamination risk in water-based pharmaceutical products. Tavares M, Kozak M, Balola A, S&#xe1;-Correia I. Clin Microbiol Rev. 2020;33</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7194853</ArticleId><ArticleId IdType="pubmed">32295766</ArticleId></ArticleIdList></Reference><Reference><Citation>Takotsubo syndrome in patients with influenza infection or anti-influenza (Flu) vaccination. Desai R, Parekh T, Raina J, et al.  https://doi.org/10.1016/j.ahr.2021.100024 Aging Health Res. 2021;1:100024.</Citation></Reference><Reference><Citation>Burden of human metapneumovirus infection in young children. Edwards KM, Zhu Y, Griffin MR, et al. N Engl J Med. 2013;368:633&#x2013;643.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3662802</ArticleId><ArticleId IdType="pubmed">23406028</ArticleId></ArticleIdList></Reference><Reference><Citation>A spectrum of cardiac events is association with human metapneumovirus infections. Jubair W, Grigg S, Junqueira M. J Am Coll Cardiol. 2020;1016:735&#x2013;1097.</Citation></Reference><Reference><Citation>Infantile takotsubo cardiomyopathy following human metapneumovirus infection. Takamizawa K, Shindo T, Ono H, Kato H. Pediatr Int. 2022;64:0.</Citation><ArticleIdList><ArticleId IdType="pubmed">35396781</ArticleId></ArticleIdList></Reference><Reference><Citation>Acute myocarditis secondary to human metapneumovirus: a case series and mini-review. Hennawi HA, Khan A, Shpilman A, Mazzoni JA. Glob Cardiol Sci Pract. 2024;2024:0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11871563</ArticleId><ArticleId IdType="pubmed">40026582</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40600233</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>03</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2514-2119</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>4</Issue><PubDate><Year>2025</Year><Month>Apr</Month></PubDate></JournalIssue><Title>European heart journal. Case reports</Title><ISOAbbreviation>Eur Heart J Case Rep</ISOAbbreviation></Journal><ArticleTitle>Smartwatch-enabled early detection and treatment of cardiomyopathy induced by premature atrial contractions: a case report.</ArticleTitle><Pagination><StartPage>ytaf151</StartPage><MedlinePgn>ytaf151</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">ytaf151</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/ehjcr/ytaf151</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Arrhythmia-induced cardiomyopathy (AiCM) is an increasingly recognized cause of heart failure. Atrial fibrillation and premature ventricular contractions are common causes of AiCM. Further, the use of wearable technology in arrhythmia detection is increasing steadily. In this case, we report on a patient suffering from AiCM as a result of frequent premature atrial contractions (PACs) detected by a wearable device.</AbstractText><AbstractText Label="CASE SUMMARY" NlmCategory="UNASSIGNED">A 34-year-old male, with no prior medical history, presented after his smartwatch detected frequent 'heart arrhythmias.' An initial electrocardiogram showed sinus rhythm with frequent PACs. Further evaluation revealed left ventricular dysfunction [left ventricular ejection fraction (LVEF) 35%]. Non-invasive tests ruled out coronary artery disease. Although the patient was initially asymptomatic, his condition worsened with a decline in LVEF to 15% despite optimal medical therapy. High-resolution 3D mapping identified the ectopic focus in the left inferior pulmonary vein, and radiofrequency ablation successfully eliminated the PACs. At the six-month follow-up, the patient was symptom-free with a recovered LVEF of 50%.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="UNASSIGNED">This case highlights the potential for frequent PACs to induce AiCM. Although PACs are typically considered benign, in this case, the high PAC burden led to significant left ventricular dysfunction. The successful resolution of the patient's symptoms and the improvement in heart function after radiofrequency ablation demonstrate the reversibility of AiCM caused by PACs if treated early. Importantly, this case underscores the emerging role of wearable technologies, like smartwatches, in the early detection of arrhythmias, enabling timely intervention to prevent the progression of heart failure.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2025. Published by Oxford University Press on behalf of the European Society of Cardiology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Soubh</LastName><ForeName>Nibras</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-0272-0525</Identifier><AffiliationInfo><Affiliation>Department of Cardiology and Pneumology, University Medical Center in G&#xf6;ttingen (UMG), Robert-Koch-Str. 40, 37085 G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rasenack</LastName><ForeName>Eva</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Cardiology and Pneumology, University Medical Center in G&#xf6;ttingen (UMG), Robert-Koch-Str. 40, 37085 G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haarmann</LastName><ForeName>Helge</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Cardiology and Pneumology, University Medical Center in G&#xf6;ttingen (UMG), Robert-Koch-Str. 40, 37085 G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zabel</LastName><ForeName>Markus</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-0895-4602</Identifier><AffiliationInfo><Affiliation>Department of Cardiology and Pneumology, University Medical Center in G&#xf6;ttingen (UMG), Robert-Koch-Str. 40, 37085 G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bergau</LastName><ForeName>Leonard</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0001-7025-9315</Identifier><AffiliationInfo><Affiliation>Department of Cardiology and Pneumology, University Medical Center in G&#xf6;ttingen (UMG), Robert-Koch-Str. 40, 37085 G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>04</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur Heart J Case Rep</MedlineTA><NlmUniqueID>101730741</NlmUniqueID><ISSNLinking>2514-2119</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Ablation therapy</Keyword><Keyword MajorTopicYN="N">Case report</Keyword><Keyword MajorTopicYN="N">Heart failure</Keyword><Keyword MajorTopicYN="N">Premature atrial contractions</Keyword><Keyword MajorTopicYN="N">Supraventricular extrasystole</Keyword><Keyword MajorTopicYN="N">Wearable devices</Keyword></KeywordList><CoiStatement>Conflict of interest. None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>10</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>12</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>3</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>2</Day><Hour>6</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>2</Day><Hour>6</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>2</Day><Hour>5</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>4</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40600233</ArticleId><ArticleId IdType="pmc">PMC12209856</ArticleId><ArticleId IdType="doi">10.1093/ehjcr/ytaf151</ArticleId><ArticleId IdType="pii">ytaf151</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Shoureshi P, Tan AY, Koneru J, Ellenbogen KA, Kaszala K, Huizar JF. Arrhythmia-induced cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol 2024;83:2214&#x2013;2232.</Citation><ArticleIdList><ArticleId IdType="pubmed">38811098</ArticleId></ArticleIdList></Reference><Reference><Citation>Gopinathannair R, Etheridge SP, Marchlinski FE, Spinale FG, Lakkireddy D, Olshansky B. Arrhythmia-induced cardiomyopathies: mechanisms, recognition, and management. J Am Coll Cardiol 2015;66:1714&#x2013;1728.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4733572</ArticleId><ArticleId IdType="pubmed">26449143</ArticleId></ArticleIdList></Reference><Reference><Citation>Pacchia CF, Akoum NW, Wasmund S, Hamdan MH. Atrial bigeminy results in decreased left ventricular function: an insight into the mechanism of PVC-induced cardiomyopathy. Pacing Clin Electrophysiol 2012;35:1232&#x2013;1235.</Citation><ArticleIdList><ArticleId IdType="pubmed">22845488</ArticleId></ArticleIdList></Reference><Reference><Citation>Gunda S, Akyeampong D, Gomez-Arroyo J, Jovin DG, Kowlgi NG, Kaszala K, et al. Consequences of chronic frequent premature atrial contractions: association with cardiac arrhythmias and cardiac structural changes. J Cardiovasc Electrophysiol 2019;30:1952&#x2013;1959.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6786912</ArticleId><ArticleId IdType="pubmed">31310360</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan F, Ahmad M, Kanwal S, Payne J, Tsai S, Anderson D. Relatively benign yet a reversible cause of dilated cardiomyopathy. JACC Case Rep 2021;3:1081&#x2013;1085.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8311370</ArticleId><ArticleId IdType="pubmed">34317689</ArticleId></ArticleIdList></Reference><Reference><Citation>Vervueren PL, Delmas C, Berry M, Rollin A, Sadron M, Duparc A, et al. Reversal of dilated cardiomyopathy after successful radio-frequency ablation of frequent atrial premature beats, a new cause for arrhythmia-induced cardiomyopathy. J Atr Fibrillation 2012;5:627.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5153155</ArticleId><ArticleId IdType="pubmed">28496791</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasdemir C, Simsek E, Yuksel A. Premature atrial contraction-induced cardiomyopathy. EP Europace 2013;15:1790.</Citation><ArticleIdList><ArticleId IdType="pubmed">23759338</ArticleId></ArticleIdList></Reference><Reference><Citation>Marrouche NF, Brachmann J, Andresen D, Siebels J, Boersma L, Jordaens L, et al. Catheter ablation for atrial fibrillation with heart failure. N Engl J Med 2018;378:417&#x2013;427.</Citation><ArticleIdList><ArticleId IdType="pubmed">29385358</ArticleId></ArticleIdList></Reference><Reference><Citation>Sohns C, Fox H, Marrouche NF, Crijns HJGM, Costard-Jaeckle A, Bergau L, et al. Catheter ablation in end-stage heart failure with atrial fibrillation. N Engl J Med 2023;389:1380&#x2013;1389.</Citation><ArticleIdList><ArticleId IdType="pubmed">37634135</ArticleId></ArticleIdList></Reference><Reference><Citation>He B, Li Y, Huang W, Yu W, Zhao F, Wu X, et al. Mapping and ablation of isolated frequent symptomatic premature atrial contractions in patients with structurally normal heart. Front Cardiovasc Med 2022;9:862659.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9041661</ArticleId><ArticleId IdType="pubmed">35497996</ArticleId></ArticleIdList></Reference><Reference><Citation>Mannhart D, Lischer M, Knecht S, de Lavallaz J dF, Strebel I, Serban T, et al. Clinical validation of 5 direct-to-consumer wearable smart devices to detect atrial fibrillation: BASEL wearable study. JACC Clin Electrophysiol 2023;9:232&#x2013;242.</Citation><ArticleIdList><ArticleId IdType="pubmed">36858690</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40577152</PMID><DateCompleted><Year>2025</Year><Month>06</Month><Day>27</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1669-9106</ISSN><JournalIssue CitedMedium="Internet"><Volume>85</Volume><Issue>3</Issue><PubDate><Year>2025</Year></PubDate></JournalIssue><Title>Medicina</Title><ISOAbbreviation>Medicina (B Aires)</ISOAbbreviation></Journal><ArticleTitle>[Takotsubo myocardiopathy with cardiac tamponade].</ArticleTitle><Pagination><StartPage>622</StartPage><EndPage>624</EndPage><MedlinePgn>622-624</MedlinePgn></Pagination><Abstract><AbstractText>Takotsubo cardiomyopathy or stress cardiomyopathy is characterized by left ventricular dysfunction, usually hypokinesia of the apical segments and basal hypercontractility, with symptoms suggestive of acute myocardial infarction in the absence of coronary atherothrombotic disease. In most cases it has a benign course. We present the case of a patient with takotsubo cardiomyopathy with cardiac tamponade secondary to hemopericardium with subsequent cardiorespiratory arrest requiring emergency pericardiocentesis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Barrios</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Servicio de Cl&#xed;nica M&#xe9;dica, Instituto de investigaciones M&#xe9;dicas Alfredo Lanari, Buenos Aires, Argentina. E-mail: laurabarrioscaceres@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Voboril</LastName><ForeName>Gonzalo R</ForeName><Initials>GR</Initials><AffiliationInfo><Affiliation>Servicio de Cl&#xed;nica M&#xe9;dica, Instituto de investigaciones M&#xe9;dicas Alfredo Lanari, Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Casas</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Servicio de Cardiolog&#xed;a, Instituto de investigaciones M&#xe9;dicas Alfredo Lanari, Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Espinoza</LastName><ForeName>Juan C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Servicio de Cirug&#xed;a Cardiovascular, Instituto de investigaciones M&#xe9;dicas Alfredo Lanari, Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suarez</LastName><ForeName>Juan P</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Servicio de Cl&#xed;nica M&#xe9;dica, Instituto de investigaciones M&#xe9;dicas Alfredo Lanari, Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Miocardiopat&#xed;a de takotsubo con taponamiento card&#xed;aco.</VernacularTitle></Article><MedlineJournalInfo><Country>Argentina</Country><MedlineTA>Medicina (B Aires)</MedlineTA><NlmUniqueID>0204271</NlmUniqueID><ISSNLinking>0025-7680</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054549" MajorTopicYN="Y">Takotsubo Cardiomyopathy</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002305" MajorTopicYN="Y">Cardiac Tamponade</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010490" MajorTopicYN="Y">Pericardial Effusion</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020519" MajorTopicYN="N">Pericardiocentesis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006323" MajorTopicYN="N">Heart Arrest</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="spa"><AbstractText>La miocardiopat&#xed;a de takotsubo o miocardiopat&#xed;a por estr&#xe9;s, se caracteriza por una disfunci&#xf3;n ventricular izquierda, habitualmente hipocinesia de los segmentos apicales e hipercontractilidad basal, con s&#xed;ntomas sugestivos de infarto agudo de miocardio en ausencia de enfermedad aterotromb&#xf3;tica coronaria. Su curso es habitualmente benigno. Presentamos el caso de una paciente con s&#xed;ndrome de takotsubo con taponamiento card&#xed;aco secundario a hemopericardio, con posterior paro cardiorrespiratorio que requiri&#xf3; pericardiocentesis de urgencia.</AbstractText></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cardiac tamponade</Keyword><Keyword MajorTopicYN="N">myocardiopathy</Keyword><Keyword MajorTopicYN="N">takotsubo</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>6</Month><Day>27</Day><Hour>18</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>6</Month><Day>27</Day><Hour>18</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>6</Month><Day>27</Day><Hour>12</Hour><Minute>43</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40577152</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40666424</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>18</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2297-055X</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><PubDate><Year>2025</Year></PubDate></JournalIssue><Title>Frontiers in cardiovascular medicine</Title><ISOAbbreviation>Front Cardiovasc Med</ISOAbbreviation></Journal><ArticleTitle>Evaluation of echocardiography monitoring in myotonic dystrophy type 1 patients.</ArticleTitle><Pagination><StartPage>1574885</StartPage><MedlinePgn>1574885</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1574885</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fcvm.2025.1574885</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="UNASSIGNED">Myotonic Dystrophy type 1 (DM1) is the most prevalent genetic neuromuscular disorder. The potential cardiac involvement, including arrhythmia and left ventricular dysfunction, demands routine follow-up with ECG and echocardiography, however recommendations on the interval of echocardiographic follow-up varies substantially. The aim of this study is to evaluate the long-term prevalence of LV dysfunction during echocardiographic follow-up of patients with DM1. Secondly, we aim to assess the association between structural abnormalities on echocardiography, ECG and clinical parameters.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">This retrospective cohort study with DM1 patients was conducted in Maastricht University Medical Center (MUMC+) and Radboud University Medical Center. All patients above 18 years old were included through the Dutch DM1 patient registry (MYODRAFT study). Patients were evaluated between January 2010 and December 2023. A total of 273 patients were included, in whom echocardiographic data was collected and correlated with clinical data, neuromuscular status and ECG parameters.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">At baseline 20/273 (7.3%) patients had LV dysfunction (LVEF&#x2009;&lt;&#x2009;50% and/or LV dilatation). When newly detected LVEF &lt;50% alone is considered then the yield of routine echocardiography follow-up was: 9/273 at baseline (3%), 2/84 at 36 months (2%), 9/184 at 72 months (5%) and 10/117 at the interval beyond 72 months (8%). The only clear correlation between ECG and echocardiography abnormalities was a widened QRS interval 125&#x2009;&#xb1;&#x2009;31&#x2005;ms vs. 103&#x2009;&#xb1;&#x2009;19&#x2005;ms (<i>p</i>&#x2009;=&#x2009;0.007). This was also demonstrated in the multivariable analysis. Of the DM1 patients developing LV dysfunction, the median interval between the diagnosis of DM1 and the first echocardiogram detecting LV dysfunction was 181 months (15.1 years) with an interquartile range of 85-301 months (7.0-25.1 years).</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="UNASSIGNED">Based on the data of this large retrospective study, the occurrence of LV dysfunction in DM1 patients is rather low (7.4%) at baseline and increases with 6.5% at 72 months follow-up. There is a significant correlation between LV dysfunction and a widened QRS interval. Which could prompt earlier echocardiographic follow up in this patient group. Routine echocardiography is useful in DM1 however the interval of echocardiography could be shifted more towards 5 years in asymptomatic patients because of the slow progressive nature of the disease.</AbstractText><CopyrightInformation>&#xa9; 2025 Bovenkerk, Janssen, Van den Heuvel, Joosten, Den Uijl, Van Engelen, Van Kuijk, Nijveldt, Evertz, Faber, Vernooy and Bijvoet.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bovenkerk</LastName><ForeName>D S H</ForeName><Initials>DSH</Initials><AffiliationInfo><Affiliation>Department of Neurology, School for Mental Health and Neuroscience, Maastricht University Medical Center, Maastricht, Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiology, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Center, Maastricht, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Janssen</LastName><ForeName>C E W</ForeName><Initials>CEW</Initials><AffiliationInfo><Affiliation>Department of Neurology, School for Mental Health and Neuroscience, Maastricht University Medical Center, Maastricht, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van den Heuvel</LastName><ForeName>F M A</ForeName><Initials>FMA</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Radboud University Medical Center, Nijmegen, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Joosten</LastName><ForeName>I B T</ForeName><Initials>IBT</Initials><AffiliationInfo><Affiliation>Department of Neurology, School for Mental Health and Neuroscience, Maastricht University Medical Center, Maastricht, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Den Uijl</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Center, Maastricht, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Engelen</LastName><ForeName>B G M</ForeName><Initials>BGM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Kuijk</LastName><ForeName>S M J</ForeName><Initials>SMJ</Initials><AffiliationInfo><Affiliation>Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht University Medical Center, Maastricht, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nijveldt</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Radboud University Medical Center, Nijmegen, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Evertz</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Center, Maastricht, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Faber</LastName><ForeName>C G</ForeName><Initials>CG</Initials><AffiliationInfo><Affiliation>Department of Neurology, School for Mental Health and Neuroscience, Maastricht University Medical Center, Maastricht, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vernooy</LastName><ForeName>K</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Center, Maastricht, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bijvoet</LastName><ForeName>G P</ForeName><Initials>GP</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Center, Maastricht, Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Cardiovasc Med</MedlineTA><NlmUniqueID>101653388</NlmUniqueID><ISSNLinking>2297-055X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">conduction abnormalities</Keyword><Keyword MajorTopicYN="N">echocardiography</Keyword><Keyword MajorTopicYN="N">left ventricular dysfunction</Keyword><Keyword MajorTopicYN="N">myotonic dystrophy type 1</Keyword><Keyword MajorTopicYN="N">routine echocardiographic follow-up</Keyword></KeywordList><CoiStatement>The authors declare that RN has an unrestricted research grant from Biotronik and Philips Volcano. He also receives speaker fees from Sanofi Genzyme, Pfizer CF receives grants from the Prinses Beatrix Spierfonds (the Dutch neuromuscular foundation. Consultancy service for Biogen, Vertex, Avidity, Olipass, and Sangamo. All reimbursements were received by MUMC+, CF did not personally benefit financially from these activities. KV, Abbott, Biosense Webster, Boston Scientific and received grants from Abbott, Medtronic, Biosense Webster; all paid to institute. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>2</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>6</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>16</Day><Hour>6</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>16</Day><Hour>6</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>16</Day><Hour>5</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>7</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40666424</ArticleId><ArticleId IdType="pmc">PMC12259553</ArticleId><ArticleId IdType="doi">10.3389/fcvm.2025.1574885</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Thornton CA. Myotonic dystrophy. Neurol Clin. (2014) 32(3):705&#x2013;19. 10.1016/j.ncl.2014.04.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ncl.2014.04.011</ArticleId><ArticleId IdType="pmc">PMC4105852</ArticleId><ArticleId IdType="pubmed">25037086</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellini M, Biagi S, Stasi C, Costa F, Mumolo MG, Ricchiuti A, et al. Gastrointestinal manifestations in myotonic muscular dystrophy. World J Gastroenterol. (2006) 12(12):1821&#x2013;8. 10.3748/wjg.v12.i12.1821</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v12.i12.1821</ArticleId><ArticleId IdType="pmc">PMC4087506</ArticleId><ArticleId IdType="pubmed">16609987</ArticleId></ArticleIdList></Reference><Reference><Citation>de Die-Smulders CE, H&#xf6;weler CJ, Thijs C, Mirandolle JF, Anten HB, Smeets HJ, et al. Age and causes of death in adult-onset myotonic dystrophy. Brain. (1998) 121(8):1557&#x2013;63. 10.1093/brain/121.8.1557</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/121.8.1557</ArticleId><ArticleId IdType="pubmed">9712016</ArticleId></ArticleIdList></Reference><Reference><Citation>Lau JK, Sy RW, Corbett A, Kritharides L. Myotonic dystrophy and the heart: a systematic review of evaluation and management. Int J Cardiol. (2015) 184:600&#x2013;8. 10.1016/j.ijcard.2015.03.069</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijcard.2015.03.069</ArticleId><ArticleId IdType="pubmed">25769007</ArticleId></ArticleIdList></Reference><Reference><Citation>Groh WJ, Groh MR, Saha C, Kincaid JC, Simmons Z, Ciafaloni E, et al. Electrocardiographic abnormalities and sudden death in myotonic dystrophy type 1. N Engl J Med. (2008) 358(25):2688&#x2013;97. 10.1056/NEJMoa062800</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa062800</ArticleId><ArticleId IdType="pubmed">18565861</ArticleId></ArticleIdList></Reference><Reference><Citation>Joosten IBT, Horlings CGC, Vosse BAH, Wagner A, Bovenkerk DSH, Evertz R, et al. Myotonic dystrophy type 1: a comparison between the adult- and late-onset subtype. Muscle Nerve. (2023) 67(2):130&#x2013;7. 10.1002/mus.27766</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.27766</ArticleId><ArticleId IdType="pmc">PMC10107795</ArticleId><ArticleId IdType="pubmed">36484161</ArticleId></ArticleIdList></Reference><Reference><Citation>Russo V, Sperlongano S, Gallinoro E, Rago A, Papa AA, Golino P, et al. Prevalence of left ventricular systolic dysfunction in myotonic dystrophy type 1: a systematic review. J Card Fail. (2020) 26(10):849&#x2013;56. 10.1016/j.cardfail.2019.07.548</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cardfail.2019.07.548</ArticleId><ArticleId IdType="pubmed">31415861</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhakta D, Lowe MR, Groh WJ. Prevalence of structural cardiac abnormalities in patients with myotonic dystrophy type I. Am Heart J. (2004) 147(2):224&#x2013;7. 10.1016/j.ahj.2003.08.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ahj.2003.08.008</ArticleId><ArticleId IdType="pubmed">14760317</ArticleId></ArticleIdList></Reference><Reference><Citation>McNally EM, Mann DL, Pinto Y, Bhakta D, Tomaselli G, Nazarian S, et al. Clinical care recommendations for cardiologists treating adults with myotonic dystrophy. J Am Heart Assoc. (2020) 9(4):e014006. 10.1161/JAHA.119.014006</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/JAHA.119.014006</ArticleId><ArticleId IdType="pmc">PMC7070199</ArticleId><ArticleId IdType="pubmed">32067592</ArticleId></ArticleIdList></Reference><Reference><Citation>Russo V, Capolongo A, Bottino R, Carbone A, Palladino A, Liccardo B, et al. Echocardiographic features of cardiac involvement in myotonic dystrophy 1: prevalence and prognostic value. J Clin Med. (2023) 12(5):1947. 10.3390/jcm12051947</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm12051947</ArticleId><ArticleId IdType="pmc">PMC10004242</ArticleId><ArticleId IdType="pubmed">36902735</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhakta D, Groh MR, Shen C, Pascuzzi RM, Groh WJ. Increased mortality with left ventricular systolic dysfunction and heart failure in adults with myotonic dystrophy type 1. Am Heart J. (2010) 160(6):1137&#x2013;41. 10.1016/j.ahj.2010.07.032</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ahj.2010.07.032</ArticleId><ArticleId IdType="pubmed">21146669</ArticleId></ArticleIdList></Reference><Reference><Citation>Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American society of echocardiography and the European association of cardiovascular imaging. Eur Heart J Cardiovasc Imaging. (2015) 16(3):233&#x2013;70. 10.1093/ehjci/jev014</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ehjci/jev014</ArticleId><ArticleId IdType="pubmed">25712077</ArticleId></ArticleIdList></Reference><Reference><Citation>Pelargonio G, Dello Russo A, Sanna T, De Martino G, Bellocci F. Myotonic dystrophy and the heart. Heart. (2002) 88(6):665&#x2013;70. 10.1136/heart.88.6.665</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/heart.88.6.665</ArticleId><ArticleId IdType="pmc">PMC1767476</ArticleId><ArticleId IdType="pubmed">12433913</ArticleId></ArticleIdList></Reference><Reference><Citation>Joosten IBT, Janssen CEW, Horlings CGC, den Uijl D, Evertz R, van Engelen BGM, et al. An evaluation of 24&#x2005;h Holter monitoring in patients with myotonic dystrophy type 1. Europace. (2023) 25(1):156&#x2013;63. 10.1093/europace/euac104</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/europace/euac104</ArticleId><ArticleId IdType="pmc">PMC9907751</ArticleId><ArticleId IdType="pubmed">35851806</ArticleId></ArticleIdList></Reference><Reference><Citation>Ali M, Monti CB, Melazzini L, Cardani R, Fossati B, Cavalli M, et al. Rare disease: cardiac risk assessment with MRI in patients with myotonic dystrophy type 1. Front Neurol. (2020) 11:192. 10.3389/fneur.2020.00192</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2020.00192</ArticleId><ArticleId IdType="pmc">PMC7098463</ArticleId><ArticleId IdType="pubmed">32265828</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri H, Ahtarovski KA, Vejlstrup N, Vissing J, Witting N, Kober L, et al. Myocardial fibrosis in patients with myotonic dystrophy type 1: a cardiovascular magnetic resonance study. J Cardiovasc Magn Reson. (2014) 16(1):59. 10.1186/s12968-014-0059-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12968-014-0059-z</ArticleId><ArticleId IdType="pmc">PMC4422258</ArticleId><ArticleId IdType="pubmed">25086734</ArticleId></ArticleIdList></Reference><Reference><Citation>Guedes H, Moreno N, Dos Santos RP, Marques L, Seabra D, Pereira A, et al. Importance of three-dimensional speckle tracking in the assessment of left atrial and ventricular dysfunction in patients with myotonic dystrophy type 1. Rev Port Cardiol. (2018) 37(4):333&#x2013;8. 10.1016/j.repc.2017.10.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.repc.2017.10.011</ArticleId><ArticleId IdType="pubmed">29650434</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40645718</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2666-0849</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>18</Issue><PubDate><Year>2025</Year><Month>Jul</Month><Day>09</Day></PubDate></JournalIssue><Title>JACC. Case reports</Title><ISOAbbreviation>JACC Case Rep</ISOAbbreviation></Journal><ArticleTitle>Interaction Between Cardiogenic Shock and Hypothyroidism in Critical Care Medicine.</ArticleTitle><Pagination><StartPage>103932</StartPage><MedlinePgn>103932</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jaccas.2025.103932</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2666-0849(25)00712-0</ELocationID><Abstract><AbstractText>A 44-year-old male smoker presented with progressive dyspnea over 10 days. Admitted while in cardiogenic shock, the patient had severe dyspnea, hypoxia, and hemodynamic instability. Diagnostics showed diffuse lung opacities, bilateral effusions, severe left ventricular dysfunction (ejection fraction [EF], 10%-15%), and a large pericardial effusion. Initial treatments with inotropes and intra-aortic balloon pump failed, necessitating veno-arterial extracorporeal membrane oxygenation and a pericardial window. Lab results confirmed severe hypothyroidism (thyroid stimulating hormone, 76 &#x3bc;U/mL, free T4 0.1 ng/dL). Treatment with intravenous levothyroxine and steroids stabilized the patient, allowing extracorporeal membrane oxygenation weaning by day 10 and significant improvement in cardiac function over 45 days. Hypothyroidism is a rare but reversible cause of cardiogenic shock, impairing myocardial function via reduced contractility and vascular resistance. Early diagnosis and treatment with hormonal therapy and mechanical support are crucial.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025. Published by Elsevier Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>La Licata Benedetto</LastName><ForeName>Martina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Sanatorio Allende, C&#xf3;rdoba, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ricarte-Bratti</LastName><ForeName>Juan P</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Coronary Care Unit, Sanatorio Allende, C&#xf3;rdoba, Argentina. Electronic address: jpricartebratti@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lozita</LastName><ForeName>Julieta</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Coronary Care Unit, Sanatorio Allende, C&#xf3;rdoba, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ravinovich</LastName><ForeName>Elizabeth Y</ForeName><Initials>EY</Initials><AffiliationInfo><Affiliation>Coronary Care Unit, Sanatorio Allende, C&#xf3;rdoba, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Allende</LastName><ForeName>Guillermo E</ForeName><Initials>GE</Initials><AffiliationInfo><Affiliation>Cardiac Imaging Department, Sanatorio Allende, C&#xf3;rdoba, Argentina.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>JACC Case Rep</MedlineTA><NlmUniqueID>101757292</NlmUniqueID><ISSNLinking>2666-0849</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cardiogenic shock</Keyword><Keyword MajorTopicYN="N">heart failure</Keyword><Keyword MajorTopicYN="N">hypothyroidism</Keyword></KeywordList><CoiStatement>Funding Support and Author Disclosures The authors have reported that they have no relationships relevant to the contents of this paper to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>3</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>3</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>12</Day><Hour>16</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>12</Day><Hour>16</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>11</Day><Hour>20</Hour><Minute>56</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40645718</ArticleId><ArticleId IdType="doi">10.1016/j.jaccas.2025.103932</ArticleId><ArticleId IdType="pii">S2666-0849(25)00712-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40647688</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>14</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2075-4418</ISSN><JournalIssue CitedMedium="Print"><Volume>15</Volume><Issue>13</Issue><PubDate><Year>2025</Year><Month>Jul</Month><Day>02</Day></PubDate></JournalIssue><Title>Diagnostics (Basel, Switzerland)</Title><ISOAbbreviation>Diagnostics (Basel)</ISOAbbreviation></Journal><ArticleTitle>Quadricuspid Aortic Valve: Out of the Shadows, into the Light.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1689</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/diagnostics15131689</ELocationID><Abstract><AbstractText>We present the case of a 63-year-old man with severe aortic valve regurgitation and left-ventricular dysfunction. The patient was scheduled for elective surgery. A quadricuspid aortic valve with fibrous thickening and calcification of the cusps was visualized intraoperatively while preoperative surface echocardiography had failed to diagnose this anomaly. The aortic valve was successfully replaced with a biological prosthesis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Panfilov</LastName><ForeName>Dmitri</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0003-2201-350X</Identifier><AffiliationInfo><Affiliation>Cardiology Research Institute, Branch of the Federal State Budgetary Scientific Institution 'Tomsk National Research Medical Center of the Russian Academy of Sciences', 634012 Tomsk, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petrakova</LastName><ForeName>Elizaveta</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Cardiology Research Institute, Branch of the Federal State Budgetary Scientific Institution 'Tomsk National Research Medical Center of the Russian Academy of Sciences', 634012 Tomsk, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kozlov</LastName><ForeName>Boris</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0002-0217-7737</Identifier><AffiliationInfo><Affiliation>Cardiology Research Institute, Branch of the Federal State Budgetary Scientific Institution 'Tomsk National Research Medical Center of the Russian Academy of Sciences', 634012 Tomsk, Russia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Diagnostics (Basel)</MedlineTA><NlmUniqueID>101658402</NlmUniqueID><ISSNLinking>2075-4418</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">aortic valve replacement</Keyword><Keyword MajorTopicYN="N">echocardiography</Keyword><Keyword MajorTopicYN="N">quadricuspid aortic valve</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>6</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>6</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>6</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>13</Day><Hour>3</Hour><Minute>36</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>13</Day><Hour>3</Hour><Minute>35</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>12</Day><Hour>1</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>7</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40647688</ArticleId><ArticleId IdType="pmc">PMC12249342</ArticleId><ArticleId IdType="doi">10.3390/diagnostics15131689</ArticleId><ArticleId IdType="pii">diagnostics15131689</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Saith S., Saith S., Murthy A. Quadricuspid Aortic Valve: An Introduction for Clinicians. Cardiol. Res. 2022;13:2&#x2013;10. doi: 10.14740/cr1308.</Citation><ArticleIdList><ArticleId IdType="doi">10.14740/cr1308</ArticleId><ArticleId IdType="pmc">PMC8827235</ArticleId><ArticleId IdType="pubmed">35211218</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan S.-M. Quadricuspid Aortic Valve: A Comprehensive Review. Braz. J. Cardiovasc. Surg. 2016;31:454&#x2013;460. doi: 10.5935/1678-9741.20160090.</Citation><ArticleIdList><ArticleId IdType="doi">10.5935/1678-9741.20160090</ArticleId><ArticleId IdType="pmc">PMC5407143</ArticleId><ArticleId IdType="pubmed">28076624</ArticleId></ArticleIdList></Reference><Reference><Citation>Suraci N., Horvath S.A., Urina D., Rosen G., Santana O. Quadricuspid aortic valve: Case series and review of literature. Echocardiography. 2019;36:406&#x2013;410. doi: 10.1111/echo.14240.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/echo.14240</ArticleId><ArticleId IdType="pubmed">30592788</ArticleId></ArticleIdList></Reference><Reference><Citation>Sohn J., Arain F.D. Two Consecutive Cases of Quadricuspid Aortic Valve and a Review of 149 Cases. J. Cardiothorac. Vasc. Anesth. 2022;36:717&#x2013;723. doi: 10.1053/j.jvca.2021.02.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.jvca.2021.02.033</ArticleId><ArticleId IdType="pubmed">33731298</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsang M.Y.C., Abudiab M.M., Ammash N.M., Naqvi T.Z., Edwards W.D., Nkomo V.T., Pellikka P.A. Quadricuspid Aortic Valve Characteristics, Associated Structural Cardiovascular Abnormalities, and Clinical Outcomes. Circulation. 2016;133:312&#x2013;319. doi: 10.1161/CIRCULATIONAHA.115.017743.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.115.017743</ArticleId><ArticleId IdType="pubmed">26635401</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40654268</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-0844</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Jul</Month><Day>14</Day></PubDate></JournalIssue><Title>European journal of heart failure</Title><ISOAbbreviation>Eur J Heart Fail</ISOAbbreviation></Journal><ArticleTitle>Immune dysregulation as a key driver of peripartum cardiomyopathy&#xa0;-&#xa0;an exploratory advanced imaging and biomarker study.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1002/ejhf.3759</ELocationID><Abstract><AbstractText Label="AIMS" NlmCategory="OBJECTIVE">Peripartum cardiomyopathy (PPCM) is an idiopathic cardiomyopathy occurring in women in the late stages of pregnancy or in the postpartum period and is associated with significant morbidity, mortality, and persistent left ventricular dysfunction. PPCM pathogenesis involves multiple putative mechanisms including inflammation. We aimed to explore the acute inflammatory processes in PPCM using <sup>18</sup>F-fluorodeoxyglucose positron emission tomography-computed tomography (<sup>18</sup>FDG-PET-CT), cardiovascular magnetic resonance (CMR), and inflammasome profiling.</AbstractText><AbstractText Label="METHODS AND RESULTS" NlmCategory="RESULTS">Women with a new diagnosis of PPCM (n&#x2009;=&#x2009;10, all within 3&#x2009;months postpartum), five healthy postpartum controls (HPC), and five healthy non-postpartum controls (HNPC), underwent <sup>18</sup>FDG-PET-CT, CMR, and serum inflammatory proteomic profiling. PPCM patients had a median age of 34&#x2009;years (interquartile range [IQR] 30.3-38.5, similar in control groups), and a median parity of 3 (IQR 1-4). PPCM patients presented with severe, symptomatic heart failure (all New York Heart Association functional class III/IV), reduced median left ventricular ejection fraction of 35.5% (IQR 18.1-37.9). PPCM and HPC groups showed higher myocardial and splenic <sup>18</sup>FDG uptake compared to HNPC. On CMR, myocardial&#xa0;interstitial&#xa0;fibrosis (elevated T1 time, extracellular volume, and late gadolinium enhancement mass) was solely present in PPCM. Inflammatory profiling showed pro-inflammatory cytokine dysregulation in PPCM (elevated neutrophil-to-lymphocyte ratio, C-reactive protein, interleukin-6, tumour necrosis factor-&#x3b1;, chemokine (C-C motif) ligand 3, hepatocyte growth factor, chemokine (C-X-C motif) ligand 10 and colony-stimulating factor-1) compared to controls.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Patients with PPCM exhibited a dysregulated immune response, associated with early myocardial interstitial fibrosis and adverse cardiac remodelling. This highlights the importance of rapid initiation of guideline-directed medical therapy especially with drugs documented to have anti-fibrotic effects.</AbstractText><CopyrightInformation>&#xa9; 2025 The Author(s). European Journal of Heart Failure published by John Wiley &amp; Sons Ltd on behalf of European Society of Cardiology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hoevelmann</LastName><ForeName>Julian</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-2023-3026</Identifier><AffiliationInfo><Affiliation>Cape Heart Institute, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine III - Cardiology, Angiology and Intensive Care Medicine, Saarland University Hospital, Saarland University, Homburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Viljoen</LastName><ForeName>Charle</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-7246-4136</Identifier><AffiliationInfo><Affiliation>Cape Heart Institute, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Cardiology, Groote Schuur Hospital, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kotze</LastName><ForeName>Tessa</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Cape Universities Body Imaging Centre, University of Cape Town, Cape Town, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Libhaber</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>School of Physiology, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jermy</LastName><ForeName>Stephen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Cape Universities Body Imaging Centre, University of Cape Town, Cape Town, South Africa.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Biomedical Engineering, Department of Human Biology, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kahts</LastName><ForeName>Morn&#xe9;</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medicine, Groote Schuur Hospital, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jakoet-Bassier</LastName><ForeName>Fareda</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Cape Heart Institute, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Samuels</LastName><ForeName>Petronella</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Cape Universities Body Imaging Centre, University of Cape Town, Cape Town, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Briton</LastName><ForeName>Olivia</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Cape Heart Institute, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cilliers</LastName><ForeName>Lynette</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Dietetics, Groote Schuur Hospital, Cape Town, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hilfiker-Kleiner</LastName><ForeName>Denise</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Institute Cardiovascular Complications in Pregnancy and Oncologic Therapies, Philipps University Marburg, Marburg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>President of the Hannover Medical School, Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van der Meer</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>B&#xf6;hm</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine III - Cardiology, Angiology and Intensive Care Medicine, Saarland University Hospital, Saarland University, Homburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ntusi</LastName><ForeName>Ntobeko A B</ForeName><Initials>NAB</Initials><AffiliationInfo><Affiliation>Cape Heart Institute, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cape Universities Body Imaging Centre, University of Cape Town, Cape Town, South Africa.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Groote Schuur Hospital, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>South African Medical Research Council, Cape Town, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sliwa</LastName><ForeName>Karen</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-8272-0911</Identifier><AffiliationInfo><Affiliation>Cape Heart Institute, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Cardiology, Groote Schuur Hospital, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>F/31/21</GrantID><Agency>Deutsche Stiftung fr Herzforschung</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur J Heart Fail</MedlineTA><NlmUniqueID>100887595</NlmUniqueID><ISSNLinking>1388-9842</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cardiovascular magnetic resonance</Keyword><Keyword MajorTopicYN="N">Immune response</Keyword><Keyword MajorTopicYN="N">Peripartum cardiomyopathy</Keyword><Keyword MajorTopicYN="N">Positron emission tomography</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>5</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>1</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>6</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>14</Day><Hour>12</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>14</Day><Hour>12</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>14</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40654268</ArticleId><ArticleId IdType="doi">10.1002/ejhf.3759</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>Bauersachs J, Konig T, van der Meer P, Petrie MC, Hilfiker&#x2010;Kleiner D, Mbakwem A, et al. Pathophysiology, diagnosis and management of peripartum cardiomyopathy: A position statement from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. Eur J Heart Fail 2019;21:827&#x2013;843. https://doi.org/10.1002/ejhf.1493</Citation></Reference><Reference><Citation>Sliwa K, Bauersachs J, Arany Z, Spracklen TF, Hilfiker&#x2010;Kleiner D. Peripartum cardiomyopathy: From genetics to management. Eur Heart J 2021;42:3094&#x2013;3102. https://doi.org/10.1093/eurheartj/ehab458</Citation></Reference><Reference><Citation>Hoevelmann J, Engel ME, Muller E, Hohlfeld A, B&#xf6;hm M, Sliwa K, et al. A global perspective on the management and outcomes of peripartum cardiomyopathy: A systematic review and meta&#x2010;analysis. Eur J Heart Fail 2022;24:1719&#x2013;1736. https://doi.org/10.1002/ejhf.2603</Citation></Reference><Reference><Citation>McNamara DM, Elkayam U, Alharethi R, Damp J, Hsich E, Ewald G, et al.; IPAC Investigators. Clinical outcomes for peripartum cardiomyopathy in North America: Results of the IPAC study (Investigations of Pregnancy&#x2010;Associated Cardiomyopathy). J Am Coll Cardiol 2015;66:905&#x2013;914. https://doi.org/10.1016/j.jacc.2015.06.1309</Citation></Reference><Reference><Citation>Hilfiker&#x2010;Kleiner D, Sliwa K. Pathophysiology and epidemiology of peripartum cardiomyopathy. Nat Rev Cardiol 2014;11:364&#x2013;370. https://doi.org/10.1038/nrcardio.2014.37</Citation></Reference><Reference><Citation>Hoes MF, Arany Z, Bauersachs J, Hilfiker&#x2010;Kleiner D, Petrie MC, Sliwa K, et al. Pathophysiology and risk factors of peripartum cardiomyopathy. Nat Rev Cardiol 2022;19:555&#x2013;565. https://doi.org/10.1038/s41569&#x2010;021&#x2010;00664&#x2010;8</Citation></Reference><Reference><Citation>Hilfiker&#x2010;Kleiner D, Kaminski K, Podewski E, Bonda T, Schaefer A, Sliwa K, et al. A cathepsin D&#x2010;cleaved 16&#x2009;kDa form of prolactin mediates postpartum cardiomyopathy. Cell 2007;128:589&#x2013;600. https://doi.org/10.1016/j.cell.2006.12.036</Citation></Reference><Reference><Citation>Arany Z. Peripartum cardiomyopathy. N Engl J Med 2024;390:154&#x2013;164. https://doi.org/10.1056/NEJMra2306667</Citation></Reference><Reference><Citation>Forster O, Hilfiker&#x2010;Kleiner D, Ansari AA, Sundstrom JB, Libhaber E, Tshani W, et al. Reversal of IFN&#x2010;gamma, oxLDL and prolactin serum levels correlate with clinical improvement in patients with peripartum cardiomyopathy. Eur J Heart Fail 2008;10:861&#x2013;868. https://doi.org/10.1016/j.ejheart.2008.07.005</Citation></Reference><Reference><Citation>Ricke&#x2010;Hoch M, Bultmann I, Stapel B, Condorelli G, Rinas U, Sliwa K, et al. Opposing roles of Akt and STAT3 in the protection of the maternal heart from peripartum stress. Cardiovasc Res 2014;101:587&#x2013;596. https://doi.org/10.1093/cvr/cvu010</Citation></Reference><Reference><Citation>Hilfiker&#x2010;Kleiner D, Haghikia A, Berliner D, Vogel&#x2010;Claussen J, Schwab J, Franke A, et al. Bromocriptine for the treatment of peripartum cardiomyopathy: A multicentre randomized study. Eur Heart J 2017;38:2671&#x2013;2679. https://doi.org/10.1093/eurheartj/ehx355</Citation></Reference><Reference><Citation>Sliwa K, Blauwet L, Tibazarwa K, Libhaber E, Smedema JP, Becker A, et al. Evaluation of bromocriptine in the treatment of acute severe peripartum cardiomyopathy: A proof&#x2010;of&#x2010;concept pilot study. Circulation 2010;121:1465&#x2013;1473. https://doi.org/10.1161/CIRCULATIONAHA.109.901496</Citation></Reference><Reference><Citation>van der Meer P, van Essen BJ, Viljoen C, B&#xf6;hm M, Jackson A, Hilfiker&#x2010;Kleiner D, et al. Bromocriptine treatment and outcomes in peripartum cardiomyopathy: The EORP PPCM registry. Eur Heart J 2025;46:1017&#x2013;1027. https://doi.org/10.1093/eurheartj/ehae559</Citation></Reference><Reference><Citation>Sliwa K, Skudicky D, Candy G, Bergemann A, Hopley M, Sareli P. The addition of pentoxifylline to conventional therapy improves outcome in patients with peripartum cardiomyopathy. Eur J Heart Fail 2002;4:305&#x2013;309. https://doi.org/10.1016/s1388&#x2010;9842(02)00008&#x2010;9</Citation></Reference><Reference><Citation>Kellman P, Arai AE, Xue H. T1 and extracellular volume mapping in the heart: Estimation of error maps and the influence of noise on precision. J Cardiovasc Magn Reson 2013;15:56. https://doi.org/10.1186/1532&#x2010;429X&#x2010;15&#x2010;56</Citation></Reference><Reference><Citation>Schulz&#x2010;Menger J, Bluemke DA, Bremerich J, Flamm SD, Fogel MA, Friedrich MG, et al. Standardized image interpretation and post&#x2010;processing in cardiovascular magnetic resonance&#xa0;&#x2013;&#xa0;2020 update: Society for Cardiovascular Magnetic Resonance (SCMR): Board of Trustees Task Force on Standardized Post&#x2010;Processing. J Cardiovasc Magn Reson 2020;22:19. https://doi.org/10.1186/s12968&#x2010;020&#x2010;00610&#x2010;6</Citation></Reference><Reference><Citation>Curran FM, Bhalraam U, Mohan M, Singh JS, Anker SD, Dickstein K, et al. Neutrophil&#x2010;to&#x2010;lymphocyte ratio and outcomes in patients with new&#x2010;onset or worsening heart failure with reduced and preserved ejection fraction. ESC Heart Fail 2021;8:3168&#x2013;3179. https://doi.org/10.1002/ehf2.13424</Citation></Reference><Reference><Citation>Gurkan U, Akgoz H, Aksoy S, Can Gurkan O, Osken A, Unal Dayi S, et al. Value of the neutrophil&#x2010;to&#x2010;lymphocyte ratio in predicting left ventricular recovery in patients with peripartum cardiomyopathy. Wien Klin Wochenschr 2017;129:893&#x2013;899. https://doi.org/10.1007/s00508&#x2010;017&#x2010;1227&#x2010;6</Citation></Reference><Reference><Citation>Reina&#x2010;Couto M, Pereira&#x2010;Terra P, Quelhas&#x2010;Santos J, Silva&#x2010;Pereira C, Albino&#x2010;Teixeira A, Sousa T. Inflammation in human heart failure: Major mediators and therapeutic targets. Front Physiol 2021;12:746494. https://doi.org/10.3389/fphys.2021.746494</Citation></Reference><Reference><Citation>Yokoyama T, Vaca L, Rossen RD, Durante W, Hazarika P, Mann DL. Cellular basis for the negative inotropic effects of tumor necrosis factor&#x2010;alpha in the adult mammalian heart. J Clin Invest 1993;92:2303&#x2013;2312. https://doi.org/10.1172/JCI116834</Citation></Reference><Reference><Citation>Yu X, Kennedy RH, Liu SJ. JAK2/STAT3, not ERK1/2, mediates interleukin&#x2010;6&#x2010;induced activation of inducible nitric&#x2010;oxide synthase and decrease in contractility of adult ventricular myocytes. J Biol Chem 2003;278:16304&#x2013;16309. https://doi.org/10.1074/jbc.M212321200</Citation></Reference><Reference><Citation>Hodgson DM, Zingman LV, Kane GC, Perez&#x2010;Terzic C, Bienengraeber M, Ozcan C, et al. Cellular remodeling in heart failure disrupts KATP channel&#x2010;dependent stress tolerance. EMBO J 2003;22:1732&#x2013;1742. https://doi.org/10.1093/emboj/cdg192</Citation></Reference><Reference><Citation>Sliwa K, Skudicky D, Candy G, Wisenbaugh T, Sareli P. Randomised investigation of effects of pentoxifylline on left&#x2010;ventricular performance in idiopathic dilated cardiomyopathy. Lancet 1998;351:1091&#x2013;1093. https://doi.org/10.1016/S0140&#x2010;6736(97)09338&#x2010;0</Citation></Reference><Reference><Citation>Sliwa K, Woodiwiss A, Candy G, Badenhorst D, Libhaber C, Norton G, et al. Effects of pentoxifylline on cytokine profiles and left ventricular performance in patients with decompensated congestive heart failure secondary to idiopathic dilated cardiomyopathy. Am J Cardiol 2002;90:1118&#x2013;1122. https://doi.org/10.1016/s0002&#x2010;9149(02)02779&#x2010;0</Citation></Reference><Reference><Citation>Sliwa K, Woodiwiss A, Kone VN, Candy G, Badenhorst D, Norton G, et al. Therapy of ischemic cardiomyopathy with the immunomodulating agent pentoxifylline: Results of a randomized study. Circulation 2004;109:750&#x2013;755. https://doi.org/10.1161/01.CIR.0000112568.48837.60</Citation></Reference><Reference><Citation>Adamo L, Rocha&#x2010;Resende C, Prabhu SD, Mann DL. Reappraising the role of inflammation in heart failure. Nat Rev Cardiol 2020;17:269&#x2013;285. https://doi.org/10.1038/s41569&#x2010;019&#x2010;0315&#x2010;x</Citation></Reference><Reference><Citation>Aukrust P, Ueland T, Muller F, Andreassen AK, Nordoy I, Aas H, et al. Elevated circulating levels of C&#x2010;C chemokines in patients with congestive heart failure. Circulation 1998;97:1136&#x2013;1143. https://doi.org/10.1161/01.cir.97.12.1136</Citation></Reference><Reference><Citation>Halkein J, Tabruyn SP, Ricke&#x2010;Hoch M, Haghikia A, Nguyen NQ, Scherr M, et al. MicroRNA&#x2010;146a is a therapeutic target and biomarker for peripartum cardiomyopathy. J Clin Invest 2013;123:2143&#x2013;2154. https://doi.org/10.1172/JCI64365</Citation></Reference><Reference><Citation>Tabruyn SP, Sabatel C, Nguyen NQ, Verhaeghe C, Castermans K, Malvaux L, et al. The angiostatic 16K human prolactin overcomes endothelial cell anergy and promotes leukocyte infiltration via nuclear factor&#x2010;kappaB activation. Mol Endocrinol 2007;21:1422&#x2013;1429. https://doi.org/10.1210/me.2007&#x2010;0021</Citation></Reference><Reference><Citation>Altara R, Manca M, Hessel MH, Gu Y, van Vark LC, Akkerhuis KM, et al. CXCL10 is a circulating inflammatory marker in patients with advanced heart failure: A pilot study. J Cardiovasc Transl Res 2016;9:302&#x2013;314. https://doi.org/10.1007/s12265&#x2010;016&#x2010;9703&#x2010;3</Citation></Reference><Reference><Citation>Altara R, Manca M, Brandao RD, Zeidan A, Booz GW, Zouein FA. Emerging importance of chemokine receptor CXCR3 and its ligands in cardiovascular diseases. Clin Sci (Lond) 2016;130:463&#x2013;478. https://doi.org/10.1042/CS20150666</Citation></Reference><Reference><Citation>Futamatsu H, Suzuki J, Mizuno S, Koga N, Adachi S, Kosuge H, et al. Hepatocyte growth factor ameliorates the progression of experimental autoimmune myocarditis: A potential role for induction of T helper 2 cytokines. Circ Res 2005;96:823&#x2013;830. https://doi.org/10.1161/01.RES.0000163016.52653.2e</Citation></Reference><Reference><Citation>Girerd N, Levy D, Duarte K, Ferreira JP, Ballantyne C, Collier T, et al. Protein biomarkers of new&#x2010;onset heart failure: Insights from the Heart Omics and Ageing cohort, the Atherosclerosis Risk in Communities study, and the Framingham Heart Study. Circ Heart Fail 2023;16:e009694. https://doi.org/10.1161/CIRCHEARTFAILURE.122.009694</Citation></Reference><Reference><Citation>Rychli K, Richter B, Hohensinner PJ, Kariem Mahdy A, Neuhold S, Zorn G, et al. Hepatocyte growth factor is a strong predictor of mortality in patients with advanced heart failure. Heart 2011;97:1158&#x2013;1163. https://doi.org/10.1136/hrt.2010.220228</Citation></Reference><Reference><Citation>Scott TE, Lewis CV, Zhu M, Wang C, Samuel CS, Drummond GR, et al. IL&#x2010;4 and IL&#x2010;13 induce equivalent expression of traditional M2 markers and modulation of reactive oxygen species in human macrophages. Sci Rep 2023;13:19589. https://doi.org/10.1038/s41598&#x2010;023&#x2010;46237&#x2010;2</Citation></Reference><Reference><Citation>Hiraiwa H, Okumura T, Murohara T. The cardiosplenic axis: The prognostic role of the spleen in heart failure. Heart Fail Rev 2022;27:2005&#x2013;2015. https://doi.org/10.1007/s10741&#x2010;022&#x2010;10248&#x2010;4</Citation></Reference><Reference><Citation>Swirski FK, Nahrendorf M, Etzrodt M, Wildgruber M, Cortez&#x2010;Retamozo V, Panizzi P, et al. Identification of splenic reservoir monocytes and their deployment to inflammatory sites. Science 2009;325:612&#x2013;616. https://doi.org/10.1126/science.1175202</Citation></Reference><Reference><Citation>Dutta P, Courties G, Wei Y, Leuschner F, Gorbatov R, Robbins CS, et al. Myocardial infarction accelerates atherosclerosis. Nature 2012;487:325&#x2013;329. https://doi.org/10.1038/nature11260</Citation></Reference><Reference><Citation>Emami H, Singh P, MacNabb M, Vucic E, Lavender Z, Rudd JH, et al. Splenic metabolic activity predicts risk of future cardiovascular events: Demonstration of a cardiosplenic axis in humans. JACC Cardiovasc Imaging 2015;8:121&#x2013;130. https://doi.org/10.1016/j.jcmg.2014.10.009</Citation></Reference><Reference><Citation>Auffray C, Sieweke MH, Geissmann F. Blood monocytes: Development, heterogeneity, and relationship with dendritic cells. Annu Rev Immunol 2009;27:669&#x2013;692. https://doi.org/10.1146/annurev.immunol.021908.132557</Citation></Reference><Reference><Citation>Boulet J, Sridhar VS, Bouabdallaoui N, Tardif J&#x2010;C, White M. Inflammation in heart failure: Pathophysiology and therapeutic strategies. Inflamm Res 2024;73:709&#x2013;723. https://doi.org/10.1007/s00011&#x2010;023&#x2010;01845&#x2010;6</Citation></Reference><Reference><Citation>Chou CH, Hung CS, Liao CW, Wei LH, Chen CW, Shun CT, et al.; TAIPAI Study Group. IL&#x2010;6 trans&#x2010;signalling contributes to aldosterone&#x2010;induced cardiac fibrosis. Cardiovasc Res 2018;114:690&#x2013;702. https://doi.org/10.1093/cvr/cvy013</Citation></Reference><Reference><Citation>Theofilis P, Sagris M, Oikonomou E, Antonopoulos AS, Siasos G, Tsioufis K, et al. The impact of SGLT2 inhibitors on inflammation: A systematic review and meta&#x2010;analysis of studies in rodents. Int Immunopharmacol 2022;111:109080. https://doi.org/10.1016/j.intimp.2022.109080</Citation></Reference><Reference><Citation>Wang H, Ding L, Tian L, Tian Y, Liao L, Zhao J. Empagliflozin reduces diffuse myocardial fibrosis by extracellular volume mapping: A meta&#x2010;analysis of clinical studies. Front Endocrinol (Lausanne) 2022;13:917761. https://doi.org/10.3389/fendo.2022.917761</Citation></Reference><Reference><Citation>Cunningham JW, Claggett BL, O'Meara E, Prescott MF, Pfeffer MA, Shah SJ, et al. Effect of sacubitril/valsartan on biomarkers of extracellular matrix regulation in patients with HFpEF. J Am Coll Cardiol 2020;76:503&#x2013;514. https://doi.org/10.1016/j.jacc.2020.05.072</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40645700</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2666-0849</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>18</Issue><PubDate><Year>2025</Year><Month>Jul</Month><Day>09</Day></PubDate></JournalIssue><Title>JACC. Case reports</Title><ISOAbbreviation>JACC Case Rep</ISOAbbreviation></Journal><ArticleTitle>Managing Thyrotoxicosis in Acute Heart Failure.</ArticleTitle><Pagination><StartPage>103935</StartPage><MedlinePgn>103935</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jaccas.2025.103935</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2666-0849(25)00715-6</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Thyrotoxicosis can lead to high-output cardiac failure, and although beta-blockers have a relative contraindication in decompensated congestive heart failure, they are commonly used in thyrotoxicosis to control hypersympathetic activity.</AbstractText><AbstractText Label="CASE SUMMARY" NlmCategory="METHODS">This is the case of a 38-year-old female who arrived with a thyroid storm, atrial fibrillation, and volume overload in physical examination. Echo revealed severely reduced left ventricular systolic function with normal diastology. She started on esmolol and successfully transitioned to propranolol.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">This case highlights the need to tailor beta-blocker therapy based on the underlying cause of left ventricular dysfunction, particularly when sustained tachycardia and decreased systemic vascular resistance are the main drivers of thyrotoxic cardiac failure.</AbstractText><AbstractText Label="TAKE-HOME MESSAGE" NlmCategory="CONCLUSIONS">Suspect thyrotoxic cardiac failure, especially in the setting of normal diastology, and consider starting BB.</AbstractText><CopyrightInformation>Published by Elsevier Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rodriguez-Santiago</LastName><ForeName>Maria A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Internal Medicine, University of Puerto Rico, San Juan, Puerto Rico. Electronic address: maria.rodriguez86@upr.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mesa-Pab&#xf3;n</LastName><ForeName>Marcel A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Internal Medicine, University of Puerto Rico, San Juan, Puerto Rico.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>JACC Case Rep</MedlineTA><NlmUniqueID>101757292</NlmUniqueID><ISSNLinking>2666-0849</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">acute heart failure</Keyword><Keyword MajorTopicYN="N">atrial fibrillation</Keyword><Keyword MajorTopicYN="N">beta blocker</Keyword><Keyword MajorTopicYN="N">tachycardia-mediated cardiomyopathy</Keyword><Keyword MajorTopicYN="N">thyroid storm</Keyword><Keyword MajorTopicYN="N">thyrotoxicosis</Keyword></KeywordList><CoiStatement>Funding Support and Author Disclosures The authors have reported that they have no relationships relevant to the contents of this paper to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>11</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>2</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>3</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>12</Day><Hour>16</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>12</Day><Hour>16</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>11</Day><Hour>20</Hour><Minute>56</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40645700</ArticleId><ArticleId IdType="doi">10.1016/j.jaccas.2025.103935</ArticleId><ArticleId IdType="pii">S2666-0849(25)00715-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40632033</PMID><DateCompleted><Year>2025</Year><Month>07</Month><Day>09</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>17</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2639-8028</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>7</Issue><PubDate><Year>2025</Year><Month>Jul</Month><Day>01</Day></PubDate></JournalIssue><Title>Critical care explorations</Title><ISOAbbreviation>Crit Care Explor</ISOAbbreviation></Journal><ArticleTitle>Temperature Trajectories Correlate With Cardiac Function in Patients With Sepsis.</ArticleTitle><Pagination><StartPage>e1282</StartPage><MedlinePgn>e1282</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/CCE.0000000000001282</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Body temperature trajectories of infected patients are associated with dynamic clinical and immune responses to infection. Our objective was to evaluate the association between temperature trajectory subphenotypes and cardiac dysfunction determined by echocardiography.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Retrospective cohort study.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">Four hospitals within an academic healthcare system from 2016 to 2019.</AbstractText><AbstractText Label="PATIENTS" NlmCategory="METHODS">Adult patients with suspicion of infection who underwent transthoracic echocardiography within 48 hours of admission.</AbstractText><AbstractText Label="INTERVENTIONS" NlmCategory="METHODS">Using a validated model, patients were classified into four temperature trajectory subphenotypes. The primary outcome compared between subphenotypes was left ventricular dysfunction, defined as ejection fraction less than or equal to 50%.</AbstractText><AbstractText Label="MEASUREMENTS AND MAIN RESULTS" NlmCategory="RESULTS">One thousand nine hundred twenty-three hospitalized septic patients were classified into four subphenotypes: "hyperthermic, slow resolvers" (n = 264, 14%), "hyperthermic, fast resolvers" (302, 16%), "normothermic" patients (903, 47%), and "hypothermic" patients (454, 24%). Left ventricular and right ventricular dysfunction was significantly different between subphenotypes. Hypothermic patients exhibited the highest levels of left ventricular dysfunction (208, 46%; p &lt; 0.01) and right ventricular dysfunction (169, 39%; p &lt; 0.01). In the multivariable logistic regression analysis, adjusting for demographics, comorbidities, and severity of illness, membership in the hypothermic group (odds ratio, 2.65; 95% CI, 1.87-3.80; p &lt; 0.01) was associated with significantly reduced left ventricular ejection fraction compared with hyperthermic slow resolvers as reference. Hypothermic patients also had the highest levels of vasopressor use (27%; p &lt; 0.01), inotrope use (11%; p &lt; 0.01), and in-hospital mortality (12%; p &lt; 0.01).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Temperature trajectories in sepsis are significantly associated with cardiac dysfunction, with hypothermic patients having the highest odds ratio of both left and right ventricular dysfunction. Bedside temperature monitoring could be a readily available marker to prompt early echocardiographic assessment, though further studies are needed to validate the relationship.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of the Society of Critical Care Medicine.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Annabel H</ForeName><Initials>AH</Initials><AffiliationInfo><Affiliation>Emory University School of Medicine, Atlanta, GA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jain</LastName><ForeName>Vardhmaan</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Emory University School of Medicine, Atlanta, GA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Po-Han</ForeName><Initials>PH</Initials><AffiliationInfo><Affiliation>Medical College of Georgia, Augusta, GA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Churpek</LastName><ForeName>Matthew M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Wisconsin, Madison, WI.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verhoef</LastName><ForeName>Philip A</ForeName><Initials>PA</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Hawaii, Honolulu, HI.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quyyumi</LastName><ForeName>Arshed A</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Emory University School of Medicine, Atlanta, GA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bhavani</LastName><ForeName>Sivasubramanium V</ForeName><Initials>SV</Initials><Identifier Source="ORCID">0000-0002-9640-6720</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Emory University, Atlanta, GA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Crit Care Explor</MedlineTA><NlmUniqueID>101746347</NlmUniqueID><ISSNLinking>2639-8028</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018805" MajorTopicYN="Y">Sepsis</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004452" MajorTopicYN="N">Echocardiography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001831" MajorTopicYN="Y">Body Temperature</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018487" MajorTopicYN="Y">Ventricular Dysfunction, Left</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007035" MajorTopicYN="N">Hypothermia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018497" MajorTopicYN="N">Ventricular Dysfunction, Right</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013318" MajorTopicYN="N">Stroke Volume</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">group-based trajectory modeling</Keyword><Keyword MajorTopicYN="N">left ventricular dysfunction</Keyword><Keyword MajorTopicYN="N">right ventricular dysfunction</Keyword><Keyword MajorTopicYN="N">sepsis</Keyword><Keyword MajorTopicYN="N">temperature</Keyword></KeywordList><CoiStatement>Dr. Bhavani is supported by National Institutes of Health/National Institute of General Medical Sciences GM144867. The remaining authors have disclosed that they do not have any potential conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>9</Day><Hour>12</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>9</Day><Hour>12</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>9</Day><Hour>10</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40632033</ArticleId><ArticleId IdType="doi">10.1097/CCE.0000000000001282</ArticleId><ArticleId IdType="pii">02107256-202507000-00004</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Guarino M, Perna B, Cesaro AE, et al.: 2023 Update on sepsis and septic shock in adult patients: Management in the emergency department. J Clin Med 2023; 12:3188</Citation></Reference><Reference><Citation>Vieillard-Baron A, Caille V, Charron C, et al.: Actual incidence of global left ventricular hypokinesia in adult septic shock. Crit Care Med 2008; 36:1701&#x2013;1706</Citation></Reference><Reference><Citation>Vallabhajosyula S, Ahmed AM, Sundaragiri PR: Role of echocardiography in sepsis and septic shock. Ann Transl Med 2020; 8:150&#x2013;150</Citation></Reference><Reference><Citation>Merx MW, Weber C: Sepsis and the heart. Circulation 2007; 116:793&#x2013;802</Citation></Reference><Reference><Citation>Lima MR, Silva D: Septic cardiomyopathy: A narrative review. Rev Port Cardiol 2023; 42:471&#x2013;481</Citation></Reference><Reference><Citation>L&#x2019;Heureux M, Sternberg M, Brath L, et al.: Sepsis-induced cardiomyopathy: A comprehensive review. Curr Cardiol Rep 2020; 22:35</Citation></Reference><Reference><Citation>Ahmed A, Aboshady I, Munir SM, et al.: Decreasing body temperature predicts early rehospitalization in congestive heart failure. J Card Fail 2008; 14:489&#x2013;496</Citation></Reference><Reference><Citation>Payvar S, Orlandi C, Stough WG, et al.; Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Congestive Heart Failure (ACTIV in CHF) Investigators: Comparison of 60-day mortality in hospitalized heart failure patients with versus without hypothermia. Am J Cardiol 2006; 98:1485&#x2013;1488</Citation></Reference><Reference><Citation>Nallamothu BK, Payvar S, Wang Y, et al.: Admission body temperature and mortality in elderly patients hospitalized for heart failure. J Am Coll Cardiol 2006; 47:2563&#x2013;2564</Citation></Reference><Reference><Citation>Bhavani SV, Carey KA, Gilbert ER, et al.: Identifying novel sepsis subphenotypes using temperature trajectories. Am J Respir Crit Care Med 2019; 200:327&#x2013;335</Citation></Reference><Reference><Citation>Bhavani SV, Wolfe KS, Hrusch CL, et al.: Temperature trajectory subphenotypes correlate with immune responses in patients with sepsis. Crit Care Med 2020; 48:1645&#x2013;1653</Citation></Reference><Reference><Citation>Singer M, Deutschman CS, Seymour CW, et al.: The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA 2016; 315:801&#x2013;810</Citation></Reference><Reference><Citation>Bhavani SV, Verhoef PA, Maier CL, et al.: Coronavirus disease 2019 temperature trajectories correlate with hyperinflammatory and hypercoagulable subphenotypes. Crit Care Med 2022; 50:212&#x2013;223</Citation></Reference><Reference><Citation>Benzoni NS, Carey KA, Bewley AF, et al.: Temperature trajectory subphenotypes in oncology patients with neutropenia and suspected infection. Am J Respir Crit Care Med 2023; 207:1300&#x2013;1309</Citation></Reference><Reference><Citation>Lang RM, Badano LP, Mor-Avi V, et al.: Recommendations for cardiac chamber quantification by echocardiography in adults: An update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2015; 28:1&#x2013;39.e14</Citation></Reference><Reference><Citation>Rowell LB: Human cardiovascular adjustments to exercise and thermal stress. Physiol Rev 1974; 54:75&#x2013;159</Citation></Reference><Reference><Citation>Cooper KE: Some responses of the cardiovascular system to heat and fever. Can J Cardiol 1994; 10:444&#x2013;448</Citation></Reference><Reference><Citation>Drewry AM, Mohr NM, Ablordeppey EA, et al.: Therapeutic hyperthermia is associated with improved survival in afebrile critically ill patients with sepsis: A pilot randomized trial. Crit Care Med 2022; 50:924&#x2013;934</Citation></Reference><Reference><Citation>Hall JE, Hall ME: Guyton and Hall Textbook of Medical Physiology. 14th Edition. Philadelphia, Elsevier, 2020</Citation></Reference><Reference><Citation>Bonow RO, Mann DL, Zipes DP, et al.: Braunwald&#x2019;s Heart Disease: A Textbook of Cardiovascular Medicine. Tenth Edition. Philadelphia, Elsevier, 2011</Citation></Reference><Reference><Citation>McKinley MJ, Albiston AL, Allen AM, et al.: The brain renin&#x2013;angiotensin system: Location and physiological roles. Int J Biochem Cell Biol 2003; 35:901&#x2013;918</Citation></Reference><Reference><Citation>Lin MT: Effects of angiotensin II on metabolic, respiratory and vasomotor activities as well as body temperatures in the rabbit. J Neural Transm 1980; 49:197&#x2013;204</Citation></Reference><Reference><Citation>Shido O, Nagasaka T: Effects of intraventricular angiotensin II on heat balance at various ambient temperatures in rats. Jpn J Physiol 1985; 35:163&#x2013;167</Citation></Reference><Reference><Citation>Andrus BW, Welch HG: Medicare services provided by cardiologists in the United States: 1999&#x2013;2008. Circ Cardiovasc Qual Outcomes 2012; 5:31&#x2013;36</Citation></Reference><Reference><Citation>Stratton L, Berlin DA, Arbo JE: Vasopressors and inotropes in sepsis. Emerg Med Clin North Am 2017; 35:75&#x2013;91</Citation></Reference><Reference><Citation>Hiraiwa H, Kasugai D, Ozaki M, et al.: Clinical impact of visually assessed right ventricular dysfunction in patients with septic shock. Sci Rep 2021; 11:18823</Citation></Reference><Reference><Citation>Vieillard-Baron A, Prigent A, Repess&#xe9; X, et al.: Right ventricular failure in septic shock: Characterization, incidence and impact on fluid responsiveness. Crit Care 2020; 24:630</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40638916</PMID><DateCompleted><Year>2025</Year><Month>07</Month><Day>10</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>31</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1929-0748</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><PubDate><Year>2025</Year><Month>Jul</Month><Day>10</Day></PubDate></JournalIssue><Title>JMIR research protocols</Title><ISOAbbreviation>JMIR Res Protoc</ISOAbbreviation></Journal><ArticleTitle>A Higher-Than-Standard-Intensity International Normalized Ratio Goal for Patients Undergoing Mechanical Aortic Valve Replacement With Additional Thrombotic Risk Factors: Protocol for a Systematic Review and Meta-Analysis.</ArticleTitle><Pagination><StartPage>e73389</StartPage><MedlinePgn>e73389</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e73389</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.2196/73389</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Lifelong anticoagulation therapy with vitamin K antagonists is recommended following mechanical aortic valve replacement (MAVR) to prevent valve thrombosis. Current guidelines recommend a standard international normalized ratio (INR) of 2.5 for patients with MAVR without additional thromboembolic risk factors, and a higher INR goal of 3.0 for those with conditions such as atrial fibrillation, prior thromboembolism, or left ventricular dysfunction. However, limited clinical evidence exists to guide anticoagulation intensity in this high-risk subgroup, necessitating a systematic review.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">We aimed to assess the safety and efficacy of higher-intensity INR goals (&gt;3.0) compared to standard-intensity goals (approximately 2.5) in patients with MAVR with additional thromboembolic risk factors.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This protocol describes a systematic review and meta-analysis following PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) 2020 guidelines. A comprehensive literature search will be conducted across PubMed, Embase, and the Cochrane Library for studies published before December 18, 2024. Eligible studies include randomized controlled trials (RCTs), cohort studies, and follow-up studies involving adult patients with MAVR on warfarin therapy, stratified by the presence of additional thromboembolic risk factors. Non-English-language studies, case reports, editorials, and animal studies will be excluded.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The review will synthesize existing data to compare the risks and benefits of intensified anticoagulation in patients with MAVR with additional thromboembolic risk factors. Data analysis and manuscript preparation are scheduled for July-August 2025.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This study will provide critical evidence on INR management in high-risk patients with MAVR, potentially informing future updates to clinical guidelines and optimizing the balance between thromboembolic prevention and bleeding risk.</AbstractText><AbstractText Label="INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID)" NlmCategory="UNASSIGNED">PRR1-10.2196/73389.</AbstractText><CopyrightInformation>&#xa9;Myung-Rho Kim, Taha Shaikh, Shawn Wang, Spencer Taylor, Vidhani Goel, Banveet Kaur Khetarpal, Chowdhury Ahsan, Kavita Batra. Originally published in JMIR Research Protocols (https://www.researchprotocols.org), 10.07.2025.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Kim</LastName><ForeName>Myung-Rho</ForeName><Initials>MR</Initials><Identifier Source="ORCID">0009-0000-3694-4335</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine, Kirk Kerkorian School of Medicine, University of Nevada, Las Vegas, Las Vegas, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Shaikh</LastName><ForeName>Taha</ForeName><Initials>T</Initials><Identifier Source="ORCID">0009-0008-6863-5391</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine, Kirk Kerkorian School of Medicine, University of Nevada, Las Vegas, Las Vegas, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Wang</LastName><ForeName>Shawn</ForeName><Initials>S</Initials><Identifier Source="ORCID">0009-0006-4410-2932</Identifier><AffiliationInfo><Affiliation>Kirk Kerkorian School of Medicine, University of Nevada, Las Vegas, Las Vegas, NV, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Taylor</LastName><ForeName>Spencer</ForeName><Initials>S</Initials><Identifier Source="ORCID">0009-0009-4935-943X</Identifier><AffiliationInfo><Affiliation>Kirk Kerkorian School of Medicine, University of Nevada, Las Vegas, Las Vegas, NV, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goel</LastName><ForeName>Vidhani</ForeName><Initials>V</Initials><Identifier Source="ORCID">0009-0002-9694-2790</Identifier><AffiliationInfo><Affiliation>School of Public Health, University of Nevada, Las Vegas, Las Vegas, NV, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Khetarpal</LastName><ForeName>Banveet Kaur</ForeName><Initials>BK</Initials><Identifier Source="ORCID">0000-0002-4205-4969</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine, Kirk Kerkorian School of Medicine, University of Nevada, Las Vegas, Las Vegas, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Kirk Kerkorian School of Medicine, University of Nevada, Las Vegas, Las Vegas, NV, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahsan</LastName><ForeName>Chowdhury</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-5269-8488</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine, Kirk Kerkorian School of Medicine, University of Nevada, Las Vegas, Las Vegas, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Kirk Kerkorian School of Medicine, University of Nevada, Las Vegas, Las Vegas, NV, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Batra</LastName><ForeName>Kavita</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-0722-0191</Identifier><AffiliationInfo><Affiliation>Office of Research and Department of Medical Education, Kirk Kerkorian School of Medicine, University of Nevada, Las Vegas, Las Vegas, NV, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>Canada</Country><MedlineTA>JMIR Res Protoc</MedlineTA><NlmUniqueID>101599504</NlmUniqueID><ISSNLinking>1929-0748</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance></Chemical><Chemical><RegistryNumber>5Q7ZVV76EI</RegistryNumber><NameOfSubstance UI="D014859">Warfarin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019934" MajorTopicYN="Y">International Normalized Ratio</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000078202" MajorTopicYN="N">Systematic Reviews as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015201" MajorTopicYN="N">Meta-Analysis as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013927" MajorTopicYN="Y">Thrombosis</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000925" MajorTopicYN="N">Anticoagulants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019918" MajorTopicYN="Y">Heart Valve Prosthesis Implantation</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001021" MajorTopicYN="Y">Aortic Valve</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014859" MajorTopicYN="N">Warfarin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006350" MajorTopicYN="Y">Heart Valve Prosthesis</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013923" MajorTopicYN="N">Thromboembolism</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Coumadin</Keyword><Keyword MajorTopicYN="N">MAVR</Keyword><Keyword MajorTopicYN="N">anticoagulation</Keyword><Keyword MajorTopicYN="N">international normalized ratio</Keyword><Keyword MajorTopicYN="N">mechanical aortic valve replacement</Keyword><Keyword MajorTopicYN="N">thromboembolic risk factors</Keyword><Keyword MajorTopicYN="N">thromboembolism</Keyword><Keyword MajorTopicYN="N">vitamin K antagonist</Keyword><Keyword MajorTopicYN="N">warfarin</Keyword></KeywordList><CoiStatement>Conflicts of Interest: None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>3</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>5</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>5</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>10</Day><Hour>18</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>10</Day><Hour>18</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>10</Day><Hour>16</Hour><Minute>54</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>7</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40638916</ArticleId><ArticleId IdType="pmc">PMC12290424</ArticleId><ArticleId IdType="doi">10.2196/73389</ArticleId><ArticleId IdType="pii">v14i1e73389</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Otto C, Nishimura R, Bonow R, Carabello Blase A, Erwin John P, Gentile Federico, Jneid Hani, Krieger Eric V, Mack Michael, McLeod Christopher, O'Gara Patrick T, Rigolin Vera H, Sundt Thoralf M, Thompson Annemarie, Toly Christopher. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021 Feb 02;143(5):e72&#x2013;e227. doi: 10.1161/CIR.0000000000000923. 
 
</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIR.0000000000000923?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub0pubmed</ArticleId><ArticleId IdType="doi">10.1161/CIR.0000000000000923</ArticleId><ArticleId IdType="pubmed">33332150</ArticleId></ArticleIdList></Reference><Reference><Citation>Pujari SH, Agasthi P. StatPearls. Treasure Island, FL: StatPearls Publishing; 2023. Apr 16, Aortic Stenosis.</Citation><ArticleIdList><ArticleId IdType="pubmed">32491560</ArticleId></ArticleIdList></Reference><Reference><Citation>Leon MB, Smith CR, Mack M, Miller DC, Moses JW, Svensson LG, Tuzcu EM, Webb JG, Fontana GP, Makkar RR, Brown DL, Block PC, Guyton RA, Pichard AD, Bavaria JE, Herrmann HC, Douglas PS, Petersen JL, Akin JJ, Anderson WN, Wang D, Pocock S, PARTNER Trial Investigators Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med. 2010 Oct 21;363(17):1597&#x2013;607. doi: 10.1056/NEJMoa1008232.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1008232</ArticleId><ArticleId IdType="pubmed">20961243</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitlock RP, Sun JC, Fremes SE, Rubens FD, Teoh KH. Antithrombotic and thrombolytic therapy for valvular disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012 Feb;141(2 Suppl):e576S&#x2013;e600S. doi: 10.1378/chest.11-2305. 
 
S0012-3692(12)60132-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.11-2305</ArticleId><ArticleId IdType="pmc">PMC3278057</ArticleId><ArticleId IdType="pubmed">22315272</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Bello V, Talarico L, Picano E, Giorgi D, Bertini A, Paterni M, Giusti C. Increased myocardial echo density in left ventricular pressure and volume overload in human aortic valvular disease: an ultrasonic tissue characterization study. J Am Soc Echocardiogr. 1997 May;10(4):320&#x2013;9. doi: 10.1016/s0894-7317(97)70068-3.S0894731797000436</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0894-7317(97)70068-3</ArticleId><ArticleId IdType="pubmed">9168353</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrovski&#x12d; P F, Torbina A, Klembovski&#x12d; A A, Za&#x12d;tsev A Iu. [Intracardiac mechanisms of compensation of isolated aortic insufficiency] Kardiologiia. 1990 Dec;30(12):51&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">2151456</ArticleId></ArticleIdList></Reference><Reference><Citation>Akinseye OA, Pathak A, Ibebuogu UN. Aortic valve regurgitation: a comprehensive review. Curr Probl Cardiol. 2018 Aug;43(8):315&#x2013;334. doi: 10.1016/j.cpcardiol.2017.10.004.S0146-2806(17)30159-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cpcardiol.2017.10.004</ArticleId><ArticleId IdType="pubmed">29174586</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanigan S, Kong X, Haymart B, Kline-Rogers E, Kaatz S, Krol G, Shah V, Ali MA, Almany S, Kozlowski J, Froehlich J, Barnes G. Standard versus higher intensity anticoagulation for patients with mechanical aortic valve replacement and additional risk factors for thromboembolism. Am J Cardiol. 2021 Nov 15;159:100&#x2013;106. doi: 10.1016/j.amjcard.2021.08.023.S0002-9149(21)00782-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjcard.2021.08.023</ArticleId><ArticleId IdType="pubmed">34656311</ArticleId></ArticleIdList></Reference><Reference><Citation>Puskas J, Gerdisch M, Nichols D, Quinn R, Anderson C, Rhenman B, Fermin L, McGrath M, Kong B, Hughes C, Sethi G, Wait M, Martin T, Graeve A, PROACT Investigators  Reduced anticoagulation after mechanical aortic valve replacement: interim results from the prospective randomized on-X valve anticoagulation clinical trial randomized Food and Drug Administration investigational device exemption trial. J Thorac Cardiovasc Surg. 2014 Apr;147(4):1202&#x2013;1210; discussion 1210. doi: 10.1016/j.jtcvs.2014.01.004. 
 
S0022-5223(14)00010-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtcvs.2014.01.004</ArticleId><ArticleId IdType="pubmed">24512654</ArticleId></ArticleIdList></Reference><Reference><Citation>Koertke H, Zittermann A, Tenderich G, Wagner O, El-Arousy M, Krian A, Ennker J, Taborski U, Kl&#xf6;vekorn Wolf Peter, Moosdorf R, Saggau W, Koerfer R. Low-dose oral anticoagulation in patients with mechanical heart valve prostheses: final report from the early self-management anticoagulation trial II. Eur Heart J. 2007 Oct;28(20):2479&#x2013;84. doi: 10.1093/eurheartj/ehm391.ehm391</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehm391</ArticleId><ArticleId IdType="pubmed">17890730</ArticleId></ArticleIdList></Reference><Reference><Citation>Bov&#xe9; Thierry, Van Belleghem Yves, Fran&#xe7;ois Katrien, Caes Frank, De Pauw Michel, Taeymans Yves, Van Nooten Guido J. Low target-INR anticoagulation is safe in selected aortic valve patients with the Medtronic Open Pivot mechanical prosthesis: long-term results of a propensity-matched comparison with standard anticoagulation. Interact Cardiovasc Thorac Surg. 2017 Jun 01;24(6):862&#x2013;868. doi: 10.1093/icvts/ivx028.3060336</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/icvts/ivx028</ArticleId><ArticleId IdType="pubmed">28329135</ArticleId></ArticleIdList></Reference><Reference><Citation>Bj&#xf6;rn Rikhard, Lehto J, Malmberg M, Anttila V, Airaksinen KJ, Gunn J, Kiviniemi T. Antithrombotic medication and major complications after mechanical aortic valve replacement. Am J Cardiol. 2023 Oct 01;204:185&#x2013;194. doi: 10.1016/j.amjcard.2023.07.097. 
 
S0002-9149(23)00636-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjcard.2023.07.097</ArticleId><ArticleId IdType="pubmed">37544143</ArticleId></ArticleIdList></Reference><Reference><Citation>Oo A, Loubani M, Gerdisch M, Zacharias Joseph, Tsang Geoffrey M, Perchinsky Michael J, Hagberg Robert Carl, Joseph Mark, Sathyamoorthy Mohanakrishnan. On-X aortic valve replacement patients treated with low-dose warfarin and low-dose aspirin. Eur J Cardiothorac Surg. 2024 May 03;65(5):e117. doi: 10.1093/ejcts/ezae117. 
 
7646070</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ejcts/ezae117</ArticleId><ArticleId IdType="pmc">PMC11136449</ArticleId><ArticleId IdType="pubmed">38621698</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgan RL, Whaley P, Thayer KA, Sch&#xfc;nemann Holger J. Identifying the PECO: a framework for formulating good questions to explore the association of environmental and other exposures with health outcomes. Environ Int. 2018 Dec;121(Pt 1):1027&#x2013;1031. doi: 10.1016/j.envint.2018.07.015. 
 
S0160-4120(18)30204-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.envint.2018.07.015</ArticleId><ArticleId IdType="pmc">PMC6908441</ArticleId><ArticleId IdType="pubmed">30166065</ArticleId></ArticleIdList></Reference><Reference><Citation>Pibarot P, Dumesnil JG. Prosthetic heart valves: selection of the optimal prosthesis and long-term management. Circulation. 2009 Feb 24;119(7):1034&#x2013;48. doi: 10.1161/CIRCULATIONAHA.108.778886.119/7/1034</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.108.778886</ArticleId><ArticleId IdType="pubmed">19237674</ArticleId></ArticleIdList></Reference><Reference><Citation>Bloomfield Peter. Choice of heart valve prosthesis. Heart. 2002 Jun;87(6):583&#x2013;9. doi: 10.1136/heart.87.6.583. 
 
</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/heart.87.6.583</ArticleId><ArticleId IdType="pmc">PMC1767148</ArticleId><ArticleId IdType="pubmed">12010950</ArticleId></ArticleIdList></Reference><Reference><Citation>Page Matthew J, McKenzie Joanne E, Bossuyt Patrick M, Boutron Isabelle, Hoffmann Tammy C, Mulrow Cynthia D, Shamseer Larissa, Tetzlaff Jennifer M, Akl Elie A, Brennan Sue E, Chou Roger, Glanville Julie, Grimshaw Jeremy M, Hr&#xf3;bjartsson Asbj&#xf8;rn, Lalu Manoj M, Li Tianjing, Loder Elizabeth W, Mayo-Wilson Evan, McDonald Steve, McGuinness Luke A, Stewart Lesley A, Thomas James, Tricco Andrea C, Welch Vivian A, Whiting Penny, Moher David. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021 Mar 29;372:n71. doi: 10.1136/bmj.n71. 
 
</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n71</ArticleId><ArticleId IdType="pmc">PMC8005924</ArticleId><ArticleId IdType="pubmed">33782057</ArticleId></ArticleIdList></Reference><Reference><Citation>Study quality assessment tools. National Heart, Lung, and Blood Institute.  [2025-01-13].  
 https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools
.</Citation></Reference><Reference><Citation>Elks Whitney, Rooks Adam, Schulte Spencer, Batra Kavita, Burke Jocelyn, Jain Varun. Resistance training in patients after metabolic and bariatric surgery: protocol for a systematic review. JMIR Res Protoc. 2023 Nov 23;12:e49513. doi: 10.2196/49513. 
 
v12i1e49513</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/49513</ArticleId><ArticleId IdType="pmc">PMC10704302</ArticleId><ArticleId IdType="pubmed">37995123</ArticleId></ArticleIdList></Reference><Reference><Citation>DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986 Sep;7(3):177&#x2013;88. doi: 10.1016/0197-2456(86)90046-2. 
 
0197-2456(86)90046-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0197-2456(86)90046-2</ArticleId><ArticleId IdType="pubmed">3802833</ArticleId></ArticleIdList></Reference><Reference><Citation>Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997 Sep 13;315(7109):629&#x2013;34. doi: 10.1136/bmj.315.7109.629. 
 
</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.315.7109.629</ArticleId><ArticleId IdType="pmc">PMC2127453</ArticleId><ArticleId IdType="pubmed">9310563</ArticleId></ArticleIdList></Reference><Reference><Citation>J&#xfc;ni Peter, Holenstein F, Sterne J, Bartlett C, Egger M. Direction and impact of language bias in meta-analyses of controlled trials: empirical study. Int J Epidemiol. 2002 Feb;31(1):115&#x2013;23. doi: 10.1093/ije/31.1.115. 
 
</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/31.1.115</ArticleId><ArticleId IdType="pubmed">11914306</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40630899</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>10</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2297-055X</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><PubDate><Year>2025</Year></PubDate></JournalIssue><Title>Frontiers in cardiovascular medicine</Title><ISOAbbreviation>Front Cardiovasc Med</ISOAbbreviation></Journal><ArticleTitle>Case Report: Onset of Takotsubo syndrome during a heart rehabilitation session.</ArticleTitle><Pagination><StartPage>1560087</StartPage><MedlinePgn>1560087</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1560087</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fcvm.2025.1560087</ELocationID><Abstract><AbstractText>Takotsubo syndrome (TTS) is an acute cardiac condition characterized by transient regional left ventricular systolic dysfunction. Traditionally, it has been associated with physical or psychological stressors. Clinically, the onset of TTS is similar to acute coronary syndrome, requiring appropriate differential diagnosis to distinguish between the two clinical entities. Its treatment is usually conservative, and the prognosis is generally favorable. We report the case of a 57-year-old woman who was referred to the Department of Rehabilitation after suffering a non-ST-segment elevation myocardial infarction. During her eighth physical rehabilitation session, she developed palpitations and hypertension. Initial telemetry monitoring showed ventricular bigeminy with extrasystoles, tachycardia episodes, and ST-segment elevation. She was admitted to the Department of Cardiology, and cardiac catheterization and subsequent coronary angiography were performed, revealing no incidence of coronary lesions. However, ventriculography demonstrated severe left ventricular dysfunction in the systolic phase, characterized by akinesia of the mid-apical segments. These findings were suggestive of Takotsubo syndrome, which was subsequently confirmed by cardiac magnetic resonance imaging.</AbstractText><CopyrightInformation>&#xa9; 2025 Jim&#xe9;nez-Jim&#xe9;nez, Mu&#xf1;oz-Paz, Ladera-Santos, Heredia-Torres, Caballero-Villarraso and Mayordomo-Riera.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jim&#xe9;nez-Jim&#xe9;nez</LastName><ForeName>Ana Bel&#xe9;n</ForeName><Initials>AB</Initials><AffiliationInfo><Affiliation>GC-28 Group, Maimonides Biomedical Research Institute of Cordoba (IMIBIC), C&#xf3;rdoba, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Physical Medicine and Rehabilitation, Reina Sof&#xed;a University Hospital, C&#xf3;rdoba, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mu&#xf1;oz-Paz</LastName><ForeName>Javier</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>GC-28 Group, Maimonides Biomedical Research Institute of Cordoba (IMIBIC), C&#xf3;rdoba, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Physical Medicine and Rehabilitation, Reina Sof&#xed;a University Hospital, C&#xf3;rdoba, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ladera-Santos</LastName><ForeName>Diana</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>GC-28 Group, Maimonides Biomedical Research Institute of Cordoba (IMIBIC), C&#xf3;rdoba, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiology, Reina Sof&#xed;a University Hospital, C&#xf3;rdoba, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heredia-Torres</LastName><ForeName>&#xc1;ngela</ForeName><Initials>&#xc1;</Initials><AffiliationInfo><Affiliation>GC-28 Group, Maimonides Biomedical Research Institute of Cordoba (IMIBIC), C&#xf3;rdoba, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Physical Medicine and Rehabilitation, Reina Sof&#xed;a University Hospital, C&#xf3;rdoba, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caballero-Villarraso</LastName><ForeName>Javier</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>GC-28 Group, Maimonides Biomedical Research Institute of Cordoba (IMIBIC), C&#xf3;rdoba, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Analysis, Reina Sof&#xed;a University Hospital, C&#xf3;rdoba, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mayordomo-Riera</LastName><ForeName>Fernando</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>GC-28 Group, Maimonides Biomedical Research Institute of Cordoba (IMIBIC), C&#xf3;rdoba, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Physical Medicine and Rehabilitation, Reina Sof&#xed;a University Hospital, C&#xf3;rdoba, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>06</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Cardiovasc Med</MedlineTA><NlmUniqueID>101653388</NlmUniqueID><ISSNLinking>2297-055X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Takotsubo</Keyword><Keyword MajorTopicYN="N">atypical onset</Keyword><Keyword MajorTopicYN="N">broken heart syndrome</Keyword><Keyword MajorTopicYN="N">heart rehabilitation</Keyword><Keyword MajorTopicYN="N">stress-induced cardiomyopathy</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>1</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>5</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>9</Day><Hour>11</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>9</Day><Hour>11</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>9</Day><Hour>5</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>6</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40630899</ArticleId><ArticleId IdType="pmc">PMC12234314</ArticleId><ArticleId IdType="doi">10.3389/fcvm.2025.1560087</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Medina de Chazal H, Del Buono MG, Keyser-Marcus L, Ma L, Moeller FG, Berrocal D, et al. Stress cardiomyopathy diagnosis and treatment: JACC state-of-the-art review. J Am Coll Cardiol. (2018) 72:1955&#x2013;71. 10.1016/j.jacc.2018.07.072</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2018.07.072</ArticleId><ArticleId IdType="pmc">PMC7058348</ArticleId><ArticleId IdType="pubmed">30309474</ArticleId></ArticleIdList></Reference><Reference><Citation>Omerovic E, Citro R, Bossone E, Redfors B, Backs J, Bruns B, et al. Pathophysiology of Takotsubo syndrome&#x2014;a joint scientific statement from the heart failure association Takotsubo syndrome study group and myocardial function working group of the European Society of Cardiology&#x2014;part 1: overview and the central role for catecholamines and sympathetic nervous system. Eur J Heart Fail. (2022) 24:257&#x2013;73. 10.1002/ejhf.2400</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ejhf.2400</ArticleId><ArticleId IdType="pubmed">34907620</ArticleId></ArticleIdList></Reference><Reference><Citation>Moady G, Vons S, Atar S. A comparative retrospective study of patients with Takotsubo syndrome and acute coronary syndrome. Isr Med Assoc J. (2021) 23(2):107&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">33595216</ArticleId></ArticleIdList></Reference><Reference><Citation>Crea F, Iannaccone G, La Vecchia G, Montone RA. An update on the mechanisms of Takotsubo syndrome: &#x201c;at the end an acute coronary syndrome&#x201d;. J Mol Cell Cardiol. (2024) 191:1&#x2013;6. 10.1016/j.yjmcc.2024.04.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yjmcc.2024.04.009</ArticleId><ArticleId IdType="pubmed">38641224</ArticleId></ArticleIdList></Reference><Reference><Citation>Padilla-Lopez M, Duran-Cambra A, Belmar-Cliville D, Soriano-Amores M, Arakama-Goikoetxea S, Vila-Perales M, et al. Comparative electrocardiographic analysis of midventricular and typical Takotsubo syndrome. Front Cardiovasc Med. (2023) 10:1286975. 10.3389/fcvm.2023.1286975</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2023.1286975</ArticleId><ArticleId IdType="pmc">PMC10725917</ArticleId><ArticleId IdType="pubmed">38111891</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang K, Nakou E, Del Buono MG, Montone RA, D'Amario D, Bucciarelli-Ducci C. The role of cardiac magnetic resonance in myocardial infarction and non-obstructive coronary arteries. Front Cardiovasc Med. (2022) 8:821067. 10.3389/fcvm.2021.821067</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2021.821067</ArticleId><ArticleId IdType="pmc">PMC8801484</ArticleId><ArticleId IdType="pubmed">35111833</ArticleId></ArticleIdList></Reference><Reference><Citation>Assad J, Femia G, Pender P, Badie T, Rajaratnam R. Takotsubo syndrome: a review of presentation, diagnosis and management. Clin Med Insights Cardiol. (2022) 16:82. 10.1177/11795468211065782</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/11795468211065782</ArticleId><ArticleId IdType="pmc">PMC8733363</ArticleId><ArticleId IdType="pubmed">35002350</ArticleId></ArticleIdList></Reference><Reference><Citation>Matta A, Delmas C, Campelo-Parada F, Lhermusier T, Bouisset F, Elbaz M, et al. Takotsubo cardiomyopathy. Rev Cardiovasc Med. (2022) 23(1):38. 10.31083/j.rcm2301038</Citation><ArticleIdList><ArticleId IdType="doi">10.31083/j.rcm2301038</ArticleId><ArticleId IdType="pubmed">35092230</ArticleId></ArticleIdList></Reference><Reference><Citation>Lau C, Chiu S, Nayak R, Lin B, Lee MS. Survival and risk of recurrence of Takotsubo syndrome. Heart. (2021) 107(14):1160&#x2013;6. 10.1136/heartjnl-2020318028</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/heartjnl-2020318028</ArticleId><ArticleId IdType="pmc">PMC8257555</ArticleId><ArticleId IdType="pubmed">33419884</ArticleId></ArticleIdList></Reference><Reference><Citation>Colantonio M, Awad M, Liriano MM, Santer M, Murshid A, Haleem A. An unlikely cause of chest pain: recurrent Takotsubo cardiomyopathy. J Community Hosp Intern Med Perspect. (2024) 14(5):114&#x2013;9. 10.55729/2000-9666.1394</Citation><ArticleIdList><ArticleId IdType="doi">10.55729/2000-9666.1394</ArticleId><ArticleId IdType="pmc">PMC11466336</ArticleId><ArticleId IdType="pubmed">39399193</ArticleId></ArticleIdList></Reference><Reference><Citation>Bader M, Mubarak M, Ali S, Hasan Z, Alsudairy N. A case of Takotsubo cardiomyopathy in a 65-year-old woman triggered by emotional stress. Cureus. (2024) 16(11):e73533. 10.7759/cureus.73533</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.73533</ArticleId><ArticleId IdType="pmc">PMC11638468</ArticleId><ArticleId IdType="pubmed">39677100</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei Juan L, Kaisbain N. Emotional stress induced broken heart syndrome: a case report. Cureus. (2022) 14(12):e32384. 10.7759/cureus.32384</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.32384</ArticleId><ArticleId IdType="pmc">PMC9828072</ArticleId><ArticleId IdType="pubmed">36632256</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia P, Zhang Y, Sun Y, Wang J. Case report: Takotsubo syndrome induced by severe hypoglycemia. Front Cardiovasc Med. (2022) 9:1059638. 10.3389/fcvm.2022.1059638</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2022.1059638</ArticleId><ArticleId IdType="pmc">PMC9719912</ArticleId><ArticleId IdType="pubmed">36479569</ArticleId></ArticleIdList></Reference><Reference><Citation>Bacro-Duverger BH, Thorburn AQ, Denney BD, Gullett JP, Thompson MA, Pigott DC. Takotsubo cardiomyopathy following traumatic hand amputation: a case report. Clin Pract Cases Emerg Med. (2022) 6(3):225&#x2013;28. 10.5811/cpcem.2022.2.55463</Citation><ArticleIdList><ArticleId IdType="doi">10.5811/cpcem.2022.2.55463</ArticleId><ArticleId IdType="pmc">PMC9436489</ArticleId><ArticleId IdType="pubmed">36049187</ArticleId></ArticleIdList></Reference><Reference><Citation>Polimeni A, Spaccarotella C, Ielapi J, Esposito G, Ravera A, Martuscelli E, et al. The impact of UEFA Euro 2020 football championship on Takotsubo syndrome: results of a multicenter national registry. Front Cardiovasc Med. (2022) 9:951882. 10.3389/fcvm.2022.951882</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2022.951882</ArticleId><ArticleId IdType="pmc">PMC9554214</ArticleId><ArticleId IdType="pubmed">36247479</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz P, Gabarre P, Chenevier-Gobeaux C, Fran&#xe7;ois H, Kerneis M, Cidlowski JA, et al. Case report: changes in the levels of stress hormones during Takotsubo syndrome. Front Cardiovasc Med. (2022) 9:931054. 10.3389/fcvm.2022.931054</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2022.931054</ArticleId><ArticleId IdType="pmc">PMC9354975</ArticleId><ArticleId IdType="pubmed">35935637</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong F, Yin L, Sisakian H, Hakobyan T, Jeong LS, Joshi H, et al. Takotsubo syndrome is a coronary microvascular disease: experimental evidence. Eur Heart J. (2023) 44(24):2244&#x2013;53. 10.1093/eurheartj/ehad274</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehad274</ArticleId><ArticleId IdType="pmc">PMC10290875</ArticleId><ArticleId IdType="pubmed">37170610</ArticleId></ArticleIdList></Reference><Reference><Citation>Alim S, Shah H, Zahera SM, Rahmatova J, Irfan M, Mahmood Z, et al. An update on Takotsubo syndrome. J Cardiovasc Med. (2023) 24(10):691&#x2013;9. 10.2459/JCM.0000000000001528</Citation><ArticleIdList><ArticleId IdType="doi">10.2459/JCM.0000000000001528</ArticleId><ArticleId IdType="pubmed">37577868</ArticleId></ArticleIdList></Reference><Reference><Citation>Li P, Wang Y, Liang J, Zuo X, Li Q, Sherif AA, et al. Takotsubo syndrome and respiratory diseases: a systematic review. Eur Heart J Open. (2022) 2(2):oeac009. 10.1093/ehjopen/oeac009</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ehjopen/oeac009</ArticleId><ArticleId IdType="pmc">PMC9242042</ArticleId><ArticleId IdType="pubmed">35919117</ArticleId></ArticleIdList></Reference><Reference><Citation>Dall'Ara G, Compagnone M, Carletti R, Piciucchi S, Gardini E, Galvani M. Case report: asymptomatic SARS-COV2 infection triggering recurrent Takotsubo syndrome. Front Cardiovasc Med. (2024) 11:1418316. 10.3389/fcvm.2024.1418316</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2024.1418316</ArticleId><ArticleId IdType="pmc">PMC11157011</ArticleId><ArticleId IdType="pubmed">38854654</ArticleId></ArticleIdList></Reference><Reference><Citation>Bairashevskaia AV, Belogubova SY, Kondratiuk MR, Rudnova DS, Sologova SS, Tereshkina OI, et al. Update of Takotsubo cardiomyopathy: present experience and outlook for the future. Int J Cardiol Heart Vasc. (2022) 39:100990. 10.1016/j.ijcha.2022.100990</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijcha.2022.100990</ArticleId><ArticleId IdType="pmc">PMC8913320</ArticleId><ArticleId IdType="pubmed">35281752</ArticleId></ArticleIdList></Reference><Reference><Citation>Gobeil K, White K, Bhat A, Szalai H, Lagu TC, Pack QR. Cardiac rehabilitation in Takotsubo cardiomyopathy: predictors of utilization and effects of exercise training. Heart Lung. (2021) 50(2):230&#x2013;4. 10.1016/j.hrtlng.2020.12.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.hrtlng.2020.12.006</ArticleId><ArticleId IdType="pmc">PMC8150163</ArticleId><ArticleId IdType="pubmed">33340825</ArticleId></ArticleIdList></Reference><Reference><Citation>Poruban T, Studencan M, Kirsch P, Novotny R. Incidence of Takotsubo cardiomyopathy in patients with acute coronary syndrome: a single center retrospective analysis. Egypt Heart J. (2024) 76(1):112. 10.1186/s43044-024-00542-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s43044-024-00542-x</ArticleId><ArticleId IdType="pmc">PMC11347531</ArticleId><ArticleId IdType="pubmed">39186244</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40620837</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>08</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2168-8184</ISSN><JournalIssue CitedMedium="Print"><Volume>17</Volume><Issue>7</Issue><PubDate><Year>2025</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Cureus</Title><ISOAbbreviation>Cureus</ISOAbbreviation></Journal><ArticleTitle>Desmoplakin Cardiomyopathy: Myocarditis-Like Episodes.</ArticleTitle><Pagination><StartPage>e87311</StartPage><MedlinePgn>e87311</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e87311</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.7759/cureus.87311</ELocationID><Abstract><AbstractText>We report a case of a 21-year-old woman who presented with recurrent chest pain over a three-year period, initially attributed to myocarditis. She first presented with elevated troponin levels and myocardial oedema on cardiac magnetic resonance imaging (MRI), consistent with acute myocarditis. Despite symptomatic management and a gradual return to activity, she experienced multiple relapses characterised by chest pain, subtle left ventricular dysfunction, and persistent myocardial scarring on serial MRI, but without active inflammation. A multidisciplinary evaluation and genetic testing revealed a heterozygous deletion in the desmoplakin (DSP) gene, confirming the diagnosis of desmoplakin cardiomyopathy. Electrocardiographic abnormalities included T-wave inversions in the anterior and lateral leads. Due to her elevated risk of sudden cardiac death, she underwent implantation of a subcutaneous implantable cardioverter-defibrillator (s-ICD) for primary prevention. This case highlights that DSP cardiomyopathy should be considered in the differential diagnosis of recurrent myocarditis-like presentations, particularly in young individuals with non-ischaemic findings and suggestive imaging features.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025, Fatrous et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fatrous</LastName><ForeName>Tarek</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Medicine, Milton Keynes University Hospital NHS Trust, Milton Keynes, GBR.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ibzea</LastName><ForeName>Sara</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Medicine and Surgery, Milton Keynes University Hospital NHS Trust, Milton Keynes, GBR.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zahir Hussain</LastName><ForeName>Sharafath Hussain</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>Medicine, Milton Keynes University Hospital NHS Trust, Milton Keynes, GBR.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cureus</MedlineTA><NlmUniqueID>101596737</NlmUniqueID><ISSNLinking>2168-8184</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cardiomyopathy</Keyword><Keyword MajorTopicYN="N">covid</Keyword><Keyword MajorTopicYN="N">desmoplakin</Keyword><Keyword MajorTopicYN="N">genetics</Keyword><Keyword MajorTopicYN="N">myocarditis</Keyword><Keyword MajorTopicYN="N">vaccine</Keyword></KeywordList><CoiStatement>Human subjects: Consent for treatment and open access publication was obtained or waived by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>7</Day><Hour>6</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>7</Day><Hour>6</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>7</Day><Hour>5</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>7</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40620837</ArticleId><ArticleId IdType="pmc">PMC12228047</ArticleId><ArticleId IdType="doi">10.7759/cureus.87311</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Diagnosis and treatment of acute myocarditis: a review. Ammirati E, Moslehi JJ. JAMA. 2023;329:1098&#x2013;1113.</Citation><ArticleIdList><ArticleId IdType="pubmed">37014337</ArticleId></ArticleIdList></Reference><Reference><Citation>'Hot phase' clinical presentation in arrhythmogenic cardiomyopathy. Bariani R, Cipriani A, Rizzo S, et al. Europace. 2021;23:907&#x2013;917.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8184227</ArticleId><ArticleId IdType="pubmed">33313835</ArticleId></ArticleIdList></Reference><Reference><Citation>Mutation in human desmoplakin domain binding to plakoglobin causes a dominant form of arrhythmogenic right ventricular cardiomyopathy. Rampazzo A, Nava A, Malacrida S, et al. Am J Hum Genet. 2002;71:1200&#x2013;1206.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC385098</ArticleId><ArticleId IdType="pubmed">12373648</ArticleId></ArticleIdList></Reference><Reference><Citation>Desmoplakin cardiomyopathy: comprehensive review of an increasingly recognized entity. Brand&#xe3;o M, Bariani R, Rigato I, Bauce B. J Clin Med. 2023;12</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10095332</ArticleId><ArticleId IdType="pubmed">37048743</ArticleId></ArticleIdList></Reference><Reference><Citation>Desmoplakin missense and non-missense mutations in arrhythmogenic right ventricular cardiomyopathy: genotype-phenotype correlation. Castelletti S, Vischer AS, Syrris P, et al. Int J Cardiol. 2017;249:268&#x2013;273.</Citation><ArticleIdList><ArticleId IdType="pubmed">28527814</ArticleId></ArticleIdList></Reference><Reference><Citation>Myocarditis-like episodes in patients with arrhythmogenic cardiomyopathy: a systematic review on the so-called hot-phase of the disease. Bariani R, Rigato I, Cipriani A, et al. Biomolecules. 2022;12</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9496041</ArticleId><ArticleId IdType="pubmed">36139162</ArticleId></ArticleIdList></Reference><Reference><Citation>Clinical characteristics and risk stratification of desmoplakin cardiomyopathy. Wang W, Murray B, Tichnell C, et al. Europace. 2022;24:268&#x2013;277.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8824516</ArticleId><ArticleId IdType="pubmed">34352074</ArticleId></ArticleIdList></Reference><Reference><Citation>Recurrent immunosuppressive-responsive myocarditis in a patient with desmoplakin cardiomyopathy: a case report. McColl H, Cordina R, Lal S, Parker M, Hunyor I, Medi C, Gray B. Eur Heart J Case Rep. 2024;8:0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11024808</ArticleId><ArticleId IdType="pubmed">38638283</ArticleId></ArticleIdList></Reference><Reference><Citation>Management of recurrent myocarditis due to desmoplakin cardiomyopathy: diagnostic and therapeutic challenges. Ghawanmeh M, Simon Frances B, Kerai A, Patel P, Du J, Kumar P. JACC Case Rep. 2022;4:59&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8743810</ArticleId><ArticleId IdType="pubmed">35036946</ArticleId></ArticleIdList></Reference><Reference><Citation>Desmoplakin cardiomyopathy in pediatric patients: a distinct, underrecognized cohort of arrhythmogenic cardiomyopathy. Choi NH, Cherny S, Berul CI, et al. Circ Arrhythm Electrophysiol. 2024;17:0.</Citation><ArticleIdList><ArticleId IdType="pubmed">39523938</ArticleId></ArticleIdList></Reference><Reference><Citation>The desmoplakin phenotype spectrum: is the inflammation the &#x201c;fil rouge&#x201d; linking myocarditis, arrhythmogenic cardiomyopathy, and uncommon autoinflammatory systemic disease? D'Elia S, Caputo A, Natale F, et al. Genes (Basel) 2024;15</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11431300</ArticleId><ArticleId IdType="pubmed">39336825</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40658069</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1533-4023</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Jul</Month><Day>14</Day></PubDate></JournalIssue><Title>Journal of cardiovascular pharmacology</Title><ISOAbbreviation>J Cardiovasc Pharmacol</ISOAbbreviation></Journal><ArticleTitle>Treating the Broken Heart: Role of Stellate Ganglion Block in Takotsubo Syndrome.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1097/FJC.0000000000001734</ELocationID><Abstract><AbstractText>Takotsubo syndrome (TTS) is an acute stress-induced cardiomyopathy characterized by transient left ventricular dysfunction, often mimicking acute myocardial infarction but without obstructive coronary artery disease. While typically reversible, TTS can be complicated by serious adverse events, including life-threatening ventricular arrhythmias (VAs). The pathophysiology is complex but strongly linked to sympathetic nervous system hyperactivity and a surge in catecholamines, often termed "neurogenic stunned myocardium". This review discusses the role of arrhythmias in TTS, the influence of the autonomic nervous system, and explores the rationale, mechanisms, and potential applications of stellate ganglion block (SGB), particularly left SGB, in the management of TTS-related arrhythmias, illustrated by a clinical case.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 Wolters Kluwer Health, Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Giuliana</LastName><ForeName>Chiara</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Catholic University of the Sacred Heart, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Filomia</LastName><ForeName>Simone</ForeName><Initials>S</Initials><Identifier Source="ORCID">0009-0006-1593-5978</Identifier><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Catholic University of the Sacred Heart, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ricci</LastName><ForeName>Marta</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pinnacchio</LastName><ForeName>Gaetano</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D'Aiello</LastName><ForeName>Alessia</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saponara</LastName><ForeName>Gianluigi</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pedicino</LastName><ForeName>Daniela</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pelargonio</LastName><ForeName>Gemma</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Del Buono</LastName><ForeName>Marco Giuseppe</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanna</LastName><ForeName>Tommaso</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Cardiovasc Pharmacol</MedlineTA><NlmUniqueID>7902492</NlmUniqueID><ISSNLinking>0160-2446</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Autonomic Nervous System</Keyword><Keyword MajorTopicYN="N">Catecholamines</Keyword><Keyword MajorTopicYN="N">QTc Prolongation</Keyword><Keyword MajorTopicYN="N">Stellate Ganglion Block</Keyword><Keyword MajorTopicYN="N">Sympathetic Hyperactivity</Keyword><Keyword MajorTopicYN="N">Takotsubo Syndrome</Keyword><Keyword MajorTopicYN="N">Ventricular Arrhythmias</Keyword></KeywordList><CoiStatement>Conflict of Interest: none</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>14</Day><Hour>12</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>14</Day><Hour>12</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>14</Day><Hour>10</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40658069</ArticleId><ArticleId IdType="doi">10.1097/FJC.0000000000001734</ArticleId><ArticleId IdType="pii">00005344-990000000-00470</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40660878</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-0844</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Jul</Month><Day>15</Day></PubDate></JournalIssue><Title>European journal of heart failure</Title><ISOAbbreviation>Eur J Heart Fail</ISOAbbreviation></Journal><ArticleTitle>Cardio-microcurrent device treatment for heart failure with reduced ejection fraction: Results from the C-MIC II open-label randomized controlled trial.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1002/ejhf.3763</ELocationID><Abstract><AbstractText Label="AIMS" NlmCategory="OBJECTIVE">In patients with heart failure, alterations in electrical fields generated within the myocardium have been associated with myocardial oedema which can act as a substrate for left ventricular dysfunction. Safety and efficacy of a direct microcurrent therapy using an implanted generator (C-MIC) remain uncertain.</AbstractText><AbstractText Label="METHODS AND RESULTS" NlmCategory="RESULTS">Ambulatory patients with non-ischaemic dilated cardiomyopathy with left ventricular ejection fraction (LVEF) of 25% to 35% and New York Heart Association (NYHA) class III-IV were randomized to C-MIC (device) or control group in addition to guideline-directed medical therapy. The primary endpoint was change in LVEF at 6 months. Pre-specified secondary endpoints included 6-min walk distance (6MWD), Kansas City Cardiomyopathy Questionnaire overall summary score (KCCQ-OSS), and NYHA functional class. Of 70 patients randomized, 65 were included in modified intention-to-treat analysis (C-MIC device: n&#x2009;=&#x2009;32; control: n&#x2009;=&#x2009;33). At 6 months, treatment with C-MIC versus control improved LVEF (mean difference: 5.1%; 95% confidence interval [CI] 3.1-7.1%, p&#x2009;&lt;&#x2009;0.001). The proportions of patients with improvement in at least one NYHA class (risk difference: 68.9%; 95% CI 50.6-87.2, p &lt;&#x2009;0.001), an increase of &#x2265;5 points in KCCQ-OSS (risk difference: 60.0%; 95% CI 42.3-77.6, p&#x2009;&lt;&#x2009;0.001), and an increase of &#x2265;30% in 6MWD (risk difference: 38.3%; 95% CI 14.4-62.2) were substantially higher in the device versus control group (p &lt;&#x2009;0.002).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In patients with non-ischaemic chronic heart failure with reduced ejection fraction, the C-MIC device compared with control improved LVEF, symptoms, functional capacity and quality of life.</AbstractText><CopyrightInformation>&#xa9; 2025 The Author(s). European Journal of Heart Failure published by John Wiley &amp; Sons Ltd on behalf of European Society of Cardiology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Rame</LastName><ForeName>Jesus E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Bruce and Robbi Toll Heart and Vascular Institute, Thomas Jefferson University, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Schmitto</LastName><ForeName>Jan D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Department of Cardiac, Thoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Kosevic</LastName><ForeName>Dragana N</ForeName><Initials>DN</Initials><AffiliationInfo><Affiliation>Cardiovascular Institute Dedinje, Belgrade, Serbia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kovacevic-Preradovic</LastName><ForeName>Tamara</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, University of Banja Luka, Banja Luka, Bosnia and Herzegovina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jovev</LastName><ForeName>Sasko</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>University Clinic of Cardiology, Skopje, North Macedonia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zdravkovic</LastName><ForeName>Marija</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>University Hospital Medical Center Bezanijska Kosa, Belgrade, Serbia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Granov</LastName><ForeName>Nermir</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Clinical Center, University of Sarajevo, Sarajevo, Bosnia and Herzegovina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Popov</LastName><ForeName>Tanja</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Institute of Cardiovascular Diseases of Vojvodina, Vojvodina, Serbia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rudez</LastName><ForeName>Igor</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>University Hospital Dubrava, Zagreb, Croatia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vukovic</LastName><ForeName>Petar</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Medical School, University Belgrade, Belgrade, Serbia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ristic</LastName><ForeName>Velibor</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Cardiovascular Institute Dedinje, Belgrade, Serbia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Neuzil</LastName><ForeName>Petr</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Cardiology Clinic, Medical Faculty of Charles University and Homolka Hospital Prague, Prague, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holtdirk</LastName><ForeName>Annette</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>RQM+, Frankfurt, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruhparwar</LastName><ForeName>Arjang</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Cardiac, Thoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khan</LastName><ForeName>Muhammad Shahzeb</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Baylor Scott and White Health-Heart Hospital Plano and Baylor Scott and White Research Institute, Dallas, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D&#xfc;ngen</LastName><ForeName>Hans-Dirk</ForeName><Initials>HD</Initials><AffiliationInfo><Affiliation>SCIRENT LLC, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brandes</LastName><ForeName>Kersten</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Berlin Heals GmbH, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goettel</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Berlin Heals GmbH, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mueller</LastName><ForeName>Johannes</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Berlin Heals GmbH, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kallel</LastName><ForeName>Faouzi</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Berlin Heals GmbH, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Friede</LastName><ForeName>Tim</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Medical Statistics, University Medical Center G&#xf6;ttingen, and DZHK (German Center for Cardiovascular Research), Partner Site Lower Saxony, G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peric</LastName><ForeName>Miodrag</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Cardiovascular Institute Dedinje, Belgrade, Serbia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fudim</LastName><ForeName>Marat</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Duke University, Durham, NC, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Duke Clinical Research Institute, Durham, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anker</LastName><ForeName>Stefan D</ForeName><Initials>SD</Initials><AffiliationInfo><Affiliation>Department of Cardiology (CVK) of German Heart Center Charit&#xe9;; German Centre for Cardiovascular Research (DZHK) Partner Site Berlin, Charit&#xe9; Universit&#xe4;tsmedizin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>C&#x2010;MIC II Trial Investigators</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Berlin Heals GmbH</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur J Heart Fail</MedlineTA><NlmUniqueID>100887595</NlmUniqueID><ISSNLinking>1388-9842</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cardio&#x2010;microcurrent device</Keyword><Keyword MajorTopicYN="N">Electrical microcurrent</Keyword><Keyword MajorTopicYN="N">Heart failure</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>6</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>5</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>6</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>15</Day><Hour>6</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>15</Day><Hour>6</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>15</Day><Hour>3</Hour><Minute>43</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40660878</ArticleId><ArticleId IdType="doi">10.1002/ejhf.3763</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>Tromp J, Bamadhaj S, Cleland JGF, Angermann CE, Dahlstrom U, Ouwerkerk W, et al. Post&#x2010;discharge prognosis of patients admitted to hospital for heart failure by world region, and national level of income and income disparity (REPORT&#x2010;HF): A cohort study. Lancet Glob Health 2020;8:e411&#x2010;e422. https://doi.org/10.1016/S2214&#x2010;109X(20)30004&#x2010;8</Citation></Reference><Reference><Citation>Rosano GMC. Clinical trial design, endpoints and regulatory considerations in heart failure. Glob Cardiol 2024;2. https://doi.org/10.4081/cardio.2024.18</Citation></Reference><Reference><Citation>Yan CL, Snipelisky D, Velez M, Baran D, Estep JD, Bauerlein EJ, et al. Protocol&#x2010;driven approach to guideline&#x2010;directed medical therapy optimization for heart failure: A real&#x2010;world application to recovery. Am Heart J Plus 2024;45:100438. https://doi.org/10.1016/j.ahjo.2024.100438</Citation></Reference><Reference><Citation>Wilcox JE, Fonarow GC, Ardehali H, Bonow RO, Butler J, Sauer AJ, et al. &#x201c;Targeting the heart&#x201d; in heart failure: Myocardial recovery in heart failure with reduced ejection fraction. JACC Heart Fail 2015;3:661&#x2013;669. https://doi.org/10.1016/j.jchf.2015.04.011</Citation></Reference><Reference><Citation>Mody R, Nee Sheth AB, Dash D, Mody B, Agrawal A, Monga IS, et al. Device therapies for heart failure with reduced ejection fraction: A new era. Front Cardiovasc Med 2024;11:1388232. https://doi.org/10.3389/fcvm.2024.1388232</Citation></Reference><Reference><Citation>Bazoukis G, Saplaouras A, Efthymiou P, Yiannikourides A, Liu T, Letsas KP, et al. Cardiac contractility modulation in patients with heart failure&#xa0;&#x2013;&#xa0;a review of the literature. Heart Fail Rev 2024;29:689&#x2013;705. https://doi.org/10.1007/s10741&#x2010;024&#x2010;10390&#x2010;1</Citation></Reference><Reference><Citation>Palmiero G, Florio MT, Rubino M, Nesti M, Marchel M, Russo V. Cardiac resynchronization therapy in patients with heart failure: What is new? Heart Fail Clin 2021;17:289&#x2013;301. https://doi.org/10.1016/j.hfc.2021.01.010</Citation></Reference><Reference><Citation>Antoniadis AP, Sieniewicz B, Gould J, Porter B, Webb J, Claridge S, et al. Updates in cardiac resynchronization therapy for chronic heart failure: Review of multisite pacing. Curr Heart Fail Rep 2017;14:376&#x2013;383. https://doi.org/10.1007/s11897&#x2010;017&#x2010;0350&#x2010;z</Citation></Reference><Reference><Citation>Kapeller B, Mueller J, Losert U, Podesser BK, Macfelda K. Microcurrent stimulation promotes reverse remodelling in cardiomyocytes. ESC Heart Fail. 2016;3:122&#x2013;130. https://doi.org/10.1002/ehf2.12080</Citation></Reference><Reference><Citation>Schmitto JD, Napp LC, Mariani S, Hanke JS, Li T, Vogel&#x2010;Claussen J, et al. First&#x2010;in&#x2010;man implantation of a cardiac microcurrent device for chronic systolic heart failure. ASAIO J 2022;68:e121&#x2013;e123. https://doi.org/10.1097/MAT.0000000000001537</Citation></Reference><Reference><Citation>Kosevic D, Wiedemann D, Vukovic P, Ristic V, Riebandt J, Radak U, et al. Cardio&#x2010;microcurrent device for chronic heart failure: First&#x2010;in&#x2010;human clinical study. ESC Heart Fail 2021;8:962&#x2013;970. https://doi.org/10.1002/ehf2.13242</Citation></Reference><Reference><Citation>Bachamanda Somesh D, J&#xfc;rchott K, Giesel T, T&#xf6;llner T, Prehn A, Richters JP, et al. Microcurrent&#x2010;mediated modulation of myofibroblasts for cardiac repair and regeneration. Int J Mol Sci 2024;25:3268. https://doi.org/10.3390/ijms25063268</Citation></Reference><Reference><Citation>Rouabhia M, Park H, Meng S, Derbali H, Zhang Z. Electrical stimulation promotes wound healing by enhancing dermal fibroblast activity and promoting myofibroblast transdifferentiation. PLoS One 2013;8:e71660. https://doi.org/10.1371/journal.pone.0071660</Citation></Reference><Reference><Citation>Avenda&#xf1;o&#x2010;Coy J, L&#xf3;pez&#x2010;Mu&#xf1;oz P, Serrano&#x2010;Mu&#xf1;oz D, Comino&#x2010;Su&#xe1;rez N, Avenda&#xf1;o&#x2010;L&#xf3;pez C, Martin&#x2010;Espinosa N. Electrical microcurrent stimulation therapy for wound healing: A meta&#x2010;analysis of randomized clinical trials. J Tissue Viability 2022;31:268&#x2013;277. https://doi.org/10.1016/j.jtv.2021.12.002</Citation></Reference><Reference><Citation>Pu Z, Shimizu Y, Hayashi T, Che Y, Suzuki J, Tsuzuki K, et al. Cardiac lymphatic insufficiency leads to diastolic dysfunction via myocardial morphologic change. JACC Basic Transl Sci 2023;8:958&#x2013;972. https://doi.org/10.1016/j.jacbts.2023.01.008</Citation></Reference><Reference><Citation>Kiseleva DG, Kirichenko TV, Markina YV, Cherednichenko VR, Gugueva EA, Markin AM. Mechanisms of myocardial edema development in CVD pathophysiology. Biomedicines 2024;12:465. https://doi.org/10.3390/biomedicines12020465</Citation></Reference><Reference><Citation>Kosevic DB, Radak U, Vukovic P, Schmitto JD, Brandes K, Goettel P, et al. Two&#x2010;year outcomes of a cardiac microcurrent device in chronic heart failure: A first&#x2010;in&#x2010;human pilot study. ESC Heart Fail 2025. https://doi.org/10.1002/ehf2.15369</Citation></Reference><Reference><Citation>Pensa AV, Zheng V, Davis L, Harap RW, Wilcox JE. Clinical perspective of myocardial recovery and improvement: Definitions, prevalence, and relevance. Methodist Debakey Cardiovasc J 2024;20:6&#x2013;15. https://doi.org/10.14797/mdcvj.1441</Citation></Reference><Reference><Citation>Park CS, Park JJ, Mebazaa A, Oh IY, Park HA, Cho HJ, et al. Characteristics, outcomes, and treatment of heart failure with improved ejection fraction. J Am Heart Assoc 2019;8:e011077. https://doi.org/10.1161/JAHA.118.011077</Citation></Reference><Reference><Citation>Sun Y, Chen X, Zhang Y, Yu Y, Zhang X, Si J, et al. Reverse atrial remodeling in heart failure with recovered ejection fraction. J Am Heart Assoc 2023;12:e026891. https://doi.org/10.1161/JAHA.122.026891</Citation></Reference><Reference><Citation>Khan MS, Butler J, Friede T, Ponikowski P, Anker SD. To clip or not to clip moderate&#x2010;to&#x2010;severe functional mitral regurgitation in patients with heart failure. Glob Cardiol 2024;2. https://doi.org/10.4081/cardio.2024.44</Citation></Reference><Reference><Citation>Oskouie S, Pandey A, Sauer AJ, Greene SJ, Mullens W, Khan MS, et al. From hospital to home: Evidence&#x2010;based care for worsening heart failure. JACC Adv 2024;3:101131. https://doi.org/10.1016/j.jacadv.2024.101131</Citation></Reference><Reference><Citation>Khariton Y, Fonarow GC, Arnold SV, Hellkamp A, Nassif ME, Sharma PP, et al. Association between sacubitril/valsartan initiation and health status outcomes in heart failure with reduced ejection fraction. JACC Heart Fail 2019;7:933&#x2013;941. https://doi.org/10.1016/j.jchf.2019.05.016</Citation></Reference><Reference><Citation>Akhtar KH, Johnston S, Zhao YD, Amil F, Ford L, Lindenfeld J, et al. Meta&#x2010;analysis analyzing the effect of therapies on 6&#x2010;min walk distance in heart failure with reduced ejection fraction. Am J Cardiol 2022;178:72&#x2013;79. https://doi.org/10.1016/j.amjcard.2022.05.023</Citation></Reference><Reference><Citation>Usman MS, Hamid A, Qazi SU, Kosiborod MN, Bhatt DL, Shahzeb Khan M, et al. The effect of SGLT2 inhibitors on health status in patients with heart failure: A systematic review and meta&#x2010;analysis. Glob Cardiol 2024;2. https://doi.org/10.4081/cardio.2024.35</Citation></Reference><Reference><Citation>Johansson I, Joseph P, Balasubramanian K, McMurray JJV, Lund LH, Ezekowitz JA, et al.; G&#x2010;CHF Investigators. Health&#x2010;related quality of life and mortality in heart failure: The Global Congestive Heart Failure study of 23&#x2009;000 patients from 40 countries. Circulation 2021;143:2129&#x2013;2142. https://doi.org/10.1161/CIRCULATIONAHA.120.050850</Citation></Reference><Reference><Citation>Yu C, Hu ZQ, Peng RY. Effects and mechanisms of a microcurrent dressing on skin wound healing: A review. Mil Med Res 2014;1:24. https://doi.org/10.1186/2054&#x2010;9369&#x2010;1&#x2010;24</Citation></Reference><Reference><Citation>Rame JE, M&#xfc;ller J. Myocardial edema revisited in a new paradigm of cardiac electrical microcurrent application in heart failure. Bioelectricity 2021;3:171&#x2013;175. https://doi.org/10.1089/bioe.2021.0021</Citation></Reference><Reference><Citation>Robich MP, Chu LM, Oyamada S, Sodha NR, Sellke FW. Myocardial therapeutic angiogenesis: A review of the state of development and future obstacles. Expert Rev Cardiovasc Ther 2011;9:1469&#x2013;1479. https://doi.org/10.1586/erc.11.148</Citation></Reference><Reference><Citation>Haight PJ, Stewart RE, Saarel EV, Pettersson GB, Najm HK, Aziz PF. Lateral thoracotomy for epicardial pacemaker placement in patients with congenital heart disease. Interact Cardiovasc Thorac Surg 2018;26:845&#x2013;851. https://doi.org/10.1093/icvts/ivx379</Citation></Reference><Reference><Citation>Kalogeropoulos AP, Fonarow GC, Georgiopoulou V, Burkman G, Siwamogsatham S, Patel A, et al. Characteristics and outcomes of adult outpatients with heart failure and improved or recovered ejection fraction. JAMA Cardiol 2016;1:510&#x2013;518. https://doi.org/10.1001/jamacardio.2016.1325</Citation></Reference><Reference><Citation>DeVore AD, Hellkamp AS, Thomas L, Albert NM, Butler J, Patterson JH, et al. The association of improvement in left ventricular ejection fraction with outcomes in patients with heart failure with reduced ejection fraction: Data from CHAMP&#x2010;HF. Eur J Heart Fail 2022;24:762&#x2013;770. https://doi.org/10.1002/ejhf.2486</Citation></Reference><Reference><Citation>Savarese G, Vedin O, D'Amario D, Uijl A, Dahlstr&#xf6;m U, Rosano G, et al. Prevalence and prognostic implications of longitudinal ejection fraction change in heart failure. JACC Heart Fail 2019;7:306&#x2013;317. https://doi.org/10.1016/j.jchf.2018.11.019</Citation></Reference><Reference><Citation>Breathett K, Allen LA, Udelson J, Davis G, Bristow M. Changes in left ventricular ejection fraction predict survival and hospitalization in heart failure with reduced ejection fraction. Circ Heart Fail 2016;9:e002962. https://doi.org/10.1161/CIRCHEARTFAILURE.115.002962</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40726613</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>31</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2514-2119</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>7</Issue><PubDate><Year>2025</Year><Month>Jul</Month></PubDate></JournalIssue><Title>European heart journal. Case reports</Title><ISOAbbreviation>Eur Heart J Case Rep</ISOAbbreviation></Journal><ArticleTitle>Temporary use of leadless pacemaker as a bridge to cardiac resynchronisation therapy: a case report of fulminant myocarditis.</ArticleTitle><Pagination><StartPage>ytaf316</StartPage><MedlinePgn>ytaf316</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">ytaf316</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/ehjcr/ytaf316</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Fulminant myocarditis can result in persistent severe left ventricular dysfunction and complete atrioventricular block (AVB), necessitating cardiac resynchronisation therapy (CRT). However, direct CRT implantation can be sometimes challenging in the context of intensive mechanical circulatory support and systemic steroid therapy, where the risks of procedure-related bleeding and infection are significantly heightened.</AbstractText><AbstractText Label="CASE SUMMARY" NlmCategory="UNASSIGNED">This report describes a 64-year-old woman with fulminant myocarditis, severe left ventricular dysfunction, and persistent complete AVB, who was initially managed with extracorporeal membrane oxygenation and the Impella 5.5, along with temporary pacing. Due to the high risks of infection and bleeding, we implanted a leadless pacemaker (Micra AV system) as a temporary measure prior to CRT. Following Micra AV implantation, temporary pacing was successfully removed, and signs of infection and bleeding tendency improved. CRT was subsequently implanted, and Impella 5.5 was successfully weaned.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="UNASSIGNED">This case underscores the potential utility of a leadless pacemaker as a bridge to CRT therapy in patients with high risks of bleeding and infection. By employing this approach, the patient's clinical condition can be optimized, enabling the safe implantation of CRT. Further studies are warranted to validate our findings and evaluate the applicability of our novel strategy.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2025. Published by Oxford University Press on behalf of the European Society of Cardiology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yamamoto</LastName><ForeName>Riona</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Second Department of Internal Medicine, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kataoka</LastName><ForeName>Naoya</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0001-7097-2495</Identifier><AffiliationInfo><Affiliation>Second Department of Internal Medicine, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Imamura</LastName><ForeName>Teruhiko</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-7294-7637</Identifier><AffiliationInfo><Affiliation>Second Department of Internal Medicine, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakamura</LastName><ForeName>Makiko</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Second Department of Internal Medicine, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kinugawa</LastName><ForeName>Koichiro</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0003-0009-8477</Identifier><AffiliationInfo><Affiliation>Second Department of Internal Medicine, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>06</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur Heart J Case Rep</MedlineTA><NlmUniqueID>101730741</NlmUniqueID><ISSNLinking>2514-2119</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cardiac resynchronisation therapy</Keyword><Keyword MajorTopicYN="N">Case report</Keyword><Keyword MajorTopicYN="N">Complete atrioventricular block</Keyword><Keyword MajorTopicYN="N">Leadless pacemaker</Keyword><Keyword MajorTopicYN="N">Myocarditis</Keyword></KeywordList><CoiStatement>Conflict of interest. None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>12</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>4</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>6</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>29</Day><Hour>6</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>29</Day><Hour>6</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>29</Day><Hour>5</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>6</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40726613</ArticleId><ArticleId IdType="pmc">PMC12301293</ArticleId><ArticleId IdType="doi">10.1093/ehjcr/ytaf316</ArticleId><ArticleId IdType="pii">ytaf316</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ammirati &#xa0;E, Frigerio &#xa0;M, Adler &#xa0;ED, Basso &#xa0;C, Birnie &#xa0;DH, Brambatti &#xa0;M, et al. &#xa0;Management of acute myocarditis and chronic inflammatory cardiomyopathy: an expert consensus document. Circ Heart Fail &#xa0;2020;13:e007405.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7673642</ArticleId><ArticleId IdType="pubmed">33176455</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogunbayo &#xa0;GO, Elayi &#xa0;SC, Ha &#xa0;LD, Olorunfemi &#xa0;O, Elbadawi &#xa0;A, Saheed &#xa0;D, et al. &#xa0;Outcomes of heart block in myocarditis: a review of 31,760 patients. Heart Lung Circ &#xa0;2019;28:272&#x2013;276.</Citation><ArticleIdList><ArticleId IdType="pubmed">29402690</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura &#xa0;T, Hirata &#xa0;Y, Ise &#xa0;T, Iwano &#xa0;H, Izutani &#xa0;H, Kinugawa &#xa0;K, et al. &#xa0;JCS/JSCVS/JCC/CVIT 2023 guideline focused update on indication and operation of PCPS/ECMO/IMPELLA. Circ J &#xa0;2024;88:1010&#x2013;1046.</Citation><ArticleIdList><ArticleId IdType="pubmed">38583962</ArticleId></ArticleIdList></Reference><Reference><Citation>Abe &#xa0;T, Tsuda &#xa0;E, Miyazaki &#xa0;A, Ishibashi-Ueda &#xa0;H, Yamada &#xa0;O. Clinical characteristics and long-term outcome of acute myocarditis in children. Heart Vessels &#xa0;2013;28:632&#x2013;638.</Citation><ArticleIdList><ArticleId IdType="pubmed">23064719</ArticleId></ArticleIdList></Reference><Reference><Citation>Heymans &#xa0;S, Eriksson &#xa0;U, Lehtonen &#xa0;J, Cooper &#xa0;LT &#xa0;Jr. The quest for new approaches in myocarditis and inflammatory cardiomyopathy. J Am Coll Cardiol &#xa0;2016;68:2348&#x2013;2364.</Citation><ArticleIdList><ArticleId IdType="pubmed">27884253</ArticleId></ArticleIdList></Reference><Reference><Citation>Ali-Ahmed &#xa0;F, Dalgaard &#xa0;F, Al-Khatib &#xa0;SM. Sudden cardiac death in patients with myocarditis: evaluation, risk stratification, and management. Am Heart J &#xa0;2020;220:29&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">31765933</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarakji &#xa0;KG, Mittal &#xa0;S, Kennergren &#xa0;C, Corey &#xa0;R, Poole &#xa0;JE, Schloss &#xa0;E, et al. &#xa0;Antibacterial envelope to prevent cardiac implantable device infection. N Engl J Med &#xa0;2019;380:1895&#x2013;1905.</Citation><ArticleIdList><ArticleId IdType="pubmed">30883056</ArticleId></ArticleIdList></Reference><Reference><Citation>Chinitz &#xa0;L, Ritter &#xa0;P, Khelae &#xa0;SK, Iacopino &#xa0;S, Garweg &#xa0;C, Grazia-Bongiorni &#xa0;M, et al. &#xa0;Accelerometer-based atrioventricular synchronous pacing with a ventricular leadless pacemaker: results from the Micra atrioventricular feasibility studies. Heart Rhythm &#xa0;2018;15:1363&#x2013;1371.</Citation><ArticleIdList><ArticleId IdType="pubmed">29758405</ArticleId></ArticleIdList></Reference><Reference><Citation>Garweg &#xa0;C, Breitenstein &#xa0;A, Cl&#xe9;menty &#xa0;N, De Asmundis &#xa0;C, Iacopino &#xa0;S, Johansen &#xa0;JB, et al. &#xa0;Strategies to improve atrioventricular synchrony in patients with a Micra AV leadless pacemaker. Europace &#xa0;2024;26:euae060.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10936979</ArticleId><ArticleId IdType="pubmed">38449430</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Chami &#xa0;MF, Bonner &#xa0;M, Holbrook &#xa0;R, Stromberg &#xa0;K, Mayotte &#xa0;J, Molan &#xa0;A, et al. &#xa0;Leadless pacemakers reduce risk of device-related infection: review of the potential mechanisms. Heart Rhythm &#xa0;2020;17:1393&#x2013;1397.</Citation><ArticleIdList><ArticleId IdType="pubmed">32247833</ArticleId></ArticleIdList></Reference><Reference><Citation>Nemer &#xa0;DM, Patel &#xa0;DR, Madden &#xa0;RA, Wilkoff &#xa0;BL, Rickard &#xa0;JW, Tarakji &#xa0;KG, et al. &#xa0;Comparative analysis of procedural outcomes and complications between De Novo and upgraded cardiac resynchronization therapy. JACC Clin Electrophysiol &#xa0;2021;7:62&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">33478714</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Edom &#xa0;CJ, Gramegna &#xa0;M, Baldetti &#xa0;L, Beneduce &#xa0;A, Castelein &#xa0;T, Dauwe &#xa0;D, et al. &#xa0;Management of bleeding and hemolysis during percutaneous microaxial flow pump support: a practical approach. JACC Cardiovasc Interv &#xa0;2023;16:1707&#x2013;1720.</Citation><ArticleIdList><ArticleId IdType="pubmed">37495347</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee &#xa0;JZ, Mulpuru &#xa0;SK, Shen &#xa0;WK. Leadless pacemaker: performance and complications. Trends Cardiovasc Med &#xa0;2018;28:130&#x2013;141.</Citation><ArticleIdList><ArticleId IdType="pubmed">28826669</ArticleId></ArticleIdList></Reference><Reference><Citation>Kolokathis &#xa0;K, Doundoulakis &#xa0;I, Tsiachris &#xa0;D, Kordalis &#xa0;A, Tsioufis &#xa0;K. Efficacy and safety of leadless cardiac resynchronization therapy: an updated meta-analysis. J Cardiol &#xa0;2025. 10.1016/j.jjcc.2025.03.010. Online ahead of print.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jjcc.2025.03.010</ArticleId><ArticleId IdType="pubmed">40118339</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40729229</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>02</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2571-841X</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Jan</Month><Day>26</Day></PubDate></JournalIssue><Title>Reports (MDPI)</Title><ISOAbbreviation>Reports (MDPI)</ISOAbbreviation></Journal><ArticleTitle>Unmasking an Intracardiac Shunt in a Case of Persistent Unexplained Hypoxia: A Case Report.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">16</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/reports8010016</ELocationID><Abstract><AbstractText><b>Background and Clinical Significance</b>: Pulmonary hypertension (PH) is characterized by an increase in mean pulmonary arterial pressure and pulmonary vascular resistance. It is frequently encountered in patients with significant intracardiac shunts, often necessitating the implementation of a closure device or surgical correction. Nevertheless, the occurrence of a concomitant atrial septal defect (ASD) with a right-to-left shunt inducing left ventricular dysfunction is a rare phenomenon. <b>Case Presentation</b>: A 69-year-old female patient with a history of heart failure (with preserved ejection fraction) and end-stage renal disease on hemodialysis presented to an outside facility, with syncope and hypoxia. She was recently diagnosed with severe pulmonary hypertension (measuring 86 mmHg). Right heart catheterization (RHC) revealed precapillary pulmonary hypertension (88/37/54 mmHg), prompting the initiation of intravenous epoprostenol. Nevertheless, the patient was persistently hypoxic, raising the possibility of a concomitant diagnosis. Upon review of the prior echocardiogram, which included a bubble study, an intracardiac shunt was identified. It was hypothesized that a combination of right ventricular failure and the right-to-left shunt resulting from the ASD contributed to the persistent hypoxemia. In light of this, prostacyclin therapy was continued alongside adjunctive vasopressors, resulting in clinical stabilization. The patient was eventually discharged with a treatment regimen that included subcutaneous Treprostinil. <b>Conclusions</b>: It is important to recognize that the consequences of PH are extensive, and that a rare yet significant etiology for persistent hypoxemia may be attributed to right-to-left shunting.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sivalokanathan</LastName><ForeName>Sanjay</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Icahn School of Medicine at Mount Sinai Morningside, New York, NY 10025, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saeedullah</LastName><ForeName>Usman</ForeName><Initials>U</Initials><Identifier Source="ORCID">0009-0000-0166-4181</Identifier><AffiliationInfo><Affiliation>Department of Cardiology, Icahn School of Medicine at Mount Sinai Morningside, New York, NY 10025, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Locke</LastName><ForeName>Auston</ForeName><Initials>A</Initials><Identifier Source="ORCID">0009-0007-1624-9176</Identifier><AffiliationInfo><Affiliation>Department of Cardiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trivieri</LastName><ForeName>Maria Giovanna</ForeName><Initials>MG</Initials><Identifier Source="ORCID">0000-0001-6601-3267</Identifier><AffiliationInfo><Affiliation>Department of Cardiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>01</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Reports (MDPI)</MedlineTA><NlmUniqueID>101757880</NlmUniqueID><ISSNLinking>2571-841X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">atrial septal defect</Keyword><Keyword MajorTopicYN="N">case report</Keyword><Keyword MajorTopicYN="N">intracardiac shunt</Keyword><Keyword MajorTopicYN="N">pulmonary hypertension</Keyword><Keyword MajorTopicYN="N">right heart catheterization</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>1</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>1</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>1</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>29</Day><Hour>18</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>29</Day><Hour>18</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>29</Day><Hour>13</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>1</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40729229</ArticleId><ArticleId IdType="pmc">PMC12199966</ArticleId><ArticleId IdType="doi">10.3390/reports8010016</ArticleId><ArticleId IdType="pii">reports8010016</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Condliffe R. Pulmonary Arterial Hypertension Associated with Congenital Heart Disease: Classification and Pathophysiology. J. Congenit. Cardiol. 2020;4:16. doi: 10.1186/s40949-020-00040-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40949-020-00040-0</ArticleId></ArticleIdList></Reference><Reference><Citation>de Moraes A.G., Vakil A., Moua T. Patent foramen ovale in idiopathic pulmonary arterial hypertension: Long-term risk and morbidity. Respir. Med. 2016;118:53&#x2013;57. doi: 10.1016/j.rmed.2016.07.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rmed.2016.07.007</ArticleId><ArticleId IdType="pubmed">27578471</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossi R., Coppi F., Monopoli D.E., Sgura F.A., Arrotti S., Boriani G. Pulmonary Arterial Hypertension and Right Ventricular Systolic Dysfunction in COVID-19 Survivors. Cardiol. J. 2022;29:163&#x2013;165. doi: 10.5603/CJ.a2021.0159.</Citation><ArticleIdList><ArticleId IdType="doi">10.5603/CJ.a2021.0159</ArticleId><ArticleId IdType="pmc">PMC8890407</ArticleId><ArticleId IdType="pubmed">34897638</ArticleId></ArticleIdList></Reference><Reference><Citation>Franklin W., Patel M. An Approach to Pulmonary Arterial Hypertension in the Adult Patient with Congenital Heart Disease.  [(accessed on 1 January 2025)];Am. Coll. Cardiol. 2013  Available online:  https://www.acc.org/latest-in-cardiology/articles/2014/07/18/12/56/an-approach-to-pulmonary-arterial-hypertension-in-the-adult-patient-with-congenital-heart-disease.</Citation></Reference><Reference><Citation>Zhang Z., Zhu S., Wang M., Wang X., Tong X., Wan J., Ding J. New Progress in Diagnosis and Treatment of Pulmonary Arterial Hypertension. J. Cardiothorac. Surg. 2022;17:216. doi: 10.1186/s13019-022-01947-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13019-022-01947-y</ArticleId><ArticleId IdType="pmc">PMC9422157</ArticleId><ArticleId IdType="pubmed">36038916</ArticleId></ArticleIdList></Reference><Reference><Citation>Piccari L., Blanco I., Torralba Y., Arismendi E., Gistau C., Ram&#xed;rez A., Gimeno-Santos E., Roca J., Burgos F., Rodr&#xed;guez-Rois&#xed;n R., et al. Mechanisms of Hypoxaemia in Severe Pulmonary Hypertension Associated with COPD. Eur. Respir. J. 2023;62:2300463. doi: 10.1183/13993003.00463-2023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.00463-2023</ArticleId><ArticleId IdType="pmc">PMC10356966</ArticleId><ArticleId IdType="pubmed">37414421</ArticleId></ArticleIdList></Reference><Reference><Citation>Toyono M. Pulmonary arterial hypertension in adults with atrial septal defect. J. Cardiol. Cases. 2012;6:e32&#x2013;e33. doi: 10.1016/j.jccase.2012.04.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jccase.2012.04.005</ArticleId><ArticleId IdType="pmc">PMC6269237</ArticleId><ArticleId IdType="pubmed">30532943</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunham-Snary K.J., Wu D., Sykes E.A., Thakrar A., Parlow L.R.G., Mewburn J.D., Parlow J.L., Archer S.L. Hypoxic Pulmonary Vasoconstriction. Chest. 2017;151:181&#x2013;192. doi: 10.1016/j.chest.2016.09.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chest.2016.09.001</ArticleId><ArticleId IdType="pmc">PMC5310129</ArticleId><ArticleId IdType="pubmed">27645688</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40711538</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1435-1544</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Jul</Month><Day>25</Day></PubDate></JournalIssue><Title>Herzschrittmachertherapie &amp; Elektrophysiologie</Title><ISOAbbreviation>Herzschrittmacherther Elektrophysiol</ISOAbbreviation></Journal><ArticleTitle>Unusual course of outflow tract tachycardia and cardiac decompensation in childhood: a&#xa0;case report and review of the literature.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00399-025-01090-w</ELocationID><Abstract><AbstractText>Outflow tract tachycardia (OT) is the most common form of idiopathic ventricular tachycardia (VT) in children. It is usually an incidental finding and presents only with mild symptoms. If affected patients have impaired left ventricular (LV) function, recovery usually progresses quickly after termination of the VT. To the best of the authors' knowledge, this is the first description of a&#xa0;9-year-old female patient who presented with incessant right ventricular OT and LV dysfunction that was initially assumed to be tachycardiomyopathy and later diagnosed to be related to underlying laminopathy. The VT was successfully treated by radiofrequency ablation, and electroanatomical mapping demonstrated no signs of endocardial scarring. The VT had most likely been present for a&#xa0;prolonged period since the patient and initially presented with only mild symptoms of cardiac congestion despite severely impaired LV function. It seems probable that the laminopathy somehow influenced the unusual course of impaired LV function in this patient, who had either idiopathic VT combined with incidentally proven laminopathy or, less likely, outflow tract VT related to the laminopathy mimicking idiopathic VT.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Weymann</LastName><ForeName>Antonia</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Klinik f&#xfc;r Kinder- und Jugendmedizin, P&#xe4;diatrische Kardiologie, Universit&#xe4;tsklinikum M&#xfc;nster, Alber-Schweitzer Campus&#xa0;1, 48149, M&#xfc;nster, Germany. Antonia.Weymann@ukmuenster.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>K&#xf6;be</LastName><ForeName>Julia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Klinik f&#xfc;r Kardiologie II-Rhythmologie, Universit&#xe4;tsklinikum M&#xfc;nster, M&#xfc;nster, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stegger</LastName><ForeName>Julia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Klinik f&#xfc;r Kinder- und Jugendmedizin, P&#xe4;diatrische Kardiologie, Universit&#xe4;tsklinikum M&#xfc;nster, Alber-Schweitzer Campus&#xa0;1, 48149, M&#xfc;nster, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wolfes</LastName><ForeName>Julian</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Klinik f&#xfc;r Kardiologie II-Rhythmologie, Universit&#xe4;tsklinikum M&#xfc;nster, M&#xfc;nster, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eckardt</LastName><ForeName>Lars</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Klinik f&#xfc;r Kardiologie II-Rhythmologie, Universit&#xe4;tsklinikum M&#xfc;nster, M&#xfc;nster, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sigler</LastName><ForeName>Matthias</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Klinik f&#xfc;r Kinder- und Jugendmedizin, P&#xe4;diatrische Kardiologie, Universit&#xe4;tsklinikum M&#xfc;nster, Alber-Schweitzer Campus&#xa0;1, 48149, M&#xfc;nster, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Ungew&#xf6;hnlicher Verlauf einer Ausflusstrakttachykardie mit kardialer Dekompensation im Kindesalter: Fallbericht und Literatur&#xfc;bersicht.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Herzschrittmacherther Elektrophysiol</MedlineTA><NlmUniqueID>9425873</NlmUniqueID><ISSNLinking>0938-7412</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><OtherAbstract Type="Publisher" Language="ger"><AbstractText>Ausflusstrakttachykardien sind die h&#xe4;ufigste Form der idiopathischen ventrikul&#xe4;ren Tachykardie (VT) im Kindesalter. Meist handelt es sich um einen Zufallsbefund, verbunden mit nur leichten Symptomen. Haben die betroffenen Patienten eine gest&#xf6;rte linksventrikul&#xe4;re (LV) Funktion, kommt es nach Beendigung der VT gew&#xf6;hnlich zu einer schnellen Erholung. Nach unserem Wissen ist dies die erste Beschreibung einer 9&#x2011;j&#xe4;hrigen Patientin mit permanenter rechtsventrikul&#xe4;rer Ausflusstrakttachykardie und LV-Dysfunktion, die zun&#xe4;chst als Tachykardiomyopathie gedeutet und sp&#xe4;ter mit einer zugrunde liegenden Laminopathie in Zusammenhang gebracht wurde. Die VT wurde unter Anwendung der Radiofrequenzablation erfolgreich behandelt, und eine elektroanatomische Kartierung ergab keine Anzeichen f&#xfc;r endokardiale Narbenbildung. Die VT hatte wahrscheinlich schon l&#xe4;ngere Zeit bestanden, da die Patientin anf&#xe4;nglich trotz sehr eingeschr&#xe4;nkter LV-Funktion nur leichte Symptome einer kardialen Stauung aufwies. Es erscheint wahrscheinlich, dass die Laminopathie auf irgendeine Weise den ungew&#xf6;hnlichen Verlauf der eingeschr&#xe4;nkten LV-Funktion im beschriebenen Fall beeinflusst hat, wobei die Patientin entweder eine idiopathische VT mit zuf&#xe4;llig diagnostizierter Laminopathie oder &#x2013;&#xa0;weniger wahrscheinlich &#x2013; eine Ausflusstrakt-VT im Zusammenhang mit der Laminopathie unter Vort&#xe4;uschung einer idiopathischen VT hatte.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Idiopathic ventricular tachycardia</Keyword><Keyword MajorTopicYN="N">Laminopathy</Keyword><Keyword MajorTopicYN="N">Left ventricular dysfunction</Keyword><Keyword MajorTopicYN="N">Radiofrequency ablation in children</Keyword><Keyword MajorTopicYN="N">Right ventriculra outflow tract tachycardia in children</Keyword></KeywordList><CoiStatement>Declarations. Conflict of interest: A.&#xa0;Weymann, J.&#xa0;K&#xf6;be, J.&#xa0;Stegger, J.&#xa0;Wolfes, L.&#xa0;Eckardt, and M.&#xa0;Sigler declare that they have no competing interests. Informed consent was obtained from the patient and her parents.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>4</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>6</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>12</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>12</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>11</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40711538</ArticleId><ArticleId IdType="doi">10.1007/s00399-025-01090-w</ArticleId><ArticleId IdType="pii">10.1007/s00399-025-01090-w</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Buxton&#xa0;AE, Waxman&#xa0;HL, Marchlinski&#xa0;FE, Simson&#xa0;MB, Cassidy&#xa0;D, Josephson&#xa0;ME (1981) Right ventricular tachycardia: clinical and electrophysiologic characteristics. Circulation 68:917&#x2013;927 (Nov)</Citation></Reference><Reference><Citation>Chiu&#xa0;SN, Wu&#xa0;WL, Lu&#xa0;CW, Wu&#xa0;KL, Tseng&#xa0;WC, Lin&#xa0;MT, Chang&#xa0;CC, Wang&#xa0;JK, Wu&#xa0;MH (2017) Special electrophysiological characteristics of pediatric idiopathic ventricular tachycardia. Int J Cardiol 227:595&#x2013;601 (Jan 15)</Citation><ArticleIdList><ArticleId IdType="pubmed">27810292</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalili&#xa0;M, Kargarfard&#xa0;M, Tabib&#xa0;A, Fathollahi&#xa0;MS, Brugada&#xa0;P (2023) Ventricular tachycardia ablation in children. Indian Pacing Electrophysiol&#xa0;J 23(4):99&#x2013;107</Citation><ArticleIdList><ArticleId IdType="pubmed">36906176</ArticleId><ArticleId IdType="pmc">10323183</ArticleId></ArticleIdList></Reference><Reference><Citation>Eckardt&#xa0;L, Doldi&#xa0;F, Anwar&#xa0;O, Gessler&#xa0;N, Scherschel&#xa0;K, Kahle&#xa0;AK, von Falkenhausen&#xa0;AS, Thaler&#xa0;R, Wolfes&#xa0;J, Metzner&#xa0;A, Meyer&#xa0;C, Willems&#xa0;S, K&#xf6;be&#xa0;J, Lange&#xa0;PS, Frommeyer&#xa0;G, Kuck&#xa0;KH, K&#xe4;&#xe4;b&#xa0;S, Steinbeck&#xa0;G, Sinner&#xa0;MF (2023) Major in-hospital complications after catheter ablation of cardiac arrhythmias: individual case analysis of 43 031 procedures. Europace 26(1):euad361 (Dec 28)</Citation><ArticleIdList><ArticleId IdType="pubmed">38102318</ArticleId><ArticleId IdType="pmc">10754182</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukuhara&#xa0;J, Sumitomo&#xa0;N, Nakamura&#xa0;T, Ichikawa&#xa0;R, Matsumura&#xa0;M, Abe&#xa0;O, Miyashita&#xa0;M, Taniguchi&#xa0;K, Kanamaru&#xa0;H, Ayusawa&#xa0;M, Karasawa&#xa0;K, Mugishima&#xa0;H (2011) Electrophysiological characteristics of idiopathic ventricular tachycardia in children. Circ&#xa0;J 75(3):672&#x2013;676</Citation><ArticleIdList><ArticleId IdType="pubmed">21224521</ArticleId></ArticleIdList></Reference><Reference><Citation>Gigli&#xa0;M, Merlo&#xa0;M, Graw&#xa0;SL, Barbati&#xa0;G, Rowland&#xa0;TJ, Slavov&#xa0;DB, Stolfo&#xa0;D, Haywood&#xa0;ME, Dal Ferro&#xa0;M, Altinier&#xa0;A, Ramani&#xa0;F, Brun&#xa0;F, Cocciolo&#xa0;A, Puggia&#xa0;I, Morea&#xa0;G, McKenna&#xa0;WJ, La Rosa&#xa0;FG, Taylor&#xa0;MRG, Sinagra&#xa0;G, Mestroni&#xa0;L (2019) Genetic Risk of Arrhythmic Phenotypes in Patients With Dilated Cardiomyopathy. J&#xa0;Am Coll Cardiol 74(11):1480&#x2013;1490 (Sep 17)</Citation><ArticleIdList><ArticleId IdType="pubmed">31514951</ArticleId><ArticleId IdType="pmc">6750731</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris&#xa0;KC, Potts&#xa0;JE, Fournier&#xa0;A, Gross&#xa0;GJ, Kantoch&#xa0;MJ, Cote&#xa0;JM, Sanatani&#xa0;S (2006) Right ventricular outflow tract tachycardia in children. J&#xa0;Pediatr 149(6):822&#x2013;826 (Dec)</Citation><ArticleIdList><ArticleId IdType="pubmed">17137900</ArticleId></ArticleIdList></Reference><Reference><Citation>Kili&#xe7;&#xa0;E, Celiker&#xa0;A, Karag&#xf6;z&#xa0;T, Alehan&#xa0;D, Ozkutlu&#xa0;S, Ozer&#xa0;S (2012) Analysis of idiopathic ventricular tachycardia in childhood. Turk J Pediatr 54(3):269&#x2013;272</Citation><ArticleIdList><ArticleId IdType="pubmed">23094537</ArticleId></ArticleIdList></Reference><Reference><Citation>K&#xf6;nemann&#xa0;H, Dagres&#xa0;N, Merino&#xa0;JL, Sticherling&#xa0;C, Zeppenfeld&#xa0;K, Tfelt-Hansen&#xa0;J, Eckardt&#xa0;L (2023) Spotlight on the 2022 ESC guideline management of ventricular arrhythmias and prevention of sudden cardiac death: 10 novel key aspects. Europace 25(5):euad91 (May 19)</Citation><ArticleIdList><ArticleId IdType="pubmed">37102266</ArticleId><ArticleId IdType="pmc">10228619</ArticleId></ArticleIdList></Reference><Reference><Citation>K&#xf6;nemann&#xa0;H, Ellermann&#xa0;C, Zeppenfeld&#xa0;K, Eckardt&#xa0;L (2023) Management of Ventricular Arrhythmias Worldwide: Comparison of the Latest ESC, AHA/ACC/HRS, and CCS/CHRS Guidelines. JACC Clin Electrophysiol 9(5):715&#x2013;728 (May)</Citation><ArticleIdList><ArticleId IdType="pubmed">37225314</ArticleId></ArticleIdList></Reference><Reference><Citation>Li&#xa0;XM, Jiang&#xa0;H, Li&#xa0;YH, Zhang&#xa0;Y, Liu&#xa0;HJ, Ge&#xa0;HY, Zhang&#xa0;Y, Li&#xa0;MT (2016) Effectiveness of Radiofrequency Catheter Ablation of Outflow Tract Ventricular Arrhythmias in Children and Adolescents. Pediatr Cardiol 37(8):1475&#x2013;1481 (Dec)</Citation><ArticleIdList><ArticleId IdType="pubmed">27562132</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfammatter&#xa0;JP, Paul&#xa0;T (1999) Idiopathic ventricular tachycardia in infancy and childhood: a&#xa0;multicenter study on clinical profile and outcome. Working Group on Dysrhythmias and Electrophysiology of the Association for European Pediatric Cardiology. J&#xa0;Am Coll Cardiol 33(7):2067&#x2013;2072 (Jun)</Citation><ArticleIdList><ArticleId IdType="pubmed">10362215</ArticleId></ArticleIdList></Reference><Reference><Citation>Ribbing&#xa0;M, Wasmer&#xa0;K, M&#xf6;nnig&#xa0;G, Kirchhof&#xa0;P, Loh&#xa0;P, Breithardt&#xa0;G, Haverkamp&#xa0;W, Eckardt&#xa0;L (2003) Endocardial mapping of right ventricular outflow tract tachycardia using noncontact activation mapping. J&#xa0;Cardiovasc Electrophysiol 14(6):602&#x2013;608 (Jun)</Citation><ArticleIdList><ArticleId IdType="pubmed">12875421</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahbi&#xa0;K, Yaou&#xa0;BR, Gandjbakhch&#xa0;E, Anselme&#xa0;F, Gossios&#xa0;T, Lakdawala&#xa0;NK, Stalens&#xa0;C, Sacher&#xa0;F, Babuty&#xa0;D, Trochu&#xa0;JN, Moubarak&#xa0;G, Savvatis&#xa0;K, Porcher&#xa0;R, Lafor&#xea;t&#xa0;P, Fayssoil&#xa0;A, Marijon&#xa0;E, Stojkovic&#xa0;T, B&#xe9;hin&#xa0;A, Leonard-Louis&#xa0;S, Sole&#xa0;G, Labombarda&#xa0;F, Richard&#xa0;P, Metay&#xa0;C, Quijano-Roy&#xa0;S, Dabaj&#xa0;I, Klug&#xa0;D, Vantyghem&#xa0;MC, Chevalier&#xa0;P, Ambrosi&#xa0;P, Salort&#xa0;E, Sadoul&#xa0;N, Waintraub&#xa0;X, Chikhaoui&#xa0;K, Mabo&#xa0;P, Combes&#xa0;N, Maury&#xa0;P, Sellal&#xa0;JM, Tedrow&#xa0;UB, Kalman&#xa0;JM, Vohra&#xa0;J, Androulakis&#xa0;AFA, Zeppenfeld&#xa0;K, Thompson&#xa0;T, Barnerias&#xa0;C, B&#xe9;cane&#xa0;HM, Bieth&#xa0;E, Boccara&#xa0;F, Bonnet&#xa0;D, Bouhour&#xa0;F, Boul&#xe9;&#xa0;S, Brehin&#xa0;AC, Chapon&#xa0;F, Cintas&#xa0;P, Cuisset&#xa0;JM, Davy&#xa0;JM, De Sandre-Giovannoli&#xa0;A, Demurger&#xa0;F, Desguerre&#xa0;I, Dieterich&#xa0;K, Durigneux&#xa0;J, Echaniz-Laguna&#xa0;A, Eschalier&#xa0;R, Ferreiro&#xa0;A, Ferrer&#xa0;X, Francannet&#xa0;C, Fradin&#xa0;M, Gaborit&#xa0;B, Gay&#xa0;A, Hag&#xe8;ge&#xa0;A, Isapof&#xa0;A, Jeru&#xa0;I, Juntas Morales&#xa0;R, Lagrue&#xa0;E, Lamblin&#xa0;N, Lascols&#xa0;O, Laugel&#xa0;V, Lazarus&#xa0;A, Leturcq&#xa0;F, Levy&#xa0;N, Magot&#xa0;A, Manel&#xa0;V, Martins&#xa0;R, Mayer&#xa0;M, Mercier&#xa0;S, Meune&#xa0;C, Michaud&#xa0;M, Minot-Myhi&#xe9;&#xa0;MC, Muchir&#xa0;A, Nadaj-Pakleza&#xa0;A, P&#xe9;r&#xe9;on&#xa0;Y, Petiot&#xa0;P, Petit&#xa0;F, Praline&#xa0;J, Rollin&#xa0;A, Sabouraud&#xa0;P, Sarret&#xa0;C, Schaeffer&#xa0;S, Taithe&#xa0;F, Tard&#xa0;C, Tiffreau&#xa0;V, Toutain&#xa0;A, Vatier&#xa0;C, Walther-Louvier&#xa0;U, Eymard&#xa0;B, Charron&#xa0;P, Vigouroux&#xa0;C, Bonne&#xa0;G, Kumar&#xa0;S, Elliott&#xa0;P, Duboc&#xa0;D (2019) Development and Validation of a&#xa0;New Risk Prediction Score for Life-Threatening Ventricular Tachyarrhythmias in Laminopathies. Circulation 140(4):293&#x2013;302 (Jul 23)</Citation><ArticleIdList><ArticleId IdType="pubmed">31155932</ArticleId></ArticleIdList></Reference><Reference><Citation>Worman&#xa0;HJ (2012) Nuclear lamins and laminopathies. J&#xa0;Pathol 226(2):316&#x2013;325. https://doi.org/10.1002/path.2999 (Epub 2011 Nov 14)</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/path.2999</ArticleId><ArticleId IdType="pubmed">21953297</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeppenfeld&#xa0;K, Tfelt-Hansen&#xa0;J, de Riva&#xa0;M, Winkel&#xa0;BG, Behr&#xa0;ER, Blom&#xa0;NA, Charron&#xa0;P, Corrado&#xa0;D, Dagres&#xa0;N, de Chillou&#xa0;C, Eckardt&#xa0;L, Friede&#xa0;T, Haugaa&#xa0;KH, Hocini&#xa0;M, Lambiase&#xa0;PD, Marijon&#xa0;E, Merino&#xa0;JL, Peichl&#xa0;P, Priori&#xa0;SG, Reichlin&#xa0;T, Schulz-Menger&#xa0;J, Sticherling&#xa0;C, Tzeis&#xa0;S, Verstrael&#xa0;A, Volterrani&#xa0;M, ESC Scientific Document Group (2022) 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart&#xa0;J 43(40):3997&#x2013;4126 (Oct 21)</Citation><ArticleIdList><ArticleId IdType="pubmed">36017572</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong&#xa0;L, Lee&#xa0;YH, Huang&#xa0;XM, Asirvatham&#xa0;SJ, Shen&#xa0;WK, Friedman&#xa0;PA, Hodge&#xa0;DO, Slusser&#xa0;JP, Song&#xa0;ZY, Packer&#xa0;DL, Cha&#xa0;YM (2014) Relative efficacy of catheter ablation vs antiarrhythmic drugs in treating premature ventricular contractions: a&#xa0;single-center retrospective study. Heart Rhythm 11(2):187&#x2013;193 (Feb)</Citation><ArticleIdList><ArticleId IdType="pubmed">24157533</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40491037</PMID><DateRevised><Year>2025</Year><Month>06</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1469-445X</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Jun</Month><Day>09</Day></PubDate></JournalIssue><Title>Experimental physiology</Title><ISOAbbreviation>Exp Physiol</ISOAbbreviation></Journal><ArticleTitle>Aortic and cardiovascular remodelling after thoracic endovascular aortic repair for blunt traumatic aortic injury in younger patients: A narrative review of physiological and clinical outcomes.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1113/EP092615</ELocationID><Abstract><AbstractText>Blunt traumatic aortic injury (BTAI) is severe, often fatal in younger populations due to high-energy deceleration mechanisms. Thoracic endovascular aortic repair (TEVAR) has revolutionised BTAI treatment, surpassing the previously standard open surgical repair in mortality and complication rates. Despite its success, concerns arise regarding TEVAR's long-term effects, especially in younger BTAI patients. Key physiological changes following TEVAR include alterations in aortic size, shape, compliance and flow dynamics, leading to loss of the Windkessel effect and a consequent increased pulse wave velocity and decreased radial strain, which can contribute to the development of hypertension. These alterations also predispose patients to changes in cardiovascular flow (increased reverse systolic flow, reduced maximum velocity and altered helical flow), potentially increasing the risk of left ventricular dysfunction and coronary artery disease. Physiological changes also increase the likelihood of complications such as graft migration. Clinical outcomes of TEVAR for BTAI have generally been favourable, with significant reductions in mortality and cerebrovascular accident rates compared to open surgical repair. However, long-term complications, including the need for re-interventions, remain a concern, though studies suggest these are infrequent. The durability of TEVAR in younger patients, who may experience decades of device use, poses unique challenges, particularly due to the natural progression of aortic morphology over time. Therefore, adapting TEVAR to the physiological needs of younger BTAI patients is essential. Developing more compliant endografts and using shorter stents with improved materials can help minimise structural and haemodynamic changes and enhance cardiovascular outcomes, supporting the long-term health of this vulnerable population.</AbstractText><CopyrightInformation>&#xa9; 2025 The Author(s). Experimental Physiology published by John Wiley &amp; Sons Ltd on behalf of The Physiological Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bokobza De la Rosa</LastName><ForeName>Marco David</ForeName><Initials>MD</Initials><AffiliationInfo><Affiliation>Lancaster Medical School, University of Lancaster, Lancaster, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jubouri</LastName><ForeName>Matti</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Hull York Medical School, University of York, York, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moothathamby</LastName><ForeName>Thurkga</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-1440-2719</Identifier><AffiliationInfo><Affiliation>Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Refaie</LastName><ForeName>Mohamed</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Ysbyty Glan Clwyd, Rhyl, Wales.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murtada</LastName><ForeName>Ali</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Ysbyty Glan Clwyd, Rhyl, Wales.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mohammed</LastName><ForeName>Idhrees</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0001-5981-9705</Identifier><AffiliationInfo><Affiliation>Institute of Cardiac and Aortic Disorders (ICAD), SRM Institutes for Medical Science (SIMS Hospital), Chennai, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Ian M</ForeName><Initials>IM</Initials><AffiliationInfo><Affiliation>Department of Vascular Surgery, University Hospital of Wales, Cardiff, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bailey</LastName><ForeName>Damian M</ForeName><Initials>DM</Initials><Identifier Source="ORCID">0000-0003-0498-7095</Identifier><AffiliationInfo><Affiliation>Neurovascular Research Laboratory, Faculty of Life Sciences and Education, University of South Wales, Pontypridd, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bashir</LastName><ForeName>Mohamad</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-8040-5811</Identifier><AffiliationInfo><Affiliation>Neurovascular Research Laboratory, Faculty of Life Sciences and Education, University of South Wales, Pontypridd, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>06</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Exp Physiol</MedlineTA><NlmUniqueID>9002940</NlmUniqueID><ISSNLinking>0958-0670</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">BTAI</Keyword><Keyword MajorTopicYN="N">TEVAR</Keyword><Keyword MajorTopicYN="N">aortic physiology</Keyword><Keyword MajorTopicYN="N">aortic remodelling</Keyword><Keyword MajorTopicYN="N">aortic surgery</Keyword><Keyword MajorTopicYN="N">cardiothoracic</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>1</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>5</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>6</Month><Day>10</Day><Hour>6</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>6</Month><Day>10</Day><Hour>6</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>6</Month><Day>10</Day><Hour>1</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40491037</ArticleId><ArticleId IdType="doi">10.1113/EP092615</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Abdou, H., Elansary, N. N., Darko, L., DuBose, J. J., Scalea, T. M., Morrison, J. J., &amp; Kundi, R. (2021). Postoperative complications of endovascular blunt thoracic aortic injury repair. Trauma Surgery &amp; Acute Care Open, 6(1), e000678.</Citation></Reference><Reference><Citation>Adams, J. D., &amp; Kern, J. A. (2014). Blunt Thoracic Aortic Injury: Current Issues and Endovascular Treatment Paradigms. Endovascular Today. https://evtoday.com/articles/2014&#x2010;sept/blunt&#x2010;thoracic&#x2010;aortic&#x2010;injury</Citation></Reference><Reference><Citation>Aghilinejad, A., Wei, H., Magee, G. A., &amp; Pahlevan, N. M. (2022). Model&#x2010;based fluid&#x2010;structure interaction approach for evaluation of thoracic endovascular aortic repair endograft length in type b aortic dissection. Frontiers in Bioengineering and Biotechnology, 10, 825015.</Citation></Reference><Reference><Citation>Agostinelli, A., Carino, D., Borrello, B., Marcato, C., Volpi, A., Gherli, T., &amp; Nicolini, F. (2019). Blunt traumatic injury to the thoracic aorta treated with thoracic endovascular aortic repair: A single&#x2010;centre 20&#x2010;year experience. Interactive CardioVascular and Thoracic Surgery, 28(1), 17&#x2013;22.</Citation></Reference><Reference><Citation>Agrafiotis, E., Mayer, C., Grabenw&#xf6;ger, M., Zimpfer, D., Regitnig, P., M&#xe4;chler, H., &amp; Holzapfel, G. A. (2023). Global and local stiffening of ex vivo&#x2010;perfused stented human thoracic aortas: A mock circulation study. Acta Biomaterialia, 161, 170&#x2013;183.</Citation></Reference><Reference><Citation>Azizzadeh, A., Ray, H. M., Dubose, J. J., Charlton&#x2010;Ouw, K. M., Miller, C. C., Coogan, S. M., Safi, H. J., &amp; Estrera, A. L. (2014). Outcomes of endovascular repair for patients with blunt traumatic aortic injury. The Journal of Trauma and Acute Care Surgery, 76(2), 510&#x2013;516.</Citation></Reference><Reference><Citation>Bae, M., &amp; Jeon, C. H. (2022). Optimal sizing of aortic stent graft for blunt thoracic aortic injury considering hypotension&#x2010;related decrease in aortic diameter. Journal of Endovascular Therapy, 31(4), 651&#x2013;657.</Citation></Reference><Reference><Citation>Bero, E. H., Nguyen&#x2010;Ho, C. T., Patel, P. J., Foley, W. D., &amp; Lee, C. J. (2020). Aortic remodeling and clinical outcomes following thoracic endovascular aortic repair for blunt thoracic aortic injury. Journal of Surgical Research, 255, 124&#x2013;129.</Citation></Reference><Reference><Citation>Boutin, L., Caballero, M. J., Guarrigue, D., Hammad, E., Rennuit, I., Delhaye, N., Neuschwander, A., Meyer, A., Bitot, V., Mathais, Q., Boutonnet, M., Julia, P., Olaf, M., Duranteau, J., &amp; Hamada, S. R. (2022). Blunt traumatic aortic injury management, a french traumabase analytic cohort. Journal of Vascular Surgery, 75(4), 1493.</Citation></Reference><Reference><Citation>Buczkowski, P., Puslecki, M., Ligowski, M., Dabrowski, M., Stefaniak, S., Fryska, Z., Kulesza, J., Juszkat, R., Jemielity, M., &amp; Perek, B. (2023). Emergency endovascular interventions on descending thoracic aorta: A single&#x2010;center experience. Emergency Medicine International, 2023, 1&#x2013;9.</Citation></Reference><Reference><Citation>Bulpitt, C. J., Rajkumar, C., &amp; Cameron, J. D. (1999). Vascular compliance as a measure of biological age. Journal of the American Geriatrics Society, 47(6), 657&#x2013;663.</Citation></Reference><Reference><Citation>Callaghan, F. M., Bannon, P., Barin, E., Celemajer, D., Jeremy, R., Figtree, G., &amp; Grieve, S. M. (2018). Age&#x2010;related changes of shape and flow dynamics in healthy adult aortas: A 4D flow MRI study. Journal of Magnetic Resonance Imaging, 49(1), 90&#x2013;100.</Citation></Reference><Reference><Citation>Canaud, L., Marty&#x2010;An&#xe9;, C., Ziza, V., Branchereau, P., &amp; Alric, P. (2015). Minimum 10&#x2010;year follow&#x2010;up of endovascular repair for acute traumatic transection of the thoracic aorta. The Journal of Thoracic and Cardiovascular Surgery, 149(3), 825&#x2013;829.</Citation></Reference><Reference><Citation>Cao, T., Jiang, Z., Zhao, H., Zhang, K.&#x2010;Q., &amp; Meng, K. (2022). Numerical simulation to study the impact of compliance mismatch between artificial and host blood vessel on hemodynamics. Medicine in Novel Technology and Devices, 15, 100152.</Citation></Reference><Reference><Citation>Cheng, Y.&#x2010;T., Cheng, C.&#x2010;T., Wang, S.&#x2010;Y., Wu, V. C.&#x2010;C., Chu, P.&#x2010;H., Chou, A.&#x2010;H., Chen, C.&#x2010;C., Ko, P.&#x2010;J., Liu, K.&#x2010;S., &amp; Chen, S.&#x2010;W. (2019). Long&#x2010;term outcomes of endovascular and open repair for traumatic thoracic aortic injury. Journal of the American Medical Association Network Open, 2(2), e187861.</Citation></Reference><Reference><Citation>Conrad, M. F., Erg&#xfc;l, E., Patel, V. I., Paruchuri, V., Kwolek, C. J., &amp; Cambria, R. P. (2010). Management of diseases of the descending thoracic aorta in the endovascular era. Annals of Surgery, 252(4), 603&#x2013;610.</Citation></Reference><Reference><Citation>Cosset, B., Boussel, L., Davila Serrano, E., Millon, A., Douek, P., Farhat, F., &amp; Sigovan, M. (2022). Hemodynamic changes before and after endovascular treatment of type B aortic dissection by 4D flow MRI. Frontiers in Cardiovascular Medicine, 9, 873144.</Citation></Reference><Reference><Citation>de Beaufort, H. W. L., Conti, M., Kamman, A. V., Nauta, F. J. H., Lanzarone, E., Moll, F. L., van Herwaarden, J. A., Auricchio, F., &amp; Trimarchi, S. (2017). Stent&#x2010;graft deployment increases aortic stiffness in an ex vivo porcine model. Annals of Vascular Surgery, 43, 302&#x2013;308.</Citation></Reference><Reference><Citation>Diaz, B., Meneses, E., Kinslow, K., McKenney, M., Elkbuli, A., &amp; Boneva, D. (2021). A rare case of a blunt thoracic aortic injury in a patient with an aberrant right subclavian artery: A case report and literature review. International Journal of Surgery Case Reports, 79, 172&#x2013;177.</Citation></Reference><Reference><Citation>DuBose, J. J., Leake, S. S., Brenner, M., Pasley, J., O'Callaghan, T. A., Luo&#x2010;Owen, X., Trust, M. D., Mooney, J. L., Zhao, F., &amp; Azizzadeh, A. (2015). Contemporary management and outcomes of blunt thoracic aortic injury. The Journal of Trauma and Acute Care Surgery, 78(2), 360&#x2013;369.</Citation></Reference><Reference><Citation>Evans, C. C. D., Li, W., Yacob, M., &amp; Brogly, S. (2022). Longer&#x2010;term rates of survival and reintervention after thoracic endovascular aortic repair (TEVAR) for blunt aortic injury: A retrospective population&#x2010;based cohort study from Ontario, Canada. Trauma Surgery &amp; Acute Care Open, 7(1), e000856.</Citation></Reference><Reference><Citation>Farber, M. A., Krishnasastry, K. V., Desai, N., Starnes, B. W., Matsumura, J. S., &amp; Tohill, B. C. (2022). Five&#x2010;year Outcomes With Conformable GORE TAG Endoprosthesis Used in Traumatic Aortic Transections. The Annals of Thoracic Surgery, 113(5), 1536&#x2013;1542.</Citation></Reference><Reference><Citation>Feczko, J. D., Lynch, L., Pless, J. E., Clark, M. A., McClain, J., &amp; Hawley, D. A. (1992). An autopsy case review of 142 nonpenetrating (Blunt) injuries of the aorta. The Journal of Trauma: Injury, Infection, and Critical Care, 33(6), 846&#x2013;849.</Citation></Reference><Reference><Citation>Fontana, F., Macchi, E., Piacentino, F., Cardim, L. N., Marchi, G. D., Barbosa, F., Piffaretti, G., Novario, R., Rampoldi, A. G., &amp; Fugazzola, C. (2018). The evaluation of aortic diameter changes during long&#x2010;term follow&#x2010;up after endovascular treatment of acute blunt traumatic thoracic aortic injuries. Vascular and Endovascular Surgery, 52(5), 335&#x2013;343.</Citation></Reference><Reference><Citation>Gable, D. R., &amp; Brinkman, W. T., LSA. (2018). LSA Preservation During TEVAR: Insights From the International GREAT Registry&#x2014;Endovascular Today. Endovascular Today. https://evtoday.com/articles/2018&#x2010;mar&#x2010;supplement/lsa&#x2010;preservation&#x2010;during&#x2010;tevar&#x2010;insights&#x2010;from&#x2010;the&#x2010;international&#x2010;great&#x2010;registry</Citation></Reference><Reference><Citation>Gallo, M., van den Berg, J. C., Torre, T., Riggi, M., Demertzis, S., &amp; Ferrari, E. (2023). Long&#x2010;term outcomes and risk factors analysis for patients undergoing thoracic endovascular aorta repair (tevar), according to the aortic pathologies. Annals of Vascular Surgery, 94, 362&#x2013;368.</Citation></Reference><Reference><Citation>Garcia Reyes, M. E., Guala, A., Rodriguez Palomares, J. F., Mu&#xf1;oz, A. R., Dominguez Gonzalez, J. M., Masip, A. E., &amp; Montoya, S. B. (2019). Hemodynamics changes in aortic flux due to tevar quantified by 4D&#x2010;flow&#x2010;MRI. European Journal of Vascular and Endovascular Surgery, 58(6), e520&#x2013;e521.</Citation></Reference><Reference><Citation>Geisb&#xfc;sch, P., Skrypnik, D., Ante, M., Trojan, M., Bruckner, T., Rengier, F., &amp; B&#xf6;ckler, D. (2019). Endograft migration after thoracic endovascular aortic repair. Journal of Vascular Surgery, 69(5), 1387&#x2013;1394.</Citation></Reference><Reference><Citation>Gennai, S., Leone, N., Andreoli, F., Munari, E., Berchiolli, R., Arcuri, L., Tusini, N., Marcheselli, L., &amp; Silingardi, R. (2020). Influence of thoracic endovascular repair on aortic morphology in patients treated for blunt traumatic aortic injuries: Long term outcomes in a multicentre study. European Journal of Vascular and Endovascular Surgery, 59(3), 428&#x2013;436.</Citation></Reference><Reference><Citation>Gennai, S., Leone, N., Mezzetto, L., Veraldi, G. F., Santi, D., Spaggiari, G., Resch, T., &amp; Silingardi, R. (2023). Systematic review and meta&#x2010;analysis of long&#x2010;term reintervention following thoracic endovascular repair for blunt traumatic aortic injury. Journal of Vascular Surgery, 78(2), 540&#x2013;547.e4.</Citation></Reference><Reference><Citation>Ghazy, T., Kirstein, B., Tomala, J., Kalaja, I., Herold, J., Irqsusi, M., Rastan, A., Lackner, H. K., Weiss, N., &amp; Mahlmann, A. (2023). MRI detects increased aortic stiffening and myocardial dysfunction after TEVAR of blunt injury in young patients. Vasa, 52(5), 317&#x2013;324.</Citation></Reference><Reference><Citation>Gil&#x2010;Sala, D., Guala, A., Garcia, M. E., Azancot, M. A., Dux&#x2010;Santoy, L., Allegue Allegue, N., Teixido Tur&#xe0;, G., Goncalves Martins, G., Ruiz Mu&#xf1;oz, A., Constenla Garc&#xed;a, I., Evangelista, A., Tello D&#xed;az, C., Ferreira Gonz&#xe1;lez, I., Rodr&#xed;guez&#x2010;Palomares, J. F., &amp; Bellmunt, S. (2021). Geometric, biomechanic and haemodynamic aortic abnormalities assessed by 4D Flow cardiovascular magnetic resonance in patients treated by TEVAR following blunt traumatic thoracic aortic injury. European Journal of Vascular and Endovascular Surgery, 62(5), 797&#x2013;807.</Citation></Reference><Reference><Citation>Girardin, L., Lind, N., Tengg&#x2010;Kobligk, H. v., Balabani, S., &amp; D&#xed;az&#x2010;Zuccarini, V. (2024). Patient&#x2010;specific compliant simulation framework informed by 4DMRI&#x2010;extracted pulse wave velocity: Application post&#x2010;TEVAR. Journal of Biomechanics, 175, 112266.</Citation></Reference><Reference><Citation>Guala, A., Gil&#x2010;Sala, D., Garcia, M. E., Azancot, M. A., Dux&#x2010;Santoy, L., Allegue, N. A., Teixido&#x2010;Tur&#xe0;, G., Martins, G. G., Galian&#x2010;Gay, L., Garrido&#x2010;Oliver, J., Garc&#xed;a, I. C., Evangelista, A., D&#xed;az, C. T., Carrasco&#x2010;Poves, A., Morales&#x2010;Gal&#xe1;n, A., Ferreira&#x2010;Gonz&#xe1;lez, I., Rodr&#xed;guez&#x2010;Palomares, J., &amp; Montoya, S. B. (2023). Impact of thoracic endovascular aortic repair following blunt traumatic thoracic aortic injury on blood pressure. Journal of Thoracic and Cardiovascular Surgery, 168(5), 1428&#x2013;1437.e3.</Citation></Reference><Reference><Citation>Harky, A., Bleetman, D., Shi, J., Eriksen, P., Chaplin, G., MacCarthy&#x2010;Ofosu, B., Theologou, T., Ambekar, S., Roberts, N., &amp; Oo, A. (2020). A systematic review and meta&#x2010;analysis of endovascular versus open surgical repair for the traumatic ruptured thoracic aorta. Journal of Vascular Surgery, 71(1), 270&#x2013;282.</Citation></Reference><Reference><Citation>Hiraoka, T., Komiya, T., &amp; Shimamoto, T. (2020). Enlargement rate of the ascending aorta after thoracic endovascular aortic repair. Seminars in Thoracic and Cardiovascular Surgery, 32(2), 211&#x2013;217.</Citation></Reference><Reference><Citation>Hirata, K., Kawakami, M., &amp; O'Rourke, M. F. (2006). Pulse wave analysis and pulse wave velocity. Circulation Journal, 70(10), 1231&#x2013;1239.</Citation></Reference><Reference><Citation>Ho, V. T., Itoga, N. K., Tran, K., Lee, J. T., &amp; Stern, J. R. (2021). Mid&#x2010;Term survival after thoracic endovascular aortic repair by indication in the medicare population. Journal of the American College of Surgeons, 232(1), 46&#x2013;53e2.</Citation></Reference><Reference><Citation>Hori, D., Fujimori, T., Kusadokoro, S., Yamamoto, T., Kimura, N., &amp; Yamaguchi, A. (2021). Treatment site does not affect changes in pulse wave velocity but treatment length and device selection are associated with increased pulse wave velocity after thoracic endovascular aortic repair. Frontiers in Physiology, 12, 739185.</Citation></Reference><Reference><Citation>Hori, D., Yuri, K., Kusadokoro, S., Shimizu, T., Kimura, N., &amp; Yamaguchi, A. (2020). Effect of endoprostheses on pulse wave velocity and its long&#x2010;term outcomes after thoracic endovascular aortic repair. General Thoracic and Cardiovascular Surgery, 68(10), 1134&#x2013;1141.</Citation></Reference><Reference><Citation>Hundersmarck, D., van der Vliet, Q. M. J., Winterink, L. M., Leenen, L. P. H., van Herwaarden, J. A., Hazenberg, C. E. V. B., &amp; Hietbrink, F. (2020). Blunt thoracic aortic injury and TEVAR: Long&#x2010;term outcomes and health&#x2010;related quality of life. European Journal of Trauma and Emergency Surgery, 48(3), 1961&#x2013;1973.</Citation></Reference><Reference><Citation>Ibrahim, E.&#x2010;S. H., Johnson, K. R., Miller, A. B., Shaffer, J. M., &amp; White, R. D. (2010). Measuring aortic pulse wave velocity using high&#x2010;field cardiovascular magnetic resonance: Comparison of techniques. Journal of Cardiovascular Magnetic Resonance, 12(1), 26.</Citation></Reference><Reference><Citation>Jubouri, M., Surkhi, A. O., Al&#x2010;Tawil, M., Geragotellis, A., Abdaljawwad, T. Z. I., Qudaih, M., Elrayes, M. I. R., Dewi, M., Moothathamby, T., Hammad, A., Mohammed, I., Awad, W. I., D'Oria, M., Piffaretti, G., Bailey, D. M., Williams, I. M., &amp; Bashir, M. (2024). Long&#x2010;Term survival and reintervention following thoracic endovascular aortic repair in blunt traumatic thoracic aortic injury: A systematic review and meta&#x2010;analysis. Annals of Vascular Surgery, 109, 162&#x2013;176.</Citation></Reference><Reference><Citation>Kadoglou, N. P. E., Moulakakis, K. G., Papadakis, I., Ikonomidis, I., Alepaki, M., Lekakis, J., &amp; Liapis, C. D. (2012). Changes in aortic pulse wave velocity of patients undergoing endovascular repair of abdominal aortic aneurysms. Journal of Endovascular Therapy, 19(5), 661&#x2013;666.</Citation></Reference><Reference><Citation>Kamenskiy, A., Aylward, P., Desyatova, A., DeVries, M., Wichman, C., &amp; MacTaggart, J. (2020). Endovascular repair of blunt thoracic aortic trauma is associated with increased left ventricular mass, hypertension, and off&#x2010;target aortic remodeling. Annals of Surgery, 274(6), 1089&#x2013;1098.</Citation></Reference><Reference><Citation>Kim, H. M., Cho, Y. K., Kim, J. H., Seo, T.&#x2010;S., Song, M. G., Jeon, Y. S., Cho, S. B., &amp; Im, N. Y. (2019). Clinical outcomes of the seal&#xae; thoracic stent graft for traumatic aortic injury in a korean multicenter retrospective study. Annals of Vascular Surgery, 61, 400&#x2013;409.</Citation></Reference><Reference><Citation>Komutrattananont, P., Mahakkanukrauh, P., &amp; Das, S. (2019). Morphology of the human aorta and age&#x2010;related changes: Anatomical facts. Anatomy &amp; Cell Biology, 52(2), 109&#x2013;114.</Citation></Reference><Reference><Citation>Kr&#xfc;ger, T., Boburg, R. S., Lescan, M., Oikonomou, A., Schneider, W., V&#xf6;hringer, L., Lausberg, H., Bamberg, F., Blumenstock, G., &amp; Schlensak, C. (2018). Aortic elongation in aortic aneurysm and dissection: The T&#xfc;bingen Aortic Pathoanatomy (TAIPAN) project&#x2020;. European Journal of Cardio&#x2010;Thoracic Surgery, 54(1), 26&#x2013;33.</Citation></Reference><Reference><Citation>Lee, W. A., Matsumura, J. S., Mitchell, R. S., Farber, M. A., Greenberg, R. K., Azizzadeh, A., Murad, M. H., &amp; Fairman, R. M. (2011). Endovascular repair of traumatic thoracic aortic injury: Clinical practice guidelines of the Society for Vascular Surgery. Journal of Vascular Surgery, 53(1), 187&#x2013;192.</Citation></Reference><Reference><Citation>Makaroun, M. S., Dillavou, E. D., &amp; Kee, S. T. (2005). Endovascular treatment of thoracic aortic aneurysms: Results of the phase II multicenter trial of the GORE TAG thoracic endoprosthesis. ACC Current Journal Review, 14(6), 39&#x2013;40.</Citation></Reference><Reference><Citation>Martin, C., Thony, F., Rodiere, M., Bouzat, P., Lavagne, P., Durand, M., &amp; Chavanon, O. (2017). Long&#x2010;term results following emergency stent graft repair for traumatic rupture of the aortic isthmus&#x2020;. European Journal of Cardio&#x2010;Thoracic Surgery, 51(4), 767&#x2013;772.</Citation></Reference><Reference><Citation>Mestres, G., Garcia, M. E., Yugueros, X., Urrea, R., Tripodi, P., Gomez, F., Maeso, J., &amp; Riambau, V. (2016). Aortic arch and thoracic aorta curvature remodeling after thoracic endovascular aortic repair. Annals of Vascular Surgery, 38, 233&#x2013;241.</Citation></Reference><Reference><Citation>Morbiducci, U., Ponzini, R., Rizzo, G., Cadioli, M., Esposito, A., Cobelli, F. D., Maschio, A. D., Montevecchi, F. M., &amp; Redaelli, A. (2009). In Vivo quantification of helical blood flow in human aorta by time&#x2010;resolved three&#x2010;dimensional cine phase contrast magnetic resonance imaging. Annals of Biomedical Engineering, 37(3), 516&#x2013;531.</Citation></Reference><Reference><Citation>Mouawad, N. J., Paulisin, J., Hofmeister, S., &amp; Thomas, M. B. (2020). Blunt thoracic aortic injury&#x2014;concepts and management. Journal of Cardiothoracic Surgery, 15(1), 62.</Citation></Reference><Reference><Citation>Mufty, H., Maleux, G., Houthoofd, S., Cornelissen, S. A., Daenens, K., Bonne, L., &amp; Fourneau, I. (2019). The effect of TEVAR for blunt traumatic thoracic aortic injury on maximal aortic diameter: Mid&#x2010; and long&#x2010;term outcome. Vascular, 27(4), 411&#x2013;416.</Citation></Reference><Reference><Citation>Nation, D., &amp; Wang, G. (2015). TEVAR: Endovascular repair of the thoracic aorta. Seminars in Interventional Radiology, 32(03), 265&#x2013;271.</Citation></Reference><Reference><Citation>Nauta, F. J. H., de Beaufort, H. W. L., Conti, M., Marconi, S., Kamman, A. V., Ferrara, A., Herwaarden, v., Moll, F. L., Auricchio, F., &amp; Trimarchi, S. (2016). Impact of thoracic endovascular aortic repair on radial strain in anex vivoporcine model. European Journal of Cardio&#x2010;Thoracic Surgery, 50(4), ezw393&#x2013;ezw393.</Citation></Reference><Reference><Citation>Piffaretti, G., Benedetto, F., Menegolo, M., Antonello, M., Tarallo, A., Grego, F., Spinelli, F., &amp; Castelli, P. (2013). Outcomes of endovascular repair for blunt thoracic aortic injury. Journal of Vascular Surgery, 58(6), 1483&#x2013;1489.</Citation></Reference><Reference><Citation>Prendes, C. F., Stana, J., Schneidwind, K. D., Rantner, B., Konstantinou, N., Bruder, J., Kammerlander, C., Banafsche, R., &amp; Tsilimparis, N. (2021). Blunt traumatic thoracic aortic injuries: A retrospective cohort analysis of 2 decades of experience. Interactive CardioVascular and Thoracic Surgery, 33(2), 293&#x2013;300.</Citation></Reference><Reference><Citation>Scalea, T. M., Feliciano, D. V., DuBose, J. J., Ottochian, M., O'Connor, J. V., &amp; Morrison, J. J. (2019). Blunt Thoracic aortic injury: Endovascular repair is now the standard. Journal of the American College of Surgeons, 228(4), 605&#x2013;610.</Citation></Reference><Reference><Citation>Skrypnik, D., &#x41a;&#x430;&#x43b;&#x43c;&#x44b;&#x43a;&#x43e;&#x432;, &#x415;. &#x41b;., Bischoff, M. S., Meisenbacher, K., Klotz, R., Hagedorn, M., Kalkum, E., Probst, P., Dammrau, R., &amp; B&#xf6;ckler, D. (2024). Late Endograft migration after thoracic endovascular aortic repair: A systematic review and meta&#x2010;analysis. Journal of Endovascular Therapy: An Official Journal of the International Society of Endovascular Specialists, 31(1), 7&#x2013;18.</Citation></Reference><Reference><Citation>Spiliotopoulos, K., Kokotsakis, J., Argiriou, M., Dedeilias, P., Farsaris, D., Diamantis, T., &amp; Charitos, C. (2014). Endovascular repair for blunt thoracic aortic injury: 11&#x2010;year outcomes and postoperative surveillance experience. The Journal of Thoracic and Cardiovascular Surgery, 148(6), 2956&#x2013;2961.</Citation></Reference><Reference><Citation>Spinella, G., Finotello, A., Conti, M., Faggiano, E., Gazzola, V., Auricchio, F., Chakf&#xe9;, N., Palombo, D., &amp; Pane, B. (2018). Assessment of geometrical remodelling of the aortic arch after hybrid treatment. European Journal of Cardio&#x2010;Thoracic Surgery, 55(6), 1045&#x2013;1053.</Citation></Reference><Reference><Citation>Starnes, B. W., Dwivedi, A., Giglia, J., Woo, K., &amp; Yeh, C. (2020). Updated outcomes from the TRANSFIX study to evaluate endovascular repair of blunt thoracic aortic injuries with the Zenith Alpha thoracic device. Journal of Vascular Surgery, 71(6), 1851&#x2013;1857.</Citation></Reference><Reference><Citation>Steuer, J., Bj&#xf6;rck, M., Sonesson, B., Resch, T., Dias, N., Hultgren, R., Tunesi, R., Wanhainen, A., Lachat, M., &amp; Pfammatter, T. (2015). Editor's choice&#x2014;durability of endovascular repair in blunt traumatic thoracic aortic injury: Long&#x2010;term outcome from four tertiary referral centers. European Journal of Vascular and Endovascular Surgery, 50(4), 460&#x2013;465.</Citation></Reference><Reference><Citation>Stonko, D. P., Edwards, J., Abdou, H., Treffalls, R. N., Walker, P., DeMartino, R. R., Mendes, B. C., Hicks, C. W., &amp; Morrison, J. J. (2023). Thoracic endovascular aortic repairacutely augments left ventricular biomechanics in an animal model: A mechanism for postoperative heart failure and hypertension. Annals of Vascular Surgery, 97, 18&#x2013;26.</Citation></Reference><Reference><Citation>Sugawara, J., Hayashi, K., Yokoi, T., &amp; Tanaka, H. (2008). Age&#x2010;associated elongation of the ascending aorta in adults. Journal of the American College of Cardiology: Cardiovascular Imaging, 1(6), 739&#x2013;748.</Citation></Reference><Reference><Citation>Sultan, S., Acharya, Y., Hazima, M., Salahat, H., Parodi, J. C., &amp; Hynes, N. (2021). Combined thoracic endovascular aortic repair and endovascular aneurysm repair and the long&#x2010;term consequences of altered cardiovascular haemodynamics on morbidity and mortality: Case series and literature review. European Heart Journal&#x2014;Case Reports, 5(10), ytab339.</Citation></Reference><Reference><Citation>Sultan, S., Acharya, Y., Soliman, O., Parodi, J. C., &amp; Hynes, N. (2022). TEVAR and EVAR, the unknown knowns of the cardiovascular hemodynamics; and the immediate and long&#x2010;term consequences of fabric material on major adverse clinical outcome. Frontiers in Surgery, 9, 940304.</Citation></Reference><Reference><Citation>Takeda, Y., Sakata, Y., Ohtani, T., Tamaki, S., Omori, Y., Tsukamoto, Y., Aizawa, Y., Shimamura, K., Shirakawa, Y., Kuratani, T., Sawa, Y., Yamamoto, K., Mano, T., &amp; Komuro, I. (2014). Endovascular aortic repair increases vascular stiffness and alters cardiac structure and function. Circulation Journal: Official Journal of the Japanese Circulation Society, 78(2), 322&#x2013;328.</Citation></Reference><Reference><Citation>Tigkiropoulos, K., Sigala, F., Tsilimigras, D. I., Moris, D., Filis, K., Melas, N., Karamanos, D., Kontogiannis, C., Lazaridis, I., &amp; Saratzis, N. (2018). Endovascular repair of blunt thoracic aortic trauma: Is postimplant hypertension an incidental finding? Annals of Vascular Surgery, 50, 160&#x2013;166.e1.</Citation></Reference><Reference><Citation>Tzilalis, V. D., Kamvysis, D., Panagou, P., Kaskarelis, I., Lazarides, M. K., Perdikides, T., Prassopoulos, P., &amp; Boudoulas, H. (2012). Increased pulse wave velocity and arterial hypertension in young patients with thoracic aortic endografts. Annals of Vascular Surgery, 26(4), 462&#x2013;467.</Citation></Reference><Reference><Citation>Ullery, B. W., Suh, G.&#x2010;Y., Hirotsu, K., Zhu, D., Lee, J. T., Dake, M. D., Fleischmann, D., &amp; Cheng, C. P. (2018). Geometric deformations of the thoracic aorta and supra&#x2010;aortic arch branch vessels following thoracic endovascular aortic repair. Vascular and Endovascular Surgery, 52(3), 173&#x2013;180.</Citation></Reference><Reference><Citation>Ultee, K. H., Soden, P. A., Chien, V., Bensley, R. P., Zettervall, S. L., Verhagen, H. J. M., &amp; Schermerhorn, M. L. (2016). National trends in utilization and outcome of thoracic endovascular aortic repair for traumatic thoracic aortic injuries. Journal of Vascular Surgery, 63(5), 1232&#x2013;1239.e1.</Citation></Reference><Reference><Citation>Vallerio, P., Maloberti, A., D'Alessio, I., Lista, A., Varrenti, M., Castelnuovo, S., Marone, M., Piccinelli, E., Grass&#x131;, G., Palmieri, B., &amp; Giannattasio, C. (2019). Cardiovascular remodeling after endovascular treatment for thoracic aortic injury. Annals of Vascular Surgery, 61, 134&#x2013;141.</Citation></Reference><Reference><Citation>van Popele, N. M., Grobbee, D. E., Bots, M. L., Asmar, R., Topouchian, J., Reneman, R. S., Hoeks, A. P. G., van der Kuip, D. A. M., Hofman, A., &amp; Witteman, J. C. M. (2001). Association between arterial stiffness and atherosclerosis. Stroke; A Journal of Cerebral Circulation, 32(2), 454&#x2013;460.</Citation></Reference><Reference><Citation>Weiss, E. K., Jarvis, K., Maroun, A., Malaisrie, S. C., Mehta, C. K., McCarthy, P. M., Bonow, R. O., Avery, R. J., Allen, B. D., Carr, J. C., Rigsby, C. K., &amp; Markl, M. (2023). Systolic reverse flow derived from 4D flow cardiovascular magnetic resonance in bicuspid aortic valve is associated with aortic dilation and aortic valve stenosis: A cross sectional study in 655 subjects. Journal of Cardiovascular Magnetic Resonance, 25(1), 3.</Citation></Reference><Reference><Citation>Wu, J., Zafar, M. A., Li, Y., Saeyeldin, A., Huang, Y., Zhao, R., Qiu, J., Tanweer, M., Abdelbaky, M., Gryaznov, A., Buntin, J., Ziganshin, B. A., Mukherjee, S. K., Rizzo, J. A., Yu, C., &amp; Elefteriades, J. A. (2019). Ascending aortic length and risk of aortic adverse events. Journal of the American College of Cardiology, 74(15), 1883&#x2013;1894.</Citation></Reference><Reference><Citation>Xu, X., Wang, B., Ren, C., Hu, J., Greenberg, D. A., Chen, T., Xie, L., &amp; Jin, K. (2017). Age&#x2010;related impairment of vascular structure and functions. Aging and Disease, 8(5), 590.</Citation></Reference><Reference><Citation>Youssef, A., Kalaja, I., Alkomi, U., Abt, T., Hoffmann, R.&#x2010;T., Reeps, C., Weiss, N., Lackner, H. K., &amp; Mahlmann, A. (2020). Aortic stiffness and related complications after endovascular repair of blunt thoracic aortic injury in young patients. Vasa, 49(4), 295&#x2013;300.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40475711</PMID><DateRevised><Year>2025</Year><Month>06</Month><Day>07</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2153-8174</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>5</Issue><PubDate><Year>2025</Year><Month>May</Month></PubDate></JournalIssue><Title>Reviews in cardiovascular medicine</Title><ISOAbbreviation>Rev Cardiovasc Med</ISOAbbreviation></Journal><ArticleTitle>"Restless Nights, Stressed Hearts": The Link Between Sleep Disorders and Takotsubo Syndrome-A Comprehensive Review.</ArticleTitle><Pagination><StartPage>28244</StartPage><MedlinePgn>28244</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">28244</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.31083/RCM28244</ELocationID><Abstract><AbstractText>Takotsubo syndrome (TTS), also known as stress-induced cardiomyopathy or "broken heart syndrome", is characterized by transient left ventricular dysfunction, often triggered by emotional or physical stress. Emerging evidence suggests that sleep-disordered breathing (SDB) and sleep disruption may play a significant role in the pathophysiology and exacerbation of TTS. This review explores the influence of conditions such as obstructive sleep apnea (OSA), insomnia, and other sleep disturbances on the onset and progression of TTS. SDB, particularly OSA, is marked by repetitive episodes of upper airway obstruction during sleep, leading to intermittent hypoxia and increased sympathetic nervous system activity. These physiological changes can trigger or exacerbate TTS by promoting myocardial stress and impairing autonomic regulation. Insomnia and other forms of sleep disruption also contribute to heightened sympathetic activity and elevated stress hormone levels, which may precipitate TTS in susceptible individuals. Thus, this review synthesizes current research on the mechanisms linking sleep disturbances to TTS, highlighting the impact of nocturnal hypoxia, sleep fragmentation, and autonomic dysregulation. Moreover, this review discusses the clinical implications of these findings, emphasizing the need to screen and manage sleep disorders in patients with or at risk of TTS. Addressing sleep disturbances through therapeutic interventions may reduce the incidence and recurrence of TTS, offering a novel approach to managing this condition. In conclusion, this review underscores the importance of recognizing and treating SDB and sleep disruption as potential contributors to Takotsubo syndrome. Future research should focus on elucidating the precise mechanisms involved and determining effective strategies for integrating sleep management into the care of patients with TTS.</AbstractText><CopyrightInformation>Copyright: &#xa9; 2025 The Author(s). Published by IMR Press.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Alevroudis</LastName><ForeName>Ioannis</ForeName><Initials>I</Initials><Identifier Source="ORCID">0009-0001-4889-677X</Identifier><AffiliationInfo><Affiliation>Adult ICU, General Hospital of Thessaloniki "Ippokrateio", 54642 Thessaloniki, Greece.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Third Department of Cardiology, General Hospital of Thessaloniki "Ippokrateio", Aristotle University of Thessaloniki, 54642 Thessaloniki, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petridou</LastName><ForeName>Magda</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Third Department of Cardiology, General Hospital of Thessaloniki "Ippokrateio", Aristotle University of Thessaloniki, 54642 Thessaloniki, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sakkou</LastName><ForeName>Agni</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Adult ICU, General Hospital of Thessaloniki "Ippokrateio", 54642 Thessaloniki, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kotoulas</LastName><ForeName>Serafeim-Chrysovalantis</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Adult ICU, General Hospital of Thessaloniki "Ippokrateio", 54642 Thessaloniki, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matzolas</LastName><ForeName>Sotirios</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Adult ICU, General Hospital of Thessaloniki "Ippokrateio", 54642 Thessaloniki, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roumelis</LastName><ForeName>Panagiotis</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Adult ICU, General Hospital of Thessaloniki "Ippokrateio", 54642 Thessaloniki, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stougianni</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Adult ICU, General Hospital of Thessaloniki "Ippokrateio", 54642 Thessaloniki, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Massa</LastName><ForeName>Eleni</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Adult ICU, General Hospital of Thessaloniki "Ippokrateio", 54642 Thessaloniki, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mouloudi</LastName><ForeName>Eleni</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Adult ICU, General Hospital of Thessaloniki "Ippokrateio", 54642 Thessaloniki, Greece.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>05</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>Singapore</Country><MedlineTA>Rev Cardiovasc Med</MedlineTA><NlmUniqueID>100960007</NlmUniqueID><ISSNLinking>1530-6550</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Takotsubo syndrome</Keyword><Keyword MajorTopicYN="N">elevated catecholamine levels</Keyword><Keyword MajorTopicYN="N">heart rate variability</Keyword><Keyword MajorTopicYN="N">hypothalamic-pituitary-adrenal (HPA) axis</Keyword><Keyword MajorTopicYN="N">insomnia</Keyword><Keyword MajorTopicYN="N">obstructive sleep apnea</Keyword><Keyword MajorTopicYN="N">restless leg syndrome</Keyword><Keyword MajorTopicYN="N">sleep deprivation</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>11</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>1</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>2</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>6</Month><Day>6</Day><Hour>6</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>6</Month><Day>6</Day><Hour>6</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>6</Month><Day>6</Day><Hour>5</Hour><Minute>16</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>5</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40475711</ArticleId><ArticleId IdType="pmc">PMC12135652</ArticleId><ArticleId IdType="doi">10.31083/RCM28244</ArticleId><ArticleId IdType="pii">S1530-6550(25)01794-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sato H. Takotsubo-type cardiomyopathy due to multivessel spasm. Clinical Aspect of Myocardial Injury: from Ischemia to Heart Failure . 1990;56</Citation></Reference><Reference><Citation>Deshmukh A, Kumar G, Pant S, Rihal C, Murugiah K, Mehta JL. Prevalence of Takotsubo cardiomyopathy in the United States. American Heart Journal . 2012;164:66&#x2013;71.e1. doi: 10.1016/j.ahj.2012.03.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ahj.2012.03.020</ArticleId><ArticleId IdType="pubmed">22795284</ArticleId></ArticleIdList></Reference><Reference><Citation>Gianni M, Dentali F, Grandi AM, Sumner G, Hiralal R, Lonn E. Apical ballooning syndrome or takotsubo cardiomyopathy: a systematic review. European Heart Journal . 2006;27:1523&#x2013;1529. doi: 10.1093/eurheartj/ehl032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehl032</ArticleId><ArticleId IdType="pubmed">16720686</ArticleId></ArticleIdList></Reference><Reference><Citation>Templin C, Ghadri JR, Diekmann J, Napp LC, Bataiosu DR, Jaguszewski M, et al. Clinical Features and Outcomes of Takotsubo (Stress) Cardiomyopathy. The New England Journal of Medicine . 2015;373:929&#x2013;938. doi: 10.1056/NEJMoa1406761.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1406761</ArticleId><ArticleId IdType="pubmed">26332547</ArticleId></ArticleIdList></Reference><Reference><Citation>Brinjikji W, El-Sayed AM, Salka S. In-hospital mortality among patients with takotsubo cardiomyopathy: a study of the National Inpatient Sample 2008 to 2009. American Heart Journal . 2012;164:215&#x2013;221. doi: 10.1016/j.ahj.2012.04.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ahj.2012.04.010</ArticleId><ArticleId IdType="pubmed">22877807</ArticleId></ArticleIdList></Reference><Reference><Citation>Wittstein IS. The Sympathetic Nervous System in the Pathogenesis of Takotsubo Syndrome. Heart Failure Clinics . 2016;12:485&#x2013;498. doi: 10.1016/j.hfc.2016.06.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.hfc.2016.06.012</ArticleId><ArticleId IdType="pubmed">27638019</ArticleId></ArticleIdList></Reference><Reference><Citation>Pelliccia F, Parodi G, Greco C, Antoniucci D, Brenner R, Bossone E, et al. Comorbidities frequency in Takotsubo syndrome: an international collaborative systematic review including 1109 patients. The American Journal of Medicine . 2015;128:654.e11&#x2013;654.e19. doi: 10.1016/j.amjmed.2015.01.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjmed.2015.01.016</ArticleId><ArticleId IdType="pubmed">25660245</ArticleId></ArticleIdList></Reference><Reference><Citation>Y-Hassan S. Acute cardiac sympathetic disruption in the pathogenesis of the takotsubo syndrome: a systematic review of the literature to date. Cardiovascular Revascularization Medicine . 2014;15:35&#x2013;42. doi: 10.1016/j.carrev.2013.09.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.carrev.2013.09.008</ArticleId><ArticleId IdType="pubmed">24140050</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghadri JR, Sarcon A, Diekmann J, Bataiosu DR, Cammann VL, Jurisic S, et al. Happy heart syndrome: role of positive emotional stress in takotsubo syndrome. European Heart Journal . 2016;37:2823&#x2013;2829. doi: 10.1093/eurheartj/ehv757.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehv757</ArticleId><ArticleId IdType="pmc">PMC5841222</ArticleId><ArticleId IdType="pubmed">26935270</ArticleId></ArticleIdList></Reference><Reference><Citation>Kume T, Kawamoto T, Okura H, Toyota E, Neishi Y, Watanabe N, et al. Local release of catecholamines from the hearts of patients with tako-tsubo-like left ventricular dysfunction. Circulation Journal . 2008;72:106&#x2013;108. doi: 10.1253/circj.72.106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1253/circj.72.106</ArticleId><ArticleId IdType="pubmed">18159109</ArticleId></ArticleIdList></Reference><Reference><Citation>Abraham J, Mudd JO, Kapur NK, Klein K, Champion HC, Wittstein IS. Stress cardiomyopathy after intravenous administration of catecholamines and beta-receptor agonists. Journal of the American College of Cardiology . 2009;53:1320&#x2013;1325. doi: 10.1016/j.jacc.2009.02.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2009.02.020</ArticleId><ArticleId IdType="pubmed">19358948</ArticleId></ArticleIdList></Reference><Reference><Citation>Haft JI. Cardiovascular injury induced by sympathetic catecholamines. Progress in Cardiovascular Diseases . 1974;17:73&#x2013;86. doi: 10.1016/0033-0620(74)90039-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0033-0620(74)90039-5</ArticleId><ArticleId IdType="pubmed">4599470</ArticleId></ArticleIdList></Reference><Reference><Citation>Y-Hassan S. Insights into the pathogenesis of takotsubo syndrome, which with persuasive reasons should be regarded as an acute cardiac sympathetic disease entity. ISRN Cardiology . 2012;2012:593735. doi: 10.5402/2012/593735.</Citation><ArticleIdList><ArticleId IdType="doi">10.5402/2012/593735</ArticleId><ArticleId IdType="pmc">PMC3478743</ArticleId><ArticleId IdType="pubmed">23119184</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghadri JR, Wittstein IS, Prasad A, Sharkey S, Dote K, Akashi YJ, et al. International Expert Consensus Document on Takotsubo Syndrome (Part I): Clinical Characteristics, Diagnostic Criteria, and Pathophysiology. European Heart Journal . 2018;39:2032&#x2013;2046. doi: 10.1093/eurheartj/ehy076.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehy076</ArticleId><ArticleId IdType="pmc">PMC5991216</ArticleId><ArticleId IdType="pubmed">29850871</ArticleId></ArticleIdList></Reference><Reference><Citation>Spieker LE, H&#xfc;rlimann D, Ruschitzka F, Corti R, Enseleit F, Shaw S, et al. Mental stress induces prolonged endothelial dysfunction via endothelin-A receptors. Circulation . 2002;105:2817&#x2013;2820. doi: 10.1161/01.cir.0000021598.15895.34.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.cir.0000021598.15895.34</ArticleId><ArticleId IdType="pubmed">12070106</ArticleId></ArticleIdList></Reference><Reference><Citation>Stiermaier T, Desch S, Blazek S, Schuler G, Thiele H, Eitel I. Frequency and significance of myocardial bridging and recurrent segment of the left anterior descending coronary artery in patients with takotsubo cardiomyopathy. The American Journal of Cardiology . 2014;114:1204&#x2013;1209. doi: 10.1016/j.amjcard.2014.07.040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjcard.2014.07.040</ArticleId><ArticleId IdType="pubmed">25175156</ArticleId></ArticleIdList></Reference><Reference><Citation>Arcari L, Limite LR, Cacciotti L, Alonzo A, Musumeci MB, Passaseo I, et al. Tortuosity, Recurrent Segments, and Bridging of the Epicardial Coronary Arteries in Patients With the Takotsubo Syndrome. The American Journal of Cardiology . 2017;119:243&#x2013;248. doi: 10.1016/j.amjcard.2016.09.055.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjcard.2016.09.055</ArticleId><ArticleId IdType="pubmed">27866652</ArticleId></ArticleIdList></Reference><Reference><Citation>von K&#xe4;nel R, Dimsdale JE. Effects of sympathetic activation by adrenergic infusions on hemostasis in vivo. European Journal of Haematology . 2000;65:357&#x2013;369. doi: 10.1034/j.1600-0609.2000.065006357.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1034/j.1600-0609.2000.065006357.x</ArticleId><ArticleId IdType="pubmed">11168493</ArticleId></ArticleIdList></Reference><Reference><Citation>Al Houri HN, Jomaa S, Jabra M, Alhouri AN, Latifeh Y. Pathophysiology of stress cardiomyopathy: A comprehensive literature review. Annals of medicine and surgery . 2022;82:104671. doi: 10.1016/j.amsu.2022.104671.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amsu.2022.104671</ArticleId><ArticleId IdType="pmc">PMC9577654</ArticleId><ArticleId IdType="pubmed">36268377</ArticleId></ArticleIdList></Reference><Reference><Citation>And&#xf2; G, Trio O, de Gregorio C. Transient left ventricular dysfunction in patients with neurovascular events. Acute Cardiac Care . 2010;12:70&#x2013;74. doi: 10.3109/17482941003732758.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482941003732758</ArticleId><ArticleId IdType="pubmed">20384473</ArticleId></ArticleIdList></Reference><Reference><Citation>Vitale C, Rosano GMC, Kaski JC. Role of Coronary Microvascular Dysfunction in Takotsubo Cardiomyopathy. Circulation Journal . 2016;80:299&#x2013;305. doi: 10.1253/circj.CJ-15-1364.</Citation><ArticleIdList><ArticleId IdType="doi">10.1253/circj.CJ-15-1364</ArticleId><ArticleId IdType="pubmed">26763468</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen RA, Shepherd JT, Vanhoutte PM. Prejunctional and postjunctional actions of endogenous norepinephrine at the sympathetic neuroeffector junction in canine coronary arteries. Circulation Research . 1983;52:16&#x2013;25. doi: 10.1161/01.res.52.1.16.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.res.52.1.16</ArticleId><ArticleId IdType="pubmed">6129074</ArticleId></ArticleIdList></Reference><Reference><Citation>Meimoun P, Clerc J, Vincent C, Flahaut F, Germain AL, Elmkies F, et al. Non-invasive detection of tako-tsubo cardiomyopathy vs. acute anterior myocardial infarction by transthoracic Doppler echocardiography. European Heart Journal. Cardiovascular Imaging . 2013;14:464&#x2013;470. doi: 10.1093/ehjci/jes192.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ehjci/jes192</ArticleId><ArticleId IdType="pubmed">23002215</ArticleId></ArticleIdList></Reference><Reference><Citation>Fries E, Hesse J, Hellhammer J, Hellhammer DH. A new view on hypocortisolism. Psychoneuroendocrinology . 2005;30:1010&#x2013;1016. doi: 10.1016/j.psyneuen.2005.04.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.psyneuen.2005.04.006</ArticleId><ArticleId IdType="pubmed">15950390</ArticleId></ArticleIdList></Reference><Reference><Citation>Golczynska A, Lenders JW, Goldstein DS. Glucocorticoid-induced sympathoinhibition in humans. Clinical Pharmacology and Therapeutics . 1995;58:90&#x2013;98. doi: 10.1016/0009-9236(95)90076-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0009-9236(95)90076-4</ArticleId><ArticleId IdType="pubmed">7628186</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghadri JR, Cammann VL, Jurisic S, Seifert B, Napp LC, Diekmann J, et al. A novel clinical score (InterTAK Diagnostic Score) to differentiate takotsubo syndrome from acute coronary syndrome: results from the International Takotsubo Registry. European Journal of Heart Failure . 2017;19:1036&#x2013;1042. doi: 10.1002/ejhf.683.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ejhf.683</ArticleId><ArticleId IdType="pubmed">27928880</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin EA, Prasad A, Rihal CS, Lerman LO, Lerman A. Endothelial function and vascular response to mental stress are impaired in patients with apical ballooning syndrome. Journal of the American College of Cardiology . 2010;56:1840&#x2013;1846. doi: 10.1016/j.jacc.2010.03.107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2010.03.107</ArticleId><ArticleId IdType="pmc">PMC3786427</ArticleId><ArticleId IdType="pubmed">21087714</ArticleId></ArticleIdList></Reference><Reference><Citation>Kastaun S, Gerriets T, Tschernatsch M, Yeniguen M, Juenemann M. Psychosocial and psychoneuroendocrinal aspects of Takotsubo syndrome. Nature Reviews. Cardiology . 2016;13:688&#x2013;694. doi: 10.1038/nrcardio.2016.108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrcardio.2016.108</ArticleId><ArticleId IdType="pubmed">27411402</ArticleId></ArticleIdList></Reference><Reference><Citation>Couch LS, Fiedler J, Chick G, Clayton R, Dries E, Wienecke LM, et al. Circulating microRNAs predispose to takotsubo syndrome following high-dose adrenaline exposure. Cardiovascular Research . 2022;118:1758&#x2013;1770. doi: 10.1093/cvr/cvab210.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cvr/cvab210</ArticleId><ArticleId IdType="pmc">PMC9214785</ArticleId><ArticleId IdType="pubmed">34155498</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaguszewski M, Osipova J, Ghadri JR, Napp LC, Widera C, Franke J, et al. A signature of circulating microRNAs differentiates takotsubo cardiomyopathy from acute myocardial infarction. European Heart Journal . 2014;35:999&#x2013;1006. doi: 10.1093/eurheartj/eht392.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/eht392</ArticleId><ArticleId IdType="pmc">PMC3985061</ArticleId><ArticleId IdType="pubmed">24046434</ArticleId></ArticleIdList></Reference><Reference><Citation>Paur H, Wright PT, Sikkel MB, Tranter MH, Mansfield C, O&#x2019;Gara P, et al. High levels of circulating epinephrine trigger apical cardiodepression in a &#x3b2;2-adrenergic receptor/Gi-dependent manner: a new model of Takotsubo cardiomyopathy. Circulation . 2012;126:697&#x2013;706. doi: 10.1161/CIRCULATIONAHA.112.111591.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.112.111591</ArticleId><ArticleId IdType="pmc">PMC4890655</ArticleId><ArticleId IdType="pubmed">22732314</ArticleId></ArticleIdList></Reference><Reference><Citation>Ueyama T, Kasamatsu K, Hano T, Tsuruo Y, Ishikura F. Catecholamines and estrogen are involved in the pathogenesis of emotional stress-induced acute heart attack. Annals of the New York Academy of Sciences . 2008;1148:479&#x2013;485. doi: 10.1196/annals.1410.079.</Citation><ArticleIdList><ArticleId IdType="doi">10.1196/annals.1410.079</ArticleId><ArticleId IdType="pubmed">19120144</ArticleId></ArticleIdList></Reference><Reference><Citation>Komesaroff PA, Esler MD, Sudhir K. Estrogen supplementation attenuates glucocorticoid and catecholamine responses to mental stress in perimenopausal women. The Journal of Clinical Endocrinology and Metabolism . 1999;84:606&#x2013;610. doi: 10.1210/jcem.84.2.5447.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/jcem.84.2.5447</ArticleId><ArticleId IdType="pubmed">10022424</ArticleId></ArticleIdList></Reference><Reference><Citation>Sung BH, Ching M, Izzo JL, Jr, Dandona P, Wilson MF. Estrogen improves abnormal norepinephrine-induced vasoconstriction in postmenopausal women. Journal of Hypertension . 1999;17:523&#x2013;528. doi: 10.1097/00004872-199917040-00010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00004872-199917040-00010</ArticleId><ArticleId IdType="pubmed">10404954</ArticleId></ArticleIdList></Reference><Reference><Citation>Scally C, Abbas H, Ahearn T, Srinivasan J, Mezincescu A, Rudd A, et al. Myocardial and Systemic Inflammation in Acute Stress-Induced (Takotsubo) Cardiomyopathy. Circulation . 2019;139:1581&#x2013;1592. doi: 10.1161/CIRCULATIONAHA.118.037975.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.118.037975</ArticleId><ArticleId IdType="pmc">PMC6438459</ArticleId><ArticleId IdType="pubmed">30586731</ArticleId></ArticleIdList></Reference><Reference><Citation>American Psychiatric Association . Diagnostic and statistical manual of mental disorders . American Psychiatric Publishing; Arlington, VA: 2013. 5th edn.</Citation><ArticleIdList><ArticleId IdType="doi">10.1176/appi.books.9780890425596</ArticleId></ArticleIdList></Reference><Reference><Citation>Pallesen S, Sivertsen B, Nordhus IH, Bjorvatn B. A 10-year trend of insomnia prevalence in the adult Norwegian population. Sleep Medicine . 2014;15:173&#x2013;179. doi: 10.1016/j.sleep.2013.10.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.sleep.2013.10.009</ArticleId><ArticleId IdType="pubmed">24382513</ArticleId></ArticleIdList></Reference><Reference><Citation>Vgontzas AN, Chrousos GP. Sleep, the hypothalamic-pituitary-adrenal axis, and cytokines: multiple interactions and disturbances in sleep disorders. Endocrinology and Metabolism Clinics of North America . 2002;31:15&#x2013;36. doi: 10.1016/s0889-8529(01)00005-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0889-8529(01)00005-6</ArticleId><ArticleId IdType="pubmed">12055986</ArticleId></ArticleIdList></Reference><Reference><Citation>Morin CM, Jarrin DC. Epidemiology of Insomnia: Prevalence, Course, Risk Factors, and Public Health Burden. Sleep Medicine Clinics . 2022;17:173&#x2013;191. doi: 10.1016/j.jsmc.2022.03.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsmc.2022.03.003</ArticleId><ArticleId IdType="pubmed">35659072</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez-Mendoza J, Vgontzas AN. Insomnia and its impact on physical and mental health. Current Psychiatry Reports . 2013;15:418. doi: 10.1007/s11920-013-0418-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11920-013-0418-8</ArticleId><ArticleId IdType="pmc">PMC3972485</ArticleId><ArticleId IdType="pubmed">24189774</ArticleId></ArticleIdList></Reference><Reference><Citation>Levenson JC, Kay DB, Buysse DJ. The pathophysiology of insomnia. Chest . 2015;147:1179&#x2013;1192. doi: 10.1378/chest.14-1617.</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.14-1617</ArticleId><ArticleId IdType="pmc">PMC4388122</ArticleId><ArticleId IdType="pubmed">25846534</ArticleId></ArticleIdList></Reference><Reference><Citation>Grimaldi D, Goldstein MR, Carter JR. Insomnia and cardiovascular autonomic control. Autonomic Neuroscience: Basic &amp; Clinical . 2019;220:102551. doi: 10.1016/j.autneu.2019.05.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autneu.2019.05.003</ArticleId><ArticleId IdType="pubmed">31331688</ArticleId></ArticleIdList></Reference><Reference><Citation>Laugsand LE, Strand LB, Platou C, Vatten LJ, Janszky I. Insomnia and the risk of incident heart failure: a population study. European Heart Journal . 2014;35:1382&#x2013;1393. doi: 10.1093/eurheartj/eht019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/eht019</ArticleId><ArticleId IdType="pubmed">23462728</ArticleId></ArticleIdList></Reference><Reference><Citation>Wittstein IS, Thiemann DR, Lima JAC, Baughman KL, Schulman SP, Gerstenblith G, et al. Neurohumoral features of myocardial stunning due to sudden emotional stress. The New England Journal of Medicine . 2005;352:539&#x2013;548. doi: 10.1056/NEJMoa043046.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa043046</ArticleId><ArticleId IdType="pubmed">15703419</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarrin DC, Ivers H, Lamy M, Chen IY, Harvey AG, Morin CM. Cardiovascular autonomic dysfunction in insomnia patients with objective short sleep duration. Journal of Sleep Research . 2018;27:e12663. doi: 10.1111/jsr.12663.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jsr.12663</ArticleId><ArticleId IdType="pmc">PMC5992004</ArticleId><ArticleId IdType="pubmed">29493063</ArticleId></ArticleIdList></Reference><Reference><Citation>Hertenstein E, Feige B, Gmeiner T, Kienzler C, Spiegelhalder K, Johann A, et al. Insomnia as a predictor of mental disorders: A systematic review and meta-analysis. Sleep Medicine Reviews . 2019;43:96&#x2013;105. doi: 10.1016/j.smrv.2018.10.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.smrv.2018.10.006</ArticleId><ArticleId IdType="pubmed">30537570</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalmbach DA, Anderson JR, Drake CL. The impact of stress on sleep: Pathogenic sleep reactivity as a vulnerability to insomnia and circadian disorders. Journal of Sleep Research . 2018;27:e12710. doi: 10.1111/jsr.12710.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jsr.12710</ArticleId><ArticleId IdType="pmc">PMC7045300</ArticleId><ArticleId IdType="pubmed">29797753</ArticleId></ArticleIdList></Reference><Reference><Citation>Meerlo P, Sgoifo A, Suchecki D. Restricted and disrupted sleep: effects on autonomic function, neuroendocrine stress systems and stress responsivity. Sleep Medicine Reviews . 2008;12:197&#x2013;210. doi: 10.1016/j.smrv.2007.07.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.smrv.2007.07.007</ArticleId><ArticleId IdType="pubmed">18222099</ArticleId></ArticleIdList></Reference><Reference><Citation>Baglioni C, Battagliese G, Feige B, Spiegelhalder K, Nissen C, Voderholzer U, et al. Insomnia as a predictor of depression: a meta-analytic evaluation of longitudinal epidemiological studies. Journal of Affective Disorders . 2011;135:10&#x2013;19. doi: 10.1016/j.jad.2011.01.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jad.2011.01.011</ArticleId><ArticleId IdType="pubmed">21300408</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng A, Ji S, Lai W, Hu D, Wang M, Zhao X, et al. The bidirectional relationship between sleep disturbance and anxiety: Sleep disturbance is a stronger predictor of anxiety. Sleep Medicine . 2024;121:63&#x2013;68. doi: 10.1016/j.sleep.2024.06.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.sleep.2024.06.022</ArticleId><ArticleId IdType="pubmed">38924831</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao X, Zhang F, Wei C, Li Z, Huang C, Sun Z, et al. The impact of insomnia on anxiety and depression: a longitudinal study of non-clinical young Chinese adult males. BMC Psychiatry . 2023;23:360. doi: 10.1186/s12888-023-04873-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12888-023-04873-y</ArticleId><ArticleId IdType="pmc">PMC10210401</ArticleId><ArticleId IdType="pubmed">37226120</ArticleId></ArticleIdList></Reference><Reference><Citation>Bard HA, O&#x2019;Driscoll C, Miller CB, Henry AL, Cape J, Espie CA. Insomnia, depression, and anxiety symptoms interact and individually impact functioning: A network and relative importance analysis in the context of insomnia. Sleep Medicine . 2023;101:505&#x2013;514. doi: 10.1016/j.sleep.2022.12.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.sleep.2022.12.005</ArticleId><ArticleId IdType="pubmed">36527942</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonnet MH, Arand DL. Hyperarousal and insomnia: state of the science. Sleep Medicine Reviews . 2010;14:9&#x2013;15. doi: 10.1016/j.smrv.2009.05.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.smrv.2009.05.002</ArticleId><ArticleId IdType="pubmed">19640748</ArticleId></ArticleIdList></Reference><Reference><Citation>Javaheri S, Redline S. Insomnia and Risk of Cardiovascular Disease. Chest . 2017;152:435&#x2013;444. doi: 10.1016/j.chest.2017.01.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chest.2017.01.026</ArticleId><ArticleId IdType="pmc">PMC5577359</ArticleId><ArticleId IdType="pubmed">28153671</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahmood A, Ray M, Dobalian A, Ward KD, Ahn S. Insomnia symptoms and incident heart failure: a population-based cohort study. European Heart Journal . 2021;42:4169&#x2013;4176. doi: 10.1093/eurheartj/ehab500.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehab500</ArticleId><ArticleId IdType="pmc">PMC8728724</ArticleId><ArticleId IdType="pubmed">34392357</ArticleId></ArticleIdList></Reference><Reference><Citation>Young T, Peppard PE, Gottlieb DJ. Epidemiology of obstructive sleep apnea: a population health perspective. American Journal of Respiratory and Critical Care Medicine . 2002;165:1217&#x2013;1239. doi: 10.1164/rccm.2109080.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.2109080</ArticleId><ArticleId IdType="pubmed">11991871</ArticleId></ArticleIdList></Reference><Reference><Citation>Kapur VK, Auckley DH, Chowdhuri S, Kuhlmann DC, Mehra R, Ramar K, et al. Clinical Practice Guideline for Diagnostic Testing for Adult Obstructive Sleep Apnea: An American Academy of Sleep Medicine Clinical Practice Guideline. Journal of Clinical Sleep Medicine . 2017;13:479&#x2013;504. doi: 10.5664/jcsm.6506.</Citation><ArticleIdList><ArticleId IdType="doi">10.5664/jcsm.6506</ArticleId><ArticleId IdType="pmc">PMC5337595</ArticleId><ArticleId IdType="pubmed">28162150</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuvat N, Tanriverdi H, Armutcu F. The relationship between obstructive sleep apnea syndrome and obesity: A new perspective on the pathogenesis in terms of organ crosstalk. The Clinical Respiratory Journal . 2020;14:595&#x2013;604. doi: 10.1111/crj.13175.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/crj.13175</ArticleId><ArticleId IdType="pubmed">32112481</ArticleId></ArticleIdList></Reference><Reference><Citation>Somers VK, White DP, Amin R, Abraham WT, Costa F, Culebras A, et al. Sleep apnea and cardiovascular disease: an American Heart Association/american College Of Cardiology Foundation Scientific Statement from the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Council On Cardiovascular Nursing. In collaboration with the National Heart, Lung, and Blood Institute National Center on Sleep Disorders Research (National Institutes of Health) Circulation . 2008;118:1080&#x2013;1111. doi: 10.1161/CIRCULATIONAHA.107.189375.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.107.189375</ArticleId><ArticleId IdType="pubmed">18725495</ArticleId></ArticleIdList></Reference><Reference><Citation>Dewan NA, Nieto FJ, Somers VK. Intermittent hypoxemia and OSA: implications for comorbidities. Chest . 2015;147:266&#x2013;274. doi: 10.1378/chest.14-0500.</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.14-0500</ArticleId><ArticleId IdType="pmc">PMC4285080</ArticleId><ArticleId IdType="pubmed">25560865</ArticleId></ArticleIdList></Reference><Reference><Citation>Peppard PE, Young T, Barnet JH, Palta M, Hagen EW, Hla KM. Increased prevalence of sleep-disordered breathing in adults. American Journal of Epidemiology . 2013;177:1006&#x2013;1014. doi: 10.1093/aje/kws342.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/aje/kws342</ArticleId><ArticleId IdType="pmc">PMC3639722</ArticleId><ArticleId IdType="pubmed">23589584</ArticleId></ArticleIdList></Reference><Reference><Citation>Somers VK, White DP, Amin R, Abraham WT, Costa F, Culebras A, et al. Sleep apnea and cardiovascular disease: an American Heart Association/American College of Cardiology Foundation Scientific Statement from the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Council on Cardiovascular Nursing. Journal of the American College of Cardiology . 2008;52:686&#x2013;717. doi: 10.1016/j.jacc.2008.05.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2008.05.002</ArticleId><ArticleId IdType="pubmed">18702977</ArticleId></ArticleIdList></Reference><Reference><Citation>Neri M, Riezzo I, Pascale N, Pomara C, Turillazzi E. Ischemia/Reperfusion Injury following Acute Myocardial Infarction: A Critical Issue for Clinicians and Forensic Pathologists. Mediators of Inflammation . 2017;2017:7018393. doi: 10.1155/2017/7018393.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2017/7018393</ArticleId><ArticleId IdType="pmc">PMC5327760</ArticleId><ArticleId IdType="pubmed">28286377</ArticleId></ArticleIdList></Reference><Reference><Citation>Datla SR, Griendling KK. Reactive oxygen species, NADPH oxidases, and hypertension. Hypertension . 2010;56:325&#x2013;330. doi: 10.1161/HYPERTENSIONAHA.109.142422.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/HYPERTENSIONAHA.109.142422</ArticleId><ArticleId IdType="pmc">PMC2947547</ArticleId><ArticleId IdType="pubmed">20644010</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuleta I, Fran&#xe7;a CN, Wenzel D, Fleischmann B, Nickenig G, Werner N, et al. Hypoxia-induced endothelial dysfunction in apolipoprotein E-deficient mice; effects of infliximab and L-glutathione. Atherosclerosis . 2014;236:400&#x2013;410. doi: 10.1016/j.atherosclerosis.2014.08.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.atherosclerosis.2014.08.021</ArticleId><ArticleId IdType="pubmed">25150938</ArticleId></ArticleIdList></Reference><Reference><Citation>Naegele M, Flammer AJ, Enseleit F, Roas S, Frank M, Hirt A, et al. Endothelial function and sympathetic nervous system activity in patients with Takotsubo syndrome. International Journal of Cardiology . 2016;224:226&#x2013;230. doi: 10.1016/j.ijcard.2016.09.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijcard.2016.09.008</ArticleId><ArticleId IdType="pubmed">27661411</ArticleId></ArticleIdList></Reference><Reference><Citation>Camici PG, Crea F. Microvascular angina: a women&#x2019;s affair? Circulation. Cardiovascular Imaging . 2015;8:e003252. doi: 10.1161/CIRCIMAGING.115.003252.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCIMAGING.115.003252</ArticleId><ArticleId IdType="pubmed">25801711</ArticleId></ArticleIdList></Reference><Reference><Citation>Pelliccia F, Parodi G, Greco C, Antoniucci D, Brenner R, Bossone E, et al. Comorbidities frequency in Takotsubo syndrome: an international collaborative systematic review including 1109 patients. The American Journal of Medicine . 2015;128:654.e11&#x2013;654.e19. doi: 10.1016/j.amjmed.2015.01.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjmed.2015.01.016</ArticleId><ArticleId IdType="pubmed">25660245</ArticleId></ArticleIdList></Reference><Reference><Citation>Pelliccia F, Kaski JC, Crea F, Camici PG. Pathophysiology of Takotsubo Syndrome. Circulation . 2017;135:2426&#x2013;2441. doi: 10.1161/CIRCULATIONAHA.116.027121.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.116.027121</ArticleId><ArticleId IdType="pubmed">28606950</ArticleId></ArticleIdList></Reference><Reference><Citation>Sateia MJ. International classification of sleep disorders-third edition: highlights and modifications. Chest . 2014;146:1387&#x2013;1394. doi: 10.1378/chest.14-0970.</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.14-0970</ArticleId><ArticleId IdType="pubmed">25367475</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Alawi A, Mulgrew A, Tench E, Ryan CF. Prevalence, risk factors and impact on daytime sleepiness and hypertension of periodic leg movements with arousals in patients with obstructive sleep apnea. Journal of Clinical Sleep Medicine . 2006;2:281&#x2013;287.</Citation><ArticleIdList><ArticleId IdType="pubmed">17561540</ArticleId></ArticleIdList></Reference><Reference><Citation>Winkelman JW, Finn L, Young T. Prevalence and correlates of restless legs syndrome symptoms in the Wisconsin Sleep Cohort. Sleep Medicine . 2006;7:545&#x2013;552. doi: 10.1016/j.sleep.2006.01.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.sleep.2006.01.004</ArticleId><ArticleId IdType="pubmed">16740407</ArticleId></ArticleIdList></Reference><Reference><Citation>Winkelman JW, Shahar E, Sharief I, Gottlieb DJ. Association of restless legs syndrome and cardiovascular disease in the Sleep Heart Health Study. Neurology . 2008;70:35&#x2013;42. doi: 10.1212/01.wnl.0000287072.93277.c9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000287072.93277.c9</ArticleId><ArticleId IdType="pubmed">18166705</ArticleId></ArticleIdList></Reference><Reference><Citation>Winter AC, Sch&#xfc;rks M, Glynn RJ, Buring JE, Gaziano JM, Berger K, et al. Vascular risk factors, cardiovascular disease, and restless legs syndrome in women. The American Journal of Medicine . 2013;126:220&#x2013;227. doi: 10.1016/j.amjmed.2012.06.040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjmed.2012.06.040</ArticleId><ArticleId IdType="pmc">PMC3574635</ArticleId><ArticleId IdType="pubmed">23410562</ArticleId></ArticleIdList></Reference><Reference><Citation>Zinchuk A, Srivali N, Qin L, Jeon S, Ibrahim A, Sands SA, et al. Association of Periodic Limb Movements and Obstructive Sleep Apnea With Risk of Cardiovascular Disease and Mortality. Journal of the American Heart Association . 2024;13:e031630. doi: 10.1161/JAHA.123.031630.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/JAHA.123.031630</ArticleId><ArticleId IdType="pmc">PMC11056155</ArticleId><ArticleId IdType="pubmed">38240208</ArticleId></ArticleIdList></Reference><Reference><Citation>Gottlieb DJ, Somers VK, Punjabi NM, Winkelman JW. Restless legs syndrome and cardiovascular disease: a research roadmap. Sleep Medicine . 2017;31:10&#x2013;17. doi: 10.1016/j.sleep.2016.08.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.sleep.2016.08.008</ArticleId><ArticleId IdType="pmc">PMC5334194</ArticleId><ArticleId IdType="pubmed">28065687</ArticleId></ArticleIdList></Reference><Reference><Citation>Srivali N, Thongprayoon C, Tangpanithandee S, Krisanapan P, Mao MA, Zinchuk A, et al. Periodic limb movements during sleep and risk of hypertension: A systematic review. Sleep Medicine . 2023;102:173&#x2013;179. doi: 10.1016/j.sleep.2023.01.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.sleep.2023.01.008</ArticleId><ArticleId IdType="pmc">PMC10388290</ArticleId><ArticleId IdType="pubmed">36701831</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Li Y, Winkelman JW, Walters AS, Han J, Hu FB, et al. Prospective study of restless legs syndrome and total and cardiovascular mortality among women. Neurology . 2018;90:e135&#x2013;e141. doi: 10.1212/WNL.0000000000004814.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000004814</ArticleId><ArticleId IdType="pmc">PMC5772151</ArticleId><ArticleId IdType="pubmed">29247069</ArticleId></ArticleIdList></Reference><Reference><Citation>Antelmi E, Rocchi L, Latorre A, Belvisi D, Magrinelli F, Bhatia KP, et al. Restless Legs Syndrome: Known Knowns and Known Unknowns. Brain Sciences . 2022;12:118. doi: 10.3390/brainsci12010118.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/brainsci12010118</ArticleId><ArticleId IdType="pmc">PMC8773543</ArticleId><ArticleId IdType="pubmed">35053861</ArticleId></ArticleIdList></Reference><Reference><Citation>Paulus W, Trenkwalder C. Less is more: pathophysiology of dopaminergic-therapy-related augmentation in restless legs syndrome. The Lancet. Neurology . 2006;5:878&#x2013;886. doi: 10.1016/S1474-4422(06)70576-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(06)70576-2</ArticleId><ArticleId IdType="pubmed">16987735</ArticleId></ArticleIdList></Reference><Reference><Citation>Galbiati A, Marelli S, Giora E, Zucconi M, Oldani A, Ferini-Strambi L. Neurocognitive function in patients with idiopathic Restless Legs Syndrome before and after treatment with dopamine-agonist. International Journal of Psychophysiology . 2015;95:304&#x2013;309. doi: 10.1016/j.ijpsycho.2014.12.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijpsycho.2014.12.005</ArticleId><ArticleId IdType="pubmed">25514234</ArticleId></ArticleIdList></Reference><Reference><Citation>Walters AS, Winkelmann J, Trenkwalder C, Fry JM, Kataria V, Wagner M, et al. Long-term follow-up on restless legs syndrome patients treated with opioids. Movement Disorders . 2001;16:1105&#x2013;1109. doi: 10.1002/mds.1214.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.1214</ArticleId><ArticleId IdType="pubmed">11748742</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Borreguero D, Williams AM. An update on restless legs syndrome (Willis-Ekbom disease): clinical features, pathogenesis and treatment. Current Opinion in Neurology . 2014;27:493&#x2013;501. doi: 10.1097/WCO.0000000000000117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WCO.0000000000000117</ArticleId><ArticleId IdType="pubmed">24978636</ArticleId></ArticleIdList></Reference><Reference><Citation>Earley CJ, Connor J, Garcia-Borreguero D, Jenner P, Winkelman J, Zee PC, et al. Altered brain iron homeostasis and dopaminergic function in Restless Legs Syndrome (Willis-Ekbom Disease) Sleep Medicine . 2014;15:1288&#x2013;1301. doi: 10.1016/j.sleep.2014.05.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.sleep.2014.05.009</ArticleId><ArticleId IdType="pubmed">25201131</ArticleId></ArticleIdList></Reference><Reference><Citation>Connor JR, Boyer PJ, Menzies SL, Dellinger B, Allen RP, Ondo WG, et al. Neuropathological examination suggests impaired brain iron acquisition in restless legs syndrome. Neurology . 2003;61:304&#x2013;309. doi: 10.1212/01.wnl.0000078887.16593.12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000078887.16593.12</ArticleId><ArticleId IdType="pubmed">12913188</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen RP, Auerbach S, Bahrain H, Auerbach M, Earley CJ. The prevalence and impact of restless legs syndrome on patients with iron deficiency anemia. American Journal of Hematology . 2013;88:261&#x2013;264. doi: 10.1002/ajh.23397.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajh.23397</ArticleId><ArticleId IdType="pubmed">23494945</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen RP, Walters AS, Montplaisir J, Hening W, Myers A, Bell TJ, et al. Restless legs syndrome prevalence and impact: REST general population study. Archives of Internal Medicine . 2005;165:1286&#x2013;1292. doi: 10.1001/archinte.165.11.1286.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archinte.165.11.1286</ArticleId><ArticleId IdType="pubmed">15956009</ArticleId></ArticleIdList></Reference><Reference><Citation>Winkelmann J, Schormair B, Lichtner P, Ripke S, Xiong L, Jalilzadeh S, et al. Genome-wide association study of restless legs syndrome identifies common variants in three genomic regions. Nature Genetics . 2007;39:1000&#x2013;1006. doi: 10.1038/ng2099.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng2099</ArticleId><ArticleId IdType="pubmed">17637780</ArticleId></ArticleIdList></Reference><Reference><Citation>Bucher SF, Seelos KC, Oertel WH, Reiser M, Trenkwalder C. Cerebral generators involved in the pathogenesis of the restless legs syndrome. Annals of Neurology . 1997;41:639&#x2013;645. doi: 10.1002/ana.410410513.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410410513</ArticleId><ArticleId IdType="pubmed">9153526</ArticleId></ArticleIdList></Reference><Reference><Citation>Schilling C, Schredl M, Strobl P, Deuschle M. Restless legs syndrome: evidence for nocturnal hypothalamic-pituitary-adrenal system activation. Movement Disorders . 2010;25:1047&#x2013;1052. doi: 10.1002/mds.23026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.23026</ArticleId><ArticleId IdType="pubmed">20535825</ArticleId></ArticleIdList></Reference><Reference><Citation>Dafkin C, McKinon W, Kerr S. Restless legs syndrome: Clinical changes in nervous system excitability at the spinal cord level. Sleep Medicine Reviews . 2019;47:9&#x2013;17. doi: 10.1016/j.smrv.2019.05.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.smrv.2019.05.005</ArticleId><ArticleId IdType="pubmed">31212170</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanza G, Ferri R. The neurophysiology of hyperarousal in restless legs syndrome: Hints for a role of glutamate/GABA. Advances in Pharmacology (San Diego, Calif.) . 2019;84:101&#x2013;119. doi: 10.1016/bs.apha.2018.12.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/bs.apha.2018.12.002</ArticleId><ArticleId IdType="pubmed">31229167</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferr&#xe9; S, Quiroz C, Rea W, Guitart X, Garc&#xed;a-Borreguero D. Adenosine mechanisms and hypersensitive corticostriatal terminals in restless legs syndrome. Rationale for the use of inhibitors of adenosine transport. Advances in Pharmacology (San Diego, Calif.) . 2019;84:3&#x2013;19. doi: 10.1016/bs.apha.2018.12.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/bs.apha.2018.12.005</ArticleId><ArticleId IdType="pmc">PMC9372712</ArticleId><ArticleId IdType="pubmed">31229176</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen RP, Barker PB, Horsk&#xe1; A, Earley CJ. Thalamic glutamate/glutamine in restless legs syndrome: increased and related to disturbed sleep. Neurology . 2013;80:2028&#x2013;2034. doi: 10.1212/WNL.0b013e318294b3f6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e318294b3f6</ArticleId><ArticleId IdType="pmc">PMC3716406</ArticleId><ArticleId IdType="pubmed">23624560</ArticleId></ArticleIdList></Reference><Reference><Citation>Erden EC, Erden &#x130;, T&#xfc;rker Y, Sivri N, Dikici S, Oz&#x15f;ahin M. Incremental effects of restless legs syndrome on nocturnal blood pressure in hypertensive patients and normotensive individuals. Blood Pressure Monitoring . 2012;17:231&#x2013;234. doi: 10.1097/MBP.0b013e32835b5a39.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MBP.0b013e32835b5a39</ArticleId><ArticleId IdType="pubmed">23111555</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Li Y, Winkelman JW, Walters AS, Han J, Hu FB, et al. Prospective study of restless legs syndrome and total and cardiovascular mortality among women. Neurology . 2018;90:e135&#x2013;e141. doi: 10.1212/WNL.0000000000004814.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000004814</ArticleId><ArticleId IdType="pmc">PMC5772151</ArticleId><ArticleId IdType="pubmed">29247069</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao X, Ba DM, Bagai K, Liu G, Ma C, Walters AS. Treating Restless Legs Syndrome Was Associated With Low Risk of Cardiovascular Disease: A Cohort Study With 3.4 Years of Follow-Up. Journal of the American Heart Association . 2021;10:e018674. doi: 10.1161/JAHA.120.018674.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/JAHA.120.018674</ArticleId><ArticleId IdType="pmc">PMC7955352</ArticleId><ArticleId IdType="pubmed">33550813</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirshkowitz M, Whiton K, Albert SM, Alessi C, Bruni O, DonCarlos L, et al. National Sleep Foundation&#x2019;s sleep time duration recommendations: methodology and results summary. Sleep Health . 2015;1:40&#x2013;43. doi: 10.1016/j.sleh.2014.12.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.sleh.2014.12.010</ArticleId><ArticleId IdType="pubmed">29073412</ArticleId></ArticleIdList></Reference><Reference><Citation>National Sleep Foundation  Sleep in America: bedroom poll. 2012.  [(Accessed: 16 November 2024)].  Available at:
 https://www.sleepfoundation.org/wp-content/uploads/2018/10/NSF_Bedroom_Poll_Report_1.pdf
.</Citation></Reference><Reference><Citation>Khan MS, Aouad R. The Effects of Insomnia and Sleep Loss on Cardiovascular Disease. Sleep Medicine Clinics . 2017;12:167&#x2013;177. doi: 10.1016/j.jsmc.2017.01.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsmc.2017.01.005</ArticleId><ArticleId IdType="pubmed">28477772</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolk R, Gami AS, Garcia-Touchard A, Somers VK. Sleep and cardiovascular disease. Current Problems in Cardiology . 2005;30:625&#x2013;662. doi: 10.1016/j.cpcardiol.2005.07.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cpcardiol.2005.07.002</ArticleId><ArticleId IdType="pubmed">16301095</ArticleId></ArticleIdList></Reference><Reference><Citation>Irwin M. Effects of sleep and sleep loss on immunity and cytokines. Brain, Behavior, and Immunity . 2002;16:503&#x2013;512. doi: 10.1016/s0889-1591(02)00003-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0889-1591(02)00003-x</ArticleId><ArticleId IdType="pubmed">12401464</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai H, Shu XO, Xiang YB, Yang G, Li H, Ji BT, et al. Sleep duration and mortality: a prospective study of 113 138 middle-aged and elderly Chinese men and women. Sleep . 2015;38:529&#x2013;536. doi: 10.5665/sleep.4564.</Citation><ArticleIdList><ArticleId IdType="doi">10.5665/sleep.4564</ArticleId><ArticleId IdType="pmc">PMC4355892</ArticleId><ArticleId IdType="pubmed">25348122</ArticleId></ArticleIdList></Reference><Reference><Citation>Heslop P, Smith GD, Metcalfe C, Macleod J, Hart C. Sleep duration and mortality: The effect of short or long sleep duration on cardiovascular and all-cause mortality in working men and women. Sleep Medicine . 2002;3:305&#x2013;314. doi: 10.1016/s1389-9457(02)00016-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1389-9457(02)00016-3</ArticleId><ArticleId IdType="pubmed">14592192</ArticleId></ArticleIdList></Reference><Reference><Citation>Sobue Y, Watanabe E, Ichikawa T, Koshikawa M, Yamamoto M, Harada M, et al. Physically triggered Takotsubo cardiomyopathy has a higher in-hospital mortality rate. International Journal of Cardiology . 2017;235:87&#x2013;93. doi: 10.1016/j.ijcard.2017.02.090.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijcard.2017.02.090</ArticleId><ArticleId IdType="pubmed">28262347</ArticleId></ArticleIdList></Reference><Reference><Citation>Covassin N, Bukartyk J, Singh P, Calvin AD, St Louis EK, Somers VK. Effects of Experimental Sleep Restriction on Ambulatory and Sleep Blood Pressure in Healthy Young Adults: A Randomized Crossover Study. Hypertension . 2021;78:859&#x2013;870. doi: 10.1161/HYPERTENSIONAHA.121.17622.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/HYPERTENSIONAHA.121.17622</ArticleId><ArticleId IdType="pmc">PMC8363516</ArticleId><ArticleId IdType="pubmed">34247512</ArticleId></ArticleIdList></Reference><Reference><Citation>Faraut B, Nakib S, Drogou C, Elbaz M, Sauvet F, De Bandt JP, et al. Napping reverses the salivary interleukin-6 and urinary norepinephrine changes induced by sleep restriction. The Journal of Clinical Endocrinology and Metabolism . 2015;100:E416&#x2013;E426. doi: 10.1210/jc.2014-2566.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/jc.2014-2566</ArticleId><ArticleId IdType="pubmed">25668196</ArticleId></ArticleIdList></Reference><Reference><Citation>Grimaldi D, Carter JR, Van Cauter E, Leproult R. Adverse Impact of Sleep Restriction and Circadian Misalignment on Autonomic Function in Healthy Young Adults. Hypertension . 2016;68:243&#x2013;250. doi: 10.1161/HYPERTENSIONAHA.115.06847.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/HYPERTENSIONAHA.115.06847</ArticleId><ArticleId IdType="pmc">PMC4902172</ArticleId><ArticleId IdType="pubmed">27271308</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenlund IM, Carter JR. Sympathetic neural responses to sleep disorders and insufficiencies. American Journal of Physiology. Heart and Circulatory Physiology . 2022;322:H337&#x2013;H349. doi: 10.1152/ajpheart.00590.2021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpheart.00590.2021</ArticleId><ArticleId IdType="pmc">PMC8836729</ArticleId><ArticleId IdType="pubmed">34995163</ArticleId></ArticleIdList></Reference><Reference><Citation>Loube DI, Gay PC, Strohl KP, Pack AI, White DP, Collop NA. Indications for positive airway pressure treatment of adult obstructive sleep apnea patients: a consensus statement. Chest . 1999;115:863&#x2013;866. doi: 10.1378/chest.115.3.863.</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.115.3.863</ArticleId><ArticleId IdType="pubmed">10084504</ArticleId></ArticleIdList></Reference><Reference><Citation>Randerath WJ, Verbraecken J, Andreas S, Bettega G, Boudewyns A, Hamans E, et al. Non-CPAP therapies in obstructive sleep apnoea. The European Respiratory Journal . 2011;37:1000&#x2013;1028. doi: 10.1183/09031936.00099710.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/09031936.00099710</ArticleId><ArticleId IdType="pubmed">21406515</ArticleId></ArticleIdList></Reference><Reference><Citation>Lofaso F, Coste A, d&#x2019;Ortho MP, Zerah-Lancner F, Delclaux C, Goldenberg F, et al. Nasal obstruction as a risk factor for sleep apnoea syndrome. The European Respiratory Journal . 2000;16:639&#x2013;643. doi: 10.1034/j.1399-3003.2000.16d12.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1034/j.1399-3003.2000.16d12.x</ArticleId><ArticleId IdType="pubmed">11106205</ArticleId></ArticleIdList></Reference><Reference><Citation>McEvoy RD, Antic NA, Heeley E, Luo Y, Ou Q, Zhang X, et al. CPAP for Prevention of Cardiovascular Events in Obstructive Sleep Apnea. The New England Journal of Medicine . 2016;375:919&#x2013;931. doi: 10.1056/NEJMoa1606599.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1606599</ArticleId><ArticleId IdType="pubmed">27571048</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Borreguero D, Kohnen R, Silber MH, Winkelman JW, Earley CJ, H&#xf6;gl B, et al. The long-term treatment of restless legs syndrome/Willis-Ekbom disease: evidence-based guidelines and clinical consensus best practice guidance: a report from the International Restless Legs Syndrome Study Group. Sleep Medicine . 2013;14:675&#x2013;684. doi: 10.1016/j.sleep.2013.05.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.sleep.2013.05.016</ArticleId><ArticleId IdType="pubmed">23859128</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40491114</PMID><DateCompleted><Year>2025</Year><Month>06</Month><Day>10</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1681-7168</ISSN><JournalIssue CitedMedium="Internet"><Volume>35</Volume><Issue>6</Issue><PubDate><Year>2025</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Journal of the College of Physicians and Surgeons--Pakistan : JCPSP</Title><ISOAbbreviation>J Coll Physicians Surg Pak</ISOAbbreviation></Journal><ArticleTitle>Clinical Outcomes and Long-Term Effects of Consolidative Radiotherapy in Paediatric Hodgkin's Lymphoma.</ArticleTitle><Pagination><StartPage>778</StartPage><EndPage>783</EndPage><MedlinePgn>778-783</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.29271/jcpsp.2025.06.778</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To evaluate the long-term effects and disease outcomes of consolidative radiotherapy in paediatric Hodgkin's lymphoma (PHL).</AbstractText><AbstractText Label="STUDY DESIGN" NlmCategory="METHODS">Descriptive study. Place and Duration of the Study: Department of Paediatric Oncology, Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, Pakistan, from March to November, 2023.</AbstractText><AbstractText Label="METHODOLOGY" NlmCategory="METHODS">This retrospective cohort study was conducted on 91 PHL patients. All patients with the presence of residual disease on interim PET scan received radiation therapy. A standard dose of 19.8 Gy was given as 11 fractions, and boost was given to bulky disease as 10 Gy in 5 fractions. Data regarding patient demographics, disease characteristics, and treatment details were collected from the institutional database.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Out of the 91 patients, 73 (80.2%) were male and 18 (19.8%) were female. The overall mean age at presentation was 7.7 &#xb1; 3.3 years. High-risk disease was found in 81 (89%), while 44 (48.4%) had stage IV disease. Complete remission was achieved in 70 (76.9%), loss to follow-up in 11 (12.1%), disease progression/relapse in 4 (4.4%), and death during treatment in 6 (6.6%) patients. The five-year overall survival was 90%, and event-free survival was 76.9%. During treatment, a total of nine patients had moderate-to- severe left ventricular dysfunction, six patients had altered thyroid profiles (hypothyroidism), three developed pulmonary fibrosis, and one patient developed cerebellar ataxia.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">There is a good five-year overall and event-free survival. Cardio toxicity, hypothyroidism, and pulmonary fibrosis were common long-term chemotherapy / radiotherapy-related side effects. Prospective randomised controlled trial is needed to reduce dose of radiotherapy by giving it to PET-positive residual disease at the end of treatment rather than at mid-assessment.</AbstractText><AbstractText Label="KEY WORDS" NlmCategory="BACKGROUND">Paediatric Hodgkin's lymphoma, Radiotherapy, Clinical outcomes.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zaidi</LastName><ForeName>Syed Muhammad Jawad</ForeName><Initials>SMJ</Initials><AffiliationInfo><Affiliation>Department of Paediatric Oncology, Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wali</LastName><ForeName>Rabia Muhammad</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Department of Paediatric Oncology, Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Inayat</LastName><ForeName>Naila</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Paediatric Oncology, Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anjum</LastName><ForeName>Sadia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Paediatric Oncology, Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, Pakistan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Pakistan</Country><MedlineTA>J Coll Physicians Surg Pak</MedlineTA><NlmUniqueID>9606447</NlmUniqueID><ISSNLinking>1022-386X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006689" MajorTopicYN="Y">Hodgkin Disease</DescriptorName><QualifierName UI="Q000532" MajorTopicYN="N">radiotherapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010154" MajorTopicYN="N" Type="Geographic">Pakistan</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>12</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>11</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>6</Month><Day>10</Day><Hour>6</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>6</Month><Day>10</Day><Hour>6</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>6</Month><Day>10</Day><Hour>2</Hour><Minute>17</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40491114</ArticleId><ArticleId IdType="doi">10.29271/jcpsp.2025.06.778</ArticleId><ArticleId IdType="pii">040579197</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">40465881</PMID><DateCompleted><Year>2025</Year><Month>06</Month><Day>13</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>13</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1414-431X</ISSN><JournalIssue CitedMedium="Internet"><Volume>58</Volume><PubDate><Year>2025</Year></PubDate></JournalIssue><Title>Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica</Title><ISOAbbreviation>Braz J Med Biol Res</ISOAbbreviation></Journal><ArticleTitle>The body weight-walking distance product as a superior parameter in determining the VO2 on-kinetics in coronary artery disease.</ArticleTitle><Pagination><StartPage>e14367</StartPage><MedlinePgn>e14367</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e14367</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1590/1414-431X2025e14367</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0100-879X2025000100642</ELocationID><Abstract><AbstractText>The 6-minute walk test is frequently used to assess the functional capacity of the cardiac disease population. Nevertheless, anthropometric differences can confound or misestimate performance, which highlights the need for new parameters. This study aimed to investigate the potential of the body weight-walking distance product (D&#xb7;W) compared to the 6-minute walk test distance to predict exercise capacity measured by oxygen uptake (VO2) on-kinetics in coronary artery disease (CAD) patients. A cross-sectional study was conducted in a tertiary-care reference institution. Forty-six participants with multivessel CAD with and without left ventricular dysfunction underwent a 6-minute walk test with simultaneous use of mobile telemetric cardiopulmonary monitoring to evaluate VO2 kinetics and other cardiorespiratory responses. The Borg rating of perceived exertion for lower limb discomfort was only correlated with the D&#xb7;W (P=0.007). The percent predicted and actual distance were only modestly to moderately correlated with VO2 on-kinetics (R2=0.12 and R2=0.29, P&lt;0.05). All the associations of VO2 on-kinetics parameters were improved, showing a stronger correlation to the D&#xb7;W (R2=0.49, P&lt;0.0001), which also had a larger effect size to identify differences between coronary disease patients compared to distance walked (d=1.32 vs d=0.84). The D&#xb7;W demonstrated potential to be better than the distance walked in determining VO2 on-kinetics in participants with CAD with and without left ventricular dysfunction.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rocco</LastName><ForeName>I S</ForeName><Initials>IS</Initials><Identifier Source="ORCID">0000-0001-8737-4328</Identifier><AffiliationInfo><Affiliation>Programa de P&#xf3;s Gradua&#xe7;&#xe3;o em Cardiologia e Disciplina de Cirurgia Cardiovascular, Universidade Federal de S&#xe3;o Paulo, S&#xe3;o Paulo, SP, Brasil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Departamento de Ci&#xea;ncias do Movimento Humano, Escola de Fisioterapia, Universidade Federal de S&#xe3;o Paulo, Santos, SP, Brasil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gomes</LastName><ForeName>W J</ForeName><Initials>WJ</Initials><Identifier Source="ORCID">0000-0003-3385-0215</Identifier><AffiliationInfo><Affiliation>Programa de P&#xf3;s Gradua&#xe7;&#xe3;o em Cardiologia e Disciplina de Cirurgia Cardiovascular, Universidade Federal de S&#xe3;o Paulo, S&#xe3;o Paulo, SP, Brasil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Viceconte</LastName><ForeName>M</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-4609-253X</Identifier><AffiliationInfo><Affiliation>Programa de P&#xf3;s Gradua&#xe7;&#xe3;o em Cardiologia e Disciplina de Cirurgia Cardiovascular, Universidade Federal de S&#xe3;o Paulo, S&#xe3;o Paulo, SP, Brasil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Departamento de Ci&#xea;ncias do Movimento Humano, Escola de Fisioterapia, Universidade Federal de S&#xe3;o Paulo, Santos, SP, Brasil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matos-Garcia</LastName><ForeName>B C</ForeName><Initials>BC</Initials><Identifier Source="ORCID">0009-0002-1813-6371</Identifier><AffiliationInfo><Affiliation>Programa de P&#xf3;s Gradua&#xe7;&#xe3;o em Cardiologia e Disciplina de Cirurgia Cardiovascular, Universidade Federal de S&#xe3;o Paulo, S&#xe3;o Paulo, SP, Brasil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Departamento de Ci&#xea;ncias do Movimento Humano, Escola de Fisioterapia, Universidade Federal de S&#xe3;o Paulo, Santos, SP, Brasil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Menezes-Rodrigues</LastName><ForeName>F S</ForeName><Initials>FS</Initials><Identifier Source="ORCID">0000-0001-7913-0585</Identifier><AffiliationInfo><Affiliation>Programa de P&#xf3;s Gradua&#xe7;&#xe3;o em Cardiologia e Disciplina de Cirurgia Cardiovascular, Universidade Federal de S&#xe3;o Paulo, S&#xe3;o Paulo, SP, Brasil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Programa de P&#xf3;s-Gradua&#xe7;&#xe3;o em Ci&#xea;ncia Cir&#xfa;rgica Interdisciplinar, Escola Paulista de Medicina, Universidade Federal de S&#xe3;o Paulo, S&#xe3;o Paulo, SP, Brasil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tallo</LastName><ForeName>F S</ForeName><Initials>FS</Initials><Identifier Source="ORCID">0000-0003-3123-024X</Identifier><AffiliationInfo><Affiliation>Programa de P&#xf3;s-Gradua&#xe7;&#xe3;o em Ci&#xea;ncia Cir&#xfa;rgica Interdisciplinar, Escola Paulista de Medicina, Universidade Federal de S&#xe3;o Paulo, S&#xe3;o Paulo, SP, Brasil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Disciplina de Medicina Cl&#xed;nica, Escola Paulista de Medicina, Universidade Federal de S&#xe3;o Paulo, S&#xe3;o Paulo, SP, Brasil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arida</LastName><ForeName>R M</ForeName><Initials>RM</Initials><Identifier Source="ORCID">0000-0002-0908-3274</Identifier><AffiliationInfo><Affiliation>Departamento de Fisiologia, Universidade Federal de S&#xe3;o Paulo, S&#xe3;o Paulo, SP, Brasil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hossne Junior</LastName><ForeName>N A</ForeName><Initials>NA</Initials><Identifier Source="ORCID">0000-0002-1270-8618</Identifier><AffiliationInfo><Affiliation>Programa de P&#xf3;s Gradua&#xe7;&#xe3;o em Cardiologia e Disciplina de Cirurgia Cardiovascular, Universidade Federal de S&#xe3;o Paulo, S&#xe3;o Paulo, SP, Brasil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arena</LastName><ForeName>R</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-6675-1996</Identifier><AffiliationInfo><Affiliation>Department of Physical Therapy and Integrative Physiology Laboratory, College of Applied Health Sciences, University of Illinois Chicago, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guizilini</LastName><ForeName>S</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-5453-2764</Identifier><AffiliationInfo><Affiliation>Programa de P&#xf3;s Gradua&#xe7;&#xe3;o em Cardiologia e Disciplina de Cirurgia Cardiovascular, Universidade Federal de S&#xe3;o Paulo, S&#xe3;o Paulo, SP, Brasil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Departamento de Ci&#xea;ncias do Movimento Humano, Escola de Fisioterapia, Universidade Federal de S&#xe3;o Paulo, Santos, SP, Brasil.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>05</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>Brazil</Country><MedlineTA>Braz J Med Biol Res</MedlineTA><NlmUniqueID>8112917</NlmUniqueID><ISSNLinking>0100-879X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>S88TT14065</RegistryNumber><NameOfSubstance UI="D010100">Oxygen</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005080" MajorTopicYN="Y">Exercise Test</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016138" MajorTopicYN="N">Walking</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010100" MajorTopicYN="Y">Oxygen</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003324" MajorTopicYN="Y">Coronary Artery Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007700" MajorTopicYN="N">Kinetics</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>9</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>4</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>6</Month><Day>4</Day><Hour>18</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>6</Month><Day>4</Day><Hour>18</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>6</Month><Day>4</Day><Hour>15</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>5</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40465881</ArticleId><ArticleId IdType="pmc">PMC12128776</ArticleId><ArticleId IdType="doi">10.1590/1414-431X2025e14367</ArticleId><ArticleId IdType="pii">S0100-879X2025000100642</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Balady GJ, Arena R, Sietsema K, Myers J, Coke L, Fletcher GF, et al. Clinician&#x2019;s guide to cardiopulmonary exercise testing in adults: a scientific statement from the American Heart Association. Circulation. 2010;122(2):191&#x2013;225. doi: 10.1161/CIR.0b013e3181e52e69.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIR.0b013e3181e52e69</ArticleId><ArticleId IdType="pubmed">20585013</ArticleId></ArticleIdList></Reference><Reference><Citation>Whipp BJ, Wasserman K. Oxygen uptake kinetics for various intensities of constant-load work. J Appl Physiol. 1972;33(3):351&#x2013;6. doi: 10.1152/jappl.1972.33.3.351.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/jappl.1972.33.3.351</ArticleId><ArticleId IdType="pubmed">5056210</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu F, Rhodes EC. Oxygen uptake kinetics during exercise. Sports Med. 1999;27(5):313&#x2013;27. doi: 10.2165/00007256-199927050-00003.</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/00007256-199927050-00003</ArticleId><ArticleId IdType="pubmed">10368878</ArticleId></ArticleIdList></Reference><Reference><Citation>Schalcher C, Rickli H, Brehm M, Weilenmann D, Oechslin E, Kiowski W, et al. Prolonged oxygen uptake kinetics during low-intensity exercise are related to poor prognosis in patients with mild-to-moderate congestive heart failure. Chest. 2003;124(2):580&#x2013;6. doi: 10.1378/chest.124.2.580.</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.124.2.580</ArticleId><ArticleId IdType="pubmed">12907546</ArticleId></ArticleIdList></Reference><Reference><Citation>Casillas JM, Hannequin A, Besson D, Bena&#xef;m S, Krawcow C, Laurent Y, et al. Walking tests during the exercise training: specific use for the cardiac rehabilitation. Ann Phys Rehabil Med. 2013;56(7-8):561&#x2013;75. doi: 10.1016/j.rehab.2013.09.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rehab.2013.09.003</ArticleId><ArticleId IdType="pubmed">24126080</ArticleId></ArticleIdList></Reference><Reference><Citation>Bittner V, Weiner DH, Yusuf S, Rogers WJ, McIntyre KM, Bangdiwala SI, et al. SOLVD Investigators Prediction of mortality and morbidity with a 6-minute walk test in patients with left ventricular dysfunction. JAMA. 1993;270(14):1702&#x2013;7. doi: 10.1001/jama.1993.03510140062030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.1993.03510140062030</ArticleId><ArticleId IdType="pubmed">8411500</ArticleId></ArticleIdList></Reference><Reference><Citation>Tueller C, Kern L, Azzola A, Baty F, Condrau S, Wiegand J, et al. Six-minute walk test enhanced by mobile telemetric cardiopulmonary monitoring. Respiration. 2010;80(5):410&#x2013;8. doi: 10.1159/000319834.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000319834</ArticleId><ArticleId IdType="pubmed">20699610</ArticleId></ArticleIdList></Reference><Reference><Citation>Guazzi M, Dickstein K, Vicenzi M, Arena R. Six-minute walk test and cardiopulmonary exercise testing in patients with chronic heart failure: a comparative analysis on clinical and prognostic insights. Circ Heart Fail. 2009;2(6):549&#x2013;55. doi: 10.1161/CIRCHEARTFAILURE.109.881326.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCHEARTFAILURE.109.881326</ArticleId><ArticleId IdType="pubmed">19919979</ArticleId></ArticleIdList></Reference><Reference><Citation>Pepera GK, Sandercock GR, Sloan R, Cleland JJF, Ingle L, Clark AL. Influence of step length on 6-minute walk test performance in patients with chronic heart failure. Physiotherapy. 2012;98(4):325&#x2013;9. doi: 10.1016/j.physio.2011.08.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.physio.2011.08.005</ArticleId><ArticleId IdType="pubmed">23122439</ArticleId></ArticleIdList></Reference><Reference><Citation>Chuang ML, Lin IF, Wasserman K. The body weight-walking distance product as related to lung function, anaerobic threshold and peak VO2 in COPD patients. Respir Med. 2001;95(7):618&#x2013;26. doi: 10.1053/rmed.2001.1115.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/rmed.2001.1115</ArticleId><ArticleId IdType="pubmed">11453321</ArticleId></ArticleIdList></Reference><Reference><Citation>Poersch K, Berton DC, Canterle DB, Castilho J, Lopes AL, Martins J, et al. Six-minute walk distance and work relationship with incremental treadmill cardiopulmonary exercise test in COPD. Clin Respir J. 2013;7(2):145&#x2013;52. doi: 10.1111/j.1752-699X.2012.00295.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1752-699X.2012.00295.x</ArticleId><ArticleId IdType="pubmed">22524795</ArticleId></ArticleIdList></Reference><Reference><Citation>Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure: part I: diagnosis, prognosis, and measurements of diastolic function. Circulation. 2002;105(11):1387&#x2013;93. doi: 10.1161/hc1102.105289.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/hc1102.105289</ArticleId><ArticleId IdType="pubmed">11901053</ArticleId></ArticleIdList></Reference><Reference><Citation>ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories ATS Statement: Guideline for the six-minute walk test. Am J Respir Crit Care Med. 2002;166(1):111&#x2013;7. doi: 10.1164/ajrccm.166.1.at1102.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/ajrccm.166.1.at1102</ArticleId><ArticleId IdType="pubmed">12091180</ArticleId></ArticleIdList></Reference><Reference><Citation>Soares MR, Pereira CA. Six-minute walk test: reference values for healthy adults in Brazil. J Bras Pneumol. 2011;37(5):576&#x2013;83. doi: 10.1590/S1806-37132011000500003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/S1806-37132011000500003</ArticleId><ArticleId IdType="pubmed">22042388</ArticleId></ArticleIdList></Reference><Reference><Citation>American Thoracic Society Standardization of spirometry. 1994 Update. Am J Respir Crit Care Med. 1995;152(3):1107&#x2013;36. doi: 10.1164/ajrccm.152.3.7663792.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/ajrccm.152.3.7663792</ArticleId><ArticleId IdType="pubmed">7663792</ArticleId></ArticleIdList></Reference><Reference><Citation>Motulsky HJ, Ransnas LA. Fitting curves to data using nonlinear regression: a practical and nonmathematical review. FASEB J. 1987;1(5):365&#x2013;74. doi: 10.1096/fasebj.1.5.3315805.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fasebj.1.5.3315805</ArticleId><ArticleId IdType="pubmed">3315805</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossiter HB, Ward SA, Doyle VL, Howe FA, Griffiths JR, Whipp BJ. Inferences from pulmonary O2 uptake with respect to intramuscular [phosphocreatine] kinetics during moderate exercise in humans. J Physiol. 1999;518(Pt 3):921&#x2013;32. doi: 10.1111/j.1469-7793.1999.0921p.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1469-7793.1999.0921p.x</ArticleId><ArticleId IdType="pmc">PMC2269465</ArticleId><ArticleId IdType="pubmed">10421675</ArticleId></ArticleIdList></Reference><Reference><Citation>van Gestel AJR, Baty F, Rausch-Osthof AK, Brutsche MH. Cardiopulmonary and gas-exchange responses during the six-minute walk test in patients with chronic obstructive pulmonary disease. Respiration. 2014;88(4):307&#x2013;14. doi: 10.1159/000365997.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000365997</ArticleId><ArticleId IdType="pubmed">25227115</ArticleId></ArticleIdList></Reference><Reference><Citation>Kern L, Condrau S, Baty F, Wiegand J, van Gestel AJR, Azzola A, et al. Oxygen kinetics during 6-minute walk tests in patients with cardiovascular and pulmonary disease. BMC Pulm Med. 2014;14:167. doi: 10.1186/1471-2466-14-167.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2466-14-167</ArticleId><ArticleId IdType="pmc">PMC4223731</ArticleId><ArticleId IdType="pubmed">25355483</ArticleId></ArticleIdList></Reference><Reference><Citation>Sullivan GM, Feinn R. Using effect size or why the P value is not enough. J Grad Med Educ. 2012;4(3):279&#x2013;82. doi: 10.4300/JGME-D-12-00156.1.</Citation><ArticleIdList><ArticleId IdType="doi">10.4300/JGME-D-12-00156.1</ArticleId><ArticleId IdType="pmc">PMC3444174</ArticleId><ArticleId IdType="pubmed">23997866</ArticleId></ArticleIdList></Reference><Reference><Citation>Yazdanyar A, Aziz MM, Enright PL, Edmundowicz D, Boudreau R, Sutton-Tyrel K, et al. Association between 6-minute walk test and all-cause mortality, coronary heart disease-specific mortality, and incident coronary heart disease. J Aging Health. 2014;26(4):583&#x2013;99. doi: 10.1177/0898264314525665.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0898264314525665</ArticleId><ArticleId IdType="pmc">PMC4485950</ArticleId><ArticleId IdType="pubmed">24695552</ArticleId></ArticleIdList></Reference><Reference><Citation>Tallaj JA, Sanderson B, Breland J, Adams C, Schumann C, Bittner V. Assessment of functional outcomes using the 6-minute walk test in cardiac rehabilitation: comparison of patients with and without left ventricular dysfunction. J Cardiopulm Rehabil. 2001;21(4):221&#x2013;4. doi: 10.1097/00008483-200107000-00005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00008483-200107000-00005</ArticleId><ArticleId IdType="pubmed">11508182</ArticleId></ArticleIdList></Reference><Reference><Citation>Kervio G, Ville NS, Leclercq C, Daubert JC, Carre F. Cardiorespiratory adaptations during the six-minute walk test in chronic heart failure patients. Eur J Cardiovasc Prev Rehabil. 2004;11(2):171&#x2013;7. doi: 10.1097/01.hjr.0000119964.42813.98.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.hjr.0000119964.42813.98</ArticleId><ArticleId IdType="pubmed">15187823</ArticleId></ArticleIdList></Reference><Reference><Citation>Rocco IS, Viceconte M, Pauletti HO, Matos-Garcia BC, Marcondi NO, Bublitz C, et al. Oxygen uptake on-kinetics during six-minute walk test predicts short-term outcomes after off-pump coronary artery bypass surgery. Disabil Rehabil. 2017;41(5):534&#x2013;40. doi: 10.1080/09638288.2017.1401673.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/09638288.2017.1401673</ArticleId><ArticleId IdType="pubmed">29279000</ArticleId></ArticleIdList></Reference><Reference><Citation>Beatty AL, Schiller NB, Whooley MA. Six-minute walk test as a prognostic tool in stable coronary heart disease: data from the heart and soul study. Arch Intern Med. 2002;172(14):1096&#x2013;102. doi: 10.1001/archinternmed.2012.2198.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archinternmed.2012.2198</ArticleId><ArticleId IdType="pmc">PMC3420342</ArticleId><ArticleId IdType="pubmed">22710902</ArticleId></ArticleIdList></Reference><Reference><Citation>Radford MJ, Arnold JM, Bennett SJ, Cinquegrani MP, Cleland JGF, Havranek EP, et al. ACC/AHA key data elements and definitions for measuring the clinical management and outcomes of patients with chronic heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Heart Failure Clinical Data Standards) Circulation. 2005;112(12):1888&#x2013;916. doi: 10.1161/CIRCULATIONAHA.105.170073.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.105.170073</ArticleId><ArticleId IdType="pubmed">16162914</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris KM, Anderson DR, Landers JD, Emery CF. Utility of walk tests in evaluating functional status among participants in an outpatient cardiac rehabilitation program. J Cardiopulm Rehabil Prev. 2017;37(5):329&#x2013;33. doi: 10.1097/HCR.0000000000000242.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/HCR.0000000000000242</ArticleId><ArticleId IdType="pubmed">28306686</ArticleId></ArticleIdList></Reference><Reference><Citation>Sutherland N, Harrison A, Doherty P. Factors influencing change in walking ability in patients with heart failure undergoing exercise-based cardiac rehabilitation. Int J Cardiol. 2018;268:162&#x2013;5. doi: 10.1016/j.ijcard.2018.05.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijcard.2018.05.021</ArticleId><ArticleId IdType="pmc">PMC6069635</ArticleId><ArticleId IdType="pubmed">29779576</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazzoni G, Sassone B, Pasanisi G, Myers J, Mandini S, Volpato S, et al. A moderate 500-m treadmill walk for estimating peak oxygen uptake in men with NYHA class I-II heart failure and reduced left ventricular ejection fraction. BMC Cardiovasc Disord. 2018;18(1):67. doi: 10.1186/s12872-018-0801-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12872-018-0801-9</ArticleId><ArticleId IdType="pmc">PMC5902976</ArticleId><ArticleId IdType="pubmed">29661150</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40471968</PMID><DateRevised><Year>2025</Year><Month>06</Month><Day>09</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2767-3170</ISSN><JournalIssue CitedMedium="Internet"><Volume>4</Volume><Issue>6</Issue><PubDate><Year>2025</Year><Month>Jun</Month></PubDate></JournalIssue><Title>PLOS digital health</Title><ISOAbbreviation>PLOS Digit Health</ISOAbbreviation></Journal><ArticleTitle>Pharmacist-led rapid uptitration clinic in heart failure patients with reduced ejection fraction: Our experience within a virtual ward.</ArticleTitle><Pagination><StartPage>e0000868</StartPage><MedlinePgn>e0000868</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e0000868</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pdig.0000868</ELocationID><Abstract><AbstractText>Heart failure with reduced ejection fraction is a chronic, progressive medical condition affecting millions of individuals worldwide. It is associated with high morbidity and mortality. The use of "foundational quadruple therapy" titrated to the maximum tolerated doses improves survival, quality of life, and reduces heart failure-related hospitalisation. Despite this evidence, there is a consistent trend of suboptimal dose up-titration, prolonged optimisation periods, and early therapy discontinuation. Virtual wards offer a potential innovative solution in transforming heart failure management by combining rapid medication optimisation with remote monitoring to improve patient outcomes. This retrospective study employed a single-group pre-post design to evaluate the effectiveness of a prescribing pharmacist in the rapid uptitration of Guidelines Directed Medical Therapy (GDMT) in patients with heart failure with reduced ejection fraction within a virtual ward setting. The study assessed clinical outcomes of 86 patients at baseline, following discharge from the virtual ward (typically after 4 weeks), and at 3-6 months post-discharge. Improvements were seen in NYHA scores, cardiac systolic function, and Optimal Medical Therapy (OMT) scores. The median Left Ventricular Ejection Fraction increased from 29% at baseline to 39% post-optimisation, signifying improved myocardial performance and a reduction in the severity of left ventricular dysfunction. Post-optimisation, 37% of patients attained an optimal OMT score of 8, 52% attained an acceptable score (5-7), and only 5% remained in the suboptimal range (0-4). Additionally, 84% of patients were prescribed all four foundational therapies. There was no notable increase in adverse events such as hypotension, bradycardia, or hyperkalaemia. Remote up-titration of heart failure medications within a virtual ward environment is a promising approach, offering a fast, feasible, safe, and efficient treatment solution for patients who are otherwise undertreated.</AbstractText><CopyrightInformation>Copyright: &#xa9; 2025 Alhakem et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Alhakem</LastName><ForeName>Hussein</ForeName><Initials>H</Initials><Identifier Source="ORCID">0009-0008-8832-9068</Identifier><AffiliationInfo><Affiliation>Chelsea &amp; Westminster NHS Foundation Trust, London, England.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murphy</LastName><ForeName>Angela</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Chelsea &amp; Westminster NHS Foundation Trust, London, England.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fusco</LastName><ForeName>Liuba</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Chelsea &amp; Westminster NHS Foundation Trust, London, England.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McQueen</LastName><ForeName>Grant</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Chelsea &amp; Westminster NHS Foundation Trust, London, England.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pearse</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Northwest London Virtual Hospital, Imperial College Healthcare NHS Trust, London, England.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barrett</LastName><ForeName>Jodian</ForeName><Initials>J</Initials><Identifier Source="ORCID">0009-0006-7961-898X</Identifier><AffiliationInfo><Affiliation>Northwest London Virtual Hospital, Imperial College Healthcare NHS Trust, London, England.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Linnard</LastName><ForeName>Deirdre</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Chelsea &amp; Westminster NHS Foundation Trust, London, England.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khan</LastName><ForeName>Sadia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Chelsea &amp; Westminster NHS Foundation Trust, London, England.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Heart and Lung Institute, Imperial College London, London, England.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>06</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLOS Digit Health</MedlineTA><NlmUniqueID>9918335064206676</NlmUniqueID><ISSNLinking>2767-3170</ISSNLinking></MedlineJournalInfo><CoiStatement>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>12</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>4</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>6</Month><Day>5</Day><Hour>18</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>6</Month><Day>5</Day><Hour>18</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>6</Month><Day>5</Day><Hour>13</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>6</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40471968</ArticleId><ArticleId IdType="pmc">PMC12140189</ArticleId><ArticleId IdType="doi">10.1371/journal.pdig.0000868</ArticleId><ArticleId IdType="pii">PDIG-D-24-00601</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Murphy SP, Ibrahim NE, Januzzi JL Jr. Heart Failure With Reduced Ejection Fraction: A Review. JAMA. 2020;324(5):488&#x2013;504. doi: 10.1001/jama.2020.10262</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.10262</ArticleId><ArticleId IdType="pubmed">32749493</ArticleId></ArticleIdList></Reference><Reference><Citation>Department of Health and Social Care. Independent investigation of the NHS in England [Internet]. England: Crown; 2024.  [cited 2 May 2025]. Available from: https://www.gov.uk/government/publications/independent-investigation-of-the-nhs-in-england</Citation></Reference><Reference><Citation>Butler J, Yang M, Manzi M, et al.. Clinical Course of Patients With Worsening Heart Failure With Reduced Ejection Fraction. JACC. 2019. Mar;73(8):935&#x2013;944. doi: 10.1016/j.jacc.2018.11.049</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2018.11.049</ArticleId><ArticleId IdType="pubmed">30819362</ArticleId></ArticleIdList></Reference><Reference><Citation>McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B&#xf6;hm M, et al.. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599&#x2013;726. doi: 10.1093/eurheartj/ehab368</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehab368</ArticleId><ArticleId IdType="pubmed">34447992</ArticleId></ArticleIdList></Reference><Reference><Citation>Savarese G, Bodegard J, Norhammar A, Sartipy P, Thuresson M, Cowie MR, et al.. Heart failure drug titration, discontinuation, mortality and heart failure hospitalization risk: a multinational observational study (US, UK and Sweden). Eur J Heart Fail. 2021;23(9):1499&#x2013;511. doi: 10.1002/ejhf.2271</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ejhf.2271</ArticleId><ArticleId IdType="pubmed">34132001</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdin A, Bauersachs J, Soltani S, Eden M, Frey N, B&#xf6;hm M. A practical approach to the guideline-directed pharmacological treatment of heart failure with reduced ejection fraction. ESC Heart Fail. 2022;10(1):24&#x2013;31. doi: 10.1002/ehf2.14197</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ehf2.14197</ArticleId><ArticleId IdType="pmc">PMC9871719</ArticleId><ArticleId IdType="pubmed">36229988</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdin A, Anker SD, Butler J, Coats AJS, Kindermann I, Lainscak M, et al.. &#x201c;Time is prognosis&#x201d; in heart failure: time-to-treatment initiation as a modifiable risk factor. ESC Heart Fail. 2021;8(6):4444&#x2013;53. doi: 10.1002/ehf2.13646</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ehf2.13646</ArticleId><ArticleId IdType="pmc">PMC8712849</ArticleId><ArticleId IdType="pubmed">34655282</ArticleId></ArticleIdList></Reference><Reference><Citation>Mebazaa A, Davison B, Chioncel O, Cohen-Solal A, Diaz R, Filippatos G, et al.. Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial. Lancet. 2022;400(10367):1938&#x2013;52. doi: 10.1016/S0140-6736(22)02076-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)02076-1</ArticleId><ArticleId IdType="pubmed">36356631</ArticleId></ArticleIdList></Reference><Reference><Citation>DeFilippis EM, Butler J, Vaduganathan M. Waiting Period Before Implantable Cardioverter-Defibrillator Implantation in Newly Diagnosed Heart Failure With Reduced Ejection Fraction: A Window of Opportunity. Circ Heart Fail. 2017;10(11):e004478. doi: 10.1161/CIRCHEARTFAILURE.117.004478</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCHEARTFAILURE.117.004478</ArticleId><ArticleId IdType="pmc">PMC5777623</ArticleId><ArticleId IdType="pubmed">29138249</ArticleId></ArticleIdList></Reference><Reference><Citation>Greene SJ, Ezekowitz JA, Anstrom KJ, Demyanenko V, Givertz MM, Pi&#xf1;a IL, et al.. Medical Therapy During Hospitalization for Heart Failure With Reduced Ejection Fraction: The VICTORIA Registry. J Card Fail. 2022;28(7):1063&#x2013;77. doi: 10.1016/j.cardfail.2022.02.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cardfail.2022.02.011</ArticleId><ArticleId IdType="pubmed">35301107</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiuzat M, Hamo CE, Butler J, Abraham WT, DeFilippis EM, Fonarow GC, et al.. Optimal Background Pharmacological Therapy for Heart Failure Patients in Clinical Trials: JACC Review Topic of the Week. J Am Coll Cardiol. 2022;79(5):504&#x2013;10. doi: 10.1016/j.jacc.2021.11.033</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2021.11.033</ArticleId><ArticleId IdType="pmc">PMC9180686</ArticleId><ArticleId IdType="pubmed">35115106</ArticleId></ArticleIdList></Reference><Reference><Citation>Veltmann C, Duncker D, Doering M, Gummadi S, Robertson M, Wittlinger T, et al.. Therapy duration and improvement of ventricular function in de novo heart failure: the Heart Failure Optimization study. Eur Heart J. 2024;45(30):2771&#x2013;81. doi: 10.1093/eurheartj/ehae334</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehae334</ArticleId><ArticleId IdType="pmc">PMC11313580</ArticleId><ArticleId IdType="pubmed">38864173</ArticleId></ArticleIdList></Reference><Reference><Citation>Greene SJ, Butler J, Albert NM, DeVore AD, Sharma PP, Duffy CI, et al.. Medical Therapy for Heart Failure With Reduced Ejection Fraction: The CHAMP-HF Registry. J Am Coll Cardiol. 2018. Jul 24;72(4):351&#x2013;66. doi: 10.1016/j.jacc.2018.04.070</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2018.04.070</ArticleId><ArticleId IdType="pubmed">30025570</ArticleId></ArticleIdList></Reference><Reference><Citation>Voors AA, Anker SD, Cleland JG, Dickstein K, Filippatos G, van der Harst P, et al.. A systems BIOlogy Study to TAilored Treatment in Chronic Heart Failure: rationale, design, and baseline characteristics of BIOSTAT-CHF. Eur J Heart Fail. 2016;18(6):716&#x2013;26. doi: 10.1002/ejhf.531</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ejhf.531</ArticleId><ArticleId IdType="pubmed">27126231</ArticleId></ArticleIdList></Reference><Reference><Citation>Tran RH, Aldemerdash A, Chang P, Sueta CA, Kaufman B, Asafu-Adjei J, et al.. Guideline-Directed Medical Therapy and Survival Following Hospitalization in Patients with Heart Failure. Pharmacotherapy. 2018;38(4):406&#x2013;16. doi: 10.1002/phar.2091</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/phar.2091</ArticleId><ArticleId IdType="pmc">PMC5902433</ArticleId><ArticleId IdType="pubmed">29423950</ArticleId></ArticleIdList></Reference><Reference><Citation>Bottle A, Aylin P, Bell D. Effect of the readmission primary diagnosis and time interval in heart failure patients: analysis of English administrative data. Eur J Heart Fail. 2014;16(8):846&#x2013;53. doi: 10.1002/ejhf.129</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ejhf.129</ArticleId><ArticleId IdType="pubmed">25044392</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawson C, Crothers H, Remsing S, Squire I, Zaccardi F, Davies M, et al.. Trends in 30-day readmissions following hospitalisation for heart failure by sex, socioeconomic status and ethnicity. EClinicalMedicine. 2021;38:101008. doi: 10.1016/j.eclinm.2021.101008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2021.101008</ArticleId><ArticleId IdType="pmc">PMC8283308</ArticleId><ArticleId IdType="pubmed">34308315</ArticleId></ArticleIdList></Reference><Reference><Citation>Koehler F, Koehler K, Deckwart O, Prescher S, Wegscheider K, Kirwan B-A, et al.. Efficacy of telemedical interventional management in patients with heart failure (TIM-HF2): a randomised, controlled, parallel-group, unmasked trial. Lancet. 2018;392(10152):1047&#x2013;57. doi: 10.1016/S0140-6736(18)31880-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(18)31880-4</ArticleId><ArticleId IdType="pubmed">30153985</ArticleId></ArticleIdList></Reference><Reference><Citation>Rangaswami J, Bhalla V, Blair JEA, Chang TI, Costa S, Lentine KL, et al., American Heart Association Council on the Kidney in Cardiovascular Disease and Council on Clinical Cardiology. Cardiorenal Syndrome: Classification, Pathophysiology, Diagnosis, and Treatment Strategies: A Scientific Statement From the American Heart Association. Circulation. 2019;139(16):e840&#x2013;78. doi: 10.1161/CIR.0000000000000664</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIR.0000000000000664</ArticleId><ArticleId IdType="pubmed">30852913</ArticleId></ArticleIdList></Reference><Reference><Citation>McMurray JJV, Solomon SD, Inzucchi SE, K&#xf8;ber L, Kosiborod MN, Martinez FA, et al.. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019;381(21):1995&#x2013;2008. doi: 10.1056/NEJMoa1911303</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1911303</ArticleId><ArticleId IdType="pubmed">31535829</ArticleId></ArticleIdList></Reference><Reference><Citation>Packer M, Anker SD, Butler J, Filippatos G, Ferreira JP, Pocock SJ, et al.. Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload: EMPEROR-Reduced Trial. J Am Coll Cardiol. 2021. Mar 23;77(11):1381&#x2013;92. doi: 10.1016/j.jacc.2021.01.033</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2021.01.033</ArticleId><ArticleId IdType="pubmed">33736819</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>